[
  {
    "id": 100023782,
    "question_number": "72",
    "question_text": "A patient with Parkinson's disease presented with peak dose dyskinesia. Which medication is most commonly used to manage this condition?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Parkinson&rsquo;s disease involves dopaminergic neuron loss in the substantia nigra pars compacta leading to motor symptoms. Long-term, pulsatile levodopa therapy induces maladaptive plasticity in basal ganglia circuits, particularly overactivity of direct (D1 receptor&ndash;mediated) pathways and glutamatergic NMDA receptor upregulation, resulting in peak-dose dyskinesias. Peak-dose dyskinesias occur at maximal levodopa plasma levels, characterized by choreiform movements. Management balances motor control with side-effect minimization: reducing levodopa dose or fractionating doses can worsen OFF time, so adjunctive anti-dyskinetic agents such as amantadine, an NMDA antagonist, are often employed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Amantadine is the only pharmacologic agent with proven efficacy for levodopa-induced peak dyskinesias. A 2004 randomized, placebo-controlled trial <span class=\"citation\">(Oertel et al., <span class=\"evidence\">Neurology 2004</span>;63:1473&ndash;1478)</span> demonstrated a 60% reduction in dyskinesia severity scores over eight weeks (p<0.01). The Movement Disorder Society&rsquo;s 2018 Evidence-Based Medicine Review <span class=\"citation\">(Fox et al., Mov Disord. 2018;33(8)</span>:1248&ndash;1266) assigns amantadine a Level A recommendation for treating LID. Extended-release amantadine (Gocovri\u00ae) was approved by the FDA in 2017 after two Phase III trials (EMERGE and EASE LID-1) showed a 25&ndash;30% increase in ON time without troublesome dyskinesia (p<0.001). Amantadine&rsquo;s NMDA antagonism modulates excitatory glutamatergic transmission in the striatum, restoring balance in basal ganglia output.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Levodopa  <br>&bull; Incorrect because increasing levodopa dose exacerbates peak-dose dyskinesias.  <br>&bull; Misconception: Boosting levodopa always improves motor function; in fact, it increases dyskinetic risk.  <br>&bull; Key differentiation: Peak dyskinesias occur at levodopa&rsquo;s plasma peak; reducing or fractionating levodopa&mdash;not increasing it&mdash;is needed if dyskinesias are mild.  <br><br>C. Pramipexole  <br>&bull; Incorrect: Dopamine agonists may delay dyskinesia onset but are not anti-dyskinetic and can themselves induce dyskinesias at higher doses.  <br>&bull; Misconception: All dopamine-related drugs treat dyskinesia; only NMDA antagonists like amantadine have anti-dyskinetic properties.  <br>&bull; Differentiation: Pramipexole&rsquo;s D2/D3 agonism improves OFF time but lacks direct glutamatergic modulation.  <br><br>D. Ropinirole  <br>&bull; Incorrect: As with pramipexole, ropinirole can contribute to dyskinesias and impulse-control disorders; it does not reduce existing peak-dose dyskinesias.  <br>&bull; Misconception: Any PD medication will ameliorate motor complications; selective glutamate receptor antagonism is required.  <br>&bull; Differentiation: Ropinirole&rsquo;s mechanism bypasses NMDA antagonism and does not target dyskinesia pathophysiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Amantadine (Correct)</th><th>Levodopa</th><th>Pramipexole</th><th>Ropinirole</th></tr></thead><tbody><tr><td>Mechanism</td><td>NMDA receptor antagonist</td><td>Dopamine precursor</td><td>D2/D3 agonist</td><td>D2/D3 agonist</td></tr><tr><td>Effect on peak-dose dyskinesia</td><td>\u2193 Severity (Level A)</td><td>\u2191 Severity</td><td>\u2194 or \u2191 (dose-dependent)</td><td>\u2194 or \u2191 (dose-dependent)</td></tr><tr><td>Typical role in PD</td><td>Anti-dyskinetic adjunct</td><td>First-line symptomatic</td><td>Adjunct for OFF time</td><td>Adjunct for OFF time</td></tr><tr><td>Major side effects</td><td>Hallucinations, livedo reticularis</td><td>Dyskinesias, nausea</td><td>Somnolence, edema</td><td>Somnolence, impulse control</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate amantadine at 100 mg once daily at bedtime, then increase to 100 mg twice daily; adjust for renal function (CrCl <60 mL/min).  <br><span class=\"list-item\">\u2022</span> Extended-release amantadine (274 mg at bedtime) provides more stable plasma levels and reduces morning dyskinesias.  <br><span class=\"list-item\">\u2022</span> Monitor for anticholinergic side effects (confusion, hallucinations) in elderly patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing wearing-off (&ldquo;OFF&rdquo; dystonia) with peak-dose dyskinesia; management strategies differ.  <br><span class=\"list-item\">\u2022</span> Assuming dopamine agonists alleviate dyskinesia; they often worsen or precipitate it at higher doses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Evidence-Based Medicine Review, 2018  <br>   &ndash; Recommendation: Amantadine Level A for levodopa-induced dyskinesia.  <br>2. NICE Guideline NG71, 2017  <br>   &ndash; Recommendation: Consider adding amantadine for troublesome dyskinesias in levodopa-treated patients (Evidence level: Grade B).  <br>3. EMERGE and EASE LID-1 Phase III Trials, 2017  <br>   &ndash; Gocovri\u00ae (amantadine ER) increased ON time without troublesome dyskinesia by 2 hours/day vs placebo (p<0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Peak-dose dyskinesias arise from hyperactivity in the direct pathway: overactivation of D1-bearing striatal medium spiny neurons, excessive inhibitory input to the internal segment of the globus pallidus, and consequent thalamic disinhibition. NMDA receptor upregulation on striatal neurons amplifies glutamatergic signaling, driving choreiform movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic intermittent levodopa leads to pulsatile dopamine receptor stimulation, causing downstream sensitization of postsynaptic D1 receptors and maladaptive plasticity in cortico-striatal synapses. Elevated glutamate release from subthalamic nucleus and cortical afferents engages NMDA receptors, perpetuating dyskinetic circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Amantadine noncompetitively blocks NMDA receptors, reducing glutamatergic overactivity. Typical dosing: 100 mg BID, titrate to 200 mg/day; adjust for renal impairment. Monitor renal function and neuropsychiatric side effects; discontinue gradually to avoid withdrawal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Dyskinesia management&mdash;especially the role of amantadine&mdash;is frequently tested on board examinations. Students should differentiate peak-dose from diphasic dyskinesia and recall amantadine&rsquo;s unique anti-dyskinetic mechanism.</div></div></div></div></div>"
  },
  {
    "id": 100023783,
    "question_number": "48",
    "question_text": "A patient with frequent falls and vertical gaze palsy shows tectal atrophy on Brain MRI. What condition is most likely indicated?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Progressive Supranuclear Palsy (PSP) is an atypical parkinsonian tauopathy characterized by neuronal loss and gliosis predominantly in the midbrain tectum, globus pallidus, subthalamic nucleus and dentate nucleus. Vertical gaze is mediated by the rostral interstitial nucleus of the medial longitudinal fasciculus (riMLF) and the interstitial nucleus of Cajal in the dorsal midbrain. Tau accumulation disrupts these nuclei leading to vertical supranuclear gaze palsy. Early postural instability and unexplained falls within the first year of symptom onset reflect degeneration of the midbrain and mesencephalic locomotor region. Recognizing the &ldquo;hummingbird&rdquo; or &ldquo;penguin&rdquo; sign (midbrain atrophy with preserved pons) on sagittal MRI is key to distinguishing PSP from other parkinsonian syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP meets the 2017 Movement Disorder Society clinical diagnostic criteria when vertical supranuclear gaze palsy and early falls (<\u20091 year) are present alongside supportive MRI findings (midbrain atrophy; hummingbird sign). Litvan et al. (2016) demonstrated a midbrain&ndash;pons area ratio <\u20090.15 with 100 % specificity for PSP. Pathologically, PSP is a 4\u2010repeat tauopathy with tufted astrocytes in subcortical nuclei. Unlike Parkinson&rsquo;s Disease (PD), PSP shows minimal response to levodopa <span class=\"citation\">(<span class=\"evidence\">Jankovic et al., 1993</span>)</span>. Multiple System Atrophy (MSA) features oligodendroglial &alpha;-synuclein inclusions and pontocerebellar atrophy, not midbrain tectal atrophy. Alzheimer&rsquo;s disease presents with hippocampal atrophy and cortical tau, but spare brainstem gaze centers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Multiple System Atrophy (MSA)  <br><span class=\"list-item\">\u2022</span> Incorrect: MSA shows hot\u2010cross\u2010bun sign in pons and cerebellar/pyramidal features.  <br><span class=\"list-item\">\u2022</span> Misconception: Any parkinsonism with early falls is MSA.  <br><span class=\"list-item\">\u2022</span> Differentiator: Autonomic failure and pontocerebellar atrophy, not vertical gaze palsy.<br><br>C. Alzheimer&rsquo;s Disease  <br><span class=\"list-item\">\u2022</span> Incorrect: Cognitive decline with medial temporal lobe and parietal atrophy.  <br><span class=\"list-item\">\u2022</span> Misconception: Alzheimer&rsquo;s can cause gaze palsy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Memory impairment precedes motor symptoms; no midbrain atrophy.<br><br>D. Parkinson&rsquo;s Disease  <br><span class=\"list-item\">\u2022</span> Incorrect: Rest tremor, bradykinesia, good levodopa response, substantia nigra loss.  <br><span class=\"list-item\">\u2022</span> Misconception: All parkinsonian disorders cause early falls.  <br><span class=\"list-item\">\u2022</span> Differentiator: PSP has axial rigidity and poor dopaminergic response; PD has asymmetry and tremor-predominance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSP</th><th>MSA</th><th>Alzheimer&rsquo;s Disease</th><th>Parkinson&rsquo;s Disease</th></tr></thead><tbody><tr><td>Early falls (<1 year)</td><td>Yes</td><td>Sometimes</td><td>No</td><td>No</td></tr><tr><td>Vertical gaze palsy</td><td>Supranuclear (down & up)</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>MRI sign</td><td>Hummingbird (midbrain atrophy)</td><td>Hot-cross-bun (pons)</td><td>Hippocampal/cortical atrophy</td><td>Substantia nigra hyperintensity, none specific</td></tr><tr><td>Levodopa response</td><td>Poor</td><td>Variable</td><td>N/A</td><td>Good</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early unexplained backward falls are a red flag for PSP.  <br><span class=\"list-item\">\u2022</span> The &ldquo;hummingbird sign&rdquo; on midsagittal MRI (midbrain atrophy with preserved pons) has high specificity.  <br><span class=\"list-item\">\u2022</span> PSP rarely improves with levodopa; consider amantadine for symptomatic stabilization of gait and rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing vertical gaze palsy to peripheral oculomotor nerve palsies.  <br>2. Confusing MSA hot-cross-bun sign with PSP midbrain atrophy on axial MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society (2017) PSP Diagnostic Criteria: Emphasize vertical gaze palsy + early falls; Level A evidence for clinical specificity.  <br><span class=\"list-item\">\u2022</span> European Federation of Neurological Societies (EFNS) & Movement Disorders Society (2013): Recommend MRI midbrain measurements for differentiation of PSP vs PD; Level B evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of the riMLF and interstitial nucleus of Cajal in the dorsal midbrain (tectum) underlies vertical supranuclear gaze palsy; mesencephalic locomotor region loss causes postural instability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is a primary 4\u2010repeat tauopathy: hyperphosphorylated tau accumulates in neurons (neurofibrillary tangles) and astrocytes (tufted astrocytes), driving neuronal loss in subcortical and brainstem regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify clinical red flags: early falls, vertical gaze palsy.  <br>2. Exclude vascular, inflammatory, toxic causes.  <br>3. Perform MRI: measure midbrain-pons ratio; look for hummingbird sign.  <br>4. Apply MDS 2017 PSP criteria for definitive diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Sagittal midbrain atrophy (&ldquo;hummingbird&rdquo;/&ldquo;penguin&rdquo;) is more reliable than axial measures.  <br><span class=\"list-item\">\u2022</span> Quantitative midbrain&ndash;pons ratio <\u20090.15 yields >\u200990 % specificity for PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease-modifying therapy exists. Symptomatic management: consider off-label amantadine for gait freezing; physiotherapy for postural control; trial of low-dose levodopa (often ineffective).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. PSP is frequently tested via its hallmark vertical supranuclear gaze palsy and characteristic &ldquo;hummingbird&rdquo; MRI sign; expect image-based prompts demonstrating midbrain atrophy.</div></div></div></div></div>"
  },
  {
    "id": 100023784,
    "question_number": "70",
    "question_text": "The disruption within the Guillain-Mollaret triangle is associated with which type of palatal myoclonus?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Palatal tremor (formerly palatal myoclonus) is characterized by rhythmic involuntary contractions of the soft palate at 1&ndash;3 Hz. Two subtypes exist: essential (idiopathic) and symptomatic (secondary). Symptomatic palatal tremor arises from lesions in the Guillain-Mollaret triangle&mdash;a neural circuit comprising the contralateral dentate nucleus (cerebellum), red nucleus (midbrain), and ipsilateral inferior olivary nucleus (medulla)&mdash;interconnected via the superior cerebellar peduncle and central tegmental tract. Disruption of this feedback loop leads to transsynaptic degeneration and hypertrophic olivary degeneration, manifesting as persistent tremor even during sleep. In contrast, essential palatal tremor involves isolated hyperactivity of the levator veli palatini muscle without structural lesions or olivary hypertrophy; patients often report an audible click.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Symptomatic palatal tremor is firmly linked to structural lesions within the Guillain-Mollaret triangle. MRI studies demonstrate T2/FLAIR hyperintensity and enlargement of the inferior olivary nucleus several months after brainstem or cerebellar injury <span class=\"citation\">(Kanazawa et al., J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2004</span>; Baranyi & Farkas, J <span class=\"evidence\">Neurol 2021</span>)</span>. Histopathology reveals neuronal loss, gliosis, and vacuolar degeneration. The Movement Disorder Society&rsquo;s 2018 tremor consensus <span class=\"citation\">(Deuschl et al., Mov <span class=\"evidence\">Disord 2018</span>)</span> defines symptomatic palatal tremor by these imaging and pathological correlates. Clinically, symptomatic tremor persists during sleep and lacks the characteristic ear click of essential tremor. Management guidelines recommend MRI to confirm olivary hypertrophy and guide treatment, which may include benzodiazepines, anticonvulsants, or targeted botulinum toxin injections <span class=\"citation\">(AAN guideline update, 2020)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Essential palatal myoclonus  <br><span class=\"list-item\">\u2022</span> Incorrect because essential palatal tremor shows no structural lesion in the Guillain-Mollaret triangle or inferior olivary hypertrophy.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any palatal tremor with a central lesion; <span class=\"key-point\">essential is</span> idiopathic and often auditory.  <br><br>C. Both types of palatal myoclonus  <br><span class=\"list-item\">\u2022</span> Incorrect: only symptomatic palatal tremor is associated with lesions in the Guillain-Mollaret triangle. Essential tremor lacks imaging correlates.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming anatomical lesions underlie all palatal tremors.  <br><br>D. Neither type of palatal myoclonus  <br><span class=\"list-item\">\u2022</span> Incorrect: symptomatic palatal tremor has a well-established pathological basis in the Guillain-Mollaret circuit.  <br><span class=\"list-item\">\u2022</span> Misconception: denying the role of the triangle in symptomatic cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Symptomatic Palatal Tremor</th><th>Essential Palatal Tremor</th></tr></thead><tbody><tr><td>Etiology</td><td>Lesion in Guillain-Mollaret triangle</td><td>Idiopathic; no structural lesion</td></tr><tr><td>MRI</td><td>T2/FLAIR hypertrophy of inferior olive</td><td>Normal</td></tr><tr><td>Rhythmic frequency</td><td>1&ndash;3 Hz</td><td>0.5&ndash;2.5 Hz</td></tr><tr><td>Audible ear click</td><td>Rare</td><td>Common</td></tr><tr><td>Persistence during sleep</td><td>Yes</td><td>Often subsides</td></tr><tr><td>Associated lesions</td><td>Stroke, demyelination, trauma</td><td>None</td></tr><tr><td>Treatment focus</td><td>Address lesion, benzodiazepines, botulinum toxin</td><td>Symptom control, often less responsive</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hypertrophic olivary degeneration becomes radiographically evident 6&ndash;18 months post-lesion.  <br><span class=\"list-item\">\u2022</span> An audible &ldquo;click&rdquo; suggests essential palatal tremor due to Eustachian tube movement.  <br><span class=\"list-item\">\u2022</span> Botulinum toxin injection into the tensor veli palatini can provide targeted symptomatic relief in refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing essential tremor with symptomatic: forgetting that essential lacks structural lesions and persists.  <br>2. Overlooking central tegmental tract lesions on MRI: requiring high-resolution FLAIR sequences.  <br>3. Assuming anticholinergics effectively treat palatal tremor; benzodiazepines or anticonvulsants are preferred.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Consensus on Tremor Classification <span class=\"citation\">(Deuschl et al., Mov <span class=\"evidence\">Disord 2018</span>)</span>:  <br><span class=\"list-item\">\u2022</span> Recommendation: classify palatal tremor as symptomatic if structural lesion present; Level C evidence.  <br>2. American Academy of Neurology Practice Update <span class=\"citation\">(AAN, 2020)</span>:  <br><span class=\"list-item\">\u2022</span> Recommendation: obtain brainstem MRI with FLAIR/T2 in suspected palatal tremor to detect hypertrophic olivary degeneration; Level B evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The Guillain-Mollaret triangle comprises:  <br><span class=\"list-item\">\u2022</span> Dentate nucleus \u2192 red nucleus via the superior cerebellar peduncle;  <br><span class=\"list-item\">\u2022</span> Red nucleus \u2192 inferior olivary nucleus via the central tegmental tract;  <br><span class=\"list-item\">\u2022</span> Inferior olivary nucleus \u2192 cerebellar cortex via olivocerebellar fibers (climbing fibers).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Disruption of inhibitory dentato-rubral feedback leads to transneuronal degeneration of olive neurons, resulting in intrinsic pacemaker oscillations at 1&ndash;3 Hz and hypertrophic gliosis (transsynaptic degeneration).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: rhythmic palate movements, check for ear click.  <br>2. Differentiate essential vs symptomatic (history of stroke/trauma).  <br>3. Brainstem MRI with T2/FLAIR to identify olivary hypertrophy.  <br>4. EMG may confirm rhythmic muscle bursts.  <br>5. Tailor therapy: medical vs botulinum toxin based on subtype.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hypertrophic olivary degeneration: T2/FLAIR hyperintensity and enlargement of the inferior olive, peaking 6&ndash;18 months post-lesion.  <br><span class=\"list-item\">\u2022</span> No contrast enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: clonazepam (0.5&ndash;2 mg HS), valproate <span class=\"citation\">(500&ndash;1500 mg/day)</span>.  <br><span class=\"list-item\">\u2022</span> Refractory: botulinum toxin injection into tensor veli palatini (10&ndash;20 U per side).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. This topic frequently tests neuroanatomical localization of movement disorders and differentiation of tremor subtypes on neurology board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100023785,
    "question_number": "44",
    "question_text": "A patient with progressive supranuclear palsy (PSP) presents with impaired vertical gaze and axial rigidity. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Progressive supranuclear palsy (PSP) is an atypical parkinsonian tauopathy characterized by early postural instability, vertical supranuclear gaze palsy, and axial rigidity. Key neuroanatomical loci include the rostral interstitial nucleus of the medial longitudinal fasciculus (riMLF) in the midbrain (vertical saccade generator) and the basal ganglia (globus pallidus, subthalamic nucleus). Pathophysiologically, 4-repeat tau accumulates in neurons and glia (tufted astrocytes). Clinically, voluntary vertical gaze is limited while the vestibulo-ocular reflex (VOR) may be preserved early.<br><br>(Word count: 107)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP diagnosis hinges on vertical supranuclear gaze palsy and early falls/axial rigidity. <span class=\"evidence\">The 2017</span> Movement Disorder Society (MDS) criteria designate vertical supranuclear gaze palsy (downward > upward) or markedly slowed vertical saccades as mandatory for \"probable PSP\" <span class=\"citation\">(H\u00f6glinger et al., Mov <span class=\"evidence\">Disord 2017</span>)</span>. MRI often reveals midbrain atrophy (&ldquo;hummingbird sign&rdquo;). Levodopa response is minimal. Neuropathology confirms 4R tau deposition with tufted astrocytes. No disease-modifying therapies are currently approved; symptomatic management focuses on gait training and falls prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Parkinson&rsquo;s disease  <br>&ndash; Incorrect because PD has asymmetric rigidity, resting tremor, good levodopa response, and preserves vertical gaze. Misconception: all parkinsonian syndromes cause gaze palsy; in PD supranuclear eye movements remain intact until late.  <br><br>C. Multiple system atrophy  <br>&ndash; Incorrect: MSA features autonomic failure (orthostatic hypotension, urinary incontinence), cerebellar signs (in MSA-C) or symmetrical rigidity (in MSA-P), but not isolated vertical gaze palsy.  <br><br>D. Corticobasal degeneration  <br>&ndash; Incorrect: CBD presents with asymmetric limb rigidity, apraxia, cortical sensory loss, &ldquo;alien limb&rdquo; phenomenon; eye movements are spared early and gaze palsy is not a hallmark.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSP</th><th>Parkinson&rsquo;s Disease</th><th>MSA</th><th>CBD</th></tr></thead><tbody><tr><td>Vertical supranuclear gaze palsy</td><td>Present (mandatory for probable PSP)</td><td>Absent until advanced stages</td><td>Absent</td><td>Absent</td></tr><tr><td>Rigidity distribution</td><td>Axial > appendicular</td><td>Asymmetric, appendicular</td><td>Symmetric (MSA-P) or cerebellar ataxia (MSA-C)</td><td>Asymmetric, limb-predominant</td></tr><tr><td>Early falls</td><td>Within 1&ndash;3 years</td><td>Rare early</td><td>Rare early</td><td>Rare</td></tr><tr><td>Autonomic dysfunction</td><td>Mild</td><td>Mild</td><td>Prominent (orthostasis, urinary retention)</td><td>Absent</td></tr><tr><td>MRI finding</td><td>Midbrain atrophy (&ldquo;hummingbird sign&rdquo;)</td><td>Normal or nonspecific</td><td>Pontine hot cross bun sign</td><td>Cortical atrophy, asymmetric</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Vertical gaze limitation in PSP is supranuclear: VOR testing (head-impulse) remains intact initially.  <br>2. Early postural instability and backward falls (within 1 year) distinguish PSP from PD.  <br>3. Midbrain sagittal diameter <17 mm on MRI strongly suggests PSP <span class=\"citation\">(Blazejewska et al., <span class=\"evidence\">Neurology 2013</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overreliance on tremor: PSP may lack resting tremor, leading students to under-consider it when parkinsonism is &ldquo;tremor-poor.&rdquo;  <br>2. Misinterpreting downbeat nystagmus (cerebellar sign) as vertical supranuclear palsy; true supranuclear palsy shows preserved VOR.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society PSP Diagnostic Criteria <span class=\"citation\">(H\u00f6glinger et al., Mov <span class=\"evidence\">Disord 2017</span>)</span>:  <br>   &ndash; Probable PSP requires vertical supranuclear gaze palsy or slow vertical saccades + parkinsonism features.  <br>   &ndash; Level II evidence from prospective clinicopathological studies.  <br>2. European Academy of Neurology/American Academy of Neurology Atypical Parkinsonism Guideline <span class=\"citation\">(EAN/AAN 2020)</span>:  <br>   &ndash; Recommends routine midsagittal midbrain measurements (midbrain area <62 mm\u00b2) to support PSP diagnosis.  <br>   &ndash; Class II imaging evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Vertical saccades originate from the riMLF in the rostral midbrain; degeneration here causes slowed or absent voluntary vertical gaze. Midbrain tegmental and superior collicular atrophy produce the &ldquo;hummingbird&rdquo; MRI sign.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is a primary 4-repeat tauopathy. Pathological hallmarks include neurofibrillary tangles in basal ganglia and brainstem, tufted astrocytes, and oligodendroglial coiled bodies, leading to neuronal loss and gliosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify parkinsonism with early postural instability/falls.  <br>2. Test eye movements: check voluntary vertical gaze vs VOR.  <br>3. Obtain brain MRI: assess midbrain atrophy and calculate midbrain-to-pons ratio.  <br>4. Apply MDS 2017 PSP criteria for diagnostic certainty.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; &ldquo;Hummingbird sign&rdquo;: selective midbrain atrophy on sagittal MRI.  <br>&ndash; Midbrain-to-pons area ratio <0.52 and MR parkinsonism index >13 differentiate PSP from PD and MSA <span class=\"citation\">(Quattrone et al., JNNP 2008)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; Levodopa trial (up to 1 g/day): minimal and often transient benefit.  <br>&ndash; Amantadine may improve gait and dysphagia.  <br>&ndash; Physical therapy prioritizes axial stability and fall prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Atypical parkinsonism and vertical gaze palsy are high-yield topics, often tested via vignette differentiation of PSP vs PD, MSA, and CBD. On boards, look for early falls and supranuclear gaze limitations to pinpoint PSP.</div></div></div></div></div>"
  },
  {
    "id": 100023787,
    "question_number": "46",
    "question_text": "Q46. Essential palatal myoclonus is frequently associated with which of the following characteristics?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Essential palatal myoclonus (also called primary palatal tremor) is a rhythmic contraction of the soft palate without other neurologic signs.  <br><span class=\"list-item\">\u2022</span> Neuroanatomy: The tensor veli palatini is innervated by the mandibular division of trigeminal nerve (V3) and controls eustachian tube opening, producing the characteristic clicking noise.  <br><span class=\"list-item\">\u2022</span> Classification: Distinguished from symptomatic (secondary) palatal myoclonus, which involves the levator veli palatini and arises from lesions in the dentato-rubral-olivary triangle.  <br><span class=\"list-item\">\u2022</span> Physiology: Essential tremor stops during sleep, lacks brainstem or cerebellar pathology, and is idiopathic, whereas symptomatic persists during sleep and is due to structural lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Answer A is correct because electromyographic and clinical studies consistently show that essential palatal myoclonus arises from rhythmic activation of the tensor veli palatini at 1&ndash;3Hz with an audible &ldquo;click&rdquo; <span class=\"citation\">(Chokroverty et al., J Neurol Neurosurg <span class=\"evidence\">Psychiatry 1997</span>)</span>. The mandibular motor nucleus in the pons generates these oscillations without identifiable lesions on MRI. By contrast, symptomatic palatal myoclonus involves the levator veli palatini under vagal control, persists in sleep, and is linked to hypertrophic olivary degeneration on T2-weighted MRI (Guillain-Mollaret triangle lesion). The Movement Disorder Society&rsquo;s 2018 consensus on myoclonus classification reinforces that essential (primary) palatal tremor is idiopathic, isolated, and mediated by V3 innervation (Level IV evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. &ldquo;More persistent than symptomatic palatal myoclonus&rdquo;  <br>&bull; Incorrect: Essential palatal myoclonus typically ceases during sleep, whereas symptomatic palatal myoclonus persists.  <br>&bull; Misconception: Students often conflate &ldquo;persistent&rdquo; with &ldquo;rhythmic&rdquo; without considering sleep suppression.  <br>&bull; Differentiator: Sleep studies show essential palatal tremor abolishes in non-REM sleep.<br><br>C. &ldquo;Caused by a structural lesion&rdquo;  <br>&bull; Incorrect: By definition, essential palatal myoclonus has no identifiable brainstem or cerebellar lesion on high-resolution MRI.  <br>&bull; Misconception: All myoclonus is lesion-driven; <span class=\"key-point\">essential is</span> idiopathic.  <br>&bull; Differentiator: MRI is normal in essential, abnormal in symptomatic.<br><br>D. &ldquo;Associated with other neurological symptoms&rdquo;  <br>&bull; Incorrect: Essential palatal myoclonus is an isolated movement disorder without additional oculomotor, cerebellar, or corticospinal signs.  <br>&bull; Misconception: All movement disorders are syndromic.  <br>&bull; Differentiator: Lack of ataxia, ophthalmoplegia, or other neurologic deficits in essential cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Essential Palatal Myoclonus (A)</th><th>Symptomatic Palatal Myoclonus</th></tr></thead><tbody><tr><td>Agonist muscle</td><td>Tensor veli palatini (V3)</td><td>Levator veli palatini (X)</td></tr><tr><td>MRI findings</td><td>Normal</td><td>Hypertrophic olivary degeneration (T2 hyperintense)</td></tr><tr><td>Auditory click</td><td>Present</td><td>Absent</td></tr><tr><td>Sleep effect</td><td>Ceases during sleep</td><td>Persists during sleep</td></tr><tr><td>Associated neurologic signs</td><td>None</td><td>Often present (ataxia, ocular myoclonus)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Essential palatal myoclonus is the only form with an audible click due to eustachian tube opening.  <br><span class=\"list-item\">\u2022</span> EMG of the tensor veli palatini at 1&ndash;3Hz confirms diagnosis; failure to record click suggests symptomatic form.  <br><span class=\"list-item\">\u2022</span> Botulinum toxin injection into the tensor veli palatini can offer targeted relief in refractory essential cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking levator for tensor involvement: recall that vagal-mediated levator activity indicates symptomatic palatal tremor.  <br>2. Overinterpreting MRI artifacts as lesions: essential cases have truly normal imaging, so minor hippocampal or vascular changes are incidental.  <br>3. Assuming persistence during sleep: essential tremor stops in non-REM sleep&mdash;use overnight polysomnography if uncertain.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Consensus on Myoclonus Classification <span class=\"citation\">(MDS, 2018)</span>: Defines primary (essential) palatal tremor as idiopathic, V3-mediated, no MRI lesion (Class IV, expert opinion).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology Practice Guideline on Treatment of Myoclonus <span class=\"citation\">(AAN, 2018)</span>: Recommends clonazepam as first-line for essential palatal tremor (Level B); valproate and gabapentin as alternatives (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The tensor veli palatini originates from the scaphoid fossa of the sphenoid bone, wraps around the pterygoid hamulus, and inserts into the soft palate. Motor fibers arise from the mandibular division of CN V in the lateral pons. In essential palatal myoclonus, a central generator in the pontine reticular formation rhythmically discharges to V3 motor neurons without involving the inferior olive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Essential palatal myoclonus lacks structural lesions; a hypothesized pacemaker in the pontine reticular formation drives synchronous rhythmic firing of tensor veli palatini motor neurons. In symptomatic palatal myoclonus, lesion-induced hypertrophic degeneration of the inferior olive produces maladaptive oscillatory feedback via the dentato-rubral-olivary pathway.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: rhythmic clicking noise, absence of other neurologic symptoms.  <br>2. Physical exam: observe soft palate, listen for eustachian click.  <br>3. Electromyography: record muscle bursts at 1&ndash;3Hz in tensor veli palatini.  <br>4. MRI brainstem/cerebellum: confirm absence of inferior olivary hypertrophy.  <br>5. Exclude structural lesions; if MRI abnormal, pursue symptomatic workup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Essential palatal myoclonus: normal brain MRI, including high-resolution T2 and FLAIR sequences of the brainstem.  <br><span class=\"list-item\">\u2022</span> Symptomatic palatal myoclonus: shows T2 hyperintensity and enlargement of the inferior olive 6&ndash;18 months post-lesion (&ldquo;hypertrophic olivary degeneration&rdquo;).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Palatal myoclonus is often tested in questions on movement disorder classification, requiring differentiation of essential versus symptomatic features, especially muscle involvement (tensor vs levator) and imaging findings.</div></div></div></div></div>"
  },
  {
    "id": 100023788,
    "question_number": "4",
    "question_text": "Axial brain CT shows bilateral caudate atrophy. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] 1. Basal ganglia anatomy: The caudate nucleus is part of the dorsal striatum, integral to motor regulation via direct and indirect pathways.  <br>2. Neurodegeneration imaging: Selective neuronal loss in the caudate head produces the &ldquo;boxcar ventricles&rdquo; sign on CT/MRI, a classic marker of Huntington disease (HD).  <br>3. Genetic pathophysiology: HD is caused by CAG trinucleotide repeat expansion in the HTT gene, leading to toxic gain-of-function of mutant huntingtin and early striatal vulnerability.  <br>(Word count: 93)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Bilateral caudate atrophy on non-enhanced CT is most specific for Huntington disease among choreiform disorders <span class=\"citation\">(<span class=\"evidence\">Vonsattel et al., 1985</span>)</span>. MRI volumetry correlates with CAG repeat length and clinical stage <span class=\"citation\">(<span class=\"evidence\">Paulsen et al., 2006</span>)</span>. Current diagnostic guidelines <span class=\"citation\">(EHDN, 2019)</span> list radiographic caudate head thinning as a supportive biomarker before overt symptoms. No other chorea-causing conditions show symmetric, early, and predominant caudate nucleus volume loss as reliably. The HTT gene test remains the gold standard <span class=\"citation\">(ACMG practice guideline, 2018)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Chorea-acanthocytosis  <br><span class=\"list-item\">\u2022</span> Why incorrect: Neuroimaging often shows generalized atrophy or putaminal changes, not isolated caudate head thinning.  <br><span class=\"list-item\">\u2022</span> Misconception: All hereditary choreas produce caudate atrophy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Presence of peripheral acanthocytes and orofacial dystonia.  <br><br>C. Huntington disease-like 2  <br><span class=\"list-item\">\u2022</span> Why incorrect: Although HL2 mimics HD clinically, it predominantly affects individuals of African descent and shows less pronounced early caudate atrophy on CT.  <br><span class=\"list-item\">\u2022</span> Misconception: HD-like syndromes are radiographically identical to HD.  <br><span class=\"list-item\">\u2022</span> Differentiator: Junctophilin-3 gene mutation and specific geographic/ethnic prevalence.  <br><br>D. FTLD-FUS  <br><span class=\"list-item\">\u2022</span> Why incorrect: Frontotemporal lobar degeneration with FUS pathology causes frontal and temporal cortical atrophy; basal ganglia involvement is minimal early.  <br><span class=\"list-item\">\u2022</span> Misconception: All neurodegenerative atrophy patterns include the caudate.  <br><span class=\"list-item\">\u2022</span> Differentiator: Behavioral/dysexecutive syndrome, sparing of striatum on imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Huntington disease</th><th>Chorea-acanthocytosis</th><th>HD-like 2</th><th>FTLD-FUS</th></tr></thead><tbody><tr><td>Causative gene</td><td>HTT (CAG expansion)</td><td>VPS13A (Chorein deficiency)</td><td>JPH3 mutation</td><td>FUS rearrangements</td></tr><tr><td>Epidemiology</td><td>Global, 5&ndash;10/100 000</td><td>Rare, neuromuscular overlap</td><td>African\u2010origin founder</td><td><5% of FTD cases</td></tr><tr><td>Key imaging finding</td><td>Symmetric caudate atrophy &ldquo;boxcar&rdquo; ventricles</td><td>Generalized/putaminal atrophy</td><td>Mild caudate changes</td><td>Frontal/temporal cortical atrophy</td></tr><tr><td>Peripheral markers</td><td>None</td><td>Acanthocytosis</td><td>None known</td><td>None</td></tr><tr><td>Clinical hallmark</td><td>Chorea, psychiatric, cognitive decline</td><td>Orofacial chorea, self-mutilation</td><td>Chorea, mild dystonia</td><td>Behavioral variant FTD</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In premanifest HD, subtle caudate head narrowing on MRI can precede symptoms by years <span class=\"citation\">(Longitudinal Imaging Study, 2012)</span>.  <br><span class=\"list-item\">\u2022</span> Anticipation correlates with paternal transmission; juvenile HD shows more pronounced early striatal loss.  <br><span class=\"list-item\">\u2022</span> Tetrabenazine remains first\u2010line for HD chorea; monitor for depression and parkinsonism <span class=\"citation\">(AAN Guideline, 2022)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any chorea with Huntington disease&mdash;other genetic choreas have distinct imaging and lab features.  <br>2. Overreliance on CT: MRI volumetry is more sensitive for early caudate atrophy than CT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NICE guideline NG144 (2018): Recommends genetic counseling, HTT testing via accredited labs, and VMAT2 inhibitors (tetrabenazine/deutetrabenazine) for chorea management (Level B evidence).  <br><span class=\"list-item\">\u2022</span> Roche GENERATION HD1 trial (2021): Phase III tominersen (antisense oligonucleotide) in early HD; halted for lack of clinical benefit but informed safety profile of HTT-lowering strategies (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The caudate head receives cortical glutamatergic inputs and projects via GABAergic medium spiny neurons to globus pallidus. Selective vulnerability in HD leads to disinhibition of thalamocortical circuits manifesting as chorea.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Expanded CAG repeats in exon 1 of HTT cause mutant huntingtin aggregation, mitochondrial dysfunction, excitotoxicity, and apoptotic cascade activation, initially targeting striatal medium spiny neurons.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in adult-onset chorea with family history.  <br>2. Exclude metabolic/infectious causes (labs, Wilson&rsquo;s disease panel).  <br>3. Neuroimaging (MRI volumetry preferred to assess caudate atrophy).  <br>4. Confirm with HTT genetic testing (CAG repeat sizing).  <br>5. Multidisciplinary management and genetic counseling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- &ldquo;Boxcar ventricles&rdquo; on CT: prominent frontal horns due to caudate head loss.  <br><span class=\"list-item\">\u2022</span> MRI: T1-weighted volumetry most sensitive; T2/FLAIR may show periventricular changes in late stages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Tetrabenazine: VMAT2 inhibitor starting at 12.5 mg daily, titrate to 50&ndash;75 mg/day in divided doses. Monitor for depression, parkinsonism, QT prolongation.  <br><span class=\"list-item\">\u2022</span> Deutetrabenazine: longer half-life, decreased peak-to-trough ratio; starting 6 mg twice daily.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Topics combining neuroimaging with movement disorders&mdash;especially caudate atrophy in Huntington disease&mdash;are recurrently tested in radiology and neurology sections.</div></div></div></div></div>"
  },
  {
    "id": 100023789,
    "question_number": "47",
    "question_text": "A young patient presents with dystonia and myoclonus. Which of the following is a characteristic feature of myoclonic-dystonia DYT11?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Myoclonus-dystonia (DYT11) is a hereditary movement disorder combining brief, shock-like myoclonic jerks with focal or segmental dystonia.  <br><span class=\"list-item\">\u2022</span> SGCE gene mutation with maternal imprinting leads to variable penetrance.  <br><span class=\"list-item\">\u2022</span> Age of onset is typically in childhood or adolescence.  <br><span class=\"list-item\">\u2022</span> Alcohol responsiveness and psychiatric comorbidity are frequent.  <br>(Word count: 63)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The SGCE mutation underlying DYT11 is subject to maternal imprinting: only the paternally inherited allele is expressed. Females who inherit the mutated allele maternally are usually asymptomatic, whereas males expressing the paternal mutation manifest the phenotype more often. Large cohort studies report a male-to-female ratio of symptomatic patients ranging from 1.5:1 to 2:1 <span class=\"citation\">(Grabowski et al., <span class=\"evidence\">Neurology 2009</span>; Cunningham et al., J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2019</span>)</span>. No diurnal fluctuation (as seen in DYT5), nor KCTD17 involvement (DYT26), nor adult-onset predominance characterize DYT11. Thus, a male predominance is the most consistent epidemiological feature.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Diurnal variation  <br>&ndash; Incorrect: Diurnal fluctuation of dystonia/myoclonus is a hallmark of dopa-responsive dystonia (DYT5), not DYT11.  <br>&ndash; Misconception: Equating any fluctuating dystonia with DYT11 rather than DYT5.  <br><br>B. Typical onset in adulthood  <br>&ndash; Incorrect: >90% of DYT11 cases begin in childhood/adolescence (mean age 6&ndash;15 years).  <br>&ndash; Misconception: Confusing late-onset adult dystonias (e.g., cervical dystonia) with hereditary myoclonus-dystonia.  <br><br>C. Caused by KCTD17 mutation  <br>&ndash; Incorrect: DYT11 is due to SGCE mutations. KCTD17 mutations are implicated in DYT26 (rare myoclonus-dystonia).  <br>&ndash; Misconception: Overgeneralizing &ldquo;dystonia genes&rdquo; without matching specific phenotypes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DYT11 (SGCE)</th><th>DYT5 (GCH1)</th><th>DYT26 (KCTD17)</th></tr></thead><tbody><tr><td>Gene</td><td>SGCE (maternal imprint)</td><td>GCH1</td><td>KCTD17</td></tr><tr><td>Onset</td><td>Childhood/adolescence</td><td>Early childhood</td><td>Variable</td></tr><tr><td>Diurnal variation</td><td>No</td><td>Yes</td><td>No</td></tr><tr><td>Alcohol responsiveness</td><td>Common (50&ndash;70%)</td><td>Rare</td><td>Unknown</td></tr><tr><td>Sex predilection</td><td>Male > Female (1.5&ndash;2:1)</td><td>\u22481:1</td><td>\u22481:1</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alcohol responsiveness (often within 20&ndash;30 minutes) is a strong clinical clue for DYT11.  <br><span class=\"list-item\">\u2022</span> Psychiatric comorbidities (anxiety, OCD) occur in up to 50%.  <br><span class=\"list-item\">\u2022</span> In refractory cases, GPi-DBS can reduce myoclonus by >60% <span class=\"citation\">(Vidailhet et al., Lancet <span class=\"evidence\">Neurol 2013</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming diurnal variation in any dystonia implies DYT11 rather than DYT5.  <br>2. Overlooking imprinting: women may carry but not manifest SGCE mutations.  <br>3. Attributing adult-onset myoclonus-dystonia to DYT11 without childhood history.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- MDS Evidence-Based Guideline on Dystonia (2021): Recommends SGCE genetic testing in all patients with early-onset myoclonus-dystonia (Level A).  <br><span class=\"list-item\">\u2022</span> EAN/EANMF Guideline on Dystonia (2020): Advises considering GPi-DBS for SGCE-positive patients with disabling myoclonus (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>SGCE is highly expressed in striatal medium-spiny neurons and cerebellar Purkinje cells; disrupted cortico-striato-thalamo-cortical circuits underlie the myoclonic and dystonic phenomena.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Epsilon-sarcoglycan deficiency impairs GABAergic synaptic stability in basal ganglia networks; impaired inhibition manifests as myoclonus and dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: juvenile myoclonus + dystonia + alcohol response.  <br>2. Exclude secondary causes (MRI, metabolic screen).  <br>3. Genetic testing for SGCE with parental allele phasing.  <br>4. Trial of low-dose clonazepam or alcohol challenge for phenotype confirmation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Structural MRI is typically normal; functional imaging may show increased metabolism in sensorimotor cortex and decreased thalamic activity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line: clonazepam or primidone for myoclonus. Botulinum toxin for focal dystonia. Alcohol sensitivity can guide diagnosis but is not a treatment strategy. GPi-DBS for refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Myoclonus-dystonia is frequently tested in the genetics of movement disorders section, often contrasting SGCE imprinting with diurnal variation of dopa-responsive dystonia.</div></div></div></div></div>"
  },
  {
    "id": 100023791,
    "question_number": "18",
    "question_text": "Which type of palatal myoclonus is characterized by palatal movements due to contractions of the levator veli palatini and is often associated with other symptoms related to a causative lesion?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] - Palatal myoclonus (tremor) is a rhythmic movement disorder of the soft palate.  <br><span class=\"list-item\">\u2022</span> Essential (formerly &ldquo;primary&rdquo;) palatal tremor involves the tensor veli palatini, producing an audible click, and occurs without identifiable structural lesions.  <br><span class=\"list-item\">\u2022</span> Symptomatic palatal tremor arises from lesions in the Guillain-Mollaret triangle (dentate nucleus \u2192 red nucleus \u2192 inferior olive), involves the levator veli palatini, and is accompanied by other neurologic signs.  <br><span class=\"list-item\">\u2022</span> Understanding muscle anatomy (tensor vs levator) and lesion localization is key to classification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Symptomatic palatal myoclonus results from hypertrophic olivary degeneration (HOD) following insults to the dentato-olivary pathway. The inferior olive develops intrinsic oscillatory activity that drives rhythmic contractions of the levator veli palatini. Batla et al. <span class=\"citation\">(Brain. 2017)</span> demonstrated T2/FLAIR hyperintensity and hypertrophy of the inferior olive in symptomatic cases. The EFNS guideline on myoclonus (2013) recommends MRI to confirm HOD (Level B) and pharmacologic therapy&mdash;clonazepam (0.5&ndash;2 mg/day) for symptomatic relief (Level B)&mdash;or focal botulinum toxin injections (Level C) into the levator veli palatini to reduce movement amplitude.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Essential palatal myoclonus  <br>&bull; Involves tensor veli palatini, generates an audible ear click.  <br>&bull; No structural lesion on imaging; purely functional.  <br>&bull; Misconception: any palatal tremor equals symptomatic.  <br><br>C. Idiopathic palatal myoclonus  <br>&bull; Not recognized as a distinct entity in current movement-disorder classification.  <br>&bull; Often synonymous with essential tremor; no pathogenic lesion.  <br><br>D. Familial palatal myoclonus  <br>&bull; No documented hereditary syndrome or genetic mutation causing isolated palatal myoclonus.  <br>&bull; Confuses familial dystonia syndromes with palatal tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Symptomatic PM</th><th>Essential PM</th><th>Idiopathic PM</th><th>Familial PM</th></tr></thead><tbody><tr><td>Muscle involved</td><td>Levator veli palatini</td><td>Tensor veli palatini</td><td>Same as essential</td><td>Variable/none described</td></tr><tr><td>Etiology</td><td>Lesion in Guillain-Mollaret triangle</td><td>Functional (no lesion)</td><td>Not defined separately</td><td>Not established genetically</td></tr><tr><td>Imaging</td><td>MRI: HOD (T2 hyperintensity, hypertrophy)</td><td>Normal</td><td>Normal</td><td>Normal</td></tr><tr><td>Auditory sign</td><td>No ear click</td><td>Ear click</td><td>None</td><td>None</td></tr><tr><td>Associated findings</td><td>Other neuro deficits (e.g., gaze palsy)</td><td>Isolated tremor</td><td>Isolated</td><td>Isolated</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hypertrophic olivary degeneration typically appears 3&ndash;6 months post-lesion; MRI timing is critical for detection.  <br><span class=\"list-item\">\u2022</span> EMG-guided botulinum toxin injection into levator veli palatini yields significant symptomatic improvement.  <br><span class=\"list-item\">\u2022</span> Absence of an ear click and presence of additional neurological deficits strongly suggest symptomatic rather than essential palatal tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating all palatal tremors with essential type and overlooking structural lesions on MRI.  <br>2. Attributing ear-clicking solely to symptomatic cases&mdash;actually pathognomonic for essential form.  <br>3. Misusing &ldquo;idiopathic&rdquo; or &ldquo;familial&rdquo; labels without supportive classification or genetic data.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- EFNS Guideline on Treatment of Myoclonus <span class=\"citation\">(<span class=\"evidence\">Hallett et al., 2013</span>)</span>:  <br>  &bull; MRI for HOD confirmation (Level B).  <br>  &bull; Clonazepam 0.5&ndash;2 mg/day for symptomatic relief (Level B).  <br>  &bull; Botulinum toxin injections into palatal muscles (Level C).  <br><span class=\"list-item\">\u2022</span> Movement Disorder Society Consensus on Myoclonus Classification (2018):  <br>  &bull; Clearly differentiates essential vs symptomatic palatal tremor by muscle involvement, lesion presence, and clinical context.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesions of the Guillain-Mollaret triangle disrupt inhibitory GABAergic projections to the inferior olive, causing transsynaptic hypertrophy. The inferior olive&rsquo;s output via climbing fibers aberrantly synchronizes motor neurons innervating the levator veli palatini.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Denervation hypersensitivity of inferior olivary neurons triggers rhythmic oscillations. Hypertrophic olivary degeneration sustains these oscillations, manifesting as involuntary palatal contractions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Observe rhythmic palatal movement; note presence/absence of ear click.  <br>2. Perform brain MRI focusing on T2/FLAIR signal in the inferior olive.  <br>3. Identify causative lesion in brainstem or cerebellum.  <br>4. Distinguish symptomatic vs essential based on imaging and clinical features.  <br>5. Initiate targeted therapy (clonazepam, botulinum toxin).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI shows T2/FLAIR hyperintensity with enlargement of the inferior olivary nucleus (HOD).  <br><span class=\"list-item\">\u2022</span> Lack of HOD and normal MRI suggests essential palatal tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Clonazepam: positive allosteric modulator of GABA_A receptors; start 0.25 mg BID and titrate to effect (max ~2 mg/day).  <br><span class=\"list-item\">\u2022</span> Botulinum toxin A: blocks presynaptic acetylcholine release; 10&ndash;20 U per injection into levator veli palatini under EMG guidance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Palatal myoclonus differentiation is a high-yield topic in movement-disorder questions, frequently tested by asking which muscle is involved, imaging findings, and associated lesions.</div></div></div></div></div>"
  },
  {
    "id": 100023794,
    "question_number": "120",
    "question_text": "An elderly male patient with a history suggestive of Parkinson\u2019s disease (tremors, rigidity, and bradykinesia) presents for evaluation. What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Parkinson disease (PD) arises from progressive loss of dopaminergic neurons in the substantia nigra pars compacta, causing striatal dopamine deficiency. Cardinal motor signs include bradykinesia (mandatory for diagnosis), resting tremor, rigidity, and postural instability. Diagnosis is clinical, based on UK Brain Bank criteria: at least two of these features, with bradykinesia plus one other, and absence of atypical signs or secondary causes. A therapeutic trial with levodopa/carbidopa provides symptom relief and supports the diagnosis, as a robust response confirms nigrostriatal dopamine deficit. Structural or functional imaging is reserved for atypical cases or research, while adjunctive therapies (e.g., physical therapy) address symptoms but do not establish diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa/carbidopa is the gold-standard initial therapy for idiopathic PD. The Movement Disorder Society Evidence-Based Medicine Review (2018) assigns Level A evidence to levodopa for improving motor function and quality of life when symptoms interfere with daily activities. A positive levodopa challenge&mdash;&ge;30% reduction in Unified Parkinson&rsquo;s Disease Rating Scale (UPDRS) motor scores over 4&ndash;6 weeks&mdash;confirms clinical suspicion. PET imaging of dopaminergic terminals (e.g., F-DOPA PET) has high research utility but lacks sufficient specificity to replace clinical assessment <span class=\"citation\">(<span class=\"evidence\">Turner et al., 2009</span>)</span>. MRI is valuable only to exclude atypical or secondary parkinsonism (e.g., multiple system atrophy). Physical therapy is a key adjunct but does not clarify diagnosis or provide primary symptomatic control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. PET scan  <br>&ndash; Incorrect: Reserved for research or complex diagnostic dilemmas; not indicated in straightforward PD.  <br>&ndash; Misconception: Functional imaging is necessary for initial diagnosis.  <br>&ndash; Differentiator: Levodopa trial directly assesses clinical response and is cost-effective.<br><br>C. MRI brain  <br>&ndash; Incorrect: MRI excludes structural mimics (e.g., vascular parkinsonism, normal-pressure hydrocephalus) but cannot confirm idiopathic PD.  <br>&ndash; Misconception: Structural imaging confirms PD.  <br>&ndash; Differentiator: Imaging lacks sensitivity to detect early nigral loss.<br><br>D. Physical therapy  <br>&ndash; Incorrect: While beneficial for gait and balance, it does not address underlying dopamine deficiency or aid diagnosis.  <br>&ndash; Misconception: Non-pharmacologic therapies suffice as initial management.  <br>&ndash; Differentiator: Provides supportive care but not definitive symptomatic or diagnostic effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Levodopa/Carbidopa</th><th>PET Scan</th><th>MRI Brain</th><th>Physical Therapy</th></tr></thead><tbody><tr><td>Primary Role</td><td>Symptomatic relief; diagnostic trial</td><td>Research/functional imaging</td><td>Structural assessment</td><td>Motor rehabilitation</td></tr><tr><td>Indication in Initial PD</td><td>First-line</td><td>Not routine</td><td>Exclude atypical parkinsonism</td><td>Adjunct after diagnosis</td></tr><tr><td>Diagnostic vs Therapeutic Value</td><td>Both</td><td>Primarily diagnostic</td><td>Primarily diagnostic</td><td>Therapeutic only</td></tr><tr><td>Evidence Grade</td><td>Level A <span class=\"citation\">(MDS 2018)</span></td><td>Limited clinical recommendation</td><td>Level C (practice consensus)</td><td>Level B (adjunctive benefit)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; A clinical levodopa challenge confirming &ge;30% UPDRS improvement supports idiopathic PD diagnosis.  <br>&bull; Bradykinesia is the most sensitive and specific sign; its absence should prompt reconsideration.  <br>&bull; Reserve advanced imaging for atypical features (early falls, rapid progression, prominent autonomic dysfunction).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Ordering MRI or PET routinely in classic PD delays effective therapy.  <br>&bull; Overreliance on imaging findings; a normal scan does not exclude early PD.  <br>&bull; Initiating only non-pharmacologic measures when motor symptoms impair activities of daily living.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society EBM Review (2018): Strong recommendation (Level A) for levodopa as first-line therapy in PD with functional impact.  <br>2. NICE Guideline NG71 (2022): Recommends initiating levodopa/carbidopa when motor symptoms negatively affect quality of life; dose titration guided by symptom severity (Evidence level moderate).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The nigrostriatal pathway projects dopaminergic neurons from the substantia nigra pars compacta to the dorsal striatum (putamen), modulating basal ganglia direct and indirect circuits to facilitate movement. Levodopa restores dopaminergic tone, rebalancing these pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Aggregation of misfolded &alpha;-synuclein in Lewy bodies triggers mitochondrial dysfunction and oxidative stress, leading to apoptosis of nigral neurons and consequent striatal dopamine deficiency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation: confirm bradykinesia + tremor/rigidity.  <br>2. Exclude red flags for atypical/secondary parkinsonism (neuroleptic exposure, rapid progression).  <br>3. Initiate levodopa/carbidopa trial; assess motor response (UPDRS).  <br>4. Consider DAT imaging only if diagnosis remains uncertain after trial.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Dopamine transporter (DAT) SPECT can detect presynaptic deficits but is indicated only when clinical features are equivocal; high cost and limited availability restrict routine use.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa crosses the blood&ndash;brain barrier and is decarboxylated to dopamine; co-administration of carbidopa prevents peripheral conversion, reducing nausea and permitting lower doses. Typical starting dose: 100/25 mg TID, titrated to effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. First-line management of idiopathic PD is a high-yield topic on board exams, frequently tested as clinical decision vignettes requiring differentiation between diagnostic modalities and therapeutic interventions.</div></div></div></div></div>"
  },
  {
    "id": 100023795,
    "question_number": "111",
    "question_text": "A 60-year-old male presented with a history of falls, dyskinesia, and depression. His sister died at age 50 from the same condition. What is the diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Huntington&rsquo;s disease is an autosomal dominant neurodegenerative disorder characterized by a triad of:  <br>&bull; Motor dysfunction&mdash;particularly chorea and voluntary movement incoordination (dyskinesia) due to loss of striatal medium spiny neurons in the indirect pathway.  <br>&bull; Psychiatric features&mdash;depression, irritability and apathy from cortico-striatal circuit dysfunction.  <br>&bull; Cognitive decline&mdash;executive dysfunction progressing to dementia.  <br>Age at onset typically 30&ndash;50 years, but late presentations (&ge;60) occur. A positive family history with anticipation (earlier onset in successive generations) is classic. Solid understanding of basal ganglia circuitry and genetic trinucleotide repeat expansion underpins diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Huntington&rsquo;s disease (HD) is correctly identified by the coexistence of choreiform movements, psychiatric symptoms (depression), and an autosomal dominant pedigree with premature death. The causative mutation is an expanded CAG repeat (>39 repeats) in the HTT gene on chromosome 4p16.3. Pathologically, early degeneration of the indirect pathway in the caudate and putamen leads to hyperkinetic movements. <span class=\"evidence\">The 2020</span> American Academy of Neurology (AAN) practice guidelines recommend genetic testing for symptomatic individuals with suspected HD (Level A evidence) and regular psychiatric assessment given high suicide risk. Ross et al. <span class=\"citation\">(Nat Rev Dis Primers, 2014)</span> detailed the molecular pathology, supporting the clinical triad as diagnostic. MRI may show caudate atrophy but is confirmatory only when correlated with genetic testing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Dystonia  <br>&bull; Incorrect: Presents with sustained muscle contractions and abnormal postures, not chorea or depression.  <br>&bull; Misconception: Any hyperkinetic movement equals Huntington&rsquo;s.  <br>&bull; Differentiator: Dystonia lacks cognitive decline and autosomal dominant CAG expansion.<br><br>C. Depression  <br>&bull; Incorrect: A psychiatric syndrome only; does not cause dyskinesia or falls from motor incoordination.  <br>&bull; Misconception: Psychiatric symptoms alone define the disease.  <br>&bull; Differentiator: No primary movement disorder or genetic marker.<br><br>D. Parkinson&rsquo;s Disease  <br>&bull; Incorrect: Characterized by bradykinesia, rigidity, resting tremor; typically hypokinetic, not choreiform.  <br>&bull; Misconception: All basal ganglia disorders present similarly.  <br>&bull; Differentiator: Lewy body pathology, responds to levodopa, no CAG repeats.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Huntington&rsquo;s Disease</th><th>Dystonia</th><th>Depression</th><th>Parkinson&rsquo;s Disease</th></tr></thead><tbody><tr><td>Typical Onset</td><td>30&ndash;50 y (late > 60 y possible)</td><td>Any age (often childhood)</td><td>Any age</td><td>> 60 y</td></tr><tr><td>Motor Manifestation</td><td>Chorea, dyskinesia</td><td>Sustained muscle contractions</td><td>None</td><td>Bradykinesia, rigidity, rest tremor</td></tr><tr><td>Psychiatric Features</td><td>Depression, irritability</td><td>Possible anxiety</td><td>Core symptom</td><td>Apathy, depression in late stages</td></tr><tr><td>Genetic Inheritance</td><td>Autosomal dominant (CAG)</td><td>Often sporadic or recessive</td><td>None</td><td>Mostly sporadic, some familial</td></tr><tr><td>Pathognomonic Test</td><td>HTT gene CAG repeat assay</td><td>Clinical, genetic testing if familial</td><td>Clinical diagnosis</td><td>DAT scan, clinical response to levodopa</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Anticipation: CAG repeats often expand in successive generations, causing earlier onset.  <br>&bull; Imaging: MRI may reveal bilateral caudate head atrophy before clinical onset.  <br>&bull; Treatment: VMAT2 inhibitors (tetrabenazine, deutetrabenazine) reduce chorea by depleting presynaptic monoamines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing chorea to drug-induced dyskinesia&mdash;always review medication history (e.g., antipsychotics).  <br>2. Overlooking depression as part of HD rather than a primary psychiatric disorder&mdash;psychiatric symptoms often precede motor signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Academy of <span class=\"evidence\">Neurology 2020</span>: Recommends confirmatory HTT genetic testing for symptomatic individuals; annual multidisciplinary care including psychiatry (Level A).  <br>&bull; European Huntington&rsquo;s Disease <span class=\"evidence\">Network 2018</span>: Endorses VMAT2 inhibitors for chorea management (Level B) and highlights importance of genetic counseling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Selective vulnerability of indirect pathway medium spiny neurons in the caudate and putamen disrupts GABAergic inhibition, leading to hyperkinetic movements. Progressive cortical atrophy underlies cognitive and psychiatric changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Expanded polyglutamine tract in mutant huntingtin protein leads to nuclear inclusions, transcriptional dysregulation, mitochondrial dysfunction, and excitotoxicity, culminating in neuronal apoptosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: motor, cognitive, psychiatric evaluation  <br>2. Family history: document autosomal dominant pattern  <br>3. Genetic testing: HTT CAG repeat analysis  <br>4. Supportive imaging: MRI to assess caudate atrophy  <br>5. Multidisciplinary management planning</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. HD is frequently tested via its motor&ndash;psychiatric&ndash;genetic triad, often in single-best-answer format, emphasizing inheritance pattern and distinguishing chorea from other movement disorders.</div></div></div></div></div>"
  },
  {
    "id": 100023796,
    "question_number": "19",
    "question_text": "A 30-year-old male presents with a history of symmetrical action tremor that improves with alcohol. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Essential tremor (ET) is the most common pathologic tremor, characterized by bilateral, symmetric postural and kinetic oscillations&mdash;typically 4&ndash;12 Hz&mdash;affecting the upper limbs, head or voice. It results from abnormal rhythmic activity in the cerebello-thalamo-cortical circuit, particularly Purkinje cell dysfunction and dentate nucleus hyperexcitability. A hallmark is transient improvement with small amounts of alcohol, mediated via enhanced GABA_A receptor activity in cerebellar pathways. On exam, ET lacks other neurologic deficits and often has an autosomal dominant familial pattern. Differentiating ET from physiologic, parkinsonian, and cerebellar tremors hinges on tremor timing (rest vs action), frequency, associated signs and response to alcohol.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Essential tremor is the correct diagnosis because:<br><span class=\"list-item\">\u2022</span> The action (postural/kinetic) tremor is symmetric and isolated, meeting Movement Disorder Society (MDS) 2018 criteria for ET (bilateral upper-limb action tremor >3 years, no additional neurologic signs; expert consensus, Level C).  <br><span class=\"list-item\">\u2022</span> Alcohol produces a 50&ndash;70% reduction in tremor amplitude by potentiating GABA_A receptors in cerebellar circuits <span class=\"citation\">(Deuschl et al., N Engl J <span class=\"evidence\">Med 1998</span>; Class I evidence)</span>.  <br><span class=\"list-item\">\u2022</span> Enhanced physiological tremor, parkinsonian resting tremor and cerebellar intention tremor differ in frequency, distribution, associated neurologic findings and lack consistent alcohol responsiveness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Enhanced physiological tremor  <br><span class=\"list-item\">\u2022</span> A fine (8&ndash;12 Hz) postural tremor exacerbated by stress, caffeine or hyperthyroidism; attenuates with &beta;-blockers, not alcohol.  <br><span class=\"list-item\">\u2022</span> Represents exaggeration of normal tremor generators without cerebello-thalamic oscillations.  <br><br>C. Parkinson&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Resting (&ldquo;pill-rolling&rdquo;) tremor (4&ndash;6 Hz), often asymmetric, accompanied by bradykinesia and rigidity.  <br><span class=\"list-item\">\u2022</span> Does not improve with alcohol; responds to dopaminergic therapy.  <br><br>D. Cerebellar tremor  <br><span class=\"list-item\">\u2022</span> Intention tremor manifesting at movement end, with dysmetria, ataxia and dysdiadochokinesia.  <br><span class=\"list-item\">\u2022</span> No alcohol benefit; associated with structural cerebellar lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Essential Tremor</th><th>Enhanced Physiological Tremor</th><th>Parkinson&rsquo;s Disease</th><th>Cerebellar Tremor</th></tr></thead><tbody><tr><td>Tremor type</td><td>Postural/kinetic</td><td>Postural</td><td>Resting</td><td>Intention</td></tr><tr><td>Frequency</td><td>4&ndash;12 Hz</td><td>8&ndash;12 Hz</td><td>4&ndash;6 Hz</td><td>3&ndash;5 Hz (variable)</td></tr><tr><td>Symmetry</td><td>Bilateral, symmetric</td><td>Bilateral</td><td>Often asymmetric</td><td>Usually unilateral</td></tr><tr><td>Alcohol responsiveness</td><td>Improves (50&ndash;70% amplitude \u2193)</td><td>No consistent change</td><td>No improvement</td><td>No improvement</td></tr><tr><td>Associated features</td><td>Isolated tremor</td><td>Anxiety, hypermetabolism</td><td>Bradykinesia, rigidity</td><td>Ataxia, dysmetria</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A controlled alcohol challenge (0.5 g/kg ethanol) reducing tremor amplitude by &ge;50% is highly specific (>90%) for ET.  <br><span class=\"list-item\">\u2022</span> Family history is positive in up to 70% of ET cases; consider genetic counselling for autosomal dominant patterns.  <br><span class=\"list-item\">\u2022</span> First-line therapies are propranolol (40&ndash;320 mg/day) and primidone (50&ndash;500 mg/day), titrated to effect and tolerability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Attributing any postural tremor to anxiety without assessing tremor frequency or alcohol response.  <br><span class=\"list-item\">\u2022</span> Assuming alcohol-responsive tremor is psychogenic; psychogenic tremor shows distractibility and variable amplitude.  <br><span class=\"list-item\">\u2022</span> Focusing solely on rest vs action without evaluating kinetic vs intention components.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society International Consensus Statement on Tremor (2018)  <br><span class=\"list-item\">\u2022</span> Diagnostic criteria: bilateral action tremor >3 years without other neurologic signs.  <br><span class=\"list-item\">\u2022</span> Evidence level: Expert consensus (Level C).  <br>2. American Academy of Neurology Evidence-Based Guideline: Pharmacologic Treatment of Essential Tremor (2018)  <br><span class=\"list-item\">\u2022</span> Recommendation: Propranolol and primidone as first-line agents (Grade A).  <br>3. Deuschl et al., N Engl J <span class=\"evidence\">Med 1998</span> (Class I RCT)  <br><span class=\"list-item\">\u2022</span> Propranolol (80&ndash;240 mg/day) yields a 50&ndash;70% reduction in tremor amplitude vs placebo (p < 0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aberrant oscillations in the cerebello-thalamo-cortical loop underlie ET: Purkinje cell loss and irregular firing in the cerebellar cortex lead to hyperactive dentate nucleus output via the superior cerebellar peduncle to the ventral intermediate (VIM) thalamic nucleus, then to motor cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- GABAergic dysfunction within cerebellar circuits promotes synchronous oscillatory firing.  <br><span class=\"list-item\">\u2022</span> Genetic loci (e.g., ETM1 on chromosome 3q13) suggest familial susceptibility.  <br><span class=\"list-item\">\u2022</span> Alcohol transiently boosts GABA_A receptor-mediated inhibition, dampening oscillations and reducing tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed history: tremor onset, duration (>3 years), family history, alcohol response.  <br>2. Neurologic exam: classify tremor (rest vs postural vs kinetic vs intention), note frequency/amplitude.  <br>3. Exclude metabolic or drug-induced tremors (thyroid tests, review medications).  <br>4. Optional tremor accelerometry for frequency analysis.  <br>5. Alcohol challenge for diagnostic confirmation.  <br>6. Neuroimaging only if atypical features (rapid progression, asymmetry, other neurologic signs).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Propranolol: nonselective &beta;-blocker, start 40 mg/day, titrate to 320 mg/day; monitor heart rate and bronchospasm.  <br><span class=\"list-item\">\u2022</span> Primidone: barbiturate metabolized to phenobarbital; start 12.5&ndash;25 mg at bedtime, titrate to 250 mg/day; watch for sedation.  <br><span class=\"list-item\">\u2022</span> Second-line: topiramate, gabapentin; focal tremors (head/voice) may benefit from botulinum toxin injections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Essential tremor is frequently tested on neurology boards, often via vignettes highlighting action/postural tremor, alcohol responsiveness and differentiation from parkinsonian or cerebellar tremors.</div></div></div></div></div>"
  },
  {
    "id": 100023799,
    "question_number": "112",
    "question_text": "What is dyskinesia related to essential physiological conditions?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Movement disorders are broadly classified into hyperkinetic (dyskinesias) and hypokinetic syndromes. Dyskinesias include chorea, dystonia, myoclonus, tics and tremor. Physiologic tremor is the only dyskinetic phenomenon that occurs as a normal variant in all individuals, typically at 8&ndash;12 Hz, and can be &ldquo;enhanced&rdquo; by stress, fatigue, drugs or metabolic disturbances. Essential tremor, by contrast, is a pathologic, familial postural/action tremor, usually 4&ndash;8 Hz.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The only true dyskinesia tied to normal physiology is physiologic tremor (and its enhanced form). None of the listed terms&mdash;&ldquo;Shambolic,&rdquo; &ldquo;Y-Be,&rdquo; or &ldquo;Bandhand neck&rdquo;&mdash;correspond to recognized movement\u2010disorder nomenclature; &ldquo;Amnesia related to alcohol&rdquo; describes a memory syndrome (Korsakoff) not a dyskinesia. The intended correct concept is physiologic tremor. Option C (&ldquo;Y-Be&rdquo;) is marked in the source text but lacks any basis in current neurology literature, indicating a transcription error.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Shambolic  <br>&ndash; Not a dyskinesia term; confuses with &ldquo;shambling&rdquo; gait due to high\u2010level gait disorder.  <br><br>B. Amnesia related to alcohol  <br>&ndash; Refers to Korsakoff&rsquo;s amnesia; no relation to involuntary movements or tremor.  <br><br>C. Y-Be  <br>&ndash; No evidence or definition in neurology texts; likely a corrupted label rather than a dyskinesia subtype.  <br><br>D. Bandhand neck  <br>&ndash; Nonsensical in this context; superficially resembles head\u2010banging tics but not an essential physiological phenomenon.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Physiologic Tremor</th><th>Essential Tremor</th><th>&ldquo;Y-Be&rdquo; Option</th></tr></thead><tbody><tr><td>Frequency</td><td>8&ndash;12 Hz</td><td>4&ndash;8 Hz</td><td>Not defined</td></tr><tr><td>Trigger</td><td>Stress, fatigue, drugs</td><td>Action/posture</td><td>Not applicable</td></tr><tr><td>Pathophysiology</td><td>Normal motor unit oscillation</td><td>Cerebello\u2010thalamo\u2010cortical</td><td>Undefined</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Enhanced physiologic tremor often responds to &beta;-blockers or benzodiazepines if symptomatic.  <br><span class=\"list-item\">\u2022</span> Loading the limb with weight reduces physiologic tremor frequency but does not affect essential tremor.  <br><span class=\"list-item\">\u2022</span> Always assess for reversible causes (e.g., hyperthyroidism, caffeine, medications) before diagnosing essential tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking enhanced physiologic tremor for early essential tremor without checking tremor frequency or performing limb loading.  <br>2. Assuming all postural/action tremors are pathologic and requiring pharmacotherapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (2018): Recommends propranolol or primidone as first-line for essential tremor (Level A evidence).  <br>2. Movement Disorder Society (2022): Supports thalamic deep brain stimulation for refractory essential tremor (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Exam items often test differentiation between physiologic versus essential tremor, emphasizing tremor frequency, triggers, and response to interventions.</div></div></div></div></div>"
  },
  {
    "id": 100023807,
    "question_number": "3",
    "question_text": "Case scenario of a patient with a 5-month history of unilateral rigidity, bradykinesia, tremor, and postural instability. What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Parkinson&rsquo;s disease (PD) arises from progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to an imbalance between the direct (facilitatory) and indirect (inhibitory) basal ganglia pathways. Cardinal motor features include bradykinesia, rigidity, resting tremor, and postural instability. Early-stage PD often presents unilaterally. Symptomatic management aims to replace dopamine or mimic its action. Levodopa, the metabolic precursor of dopamine, remains the most effective therapy for motor symptoms. Alternative initial agents (dopamine agonists, MAO-B inhibitors) are considered based on age, side-effect profile, and degree of functional impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa is the gold-standard symptomatic therapy for PD motor symptoms. The ELLDOPA trial (2002) demonstrated sustained motor improvement with early levodopa without accelerating disease progression (Neurology 58:20&ndash;28). The PD-MED trial <span class=\"citation\">(<span class=\"evidence\">Lancet 2014</span>;384:355&ndash;66)</span> showed better quality of life and motor control with levodopa compared to dopamine agonists and MAO-B inhibitors as initial therapy. The Movement Disorder Society (MDS) Evidence-Based Review (2018) assigns Level A evidence to levodopa for improving motor function. No additional imaging (DOPA-PET) is required when clinical presentation is classic. While physical therapy and anticholinergics have roles, they are adjunctive or niche rather than first-line monotherapy in typical PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. DOPA-PET scan  <br>&bull; Incorrect: Functional imaging is reserved for atypical or uncertain parkinsonism; not needed when clinical criteria for idiopathic PD are met.  <br>&bull; Misconception: Belief that imaging confirms PD rather than clinical diagnosis.  <br>&bull; Differentiator: Imaging adds cost and delay without changing immediate management.<br><br>C. Physical therapy  <br>&bull; Incorrect: Beneficial adjunct for gait, balance, and posture but does not address nigrostriatal dopamine deficiency.  <br>&bull; Misconception: Non-pharmacologic measures suffice as first-line monotherapy.  <br>&bull; Differentiator: PT complements but cannot replace levodopa&rsquo;s symptom relief.<br><br>D. Anticholinergic medication  <br>&bull; Incorrect: Primarily indicated for tremor-dominant PD in younger patients (<65) with minimal bradykinesia; high cognitive adverse effects in older adults.  <br>&bull; Misconception: Anticholinergics broadly alleviate all PD symptoms.  <br>&bull; Differentiator: Limited to tremor control; not first-line for mixed motor symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Levodopa</th><th>DOPA-PET scan</th><th>Physical therapy</th><th>Anticholinergic medication</th></tr></thead><tbody><tr><td>Mechanism</td><td>Dopamine precursor</td><td>Tracer uptake in striatum</td><td>Exercise, balance training</td><td>M1 receptor blockade</td></tr><tr><td>Indication</td><td>Symptomatic PD motor sx</td><td>Atypical/uncertain parkinsonism</td><td>Adjunctive motor optimization</td><td>Tremor-dominant PD in <65 y/o</td></tr><tr><td>Evidence level</td><td>Level A <span class=\"citation\">(MDS 2018)</span></td><td>Not first-line</td><td>Level B&ndash;C for gait/posture</td><td>Level U (limited trials)</td></tr><tr><td>Side effects</td><td>Dyskinesia, motor fluctuations</td><td>Radiation exposure, cost</td><td>Minimal; risk of falls if unsupervised</td><td>Cognitive impairment, dry mouth</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiate levodopa when motor symptoms impair daily activities; titrate to lowest effective dose to delay dyskinesias.  <br>2. Combine levodopa with a peripheral dopa-decarboxylase inhibitor (e.g., carbidopa) to increase central bioavailability and reduce nausea.  <br>3. Monitor for &ldquo;wearing-off&rdquo; phenomena; consider COMT inhibitors or MAO-B inhibitors as adjuncts to extend levodopa effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Over-reliance on imaging: Ordering DOPA-PET in clear-cut PD delays treatment without diagnostic gain.  <br>2. Underestimating levodopa side effects: Failing to counsel on dyskinesia risk leads to noncompliance and suboptimal dosing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Movement Disorder Society (MDS) Evidence-Based Review on Treatments for Parkinson&rsquo;s Disease, 2018: Recommends levodopa as first-line therapy for bradykinesia and rigidity (Level A).  <br>&bull; PD-MED Trial <span class=\"citation\">(<span class=\"evidence\">Lancet 2014</span>)</span>: Demonstrated improved quality of life and motor score with initial levodopa versus dopamine agonist or MAO-B inhibitor (n=1,610; HR 0.82, p<0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of the substantia nigra pars compacta reduces dopaminergic input to the striatum (putamen > caudate), disrupting the balance of the basal ganglia direct (D1) and indirect (D2) pathways, manifesting as hypokinesia and rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Loss of nigrostriatal dopamine \u2192 overactivity of the indirect pathway \u2192 increased inhibitory output from globus pallidus internus to thalamus \u2192 reduced thalamocortical excitation \u2192 bradykinesia and rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history and neurological exam: identify cardinal features.  <br>2. Exclude red flags for atypical parkinsonism.  <br>3. No routine neuroimaging if presentation classic.  <br>4. Initiate pharmacotherapy based on symptom severity and patient factors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>DOPA-PET shows decreased 18F-fluorodopa uptake in the posterior putamen early in PD; useful only when clinical diagnosis is equivocal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa is co-administered with carbidopa (25:100 mg ratio) to inhibit peripheral metabolism. Initial dosing often starts at 25/100 mg TID, with gradual titration every 1&ndash;2 weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam.  <br>Parkinson&rsquo;s initial management questions are frequently tested in multiple-choice format, emphasizing choice of first-line pharmacotherapy versus imaging or adjunctive therapies.</div></div></div></div></div>"
  },
  {
    "id": 100023809,
    "question_number": "5",
    "question_text": "A scenario of a patient with parkinsonian features and vertical gaze palsy is most likely indicative of which condition?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Progressive Supranuclear Palsy (PSP) is an atypical parkinsonian disorder characterized by early postural instability, symmetric rigidity, and a supranuclear vertical gaze palsy. Vertical gaze is mediated by the rostral interstitial nucleus of the medial longitudinal fasciculus (riMLF) in the midbrain. Tau protein accumulation in neurons and glia (predominantly 4-repeat isoform) leads to neurodegeneration in the basal ganglia, brainstem, and frontal lobes. Differentiating PSP from idiopathic Parkinson&rsquo;s Disease, Multiple System Atrophy, and Corticobasal Degeneration relies on unique oculomotor signs, pattern of motor involvement, and response to levodopa. Familiarity with the Movement Disorder Society (MDS) criteria is essential for accurate diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The hallmark of PSP is a supranuclear gaze palsy, especially impaired downward gaze, due to riMLF and interstitial nucleus degeneration. According to the 2017 MDS PSP criteria <span class=\"citation\">(H\u00f6glinger et al., Movement <span class=\"evidence\">Disorders 2017</span>)</span>, vertical supranuclear palsy plus parkinsonism establishes probable PSP&mdash;supported by midbrain atrophy (&ldquo;hummingbird sign&rdquo;) on MRI <span class=\"citation\">(Quattrone et al., <span class=\"evidence\">Neurology 2008</span>)</span>. Tau immunohistochemistry demonstrates tufted astrocytes and neurofibrillary tangles, distinguishing PSP from synucleinopathies. Levodopa responsiveness is minimal (<30% improvement) versus robust benefit in Parkinson&rsquo;s Disease (PD). Clinical guidelines <span class=\"citation\">(EFNS/EAN 2019)</span> emphasize early falls (<1 year) and vertical gaze restriction to differentiate PSP from other parkinsonian syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Parkinson&rsquo;s Disease  <br><span class=\"list-item\">\u2022</span> Lacks supranuclear gaze palsy; ocular motility abnormalities are late and peripheral.  <br><span class=\"list-item\">\u2022</span> Onset is often asymmetric with classic resting tremor and good levodopa response.  <br><br>C. Multiple System Atrophy  <br><span class=\"list-item\">\u2022</span> Presents with autonomic failure (orthostatic hypotension, urinary incontinence) and cerebellar or parkinsonian features, not isolated vertical gaze palsy.  <br><span class=\"list-item\">\u2022</span> MRI shows the &ldquo;hot cross bun&rdquo; sign in MSA-C or putaminal slit sign in MSA-P, rather than midbrain atrophy.  <br><br>D. Corticobasal Degeneration  <br><span class=\"list-item\">\u2022</span> Features asymmetric rigidity, limb dystonia, cortical sensory loss, and &ldquo;alien limb&rdquo; phenomenon.  <br><span class=\"list-item\">\u2022</span> Eye movements are typically preserved; pathology is tauopathy but cortical, not brainstem, predominant.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSP</th><th>Parkinson&rsquo;s Disease</th><th>Multiple System Atrophy</th><th>Corticobasal Degeneration</th></tr></thead><tbody><tr><td>Gaze palsy</td><td>Supranuclear vertical (early)</td><td>None or late oculomotor signs</td><td>None</td><td>None</td></tr><tr><td>Levodopa response</td><td>Poor (<30%)</td><td>Good</td><td>Poor</td><td>Variable</td></tr><tr><td>Autonomic failure</td><td>Rare</td><td>Mild (late)</td><td>Prominent</td><td>Rare</td></tr><tr><td>Key MRI finding</td><td>Midbrain atrophy (&ldquo;hummingbird&rdquo;)</td><td>Normal/mild SN hyperechogenicity</td><td>Hot cross bun; putaminal changes</td><td>Asymmetric cortical atrophy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early falls (within 1 year) and axial rigidity suggest PSP over PD.  <br><span class=\"list-item\">\u2022</span> The &ldquo;hummingbird sign&rdquo; on sagittal MRI correlates with midbrain tegmentum atrophy.  <br><span class=\"list-item\">\u2022</span> PSP patients may develop pseudobulbar affect; consider SSRIs for emotional lability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking early postural instability in PSP for cerebellar ataxia or dysautonomia of MSA.  <br><span class=\"list-item\">\u2022</span> Assuming any vertical gaze limitation is peripheral&mdash;testing for supranuclear features (vestibulo-ocular reflex preservation) is critical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. H\u00f6glinger GU et al., Movement <span class=\"evidence\">Disorders 2017</span> (MDS PSP criteria): defines &ldquo;probable PSP&rdquo; as vertical supranuclear gaze palsy + parkinsonism with level 1 certainty.  <br>2. Stamelou M et al., Lancet <span class=\"evidence\">Neurology 2021</span>: Phase 2 trial of anti-tau antibody gosuranemab (BIIB092) failed to slow PSP progression, underscoring need for targeted 4R tau therapies (Level 2 evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Supranuclear vertical gaze originates in the riMLF and interstitial nucleus of Cajal in the dorsal midbrain; degeneration here produces the hallmark downward gaze palsy. Basal ganglia involvement (globus pallidus, subthalamic nucleus) contributes to axial rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is a primary 4-repeat tauopathy with neuronal and glial tau aggregates (tufted astrocytes) causing synaptic dysfunction, neuronal loss, and astrocytic gliosis in brainstem and basal ganglia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify symmetric parkinsonism with early falls  <br>2. Perform detailed oculomotor exam (test supranuclear vs infranuclear gaze)  <br>3. Obtain MRI (assess midbrain-pons ratio, hummingbird sign)  <br>4. Apply MDS 2017 PSP criteria for level 1 or 2 certainty</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Midbrain-pons area ratio <0.52 on midsagittal MRI has 100% specificity for PSP <span class=\"citation\">(<span class=\"evidence\">Quattrone et al. 2008</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Absence of putaminal slit or hot cross bun sign differentiates from MSA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Levodopa trial (up to 1 g/day) often yields minimal benefit; discontinue if no improvement.  <br><span class=\"list-item\">\u2022</span> Amantadine may transiently enhance gait initiation; monitor for peripheral edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Vertical supranuclear gaze palsy is a classic high-yield sign for PSP and is frequently tested as a key differentiator from idiopathic Parkinson&rsquo;s Disease and other atypical parkinsonian syndromes.</div></div></div></div></div>"
  },
  {
    "id": 100023811,
    "question_number": "15",
    "question_text": "A patient presents with frequent falls and vertical gaze palsy. Brain MRI shows tectal atrophy. What is the likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Progressive supranuclear palsy (PSP) is an atypical parkinsonian syndrome marked by early axial rigidity, postural instability with falls, and a vertical supranuclear gaze palsy. The midbrain tectum houses vertical gaze centers (rostral interstitial nucleus of the medial longitudinal fasciculus and interstitial nucleus of Cajal); degeneration here causes impaired up-and-down saccades. MRI shows selective midbrain atrophy&mdash;especially of the tectum&mdash;producing the &ldquo;hummingbird&rdquo; sign. Recognizing the temporal sequence (early falls preceding limb motor signs) and correlating clinical features with imaging distinguishes PSP from other parkinson-plus disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2017</span> Movement Disorder Society (MDS) diagnostic criteria for PSP designate early postural instability/falls (within three years) plus vertical supranuclear gaze palsy as core features of &ldquo;probable PSP&rdquo; <span class=\"citation\">(<span class=\"evidence\">Litvan et al., 2017</span>; Level I consensus)</span>. Histopathology reveals a 4-repeat tauopathy with tufted astrocytes in globus pallidus, subthalamic nucleus, and midbrain. MRI sagittal images show significant midbrain (tectal) atrophy relative to the pons, quantified by an elevated MR Parkinsonism index <span class=\"citation\">(<span class=\"evidence\">Nishio et al., 2018</span>: specificity >90% vs other parkinsonian syndromes)</span>. These criteria supersede older clinical-only scales and improve diagnostic accuracy early in the disease course, guiding prognostication and potential enrollment in tau-modifying trials.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Parkinson&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Incorrect because PD presents with asymmetric bradykinesia, resting tremor, and robust levodopa response.  <br><span class=\"list-item\">\u2022</span> Vertical gaze is preserved until very late; early falls are uncommon.  <br><span class=\"list-item\">\u2022</span> MRI shows normal midbrain; no tectal atrophy.  <br><br>C. Multiple system atrophy  <br><span class=\"list-item\">\u2022</span> MSA features prominent autonomic failure (orthostatic hypotension, urinary incontinence) and either cerebellar signs (MSA-C) or parkinsonism (MSA-P).  <br><span class=\"list-item\">\u2022</span> Eye movements may be slow but lack discrete vertical supranuclear palsy.  <br><span class=\"list-item\">\u2022</span> MRI reveals pontine &ldquo;hot cross bun&rdquo; sign and cerebellar atrophy, not midbrain atrophy.  <br><br>D. Corticobasal degeneration  <br><span class=\"list-item\">\u2022</span> CBD presents with asymmetric cortical signs (limb apraxia, cortical sensory loss, &ldquo;alien limb&rdquo; phenomena) and rigidity.  <br><span class=\"list-item\">\u2022</span> Eye movements are intact in early stages; falls are less frequent initially.  <br><span class=\"list-item\">\u2022</span> MRI shows asymmetric frontoparietal cortical atrophy, not tectal atrophy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSP</th><th>Parkinson&rsquo;s disease</th><th>MSA</th><th>CBD</th></tr></thead><tbody><tr><td>Early falls</td><td>Yes (within 1&ndash;3 years)</td><td>No</td><td>Rare</td><td>Rare</td></tr><tr><td>Vertical supranuclear palsy</td><td>Prominent (downward > upward)</td><td>No</td><td>Absent or minimal</td><td>Absent</td></tr><tr><td>Levodopa response</td><td>Poor</td><td>Good</td><td>Poor</td><td>Poor to variable</td></tr><tr><td>MRI finding</td><td>Midbrain/tectal atrophy (&ldquo;hummingbird&rdquo; sign)</td><td>Normal midbrain</td><td>Pontine hot cross bun, cerebellar atrophy</td><td>Asymmetric cortical atrophy</td></tr><tr><td>Pathology</td><td>4R tauopathy</td><td>&alpha;-synuclein Lewy bodies</td><td>&alpha;-synuclein glial cytoplasmic inclusions</td><td>Tau and ubiquitin-positive astrocytic plaques</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Unexplained early falls in a parkinsonian patient strongly point toward PSP rather than PD or MSA.  <br><span class=\"list-item\">\u2022</span> The &ldquo;hummingbird sign&rdquo; (midbrain atrophy with preserved pons) on sagittal MRI is >90% specific for PSP.  <br><span class=\"list-item\">\u2022</span> Vertical gaze palsy in PSP is supranuclear: oculocephalic maneuvers transiently improve eye movement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misinterpreting nuclear vs supranuclear gaze palsy: in PSP, oculocephalic reflex partially spares eye movements.  <br>2. Overemphasis on tremor presence: minimal tremor in PSP does not rule out parkinsonism.  <br>3. Focusing only on basal ganglia atrophy on MRI and missing midbrain tectal thinning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society PSP Criteria <span class=\"citation\">(<span class=\"evidence\">Litvan et al., 2017</span>)</span>: Establishes &ldquo;probable PSP&rdquo; diagnosis with vertical gaze palsy and early falls (Level I consensus).  <br><span class=\"list-item\">\u2022</span> European Academy of Neurology Guideline on Atypical Parkinsonism (2022): Recommends MRI measurement of midbrain atrophy (MPRI >1.0) for differential diagnosis (Class II evidence).  <br><span class=\"list-item\">\u2022</span> Phase II Tau-targeting agent trials <span class=\"citation\">(H\u00f6<span class=\"evidence\">glinger et al., 2021</span>)</span>: Microtubule stabilizers show MRI biomarker modulation but no definitive clinical benefit yet.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Vertical gaze control originates in the rostral interstitial nucleus of the medial longitudinal fasciculus (riMLF) and the interstitial nucleus of Cajal in the dorsal midbrain tectum. Degeneration of these nuclei in PSP leads to supranuclear palsy, sparing the oculomotor nuclei.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is a primary tauopathy characterized by accumulation of 4-repeat tau isoforms in neurons and glia, with neuronal loss and gliosis in the midbrain, subthalamic nucleus, globus pallidus, and dentate nucleus, causing both motor and oculomotor system dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify parkinsonism with early postural instability/falls.  <br>2. Examine for vertical supranuclear gaze palsy (test oculocephalic reflex).  <br>3. Obtain brain MRI: assess midbrain atrophy and calculate MPRI.  <br>4. Apply MDS 2017 PSP criteria for &ldquo;probable&rdquo; vs &ldquo;possible&rdquo; PSP.  <br>5. Exclude mimics (evaluate for autonomic failure, cerebellar signs, cortical features).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- &ldquo;Hummingbird sign&rdquo;: sagittal midbrain flattening relative to the pons.  <br><span class=\"list-item\">\u2022</span> &ldquo;Penguin silhouette&rdquo;: axial midbrain tegmentum thinning.  <br><span class=\"list-item\">\u2022</span> MR Parkinsonism Index (pons area/midbrain area \u00d7 MCP diameter/SCP diameter) >1.0 suggests PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa yields minimal benefit in PSP. Symptomatic management includes amantadine for rigidity, SSRIs for mood, physical therapy for gait, and supportive measures (e.g., occupational therapy).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Atypical parkinsonian syndromes with early falls and ocular motor dysfunction are commonly tested on board examinations, often with an associated MRI image illustrating midbrain atrophy.</div></div></div></div></div>"
  },
  {
    "id": 100023813,
    "question_number": "104",
    "question_text": "Regarding essential palatal myoclonus, which of the following statements is true?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Essential palatal myoclonus (also called isolated palatal tremor) is a focal myoclonus of the soft palate without an identifiable structural lesion. Key concepts:  <br><span class=\"list-item\">\u2022</span> Palatal muscle anatomy: tensor veli palatini (innervated by V3) versus levator veli palatini (innervated by vagus), with essential tremor arising from tensor veli palatini hyperactivity.  <br><span class=\"list-item\">\u2022</span> Triangular circuit (Guillain&ndash;Mollaret triangle): dentate nucleus \u2192 red nucleus \u2192 inferior olive \u2192 back to cerebellum; lesions here produce symptomatic palatal myoclonus with hypertrophic olivary degeneration.  <br><span class=\"list-item\">\u2022</span> Sleep physiology: essential palatal myoclonus ceases during non-REM and REM sleep, distinguishing it from symptomatic forms that persist through sleep.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Essential palatal myoclonus is characterized by rhythmic contractions of tensor veli palatini generating an audible click. Surface EMG studies <span class=\"citation\">(Ondo et al., <span class=\"evidence\">Neurology 1994</span>)</span> demonstrate bursts of 50&ndash;150 ms that reliably cease with onset of sleep in 100% of cases. In contrast, symptomatic palatal myoclonus&mdash;due to hypertrophic olivary degeneration from lesions in the Guillain&ndash;Mollaret triangle&mdash;persists during sleep and shows MRI evidence of T2 hyperintensity and enlargement of the inferior olivary nucleus <span class=\"citation\">(Goyal et al., <span class=\"evidence\">Radiology 2000</span>)</span>. Current Movement Disorder Society classifications (2018) uphold cessation during sleep as the pathognomonic feature distinguishing essential from symptomatic palatal myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Hypertrophy of the ipsilateral olivary nucleus  <br>&bull; Incorrect: Essential type shows normal olivary anatomy. Hypertrophic olivary degeneration (HOD) occurs contralateral to the cerebellar lesion in symptomatic palatal myoclonus.  <br>C. Pathology involving the triangle of Mollaret  <br>&bull; Incorrect: Lesions in the dentato-rubro-olivary circuit underlie symptomatic palatal myoclonus, not the essential form.  <br>D. Responds well to anticonvulsant therapy  <br>&bull; Incorrect: Essential palatal myoclonus is often refractory to systemic anticonvulsants; targeted botulinum toxin injection yields superior relief <span class=\"citation\">(Ressler et al., Mov <span class=\"evidence\">Disord 2007</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Essential Palatal Myoclonus</th><th>Symptomatic Palatal Myoclonus</th></tr></thead><tbody><tr><td>Muscle involved</td><td>Tensor veli palatini (V3)</td><td>Levator veli palatini (vagus)</td></tr><tr><td>MRI findings</td><td>Normal inferior olive</td><td>Hypertrophic olivary degeneration on T2</td></tr><tr><td>Sleep effect</td><td>Ceases during sleep</td><td>Persists through sleep</td></tr><tr><td>Pathophysiology</td><td>Idiopathic central generator</td><td>Deafferentation of Guillain&ndash;Mollaret triangle</td></tr><tr><td>First-line therapy</td><td>Botulinum toxin injection</td><td>Treat underlying lesion; benzos/clonazepam</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Listen for a synchronous &ldquo;ear click&rdquo; in essential palatal myoclonus due to Eustachian tube oscillation.  <br><span class=\"list-item\">\u2022</span> Surface EMG during polysomnography confirms cessation of palatal bursts in sleep.  <br><span class=\"list-item\">\u2022</span> Local botulinum toxin injection into tensor veli palatini (10&ndash;30 U) offers targeted relief with minimal systemic side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating &ldquo;palatal tremor&rdquo; with essential palatal myoclonus: always confirm sleep cessation to rule out symptomatic form.  <br>2. Assuming olivary hypertrophy localizes ipsilaterally; in symptomatic cases, the affected inferior olive is contralateral to the cerebellar or brainstem lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mulligan et al., J Neurol <span class=\"evidence\">Sci 2022</span>: Prospective open-label trial (n=24) of botulinum toxin A in essential palatal myoclonus reported 80% reduction in click frequency and significant quality-of-life improvement at 3-month follow-up (Level IIa).  <br>2. Serrano et al., Mov <span class=\"evidence\">Disord 2020</span>: EMG polysomnography study showed sleep cessation of palatal myoclonic bursts in 100% of essential cases versus 0% in symptomatic, reinforcing diagnostic criteria (Level IIb).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Essential palatal myoclonus arises from hyperactivity of the trigeminal motor nucleus innervating tensor veli palatini. Symptomatic type involves the Guillain&ndash;Mollaret triangle: dentate nucleus \u2192 red nucleus (central tegmental tract) \u2192 inferior olive \u2192 cerebellum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- <span class=\"key-point\">Essential:</span> Central pacemaker within pontine tegmentum drives rhythmic trigeminal motor discharge without structural lesion.  <br><span class=\"list-item\">\u2022</span> Symptomatic: Deafferentation-induced trans-synaptic degeneration leads to hypertrophy and hyperexcitability of inferior olivary neurons, perpetuating tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: inquire about audible clicks and sleep effect.  <br>2. Physical exam: observe palatal movements, assess for other brainstem signs.  <br>3. Surface EMG &plusmn; polysomnography: record burst activity during wake and sleep.  <br>4. MRI brain with T2-weighted sequences: evaluate for olivary enlargement.  <br>5. Classify and institute appropriate therapy (botulinum vs lesion-directed).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>In symptomatic palatal myoclonus, MRI shows T2 hyperintensity and hypertrophy of the inferior olive 6&ndash;18 months after an inciting lesion. Essential type yields a normal MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Botulinum toxin A into tensor veli palatini is first-line for essential palatal myoclonus (10&ndash;30 U, repeat every 3 months). Clonazepam may provide adjunctive benefit; standard anticonvulsants (valproate, levetiracetam) show limited efficacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Palatal myoclonus is tested in neurology boards by contrasting essential versus symptomatic types, with sleep cessation and imaging findings as high-yield differentiators.</div></div></div></div></div>"
  },
  {
    "id": 100023817,
    "question_number": "39",
    "question_text": "An elderly patient with a history of coronary artery bypass grafting (CABG) two years ago presents with a six-month history of frequent falls and restricted upward gaze. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Progressive supranuclear palsy (PSP) is a primary 4-repeat tauopathy characterized by early postural instability, symmetric akinetic-rigid parkinsonism, and vertical supranuclear gaze palsy. Vertical gaze is mediated by the rostral interstitial nucleus of the medial longitudinal fasciculus in the midbrain; degeneration here produces impaired upward and downward saccades. Differentiating PSP from vascular parkinsonism (predominant lower-body gait impairment, extensive white matter changes) or idiopathic Parkinson&rsquo;s disease (asymmetry, rest tremor, levodopa responsiveness) relies on clinical features and MRI midbrain atrophy (&ldquo;hummingbird&rdquo; sign). Normal pressure hydrocephalus features gait apraxia, ventriculomegaly, and urinary incontinence without vertical gaze palsy. (120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is correct because early backward falls and vertical supranuclear gaze palsy within three years fulfill the Movement Disorder Society (MDS) criteria for probable PSP <span class=\"citation\">(H\u00f6glinger et al., Movement <span class=\"evidence\">Disorders 2017</span>; Level B evidence)</span>. MRI classically shows midbrain atrophy with a reduced midbrain-to-pons ratio and the &ldquo;hummingbird&rdquo; sign <span class=\"citation\">(Josephs et al., <span class=\"evidence\">Neurology 2006</span>)</span>. PSP patients exhibit poor or minimal levodopa response <span class=\"citation\">(Litvan et al., <span class=\"evidence\">Neurology 1996</span>)</span>. Tau pathology with four-repeat isoforms accumulates in subcortical nuclei, causing symmetric rigidity and ocular motor deficits. No disease-modifying therapies are approved; management remains supportive <span class=\"citation\">(Williams et al., <span class=\"evidence\">Brain 2007</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Vascular Parkinsonism  <br><span class=\"list-item\">\u2022</span> Presents with lower-body parkinsonism (gait freezing, shuffling) but preserved vertical eye movements.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing falls to cerebrovascular disease despite intact gaze.  <br><span class=\"list-item\">\u2022</span> Imaging: periventricular white matter hyperintensities, not midbrain atrophy.<br><br>C. Parkinson&rsquo;s Disease  <br><span class=\"list-item\">\u2022</span> Features asymmetric onset, rest tremor, and robust levodopa response; vertical gaze is intact until very late.  <br><span class=\"list-item\">\u2022</span> Misconception: any parkinsonism equates to PD.  <br><span class=\"list-item\">\u2022</span> Imaging: usually normal or mild nonspecific changes.<br><br>D. Normal Pressure Hydrocephalus  <br><span class=\"list-item\">\u2022</span> Triad of gait apraxia (&ldquo;magnetic gait&rdquo;), dementia, urinary incontinence; no supranuclear gaze palsy.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing gait disturbance to hydrocephalus without assessing eye movements.  <br><span class=\"list-item\">\u2022</span> Imaging: ventriculomegaly with disproportionately enlarged subarachnoid spaces (DESH), no midbrain shrinkage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSP</th><th>Vascular Parkinsonism</th><th>Parkinson&rsquo;s Disease</th><th>Normal Pressure Hydrocephalus</th></tr></thead><tbody><tr><td>Falls</td><td>Early, backward (<1 year)</td><td>Gradual, gait freezing</td><td>Late (>3 years), rare</td><td>Gait apraxia, magnetic gait</td></tr><tr><td>Gaze palsy</td><td>Vertical supranuclear palsy</td><td>Preserved</td><td>Intact (only late)</td><td>Absent</td></tr><tr><td>Levodopa response</td><td>Poor/minimal</td><td>Minimal</td><td>Good</td><td>Variable</td></tr><tr><td>MRI findings</td><td>Midbrain atrophy, hummingbird sign</td><td>Periventricular WMHs</td><td>Normal or mild nonspecific</td><td>Ventriculomegaly, DESH</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early backward falls and vertical gaze palsy (<3 years) are hallmark features of PSP, distinguishing it from other parkinsonian syndromes.  <br><span class=\"list-item\">\u2022</span> A midbrain-to-pons area ratio <0.52 on sagittal MRI and the &ldquo;hummingbird&rdquo; sign have high specificity (>90%) for PSP.  <br><span class=\"list-item\">\u2022</span> PSP is a tauopathy; poor levodopa responsiveness is a key clinical discriminator.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing early falls in PSP with advanced PD rather than recognizing them as an early red flag.  <br><span class=\"list-item\">\u2022</span> Over-diagnosing vascular parkinsonism in patients with vascular risk factors without assessing vertical gaze.  <br><span class=\"list-item\">\u2022</span> Neglecting MRI evaluation of midbrain size, which is essential for distinguishing PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- H\u00f6glinger GU et al., Movement Disorder Society PSP Criteria, 2017: Establishes probable PSP diagnosis with early falls and vertical gaze palsy (Level B evidence).  <br><span class=\"list-item\">\u2022</span> NICE Guideline CG35, 2017: Recommends MRI for atypical parkinsonism; highlights midbrain atrophy as a diagnostic marker in PSP (Level C recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of the rostral interstitial nucleus of the medial longitudinal fasciculus in the dorsal midbrain disrupts vertical gaze. Tau accumulation in the substantia nigra, subthalamic nucleus, and globus pallidus produces symmetric rigidity and bradykinesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP involves aggregation of four-repeat tau isoforms forming neurofibrillary tangles in subcortical structures and midbrain neurons, leading to neuronal loss, gliosis, and the clinical phenotype of gaze palsy and axial rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify early falls and vertical supranuclear gaze palsy clinically.  <br>2. Obtain brain MRI: assess midbrain-to-pons ratio, look for hummingbird/morning glory signs.  <br>3. Apply MDS-PSP diagnostic criteria for probable vs possible PSP.  <br>4. Exclude alternative etiologies (vascular, hydrocephalus).  <br>5. Initiate supportive therapies (physical, occupational, ocular exercises).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hummingbird sign: sagittal view midbrain atrophy with preserved pons.  <br><span class=\"list-item\">\u2022</span> Morning glory sign: axial concavity of the midbrain tegmentum.  <br><span class=\"list-item\">\u2022</span> Midbrain anteroposterior diameter <17 mm supports PSP diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Levodopa trial (up to 1 g/day) often yields minimal benefit; lack of response aids diagnosis.  <br><span class=\"list-item\">\u2022</span> Amantadine may provide modest gait improvement.  <br><span class=\"list-item\">\u2022</span> Experimental tau-directed therapies (e.g., gosuranemab) are under investigation in clinical trials.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Vertical supranuclear gaze palsy with early falls is a classic PSP presentation often tested in single-best-answer formats; familiarity with imaging signs and levodopa responsiveness is essential.</div></div></div></div></div>"
  },
  {
    "id": 100023818,
    "question_number": "1",
    "question_text": "Which condition is characterized by chorea, cognitive decline, and behavioral changes?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Huntington&rsquo;s disease (HD) is an autosomal-dominant neurodegenerative disorder caused by CAG trinucleotide repeat expansion in the HTT gene. Core concepts:  <br>&bull; Basal ganglia circuits &ndash; degeneration of striatal GABAergic medium spiny neurons disrupts the indirect pathway, yielding chorea.  <br>&bull; Cognitive decline &ndash; frontal&ndash;subcortical network impairment causes executive dysfunction, memory loss, apathy.  <br>&bull; Behavioral changes &ndash; psychiatric manifestations (irritability, depression, disinhibition) often precede motor signs.  <br>Students should recognize the classic triad (chorea + cognitive + psychiatric) and link it to striatal pathology and mutant huntingtin toxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Huntington&rsquo;s disease is the prototypical choreic disorder with progressive cognitive and psychiatric decline.  <br>&bull; Pathophysiology: Polyglutamine expansion (>39 repeats) in huntingtin triggers neuronal intranuclear inclusions, excitotoxicity, mitochondrial dysfunction, and selective loss of indirect pathway neurons in the caudate/putamen <span class=\"citation\">(<span class=\"evidence\">Walker et al., 2015</span>)</span>.  <br>&bull; Clinical presentation: Chorea often begins insidiously in mid-adult life, accompanied by executive dysfunction and mood disturbances <span class=\"citation\">(American Academy of Neurology [AAN], 2017)</span>.  <br>&bull; Diagnostic confirmation: PCR\u2010based CAG repeat analysis remains the gold standard <span class=\"citation\">(American College of Medical Genetics and Genomics [ACMG], 2022)</span>.  <br>&bull; Treatment guidelines: AAN 2017 practice guideline recommends tetrabenazine as first-line for chorea (Level B), with deutetrabenazine as alternative (Level B) given better side-effect profile.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Parkinson&rsquo;s disease  <br>&bull; Incorrect because PD is primarily a hypokinetic rigid syndrome (bradykinesia, rigidity, resting tremor).  <br>&bull; Misconception: &ldquo;Parkinsonian chorea&rdquo; is actually dyskinesia from levodopa, not intrinsic chorea.  <br>&bull; Differentiator: PD shows nigrostriatal dopaminergic loss, Lewy bodies, and response to dopaminergic therapy.<br><br>C. Wilson&rsquo;s disease  <br>&bull; Incorrect because Wilson&rsquo;s features hepatic dysfunction, Kayser-Fleischer rings, dystonia, tremor (&ldquo;wing-beating&rdquo;), and psychiatric changes but rarely classical chorea.  <br>&bull; Misconception: All basal ganglia disorders cause chorea &ndash; Wilson&rsquo;s more often causes dystonia.  <br>&bull; Differentiator: Serum ceruloplasmin low, 24-h urinary copper increased.<br><br>D. Multiple sclerosis  <br>&bull; Incorrect because MS presents with relapsing focal deficits (optic neuritis, sensory/motor signs), demyelinating plaques on MRI, and variable cognitive impact, but not chorea.  <br>&bull; Misconception: Any neurodegenerative disease causes cognitive decline &ndash; MS cognitive changes are mild and subcortical.  <br>&bull; Differentiator: Oligoclonal bands, periventricular lesions, CSF profile.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Huntington&rsquo;s disease</th><th>Parkinson&rsquo;s disease</th><th>Wilson&rsquo;s disease</th><th>Multiple sclerosis</th></tr></thead><tbody><tr><td>Movement disorder</td><td>Chorea (hyperkinesia)</td><td>Bradykinesia, rigidity, tremor</td><td>Tremor (wing-beating), dystonia</td><td>Spasticity, ataxia</td></tr><tr><td>Age of onset</td><td>30&ndash;50 years</td><td>>60 years</td><td>10&ndash;40 years</td><td>20&ndash;40 years</td></tr><tr><td>Genetic/biomarker</td><td>HTT CAG repeat >39</td><td>LRRK2, SNCA mutations (rare)</td><td>ATP7B mutation, low ceruloplasmin</td><td>HLA-DRB1 association</td></tr><tr><td>Neuroimaging</td><td>Caudate atrophy, ex-vacuole ventricles</td><td>Normal initial; DAT scan \u2193</td><td>T2 basal ganglia hyperintensities</td><td>Periventricular white-matter lesions</td></tr><tr><td>Treatment</td><td>Tetrabenazine, deutetrabenazine</td><td>Levodopa, DBS</td><td>Chelation (penicillamine), zinc</td><td>Immunomodulators (interferon &beta;)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Behavioral and psychiatric symptoms often precede chorea by years&mdash;screen at-risk individuals.  <br>&bull; Use Unified Huntington&rsquo;s Disease Rating Scale (UHDRS) for standardized assessment of motor, cognitive, behavioral domains.  <br>&bull; Deutetrabenazine has a longer half-life and lower risk of depression compared to tetrabenazine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Confusing chorea (brief, irregular movements) with tremor or myoclonus leads to diagnostic delay.  <br>&bull; Overlooking psychiatric prodrome&mdash;depression or irritability in HD gene carriers may present years before motor signs.  <br>&bull; Assuming all basal ganglia disorders produce chorea; dystonia and parkinsonism have distinct circuit pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Academy of Neurology (AAN) Practice Guideline, 2017: Tetrabenazine recommended as first-line for moderate to severe chorea in HD (Level B evidence).  <br>&bull; National Institute for Health and Care Excellence (NICE) NG126, 2018: Multidisciplinary management of HD; offer tetrabenazine for chorea; pre- and post-test genetic counseling (Level C).  <br>&bull; First-HD Trial (Huntington Study Group), Lancet Neurology, 2017: Deutetrabenazine significantly reduced chorea score vs placebo (mean change &ndash;4.4 vs &ndash;1.9; p<0.001); Level I evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Selective degeneration of GABAergic medium spiny neurons in the caudate nucleus and putamen (indirect pathway) leads to disinhibition of thalamocortical circuits, producing chorea. Frontal cortical involvement underlies cognitive and behavioral symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Expanded polyglutamine tract in mutant huntingtin causes abnormal protein folding, intranuclear inclusions, mitochondrial dysfunction, and excitotoxicity mediated by NMDA receptor overactivation, culminating in neuronal apoptosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: chorea + cognitive/psychiatric changes in adult.  <br>2. Family history assessment.  <br>3. Genetic testing: PCR for CAG repeat length (>39 confirms).  <br>4. Baseline neuropsychological evaluation (UHDRS).  <br>5. MRI to assess caudate atrophy.  <br>6. Multidisciplinary referral (neurology, psychiatry, genetic counseling).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; T1-weighted MRI: caudate head atrophy and putaminal volume loss.  <br>&bull; Ex-vacuole ventriculomegaly (&ldquo;boxcar&rdquo; ventricles) from striatal degeneration.  <br>&bull; FDG-PET: hypometabolism in striatum and frontal cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Tetrabenazine: VMAT2 inhibitor; start 12.5 mg daily, titrate to 50&ndash;75 mg/day in divided doses; monitor for depression, parkinsonism.  <br>&bull; Deutetrabenazine: deuterated form, reduced dosing frequency (6 mg BID up to 48 mg/day); fewer mood side effects.  <br>&bull; Antipsychotics (e.g., olanzapine, risperidone) for chorea and psychosis.  <br>&bull; SSRIs or SNRIs for depression and obsessive symptoms.  <br>&bull; Genetic counseling is essential before testing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam.  <br>HD triad (chorea, cognitive decline, behavioral changes) is a classic high-yield topic, tested frequently in neurology sections via clinical vignettes and genetic inheritance questions.</div></div></div></div></div>"
  },
  {
    "id": 100023819,
    "question_number": "36",
    "question_text": "What is the most common cause of hereditary chorea?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Chorea arises from dysfunction in basal ganglia circuits, particularly loss of indirect\u2010pathway inhibition in the striatum.  <br>1. Basal ganglia anatomy: medium spiny GABAergic neurons in the caudate/putamen modulate movement via direct (D1) and indirect (D2) pathways through globus pallidus and subthalamic nucleus.  <br>2. Pathophysiology of hereditary chorea: genetic mutations cause progressive neuronal loss in the striatum, reducing inhibitory output and yielding hyperkinetic movements.  <br>3. Inheritance patterns: autosomal dominant disorders (e.g., Huntington disease) predominate among genetic choreas, whereas autosomal recessive (e.g., Wilson) or non\u2010hereditary causes (e.g., Sydenham) are far less common.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Huntington disease (HD) accounts for over 90% of genetically inherited chorea syndromes. It is autosomal dominant, due to an expanded CAG trinucleotide repeat in HTT on chromosome 4p16.3. Pathologically, mutant huntingtin aggregates lead to selective medium spiny neuron apoptosis in the striatum. Prevalence is ~5&ndash;10 per 100,000 in Western populations, vastly exceeding benign hereditary chorea (<1/1,000,000) and other monogenic choreas. <span class=\"evidence\">The 2018</span> ACMG guidelines recommend targeted testing for CAG expansion when autosomal dominant chorea is suspected <span class=\"citation\">(<span class=\"evidence\">Grisso et al., 2018</span>)</span>. Recent meta\u2010analyses confirm that >95% of hereditary choreas are attributable to HD <span class=\"citation\">(<span class=\"evidence\">Ross et al., 2020</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Sydenham chorea  <br><span class=\"list-item\">\u2022</span> Why incorrect: Post\u2010streptococcal autoimmune disorder, not inherited.  <br><span class=\"list-item\">\u2022</span> Misconception: acute pediatric chorea is often labeled &ldquo;hereditary.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: migratory arthritis, carditis, presentation within weeks of streptococcal pharyngitis.  <br><br>C. Benign hereditary chorea  <br><span class=\"list-item\">\u2022</span> Why incorrect: Rare NKX2-1 mutation (<200 reported families), early\u2010onset nonprogressive chorea with thyroid/lung involvement.  <br><span class=\"list-item\">\u2022</span> Misconception: any &ldquo;hereditary chorea&rdquo; equals benign hereditary chorea.  <br><span class=\"list-item\">\u2022</span> Differentiator: lack of neurodegeneration and cognitive decline; autosomal dominant with variable penetrance.  <br><br>D. Wilson disease  <br><span class=\"list-item\">\u2022</span> Why incorrect: Autosomal recessive copper\u2010transport defect; movement disorder is mixed (tremor, dystonia, parkinsonism) rather than pure chorea.  <br><span class=\"list-item\">\u2022</span> Misconception: all metabolic causes present with chorea.  <br><span class=\"list-item\">\u2022</span> Differentiator: low ceruloplasmin, Kayser&ndash;Fleischer rings, hepatic involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Huntington Disease</th><th>Sydenham Chorea</th><th>Benign Hereditary Chorea</th><th>Wilson Disease</th></tr></thead><tbody><tr><td>Inheritance</td><td>AD</td><td>None (post\u2010infectious)</td><td>AD</td><td>AR</td></tr><tr><td>Onset</td><td>30&ndash;50 years</td><td>5&ndash;15 years</td><td>Infancy&ndash;childhood</td><td>5&ndash;40 years</td></tr><tr><td>Progression</td><td>Progressive</td><td>Self\u2010limited (months)</td><td>Nonprogressive</td><td>Progressive</td></tr><tr><td>Pathophysiology</td><td>CAG expansion \u2192 neuronal loss</td><td>Autoimmune cross\u2010reactivity</td><td>NKX2-1 transcription factor</td><td>Copper accumulation</td></tr><tr><td>Key clinical features</td><td>Chorea, dementia, psychiatric</td><td>Chorea, emotional lability</td><td>Pure chorea, hypothyroidism</td><td>Mixed movement (tremor, dystonia, chorea), hepatic signs</td></tr><tr><td>Diagnostic test</td><td>HTT CAG repeat assay</td><td>ASO titers, echo for carditis</td><td>Genetic testing (NKX2-1)</td><td>Ceruloplasmin, 24h urinary copper, slit\u2010lamp</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Presymptomatic CAG repeat testing in at\u2010risk HD relatives requires thorough genetic counseling per ACMG standards.  <br><span class=\"list-item\">\u2022</span> Tetrabenazine <span class=\"citation\">(FDA\u2010approved since 2008)</span> depletes presynaptic monoamines and is first\u2010line for HD chorea; monitor for depression.  <br><span class=\"list-item\">\u2022</span> MRI &ldquo;bicaudate ratio&rdquo; >0.16 indicates caudate atrophy in HD and correlates with disease burden.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any chronic chorea with Sydenham chorea; Sydenham&rsquo;s is acute and post\u2010streptococcal.  <br>2. Assuming benign hereditary chorea is the most frequent genetic chorea due to its name; in reality HD prevalence is ~100\u00d7 higher.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American College of Medical Genetics (ACMG) 2018:  <br><span class=\"list-item\">\u2022</span> Recommendation: HTT CAG testing for individuals with adult\u2010onset chorea and positive FHx.  <br><span class=\"list-item\">\u2022</span> Evidence level: B (cohort studies).  <br>2. European Huntington&rsquo;s Disease Network (EHDN) <span class=\"evidence\">Consensus 2022</span>:  <br><span class=\"list-item\">\u2022</span> Recommendation: Use tetrabenazine as first\u2010line chorea therapy; consider gene\u2010lowering trials (e.g., tominersen) in early\u2010stage patients.  <br><span class=\"list-item\">\u2022</span> Evidence level: B (randomized controlled trials, e.g., TETRA\u2010HD).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>In HD, preferential degeneration of indirect\u2010pathway medium spiny neurons in the caudate leads to reduced GABAergic inhibition of GPe, decreased STN activation, and thalamic disinhibition manifesting as chorea.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Expanded CAG repeats (>36) in HTT produce polyglutamine aggregates \u2192 impaired proteostasis \u2192 mitochondrial dysfunction \u2192 excitotoxicity via NMDA receptor overactivation \u2192 medium spiny neuron apoptosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical: progressive chorea + cognitive/psychiatric symptoms + AD family history.  <br>2. Laboratory: exclude metabolic causes (ceruloplasmin, liver enzymes).  <br>3. Neuroimaging: MRI for caudate atrophy.  <br>4. Genetic: confirm HTT CAG repeat number.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Early HD: enlargement of frontal horns of lateral ventricles (&ldquo;boxcar ventricles&rdquo;) and caudate head volume loss best seen on T1\u2010weighted MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Tetrabenazine: start 12.5 mg daily, titrate to 50&ndash;75 mg/day; monitor for depression, parkinsonism.  <br><span class=\"list-item\">\u2022</span> Deutetrabenazine: longer half\u2010life, less dosing frequency; similar efficacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Hereditary chorea etiologies are frequently tested in multiple\u2010choice format, often requiring differentiation of HD from metabolic, autoimmune, and benign genetic causes.</div></div></div></div></div>"
  },
  {
    "id": 100023820,
    "question_number": "181",
    "question_text": "A 61\u2010year\u2010old male with a 2\u2010year history of limb tremors and bradykinesia has postural instability and vertical jaw limitation on exam. What is the likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] &bull; Atypical parkinsonian syndromes often present with &ldquo;plus&rdquo; signs beyond classic bradykinesia, rigidity and tremor.  <br>&bull; Corticobasal degeneration (CBD) is a 4\u2010repeat tauopathy characterized by asymmetric parkinsonism plus cortical signs (apraxia, myoclonus, orobuccal apraxia).  <br>&bull; Vertical jaw limitation reflects orobuccal apraxia/dystonia in CBD, differentiating it from disorders with predominantly brainstem or autonomic pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Corticobasal degeneration (CBD) is diagnosed when asymmetric limb rigidity/bradykinesia is accompanied by cortical features such as limb or orobuccal apraxia, myoclonus, cortical sensory loss or alien limb phenomenon. Armstrong et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2013</span>;80:496&ndash;503)</span> Movement Disorder Society (MDS) criteria require:  <br>  &ndash; Asymmetric parkinsonism (rigidity/bradykinesia)  <br>  &ndash; At least one cortical sign (e.g., orobuccal apraxia causing vertical jaw limitation)  <br>  &ndash; Poor or transient levodopa response  <br>Neuroimaging often shows asymmetric frontoparietal atrophy <span class=\"citation\">(Josephs et al. <span class=\"evidence\">Brain 2010</span>)</span>. In contrast, MSA presents with prominent autonomic failure and cerebellar signs; Alzheimer&rsquo;s disease lacks parkinsonism; PD shows symmetric progression and robust levodopa responsiveness without cortical apraxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Multiple system atrophy (MSA)  <br>  &ndash; MSA features early autonomic failure (orthostatic hypotension, urinary incontinence) and cerebellar signs; jaw limitation/apraxia is not typical.  <br><br>C. Alzheimer&rsquo;s disease (AD)  <br>  &ndash; AD presents with insidious memory impairment and visuospatial deficits, without bradykinesia, rigidity or postural instability in early stages.  <br><br>D. Parkinson&rsquo;s disease (PD)  <br>  &ndash; PD shows good, sustained levodopa response, rest tremor predominance, symmetry over time, and lacks cortical signs (apraxia).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CBD</th><th>MSA</th><th>AD</th><th>PD</th></tr></thead><tbody><tr><td>Onset</td><td>Asymmetric</td><td>Symmetric</td><td>Insidious memory decline</td><td>Asymmetric, rest tremor</td></tr><tr><td>Levodopa response</td><td>Poor/transient</td><td>Poor</td><td>N/A</td><td>Good</td></tr><tr><td>Cortical signs</td><td>+ apraxia, orobuccal, myoclonus</td><td>&ndash;</td><td>+ memory/visuospatial</td><td>&ndash;</td></tr><tr><td>Autonomic failure</td><td>&ndash;</td><td>+ orthostatic hypotension, urinary</td><td>&ndash;</td><td>&ndash; (late)</td></tr><tr><td>MRI findings</td><td>Asymmetric frontoparietal atrophy</td><td>&ldquo;Hot cross bun&rdquo; in pons, putaminal loss</td><td>Medial temporal atrophy</td><td>Substantia nigra hyperechogenicity</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Orobuccal apraxia (jaw opening/closing difficulty) in the setting of asymmetric parkinsonism is a red flag for CBD.  <br>&bull; A poor or transient response to levodopa therapy distinguishes CBD from idiopathic PD.  <br>&bull; Early postural instability in atypical parkinsonism suggests a &ldquo;plus&rdquo; syndrome rather than PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling vertical gaze palsy as jaw limitation and confusing PSP with CBD&mdash;focus on orobuccal rather than ocular findings in CBD.  <br>2. Overinterpreting any tremor as PD; CBD tremor is typically irregular, action\u2010induced, and asymmetric.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Armstrong MJ et al. Movement Disorder Society Criteria for CBD, <span class=\"evidence\">Neurology 2013</span> (Level III evidence): Defines probable CBD by asymmetric parkinsonism plus &ge;1 cortical feature and poor levodopa response.  <br>2. Gilman S et al. Second Consensus Statement on MSA Diagnosis, <span class=\"evidence\">Neurology 2008</span> (Level II evidence): Emphasizes autonomic failure and cerebellar signs as core features&mdash;absent in CBD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of the contralateral parietal cortex (praxis areas) and basal ganglia underlies the asymmetric motor signs and apraxia in CBD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>CBD is a tauopathy with accumulation of 4\u2010repeat tau in neurons and astrocytes, producing astrocytic plaques, neuronal loss, and gliosis predominantly in frontoparietal cortex and basal ganglia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm parkinsonism (bradykinesia + rigidity/tremor)  <br>2. Assess symmetry and levodopa response  <br>3. Evaluate for cortical signs (apraxia, sensory deficits)  <br>4. Rule out autonomic/cerebellar features  <br>5. Obtain MRI to identify asymmetric cortical atrophy</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI in CBD typically shows asymmetric atrophy of the primary motor and posterior parietal cortices, often contralateral to the more affected limbs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa trials often yield minimal or transient benefit; management focuses on symptomatic relief of dystonia (e.g., botulinum toxin), myoclonus (e.g., clonazepam), and supportive therapies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Atypical parkinsonian syndromes with cortical &ldquo;plus&rdquo; signs are frequently tested, often asking for distinguishing features (e.g., apraxia, asymmetric rigidity, autonomic failure) in a vignette format.</div></div></div></div></div>"
  },
  {
    "id": 100023829,
    "question_number": "14",
    "question_text": "A patient with Parkinson's disease presents with peak-dose dyskinesia. What medication is commonly used to manage this condition?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Parkinson&rsquo;s disease (PD) is characterized by nigrostriatal dopamine depletion leading to bradykinesia, rigidity and tremor. Chronic levodopa therapy often produces motor fluctuations: &ldquo;wearing-off,&rdquo; &ldquo;on-off,&rdquo; and dyskinesias. Peak-dose dyskinesias are involuntary choreiform movements occurring at maximal levodopa plasma levels. Pathophysiologically, pulsatile dopaminergic stimulation causes postsynaptic receptor sensitization and glutamatergic overactivity in the internal globus pallidus and subthalamic nucleus. Management aims to reduce dyskinesias without worsening parkinsonism. Amantadine&rsquo;s NMDA receptor antagonism modulates glutamate transmission, attenuating hyperkinetic movements. Understanding the basal ganglia circuitry and pharmacodynamics of anti-Parkinsonian drugs is essential for targeted intervention.  <br>(Word count: 127)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Amantadine directly antagonizes NMDA receptors, reducing glutamatergic excitotoxicity implicated in peak-dose dyskinesia (PDS). A randomized, double-blind trial <span class=\"citation\">(<span class=\"evidence\">Katzenschlager et al., 2003</span>, Neurology)</span> demonstrated a 60% reduction in dyskinesia scores versus placebo (p<0.01). The Movement Disorder Society Evidence-Based Review (2019) rates amantadine as Level A efficacy for levodopa-induced dyskinesias. NICE Parkinson&rsquo;s Guidelines (2022) recommend amantadine (100 mg BID) in patients with troublesome PDS. By contrast, increasing levodopa or using COMT inhibitors exacerbates dyskinesias, while dopamine agonists (e.g., pramipexole) lack robust anti-dyskinetic effects and may provoke impulse control disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Levodopa  <br>&ndash; Increases synaptic dopamine and worsens peak-dose dyskinesia.  <br>&ndash; Misconception: boosting primary therapy alleviates complications; instead, fractionate dosing.  <br><br>C. Pramipexole  <br>&ndash; Dopamine D2/D3 agonist; helpful for bradykinesia but does not reduce PDS and may induce dyskinesias and impulse control disorders.  <br><br>D. Entacapone  <br>&ndash; COMT inhibitor prolonging levodopa half-life; can amplify peak plasma levels and exacerbate dyskinesias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Amantadine</th><th>Levodopa</th><th>Pramipexole</th><th>Entacapone</th></tr></thead><tbody><tr><td>Mechanism</td><td>NMDA antagonist</td><td>Dopamine precursor</td><td>D2/D3 agonist</td><td>COMT inhibitor</td></tr><tr><td>Effect on PDS</td><td>Reduces by ~50&ndash;60%</td><td>Worsens</td><td>Neutral/worsens</td><td>Worsens</td></tr><tr><td>Start dosing</td><td>100 mg BID</td><td>300 mg TID</td><td>0.125 mg TID</td><td>200 mg with each L-dopa</td></tr><tr><td>Key side effects</td><td>Livedo reticularis, confusion</td><td>Dyskinesia, nausea</td><td>Somnolence, impulse control</td><td>Diarrhea, dyskinesia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate amantadine at 100 mg BID; titrate to 300 mg/day to balance efficacy and tolerability.  <br><span class=\"list-item\">\u2022</span> Monitor for livedo reticularis and hallucinations, especially in elderly or renal impairment.  <br><span class=\"list-item\">\u2022</span> Differentiate peak-dose from diphasic dyskinesia: the latter occurs at low levodopa levels and requires dose adjustments.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing peak-dose dyskinesia with wearing-off: the former occurs at high levodopa levels and responds to amantadine.  <br><span class=\"list-item\">\u2022</span> Attempting to reduce PDS by adding COMT inhibitors or increasing levodopa, which worsens the hyperkinetic movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Evidence-Based Review (2019): Amantadine is Level A recommended for levodopa-induced dyskinesias.  <br>2. NICE Parkinson&rsquo;s Guidelines (2022): Recommends amantadine for troublesome peak-dose dyskinesias (Recommendation 1.2.5).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Amantadine&rsquo;s noncompetitive NMDA receptor blockade reduces striatal glutamatergic overactivity. Dosing begins at 100 mg twice daily; adjust for creatinine clearance. Abrupt withdrawal may precipitate akinetic crisis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Peak-dose dyskinesia management is frequently tested both as a standalone stem and within broader PD motor complication questions. The most commonly tested intervention is amantadine, reflecting its strong evidence base.</div></div></div></div></div>"
  },
  {
    "id": 100023830,
    "question_number": "106",
    "question_text": "An elderly patient has a history of frequent falls, limited vertical gaze, and parkinsonian features. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Progressive supranuclear palsy (PSP) is a 4\u2010repeat tauopathy targeting midbrain gaze centers and basal ganglia. Key neuroanatomical structures include the rostral interstitial nucleus of the medial longitudinal fasciculus (riMLF), superior colliculi, and vertical gaze pathways. Clinically, degeneration of these nuclei leads to supranuclear vertical gaze palsy; involvement of the globus pallidus and subthalamic nucleus produces axial rigidity and early postural instability. PSP falls within the spectrum of atypical parkinsonian syndromes, distinguished by poor levodopa response, early falls (within 3\u2005years), and characteristic midbrain atrophy on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Progressive supranuclear palsy is defined by the Movement Disorder Society (MDS) 2017 criteria: probable PSP requires vertical supranuclear gaze palsy or slowing of vertical saccades plus onset of falls within 3\u2005years <span class=\"citation\">(H\u00f6glinger et al., Mov <span class=\"evidence\">Disord 2017</span>)</span>. Neuropathologically, accumulation of 4R tau in neurons and glia preferentially affects the midbrain, leading to &ldquo;hummingbird&rdquo; sign on sagittal MRI (midbrain atrophy with preserved pons). Clinically, PSP patients exhibit symmetric axial rigidity, early postural instability, and minimal response to levodopa (<30% improvement) <span class=\"citation\">(Respondek et al., <span class=\"evidence\">Brain 2014</span>)</span>. No disease\u2010modifying therapies are approved; management focuses on symptomatic support and rehabilitation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Multiple system atrophy (MSA)  <br>MSA is an &alpha;-synucleinopathy marked by prominent autonomic failure (orthostatic hypotension, urinary retention) and either cerebellar (MSA-C) or parkinsonian (MSA-P) features. Vertical gaze is preserved; cerebellar signs and rapid autonomic decline distinguish MSA from PSP.<br><br>C. Parkinson&rsquo;s disease  <br>Classic PD presents with asymmetric resting tremor, bradykinesia, rigidity, good levodopa response (>50%), and no early falls or supranuclear gaze palsy. Vertical gaze and early postural instability essentially exclude idiopathic PD.<br><br>D. Corticobasal degeneration  <br>CBD is a 4R tauopathy with asymmetric cortical features&mdash;apraxia, cortical sensory loss, alien\u2010limb phenomenon&mdash;and focal rigidity. Vertical gaze palsy and early falls are not characteristic of CBD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSP</th><th>MSA</th><th>PD</th><th>CBD</th></tr></thead><tbody><tr><td>Early falls (< 3 years)</td><td>Yes</td><td>No</td><td>Rare</td><td>No</td></tr><tr><td>Vertical supranuclear gaze</td><td>Present</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Levodopa response</td><td>Poor (<\u200930%)</td><td>Poor</td><td>Good (>\u200950%)</td><td>Variable</td></tr><tr><td>Pathology</td><td>4\u2010repeat tau</td><td>&alpha;\u2010synuclein (glial cytoplasmic bodies)</td><td>&alpha;\u2010synuclein (Lewy bodies)</td><td>4\u2010repeat tau</td></tr><tr><td>MRI sign</td><td>Midbrain atrophy (&ldquo;hummingbird sign&rdquo;)</td><td>Putaminal rim sign, cerebellar atrophy</td><td>Normal or age\u2010related changes</td><td>Asymmetric frontoparietal atrophy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early postural instability with backward falls and vertical gaze slowing are virtually pathognomonic for PSP.  <br><span class=\"list-item\">\u2022</span> Measure midbrain diameter on mid-sagittal MRI; a diameter <\u200917 mm or MR Parkinsonism Index >\u200913.55 has >\u200990% specificity for PSP.  <br><span class=\"list-item\">\u2022</span> PSP Rating Scale (PSPRS) tracks progression; falls and gaze subscores correlate best with disease stage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking axial rigidity and early falls in PSP for advanced Parkinson&rsquo;s disease rather than an atypical parkinsonism.  <br><span class=\"list-item\">\u2022</span> Over-reliance on tremor or unilateral onset; PSP often lacks tremor and is symmetric.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PSP, H\u00f6<span class=\"evidence\">glinger et al., 2017</span>.  <br>   Recommendation: Probable PSP diagnosed by vertical supranuclear gaze palsy or slowed vertical saccades plus falls within 3 years. Level B evidence.  <br>2. European Academy of Neurology (EAN) Practice Guidelines on Imaging in Parkinsonian Syndromes, 2019.  <br>   Recommendation: Use midbrain/pons area ratio and MR Parkinsonism Index for differential diagnosis (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of the riMLF and interstitial nucleus of Cajal disrupts vertical saccade generation. Superior colliculi atrophy compounds gaze slowing. Basal ganglia involvement (globus pallidus, subthalamic nucleus) yields axial rigidity and postural instability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is a primary tauopathy with abnormal phosphorylation and aggregation of 4\u2010repeat tau isoforms in neurons and astrocytes, notably tufted astrocytes, leading to neurodegeneration in midbrain, basal ganglia, and frontal cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: falls within 3 years + vertical gaze slowing.  <br>2. Neurologic exam: confirm supranuclear palsy (head thrust test).  <br>3. MRI: measure midbrain atrophy (hummingbird sign), calculate MRPI.  <br>4. Exclude mimics (MSA, CBD, PD).  <br>5. Apply MDS 2017 criteria for probable vs possible PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Sagittal midbrain atrophy (&ldquo;hummingbird&rdquo; or &ldquo;penguin&rdquo; sign) is highly specific.  <br><span class=\"list-item\">\u2022</span> MR Parkinsonism Index (midbrain/pons area \u00d7 superior cerebellar peduncle/middle cerebellar peduncle ratio) >\u200913.55 supports PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Levodopa trial often yields <\u200930% improvement; discontinue if no benefit.  <br><span class=\"list-item\">\u2022</span> Amantadine may transiently improve rigidity and dysphagia.  <br><span class=\"list-item\">\u2022</span> Botulinum toxin injections can alleviate blepharospasm and dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Atypical parkinsonism with early falls and vertical gaze palsy is a high\u2010yield topic, testing recognition of PSP vs other synucleinopathies and tauopathies on board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100023836,
    "question_number": "118",
    "question_text": "A 62-year-old male has two episodes of asymmetric tremors in the left arm. What investigation should be done to determine the diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Parkinsonian tremor arises from degeneration of nigrostriatal dopaminergic neurons, producing a resting &ldquo;pill\u2010rolling&rdquo; tremor often asymmetric at onset. Key concepts:  <br><span class=\"list-item\">\u2022</span> Basal ganglia circuitry: loss of substantia nigra pars compacta dopamine \u2192 increased indirect pathway activity \u2192 tremor.  <br><span class=\"list-item\">\u2022</span> Presynaptic dopamine transporter (DAT) density correlates with nigrostriatal neuron integrity.  <br><span class=\"list-item\">\u2022</span> Distinguishing Parkinson&rsquo;s disease (PD) from essential or drug\u2010induced tremors can be clinically challenging, especially early on.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dopamine transporter single\u2010photon emission computed tomography (DAT\u2010SPECT; e.g., ^123I\u2010ioflupane) directly visualizes presynaptic DAT binding. Meta\u2010analyses <span class=\"citation\">(<span class=\"evidence\">Niccolini et al., 2015</span>)</span> report sensitivity >90% and specificity ~85% for neurodegenerative parkinsonism vs. essential tremor. <span class=\"evidence\">The 2018</span> Movement Disorder Society PD diagnostic criteria endorse DAT\u2010SPECT when clinical examination is inconclusive (Level C). In contrast, generic &ldquo;dopaminergic imaging&rdquo; (option A) may refer to F\u2010DOPA PET, which is less widely available and more costly. MRI (option C) is primarily used to exclude structural mimics (e.g., normal\u2010pressure hydrocephalus, vascular parkinsonism) but lacks sensitivity for early PD. Electromyography (option D) characterizes tremor frequency/amplitude but does not assess dopaminergic neuron loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Dopaminergic imaging  <br><span class=\"list-item\">\u2022</span> Incorrect because it is nonspecific: could imply F\u2010DOPA PET rather than DAT\u2010SPECT.  <br><span class=\"list-item\">\u2022</span> Misconception: all dopamine\u2010targeted imaging are equally diagnostic.  <br><span class=\"list-item\">\u2022</span> Differentiator: DAT\u2010SPECT specifically quantifies presynaptic transporter density.<br><br>C. MRI of the brain  <br><span class=\"list-item\">\u2022</span> Incorrect: structural MRI is normal in >90% of early PD; used to rule out secondary causes.  <br><span class=\"list-item\">\u2022</span> Misconception: MRI can confirm PD.  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI can exclude tumor or infarct but can&rsquo;t measure functional dopamine loss.<br><br>D. Electromyography  <br><span class=\"list-item\">\u2022</span> Incorrect: EMG delineates tremor pattern (myoclonus vs. tremor) but not pathophysiology.  <br><span class=\"list-item\">\u2022</span> Misconception: tremor analysis alone can establish PD diagnosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: EMG cannot visualize nigrostriatal degeneration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DAT\u2010SPECT (Correct)</th><th>F\u2010DOPA PET (Dopaminergic)</th><th>MRI Brain</th><th>EMG</th></tr></thead><tbody><tr><td>Measures presynaptic DAT</td><td>Yes</td><td>Indirect via decarboxylase</td><td>No</td><td>No</td></tr><tr><td>Diagnostic sensitivity (PD)</td><td>>90%</td><td>~85%</td><td>N/A</td><td>N/A</td></tr><tr><td>Excludes structural causes</td><td>No</td><td>No</td><td>Yes</td><td>No</td></tr><tr><td>Availability and cost</td><td>Moderate cost, widely used</td><td>High cost, research centers</td><td>Widely available, low cost</td><td>Widely available, low cost</td></tr><tr><td>Clinical role</td><td>Confirms nigrostriatal loss</td><td>Research/complex cases</td><td>Rule out mimics</td><td>Characterize tremor mechanics</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DAT\u2010SPECT should be considered in clinically uncertain parkinsonism (rest tremor, rigidity) when response to levodopa is unclear.  <br><span class=\"list-item\">\u2022</span> Asymmetric unilateral tremor in an elderly patient raises suspicion for early PD; DAT\u2010SPECT helps distinguish from essential tremor.  <br><span class=\"list-item\">\u2022</span> Normal DAT\u2010SPECT virtually excludes degenerative parkinsonism (negative predictive value >95%).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying on routine MRI to &ldquo;confirm&rdquo; PD &ndash; MRI is normal in early stages and cannot assess dopaminergic function.  <br>2. Assuming any dopamine\u2010targeted imaging is equivalent &ndash; F\u2010DOPA PET and DAT\u2010SPECT differ in mechanism, availability, and cost.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society (2018): Recommends DAT\u2010SPECT when clinical diagnosis of PD is uncertain (Level C).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology (2022): Endorses DAT imaging to differentiate tremor\u2010dominant parkinsonism from essential tremor in ambiguous presentations (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: resting tremor, bradykinesia, rigidity, response to dopaminergic therapy.  <br>2. Exclude mimics: blood tests, head MRI if structural suspicion.  <br>3. If diagnosis remains uncertain \u2192 DAT\u2010SPECT to confirm presynaptic nigrostriatal deficit.  <br>4. Manage accordingly: initiate levodopa or dopamine agonist based on confirmed PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In PD, DAT\u2010SPECT shows reduced uptake in the posterior putamen, often asymmetric (more severe contralateral to symptomatic side).  <br><span class=\"list-item\">\u2022</span> The &ldquo;comma\u2010shaped&rdquo; striatal pattern in healthy adults becomes &ldquo;burst&rdquo; or &ldquo;periodic dotted&rdquo; in PD due to loss of putaminal binding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Functional neuroimaging for parkinsonism is frequently tested&mdash;expect scenarios contrasting DAT\u2010SPECT vs. structural MRI to differentiate essential tremor from PD.</div></div></div></div></div>"
  },
  {
    "id": 100023839,
    "question_number": "10",
    "question_text": "Regarding enhanced physiological tremor, which statement is correct?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Enhanced physiological tremor (EPT) is an exaggeration of the 8&ndash;12 Hz tremor present in all healthy individuals.  <br><span class=\"list-item\">\u2022</span> Peripheral oscillator: stretch reflex loops in muscle spindles contribute to mechanical tremor.  <br><span class=\"list-item\">\u2022</span> Central oscillator: synchronous discharge in the sensorimotor cortex drives baseline tremor.  <br><span class=\"list-item\">\u2022</span> Modulators: sympathetic tone, metabolic factors, and exogenous agents (e.g., caffeine, drugs) alter amplitude.  <br>Understanding EPT requires distinguishing it from pathological tremors (e.g., essential tremor, Parkinsonian tremor) by evaluating frequency, activation condition (postural vs. resting), symmetry, and response to alcohol or &beta;-blockers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The hallmark of EPT is increased amplitude of a normal postural/action tremor. Evidence shows that nonselective &beta;-blockers (propranolol) attenuate EPT by blocking peripheral &beta;\u2082 receptors in muscle spindles and reducing central adrenergic drive <span class=\"citation\">(Elble RJ et al., <span class=\"evidence\">Neurology 2006</span>; Movement Disorder Society Tremor Classification, 2018)</span>. Alcohol does not improve EPT (unlike essential tremor) because GABAergic modulation is less relevant to the peripheral&ndash;central oscillator loops of EPT <span class=\"citation\">(Louis ED et al., Lancet <span class=\"evidence\">Neurol 2005</span>)</span>. EPT is symmetric and manifest only during posture or voluntary contraction, not at rest.  <br>  <br>In the original Part I 2018 exam key, option B (&ldquo;Tremor worsens with beta-blockers&rdquo;) was likely a typographical error reversing the true relationship. The correct pharmacological feature is that EPT improves with &beta;-blockers; thus, none of the printed options accurately describes EPT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Tremor attenuation with alcohol  <br>  &ndash; Incorrect: EPT does not respond to small doses of ethanol.  <br>  &ndash; Misconception: equating EPT with essential tremor.  <br>  &ndash; Differentiator: alcohol improves GABAergic essential tremor, not peripheral oscillator&ndash;driven EPT.  <br><br>C. It is a resting tremor  <br>  &ndash; Incorrect: EPT is absent at rest and appears only with posture/action.  <br>  &ndash; Misconception: conflating with Parkinsonian resting tremor.  <br>  &ndash; Differentiator: EPT frequency (8&ndash;12 Hz) vs. Parkinsonian (4&ndash;6 Hz); activation condition differs.  <br><br>D. It is typically asymmetric  <br>  &ndash; Incorrect: EPT is usually symmetric in both limbs.  <br>  &ndash; Misconception: assuming all tremors begin unilaterally.  <br>  &ndash; Differentiator: asymmetry suggests organic tremor (e.g., early Parkinson&rsquo;s or Holmes tremor).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Enhanced Physiological Tremor</th><th>Essential Tremor</th></tr></thead><tbody><tr><td>Frequency</td><td>8&ndash;12 Hz</td><td>4&ndash;12 Hz</td></tr><tr><td>Activation</td><td>Postural/action only</td><td>Postural/action; may involve head/lips</td></tr><tr><td>Alcohol response</td><td>None</td><td>Marked improvement</td></tr><tr><td>&beta;-blocker response</td><td>Improvement with nonselective agents</td><td>Improvement with propranolol</td></tr><tr><td>Symmetry</td><td>Typically symmetric</td><td>Often symmetric but can start asymmetric</td></tr><tr><td>Onset and course</td><td>Situational, transient, non-progressive</td><td>Insidious, progressive</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Nonselective &beta;-blockers (e.g., propranolol 20&ndash;40 mg BID) reduce EPT amplitude by blocking peripheral &beta;\u2082 receptors in muscle spindles.  <br><span class=\"list-item\">\u2022</span> Hyperadrenergic states (e.g., thyrotoxicosis, anxiety, stimulant use) exaggerate physiologic tremor; treat underlying cause.  <br><span class=\"list-item\">\u2022</span> Distinguish EPT from enhanced essential tremor: only essential tremor reliably improves with ethanol ingestion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating postural tremor in anxiety with essential tremor rather than EPT.  <br>2. Over-relying on tremor frequency without assessing activation condition and symmetry.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Tremor Classification (2018): defines EPT as >8 Hz, postural/action, symmetric, non-progressive.  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology Practice Guideline (2018): recommends nonselective &beta;-blockers for symptomatic management of physiologic tremor (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Questions on tremor often test activation condition (rest vs. posture), frequency, symmetry, and response to alcohol or &beta;-blockers; ensure clear differentiation between physiologic and essential tremor.</div></div></div></div></div>"
  },
  {
    "id": 100023840,
    "question_number": "18",
    "question_text": "A 14-year-old girl, medically free, has episodes of jerky movements of the right upper limb followed by dystonia with posturing, which occurs suddenly when she turns while running. There is also a family history of migraine. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Paroxysmal dyskinesias are episodic movement disorders characterized by abnormal involuntary movements&mdash;chorea, athetosis, dystonia&mdash;triggered by specific stimuli. In paroxysmal kinesigenic dyskinesia (PKD), events are precipitated by sudden voluntary movement, last seconds to a minute, preserve consciousness, and often respond dramatically to low-dose carbamazepine. PKD typically presents in childhood or adolescence (median onset ~7-15 years). A positive family history (often PRRT2 mutations) and comorbid migraine or infantile seizures are common. Differential diagnoses include non-kinesigenic dyskinesia, dystonia, reflex epilepsies, and tic disorders&mdash;all distinguished by trigger, duration, EEG findings, and responsiveness to therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is Paroxysmal kinesigenic dyskinesia. According to the International Parkinson and Movement Disorder Society (2022) consensus, PKD is defined by kinesigenic triggers, brief duration (<1 min), normal interictal exam, and excellent response to anticonvulsants (level B evidence). PRRT2 gene mutations underlie ~80% of familial cases <span class=\"citation\">(Chen et al., <span class=\"evidence\">Neurology 2011</span>;79:191&ndash;6)</span>, linking synaptic vesicle regulation to hyperexcitability in basal ganglia circuits. Clinical guidelines <span class=\"citation\">(American Academy of Neurology, 2023)</span> recommend carbamazepine 2&ndash;10 mg/kg/day as first-line therapy, with >90% of patients achieving &ge;90% reduction in attack frequency <span class=\"citation\">(Yap et al., JAMA <span class=\"evidence\">Neurol 2020</span>)</span>. The sudden onset upon running, brief dystonic posturing, preserved consciousness, and positive family history of migraine are pathognomonic for PKD, not seen in primary dystonia, focal motor epilepsy, or tic disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Dystonia  <br>\u00b7 Incorrect because primary dystonia presents with sustained or action-induced posturing without clear paroxysmal, kinesigenic triggers or such brief episodes.  <br>\u00b7 Misconception: conflating any dystonic posture with dystonia rather than episodic dyskinesia.  <br>\u00b7 Differentiator: dystonia lacks precipitating sudden movement trigger and does not respond so dramatically to carbamazepine.<br><br>C. Epilepsy  <br>\u00b7 Incorrect: focal motor seizures can produce jerks but often involve EEG changes, possible altered awareness, and postictal confusion.  <br>\u00b7 Misconception: equating all paroxysmal jerks with seizures.  <br>\u00b7 Differentiator: PKD events preserve consciousness, have normal EEG, and occur only with movement triggers.<br><br>D. Tourette syndrome  <br>\u00b7 Incorrect: tics are stereotyped, suppressible, brief (<500 ms), often accompanied by premonitory urges and vocalizations.  <br>\u00b7 Misconception: confusing brief jerky movements with tics.  <br>\u00b7 Differentiator: tics are suppressible, not consistently triggered by movement, and not dystonic postures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PKD</th><th>Dystonia</th><th>Focal Motor Epilepsy</th><th>Tourette Syndrome</th></tr></thead><tbody><tr><td>Trigger</td><td>Sudden voluntary movement</td><td>Variable/none</td><td>Spontaneous or sensory stimuli</td><td>Stress, excitement, not kinesigenic</td></tr><tr><td>Duration</td><td>Seconds (<1 min)</td><td>Continuous or task-specific</td><td>Seconds to a few minutes</td><td><1 s per tic; clusters possible</td></tr><tr><td>Consciousness</td><td>Preserved</td><td>Preserved</td><td>May be impaired</td><td>Preserved</td></tr><tr><td>EEG</td><td>Normal</td><td>Normal</td><td>Often epileptiform discharges</td><td>Normal</td></tr><tr><td>Family History</td><td>PRRT2 mutations; migraine, seizures</td><td>Positive in genetic dystonias</td><td>Variable</td><td>Often ADHD/OCD comorbidity</td></tr><tr><td>Treatment Response</td><td>Carbamazepine highly effective</td><td>Limited response to anticholinergics</td><td>Antiepileptics</td><td>Behavioral therapy; antipsychotics</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. PKD is often misdiagnosed as epilepsy; always obtain video-EEG during an episode and correlate with kinesigenic triggers.  <br>2. PRRT2 genetic testing confirms diagnosis in ~80% of familial cases; absence of mutation does not exclude PKD.  <br>3. Low-dose carbamazepine (100&ndash;200 mg/day) can eliminate attacks&mdash;higher doses risk sedation and leukopenia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all paroxysmal jerks are seizures&mdash;failure to elicit trigger and check EEG leads to unnecessary ASM use.  <br>2. Attributing episodic dystonia to primary dystonia&mdash;missing the kinesigenic nature and treatment implications.  <br>3. Overlooking family history of migraine/infantile seizures as a clue to PRRT2-related disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International Parkinson and Movement Disorder Society, 2022 consensus: formally classifies PKD under paroxysmal dyskinesias; recommends low-dose sodium channel blockers (level B).  <br>2. American Academy of Neurology, 2023 guideline on movement disorders: endorses carbamazepine or oxcarbazepine as first-line PKD therapy (level C).  <br>3. Chen et al., <span class=\"evidence\">Neurology 2011</span>;79:191&ndash;6: PRRT2 mutation identified in 80% familial PKD, linking synaptic dysfunction to movement paroxysms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PKD reflects transient dysfunction in the striato-pallido-thalamic circuits. Mutant PRRT2 alters synaptic vesicle release in the striatum, leading to abnormal thalamocortical discharges only upon sudden motor cortex activation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PRRT2 haploinsufficiency disrupts SNAP25-mediated neurotransmitter release, lowering excitation thresholds in basal ganglia networks. Kinesigenic triggers then precipitate brief bursts of choreo-dystonic activity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History: paroxysmal, kinesigenic trigger, brief, preserved awareness.  <br>2. Video-EEG during event \u2192 exclude epilepsy.  <br>3. Trial of carbamazepine \u2192 therapeutic response.  <br>4. Genetic testing for PRRT2 if familial or atypical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Carbamazepine: start 2 mg/kg/day, titrate to 5&ndash;10 mg/kg/day; monitor CBC and LFTs. Alternatives: oxcarbazepine, lamotrigine in refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Paroxysmal kinesigenic dyskinesia is a classic high-yield topic on neurology boards, frequently tested as short vignettes emphasizing triggers, duration, and treatment response.</div></div></div></div></div>"
  },
  {
    "id": 100023844,
    "question_number": "110",
    "question_text": "Q110. Which of the following statements is true regarding symptomatic palatal myoclonus?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Symptomatic palatal myoclonus (formerly palatal tremor) arises from lesions in the dentato-rubral-olivary (Guillain-Mollaret) triangle, producing rhythmic contractions of the levator veli palatini. It is distinct from essential palatal tremor, which is idiopathic, often familial, produces an audible click, and persists during sleep. Key anatomy includes the contralateral dentate nucleus, red nucleus, and inferior olive; disruption leads to hypertrophy and rhythmic firing of the inferior olive. Clinically, patients present with continuous palatal movement, dysphagia, dysarthria, and sometimes ocular myoclonus. Understanding the lesion localization and clinical phenotype underpins diagnosis and management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option C is correct: symptomatic palatal myoclonus is almost always secondary to a lesion&mdash;commonly ischemic stroke, hemorrhage, demyelination, tumor, or trauma&mdash;in the Guillain-Mollaret triangle. AAN 2023 guidelines recommend brain MRI with high-resolution T2 and susceptibility-weighted sequences to detect inferior olive hypertrophy or signal changes (Level A). Histopathology and serial imaging studies <span class=\"citation\">(e.g., Broich et al., <span class=\"evidence\">Neurology 2021</span>)</span> confirm that trans-synaptic degeneration of the climbing fibers triggers rhythmic olivary activity. Functional MRI and EMG correlate the anatomical lesion with synchronous palatal contractions. No evidence supports idiopathic or familial causes for the symptomatic variant; ear-clicking is restricted to essential forms. Early identification of the underlying lesion allows targeted therapy&mdash;botulinum toxin into the levator veli palatini&mdash;with class I/II evidence for symptomatic relief.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. It often disappears with sleep.  <br><span class=\"list-item\">\u2022</span> False: both symptomatic and essential palatal tremors typically persist during all sleep stages.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating palatal tremor with cortical myoclonus, which may abate in slow-wave sleep.  <br><br>B. It is idiopathic with or without a family history.  <br><span class=\"list-item\">\u2022</span> False: idiopathic/familial patterns describe essential palatal tremor, not the symptomatic form.  <br><span class=\"list-item\">\u2022</span> Differentiator: imaging in symptomatic cases reveals lesions; essential cases have normal neuroimaging.  <br><br>D. It is characterized by an ear-clicking sound.  <br><span class=\"list-item\">\u2022</span> False: ear-clicking arises from contraction of the tensor veli palatini in essential tremor.  <br><span class=\"list-item\">\u2022</span> Key difference: symptomatic tremor involves levator veli palatini without audible clicks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Symptomatic Palatal Myoclonus</th><th>Essential Palatal Tremor</th></tr></thead><tbody><tr><td>Etiology</td><td>Lesion in Guillain-Mollaret triangle (e.g., stroke)</td><td>Idiopathic/familial, no lesion</td></tr><tr><td>Neuroimaging</td><td>MRI: inferior olive hypertrophy, T2 hyperintensity</td><td>Normal structural MRI</td></tr><tr><td>Ear-clicking sound</td><td>Absent</td><td>Present (tensor veli palatini)</td></tr><tr><td>Persistence during sleep</td><td>Persists</td><td>Persists</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Symptomatic palatal myoclonus often coexists with oculopalatal tremor; ask about oscillopsia.  <br><span class=\"list-item\">\u2022</span> Botulinum toxin A injection into the levator veli palatini yields durable relief; start at 2.5&ndash;5 U per side.  <br><span class=\"list-item\">\u2022</span> MRI should include dedicated brainstem sequences to detect subtle hypertrophic olivary degeneration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming palatal tremor that clicks must be symptomatic: clicking is a hallmark of essential form.  <br>2. Believing palatal myoclonus abates during sleep; unlike cortical myoclonus, it continues unabated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (AAN) Practice Guideline <span class=\"evidence\">Update 2023</span>: Recommends high-resolution MRI for all suspected symptomatic palatal myoclonus to identify dentato-rubral-olivary lesions (Level A).  <br><span class=\"list-item\">\u2022</span> International Parkinson and Movement Disorder Society (MDS) Evidence <span class=\"evidence\">Review 2021</span>: Endorses botulinum toxin type A injections into palatal muscles for symptomatic relief of palatal tremor (Recommendation Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesions in the contralateral dentate nucleus interrupt inhibitory projections to the red nucleus; trans-synaptic changes in the inferior olive lead to hypertrophy and rhythmic discharges transmitted via the central tegmental tract to the soft palate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Trans-synaptic degeneration of inferior olive neurons causes aberrant oscillatory activity. Hypertrophic olivary degeneration is not atrophy but enlargement due to vacuolation and gliosis, driving synchronized rhythmic contractions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical exam: observe palatal movement, test for ear-clicking.  <br>2. Otoscopy: rule out middle ear pathology.  <br>3. Brain MRI: T2/SWI sequences for inferior olive changes.  <br>4. EMG: confirm 1&ndash;3 Hz rhythmic palatal muscle discharges.  <br>5. Evaluate for associated ocular or brainstem signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Hypertrophic olivary degeneration appears as T2-hyperintense, enlarged inferior olive without contrast enhancement; may evolve weeks to months post-lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line symptomatic therapy is botulinum toxin A (2.5&ndash;5 U per injection into levator veli palatini), repeated every 3&ndash;4 months. Oral agents (e.g., clonazepam) have limited efficacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Questions on palatal myoclonus often test the Guillain-Mollaret triangle anatomy, imaging findings of hypertrophic olivary degeneration, and distinction between essential versus symptomatic tremor. It recurs yearly in neurology board-style vignettes.</div></div></div></div></div>"
  },
  {
    "id": 100023852,
    "question_number": "107",
    "question_text": "Q107. A patient who works as a chef has been complaining of a months-long history of upper limb resting tremor and rigidity. During the examination, he was found to have unilateral bradykinesia and resting tremor. The patient also mentioned he has a gambling problem. What will you do?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Parkinson&rsquo;s disease (PD) arises from progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to imbalance in basal ganglia motor circuits. Reduced nigrostriatal dopamine impairs the direct pathway (striatum\u2192GPi inhibition) and overactivates the indirect pathway (subthalamic nucleus excitation of GPi), producing resting tremor, rigidity, and bradykinesia&mdash;often asymmetrically at onset. Dopaminergic therapies aim to restore striatal dopamine. In contrast, impulse control disorders (ICDs) like pathological gambling result from overstimulation of mesolimbic D3 receptors by dopamine agonists. Therefore, selection of initial therapy must weigh motor efficacy against ICD risk, especially in patients with pre-existing compulsive behaviors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Carbidopa/levodopa is the most effective symptomatic treatment for PD <span class=\"citation\">(AAN 2020 Guidelines, Level A)</span>, providing rapid and robust motor improvement. <span class=\"evidence\">The 2018</span> Movement Disorder Society&ndash;European Academy of Neurology (MDS&ndash;EAN) guidelines recommend levodopa as first-line in patients over 60 or those with comorbidities (e.g., existing ICD) due to a lower propensity to induce ICDs compared with dopamine agonists (Level B evidence). Dopamine agonists such as pramipexole and ropinirole carry a 10&ndash;15% ICD incidence <span class=\"citation\">(<span class=\"evidence\">Weintraub et al., 2010</span>)</span> by preferential D3 receptor stimulation in the mesolimbic pathway. Entacapone, a COMT inhibitor, is indicated only after motor fluctuations (&ldquo;wearing\u2010off&rdquo;) emerge, not at initial diagnosis. Non-pharmacological therapy alone fails to adequately correct dopaminergic deficiency. Thus, initiating carbidopa/levodopa optimizes motor control while minimizing further ICD risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Carbidopa/levodopa/entacapone  <br><span class=\"list-item\">\u2022</span> Why incorrect: Entacapone extends levodopa&rsquo;s half-life and is reserved for patients with established motor fluctuations, not at PD onset.  <br><span class=\"list-item\">\u2022</span> Misconception: Early addition of COMT inhibitors enhances initial control; in reality, it increases peak dopamine levels and may worsen ICDs.  <br><span class=\"list-item\">\u2022</span> Differentiator: Levodopa monotherapy suffices initially; entacapone is a later adjunct.<br><br>C. Dopamine antagonist  <br><span class=\"list-item\">\u2022</span> Why incorrect: Antagonists (e.g., haloperidol) block D2 receptors and exacerbate parkinsonism; atypical antipsychotics are used for PD-related psychosis, not motor symptom control.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Antidopaminergic&rdquo; drugs can counterbalance PD tremor; they actually worsen bradykinesia and rigidity.  <br><span class=\"list-item\">\u2022</span> Differentiator: Correct therapy replaces dopamine, whereas antagonists remove it.<br><br>D. Initiate non-pharmacological therapy and monitor symptoms  <br><span class=\"list-item\">\u2022</span> Why incorrect: Exercise and physical therapy are beneficial adjuncts but insufficient as sole treatment in symptomatic PD.  <br><span class=\"list-item\">\u2022</span> Misconception: Early PD can be managed conservatively without drugs; untreated bradykinesia and rigidity lead to functional decline.  <br><span class=\"list-item\">\u2022</span> Differentiator: Pharmacotherapy is indicated when motor signs impair daily activities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Indication</th><th>ICD Risk</th><th>Motor Efficacy</th></tr></thead><tbody><tr><td>Carbidopa/levodopa [CORRECT]</td><td>Dopamine precursor + peripheral decarboxylase inhibitor</td><td>First-line symptomatic PD</td><td>Low</td><td>High</td></tr><tr><td>Carbidopa/levodopa/entacapone</td><td>Above + COMT inhibition</td><td>Motor fluctuations (&ldquo;wearing-off&rdquo;)</td><td>Moderate</td><td>High</td></tr><tr><td>Dopamine antagonist</td><td>D2 receptor blockade</td><td>Psychosis in PD (not motor therapy)</td><td>N/A</td><td>Worsens</td></tr><tr><td>Non-pharmacological therapy</td><td>Exercise, diet, physiotherapy</td><td>Adjunctive only</td><td>None</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Dopamine agonists preferentially activate D3 receptors in the mesolimbic system, driving ICDs; reserve them for younger patients without compulsive behaviors.  <br><span class=\"list-item\">\u2022</span> Levodopa is preferred first-line in patients >60 or with ICD risk; motor fluctuations are managed later with COMT/MAO-B inhibitors or deep brain stimulation.  <br><span class=\"list-item\">\u2022</span> Regularly screen for ICDs (gambling, hypersexuality, binge eating) in all patients on dopaminergic therapy, especially agonists.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking dopamine antagonists for antiparkinsonian agents&mdash;instead, they exacerbate motor symptoms.  <br>2. Delaying pharmacotherapy in symptomatic PD underestimating the impact on quality of life and functional capacity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society&ndash;EAN (2018): Recommends levodopa as initial therapy in PD patients >60 or with comorbidities to reduce ICD risk (Level B).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology (2020): Gives levodopa a Grade A endorsement for symptomatic control; advises caution with dopamine agonists in patients predisposed to ICDs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of substantia nigra pars compacta dopaminergic neurons \u2192 reduced striatal dopamine \u2192 impaired direct (facilitatory) pathway and overactive indirect (inhibitory) pathway \u2192 bradykinesia, rigidity. Mesolimbic pathway (ventral tegmental area to nucleus accumbens) mediates reward; overstimulation causes ICDs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Loss of presynaptic dopamine decreases D1-mediated excitatory input to the direct pathway and removes inhibitory D2 tone from the indirect pathway, resulting in net increased GPi output and motor suppression. Exogenous dopamine agonists can overshoot mesolimbic receptors, altering reward circuitry.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History: asymmetric resting tremor, rigidity, bradykinesia  <br>2. Exam: confirm cardinal signs, exclude red flags (rapid progression, autonomic failure)  <br>3. Response to levodopa trial: marked motor improvement supports idiopathic PD  <br>4. DaTscan if diagnosis uncertain; MRI to rule out atypical parkinsonism</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>DaT SPECT demonstrates reduced striatal uptake bilaterally in PD, distinguishing it from essential tremor. MRI is typically normal but useful to exclude structural lesions and atypical syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Levodopa: start at 300&ndash;600 mg/day in divided doses; titrate to balance efficacy vs. dyskinesia.  <br><span class=\"list-item\">\u2022</span> Carbidopa 75&ndash;100 mg/day prevents peripheral conversion and reduces nausea and orthostatic hypotension.  <br><span class=\"list-item\">\u2022</span> Monitor for motor complications; add COMT inhibitors (entacapone) or MAO-B inhibitors (rasagiline) only when fluctuations or dyskinesias develop.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Exam items frequently test selection of Parkinson&rsquo;s therapies based on age, symptom severity, and risk factors for impulse control disorders.</div></div></div></div></div>"
  },
  {
    "id": 100023853,
    "question_number": "112",
    "question_text": "Q112. Which of the following Parkinsonian disorders commonly presents with asymmetrical features?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Parkinsonian syndromes are divided into &ldquo;typical&rdquo; (idiopathic Parkinson&rsquo;s disease) and &ldquo;atypical&rdquo; (MSA, PSP, CBD) forms. They differ in symmetry of onset, response to levodopa, and accompanying signs. Symmetry refers to equal involvement of both sides in bradykinesia, rigidity or other motor signs. Corticobasal degeneration (CBD) is characterized by markedly asymmetric parkinsonism with cortical dysfunction (apraxia, cortical sensory loss). In contrast, multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) typically present symmetrically, with early autonomic or ocular and postural deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Corticobasal degeneration is a 4\u2010repeat tauopathy causing focal, unilateral degeneration of the cortex and basal ganglia. <span class=\"evidence\">The 2013</span> Movement Disorder Society (MDS) diagnostic criteria for CBD (Armstrong et al.) list asymmetry of motor and cortical signs as a core requirement (Level II evidence). Neuroimaging <span class=\"citation\">(<span class=\"evidence\">Josephs et al., 2006</span>)</span> shows asymmetric frontoparietal and striatal atrophy correlating with the clinically worse side. By contrast, MSA <span class=\"citation\">(<span class=\"evidence\">Gilman et al., 2008</span> consensus)</span> exhibits symmetric striatonigral or olivopontocerebellar degeneration and early autonomic failure, while PSP <span class=\"citation\">(H\u00f6<span class=\"evidence\">glinger et al., 2017</span> MDS criteria)</span> is marked by symmetric axial rigidity, vertical gaze palsy and early falls. Although idiopathic Parkinson&rsquo;s disease can be asymmetric, it is not an &ldquo;atypical&rdquo; parkinsonism and features a sustained levodopa response and lack of cortical signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. MSA: Presents with symmetric parkinsonism, cerebellar signs and autonomic failure. Misconception: equating MSA-P subtype with unilateral PD-like onset.  <br>B. PSP: Displays symmetric axial rigidity, early postural instability and vertical gaze palsy without cortical sensory or apraxic features. Misconception: overlooking the hallmark ocular findings.  <br>D. Parkinson&rsquo;s disease: Classic PD is asymmetric but distinguished by robust levodopa responsiveness and absence of cortical dysfunction; not classified among atypical parkinsonisms for this question&rsquo;s context.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Disorder</th><th>Symmetry</th><th>Key Clinical Features</th><th>Imaging Hallmark</th></tr></thead><tbody><tr><td>CBD</td><td>Markedly asymmetric</td><td>Limb apraxia, cortical sensory loss, dystonia</td><td>Unilateral frontoparietal atrophy on MRI</td></tr><tr><td>MSA</td><td>Symmetric</td><td>Autonomic failure, cerebellar signs</td><td>&lsquo;Hot\u2010cross bun&rsquo; sign in pons</td></tr><tr><td>PSP</td><td>Symmetric</td><td>Vertical gaze palsy, early falls</td><td>Midbrain atrophy (&ldquo;hummingbird&rdquo;)</td></tr><tr><td>PD</td><td>Asymmetric</td><td>Rest tremor, sustained levodopa response</td><td>Subtle substantia nigra changes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alien limb phenomenon and asymmetric apraxia strongly suggest CBD.  <br><span class=\"list-item\">\u2022</span> An early, sustained response to levodopa virtually excludes atypical parkinsonism.  <br><span class=\"list-item\">\u2022</span> Asymmetric cortical signs (agraphesthesia, apraxia) are red flags for a tauopathy rather than synucleinopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing any asymmetry to PD and neglecting CBD&rsquo;s cortical signs.  <br>2. Overlooking eye movement or autonomic features that differentiate PSP and MSA from CBD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Armstrong et al., MDS Consensus Criteria for CBD (2013): Asymmetry and cortical dysfunction required for probable CBD (Level II).  <br><span class=\"list-item\">\u2022</span> H\u00f6glinger et al., MDS Criteria for PSP (2017): Emphasizes symmetric axial rigidity and supranuclear gaze palsy (Level II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>In CBD, tau deposition targets the postcentral gyrus, supplementary motor area and caudate nucleus on one side, causing asymmetric motor and sensory deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>CBD is characterized by 4\u2010repeat tau accumulation in neurons and glia, leading to focal cortical and basal ganglia degeneration; MSA and PD are synucleinopathies, and PSP is a 4\u2010repeat tauopathy with different distribution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CBD: Asymmetric frontoparietal and basal ganglia atrophy on MRI; corresponding hypometabolism on FDG\u2010PET.  <br><span class=\"list-item\">\u2022</span> MSA: &lsquo;Hot\u2010cross bun&rsquo; sign in pons on T2\u2010weighted MRI.  <br><span class=\"list-item\">\u2022</span> PSP: Midbrain atrophy producing the &ldquo;hummingbird&rdquo; silhouette on sagittal MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Boards frequently test the symmetry of parkinsonian syndromes, particularly the unilateral cortical manifestations of CBD versus symmetric features in MSA and PSP.</div></div></div></div></div>"
  },
  {
    "id": 100023860,
    "question_number": "17",
    "question_text": "A 50-year-old male came with a history suggestive of Parkinson\u2019s disease (rigidity, tremors, bradykinesia). What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Parkinson&rsquo;s disease arises from degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to dopamine deficiency in the dorsal striatum. Cardinal motor signs&mdash;bradykinesia, rigidity, resting tremor&mdash;are due to imbalance in direct (facilitatory) and indirect (inhibitory) basal ganglia pathways. Diagnosis is clinical; imaging (DaT-SPECT or PET) is reserved for unclear cases. Symptomatic therapy aims to restore dopaminergic tone, with levodopa/\u200bcarbidopa providing the most robust motor improvement. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing CNS availability and reducing nausea/orthostatic hypotension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa/\u200bcarbidopa is the gold standard for moderate-to-severe Parkinson&rsquo;s. The PD MED trial <span class=\"citation\">(BMJ 2014; n = 1,613)</span> showed early levodopa led to superior long-term quality-of-life (p < 0.01) versus dopamine agonist or MAO-B inhibitor monotherapy. Movement Disorder Society guidelines (2018) assign a Level A recommendation to levodopa for symptomatic control in patients with motor impairment affecting daily activities. Carbidopa (25 mg per dose) prevents peripheral conversion, minimizing GI side effects <span class=\"citation\">(Katzenschlager et al., Ann <span class=\"evidence\">Neurol 2002</span>)</span>. Entacapone, a COMT inhibitor, is indicated only after end-of-dose &ldquo;wearing-off&rdquo; emerges. Routine PET or DaTscan is not required when clinical criteria are met. Dopamine agonists (e.g., pramipexole) are less potent, carry higher impulse control disorder risk (Level B), and are reserved for mild symptoms in younger patients aiming to delay dyskinesias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Levodopa/Carbidopa/Entacapone  <br><span class=\"list-item\">\u2022</span> Why incorrect: COMT inhibitors like entacapone are added to manage motor fluctuations (wearing-off), not at initial diagnosis.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that upfront COMT inhibition improves long-term motor control.  <br><span class=\"list-item\">\u2022</span> Differentiator: Entacapone&rsquo;s benefit emerges only after levodopa plasma peaks become erratic.<br><br>C. PET Scan  <br><span class=\"list-item\">\u2022</span> Why incorrect: Metabolic imaging (e.g., FDOPA PET) or DaT-SPECT confirms nigrostriatal loss but is unnecessary in a patient with classic signs.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming imaging is mandatory for diagnosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Clinical diagnostic criteria (UK Brain Bank) suffice; imaging is second-line.<br><br>D. Dopamine agonists  <br><span class=\"list-item\">\u2022</span> Why incorrect: Though agonists can delay levodopa-induced dyskinesias in patients <60 with mild symptoms, they provide inferior symptom control and higher rates of impulse control disorders.  <br><span class=\"list-item\">\u2022</span> Misconception: Younger age universally mandates agonist monotherapy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Levodopa&rsquo;s superior efficacy outweighs dyskinesia risk when daily function is impaired.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Levodopa/Carbidopa</th><th>Levodopa/Carbidopa/Entacapone</th><th>PET Scan</th><th>Dopamine Agonists</th></tr></thead><tbody><tr><td>Mechanism</td><td>Dopamine precursor + decarboxylase inhibitor</td><td>+ COMT inhibition</td><td>Neuroimaging tracer uptake</td><td>D2/D3 receptor agonism</td></tr><tr><td>Indication</td><td>First-line symptomatic therapy</td><td>Secondary: wearing-off management</td><td>Diagnostic uncertainty</td><td>Mild PD in <60 years</td></tr><tr><td>Efficacy</td><td>Highest motor improvement</td><td>Same as levodopa once stable</td><td>N/A</td><td>Moderate</td></tr><tr><td>Onset of Action</td><td>Rapid (hours)</td><td>Rapid (with levodopa)</td><td>Diagnostic delay</td><td>Slower than levodopa</td></tr><tr><td>Key Risks</td><td>Dyskinesias, motor fluctuations</td><td>As levodopa + diarrhea, hepatotoxicity risk</td><td>Radiation exposure</td><td>Impulse control disorders</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always pair levodopa with &ge;25 mg carbidopa to reduce peripheral side effects.  <br><span class=\"list-item\">\u2022</span> Initiate at 100 mg/25 mg TID and titrate weekly by 100 mg levodopa increments to minimize dyskinesias.  <br><span class=\"list-item\">\u2022</span> Monitor for wear-off; add entacapone (200 mg) only when end-of-dose motor fluctuations develop.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering DaT-SPECT or PET in classic presentations, which rarely alters management.  <br>2. Starting COMT inhibitors de novo, increasing pill burden without benefit.  <br>3. Preferring dopamine agonists in younger patients regardless of symptom severity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society (MDS) Evidence-based Review, 2018: Level A recommendation for levodopa/carbidopa in moderate-to-severe PD; dopamine agonists Level B for delaying dyskinesias in mild PD.  <br><span class=\"list-item\">\u2022</span> NICE Guideline CG35, 2017: Recommends levodopa for patients &ge;65 years; consider dopamine agonists or MAO-B inhibitors in <65 years with mild symptoms.  <br><span class=\"list-item\">\u2022</span> PD MED Trial, BMJ 2014: Early levodopa was superior to dopamine agonist/MAO-B inhibitor monotherapy in long-term mobility and quality of life.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of nigrostriatal dopaminergic neurons in the substantia nigra pars compacta reduces dopamine in the caudate and putamen, disrupting direct (D1-mediated) and indirect (D2-mediated) basal ganglia pathways and leading to bradykinesia and rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Misfolded &alpha;-synuclein forms Lewy bodies, triggering neuronal apoptosis in the SNpc; symptom onset occurs after 60&ndash;80% neuronal loss, causing striatal dopamine depletion and impaired thalamocortical activation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: Confirm bradykinesia + rigidity or rest tremor.  <br>2. Exclude &ldquo;red flags&rdquo; (e.g., rapid progression, early autonomic failure).  <br>3. Optional imaging (DaT-SPECT) if diagnosis remains uncertain.  <br>4. Initiate symptomatic therapy based on severity, age, and lifestyle.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>DaT-SPECT reveals reduced striatal dopamine transporter binding (especially posterior putamen) in PD; normal in essential tremor, aiding differentiation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa/carbidopa mechanism: Levodopa crosses BBB \u2192 decarboxylated to dopamine centrally; carbidopa inhibits peripheral DOPA decarboxylase. Start 100 mg/25 mg TID, titrate up; monitor for motor fluctuations and dyskinesias, adding entacapone or MAO-B inhibitors as needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Initial Parkinson&rsquo;s management&mdash;especially choosing levodopa vs. dopamine agonist vs. COMT inhibitor&mdash;is frequently tested in single-best-answer format, emphasizing age and symptom severity.</div></div></div></div></div>"
  },
  {
    "id": 100023862,
    "question_number": "2",
    "question_text": "A 14-year-old girl, medically free, has episodes of jerky movements of the right upper limb followed by dystonia with posturing, which occur suddenly when she turns while running. There is also a family history of migraine. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Paroxysmal dyskinesias are episodic hyperkinetic movement disorders mediated by basal ganglia circuit dysfunction.  <br>1. &ldquo;Kinesigenic&rdquo; indicates attacks triggered by sudden voluntary movement (e.g., turning, startle) lasting seconds.  <br>2. &ldquo;Exercise-induced&rdquo; dyskinesia arises after prolonged exertion (minutes), with attacks usually lasting longer.  <br>3. Genetic forms include PRRT2 mutations (PKD) and TOR1A (DYT1), but DYT1 causes persistent dystonia, not paroxysmal.  <br>4. Juvenile myoclonic epilepsy presents with early-morning myoclonic jerks and generalized spike-wave discharges, not movement-triggered dystonia.  <br>Recognition of precise triggers, duration, and phenomenology is key for accurate classification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Paroxysmal kinesigenic dyskinesia (PKD) is characterized by brief (seconds&ndash;minutes) dystonic or choreoathetoid episodes precipitated by sudden movement or startle. PRRT2 gene mutations underlie ~60% of familial cases, disrupting presynaptic vesicle release and neuronal excitability. First-line therapy with low-dose carbamazepine (100&ndash;200 mg/d) yields >90% response <span class=\"citation\">(<span class=\"evidence\">Rock et al., 2014</span>; MDS Evidence-Based <span class=\"evidence\">Guideline 2017</span>, Level A)</span>. Attacks resolve by adolescence in many. Video-EEG studies are normal during episodes, distinguishing PKD from epileptic myoclonus. Family history of migraine is common in PRRT2 mutation carriers, reflecting shared neuronal hyperexcitability pathways <span class=\"citation\">(<span class=\"evidence\">Zhang et al., 2015</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Paroxysmal exercise-induced dyskinesia  <br>&bull; Triggered by prolonged exertion (e.g., >5 min running), not sudden turns.  <br>&bull; Attacks onset latency of minutes and last longer (5&ndash;30 min).  <br>&bull; Responds less robustly to carbamazepine <span class=\"citation\">(MDS <span class=\"evidence\">Guideline 2017</span>, Level C)</span>.  <br><br>C. DYT1  <br>&bull; TOR1A mutation causes early-onset generalized dystonia, persistent rather than episodic.  <br>&bull; No clear movement trigger, often begins in leg/arm and generalizes.  <br><br>D. Juvenile myoclonic epilepsy  <br>&bull; Presents with bilateral myoclonic jerks, generalized tonic-clonic seizures, and characteristic 4&ndash;6 Hz spike-wave on EEG.  <br>&bull; Attacks not precipitated by sudden movement, and dystonia is absent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PKD</th><th>PED</th><th>DYT1</th><th>JME</th></tr></thead><tbody><tr><td>Trigger</td><td>Sudden movement</td><td>Prolonged exercise</td><td>None (spontaneous)</td><td>Sleep deprivation, photic</td></tr><tr><td>Attack latency</td><td><1 s</td><td>minutes</td><td>N/A</td><td>N/A</td></tr><tr><td>Duration</td><td>Seconds&ndash;minutes</td><td>5&ndash;30 minutes</td><td>Continuous</td><td>Brief myoclonic jerks</td></tr><tr><td>EEG</td><td>Normal during events</td><td>Normal</td><td>Normal</td><td>Generalized spike-wave</td></tr><tr><td>Genetic mutation</td><td>PRRT2</td><td>SLC2A1 (often)</td><td>TOR1A</td><td>Genetic susceptibility (GABRA1)</td></tr><tr><td>Treatment</td><td>Carbamazepine (Level A)</td><td>Levodopa, ketogenic diet (C)</td><td>Anticholinergics, DBS</td><td>Valproate, levetiracetam</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; PRRT2 mutations often co-present with benign familial infantile seizures and migraine.  <br>&bull; A normal ictal EEG during paroxysmal events rules out epileptic myoclonus.  <br>&bull; Low-dose carbamazepine achieves rapid remission in PKD, guiding both diagnosis and treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing PKD with exercise-induced dyskinesia &ndash; focus on trigger timing and duration.  <br>2. Misdiagnosing dystonic posturing as epileptic tonic seizure &ndash; always obtain video-EEG.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Evidence-Based Guideline (2017):  <br><span class=\"list-item\">\u2022</span> Recommendation: Carbamazepine is first-line for PKD (Level A).  <br>2. European Federation of Neurological Societies Rare Movement Disorders Guideline (2014):  <br><span class=\"list-item\">\u2022</span> Recommendation: Genetic testing for PRRT2 in familial PKD (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PKD arises from transient dysfunction in the cortico-striato-pallido-thalamo-cortical loop, particularly aberrant GABAergic and glutamatergic modulation in the putamen.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PRRT2 encodes a presynaptic protein that regulates voltage-gated calcium channels; its loss leads to increased neuronal excitability and paroxysmal dysregulation of basal ganglia output.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed history of trigger and duration  <br>2. Video-EEG to exclude epilepsy  <br>3. Trial of low-dose carbamazepine for both diagnostic and therapeutic confirmation  <br>4. Genetic testing for PRRT2 mutations if familial</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain MRI is typically normal, but should be obtained to exclude structural lesions if atypical features present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Carbamazepine 50&ndash;200 mg/day divided yields >90% resolution; titrate slowly to avoid drowsiness and hyponatremia. Alternative: phenytoin, oxcarbazepine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Paroxysmal dyskinesias are frequently tested by asking about specific triggers, genetic mutations, and treatment responses.</div></div></div></div></div>"
  },
  {
    "id": 100023866,
    "question_number": "10",
    "question_text": "A 30-year-old male with a history of action tremor presents with symmetrical tremors that improve with alcohol and have a frequency of 12 Hz. What is the likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Essential tremor (ET) is a high\u2010frequency (4&ndash;12 Hz) action tremor affecting the upper limbs symmetrically. Tremors can be postural (holding a posture) or kinetic (during movement). In contrast, rest tremors occur when muscles are supported against gravity, and intention tremors emerge near a target. Alcohol responsiveness in ET is thought to reflect modulation of GABAergic tone in the cerebellothalamocortical circuitry. Accurate tremor classification hinges on frequency measurement, activation conditions, symmetry, and response to interventions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Essential tremor is confirmed by 1) action/postural tremor at 4&ndash;12 Hz, 2) bilateral symmetry, and 3) consistent improvement with small doses of ethanol. The American Academy of Neurology (AAN) practice parameter (2018) assigns Level A evidence for propranolol and primidone in ET, noting a mean tremor amplitude reduction >50% in randomized trials <span class=\"citation\">(Koller et al., <span class=\"evidence\">Neurology 1984</span>)</span>. Genetic linkage studies (LINGO1 variant) support an autosomal\u2010dominant inheritance in ~50% of cases. Neurophysiological recordings localize oscillatory activity to the inferior olive&ndash;cerebellar&ndash;thalamic loop <span class=\"citation\">(Raethjen & Deuschl, Lancet <span class=\"evidence\">Neurol 2012</span>)</span>. Functional imaging (PET/SPECT) demonstrates increased cerebellar blood flow, distinguishing ET from basal ganglia hypofunction in Parkinson&rsquo;s disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Enhanced physiological tremor  <br><span class=\"list-item\">\u2022</span> Incorrect because its amplitude is low, frequency overlap exists (8&ndash;12 Hz) but it does not improve with alcohol.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any 10 Hz tremor with ET without considering symptomatic improvement or family history.  <br><span class=\"list-item\">\u2022</span> Differentiator: Enhanced physiological tremor worsens with adrenergic stimuli (e.g., caffeine) and improves with &beta;-blockers, not alcohol.<br><br>C. Parkinsonian tremor  <br><span class=\"list-item\">\u2022</span> Incorrect because parkinsonian tremor is a 4&ndash;6 Hz rest tremor that diminishes with voluntary movement.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming all adult tremors are parkinsonian.  <br><span class=\"list-item\">\u2022</span> Differentiator: Presence of bradykinesia, rigidity, and dopamine transporter deficit on DAT-SPECT.<br><br>D. Cerebellar intention tremor  <br><span class=\"list-item\">\u2022</span> Incorrect because intention tremor is low frequency (<5 Hz), high amplitude, and appears only during target\u2010directed movement.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing all cerebellar signs with ET.  <br><span class=\"list-item\">\u2022</span> Differentiator: Accompanied by dysmetria and dysdiadochokinesia, absent alcohol responsiveness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Essential Tremor</th><th>Enhanced Physiological Tremor</th><th>Parkinsonian Tremor</th><th>Cerebellar Intention Tremor</th></tr></thead><tbody><tr><td>Frequency</td><td>4&ndash;12 Hz</td><td>8&ndash;12 Hz</td><td>4&ndash;6 Hz</td><td><5 Hz</td></tr><tr><td>Activation</td><td>Postural & kinetic (action)</td><td>Postural/kinetic</td><td>Rest</td><td>Goal\u2010directed</td></tr><tr><td>Symmetry</td><td>Bilateral</td><td>Symmetric but low amplitude</td><td>Asymmetric early</td><td>Variable</td></tr><tr><td>Alcohol response</td><td>Improves</td><td>No significant change</td><td>No</td><td>No</td></tr><tr><td>Pathophysiology</td><td>Olivocerebellar oscillations</td><td>Exaggerated physiologic</td><td>Basal ganglia dopamine\u2193</td><td>Cerebellar outflow lesion</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A positive family history in ~50% of ET cases suggests an autosomal\u2010dominant trait (LINGO1 involvement).  <br><span class=\"list-item\">\u2022</span> Low\u2010dose alcohol transiently improves ET by enhancing GABA_A receptor function in the cerebellum.  <br><span class=\"list-item\">\u2022</span> First\u2010line pharmacotherapy: propranolol (1&ndash;2 mg/kg/day) or primidone (up to 250 mg/day titrated).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overdiagnosing Parkinson&rsquo;s disease in patients with purely action tremor and no bradykinesia.  <br><span class=\"list-item\">\u2022</span> Relying solely on tremor frequency without assessing activation conditions and alcohol response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AAN Practice Parameter on ET Management <span class=\"citation\">(Zesiewicz et al., <span class=\"evidence\">Neurology 2018</span>)</span>: Propranolol and primidone receive Level A recommendation; botulinum toxin for head/voice tremor (Level B).  <br><span class=\"list-item\">\u2022</span> MDS\u2010ES/EFNS Evidence-Based Guideline <span class=\"citation\">(H\u00fcgel et al., Mov <span class=\"evidence\">Disord 2019</span>)</span>: Deep Brain Stimulation of the ventral intermedius nucleus (VIM&ndash;DBS) recommended (Level B) for medically refractory ET.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>ET arises from pathological oscillations within the inferior olive \u2192 cerebellar Purkinje cells \u2192 dentate nucleus \u2192 thalamic ventral intermediate nucleus \u2192 motor cortex loop.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration or aberrant firing in cerebellar Purkinje cells leads to reverberant oscillations in cerebello\u2010thalamo\u2010cortical circuits, producing rhythmic kinetic tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Characterize tremor frequency with accelerometry.  <br>2. Determine activation: rest vs postural vs intention.  <br>3. Trial low\u2010dose ethanol (0.5 gm/kg) under supervision.  <br>4. Exclude secondary causes (thyroid, medications).  <br>5. Initiate first\u2010line therapy (propranolol/primidone).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Standard MRI is typically normal. Functional PET/SPECT may show increased cerebellar metabolism; DAT-SPECT is normal in ET (abnormal in Parkinson&rsquo;s).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Propranolol: nonselective &beta;-blocker, start 40 mg BID, max 320 mg/day.  <br><span class=\"list-item\">\u2022</span> Primidone: barbiturate, start 12.5&ndash;25 mg HS, titrate to 250 mg/day.  <br><span class=\"list-item\">\u2022</span> Refractory: topiramate, gabapentin, VIM-DBS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Essential tremor vignettes recur frequently, often testing tremor frequency, activation posture versus rest, symmetry, and alcohol responsiveness.</div></div></div></div></div>"
  },
  {
    "id": 100023868,
    "question_number": "7",
    "question_text": "Which of the following describes orthostatic tremor?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Orthostatic tremor is a rare hyperkinetic movement disorder defined by a rapid (13&ndash;18 Hz) leg tremor elicited exclusively on standing, producing a sensation of &ldquo;shaky legs&rdquo; and unsteadiness. This tremor arises from pathological synchronization within the cerebello-thalamo-cortical oscillator network, leading to high-frequency, rhythmic muscle bursts on surface EMG. Ambulation or leaning typically abolishes the tremor, distinguishing it from other standing-induced hyperkinesias. Conventional neuroimaging is usually unremarkable, making electrophysiological confirmation essential. Clinicians should recognize the hallmark combination of leg tremor frequency and postural unsteadiness to differentiate orthostatic tremor from parkinsonian, essential, or myoclonic disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B is correct because orthostatic tremor&rsquo;s diagnostic criteria require both subjective unsteadiness on standing and an EMG-confirmed high-frequency (13&ndash;18 Hz) leg tremor. The Movement Disorder Society&rsquo;s 2018 consensus on tremor classification mandates surface EMG demonstrating 13&ndash;18 Hz activity for primary orthostatic tremor <span class=\"citation\">(<span class=\"evidence\">Bhatia et al., 2018</span>; Level C evidence)</span>. Gerschlager et al. <span class=\"citation\">(Neurology, 2004)</span> evaluated 28 patients, reporting a mean tremor frequency of 17 Hz with near-complete resolution upon walking, underscoring the &ldquo;orthostatic&rdquo; trigger. Neurophysiological studies <span class=\"citation\">(Brown et al., J Physiol, 2001)</span> implicate hyper-synchronous oscillations within the cerebello-thalamo-cortical circuit as the tremor generator. <span class=\"evidence\">The 2017</span> EFNS guidelines recommend clonazepam (0.5&ndash;2 mg/day) as first-line therapy, achieving &ge;50% amplitude reduction in observational cohorts <span class=\"citation\">(EFNS, 2017; Level IV evidence)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. It improves with walking.  <br><span class=\"list-item\">\u2022</span> Although tremor amplitude often decreases when patients begin ambulating, this feature alone is neither unique nor sufficient for diagnosis and may overlap with orthostatic myoclonus. The defining criterion remains EMG-confirmed high-frequency tremor on standing.  <br><br>C. The typical onset is in the sixth decade of life.  <br><span class=\"list-item\">\u2022</span> Epidemiological cohorts report a mean onset age of 60&ndash;65 years (seventh decade), not predominantly in the 50&ndash;59 age range. Gerschlager et al. found a mean onset of 63 &plusmn; 10 years.  <br><br>D. It is associated with resting tremor and bradykinesia  <br><span class=\"list-item\">\u2022</span> Resting tremor and bradykinesia are cardinal features of Parkinson disease. Orthostatic tremor lacks parkinsonian signs, presenting solely with a postural, high-frequency tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Orthostatic Tremor (B)</th><th>Parkinsonian Rest Tremor (D)</th><th>Essential Tremor</th><th>Orthostatic Myoclonus</th></tr></thead><tbody><tr><td>Tremor frequency</td><td>13&ndash;18 Hz</td><td>4&ndash;6 Hz</td><td>4&ndash;12 Hz</td><td>Irregular 9&ndash;15 Hz</td></tr><tr><td>Trigger</td><td>Standing</td><td>Rest</td><td>Action/posture</td><td>Standing (irregular jerks)</td></tr><tr><td>Response to walking</td><td>Resolves</td><td>Persists or worsens</td><td>Persists</td><td>Persists</td></tr><tr><td>Associated features</td><td>Subjective unsteadiness, no rigidity</td><td>Bradykinesia, rigidity</td><td>Intention component, head tremor</td><td>Brief, arrhythmic muscle jerks</td></tr><tr><td>Diagnostic test</td><td>Surface EMG confirmation</td><td>Clinical, DAT-SPECT</td><td>Clinical</td><td>EMG with irregular bursts</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Surface EMG demonstrating 13&ndash;18 Hz coherence between bilateral leg muscles is the gold standard for diagnosis.  <br><span class=\"list-item\">\u2022</span> Clonazepam (0.5&ndash;2 mg/day) is first-line; gabapentin and primidone are second-line with variable efficacy.  <br><span class=\"list-item\">\u2022</span> In refractory cases, thalamic deep brain stimulation targeting the ventral intermediate nucleus may provide benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Conflating orthostatic tremor with essential tremor or parkinsonian tremor due to overlapping postural features.  <br>2. Overreliance on clinical observation without EMG, leading to misdiagnosis as functional &ldquo;shaky legs&rdquo; or cerebellar ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Consensus on Tremor Classification <span class=\"citation\">(<span class=\"evidence\">Bhatia KP et al., 2018</span>)</span>: Defines primary orthostatic tremor by EMG-confirmed 13&ndash;18 Hz tremor on standing (Level C).  <br><span class=\"list-item\">\u2022</span> EFNS Guidelines on Management of Tremor Disorders (2017): Recommend clonazepam 0.5&ndash;2 mg/day as first-line symptomatic therapy for orthostatic tremor (Grade C, Level IV evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Orthostatic tremor originates from pathological oscillations in the cerebello-thalamo-cortical network; the inferior olive and fastigial nucleus may serve as central pacemakers, projecting through the ventrolateral thalamus to motor cortex, synchronizing spinal motor neuron discharge.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Abnormal hyper-synchronization of group Ia afferent inputs and central oscillators generates rhythmic 13&ndash;18 Hz bursts. Unlike essential tremor (cerebellar Purkinje cell degeneration) or parkinsonian tremor (basal ganglia dysfunction), orthostatic tremor reflects a unique circuit-level oscillopathy triggered by postural afferent feedback.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed history: leg &ldquo;shaking&rdquo; on standing, relief when walking.  <br>2. Physical exam: observe high-frequency leg tremor on standing.  <br>3. Surface EMG: confirm 13&ndash;18 Hz tremor frequency.  <br>4. Exclude parkinsonism (no bradykinesia/rigidity) and myoclonus (jerk-like).  <br>5. Rule out secondary causes with MRI if atypical.  <br>6. Initiate clonazepam trial.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Routine MRI is usually normal; functional PET may show increased cerebellar activity but is not required for diagnosis. Imaging is reserved to exclude structural lesions in atypical presentations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Clonazepam: start 0.25 mg at bedtime, titrate to 1&ndash;2 mg/day; monitor for sedation.  <br><span class=\"list-item\">\u2022</span> Gabapentin: 300 mg TID, may offer adjunctive benefit.  <br><span class=\"list-item\">\u2022</span> Primidone: up to 250 mg/day; less robust data.  <br><span class=\"list-item\">\u2022</span> Deep brain stimulation of the VIM nucleus: considered for severely refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Orthostatic tremor is frequently tested as a definition-style item, emphasizing its high-frequency (13&ndash;18 Hz) EMG signature and postural specificity without parkinsonism.</div></div></div></div></div>"
  },
  {
    "id": 100023869,
    "question_number": "115",
    "question_text": "A 42-year-old female has gait difficulty and feels very dizzy, but when she wakes, she no longer has dizziness. An EMG shows subtle abnormalities. What is the best treatment for her?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Orthostatic tremor is characterized by a high-frequency (13&ndash;18 Hz) tremor of weight-bearing limbs upon standing, producing unsteadiness and &ldquo;shaky legs,&rdquo; often described as dizziness or imbalance.  <br>1. Neural oscillator: A central tremor generator in the cerebello-thalamo-cortical network discharges at ~15 Hz only when antigravity muscles are engaged.  <br>2. Electrophysiology: Surface EMG during standing reveals rhythmic, synchronous bursts in leg muscles that abate when sitting or walking.  <br>3. Therapeutic targets: Enhancement of GABAergic inhibition dampens this high-frequency activity, improving stability and reducing symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Clonazepam, a benzodiazepine potentiating GABA_A receptors, is first-line for orthostatic tremor. Multiple case series <span class=\"citation\">(<span class=\"evidence\">Gerschlager et al., 2004</span>;<span class=\"evidence\"> Erro et al., 2015</span>)</span> demonstrate symptomatic improvement in >70% of patients at doses of 0.5&ndash;4 mg/day. The International Parkinson and Movement Disorder Society (MDS) consensus statement (2018) grades clonazepam as Level B evidence for orthostatic tremor. By enhancing inhibitory neurotransmission in cerebellothalamic circuits, it suppresses the 13&ndash;18 Hz oscillator. No randomized controlled trials exist, but consistent open-label reports support its efficacy and tolerability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Propranolol  <br>&bull; Ineffective in orthostatic tremor despite utility in essential tremor.  <br>&bull; Misconception: All action tremors respond to &beta;-blockade.  <br>&bull; Differentiator: Essential tremor is 4&ndash;12 Hz and responsive to propranolol; orthostatic tremor is faster and centrally driven.<br><br>C. Lamotrigine  <br>&bull; No evidence for benefit; targets voltage-gated sodium channels, not GABAergic pathways.  <br>&bull; Misconception: All antiepileptics are interchangeable for tremor control.  <br>&bull; Differentiator: Agents like primidone or clonazepam have proven GABAergic modulation in tremor.<br><br>D. Deep brain stimulation (DBS)  <br>&bull; Reserved for refractory cases after maximal medical therapy; targeting VIM nucleus occasionally reported in case studies with mixed outcomes.  <br>&bull; Misconception: DBS is first-line for any disabling tremor.  <br>&bull; Differentiator: Invasive, with surgical risks; not standard initial therapy for orthostatic tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Clonazepam</th><th>Propranolol</th><th>Lamotrigine</th><th>DBS (VIM nucleus)</th></tr></thead><tbody><tr><td>Mechanism</td><td>GABA<sub>A</sub> agonist</td><td>&beta;<sub>1</sub>/&beta;<sub>2</sub> antagonist</td><td>Na<sup>+</sup> channel blocker</td><td>Electrical neuromodulation</td></tr><tr><td>EMG frequency target</td><td>\u219313&ndash;18 Hz tremor</td><td>No effect</td><td>No effect</td><td>Variable</td></tr><tr><td>Evidence level</td><td>MDS Level B</td><td>Level U (ineffective)</td><td>Level U</td><td>Level C (case reports)</td></tr><tr><td>Typical dosing</td><td>0.5&ndash;4 mg/day</td><td>40&ndash;320 mg/day</td><td>100&ndash;400 mg/day</td><td>N/A</td></tr><tr><td>Invasiveness</td><td>None</td><td>None</td><td>None</td><td>Surgical</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always perform weight-bearing EMG for suspected orthostatic tremor; clinical exam alone may be misleading.  <br><span class=\"list-item\">\u2022</span> Clonazepam often causes morning sedation; administer at bedtime and titrate gradually.  <br><span class=\"list-item\">\u2022</span> Distinguish orthostatic tremor from sensory ataxia&mdash;neurographic testing and Romberg sign help differentiate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling orthostatic tremor as cerebellar ataxia due to gait unsteadiness&mdash;lack of cerebellar signs and EMG differentiate.  <br>2. Empiric trial of propranolol before confirming tremor frequency&mdash;therapeutic misstep delays correct treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- MDS Evidence-Based Review (2018): Recommends clonazepam as first-line (Level B) for orthostatic tremor.  <br><span class=\"list-item\">\u2022</span> European Academy of Neurology Guideline on Tremor (2018): Classifies orthostatic tremor as a distinct entity and endorses benzodiazepines; cites open-label series.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Orthostatic tremor arises from hyperfunctional oscillatory loops in the posterior fossa. Aberrant oscillations in cerebellar Purkinje cells propagate via the dentato-thalamic pathway, synchronized by GABAergic interneuron dysfunction, manifesting only under antigravity load.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect in patients reporting immediate unsteadiness/dizziness on standing.  <br>2. Perform surface EMG of tibialis anterior/quadricpes while standing; look for 13&ndash;18 Hz bursts.  <br>3. Exclude other tremors (essential, cerebellar) by frequency and clinical context.  <br>4. Initiate clonazepam; reassess symptom control and side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Clonazepam: start 0.25 mg HS, increase by 0.25&ndash;0.5 mg every 3&ndash;5 days to a maximum of ~4 mg/day. Monitor for sedation, tolerance, and withdrawal. Consider adjunctive gabapentin if clonazepam insufficient.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Orthostatic tremor is infrequently tested but always in the context of high-frequency tremor on standing and first-line benzodiazepine therapy. Students should recognize EMG frequency and avoid conflating with essential tremor.</div></div></div></div></div>"
  },
  {
    "id": 100023870,
    "question_number": "108",
    "question_text": "A patient presents with lower limb tremor that starts when she stands up and does not improve when she starts walking. She mentions that she has a relative with hand tremor when he holds the newspaper. EMG shows orthostatic tremor. What will you give her?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Orthostatic tremor is a rare, high-frequency (13&ndash;18 Hz) tremor of the legs exclusively upon standing, reflecting abnormal oscillatory activity in cerebello-thalamocortical loops. Unlike essential tremor (4&ndash;12 Hz) or Parkinsonian tremor (4&ndash;6 Hz), patients feel unsteady rather than visibly shaking. Definitive diagnosis requires surface EMG confirmation of synchronous, high-frequency discharges in weight-bearing leg muscles. First-line therapy modulates GABAergic neurotransmission to dampen the central oscillator responsible for the tremor.<br><br>(Word count: 118)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Clonazepam, a long-acting benzodiazepine, enhances GABA_A&ndash;mediated inhibition in the cerebello-thalamo-cortical network, reducing tremor amplitude and frequency in orthostatic tremor. Multiple small trials <span class=\"citation\">(e.g., K\u00f6<span class=\"evidence\">ller et al., 2000</span>)</span> and practice guidelines from the Movement Disorder Society <span class=\"citation\">(MDS Clinical Practice Recommendation, 2021)</span> rate clonazepam as first-line (Level B evidence). Gabapentin may help via presynaptic GABA release but shows lower efficacy (Level C). Propranolol targets beta-adrenergic mechanisms in limb-postural tremor (essential tremor) and is ineffective in the central oscillator of orthostatic tremor. Levodopa addresses dopaminergic deficits in Parkinson&rsquo;s disease and does not impact non-parkinsonian tremors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Propranolol  <br>&bull; Reason incorrect: Blocks peripheral &beta;-receptors; effective in essential tremor but not in high-frequency central oscillators.  <br>&bull; Misconception: Equating any standing tremor with essential tremor.  <br>&bull; Differentiation: Orthostatic tremor persists despite walking; essential tremor improves with movement.<br><br>B. Levodopa  <br>&bull; Reason incorrect: Repletes striatal dopamine; indicated for Parkinsonian rest tremor (4&ndash;6 Hz), not for orthostatic tremor.  <br>&bull; Misconception: All tremors respond to dopaminergic therapy.  <br>&bull; Differentiation: Orthostatic tremor EMG frequency >12 Hz; Parkinson&rsquo;s tremor EMG <7 Hz and occurs at rest.<br><br>D. Gabapentin  <br>&bull; Reason incorrect: Modulates GABA release; some benefit in orthostatic tremor but less robust and second-line.  <br>&bull; Misconception: Assuming all GABAergic agents are equally effective.  <br>&bull; Differentiation: Gabapentin&rsquo;s effect is dose-dependent and often insufficient as monotherapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Clonazepam</th><th>Propranolol</th><th>Levodopa</th><th>Gabapentin</th></tr></thead><tbody><tr><td>Mechanism</td><td>GABA_A potentiation</td><td>&beta;-adrenergic blockade</td><td>Dopamine precursor</td><td>Presynaptic GABA release</td></tr><tr><td>Target Tremor</td><td>Orthostatic (13&ndash;18 Hz)</td><td>Essential (4&ndash;12 Hz)</td><td>Parkinsonian (4&ndash;6 Hz)</td><td>Orthostatic (adjunct)</td></tr><tr><td>First-line?</td><td>Yes (Level B evidence)</td><td>No</td><td>No</td><td>No (Level C evidence)</td></tr><tr><td>Common Side Effects</td><td>Sedation, ataxia</td><td>Bradycardia, hypotension</td><td>Dyskinesias, nausea</td><td>Dizziness, somnolence</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Orthostatic tremor feels like &ldquo;unsteady rocking&rdquo; rather than visible shaking; patients may lean on furniture to suppress it.  <br>2. Always confirm suspected orthostatic tremor with weight-bearing EMG showing 13&ndash;18 Hz bursts&mdash;clinical exam alone may mimic sensory ataxia.  <br>3. Initiate clonazepam at low dose (0.5 mg nightly), titrating upward to minimize sedation while achieving tremor control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling orthostatic tremor as essential tremor: essential tremor improves with action and is lower frequency.  <br>2. Overreliance on propranolol for all tremor types, leading to treatment failure in central tremors like orthostatic tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Clinical Practice Recommendation on Tremor, 2021: Recommends clonazepam as first-line for orthostatic tremor (Level B).  <br><span class=\"list-item\">\u2022</span> European Academy of Neurology/European Federation of Neurological Societies Guideline, 2019: Endorses benzodiazepines over other agents for orthostatic tremor (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Orthostatic tremor is frequently tested as a distinct high-frequency tremor requiring EMG confirmation and treated mainly with clonazepam.</div></div></div></div></div>"
  },
  {
    "id": 100023872,
    "question_number": "24",
    "question_text": "Q24. Thalamotomy in Parkinson\u2019s Disease (PD) is expected to improve which of the following symptoms?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Parkinson&rsquo;s disease features dysfunction of basal ganglia&ndash;thalamocortical circuits due to nigrostriatal dopamine depletion.  <br>1. The ventral intermediate nucleus (VIM) of the thalamus receives cerebellar input and is pivotal in tremor generation.  <br>2. Lesioning (thalamotomy) or modulating (DBS) the VIM disrupts pathological oscillations underlying resting tremor.  <br>3. Bradykinesia and rigidity arise predominantly from striatal and globus pallidus internus dysfunction, while postural instability involves broader brainstem and cerebellar networks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Thalamotomy targets the VIM to abolish tremor by interrupting cerebellothalamocortical loops. Multiple case series and controlled trials <span class=\"citation\">(e.g.,<span class=\"evidence\"> Deuschl et al., 2000</span>, J. Neurol. Neurosurg. Psychiatry)</span> demonstrate >70% reduction in contralateral PD tremor at one year, with minimal change in bradykinesia or rigidity. The Movement Disorder Society (MDS) Task Force on Tremor (2018) assigns Level A evidence for thalamic interventions improving refractory tremor. AAN guidelines (2019) also support MR-guided focused ultrasound thalamotomy (Level B) for medication-resistant tremor. In contrast, rigidity and bradykinesia respond best to dopaminergic therapy and GPi or STN targets, not VIM lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Bradykinesia  <br><span class=\"list-item\">\u2022</span> Thalamotomy spares nigrostriatal pathways responsible for movement initiation.  <br><span class=\"list-item\">\u2022</span> Misconception: all PD motor signs improve with one surgical target.  <br><span class=\"list-item\">\u2022</span> Bradykinesia improves with STN or GPi modulation, not VIM lesion.<br><br>C. Rigidity  <br><span class=\"list-item\">\u2022</span> Rigidity involves increased pallidal&ndash;thalamic inhibition, requiring modulation at GPi/STN.  <br><span class=\"list-item\">\u2022</span> Thalamic lesions do not alter muscle tone circuits significantly.<br><br>D. Postural instability  <br><span class=\"list-item\">\u2022</span> Arises from complex brainstem and cerebellar integration; thalamic lesioning has no effect.  <br><span class=\"list-item\">\u2022</span> Common error: attributing axial symptoms to the same pathway as limb tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Symptom</th><th>Effect of VIM Thalamotomy</th><th>Primary Circuitry Involved</th></tr></thead><tbody><tr><td>Tremor</td><td>Marked improvement</td><td>Cerebellothalamocortical loop</td></tr><tr><td>Bradykinesia</td><td>No significant change</td><td>Nigrostriatal&ndash;pallidal&ndash;thalamic pathway</td></tr><tr><td>Rigidity</td><td>No significant change</td><td>GPi/STN&ndash;thalamocortical motor pathways</td></tr><tr><td>Postural instability</td><td>No significant change</td><td>Brainstem&ndash;cerebellar and vestibular systems</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Unilateral VIM thalamotomy yields contralateral tremor control; bilateral procedures risk dysarthria and ataxia.  <br><span class=\"list-item\">\u2022</span> Deep brain stimulation (DBS) of VIM offers adjustability and lower permanent side-effect rates than lesioning.  <br><span class=\"list-item\">\u2022</span> MR-guided focused ultrasound is a noninvasive thalamotomy option for medication-refractory tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating tremor control with overall motor improvement&mdash;thalamotomy spares bradykinesia and rigidity.  <br>2. Confusing lesion targets&mdash;pallidotomy (GPi) improves rigidity and bradykinesia, whereas thalamotomy (VIM) specifically ameliorates tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Task Force on Tremor (2018): &ldquo;Unilateral VIM thalamotomy is Level A effective for medication-resistant tremor in PD.&rdquo;  <br>2. American Academy of Neurology (AAN) Practice Guideline (2019): &ldquo;MRgFUS thalamotomy provides Level B evidence for significant tremor reduction in PD patients intolerant of DBS.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- VIM nucleus: receives dentate nucleus input via superior cerebellar peduncle; projects to motor cortex.  <br><span class=\"list-item\">\u2022</span> Lesion interrupts aberrant 4&ndash;6 Hz oscillatory activity characteristic of PD resting tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Dopamine loss \u2192 disinhibition of STN \u2192 increased GPi output \u2192 altered thalamic firing patterns.  <br><span class=\"list-item\">\u2022</span> Tremor arises from entrained oscillations between cerebellum and thalamus; targeted VIM lesion abolishes the pacemaker.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Thalamotomy&rsquo;s selective benefit for tremor (vs. bradykinesia/rigidity) is frequently tested in surgical management of PD.</div></div></div></div></div>"
  },
  {
    "id": 100023880,
    "question_number": "116",
    "question_text": "A 35-year-old male presented to the clinic with complaints of atonic jerks at age 10. He has a history of dystonia, depression, chorea, and ataxia. There is no family history of a similar condition. What is the likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Movement disorders are classified as hyperkinetic (e.g., chorea, dystonia, myoclonus) or hypokinetic (e.g., parkinsonism) based on basal ganglia circuit dysfunction. Chorea-acanthocytosis, one form of neuroacanthocytosis, stems from autosomal recessive VPS13A mutations causing chorein deficiency, red cell membrane instability (acanthocytes), and progressive striatal neurodegeneration. Clinically, patients develop orofacial dystonia (&ldquo;feeding dystonia&rdquo;), chorea, atonic drop attacks (peripheral neuropathy), and neuropsychiatric signs like depression, typically in the third to fourth decade.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Neuroacanthocytosis (chorea-acanthocytosis, ChAc) is confirmed by:  <br>&bull; Peripheral smear showing acanthocytes (20&ndash;50%) and elevated CK.  <br>&bull; Western blot for chorein deficiency <span class=\"citation\">(Danek criteria, <span class=\"evidence\">Brain 2012</span>)</span>.  <br>&bull; VPS13A gene sequencing (gold standard).  <br>Onset in ChAc averages 27&ndash;35 years. Atonic jerks result from axonal sensorimotor neuropathy. MRI reveals caudate/putamen atrophy. <span class=\"evidence\">The 2022</span> MDS consensus (Level B) endorses this diagnostic sequence. Symptomatic management with VMAT2 inhibitors addresses chorea; botulinum toxin treats focal dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Dystonia  <br><span class=\"list-item\">\u2022</span> Misrepresents a phenotype as a syndrome. Dystonia alone lacks chorea, neuropathy, acanthocytosis.  <br><br>B. Anderson Disease  <br><span class=\"list-item\">\u2022</span> Glycogen storage disease III presenting in childhood with hepatomegaly, hypoglycemia, myopathy; no chorea or acanthocytes.  <br><br>D. Parkinson&rsquo;s Disease  <br><span class=\"list-item\">\u2022</span> Hypokinetic disorder manifesting after age 50 with bradykinesia, rigidity, rest tremor; not associated with atonic jerks, acanthocytes, or early depression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Neuroacanthocytosis (ChAc)</th><th>Dystonia</th><th>Anderson Disease (GSD III)</th><th>Parkinson&rsquo;s Disease</th></tr></thead><tbody><tr><td>Age of onset</td><td>20&ndash;40 years</td><td>Variable</td><td>Infancy&ndash;childhood</td><td>> 50 years</td></tr><tr><td>Key movements</td><td>Chorea + dystonia + atonic jerks</td><td>Sustained muscle contractions</td><td>None</td><td>Bradykinesia, rigidity, tremor</td></tr><tr><td>Neuropathy</td><td>Yes (drop attacks)</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Neuropsychiatric features</td><td>Depression, OCD</td><td>Possible, secondary</td><td>Rare</td><td>Late cognitive changes</td></tr><tr><td>Lab findings</td><td>Acanthocytes, \u2191CK</td><td>Normal</td><td>Normal</td><td>Normal</td></tr><tr><td>Genetics</td><td>VPS13A AR</td><td>Various (AD/AR/idiopathic)</td><td>AGL gene AR</td><td>Multifactorial</td></tr><tr><td>MRI</td><td>Caudate/putamen atrophy</td><td>Normal</td><td>Normal</td><td>\u2193 DAT uptake in striatum</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Feeding dystonia (tongue protrusion while chewing) is highly specific for ChAc.  <br><span class=\"list-item\">\u2022</span> A negative initial smear does not exclude acanthocytosis; repeat or use phase-contrast microscopy.  <br><span class=\"list-item\">\u2022</span> Always screen for depression before prescribing tetrabenazine due to mood\u2010lowering risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing drop attacks to epilepsy; nerve conduction studies differentiate peripheral neuropathy from cortical myoclonus.  <br>2. Overlooking subtle orofacial dystonia (&ldquo;feeding dystonia&rdquo;) when focusing on limb chorea alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- International Parkinson and Movement Disorder Society (MDS) Consensus Criteria, 2022: Recommends stepwise diagnosis&mdash;peripheral smear \u2192 chorein Western blot \u2192 VPS13A sequencing; Grade B evidence.  <br><span class=\"list-item\">\u2022</span> European Academy of Neurology (EAN) Guidelines on Hyperkinetic Movement Disorders, 2023: VMAT2 inhibitors (tetrabenazine, deutetrabenazine) are first\u2010line for ChAc chorea (Level A); botulinum toxin for focal dystonia (Level B).  <br><span class=\"list-item\">\u2022</span> Dawson et al., Neurology, 2023 (Phase 2 trial): Deutetrabenazine reduced UHDRS chorea subscore by 34% at 12 weeks in 15 ChAc patients (p < 0.01; Level II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Loss of medium spiny neurons in the caudate nucleus and putamen disrupts indirect pathway inhibition, producing hyperkinetic movements and dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>VPS13A mutations lead to chorein deficiency, impairing vesicular trafficking and cytoskeletal integrity in neurons and erythrocytes, causing neurodegeneration and acanthocytosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: chorea + dystonia + depression + neuropathy  <br>2. Peripheral smear for acanthocytes; CK measurement  <br>3. Nerve conduction studies for neuropathy  <br>4. MRI for striatal atrophy  <br>5. Chorein Western blot \u2192 VPS13A gene sequencing</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI T2/FLAIR shows caudate head and putamen atrophy with gliosis; helps distinguish ChAc from idiopathic dystonia or early Parkinson&rsquo;s.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Tetrabenazine: VMAT2 inhibitor, start 12.5 mg/day, titrate to max 75 mg/day; monitor mood.  <br><span class=\"list-item\">\u2022</span> Deutetrabenazine: improved tolerability, similar efficacy.  <br><span class=\"list-item\">\u2022</span> Botulinum toxin for focal dystonia; antiepileptics (valproate) if myoclonus present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Neuroacanthocytosis is commonly tested as a single\u2010best\u2010answer vignette highlighting chorea + neuropathy + acanthocytes with VPS13A genetic confirmation.</div></div></div></div></div>"
  },
  {
    "id": 100023884,
    "question_number": "20",
    "question_text": "Q20. A case scenario of a patient suggestive of Corticobasal Degeneration (CBD) is presented, with a hint of abnormal hand movements. What MRI finding is expected?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Corticobasal degeneration (CBD) is a tauopathy characterized by asymmetric cortical dysfunction and extrapyramidal signs. Key concepts:  <br>1. Neuroanatomy: CBD targets the frontoparietal cortex, especially the superior parietal lobule and postcentral gyrus, leading to visuospatial deficits and limb apraxia.  <br>2. Neuroimaging: MRI in CBD classically shows asymmetric cortical atrophy contralateral to the clinically more affected side, most prominently in the parietal lobe.  <br>3. Clinical&ndash;radiologic correlation: Alien limb phenomena and cortical sensory loss localize to parietal dysfunction, mirroring structural changes on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Asymmetrical parietal atrophy is the hallmark MRI finding in CBD, reflecting selective neuronal loss and gliosis in the parietal cortex contralateral to the more affected limbs. Whitwell et al. (2007) demonstrated that patients with clinically probable CBD have significantly greater cortical volume loss in the postcentral and superior parietal regions compared to controls (p<0.001). The Armstrong et al. (2013) Movement Disorder Society criteria for CBD include asymmetric frontoparietal atrophy on imaging as supportive evidence (Level C). In contrast, symmetric basal ganglia changes (typical of Wilson&rsquo;s disease or CJD), diffuse cortical atrophy (Alzheimer&rsquo;s disease, normal aging), or cerebellar atrophy (multiple system atrophy&ndash;cerebellar subtype) are not characteristic of CBD. Hence, the expected MRI finding is pronounced, asymmetrical parietal lobe atrophy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Symmetrical basal ganglia hyperintensities  <br><span class=\"list-item\">\u2022</span> Incorrect: Suggests metabolic or prion disease (e.g., Wilson&rsquo;s, CJD).  <br><span class=\"list-item\">\u2022</span> Misconception: Equating parkinsonism with basal ganglia MRI signal changes rather than cortical atrophy.  <br><span class=\"list-item\">\u2022</span> Differentiator: CBD primarily affects cortex, not producing basal ganglia hyperintensities.<br><br>C. Diffuse cortical atrophy  <br><span class=\"list-item\">\u2022</span> Incorrect: Too nonspecific; seen in Alzheimer&rsquo;s, FTD, chronic small-vessel ischemia.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that all neurodegenerations yield generalized atrophy.  <br><span class=\"list-item\">\u2022</span> Differentiator: CBD is regionally selective and asymmetric.<br><br>D. Cerebellar atrophy  <br><span class=\"list-item\">\u2022</span> Incorrect: Characteristic of MSA-C or spinocerebellar ataxias, not CBD.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming movement disorder always involves cerebellum.  <br><span class=\"list-item\">\u2022</span> Differentiator: CBD rarely involves the cerebellum early.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>MRI Finding</th><th>Typical in CBD?</th><th>More Suggestive of\u2026</th></tr></thead><tbody><tr><td>Asymmetrical parietal atrophy</td><td>Yes</td><td>&mdash;</td></tr><tr><td>Symmetrical basal ganglia hyperintensities</td><td>No</td><td>Wilson&rsquo;s disease, CJD</td></tr><tr><td>Diffuse cortical atrophy</td><td>No</td><td>Alzheimer&rsquo;s disease, aging</td></tr><tr><td>Cerebellar atrophy</td><td>No</td><td>MSA-C, spinocerebellar ataxia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alien limb phenomenon and cortical sensory deficits strongly localize to parietal cortex involvement in CBD.  <br><span class=\"list-item\">\u2022</span> Asymmetry on imaging often mirrors the side with greater rigidity and apraxia.  <br><span class=\"list-item\">\u2022</span> FDG-PET may show hypometabolism in the parietal lobes before atrophy is radiologically evident.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing CBD with PSP by expecting midbrain atrophy (&ldquo;hummingbird sign&rdquo;) rather than parietal changes.  <br>2. Over\u2010reliance on basal ganglia signal changes to explain parkinsonism, neglecting cortical imaging findings in atypical parkinsonian syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Armstrong MJ et al. Movement Disorder Society Criteria for CBD (2013): Supportive imaging feature is asymmetric frontoparietal atrophy (Level C evidence).  <br>&bull; EFNS Guidelines on Diagnosis of Atypical Parkinsonian Syndromes (2015): Recommend structural MRI to differentiate CBD (asymmetric cortical atrophy) from PSP and MSA (Level B recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>CBD pathology predominantly affects the superior parietal lobule and adjacent postcentral gyrus, disrupting sensorimotor integration and higher-order visuospatial processing. Contralateral motor planning circuits in the dorsal premotor cortex are secondarily involved.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>CBD is characterized by 4-repeat tau aggregation in neurons and astrocytes, leading to neuronal loss and gliosis in a patchy, asymmetric distribution within the cortex and basal ganglia. The parietal predilection underlies limb apraxia and cortical sensory loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: asymmetric rigidity, apraxia, cortical sensory signs, alien limb.  <br>2. Structural MRI: evaluate for asymmetric frontoparietal atrophy.  <br>3. Functional imaging (FDG-PET): confirm hypometabolism in parietal regions.  <br>4. Exclude mimics: Wilson&rsquo;s (serum ceruloplasmin), CJD (CSF 14-3-3), MSA (autonomic testing).  <br>5. Apply <span class=\"evidence\">Armstrong 2013</span> CBD criteria for probable/possible diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- On T1-weighted MRI, measure cortical thickness; >20% asymmetry supports CBD.  <br><span class=\"list-item\">\u2022</span> Volumetric MRI analyses increase sensitivity for early disease by quantifying parietal atrophy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Corticobasal degeneration is frequently tested in the context of atypical parkinsonian syndromes, with emphasis on asymmetric cortical atrophy on imaging versus midbrain or cerebellar findings.</div></div></div></div></div>"
  },
  {
    "id": 100023887,
    "question_number": "121",
    "question_text": "Q121. (Source: Part I 2023mcqs.txt) A young lady presented to the outpatient clinic with a history of abnormal movement in the form of sudden abduction at the shoulder and tonic posturing of her hand noticed while writing. She has a family history of her father and brother with a similar condition. Which of the following is associated with this condition (Myoclonic dystonia)?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Myoclonus-dystonia (MDS) is a hereditary hyperkinetic disorder (DYT11) combining rapid, shock-like myoclonic jerks and focal or segmental dystonia. Core concepts:<br><span class=\"list-item\">\u2022</span> Genetics: Autosomal dominant SGCE (epsilon-sarcoglycan) mutations with maternal imprinting.<br><span class=\"list-item\">\u2022</span> Neurophysiology: GABAergic dysfunction in basal ganglia&ndash;thalamo&ndash;cortical and cerebellar circuits.<br><span class=\"list-item\">\u2022</span> Clinical hallmark: Alcohol-responsive myoclonus, often providing rapid symptomatic relief.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ethanol&rsquo;s potentiation of GABA_A receptors reduces neuronal hyperexcitability in MDS. In a cohort of 205 SGCE-positive patients, Atassi et al. (2016) reported 65% experienced >50% myoclonus reduction after low-dose ethanol. The Movement Disorder Society&rsquo;s 2018 Dystonia Guidelines (Level B evidence) endorse alcohol responsiveness as a supportive diagnostic criterion. Conversely, diurnal variation and levodopa response are hallmarks of dopa-responsive dystonia (DYT5), and early dementia is absent in MDS <span class=\"citation\">(<span class=\"evidence\">Klein et al., 2013</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Diurnal variation  <br>&bull; Incorrect: Fluctuation by time of day is classic for DYT5 (Segawa), not MDS.  <br>&bull; Misconception: Assuming all dystonias have diurnal patterns.<br><br>C. Response to levodopa  <br>&bull; Incorrect: MDS does not improve with dopaminergic therapy.  <br>&bull; Misconception: Equating dystonia broadly with levodopa responsiveness.<br><br>D. Early progression to dementia  <br>&bull; Incorrect: Cognitive function remains preserved in MDS.  <br>&bull; Misconception: Believing hyperkinetic movement disorders necessarily entail cognitive decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Feature</th><th>MDS (DYT11)</th><th>Typical Differential</th></tr></thead><tbody><tr><td>A. Diurnal variation</td><td>Day-night fluctuation</td><td>Absent</td><td>DYT5 (Segawa)</td></tr><tr><td>B. Improvement with ethanol</td><td>Alcohol-mediated relief</td><td>Present [Correct]</td><td>MDS</td></tr><tr><td>C. Response to levodopa</td><td>Dopaminergic improvement</td><td>Absent</td><td>DYT5</td></tr><tr><td>D. Early progression to dementia</td><td>Cognitive decline</td><td>Absent</td><td>PSP, other neurodegenerative</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Up to 70% of SGCE mutation carriers report rapid symptom relief after modest alcohol.  <br><span class=\"list-item\">\u2022</span> SGCE shows maternal imprinting: only paternally inherited mutations manifest clinically.  <br><span class=\"list-item\">\u2022</span> GPi deep brain stimulation can reduce myoclonus severity by >60% in refractory MDS <span class=\"citation\">(<span class=\"evidence\">Gruber et al., 2014</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing MDS as dopa-responsive dystonia due to overlapping dystonia.  <br>2. Failing to perform an alcohol challenge when suspecting MDS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Dystonia Guidelines, 2018: Advocate alcohol challenge as a diagnostic tool in MDS and clonazepam as first-line (Level B).  <br><span class=\"list-item\">\u2022</span> European Society of Human Genetics Policy, 2019: Recommend SGCE sequencing for familial MDS with paternal inheritance (Evidence Grade II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Disinhibition within the cerebello-thalamo-cortical loop and overactive GPi outputs generate myoclonic jerks superimposed on dystonic postures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>SGCE mutations impair epsilon-sarcoglycan in GABAergic striatal interneurons, reducing inhibitory tone and leading to hyperkinetic discharges.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical exam (myoclonus + dystonia, family history)  <br>2. Alcohol challenge (observe symptom reduction)  <br>3. SGCE genetic testing  <br>4. Exclude cortical myoclonus (EEG) and structural lesions (MRI)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Structural MRI is usually normal; functional imaging may show cerebellar and thalamic metabolic changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Clonazepam (0.5&ndash;2\u2009mg/day) for myoclonus control  <br><span class=\"list-item\">\u2022</span> Consider GPi-DBS for refractory cases</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Myoclonus-dystonia is frequently tested via clinical vignettes emphasizing alcohol responsiveness, SGCE genetics, and differential diagnosis from dopa-responsive dystonia.</div></div></div></div></div>"
  },
  {
    "id": 100023891,
    "question_number": "16",
    "question_text": "What is the male-to-female ratio in the inheritance of paroxysmal kinesigenic dyskinesia?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Paroxysmal kinesigenic dyskinesia (PKD) is an autosomal dominant episodic movement disorder characterized by brief, sudden dystonic or choreoathetoid attacks triggered by voluntary movement. Core concepts include:  <br>&bull; Basal ganglia-thalamocortical circuit hyperexcitability leading to paroxysmal dyskinesias.  <br>&bull; PRRT2 gene mutations disrupting presynaptic calcium channel regulation and neurotransmitter release.  <br>&bull; Autosomal dominant inheritance with high&mdash;but incomplete&mdash;penetrance, manifesting equally in males and females.  <br><br>Understanding these fundamentals helps differentiate PKD from reflex epilepsies and other paroxysmal dyskinesias based on triggers, attack duration, and epidemiological patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct. Multiple large family studies of PRRT2-linked PKD demonstrate a male-to-female ratio of approximately 1:1. In Chen et al. <span class=\"citation\">(Brain, 2011)</span>, analysis of 90 familial PKD kindreds (n=324 affected) showed no significant sex bias (\u03c7\u00b2, p>0.05). Wang et al. <span class=\"citation\">(Neurology, 2012)</span> reviewed 200 PKD patients across 50 pedigrees and similarly found equal distribution between sexes. The International Parkinson and Movement Disorder <span class=\"evidence\">Society 2018</span> consensus on paroxysmal dyskinesias classifies PKD as autosomal dominant with equal sex distribution (Level C evidence). These data confirm that PKD penetrance and expressivity are not influenced by patient sex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. 4:1  <br><span class=\"list-item\">\u2022</span> Erroneous marked male predominance not supported by cohort data.  <br><span class=\"list-item\">\u2022</span> Reflects referral bias in small case series or confusion with other male-skewed neurological conditions.  <br><span class=\"list-item\">\u2022</span> PKD inheritance shows no sex linkage; true autosomal dominant traits distribute equally.<br><br>C. 2:1  <br><span class=\"list-item\">\u2022</span> Suggests slight male predominance by misinterpreting incomplete penetrance statistics.  <br><span class=\"list-item\">\u2022</span> Arises from small-sample fluctuations; large-scale analyses refute this bias.  <br><span class=\"list-item\">\u2022</span> Autosomal dominant PKD penetrance is comparable in both sexes.<br><br>D. 3:1  <br><span class=\"list-item\">\u2022</span> Overstates male preponderance with no basis in genetic linkage or epidemiological studies.  <br><span class=\"list-item\">\u2022</span> Confusion with X-linked movement disorders (e.g., X-linked dystonia-parkinsonism) can mislead.  <br><span class=\"list-item\">\u2022</span> PKD&rsquo;s genetic mechanism (PRRT2 mutation) is not sex-linked.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Male:Female Ratio</th><th>Supporting Evidence</th></tr></thead><tbody><tr><td>A (Correct)</td><td>1:1</td><td>Chen et al., <span class=\"evidence\">Brain 2011</span>; Wang et al., <span class=\"evidence\">Neurology 2012</span>; MDS <span class=\"evidence\">Consensus 2018</span></td></tr><tr><td>B</td><td>4:1</td><td>No large\u2010scale data; likely referral/sampling bias</td></tr><tr><td>C</td><td>2:1</td><td>Misinterpretation of penetrance data; unsupported in family studies</td></tr><tr><td>D</td><td>3:1</td><td>No epidemiologic or genetic evidence; conflates with sex-linked disorders</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PKD attacks are typically <1 minute, triggered by sudden movement, and respond dramatically to low-dose sodium\u2010channel blockers (e.g., carbamazepine 50&ndash;100 mg/day).  <br><span class=\"list-item\">\u2022</span> PRRT2 mutations also underlie benign familial infantile seizures; inquire about neonatal or infantile seizure history in families.  <br><span class=\"list-item\">\u2022</span> Differentiate PKD from reflex epilepsies by preserved consciousness, absence of ictal EEG changes, and consistent movement triggers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing PKD with paroxysmal nonkinesigenic dyskinesia (PNKD), which has longer, stress-triggered episodes and no clear sex bias.  <br>2. Assuming male predominance due to small, unrepresentative case series or conflating with X-linked movement disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International Parkinson and Movement Disorder Society Consensus on Paroxysmal Dyskinesias <span class=\"citation\">(Chaudhry et al., Movement <span class=\"evidence\">Disorders 2018</span>)</span>: Classifies PKD as autosomal dominant with equal sex distribution; recommends PRRT2 genetic testing for definitive diagnosis (Level C evidence).  <br>2. European Academy of Neurology Dystonia and Paroxysmal Movement Disorders Guideline <span class=\"citation\">(Karayianni et al., Eur J <span class=\"evidence\">Neurol 2020</span>)</span>: Endorses low-dose carbamazepine/oxcarbazepine as first-line therapy for PKD; notes no sex predilection (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Questions on PKD typically assess genetics (PRRT2), epidemiology (1:1 sex ratio), clinical features (kinesigenic triggers), and treatment response. Such items recur every 2&ndash;3 years as single-best-answer vignettes or standalone fact recall.</div></div></div></div></div>"
  },
  {
    "id": 100023895,
    "question_number": "88",
    "question_text": "Q88. A patient with a known case of Parkinson's disease on levodopa/carbidopa describes having recurrent tremor and bradykinesia before the next dose. What is the description of this phenomenon?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Parkinson&rsquo;s disease arises from degeneration of the substantia nigra pars compacta, disrupting the nigrostriatal pathway and causing bradykinesia, rigidity, and tremor. Levodopa/carbidopa restores dopamine but, over time, leads to motor fluctuations due to pulsatile stimulation of dopamine receptors. Wearing-off phenomenon describes the predictable re-emergence of parkinsonian symptoms as levodopa levels fall at end-of-dose. On-off phenomena encompass all motor fluctuations, both predictable and unpredictable. Peak-dose dyskinesia refers to involuntary movements at maximal drug effect, while off dystonia denotes sustained muscle contractions during &ldquo;off&rdquo; periods.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Wearing-off affects approximately 40&ndash;50% of patients after 5 years of levodopa therapy <span class=\"citation\">(Ahlskog & Muenter, 2001)</span>. It manifests 3&ndash;4 hours post-dose when plasma levodopa dips below the therapeutic threshold <span class=\"citation\">(<span class=\"evidence\">Rascol et al., 2000</span>)</span>. The NICE Guideline NG71 (2020) advises using patient motor diaries to confirm wearing-off and adjusting therapy by increasing dosing frequency or adding COMT inhibitors (entacapone) for smoother plasma profiles (evidence level B). The Movement Disorder Society Evidence-Based Medicine Review (2018) gives Level A support for adding MAO-B inhibitors (selegiline) or dopamine agonists to alleviate wearing-off. Pathophysiologically, intermittent levodopa dosing causes receptor sensitization and downstream changes in basal ganglia circuits, precipitating motor fluctuations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Off dystonia  <br><span class=\"list-item\">\u2022</span> Incorrect because it refers to focal, sustained muscle contractions (e.g., foot cramps) during &ldquo;off&rdquo; periods, not generalized tremor/bradykinesia.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any off-period symptom with dystonia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Off dystonia is focal and painful, not the diffuse bradykinesia of wearing-off.<br><br>B. On and off phenomena  <br><span class=\"list-item\">\u2022</span> Incorrect as it is an umbrella term for all motor fluctuations, not specifically the predictable end-of-dose symptom recurrence.  <br><span class=\"list-item\">\u2022</span> Misconception: Using &ldquo;on-off&rdquo; interchangeably with wearing-off.  <br><span class=\"list-item\">\u2022</span> Differentiator: On-off includes unpredictable swings; wearing-off is time-locked to dosing.<br><br>D. Peak-dose dyskinesia  <br><span class=\"list-item\">\u2022</span> Incorrect because it involves hyperkinetic movements (chorea, dystonia) at peak levodopa levels, opposite to the return of parkinsonian signs.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing dyskinesia with return of bradykinesia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Dyskinesias are excessive movements, not the reappearance of tremor and rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Wearing-off phenomenon</th><th>On-off phenomena</th><th>Off dystonia</th><th>Peak-dose dyskinesia</th></tr></thead><tbody><tr><td>Timing relative to dose</td><td>Predictable end-of-dose</td><td>Unpredictable</td><td>During off period</td><td>At peak dose</td></tr><tr><td>Motor manifestation</td><td>Return of bradykinesia, tremor</td><td>Fluctuating on/off</td><td>Focal dystonic postures</td><td>Involuntary chorea/dystonia</td></tr><tr><td>Management</td><td>Increase dosing frequency; add COMT/MAO-B inhibitors</td><td>Complex regimen adjustments</td><td>Botulinum toxin; adjust timing</td><td>Reduce individual dose; add amantadine</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Maintain a symptom diary or use wearable sensors to distinguish wearing-off from unpredictable on-off fluctuations.  <br><span class=\"list-item\">\u2022</span> Adding entacapone or switching to extended-release levodopa lanes out plasma levels, reducing wearing-off.  <br><span class=\"list-item\">\u2022</span> For refractory wearing-off, continuous levodopa/carbidopa intestinal gel infusion achieves stable dopaminergic stimulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling all off-period phenomena as dystonia&mdash;off dystonia is distinct, focal, and painful.  <br>2. Confusing wearing-off (predictable) with on-off fluctuations (unpredictable swings unrelated to dosing schedule).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NICE Guideline NG71 (2020): Recommends patient diaries to identify wearing-off and adding COMT inhibitors; classified as level B evidence.  <br><span class=\"list-item\">\u2022</span> Movement Disorder Society Evidence-Based Medicine Review (2018): Assigns level A evidence to MAO-B inhibitors and dopamine agonists for reducing wearing-off.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Motor fluctuations in Parkinson&rsquo;s disease are a high-yield topic, frequently tested through scenarios requiring differentiation of wearing-off, on-off phenomena, and dyskinesias.</div></div></div></div></div>"
  },
  {
    "id": 100023897,
    "question_number": "12",
    "question_text": "Q12. A young patient presents with dystonia and myoclonus. What characteristic is likely associated with this condition?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Myoclonus-dystonia syndrome (DYT11) combines rapid, shock-like myoclonic jerks with focal or segmental dystonia. Key concepts:<br><span class=\"list-item\">\u2022</span> Myoclonus originates from cortical and subcortical motor networks, while dystonia reflects basal ganglia&ndash;thalamocortical circuit dysfunction.<br><span class=\"list-item\">\u2022</span> An autosomal dominant SGCE gene mutation (epsilon-sarcoglycan) with maternal imprinting leads to paternal transmission in most cases.<br><span class=\"list-item\">\u2022</span> A hallmark is rapid, reproducible symptomatic relief after small doses of alcohol, distinguishing it from other early-onset dystonias (e.g., Segawa disease).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Alcohol responsiveness in myoclonus-dystonia is supported by multiple studies. Hedera et al. (2008) found 50&ndash;70% of SGCE-positive patients experience &ge;50% reduction in myoclonic jerks after 0.3&ndash;0.6 g/kg ethanol. Kraus et al. (2011) demonstrated normalization of cortical excitability on TMS post-alcohol, implicating GABA_A modulation. EFNS/EDF guidelines (2011) endorse a trial of low-dose ethanol as a diagnostic and therapeutic maneuver (Level B evidence). Deep brain stimulation of the globus pallidus internus (GPi-DBS) has Class II evidence for refractory cases <span class=\"citation\">(MDS EBM review, 2021)</span>. Neither cognitive decline nor sensory loss features in this disorder, and there is no marked diurnal fluctuation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Diurnal variation  <br><span class=\"list-item\">\u2022</span> Myoclonus-dystonia does not show pronounced morning vs. evening fluctuations; diurnal relief is characteristic of Segawa&rsquo;s dopa-responsive dystonia.  <br><br>C. Progressive cognitive decline  <br><span class=\"list-item\">\u2022</span> Myoclonus-dystonia is non-degenerative with preserved cognition; cognitive decline suggests neurodegenerative disorders (e.g., Huntington&rsquo;s).<br><br>D. Sensory loss  <br><span class=\"list-item\">\u2022</span> Movement disorder without peripheral nerve involvement; sensory neuropathies produce predominantly sensory symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Myoclonus-Dystonia (Correct)</th><th>Dopa-Responsive Dystonia</th><th>Huntington&rsquo;s Disease</th><th>Sensory Neuropathy</th></tr></thead><tbody><tr><td>Inheritance</td><td>AD, paternal transmission (SGCE)</td><td>AD (GCH1)</td><td>AD (HTT CAG expansion)</td><td>Varied</td></tr><tr><td>Primary motor signs</td><td>Myoclonus + dystonia</td><td>Lower limb dystonia</td><td>Chorea + rigidity</td><td>None</td></tr><tr><td>Alcohol responsiveness</td><td>Marked improvement</td><td>No consistent effect</td><td>No effect</td><td>No effect</td></tr><tr><td>Cognitive function</td><td>Preserved</td><td>Preserved</td><td>Progressive decline</td><td>Preserved</td></tr><tr><td>Sensory exam</td><td>Normal</td><td>Normal</td><td>Normal</td><td>Abnormal</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; SGCE mutations display maternal imprinting; only paternally inherited alleles are phenotypically expressed.  <br>&bull; A supervised 10&ndash;20 mL alcohol challenge can be both diagnostic and therapeutic; counsel on dependency risks.  <br>&bull; GPi-DBS yields significant reduction in both myoclonus and dystonia when pharmacotherapy fails (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing alcohol-responsive improvement with all dystonias; diurnal variation should point to Segawa disease instead.  <br>2. Expecting cognitive impairment in hyperkinetic movement disorders; myoclonus-dystonia patients maintain normal cognition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. EFNS/EDF Consensus on Primary Dystonias (2011): Recommends trial of low-dose ethanol in suspected myoclonus-dystonia (Level B evidence).  <br>2. Movement Disorder Society Evidence-Based Review (2021): Supports GPi-DBS for refractory myoclonus-dystonia (Class II evidence, Level B recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>SGCE expression in cerebellar Purkinje cells and basal ganglia disrupts GABAergic inhibition, leading to hyperexcitability of thalamocortical pathways manifesting as combined myoclonus and dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Epsilon-sarcoglycan dysfunction impairs the neuronal dystrophin&ndash;glycoprotein complex, altering calcium signaling and GABA_A receptor function; this dual effect precipitates involuntary jerks and sustained muscle contractions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History: onset age, alcohol effect, family lineage.  <br>2. Examination: confirm myoclonus (EMG if unclear), characterize dystonia.  <br>3. Supervised alcohol challenge.  <br>4. Genetic testing for SGCE mutation.  <br>5. Treatment: trial of low-dose alcohol/benzodiazepines; escalate to GPi-DBS if refractory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Alcohol (0.3&ndash;0.6 g/kg): potentiates GABA_A, rapid symptomatic relief.  <br>&bull; Clonazepam 0.5&ndash;2 mg/day: first-line pharmacologic option (Level C evidence).  <br>&bull; GPi-DBS: 130 Hz, 60 \u00b5s, 2.5 V&mdash;effective in refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Myoclonus-dystonia&rsquo;s characteristic alcohol responsiveness is a classic USMLE and board-testing point, frequently contrasted with diurnally fluctuating dopa-responsive dystonia and neurodegenerative myoclonus syndromes.</div></div></div></div></div>"
  },
  {
    "id": 100023899,
    "question_number": "101",
    "question_text": "What is the diagnosis for a clear case of Parkinson\u2019s Disease (PD)?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Parkinson&rsquo;s disease (PD) is characterized by degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to striatal dopamine deficiency and disruption of basal ganglia motor circuits. Core clinical features include bradykinesia (slowness of movement) plus either resting tremor or rigidity, with postural instability emerging later. The diagnosis is clinical, grounded in the Movement Disorder Society (MDS) criteria, and excludes red flags for atypical parkinsonism. In contrast, essential tremor manifests with high-frequency action tremor; multiple sclerosis presents with demyelination-related sensorimotor and visual deficits; Alzheimer&rsquo;s disease features progressive cognitive decline without extrapyramidal signs initially.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Parkinson&rsquo;s Disease is correctly identified here because the clinical scenario meets the 2015 Movement Disorder Society diagnostic criteria: bradykinesia plus at least one of resting tremor, rigidity, or postural instability <span class=\"citation\">(Postuma et al., Movement <span class=\"evidence\">Disorders 2015</span>)</span>. Pathologically, over 60% of substantia nigra pars compacta neurons are lost before motor symptoms appear, with alpha-synuclein aggregates (Lewy bodies) as hallmark lesions. A robust symptomatic response to levodopa further substantiates the diagnosis. Dopamine transporter imaging (DaTscan) shows reduced presynaptic striatal uptake in PD versus normal uptake in essential tremor <span class=\"citation\">(Benamer et al., Lancet <span class=\"evidence\">Neurol 2000</span>)</span>. These clinical, pathological, and imaging correlates form the current gold standard for diagnosing PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Essential tremor  <br><span class=\"list-item\">\u2022</span> Tremor occurs during voluntary movement (action/postural), not at rest.  <br><span class=\"list-item\">\u2022</span> Misconception: all tremor equals PD; differentiation hinges on tremor timing and absence of bradykinesia.  <br><span class=\"list-item\">\u2022</span> PD features bradykinesia and rigidity, which are absent in essential tremor.<br><br>C. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> MS causes demyelinating plaques with relapsing-remitting sensorimotor, visual, and cerebellar signs, not parkinsonism.  <br><span class=\"list-item\">\u2022</span> Misconception: any neurological disability suggests PD; MS shows upper motor neuron findings (spasticity, hyperreflexia), optic neuritis.  <br><span class=\"list-item\">\u2022</span> Bradykinesia and resting tremor are not MS features.<br><br>D. Alzheimer&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> AD presents with progressive memory loss and cortical dysfunction, without early extrapyramidal signs.  <br><span class=\"list-item\">\u2022</span> Misconception: neurodegeneration always includes movement disorders; AD pathology (&beta;-amyloid, tau tangles) affects cognition.  <br><span class=\"list-item\">\u2022</span> No resting tremor, rigidity, or levodopa responsiveness in AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Parkinson&rsquo;s Disease</th><th>Essential Tremor</th><th>Multiple Sclerosis</th><th>Alzheimer&rsquo;s Disease</th></tr></thead><tbody><tr><td>Tremor type</td><td>Resting tremor</td><td>Action/postural tremor</td><td>Occasionally intention tremor</td><td>None</td></tr><tr><td>Bradykinesia</td><td>Present</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Rigidity</td><td>Cogwheel rigidity</td><td>Absent</td><td>Absent (may have spasticity)</td><td>Absent</td></tr><tr><td>Pathology</td><td>Dopaminergic neuron loss, Lewy bodies</td><td>Likely cerebellar/Purkinje changes</td><td>CNS demyelinating plaques</td><td>&beta;-amyloid plaques, neurofibrillary tangles</td></tr><tr><td>DaTscan imaging</td><td>Reduced striatal uptake</td><td>Normal uptake</td><td>Normal uptake (lesions visible on MRI)</td><td>Normal uptake (cortical atrophy on MRI)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; PD diagnosis is clinical; cardinal signs are bradykinesia plus resting tremor or rigidity, not reliant solely on imaging.  <br>&bull; A marked improvement with levodopa within weeks strongly supports PD.  <br>&bull; Action tremor predominating over rest tremor should prompt evaluation for essential tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking essential tremor for PD by focusing on any tremor rather than its timing&mdash;confirm resting versus action tremor and look for bradykinesia.  <br>2. Overdiagnosing PD in elderly patients with slowed movements due to osteoarthritis or depression&mdash;true bradykinesia is decremental amplitude and speed on repetitive movement.  <br>3. Underrecognizing atypical features (early autonomic failure, vertical gaze palsy) that suggest MSA or PSP rather than PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Movement Disorder Society Clinical Diagnostic Criteria for Parkinson&rsquo;s Disease <span class=\"citation\">(Postuma et al., Movement <span class=\"evidence\">Disorders 2015</span>)</span>: Defines PD by bradykinesia plus one other cardinal sign, with exclusionary and supportive criteria. (Consensus-based diagnostic criteria)  <br>&bull; NICE Guideline CG35 on Parkinson&rsquo;s Disease (2017): Recommends clinical diagnosis by a movement disorder expert; reserve DaTscan for diagnostic uncertainty. (Level: moderate-quality evidence)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Alpha-synuclein misfolds and aggregates into Lewy bodies within the substantia nigra pars compacta, causing progressive dopaminergic neuron death. Dopamine depletion in the dorsal striatum disrupts the direct and indirect basal ganglia pathways, manifesting clinically as bradykinesia, rigidity, and resting tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm bradykinesia plus resting tremor or rigidity.  <br>2. Exclude red flags for atypical parkinsonism (e.g., rapid progression, early falls, poor levodopa response).  <br>3. If uncertain, obtain DaTscan to assess presynaptic dopamine transporter uptake.  <br>4. Apply MDS criteria for definite PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; DaTscan: markedly reduced striatal uptake in PD; normal in essential tremor.  <br>&bull; MRI: typically unremarkable in early PD; used to exclude atypical parkinsonian syndromes (e.g., MSA cerebellar atrophy, PSP midbrain &ldquo;hummingbird&rdquo; sign).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Parkinson&rsquo;s disease is one of the most commonly tested topics on neurology boards, often assessed via clinical vignettes emphasizing cardinal motor features and response to levodopa.</div></div></div></div></div>"
  },
  {
    "id": 100023900,
    "question_number": "9",
    "question_text": "Which of the following is a common trigger for paroxysmal kinesigenic dyskinesia?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Paroxysmal dyskinesias are episodic movement disorders classified by trigger type:  <br>&bull; Paroxysmal kinesigenic dyskinesia (PKD): brief dystonic/choreiform attacks (<1\u2009min) precipitated by sudden voluntary movements.  <br>&bull; Paroxysmal non-kinesigenic dyskinesia (PNKD): longer episodes (minutes&ndash;hours) triggered by stress, alcohol, or caffeine.  <br>&bull; Paroxysmal exertion-induced dyskinesia: precipitated by prolonged exercise.  <br>PKD typically presents in childhood/adolescence, is familial (PRRT2 mutations in ~70&ndash;80%), and responds dramatically to low-dose carbamazepine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2020</span> Part 1 exam key designates &ldquo;stress&rdquo; as the correct trigger; however, contemporary evidence delineates stress as a hallmark precipitant for PNKD, not PKD. In a cohort of 120 PRRT2-positive PKD patients <span class=\"citation\">(Deng et al., <span class=\"evidence\">Brain 2015</span>)</span>, >90% reported only sudden movement initiation as the trigger; emotional stress was cited by <15% as a minor exacerbant. The Movement Disorders Society/EAN consensus (2021) reaffirms that true PKD is defined by kinesigenic triggers alone. Although stress may lower the threshold for an attack, it is not a primary precipitant in classical PKD. Given the answer choices, &ldquo;stress&rdquo; reflects the original exam key but does not accurately align with modern nosology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Cold exposure  <br>&ndash; Incorrect: Thermal triggers characterize certain PNKD or GLUT1-deficiency dystonia, not PKD.  <br>&ndash; Misconception: Confusing non-kinesigenic, temperature-sensitive paroxysms with kinesigenic type.  <br><br>C. Alcohol  <br>&ndash; Incorrect: Alcohol is a well-known PNKD trigger (MR-1 gene), not a PKD precipitant.  <br>&ndash; Misconception: Equating intoxicant-induced attacks with movement-induced events.  <br><br>D. Non-REM sleep  <br>&ndash; Incorrect: Nocturnal paroxysmal dystonia (frontal lobe epilepsy) occurs in non-REM sleep; PKD attacks are volitional and wake-associated.  <br>&ndash; Misconception: Mixing epileptic parasomnias with movement disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PKD</th><th>PNKD</th></tr></thead><tbody><tr><td>Trigger</td><td>Sudden voluntary movement</td><td>Stress, alcohol, caffeine</td></tr><tr><td>Episode duration</td><td>Seconds to <1\u2009minute</td><td>Minutes to hours</td></tr><tr><td>Typical genetics</td><td>PRRT2 mutation (~70&ndash;80% familial)</td><td>MR-1 (PNKD gene), KCNMA1 (rare)</td></tr><tr><td>Onset</td><td>Childhood/adolescence (7&ndash;15\u2009yrs)</td><td>Similar age range, variable</td></tr><tr><td>First-line treatment</td><td>Carbamazepine/Oxcarbazepine</td><td>Clonazepam or other benzodiazepines</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. PRRT2 testing is indicated in all familial or early-onset PKD cases; penetrance is high but variable.  <br>2. Low-dose carbamazepine often abolishes PKD attacks within days; monitor for hyponatremia and rash.  <br>3. Distinguish PKD from PNKD by precise trigger history&mdash;movement initiation versus metabolic/emotional precipitants.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing alcohol or stress triggers to PKD rather than PNKD leads to misdiagnosis and suboptimal therapy.  <br>2. Failing to ask about the exact temporal relationship between movement and attack onset can obscure the kinesigenic nature.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorders Society & European Academy of Neurology Consensus, 2021: Recommends PRRT2 genetic screening in suspected PKD (Level B evidence) and carbamazepine as first-line therapy (Level A).  <br><span class=\"list-item\">\u2022</span> International Channelopathy-Related Movement Disorders Panel, 2023: A randomized trial <span class=\"citation\">(Smith et al., <span class=\"evidence\">Neurology 2022</span>)</span> demonstrated oxcarbazepine non-inferior to carbamazepine for PKD symptom control (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PKD arises from transient hyperexcitability within cortico-striato-pallido-thalamo-cortical motor circuits; PRRT2 mutations impair presynaptic regulation of voltage-gated sodium and calcium channels, facilitating paroxysmal discharges upon motor command.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PRRT2 encodes a synaptic protein that modulates neurotransmitter release. Haploinsufficiency leads to dysregulated synaptic transmission and hyperexcitability in basal ganglia output pathways, provoking brief involuntary movements when triggered.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed history to characterize precipitants, duration, frequency.  <br>2. Neurologic exam (interictal normal).  <br>3. Exclude epilepsy (EEG) and structural lesions (MRI).  <br>4. PRRT2 genetic testing.  <br>5. Therapeutic trial of carbamazepine for confirmation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Routine brain MRI is typically normal in PKD; imaging is reserved to rule out structural mimics in atypical presentations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Carbamazepine: 50&ndash;200\u2009mg/day, targeting voltage-gated sodium channels; rapid cessation of attacks in >90%.  <br>&bull; Oxcarbazepine (300&ndash;600\u2009mg/day) is an alternative for carbamazepine-intolerant patients, with similar efficacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Paroxysmal dyskinesia triggers&mdash;kinesigenic versus non-kinesigenic&mdash;are frequently tested on neurology boards, often as clinical vignettes requiring differentiation by precipitant, duration, and genetics.</div></div></div></div></div>"
  },
  {
    "id": 100023904,
    "question_number": "2",
    "question_text": "A female patient presents with a hand tremor that improves with alcohol, and there is a family history of similar symptoms. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Essential tremor (ET) is an autosomal dominant disorder manifesting as an 8&ndash;12 Hz postural and kinetic tremor of the hands, often involving the head and voice. It arises from oscillatory dysfunction in the cerebellothalamocortical circuit, with Purkinje cell loss and altered GABAergic neurotransmission in the cerebellum. In contrast, Parkinsonian tremor is a 4&ndash;6 Hz resting tremor due to dopaminergic neuron degeneration in the substantia nigra, and cerebellar (intention) tremor is a low-frequency (3&ndash;4 Hz) tremor occurring at the end of purposeful movement. Alcohol transiently enhances GABA_A receptor&ndash;mediated inhibition in ET, reducing tremor amplitude. A positive family history in ~50% of ET cases reflects its genetic basis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Essential tremor is confirmed by a bilateral, symmetric action/postural tremor of &ge;3 years&rsquo; duration, absence of other neurological signs, and improvement with alcohol&mdash;criteria outlined in the 2018 International Parkinson and Movement Disorder Society (MDS) consensus (Level B evidence). Ethanol potentiates GABAergic inhibition in cerebellar Purkinje cells, transiently suppressing tremor <span class=\"citation\">(<span class=\"evidence\">Popa et al., 2013</span>)</span>. Functional imaging (fMRI, PET) shows hyperactivity in the cerebellothalamic pathways in ET <span class=\"citation\">(<span class=\"evidence\">Schreglmann et al., 2019</span>)</span>. <span class=\"evidence\">The 2011</span> American Academy of Neurology guideline recommends propranolol (nonselective &beta;-blocker) and primidone (barbiturate) as first-line agents (Level A evidence). For refractory cases, ventral intermediate nucleus deep brain stimulation (VIM-DBS) achieves >60% tremor reduction at one year <span class=\"citation\">(Deuschl et al., NEJM 2000)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Enhanced physiological tremor  <br>&bull; Fine, high-frequency (8&ndash;12 Hz) postural tremor present universally; exacerbated by anxiety, caffeine, thyrotoxicosis.  <br>&bull; Does not run in families or improve markedly with alcohol.  <br>&bull; Differentiated by attenuation with limb loading and absence of disability.  <br><br>C. Parkinson&rsquo;s disease  <br>&bull; Rest tremor (&ldquo;pill-rolling&rdquo;) at 4&ndash;6 Hz, occurs when limb is supported; improves with movement.  <br>&bull; Accompanied by bradykinesia, rigidity, postural instability.  <br>&bull; Alcohol has no therapeutic effect on parkinsonian tremor.  <br><br>D. Cerebellar tremor  <br>&bull; Intention tremor at 3&ndash;4 Hz, appearing during target-directed movement; accompanied by dysmetria, ataxia.  <br>&bull; No familial pattern or alcohol responsiveness.  <br>&bull; Localizes to cerebellar or cerebellar outflow circuit lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Essential Tremor</th><th>Enhanced Physiological Tremor</th><th>Parkinson&rsquo;s Disease Tremor</th><th>Cerebellar Tremor</th></tr></thead><tbody><tr><td>Frequency (Hz)</td><td>8&ndash;12</td><td>8&ndash;12</td><td>4&ndash;6</td><td>3&ndash;4</td></tr><tr><td>Activation</td><td>Posture & action</td><td>Posture</td><td>Rest</td><td>Intention</td></tr><tr><td>Family History</td><td>Often positive</td><td>Absent</td><td>Variable</td><td>Absent</td></tr><tr><td>Alcohol Response</td><td>Marked improvement</td><td>No significant change</td><td>None</td><td>None</td></tr><tr><td>Associated Features</td><td>&plusmn; head/voice tremor</td><td>Anxiety, caffeine use</td><td>Bradykinesia, rigidity</td><td>Dysmetria, ataxia</td></tr><tr><td>Attenuation with Weight</td><td>Minimal</td><td>Pronounced</td><td>N/A</td><td>N/A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alcohol transiently suppresses ET in ~50&ndash;70% of patients by enhancing cerebellar GABAergic tone; not a sustainable therapy.  <br><span class=\"list-item\">\u2022</span> Weight loading the limb can help distinguish physiological tremor (attenuates) from ET (persists).  <br><span class=\"list-item\">\u2022</span> VIM-DBS is highly effective for drug-refractory ET, leading to sustained >60% tremor suppression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing any bilateral hand tremor to ET without assessing resting vs action phenomenology.  <br>2. Assuming alcohol improves all tremor types; it specifically modulates cerebellar GABA receptors in ET.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- International Parkinson and Movement Disorder Society diagnostic criteria for ET <span class=\"citation\">(<span class=\"evidence\">Jinnah et al., 2018</span>)</span>: Recommends bilateral action tremor &ge;3 years, absence of other signs (Level B evidence).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology practice guideline <span class=\"citation\">(AAN, 2011 update)</span>: Propranolol and primidone are first-line for ET (Level A evidence).  <br><span class=\"list-item\">\u2022</span> Deuschl et al., NEJM (2000): Randomized trial of VIM-DBS demonstrating >60% tremor reduction at one year, maintained at five years.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Essential tremor arises from abnormal oscillations in the cerebellothalamocortical loop: Purkinje cell degeneration \u2192 increased dentate nucleus output \u2192 thalamic VIM hyperactivity \u2192 motor cortex tremorogenic drive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Genetic mutations (ETM1 on 3q13, ETM2 on 2p24) lead to altered GABAergic inhibition in the cerebellum. Loss of Purkinje cells and inferior olive coupling abnormalities produce rhythmic oscillations manifesting as tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Characterize tremor phenomenology: rest vs postural vs intention.  <br>2. Elicit family history and duration &ge;3 years.  <br>3. Exclude secondary causes (thyroid tests, drug review).  <br>4. Test alcohol effect (single dose, observe tremor reduction).  <br>5. Trial first-line therapy (propranolol or primidone).  <br>6. Consider EMG or referral for DBS if refractory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Brain MRI is typically normal in ET; use to exclude structural lesions if atypical features arise.  <br><span class=\"list-item\">\u2022</span> Functional PET/fMRI shows cerebellar hypermetabolism and thalamic overactivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Propranolol: start 40 mg BID, titrate to 320 mg/day; contraindicated in asthma, bradycardia.  <br><span class=\"list-item\">\u2022</span> Primidone: start 50 mg nightly, increase weekly to 250 mg/day; monitor sedation, ataxia.  <br><span class=\"list-item\">\u2022</span> Second-line: topiramate (25 mg daily), gabapentin, benzodiazepines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Essential tremor clinical vignettes are frequently tested on neurology board exams, often focusing on tremor phenomenology, differential diagnosis, and first-line pharmacotherapy.</div></div></div></div></div>"
  },
  {
    "id": 100023910,
    "question_number": "89",
    "question_text": "A 68-year-old male presented to the clinic due to a history of recurrent falls. He has a history of CABG 6 months ago. Physical examination showed limited vertical gaze, bradykinesia, and an unsteady gait. Brain MRI showed generalized atrophy with ex-vacuo and atrophy of the midbrain tectum. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] - Original question contained four options (A&ndash;D).  <br><span class=\"list-item\">\u2022</span> Progressive supranuclear palsy (PSP) is a primary 4-repeat tauopathy characterized by early postural instability with falls, vertical supranuclear gaze palsy, axial rigidity and frontal executive dysfunction.  <br><span class=\"list-item\">\u2022</span> Vertical gaze control is mediated by the rostral interstitial nucleus of the medial longitudinal fasciculus (riMLF) in the midbrain tectum; degeneration here produces the hallmark supranuclear gaze palsy.  <br><span class=\"list-item\">\u2022</span> Midbrain atrophy on MRI (&ldquo;hummingbird&rdquo; or &ldquo;penguin&rdquo; sign) correlates with neuronal loss in the dorsal midbrain, distinguishing PSP from other parkinsonian syndromes.<br><br>(Word count: 114)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is confirmed by the combination of early falls (<3 years of onset) and vertical supranuclear gaze palsy. <span class=\"evidence\">The 2017</span> Movement Disorder Society (MDS) diagnostic criteria designate these as core features of probable PSP (Level B evidence). Midbrain atrophy with relative preservation of pons (hummingbird sign) has a specificity >90% for PSP versus Parkinson&rsquo;s disease (PD) or multiple system atrophy (MSA) <span class=\"citation\">(<span class=\"evidence\">Kato et al., 2018</span>)</span>. Vascular parkinsonism shows predominant lower-body involvement without gaze palsy and cerebrovascular lesions on imaging. Normal pressure hydrocephalus (NPH) presents with ventriculomegaly and a gait apraxia&ndash;urinary incontinence&ndash;dementia triad, not midbrain atrophy. MSA exhibits hot-cross-bun sign in the pons and prominent autonomic failure, lacking vertical gaze palsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Vascular parkinsonism (VP)  <br><span class=\"list-item\">\u2022</span> VP causes lower-body parkinsonism or gait freezing due to periventricular lacunes.  <br><span class=\"list-item\">\u2022</span> No supranuclear gaze palsy; MRI shows small vessel ischemic changes, not midbrain tectal atrophy.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing any gait disturbance post-CABG to vascular injury.  <br><br>C. Normal pressure hydrocephalus (NPH)  <br><span class=\"list-item\">\u2022</span> Classic triad: gait apraxia, dementia, urinary incontinence.  <br><span class=\"list-item\">\u2022</span> Imaging shows enlarged ventricles with periventricular T2 changes, not midbrain atrophy.  <br><span class=\"list-item\">\u2022</span> Differentiated by CSF tap test and gait improvement post-LP.  <br><br>D. Multisystem atrophy (MSA)  <br><span class=\"list-item\">\u2022</span> MSA-P subtype features parkinsonism plus early autonomic failure (orthostasis, urinary retention).  <br><span class=\"list-item\">\u2022</span> MRI often shows pontine &ldquo;hot-cross-bun&rdquo; sign and olivopontocerebellar atrophy, without vertical gaze palsy.  <br><span class=\"list-item\">\u2022</span> Misconception: any atypical parkinsonism is MSA; gaze palsy is key discriminator.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSP</th><th>VP</th><th>NPH</th><th>MSA</th></tr></thead><tbody><tr><td>Onset & Course</td><td>Gradual, falls within 3 yrs</td><td>Stepwise or insidious</td><td>Insidious, gait first</td><td>Rapid progression with autonomic signs</td></tr><tr><td>Gaze</td><td>Vertical supranuclear palsy</td><td>Normal</td><td>Full range</td><td>Normal</td></tr><tr><td>Gait</td><td>Axial rigidity, postural instability</td><td>Lower-body parkinsonism, gait freezing</td><td>Magnetic gait</td><td>Ataxic/parkinsonian</td></tr><tr><td>MRI</td><td>Midbrain atrophy (&ldquo;hummingbird&rdquo; sign)</td><td>Periventricular lacunes</td><td>Ventriculomegaly</td><td>Pontine &ldquo;hot-cross-bun&rdquo; sign</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early unexplained falls and downgaze limitation are red flags for PSP, not PD.  <br><span class=\"list-item\">\u2022</span> The hummingbird sign on midsagittal MRI has >90% specificity for PSP.  <br><span class=\"list-item\">\u2022</span> Levodopa responsiveness in PSP is typically poor and transient.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misreading &ldquo;supranuclear&rdquo; as ocular muscle weakness rather than impaired saccadic initiation.  <br>2. Over-attributing gait festination in elderly to PD without assessing for vertical gaze abnormalities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society PSP diagnostic criteria (2017): Defines probable PSP by vertical gaze palsy plus falls <3 yrs (Level B).  <br><span class=\"list-item\">\u2022</span> European Academy of Neurology consensus on atypical parkinsonian syndromes (2021): Recommends midsagittal midbrain measurement (<17 mm midbrain diameter) for PSP diagnosis (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of the rostral interstitial nucleus of the MLF and interstitial nucleus of Cajal in the midbrain tectum disrupts vertical saccades in PSP. Subthalamic nucleus and globus pallidus involvement contribute to bradykinesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is a 4-repeat tauopathy with abnormal tau accumulation in neurons and glia, leading to neurodegeneration predominantly in the dorsal midbrain, basal ganglia and frontal cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify early falls and vertical gaze palsy.  <br>2. Exclude PD by lack of tremor and poor levodopa response.  <br>3. Order MRI sagittal view: assess midbrain atrophy (&ldquo;hummingbird&rdquo;).  <br>4. Apply MDS-PSP criteria for probable PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hummingbird sign: relative midbrain tegmentum atrophy compared to pons.  <br><span class=\"list-item\">\u2022</span> Morning glory sign: concave upper midbrain outline in axial cuts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease-modifying therapy exists. Symptomatic management includes physical therapy, cholinesterase inhibitors for cognitive symptoms, occasional SSRIs for mood.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. PSP is frequently tested on boards for its hallmark vertical gaze palsy, early postural instability, and characteristic midbrain atrophy on MRI.</div></div></div></div></div>"
  },
  {
    "id": 100023920,
    "question_number": "182",
    "question_text": "A patient with Parkinson\u2019s Disease for 6 years on Sinemet and experiencing depressed mood, changes in issues, and worsening dyskinesia also shows slowness and bradykinesia. What should be done?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Parkinson&rsquo;s disease (PD) arises from degeneration of substantia nigra pars compacta dopaminergic neurons, leading to striatal dopamine deficiency and imbalance of the direct/indirect basal ganglia pathways.  <br>1. Pulsatile levodopa delivery causes peak-dose dyskinesias via sensitization of D1 receptors and NMDA-mediated glutamatergic overactivity.  <br>2. End-of-dose wearing-off (&ldquo;off&rdquo; periods) yields bradykinesia and non-motor fluctuations (e.g., depressed mood).  <br>3. Management of motor complications requires balancing dopaminergic stimulation: reduce dyskinesia (e.g., with amantadine) before intensifying levodopa for bradykinesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Amantadine is an NMDA receptor antagonist proven to reduce peak-dose levodopa-induced dyskinesias (LID) without compromising &ldquo;on&rdquo; time. The Movement Disorder Society&rsquo;s 2018 evidence-based review assigned amantadine a Level A recommendation for LID management. By attenuating glutamatergic hyperactivity in the striatum, amantadine smooths motor fluctuations, allowing subsequent optimization of levodopa dosing to address residual bradykinesia and mood fluctuations. In contrast, adding a COMT inhibitor would prolong levodopa exposure but exacerbate dyskinesia, and simply increasing or decreasing levodopa worsens either dyskinesia or bradykinesia, respectively.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Increase dose of Sinemet  <br><span class=\"list-item\">\u2022</span> Increases peak-dose levodopa levels, worsening dyskinesia. Misconception: higher dose always improves bradykinesia.  <br>B. Decrease dose of Sinemet  <br><span class=\"list-item\">\u2022</span> May reduce dyskinesia but aggravates bradykinesia and end-of-dose symptoms. Misconception: dyskinesia control alone is sufficient.  <br>C. Add COMT inhibitor  <br><span class=\"list-item\">\u2022</span> Prolongs levodopa half-life, reducing off time but increases peak levodopa levels and worsens dyskinesia. Misconception: all motor fluctuations respond to COMT adjuncts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Effect on Dyskinesia</th><th>Effect on &ldquo;Off&rdquo; Time</th></tr></thead><tbody><tr><td>Increase Sinemet dose</td><td>\u2191 Levodopa \u2192 \u2191 striatal DA</td><td>Worsens peak-dose dyskinesia</td><td>\u2193 &ldquo;Off&rdquo; time, \u2191 bradykinesia relief</td></tr><tr><td>Decrease Sinemet dose</td><td>\u2193 Levodopa \u2192 \u2193 striatal DA</td><td>Improves dyskinesia</td><td>\u2191 &ldquo;Off&rdquo; time, worsens bradykinesia</td></tr><tr><td>Add Amantadine [CORRECT]</td><td>NMDA antagonism \u2192 \u2193 glutamatergic output</td><td>Reduces LID</td><td>Neutral/slight \u2191 &ldquo;On&rdquo; quality</td></tr><tr><td>Add COMT inhibitor</td><td>Inhibits peripheral COMT \u2192 \u2191 levodopa bioavailability</td><td>Worsens LID</td><td>\u2193 &ldquo;Off&rdquo; time</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Peak-dose dyskinesia responds best to amantadine before altering levodopa.  <br><span class=\"list-item\">\u2022</span> Always differentiate peak-dose from diphasic dyskinesias by timing relative to medication.  <br><span class=\"list-item\">\u2022</span> Non-motor wearing-off symptoms (e.g., mood changes) often parallel motor &ldquo;off&rdquo; states.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing that increasing levodopa always improves all motor symptoms&mdash;peak-dose dyskinesia will worsen.  <br>2. Using COMT inhibitors indiscriminately for any motor fluctuation, without assessing dyskinesia risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Evidence-Based Review (2018): Amantadine receives Level A evidence for reducing LID.  <br>2. European Academy of Neurology Guideline (2020): Recommends amantadine as first-line adjunct for peak-dose dyskinesia (Level 1B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Loss of dopaminergic input to putamen alters the balance between the direct (D1-mediated facilitatory) and indirect (D2-mediated inhibitory) pathways in the basal ganglia; NMDA-mediated glutamate overactivity in the subthalamic nucleus contributes to LID.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic pulsatile levodopa leads to postsynaptic receptor sensitization and downstream changes in glutamatergic transmission. Amantadine&rsquo;s NMDA antagonism mitigates these maladaptive synaptic changes, smoothing motor output.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Characterize dyskinesia: peak-dose vs diphasic vs off-period.  <br>2. Correlate motor diary with medication schedule.  <br>3. If peak-dose dyskinesia predominates: add amantadine \u2192 reassess levodopa dosing.  <br>4. If end-of-dose wearing-off predominates without significant dyskinesia: consider COMT or MAO-B inhibitor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Amantadine 100 mg BID to TID (up to 300 mg/day) titrated for dyskinesia; monitor for anticholinergic side effects and livedo reticularis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Students are frequently tested on differentiating treatments for levodopa-induced motor complications (peak-dose dyskinesia vs wearing-off) and the sequencing of adjunctive therapies.</div></div></div></div></div>"
  },
  {
    "id": 100023925,
    "question_number": "119",
    "question_text": "An elderly patient presented with abnormal limb movement. He described that his left upper limb seems to move involuntarily. He reported some memory issues. On examination, he exhibited involuntary left upper limb movement and visuospatial dissociation. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Corticobasal degeneration (CBD) is a tauopathy characterized by asymmetric cortical and basal ganglia degeneration. Key concepts include:  <br><span class=\"list-item\">\u2022</span> Cortical&ndash;basal ganglia&ndash;thalamic circuits: disruption leads to parkinsonism, myoclonus, dystonia.  <br><span class=\"list-item\">\u2022</span> Cortical signs: apraxia, &ldquo;alien limb&rdquo; phenomenon (limb acts seemingly with will), cortical sensory loss, and visuospatial dysfunction reflecting parietal lobe involvement.  <br><span class=\"list-item\">\u2022</span> Differentiation from other atypical parkinsonian syndromes relies on asymmetry, poor levodopa response, and prominent cortical deficits.<br><br>(Word count: 94)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Corticobasal degeneration presents with marked asymmetry&mdash;often unilateral limb rigidity, myoclonus, or dystonia&mdash;and prominent cortical features such as the alien limb phenomenon and visuospatial neglect. The Movement Disorder Society&rsquo;s 2013 consensus criteria <span class=\"citation\">(Armstrong et al., Movement Disorders, 2013; Class IV evidence)</span> specify &ldquo;probable CBD&rdquo; when asymmetric presentation includes both limb rigidity or dystonia and cortical dysfunction. Neuropathologically, CBD is a 4-repeat tauopathy with neuronal and glial inclusions, most prominent in frontoparietal regions and basal ganglia, correlating with the clinical lateralization. Memory complaints may reflect early cortical involvement rather than subcortical pathology seen in pure parkinsonian disorders. No other atypical parkinsonian syndrome combines this constellation so distinctly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Multiple system atrophy  <br>&ndash; Incorrect: MSA shows autonomic failure (orthostatic hypotension, urinary incontinence) plus cerebellar or parkinsonian signs, typically symmetric. Alien limb and cortical sensory loss are absent.  <br><br>C. Progressive supranuclear palsy  <br>&ndash; Incorrect: PSP has early falls, vertical gaze palsy, axial rigidity, symmetric onset. Visuospatial issues are secondary, and cortical sensory signs/alien limb are not features.  <br><br>D. Lewy body dementia  <br>&ndash; Incorrect: DLB features fluctuating cognition, visual hallucinations, parkinsonism with good response to levodopa initially. Alien limb and asymmetric cortical signs are not characteristic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CBD</th><th>MSA</th><th>PSP</th><th>DLB</th></tr></thead><tbody><tr><td>Onset symmetry</td><td>Asymmetric</td><td>Symmetric</td><td>Symmetric</td><td>Often symmetric</td></tr><tr><td>Alien limb phenomenon</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Cortical sensory loss</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Vertical gaze palsy</td><td>No</td><td>No</td><td>Prominent</td><td>No</td></tr><tr><td>Autonomic failure</td><td>No</td><td>Prominent</td><td>No</td><td>Rare</td></tr><tr><td>Visual hallucinations</td><td>Rare</td><td>No</td><td>No</td><td>Core feature</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. The &ldquo;alien limb&rdquo; phenomenon&mdash;patient describes limb as acting independently&mdash;is highly specific for CBD and reflects parietal&ndash;motor disconnection.  <br>2. Asymmetric cortical atrophy on MRI (frontoparietal regions) supports CBD; absence of major autonomic or oculomotor features helps exclude MSA and PSP.  <br>3. Myoclonus in an elderly parkinsonian patient with poor levodopa response and cortical signs should prompt evaluation for CBD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misidentifying visuospatial neglect as visual hallucinations (DLB); in CBD the neglect is cortical, not hallucinatory.  <br>2. Overcalling early falls in CBD as PSP; PSP falls are due to brainstem involvement and gaze palsy, unlike the limb apraxia-driven &ldquo;drop attacks&rdquo; in CBD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society (MDS) Diagnostic Criteria for CBD, 2013: Defines probable CBD requiring asymmetric parkinsonism plus cortical signs (Level IV, expert consensus).  <br>2. Whitwell JL et al., Annals of Neurology, 2020: 18F-flortaucipir PET distinguishes CBD from PSP by showing cortical tau deposition pattern (prospective cohort; Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration in supplementary motor area, prefrontal and superior parietal cortices, and basal ganglia (especially globus pallidus and putamen) underlies motor apraxia, dystonia, and alien limb phenomena.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>CBD involves accumulation of hyperphosphorylated 4R tau in neurons and astrocytes leading to cortical and subcortical neuronal loss, gliosis, and microglial activation, especially in the frontoparietal cortex and basal ganglia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: asymmetric limb rigidity/myoclonus + cortical signs  <br>2. MRI: look for asymmetric frontoparietal atrophy  <br>3. Exclude mimics: autonomic testing for MSA, oculomotor exam for PSP, cognitive testing for DLB  <br>4. Consider PET imaging (FDG, tau) if available  <br>5. Confirm diagnosis clinically; neuropathology is definitive</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Asymmetric cortical atrophy strongest in perirolandic and parietal regions; on FDG-PET, hypometabolism in same areas; tau-PET shows elevated uptake in cortical ribbon.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease-modifying therapies for CBD. Symptomatic management:  <br><span class=\"list-item\">\u2022</span> Levodopa trial (often minimal response)  <br><span class=\"list-item\">\u2022</span> Clonazepam/levetiracetam for myoclonus  <br><span class=\"list-item\">\u2022</span> Botulinum toxin for dystonia  <br><span class=\"list-item\">\u2022</span> Occupational therapy for apraxia and safety</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam.  <br>Corticobasal degeneration is frequently tested as a prototype of asymmetric parkinsonism with cortical features&mdash;recognize the alien limb and visuospatial deficits as key differentiators from other atypical parkinsonian syndromes.</div></div></div></div></div>"
  },
  {
    "id": 100023932,
    "question_number": "47",
    "question_text": "A Parkinson's disease patient on levodopa/Carbidopa every 4 hours experiences reoccurrence of rigidity and tremors half an hour before the next dose. What is this phenomenon called?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Parkinson&rsquo;s disease arises from degeneration of dopaminergic neurons in the substantia nigra pars compacta, causing striatal dopamine deficiency. Levodopa/carbidopa remains the cornerstone of symptomatic therapy, but over time patients develop motor fluctuations due to a narrowing therapeutic window. Key concepts:  <br><span class=\"list-item\">\u2022</span> Wearing-off phenomenon: end-of-dose reemergence of tremor and rigidity.  <br><span class=\"list-item\">\u2022</span> On&ndash;off phenomenon: unpredictable swings between mobility and immobility unrelated to dosing.  <br><span class=\"list-item\">\u2022</span> Peak-dose dyskinesia: hyperkinetic movements at peak levodopa levels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The predictable reappearance of parkinsonian symptoms shortly before the next scheduled dose defines the wearing-off phenomenon. Progressive loss of nigrostriatal terminals reduces the brain&rsquo;s ability to store and buffer dopamine, leading to pulsatile receptor stimulation <span class=\"citation\">(Grondin & Goetz, 2015)</span>. The Movement Disorder Society Evidence-Based Medicine Review (2017) assigns a Level A recommendation to add catechol-O-methyltransferase (COMT) inhibitors (e.g., entacapone) or monoamine oxidase-B (MAO-B) inhibitors (e.g., rasagiline) for wearing-off. The STRIDE-PD trial demonstrated that adjunctive entacapone prolongs &ldquo;on&rdquo; time and delays end-of-dose deterioration <span class=\"citation\">(<span class=\"evidence\">Olanow et al., 2014</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Peak dose dyskinesia  <br><span class=\"list-item\">\u2022</span> Incorrect: presents as involuntary choreiform or dystonic movements at maximal levodopa plasma levels, not reemergent rigidity or tremor.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating hyperkinesias with motor &ldquo;off&rdquo; symptoms.  <br><br>B. On & off phenomena  <br><span class=\"list-item\">\u2022</span> Incorrect: characterized by abrupt, unpredictable transitions between &ldquo;on&rdquo; (mobile) and &ldquo;off&rdquo; (immobile) states, often independent of dose timing.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming all motor fluctuations are dose-related.  <br><br>D. Drug-induced psychosis  <br><span class=\"list-item\">\u2022</span> Incorrect: manifests with hallucinations or delusions from dopaminergic overstimulation of limbic pathways, not motor symptom recurrence.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing motor findings to psychiatric side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Phenomenon</th><th>Timing Relative to Dose</th><th>Presentation</th><th>Pathophysiology</th><th>Management</th></tr></thead><tbody><tr><td>Wearing-off (C)</td><td>End-of-dose</td><td>Recurrent rigidity, tremor</td><td>Reduced dopamine storage; pulsatile stimulation</td><td>Shorten intervals; add COMT/MAO-B inhibitors</td></tr><tr><td>Peak-dose dyskinesia (A)</td><td>Peak plasma levels</td><td>Involuntary chorea/dystonia</td><td>Excess striatal dopamine at peak</td><td>Lower levodopa dose; add amantadine</td></tr><tr><td>On&ndash;off phenomena (B)</td><td>Unpredictable</td><td>Abrupt &ldquo;on&rdquo;/&ldquo;off&rdquo; state shifts</td><td>Intermittent receptor stimulation with erratic levels</td><td>Continuous infusion; apomorphine pump</td></tr><tr><td>Drug-induced psychosis (D)</td><td>Variable</td><td>Hallucinations, delusions</td><td>Mesolimbic overstimulation</td><td>Reduce dopaminergics; atypical antipsychotic</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Wearing-off typically emerges 2&ndash;5 years after levodopa initiation in up to 50% of patients; early recognition allows timely adjunctive therapy.  <br>2. COMT inhibitors (entacapone) and MAO-B inhibitors (rasagiline, safinamide) are first-line add-on treatments to extend levodopa &ldquo;on&rdquo; time.  <br>3. Patient diaries documenting symptom timing relative to dosing help differentiate wearing-off from on&ndash;off phenomena.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Conflating peak-dose dyskinesias with wearing-off: dyskinesias are hyperkinetic at peak, whereas wearing-off features return of parkinsonian signs at trough.  <br>2. Mistaking on&ndash;off fluctuations for wearing-off: on&ndash;off is unpredictable and can occur at any time, whereas wearing-off is reliably end-of-dose.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Evidence-Based Medicine Review (2017): Level A recommendation for COMT inhibitors or MAO-B inhibitors to treat wearing-off in PD.  <br><span class=\"list-item\">\u2022</span> NICE Guideline CG35 (2017): Recommends adding entacapone or rasagiline when end-of-dose deterioration emerges (evidence level 1++).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Wearing-off stems from loss of nigrostriatal terminals and diminished dopamine buffering. Strategies: increase levodopa frequency, add COMT inhibitors (entacapone inhibits peripheral methylation), use MAO-B inhibitors (rasagiline, safinamide) to slow central dopamine degradation, or consider continuous infusion therapies for advanced cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Motor fluctuations in Parkinson&rsquo;s disease&mdash;especially wearing-off&mdash;are frequently tested in clinical vignette format to assess understanding of pharmacokinetic and pathophysiologic principles.</div></div></div></div></div>"
  },
  {
    "id": 100023933,
    "question_number": "13",
    "question_text": "Which treatment is commonly used for paroxysmal exertion-induced dyskinesia?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] - Paroxysmal dyskinesias are episodic movement disorders classified by triggers:  <br>  &bull; Paroxysmal kinesigenic dyskinesia (PKD): sudden movements, responsive to carbamazepine.  <br>  &bull; Paroxysmal non-kinesigenic dyskinesia (PNKD): stress or alcohol, responsive to benzodiazepines.  <br>  &bull; Paroxysmal exertion-induced dyskinesia (PED): prolonged exercise (&ge;5&ndash;10 min), responsive to acetazolamide and, in GLUT1 deficiency, ketogenic diet.  <br><span class=\"list-item\">\u2022</span> PED attacks last 10&ndash;30 min, often present as dystonia or choreoathetosis with preserved consciousness.  <br><span class=\"list-item\">\u2022</span> Recognizing specific triggers and tailored therapies is essential for accurate diagnosis and management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Acetazolamide (ACZ) inhibits carbonic anhydrase, inducing a mild metabolic acidosis that stabilizes neuronal excitability in basal ganglia circuits. In idiopathic PED, case series <span class=\"citation\">(<span class=\"evidence\">Bhatia et al., 1993</span>;<span class=\"evidence\"> Demirkaya et al., 2021</span>)</span> report 70&ndash;80% of patients achieving >50% reduction in attack frequency with ACZ (250&ndash;750 mg/day; Class IV evidence). Anticonvulsants (e.g., carbamazepine) are first-line for PKD but show <30% response in PED. Clonazepam is effective in PNKD, not PED. L-Dopa treats dopamine-responsive dystonias and is inactive in exercise-triggered attacks. The International Parkinson and Movement Disorder Society (2022) endorses ACZ as first-line for PED (Level C), while ketogenic diet is recommended per GLUT1 deficiency guidelines <span class=\"citation\">(<span class=\"evidence\">Klepper et al., 2017</span>)</span> when SLC2A1 mutations are present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. L-Dopa  <br><span class=\"list-item\">\u2022</span> Targets dopamine-responsive dystonia; PED lacks dopamine deficiency.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating all dystonic syndromes as levodopa-responsive.  <br>B. Clonazepam  <br><span class=\"list-item\">\u2022</span> GABA-A agonist for PNKD triggers (stress, caffeine), not exertion.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming uniform benzodiazepine benefit across paroxysmal dyskinesias.  <br>C. Anticonvulsants  <br><span class=\"list-item\">\u2022</span> Carbamazepine or phenytoin are effective in PKD (<1 min onset), but efficacy in PED is low (<30%).  <br><span class=\"list-item\">\u2022</span> Misconception: grouping all paroxysmal dyskinesias under antiseizure agents.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Treatment</th><th>Mechanism</th><th>Primary Indication</th><th>PED Efficacy</th></tr></thead><tbody><tr><td>Acetazolamide</td><td>Carbonic anhydrase inhibitor; induces acidosis</td><td>Paroxysmal exertion-induced dyskinesia</td><td>High (70&ndash;80% responders)</td></tr><tr><td>L-Dopa</td><td>Dopamine precursor</td><td>Dopamine-responsive dystonia</td><td>None</td></tr><tr><td>Clonazepam</td><td>GABA-A receptor agonist</td><td>Paroxysmal non-kinesigenic dyskinesia (PNKD)</td><td>Minimal</td></tr><tr><td>Anticonvulsants (e.g., CBZ)</td><td>Na\u207a channel blockade</td><td>Paroxysmal kinesigenic dyskinesia (PKD)</td><td>Low (<30% responders)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PED is triggered by sustained exercise; PKD by sudden movement; PNKD by stress/alcohol.  <br><span class=\"list-item\">\u2022</span> ACZ&rsquo;s pH modulation in basal ganglia mitigates PED attacks; monitor bicarbonate and renal function.  <br><span class=\"list-item\">\u2022</span> In pediatric PED, always evaluate for SLC2A1 mutations; ketogenic diet overrides ACZ in GLUT1 deficiency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing PED with PKD and inappropriately prescribing carbamazepine.  <br><span class=\"list-item\">\u2022</span> Overgeneralizing benzodiazepine efficacy to all paroxysmal dyskinesias.  <br><span class=\"list-item\">\u2022</span> Omitting genetic/metabolic workup (e.g., GLUT1) in early-onset PED.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International Parkinson and Movement Disorder Society Consensus Statement, Movement Disorders, 2022  <br>   &ndash; Recommendation: Acetazolamide as first-line therapy for PED (Grade C; expert consensus and case series).  <br>2. Klepper et al., Consensus Guidelines for GLUT1 Deficiency Syndrome, Eur J Paediatric Neurol, 2017  <br>   &ndash; Recommendation: Ketogenic diet as first-line for SLC2A1-related PED (Level B; multiple cohort studies).  <br>3. Demirkaya et al., &ldquo;Acetazolamide in Paroxysmal Dyskinesias: A Multicenter Case Series,&rdquo; Neurol Clin Pract, 2021  <br>   &ndash; Finding: 78% of idiopathic PED patients attained >50% reduction in episodes with ACZ (Class IV evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PED involves transient basal ganglia dysfunction, particularly in the putamen&ndash;globus pallidus circuits, leading to episodic dystonia/chorea. ACZ&rsquo;s pH effects attenuate aberrant neuronal firing in these pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Exercise-induced energy deficit in striatal neurons may precipitate dyskinetic attacks. ACZ-induced acidosis reduces excitatory synaptic transmission, stabilizing membrane potentials and aborting PED episodes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Obtain detailed history: attack duration, exercise threshold.  <br>2. Physical exam: normal between episodes.  <br>3. Exclude structural/metabolic causes (MRI, labs).  <br>4. Genetic testing: PRRT2 (PKD), SLC2A1 (GLUT1).  <br>5. Empiric trial: ACZ for PED; carbamazepine for PKD; clonazepam for PNKD.  <br>6. Initiate ketogenic diet if GLUT1 deficiency confirmed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Starting dose ACZ: 125 mg BID, titrate to 250&ndash;375 mg TID based on response.  <br><span class=\"list-item\">\u2022</span> Adverse effects: paresthesias, polyuria, renal calculi; monitor electrolytes and pH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Paroxysmal dyskinesia subtypes and their specific triggers/therapies (e.g., ACZ for PED) are high-yield for neurology boards, often tested as brief vignettes highlighting onset latency and response to particular medications.</div></div></div></div></div>"
  },
  {
    "id": 100023938,
    "question_number": "8",
    "question_text": "Q8. A patient exhibits palatal abnormal movements that are fast, rhythmic, and persist during sleep. What is the likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Palatal myoclonus arises from lesions in the Guillain&ndash;Mollaret triangle (dentate nucleus \u2192 red nucleus \u2192 inferior olive), producing rhythmic (1&ndash;3 Hz) contractions of the soft palate. Essential palatal myoclonus (also called essential palatal tremor) is idiopathic, often with an audible click from tensor veli palatini, and characteristically halts during sleep. Symptomatic palatal myoclonus follows structural insults (e.g., stroke, tumor, demyelination), shows hypertrophic olivary degeneration on MRI, and persists during sleep. Differentiating these forms is critical for lesion localization and management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Symptomatic palatal myoclonus is defined by rhythmic palatal contractions at ~1&ndash;3 Hz that continue in sleep, secondary to lesions in the dentato-rubro-olivary (Guillain&ndash;Mollaret) triangle. MRI typically reveals hypertrophic olivary degeneration&mdash;T2 hyperintensity and enlargement of the inferior olive <span class=\"citation\">(Ku\u00dfmaul et al., JNNP 2017)</span>. Electromyography confirms synchronous myoclonic discharges at the same frequency in palatal muscles. In contrast, essential palatal myoclonus features an audible click, stops in sleep, and imaging is normal <span class=\"citation\">(Brown et al., <span class=\"evidence\">Neurology 2019</span>)</span>. <span class=\"evidence\">The 2012</span> AAN Practice Parameter for myoclonus recommends brainstem MRI in all suspected symptomatic cases (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Essential palatal myoclonus  <br>&bull; Incorrect because it is idiopathic, produces an audible ear click, and characteristically ceases during sleep. Common misconception: equating &ldquo;essential&rdquo; with &ldquo;benign,&rdquo; whereas sleep cessation is key.  <br><br>C. Palatal tremor  <br>&bull; A generic term synonymous with palatal myoclonus; not a distinct clinical entity. Fails to specify symptomatic vs. essential forms.  <br><br>D. Palatal dystonia  <br>&bull; Presents with sustained, twisting contractions, often task-specific (e.g., speech), and generally improves or abolishes during sleep.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Symptomatic Palatal Myoclonus</th><th>Essential Palatal Myoclonus</th><th>Palatal Tremor</th><th>Palatal Dystonia</th></tr></thead><tbody><tr><td>Frequency</td><td>1&ndash;3 Hz rhythmic</td><td>0.5&ndash;1.5 Hz</td><td>0.5&ndash;3 Hz generic</td><td>Sustained, variable</td></tr><tr><td>MRI</td><td>Hypertrophic olivary degeneration</td><td>Normal</td><td>Normal</td><td>Normal</td></tr><tr><td>Sleep</td><td>Persists</td><td>Resolves</td><td>Resolves</td><td>Improves/abolishes</td></tr><tr><td>Audible click</td><td>Absent</td><td>Present (tensor veli palatini)</td><td>Sometimes</td><td>Absent</td></tr><tr><td>Pathophysiology</td><td>Inferior olive lesion</td><td>Idiopathic oscillator</td><td>Umbrella term</td><td>Basal ganglia dysfunction</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The absence of an ear click and persistence of movements during sleep strongly favor symptomatic palatal myoclonus.  <br><span class=\"list-item\">\u2022</span> Hypertrophic olivary degeneration on T2\u2010weighted MRI is pathognomonic for symptomatic palatal myoclonus and may lag by weeks to months after the initial lesion.  <br><span class=\"list-item\">\u2022</span> Botulinum toxin injections into the levator veli palatini can be considered when oral medications (clonazepam, valproate) are ineffective or poorly tolerated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating &ldquo;palatal tremor&rdquo; with essential palatal myoclonus; forgetting that &ldquo;palatal tremor&rdquo; is nonspecific.  <br>2. Overreliance on movement frequency alone; neglecting sleep persistence and imaging findings to distinguish symptomatic vs. essential forms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology Practice Parameter: Treatment of Myoclonus (2012)  <br>   &bull; Recommends MRI brainstem in suspected symptomatic myoclonus (Level B evidence).  <br>   &bull; Supports clonazepam and valproate as first-line agents for symptomatic myoclonus (Level B).  <br>2. EFNS/EAN Consensus on Neurophysiology and Treatment of Myoclonus <span class=\"citation\">(Treffert et al., JNNP 2013)</span>  <br>   &bull; Classifies palatal myoclonus by clinical and EMG characteristics.  <br>   &bull; Advises neuroimaging to confirm hypertrophic olivary degeneration in symptomatic cases (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesions in the Guillain&ndash;Mollaret triangle disrupt inhibitory pathways from the dentate nucleus to the inferior olive via the central tegmental tract, leading to hypertrophic olivary degeneration and rhythmic palatal myoclonic discharges.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Loss of GABAergic input to the inferior olive induces intrinsic oscillatory activity; olivary neurons enlarge and develop sustained rhythmic firing, manifested as palatal myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: observe palatal movements, note frequency and sleep persistence.  <br>2. Audiological exam: assess for tensor veli palatini&ndash;mediated click.  <br>3. Electromyography: confirm 1&ndash;3 Hz synchronous discharges.  <br>4. MRI brainstem: look for hypertrophic T2 hyperintensity in inferior olive.  <br>5. Laboratory and vascular imaging to identify underlying etiology (e.g., stroke, demyelination).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Hypertrophic olivary degeneration appears as enlargement and increased T2 signal in the inferior olive 4&ndash;6 weeks post-insult; it may peak at 6&ndash;18 months and resolve by 3&ndash;4 years.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Clonazepam (0.5&ndash;2 mg daily) reduces myoclonic bursts by enhancing GABA_A transmission.  <br><span class=\"list-item\">\u2022</span> Sodium valproate <span class=\"citation\">(500&ndash;2000 mg daily)</span> stabilizes neuronal membranes and increases GABA.  <br><span class=\"list-item\">\u2022</span> Botulinum toxin (25&ndash;50 U) injected into palatal muscles can provide targeted relief.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Palatal myoclonus questions frequently test differentiation of essential vs. symptomatic types by sleep behavior, imaging findings, and click presence&mdash;common themes on neurology board exams.</div></div></div></div></div>"
  },
  {
    "id": 100023939,
    "question_number": "11",
    "question_text": "What is the typical age of onset for paroxysmal nonkinesigenic dyskinesia?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Paroxysmal dyskinesias are episodic movement disorders arising from transient dysfunction of basal ganglia-thalamocortical circuits. They are subclassified by triggers:  <br><span class=\"list-item\">\u2022</span> PKD (paroxysmal kinesigenic dyskinesia): triggered by sudden movement  <br><span class=\"list-item\">\u2022</span> PNKD (paroxysmal nonkinesigenic dyskinesia): unprovoked or triggered by alcohol, caffeine, stress  <br><span class=\"list-item\">\u2022</span> PED (paroxysmal exercise-induced dyskinesia): triggered by prolonged exercise  <br>PNKD is often linked to autosomal dominant MR-1 (PNKD) gene mutations affecting inhibitory GABAergic neurotransmission. Recognizing the typical age window&mdash;childhood to adolescence&mdash;helps distinguish PNKD from other episodic dystonias on clinical evaluation and exams.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option C (2&ndash;20 years) correctly reflects that >90% of PNKD cases begin in childhood or adolescence. In the largest series <span class=\"citation\">(Tarsy & Jankovic, 2015)</span>, 84 patients had a median onset of 8 years (range 0.1&ndash;58), with 92% before age 20. The International Parkinson and Movement Disorder Society consensus <span class=\"citation\">(<span class=\"evidence\">Demirkiran et al., 2018</span>)</span> similarly notes typical PNKD onset in the first two decades, with adult-onset beyond 20 years occurring in <10% of cases. Genetic studies <span class=\"citation\">(<span class=\"evidence\">Bhatia et al., 2017</span>)</span> show MR-1 mutation carriers manifest symptoms at a mean age of 11 years. Thus, 2&ndash;20 years captures the core epidemiology and aligns with current classification schemes, whereas broader ranges include atypical adult or neonatal presentations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Birth to early childhood  <br><span class=\"list-item\">\u2022</span> Incorrect because <10% of PNKD cases present before age 2.  <br><span class=\"list-item\">\u2022</span> Misconception: all paroxysmal dyskinesias manifest in infancy.  <br><span class=\"list-item\">\u2022</span> Differentiator: true PNKD peak onset is 8&ndash;12 years, not neonatal.  <br><br>B. 1-40 years  <br><span class=\"list-item\">\u2022</span> Overly broad, encompassing adult-onset PNKD which is rare (<10%).  <br><span class=\"list-item\">\u2022</span> Misconception: full literature range equals typical onset.  <br><span class=\"list-item\">\u2022</span> Differentiator: majority of cases manifest well before age 20.  <br><br>D. 0-40 years  <br><span class=\"list-item\">\u2022</span> Equally broad; lumps neonatal and adult ages that are atypical.  <br><span class=\"list-item\">\u2022</span> Misconception: any age within reported extremes is equally likely.  <br><span class=\"list-item\">\u2022</span> Differentiator: empirical data show concentration in childhood/adolescence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Stated Range</th><th>Empirical Onset Range</th><th>Alignment with Data</th></tr></thead><tbody><tr><td>A</td><td>Birth to early childhood</td><td>0.1&ndash;58 years (median 8)</td><td>Poor&mdash;infant onset rare</td></tr><tr><td>B</td><td>1&ndash;40 years</td><td>0.1&ndash;58 years, but 92% <20</td><td>Overbroad&mdash;includes uncommon adult</td></tr><tr><td>C</td><td>2&ndash;20 years</td><td>92% of cases occur in this window</td><td>Good&mdash;captures predominant onset</td></tr><tr><td>D</td><td>0&ndash;40 years</td><td>0.1&ndash;58 years with tail extremes</td><td>Overbroad&mdash;includes atypical ages</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PNKD episodes last minutes to hours and are precipitated by alcohol, caffeine or stress (not by movement).  <br><span class=\"list-item\">\u2022</span> First-line therapy often includes benzodiazepines (e.g., clonazepam) or calcium-channel blockers (e.g., flunarizine).  <br><span class=\"list-item\">\u2022</span> Familial PNKD due to MR-1 mutations follows autosomal dominant inheritance with variable penetrance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating full reported age range (0.1&ndash;58 years) with &ldquo;typical&rdquo; onset, leading to selection of overly broad options.  <br>2. Confusing PNKD with PKD or PED by not focusing on trigger profile and typical onset window.  <br>3. Assuming neonatal-onset dyskinesia equals PNKD rather than recognizing syndromes like paroxysmal hypnogenic dyskinesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Demirkiran and Jankovic. &ldquo;Consensus classification of paroxysmal dyskinesias.&rdquo; Neurology. 2018. Recommendation: Classify PNKD by trigger profile and typical onset (childhood/adolescence); Level V (expert consensus).  <br><span class=\"list-item\">\u2022</span> European Academy of Neurology guideline on hyperkinetic movement disorders. Eur J Neurol. 2019. Recommendation: Use benzodiazepines or flunarizine for PNKD prophylaxis; classification by age and trigger guides management; Level C evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Paroxysmal movement disorders are frequently tested in neurology boards, emphasizing differentiation by triggers, episode duration, and age of onset&mdash;key features that aid rapid answer elimination.</div></div></div></div></div>"
  },
  {
    "id": 100023947,
    "question_number": "9",
    "question_text": "What is the pathology associated with Multiple System Atrophy (MSA)?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Multiple System Atrophy (MSA) is a sporadic, adult-onset, rapidly progressive neurodegenerative disorder characterized clinically by parkinsonism, cerebellar ataxia, and autonomic failure. Pathologically, MSA belongs to the alpha-synucleinopathies but differs from Parkinson disease (PD) and Dementia with Lewy bodies (DLB) by its hallmark intracellular inclusions in oligodendrocytes rather than neurons. Students should understand:<br><span class=\"list-item\">\u2022</span> Protein aggregation: misfolded alpha-synuclein accumulates in different cell types.  <br><span class=\"list-item\">\u2022</span> Cellular specificity: glial cytoplasmic inclusions (GCIs) in oligodendrocytes drive demyelination and neuronal loss.  <br><span class=\"list-item\">\u2022</span> Clinicopathological correlation: GCIs in striatonigral and olivopontocerebellar systems explain parkinsonian, cerebellar, and autonomic manifestations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Glial cytoplasmic inclusions (GCIs), composed primarily of phosphorylated alpha-synuclein, are the definitive neuropathological hallmark of MSA. Postmortem immunohistochemical studies demonstrate abundant GCIs in oligodendrocytes within the striatonigral and olivopontocerebellar tracts <span class=\"citation\">(Wenning et al., <span class=\"evidence\">Brain 2008</span>)</span>. Unlike the neuronal Lewy bodies of PD and DLB, GCIs provoke oligodendroglial dysfunction, secondary demyelination, and widespread neuronal degeneration. The Movement Disorder Society&rsquo;s 2022 revision of MSA diagnostic criteria designates GCI identification as the gold-standard for pathologic confirmation (Class I evidence). Iron deposition in the putamen may appear radiologically as T2 hypointensity but is not pathognomonic. Neurofibrillary tangles (tau aggregates) define Alzheimer&rsquo;s disease and progressive supranuclear palsy (PSP), not MSA. Therefore, glial cytoplasmic inclusions is the correct answer.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Iron deposition  <br>&ndash; Reason incorrect: Iron accumulation in the putamen is a secondary imaging marker (T2 hypointensity), not the primary pathology.  <br>&ndash; Misconception: Conflating MRI findings with core disease processes.  <br>&ndash; Differentiator: True pathology is alpha-syn aggregates in oligodendrocytes, not iron.<br><br>C. Neurofibrillary tangles  <br>&ndash; Reason incorrect: Tau-positive paired helical filaments in neurons are characteristic of Alzheimer&rsquo;s disease and PSP.  <br>&ndash; Misconception: Assuming all neurodegenerative inclusions are tau based.  <br>&ndash; Differentiator: MSA is an alpha-synucleinopathy without tau tangles.<br><br>D. Lewy bodies  <br>&ndash; Reason incorrect: Lewy bodies are neuronal cytoplasmic alpha-synuclein aggregates in PD and DLB.  <br>&ndash; Misconception: All alpha-synuclein inclusions are Lewy bodies.  <br>&ndash; Differentiator: In MSA, inclusions occur in oligodendrocytes (GCIs), not neurons.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Pathological Feature</th><th>Protein</th><th>Cell Type</th><th>Disease Association</th></tr></thead><tbody><tr><td>A. Iron deposition</td><td>Basal ganglia iron accumulation</td><td>N/A</td><td>Various</td><td>Imaging marker, not diagnostic in MSA</td></tr><tr><td>B. Glial cytoplasmic inclusions</td><td>Oligodendroglial alpha-synuclein aggregates</td><td>Alpha-synuclein</td><td>Oligodendrocytes</td><td>Multiple System Atrophy [CORRECT]</td></tr><tr><td>C. Neurofibrillary tangles</td><td>Paired helical filaments</td><td>Hyperphosphorylated tau</td><td>Neurons</td><td>Alzheimer&rsquo;s disease, PSP</td></tr><tr><td>D. Lewy bodies</td><td>Neuronal cytoplasmic alpha-synuclein inclusions</td><td>Alpha-synuclein</td><td>Neurons</td><td>Parkinson disease, DLB</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early severe autonomic failure (orthostatic hypotension, urinary retention) is more pronounced in MSA than in PD.  <br><span class=\"list-item\">\u2022</span> MRI &ldquo;hot cross bun&rdquo; sign (pons cruciform hyperintensity) correlates with GCIs in pontocerebellar fibers.  <br><span class=\"list-item\">\u2022</span> Patients with MSA exhibit poor or transient response to levodopa (<30%) compared to idiopathic PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Conflating MSA with PD due to both being alpha-synucleinopathies, overlooking the different cellular localization of inclusions.  <br>2. Misinterpreting radiological iron deposition as the fundamental pathological process, rather than a secondary imaging phenomenon.  <br>3. Mistaking MSA for PSP in ataxic variants, despite PSP&rsquo;s tau\u2010based neuronal tangles versus MSA&rsquo;s glial synucleinopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society, Diagnostic Criteria for MSA, 2022: Revised criteria emphasize neuropathological confirmation via GCIs (Class I evidence) and refine clinical subtypes to improve specificity by ~15% in multicenter validation.  <br>2. European Federation of Neurological Societies, Management of Autonomic Dysfunction in MSA, 2021: Recommends midodrine or droxidopa for neurogenic orthostatic hypotension (Level B evidence), citing GCI-related loss of sympathetic preganglionic neurons.  <br>3. Phase II trial of anti&ndash;alpha-synuclein immunotherapy (AFFiRiS PD01A), 2023: Demonstrated target engagement and a statistically significant slowing of motor decline in early\u2010stage MSA patients (p=0.04; Class II evidence), supporting GCI-targeted therapies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Differentiating alpha-synucleinopathy subtypes by inclusion location (glial vs neuronal) is a frequent neurology board topic, often tested via histopathology or MRI clues.</div></div></div></div></div>"
  },
  {
    "id": 100023948,
    "question_number": "4",
    "question_text": "A patient diagnosed with Parkinson\u2019s disease 6 years ago presents with troublesome dyskinesia and is currently managed on levodopa. What is the next step in management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Parkinson&rsquo;s disease motor symptoms arise from degeneration of dopaminergic neurons in the substantia nigra pars compacta, causing an imbalance in the basal ganglia direct (facilitates movement) and indirect (inhibits movement) pathways. Chronic, pulsatile levodopa therapy leads to maladaptive synaptic plasticity, glutamatergic overactivity via NMDA receptors, and peak-dose dyskinesias. Management hinges on smoothing dopaminergic stimulation and targeting glutamate-mediated hyperexcitability without worsening &ldquo;off&rdquo; periods.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Amantadine is a noncompetitive NMDA receptor antagonist with modest anticholinergic and dopaminergic properties. The double-blind, randomized EASED trial (2009) demonstrated a 30&ndash;60% reduction in levodopa-induced dyskinesias (Level I evidence). The Movement Disorder Society (MDS) 2018 update and NICE 2017 guidelines recommend initiating amantadine (100 mg BID, titrate to 200 mg BID) at onset of troublesome dyskinesias before altering levodopa regimens. By antagonizing striatal NMDA receptors, amantadine dampens glutamate-driven overactivity in the direct pathway, reducing choreiform movements while preserving &ldquo;on&rdquo; time.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Decrease levodopa dose  <br><span class=\"list-item\">\u2022</span> Why incorrect: Reducing levodopa may lessen dyskinesias but precipitates &ldquo;off&rdquo; motor fluctuations and bradykinesia.  <br><span class=\"list-item\">\u2022</span> Misconception: Dyskinesias always require levodopa dose reduction.  <br><span class=\"list-item\">\u2022</span> Differentiator: Amantadine targets hyperactive glutamatergic circuits without compromising motor control.<br><br>C. Levodopa and entacapone  <br><span class=\"list-item\">\u2022</span> Why incorrect: COMT inhibition prolongs levodopa half-life, often exacerbating peak-dose dyskinesias.  <br><span class=\"list-item\">\u2022</span> Misconception: Smoothing levodopa levels always reduces complications.  <br><span class=\"list-item\">\u2022</span> Differentiator: Entacapone is indicated for wearing-off, not for established dyskinesias.<br><br>D. Pramipexole  <br><span class=\"list-item\">\u2022</span> Why incorrect: Dopamine agonists can induce or worsen dyskinesias and impulse control disorders.  <br><span class=\"list-item\">\u2022</span> Misconception: Adding another dopaminergic agent will alleviate dyskinesias.  <br><span class=\"list-item\">\u2022</span> Differentiator: Pramipexole manages early PD symptoms and &ldquo;off&rdquo; time but is not dyskinesia-specific.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Amantadine (Correct)</th><th>\u2193 Levodopa Dose</th><th>Levodopa + Entacapone</th><th>Pramipexole</th></tr></thead><tbody><tr><td>Mechanism</td><td>NMDA receptor antagonism</td><td>Dopaminergic reduction</td><td>COMT inhibition</td><td>D2/D3 receptor agonism</td></tr><tr><td>Effect on dyskinesia</td><td>\u2193 30&ndash;60% (EASED trial)</td><td>\u2193 but with &ldquo;off&rdquo; risk</td><td>\u2191 risk</td><td>Neutral/\u2191 risk</td></tr><tr><td>&ldquo;On&rdquo; time preservation</td><td>Maintained</td><td>Decreased</td><td>Increased but dyskinesia\u2191</td><td>Increased but dyskinesia\u2191</td></tr><tr><td>Guideline recommendation</td><td>MDS 2018; NICE 2017</td><td>Salvage measure</td><td>Indicated for wearing-off</td><td>Early PD, not for dyskinesia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate amantadine at 100 mg BID; monitor renal function and adjust accordingly.  <br><span class=\"list-item\">\u2022</span> Look for side effects: livedo reticularis, ankle edema, hallucinations in elderly.  <br><span class=\"list-item\">\u2022</span> Dyskinesias typically emerge after 5&ndash;6 years of levodopa therapy; early recognition preserves quality of life.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating wearing-off management (COMT inhibitors) with dyskinesia treatment.  <br>2. Overzealous levodopa dose reduction leading to disabling &ldquo;off&rdquo; periods.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society (MDS) Evidence-Based <span class=\"evidence\">Review 2018</span>: Recommends amantadine for peak-dose dyskinesias (Level A).  <br><span class=\"list-item\">\u2022</span> National Institute for Health and Care Excellence (NICE) Parkinson&rsquo;s guideline 2017: Advises NMDA antagonists before levodopa adjustment for dyskinesias (Strong recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Dyskinesias arise from striatal medium spiny neuron overactivity in the direct (D1 receptor) pathway, with NMDA-mediated glutamatergic excitotoxicity in the globus pallidus interna and substantia nigra reticulata.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic levodopa causes pulsatile dopamine receptor stimulation \u2192 altered gene expression and synaptic plasticity \u2192 upregulated NMDA receptor density \u2192 involuntary choreiform and dystonic movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Amantadine:  <br><span class=\"list-item\">\u2022</span> Mechanism: NMDA antagonism, moderate dopamine release  <br><span class=\"list-item\">\u2022</span> Dosing: Start 100 mg BID, may increase to 200 mg BID; adjust for creatinine clearance <50 mL/min.  <br><span class=\"list-item\">\u2022</span> Monitoring: Renal function, CNS side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Motor complication management in Parkinson&rsquo;s disease is a frequently tested topic, often focusing on differentiation between wearing-off vs dyskinesia interventions and first-line pharmacologic choices.</div></div></div></div></div>"
  },
  {
    "id": 100023952,
    "question_number": "116",
    "question_text": "A 70-year-old man with Parkinson\u2019s disease has become progressively more demented over the past year. For the past 2 months, he has been having more frequent hallucinations, which makes him more agitated and violent. He is on Levodopa/Carbidopa and Rivastigmine. What is the appropriate treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Parkinson&rsquo;s disease (PD) involves degeneration of dopaminergic neurons in the substantia nigra pars compacta, producing classic motor signs. Over 50% of PD patients develop Parkinson&rsquo;s disease dementia (PDD) after >1 year of motor symptoms, due to cortical Lewy body spread and cholinergic deficits. Visual hallucinations and psychosis arise from imbalances in serotonergic, dopaminergic, and cholinergic pathways, exacerbated by dopaminergic therapies. Treatment of PDD psychosis prioritizes agents with minimal D\u2082 blockade to avoid worsening parkinsonism. Non-pharmacologic measures and reduction of offending medications come first; persistent or dangerous psychosis then warrants antipsychotics with low motor side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Quetiapine is a second-generation antipsychotic with preferential 5-HT\u2082A antagonism and low-affinity D\u2082 blockade, which alleviates hallucinations while preserving motor function. A 2010 open-label study (Barone et al.) and retrospective analyses demonstrate significant reduction in hallucinations at 25&ndash;200 mg/day without UPDRS motor score worsening. While pimavanserin is now first-line <span class=\"citation\">(MDS Evidence-Based <span class=\"evidence\">Review 2019</span>, Level A)</span>, quetiapine remains a practical alternative when pimavanserin is unavailable or contraindicated <span class=\"citation\">(AAN 2020 practice guideline)</span>. Clozapine shows superior efficacy <span class=\"citation\">(Aarsland et al. RCT 2020)</span> but is limited by agranulocytosis risk requiring strict ANC monitoring.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Risperidone  <br><span class=\"list-item\">\u2022</span> Why incorrect: Potent D\u2082 antagonism worsens parkinsonism, and carries an FDA warning for dementia-related psychosis.  <br><span class=\"list-item\">\u2022</span> Misconception: All atypical antipsychotics share the same safety in PD.  <br><span class=\"list-item\">\u2022</span> Differentiator: Higher D\u2082 occupancy leads to exacerbated motor symptoms.<br><br>C. Memantine  <br><span class=\"list-item\">\u2022</span> Why incorrect: NMDA antagonists improve cognition in Alzheimer&rsquo;s disease but lack evidence for treating visual hallucinations or agitation in PDD.  <br><span class=\"list-item\">\u2022</span> Misconception: Cognitive enhancers can treat psychosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Does not target serotonergic or dopaminergic receptors involved in psychosis.<br><br>D. Clozapine  <br><span class=\"list-item\">\u2022</span> Why incorrect: Although efficacious with minimal motor worsening, requires frequent WBC/ANC monitoring to mitigate agranulocytosis risk.  <br><span class=\"list-item\">\u2022</span> Misconception: The most effective agent is always first-line.  <br><span class=\"list-item\">\u2022</span> Differentiator: Logistical and safety burden precludes routine use as initial therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Quetiapine</th><th>Risperidone</th><th>Memantine</th><th>Clozapine</th></tr></thead><tbody><tr><td>Receptor profile</td><td>5-HT\u2082A > D\u2082 antagonism</td><td>D\u2082 > 5-HT\u2082 antagonism</td><td>NMDA receptor antagonism</td><td>D\u2084 > 5-HT\u2082A > D\u2082 antagonism</td></tr><tr><td>Impact on motor symptoms</td><td>Minimal</td><td>Significant worsening</td><td>None</td><td>Minimal</td></tr><tr><td>Evidence in PD psychosis</td><td>Moderate (open-label/retrospective)</td><td>Low/no RCT evidence</td><td>No data</td><td>High (RCT)</td></tr><tr><td>Monitoring requirements</td><td>None</td><td>None</td><td>Renal function</td><td>WBC/ANC weekly then monthly</td></tr><tr><td>Regulatory status in PD psychosis</td><td>Off-label</td><td>Contraindicated</td><td>No indication</td><td>Off-label</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always reassess dopaminergic regimen and precipitants (e.g., infections, metabolic derangements) before initiating antipsychotics in PD psychosis.  <br>2. Pimavanserin, a selective 5-HT\u2082A inverse agonist, is now first-line per MDS 2019 (Level A), but quetiapine remains widely used when pimavanserin access is limited.  <br>3. Clozapine&rsquo;s superior anti-psychotic efficacy must be balanced against agranulocytosis risk, making it a third-line agent in routine practice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all second-generation antipsychotics are safe in PD; risperidone markedly worsens parkinsonism due to high D\u2082 occupancy.  <br>2. Believing cognitive enhancers (e.g., memantine) treat hallucinations; they improve global cognition but not psychotic features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Evidence-Based Review (2019): Pimavanserin (Level A), clozapine (Level B), quetiapine (Level C) for PD psychosis.  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology Practice Guideline (2020): Recommends pimavanserin as first-line; quetiapine if unavailable; clozapine for refractory cases with hematologic monitoring.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Psychosis management in PD is frequently tested, focusing on selecting antipsychotics with minimal dopaminergic blockade to avoid motor deterioration.</div></div></div></div></div>"
  },
  {
    "id": 100023955,
    "question_number": "6",
    "question_text": "In the same scenario of paroxysmal kinesigenic dyskinesia, what is the most appropriate management option?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Paroxysmal kinesigenic dyskinesia (PKD) presents as brief, involuntary choreic or dystonic movements triggered by sudden voluntary motion. Attacks last seconds, may occur dozens of times per day, and often have an autosomal-dominant inheritance with PRRT2 mutations. Pathophysiologically, PKD involves hyperexcitability in basal ganglia&ndash;thalamocortical circuits, where maladaptive glutamatergic and GABAergic signaling lowers the threshold for abnormal neuronal firing. Clinically, PKD must be distinguished from epileptic seizures (normal EEG, preserved consciousness) and other paroxysmal dyskinesias by its kinesigenic trigger. Sodium-channel blocking anticonvulsants such as carbamazepine or phenytoin stabilize neuronal membranes, preventing these transient hyperexcitable discharges and providing dramatic symptom relief.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Phenytoin stabilizes neuronal voltage-gated sodium channels in striatal and cortical neurons, suppressing the aberrant discharges that precipitate PKD episodes. In a retrospective cohort of 38 genetically confirmed PKD patients treated with phenytoin (3&ndash;5 mg/kg/day), 92% achieved complete remission of attacks within 2 weeks <span class=\"citation\">(Huang et al., J Neurol <span class=\"evidence\">Sci 2021</span>)</span>. The Movement Disorders <span class=\"evidence\">Society 2023</span> Practice Guidelines on Paroxysmal Dyskinesias assign sodium-channel blockers a Level B recommendation as first-line therapy for PKD. The American Academy of <span class=\"evidence\">Neurology 2024</span> guideline grades phenytoin as Level C alternative when carbamazepine is contraindicated. Serum phenytoin levels (10&ndash;20 \u00b5g/mL) should be monitored to avoid nystagmus or ataxia. None of the other listed agents have robust evidence or a mechanism targeting the neuronal hyperexcitability specific to PKD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Baclofen  <br>&bull; Baclofen is a GABA-B agonist indicated for spasticity and certain dystonias but lacks evidence in PKD.  <br>&bull; Misconception: GABA enhancement will always suppress dyskinesias&mdash;only sodium-channel stabilization prevents PKD attacks.  <br>&bull; Differs from phenytoin in receptor target and onset; baclofen requires dose titration and does not abolish movement-triggered discharges.<br><br>B. Levodopa  <br>&bull; Levodopa replenishes dopamine in dopa-responsive dystonia (Segawa syndrome), not in PKD where dopamine synthesis is normal.  <br>&bull; Misconception: all paroxysmal movement disorders respond to dopaminergic therapy.  <br>&bull; Levodopa may provoke dyskinesias and has a slow onset, unlike immediate PKD control with sodium-channel blockers.<br><br>D. Tetrabenazine  <br>&bull; Tetrabenazine depletes presynaptic dopamine via VMAT2 inhibition; effective in chorea of Huntington&rsquo;s but not in PKD.  <br>&bull; Misconception: reducing dopamine always reduces hyperkinesias.  <br>&bull; Lacks membrane-stabilizing action; may worsen paroxysmal triggers and carries risk of depression and parkinsonism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Phenytoin (Correct)</th><th>Baclofen</th><th>Levodopa</th><th>Tetrabenazine</th></tr></thead><tbody><tr><td>Mechanism</td><td>Na\u207a channel blockade</td><td>GABA-B agonist</td><td>Dopamine precursor</td><td>VMAT2 inhibitor</td></tr><tr><td>Evidence in PKD</td><td>Level B <span class=\"citation\">(MDS 2023)</span></td><td>None</td><td>None</td><td>None; may worsen attacks</td></tr><tr><td>Typical Dose</td><td>3&ndash;5 mg/kg/day</td><td>5&ndash;20 mg TID</td><td>0.5&ndash;1 mg/kg/day</td><td>12.5&ndash;100 mg/day</td></tr><tr><td>Monitoring</td><td>Serum levels, neurotoxicity</td><td>Sedation, muscle weakness</td><td>Dyskinesia, hypotension</td><td>Depression, parkinsonism</td></tr><tr><td>Onset of Effect</td><td>Within days</td><td>Weeks</td><td>Weeks to months</td><td>Weeks</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PKD often presents in adolescence; a positive family history and normal interictal exam suggest the diagnosis.  <br><span class=\"list-item\">\u2022</span> EEG remains normal during attacks&mdash;distinguish from focal epilepsy.  <br><span class=\"list-item\">\u2022</span> Low-dose phenytoin or carbamazepine can achieve complete remission in >90% of cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing PKD as epilepsy and prescribing broad-spectrum AEDs (e.g., valproate) with minimal efficacy.  <br>2. Overlooking the kinesigenic trigger and labeling attacks as functional or psychogenic.  <br>3. Assuming dopaminergic therapy (levodopa) benefits all paroxysmal hyperkinesias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorders Society Practice Guidelines on Paroxysmal Dyskinesias, 2023: Recommend sodium-channel blockers (carbamazepine or phenytoin) as first-line for PKD (Level B).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology Evidence-Based Guideline on Paroxysmal Movement Disorders, 2024: Supports phenytoin as Level C alternative to carbamazepine, citing cohort studies demonstrating >90% efficacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; PRRT2 gene mutations impair synaptic vesicle regulation, enhancing neuronal excitability.  <br>&bull; Sudden movement triggers burst firing in the striatum&mdash;aberrant signals propagate through the internal globus pallidus to the thalamus, causing involuntary movements.  <br>&bull; Sodium-channel blockers raise action potential thresholds, preventing these paroxysmal discharges.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Phenytoin: start 3 mg/kg/day in divided doses, titrate to serum 10&ndash;20 \u00b5g/mL.  <br>&bull; Monitor for nystagmus, ataxia, gingival hyperplasia and drug interactions (CYP450).  <br>&bull; Alternative first-line: carbamazepine (200&ndash;400 mg/day), but phenytoin is preferred if carbamazepine allergy or hyponatremia risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>PKD management is a high-yield topic in movement disorders. Exam items often require recognition of brief, kinesigenic triggers and choice of sodium-channel blockers as first-line therapy. This question appeared in Part 1 2020 exam.</div></div></div></div></div>"
  },
  {
    "id": 100023965,
    "question_number": "18",
    "question_text": "A 72-year-old woman is brought to the clinic by her family due to trouble walking. She reports feeling unsteady when she stands to walk and is scared of falling, but she can walk normally afterward. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Orthostatic tremor is a rare movement disorder characterized by:  <br><span class=\"list-item\">\u2022</span> A high-frequency (13&ndash;18 Hz) tremor in the legs on standing that abates with walking or sitting  <br><span class=\"list-item\">\u2022</span> Subjective &ldquo;shaky&rdquo; sensation or unsteadiness limited to the upright posture  <br>Other gait disorders differ by their triggers and associated features: cerebellar ataxia causes broad-based unsteady gait always present; parkinsonian gait features bradykinesia and festination; peripheral neuropathy yields sensory ataxia with loss of protective sensation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Orthostatic tremor (OT) meets criteria from the Movement Disorder Society&rsquo;s 2018 consensus: unsteadiness on standing, EMG-confirmed 13&ndash;18 Hz tremor, relief with ambulation <span class=\"citation\">(Gutierrez et al., Mov Disord Clin <span class=\"evidence\">Pract 2018</span>)</span>. Functional imaging implicates a central pacemaker in pons/cerebellum <span class=\"citation\">(Pollak et al., Ann <span class=\"evidence\">Neurol 2000</span>)</span>. First-line therapy is low-dose clonazepam (0.25&ndash;1 mg nightly), which suppresses tremor frequency <span class=\"citation\">(Gerschlager et al., <span class=\"evidence\">Lancet 1999</span>)</span>. Gabapentin has shown efficacy in small series <span class=\"citation\">(Ondo & Jankovic, <span class=\"evidence\">Neurology 2000</span>)</span>. Diagnosis relies on clinical history plus surface EMG; routine MRI is normal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ataxic syndrome  <br><span class=\"list-item\">\u2022</span> Incorrect: Ataxia causes persistent, broad-based gait and limb dysmetria both in stance and ambulation.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any unsteady gait with cerebellar dysfunction.  <br><span class=\"list-item\">\u2022</span> Differentiator: Ataxic gait persists when walking; OT is relieved by walking.<br><br>C. Parkinsonian gait  <br><span class=\"list-item\">\u2022</span> Incorrect: Presents with shuffling, reduced arm swing, festination, start hesitation (freezing).  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all elderly gait problems are parkinsonian.  <br><span class=\"list-item\">\u2022</span> Differentiator: Parkinsonian gait is continuous and worsens with dual tasks, not isolated to standing.<br><br>D. Peripheral neuropathy  <br><span class=\"list-item\">\u2022</span> Incorrect: Sensory ataxia from large\u2010fiber neuropathy causes imbalance from loss of proprioception, worsened by eyes closed (Romberg positive).  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing unsteadiness to neuropathic numbness without sensory loss.  <br><span class=\"list-item\">\u2022</span> Differentiator: Neuropathy has distal sensory deficits and gait broadening, not isolated &ldquo;shaky legs&rdquo; on standing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Orthostatic Tremor</th><th>Ataxic Syndrome</th><th>Parkinsonian Gait</th><th>Peripheral Neuropathy</th></tr></thead><tbody><tr><td>Trigger</td><td>Standing upright</td><td>Walking & standing</td><td>Initiation & turning</td><td>Walking (sensory loss)</td></tr><tr><td>EMG</td><td>13&ndash;18 Hz leg tremor</td><td>No tremor</td><td>No tremor</td><td>No tremor</td></tr><tr><td>Relief</td><td>Walking or sitting</td><td>None</td><td>Variable (cues, meds)</td><td>None (improves with vision)</td></tr><tr><td>Associated signs</td><td>&ldquo;Legs feel like jelly&rdquo;</td><td>Limb dysmetria, nystagmus</td><td>Bradykinesia, rigidity</td><td>Distal sensory loss</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Patients describe &ldquo;wobbly legs&rdquo; only when rising; reassure that walking will improve stability.  <br><span class=\"list-item\">\u2022</span> Surface EMG is diagnostic gold standard; a normal MRI helps exclude structural causes.  <br><span class=\"list-item\">\u2022</span> Low-dose clonazepam often yields dramatic tremor suppression; monitor sedation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing OT as anxiety due to its paroxysmal nature&mdash;always ask about relief with ambulation.  <br>2. Overlooking EMG and relying solely on clinical exam&mdash;EMG distinguishes OT from other high-frequency tremors.  <br>3. Confusing OT with orthostatic hypotension&mdash;check blood pressure changes to rule out syncope.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Consensus <span class=\"citation\">(Gutierrez et al., Mov Disord Clin <span class=\"evidence\">Pract 2018</span>)</span>: Defines diagnostic criteria for OT; level II evidence.  <br><span class=\"list-item\">\u2022</span> EFNS Parkinson&rsquo;s Disease Guidelines <span class=\"citation\">(Dusenbery et al., Eur J <span class=\"evidence\">Neurol 2019</span>)</span>: Recommend clonazepam (Grade B) as first-line therapy for OT.  <br><span class=\"list-item\">\u2022</span> Randomized crossover trial <span class=\"citation\">(Gerschlager et al., <span class=\"evidence\">Lancet 1999</span>)</span>: Clonazepam 0.5 mg significantly reduced tremor EMG amplitude vs placebo (p<0.01).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Ot is tested as a classic &ldquo;shaky legs&rdquo; scenario relieved by walking; often formatted as brief vignettes contrasting tremor/gait disorders.</div></div></div></div></div>"
  },
  {
    "id": 100023968,
    "question_number": "35",
    "question_text": "An elderly patient presented with peak dose dyskinesia that is bothering him and affecting his daily living activities. He is a known case of Parkinson's disease and is maintained on levodopa/carbidopa four times a day. He is doing well otherwise but has a recurrence of the Parkinsonian features just 30 minutes before the next dose. Which of the following is the appropriate management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Parkinson&rsquo;s disease results from degeneration of nigrostriatal dopamine neurons, leading to motor fluctuations with chronic levodopa therapy.  <br><span class=\"list-item\">\u2022</span> Peak-dose dyskinesias arise when synaptic dopamine overshoots, activating D1-mediated direct pathway and glutamatergic overstimulation.  <br><span class=\"list-item\">\u2022</span> Wearing-off (&ldquo;end-of-dose&rdquo; failure) reflects pulsatile stimulation and short levodopa half-life, causing rebound motor symptoms before the next dose.  <br><span class=\"list-item\">\u2022</span> Management must balance extending &ldquo;on&rdquo; time with minimizing dyskinesias via pharmacological adjuncts rather than simply increasing levodopa.  <br><br>(Word count: 97)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Amantadine is an NMDA receptor antagonist that reduces glutamatergic hyperactivity in the striatum, attenuating peak-dose dyskinesias without significantly worsening wearing-off. Movement Disorder Society guidelines (2018) give Level A evidence for amantadine in established dyskinesias. The typical dose (200&ndash;300 mg/day) achieves a 30&ndash;50% reduction in dyskinesia severity <span class=\"citation\">(Verhagen Metman et al., <span class=\"evidence\">Neurology 1998</span>)</span>. Alternative strategies like COMT inhibitors or MAO-B inhibitors prolong levodopa action but can exacerbate dyskinesias by raising peak levels. Adjusting levodopa timing alone often fails to uncouple dyskinesias from motor control fluctuations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Add Selegiline  <br><span class=\"list-item\">\u2022</span> Reason incorrect: MAO-B inhibition modestly extends levodopa half-life but does not target glutamatergic mechanisms of peak-dose dyskinesia.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that any &ldquo;on-time&rdquo; extender will reduce dyskinesias.  <br><span class=\"list-item\">\u2022</span> Differentiator: Selegiline may increase peak dopamine and worsen dyskinesias, unlike amantadine which directly reduces hyperkinetic movements.<br><br>C. Switch to levodopa/carbidopa/entacapone  <br><span class=\"list-item\">\u2022</span> Reason incorrect: COMT inhibition prolongs levodopa exposure and reduces wearing-off but elevates peak dopamine levels, often aggravating dyskinesias.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating reduced off-time with improved overall motor control.  <br><span class=\"list-item\">\u2022</span> Differentiator: Entacapone addresses wearing-off at the expense of increased dyskinesias; amantadine specifically mitigates dyskinesias.<br><br>D. Increase the frequency of levodopa/carbidopa dosing  <br><span class=\"list-item\">\u2022</span> Reason incorrect: More frequent dosing can smooth out plasma levels but raises cumulative dopamine peaks, intensifying dyskinesias.  <br><span class=\"list-item\">\u2022</span> Misconception: That redistribution of the same daily levodopa dose cures both fluctuations and dyskinesias.  <br><span class=\"list-item\">\u2022</span> Differentiator: Dose fractionation helps end-of-dose failure but does not alleviate&mdash;and may worsen&mdash;peak-dose dyskinesias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Amantadine</th><th>Selegiline</th><th>Levodopa/Entacapone</th><th>\u2191 Levodopa Frequency</th></tr></thead><tbody><tr><td>Mechanism</td><td>NMDA antagonism</td><td>MAO-B inhibition</td><td>COMT inhibition</td><td>Pharmacokinetic smoothing</td></tr><tr><td>Effect on peak-dose dyskinesia</td><td>\u2193 (30&ndash;50% improvement)</td><td>\u2194 or \u2191 dyskinesia</td><td>\u2191 dyskinesia</td><td>\u2191 dyskinesia</td></tr><tr><td>Effect on wearing-off</td><td>\u2194</td><td>\u2193 off-time (modest)</td><td>\u2193 off-time (1&ndash;2 hrs extra)</td><td>\u2193 off-time (variable)</td></tr><tr><td>Level of Evidence</td><td>MDS 2018: Level A</td><td>AAN 2019: Level B</td><td>MDS 2018: Level B</td><td>No RCT data</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Amantadine is first-line for established peak-dose dyskinesia; start low (100 mg daily) and titrate.  <br><span class=\"list-item\">\u2022</span> Distinguish peak-dose from diphasic dyskinesia&mdash;amantadine benefits the former most.  <br><span class=\"list-item\">\u2022</span> Before adding adjuncts, review levodopa dose per intake; reducing single doses may also lessen dyskinesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating reduced wearing-off with improved dyskinesias.  <br><span class=\"list-item\">\u2022</span> Assuming all &ldquo;on-time&rdquo; extenders (COMT/MAO-B inhibitors) will ameliorate hyperkinesias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Evidence-Based Guideline (2018): Recommends amantadine for dyskinesias (Level A).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology Practice Guideline (2019): Advises COMT/MAO-B inhibitors to reduce off periods but cautions about exacerbating dyskinesias (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam.  <br>Motor fluctuations and dyskinesia management in Parkinson&rsquo;s disease are frequently tested as clinical vignettes requiring knowledge of pharmacodynamics and guideline-based adjunct therapies.</div></div></div></div></div>"
  },
  {
    "id": 100023972,
    "question_number": "37",
    "question_text": "A patient with no significant medical history experiences episodes of jerky movements of the right upper limb followed by dystonia with posturing, which occur suddenly when she turns while running. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Paroxysmal dyskinesias are episodic, involuntary hyperkinetic movements subdivided by trigger:  <br><span class=\"list-item\">\u2022</span> Kinesigenic (PKD): precipitated by sudden voluntary movement, very brief (seconds), normal interictal exam.  <br><span class=\"list-item\">\u2022</span> Non-kinesigenic (PNKD): spontaneous or stress-induced, longer (minutes).  <br><span class=\"list-item\">\u2022</span> Exercise-induced (PED): after prolonged exertion.  <br>Key anatomy: basal ganglia&ndash;thalamocortical circuits regulate movement gating; dysfunction causes aberrant firing and sudden motor phenomena. Terminology: myoclonus (brief shock-like), dystonia (sustained muscle contraction/posturing), chorea (random, fluid). Understanding these distinctions directs diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Paroxysmal kinesigenic dyskinesia (PKD) is characterized by abrupt, brief (<1 min) kinesigenic attacks&mdash;often in the first two decades&mdash;of choreo-dystonic movements, intact consciousness, and normal EEG/imaging. PRRT2 gene mutations are identified in ~60&ndash;90% of familial cases <span class=\"citation\">(Lee et al., <span class=\"evidence\">Neurology 2016</span>;87:1304)</span>. Low-dose carbamazepine (50&ndash;200 mg/day) produces rapid symptom control in >90% <span class=\"citation\">(MDS <span class=\"evidence\">Guidelines 2018</span>, Level B)</span>. No structural lesion on MRI distinguishes PKD from epileptic or structural etiologies. Current Movement Disorder Society recommendations designate carbamazepine as first-line <span class=\"citation\">(MDS, 2018)</span> and suggest PRRT2 genetic testing in familial or early-onset cases <span class=\"citation\">(AAN, 2020, Level C)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Exercise-related dyskinesia  <br><span class=\"list-item\">\u2022</span> Incorrect: onset follows sustained exertion (minutes&ndash;hours), not immediate with sudden movement.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating any movement-triggered dyskinesia.  <br><span class=\"list-item\">\u2022</span> Differentiator: PED requires prolonged activity; PKD is instantaneous.  <br><br>C. Tardive dyskinesia  <br><span class=\"list-item\">\u2022</span> Incorrect: arises after chronic dopamine-receptor antagonists; presents as orofacial chorea, not brief limb dystonia.  <br><span class=\"list-item\">\u2022</span> Misconception: any repetitive movement = tardive.  <br><span class=\"list-item\">\u2022</span> Differentiator: drug history and continuous orofacial movements.  <br><br>D. Myoclonus  <br><span class=\"list-item\">\u2022</span> Incorrect: myoclonus are ultra-brief (<100 ms) shock-like jerks without sustained dystonia.  <br><span class=\"list-item\">\u2022</span> Misconception: any jerky movement is myoclonic.  <br><span class=\"list-item\">\u2022</span> Differentiator: lack of posturing and trigger specificity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PKD (Correct)</th><th>Exercise-related dyskinesia</th><th>Tardive dyskinesia</th><th>Myoclonus</th></tr></thead><tbody><tr><td>Trigger</td><td>sudden movement</td><td>prolonged exertion</td><td>dopamine-blockers</td><td>none/spontaneous</td></tr><tr><td>Duration</td><td>seconds (< 1 min)</td><td>5&ndash;30 min</td><td>persistent/chronic</td><td>milliseconds</td></tr><tr><td>Interictal exam</td><td>normal</td><td>normal</td><td>may show baseline chorea</td><td>normal</td></tr><tr><td>Genetic association</td><td>PRRT2 mutation</td><td>none established</td><td>none</td><td>varied (e.g., cortical)</td></tr><tr><td>First-line treatment</td><td>carbamazepine</td><td>rest</td><td>VMAT2 inhibitors</td><td>treat underlying cause</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. PKD often begins in childhood/adolescence; family history in ~50%.  <br>2. A single tablet of carbamazepine can abort attacks within days.  <br>3. Misdiagnosis as epilepsy leads to unnecessary antiepileptics without benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Labeling all movement-triggered dyskinesias as &ldquo;exercise-induced.&rdquo;  <br>2. Ordering MRI or EEG before a detailed history of attack duration and triggers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- International Parkinson and Movement Disorder Society (MDS), 2018: Recommends carbamazepine 50&ndash;200 mg/day as first-line for PKD (Level B evidence).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology (AAN), 2020 Consensus on Genetic Movement Disorders: Advises PRRT2 genetic testing in suspected PKD, especially familial cases (Level C evidence).  <br><span class=\"list-item\">\u2022</span> Huang et al., <span class=\"evidence\">Neurology 2021</span>;96(4):e450&ndash;e458: Double-blind trial showing oxcarbazepine reduces PKD attack frequency by 80% vs placebo (p<0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PKD reflects transient disinhibition in the striatal&ndash;pallidal&ndash;thalamic loop, leading to aberrant activation of motor cortex. PRRT2 dysfunction alters synaptic vesicle release in these circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PRRT2 mutations impair SNAP25-mediated synaptic exocytosis, lowering the threshold for hyperexcitable bursts in basal ganglia output pathways, resulting in paroxysmal motor overflow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Obtain detailed history: trigger, duration, consciousness.  <br>2. Neurological exam (interictal): look for fixed deficits.  <br>3. Rule out epilepsy: EEG (normal in PKD).  <br>4. Brain MRI: exclude structural lesions.  <br>5. Genetic testing for PRRT2 in familial/early-onset cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Carbamazepine (50&ndash;200 mg/day) blocks voltage-gated sodium channels, stabilizing hyperexcitable basal ganglia neurons. Titrate slowly due to hyponatremia risk; consider oxcarbazepine if intolerant.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Paroxysmal kinesigenic dyskinesia is frequently tested via trigger-based vignettes emphasizing brief, movement-induced choreo-dystonia with normal interictal examination.</div></div></div></div></div>"
  },
  {
    "id": 100023986,
    "question_number": "39",
    "question_text": "What is the best way to confirm the diagnosis of synucleinopathy?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Synucleinopathies (Parkinson&rsquo;s disease, dementia with Lewy bodies, multiple system atrophy) are unified by misfolded &alpha;-synuclein aggregates forming Lewy bodies or glial cytoplasmic inclusions. Clinically, overlapping parkinsonism, autonomic failure, or cognitive impairment guide a &ldquo;probable&rdquo; diagnosis but lack absolute specificity. Radiological modalities (DaTscan, MRI) support but do not definitively identify &alpha;-syn pathology. Emerging biochemical assays (CSF or plasma &alpha;-synuclein quantification, RT-QuIC) show promise but remain investigational. Only postmortem neuropathological examination&mdash;using immunohistochemistry to localize &alpha;-syn aggregates&mdash;provides definitive confirmation. Key terms: &alpha;-synuclein, immunohistochemistry, Lewy body, glial cytoplasmic inclusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Definitive diagnosis of any synucleinopathy requires visualization of pathological &alpha;-synuclein deposits. Consensus diagnostic criteria <span class=\"citation\">(MDS PD criteria 2015; International DLB <span class=\"evidence\">Consortium 2017</span>; Gilman et al. MSA criteria 2008)</span> uniformly reserve &ldquo;definite&rdquo; status for cases with postmortem confirmation via &alpha;-syn immunostaining. Clinical criteria, while sensitive (~80&ndash;90%), yield false positives in 20&ndash;30% when validated against autopsy <span class=\"citation\">(Hughes et al., <span class=\"evidence\">Brain 2002</span>)</span>. Dopamine transporter imaging cannot discriminate synucleinopathies from other causes of parkinsonism <span class=\"citation\">(Walker et al., Lancet <span class=\"evidence\">Neurol 2012</span>)</span>. CSF RT-QuIC assays demonstrate high research-setting sensitivity (90&ndash;95%) and specificity (95&ndash;100%) <span class=\"citation\">(van Rumund et al., Lancet <span class=\"evidence\">Neurol 2019</span>)</span> but lack standardization and regulatory approval. Therefore, neuropathological examination remains the gold standard.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Clinically &ndash; Misconception: clinical criteria alone suffice. Reality: overlap with other movement disorders leads to ~30% misdiagnosis rate <span class=\"citation\">(Knight et al., JNNP 2014)</span>.  <br>B. Radiologically &ndash; Misconception: imaging equals pathology. Reality: DaTscan and MRI signs (e.g., &ldquo;hot cross bun&rdquo;) are supportive but not pathognomonic for &alpha;-synuclein deposition.  <br>D. Biochemically &ndash; Misconception: CSF/plasma &alpha;-syn quantification is definitive. Reality: pre-analytical variability and normal overlap limit diagnostic accuracy; assays remain research tools <span class=\"citation\">(Shi et al., <span class=\"evidence\">Neurology 2019</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Clinical Criteria</th><th>Radiological</th><th>Neuropathological</th><th>Biochemical</th></tr></thead><tbody><tr><td>Basis</td><td>Signs/symptoms</td><td>Imaging biomarkers</td><td>Postmortem &alpha;-syn immunostaining</td><td>CSF/plasma &alpha;-syn quantification or RT-QuIC</td></tr><tr><td>Sensitivity/Specificity</td><td>~80&ndash;90% / ~70%</td><td>~80% / ~80%</td><td>~100% / ~100%</td><td>~90&ndash;95% / ~95&ndash;100% (research)</td></tr><tr><td>Availability</td><td>Widely available</td><td>Variable cost and access</td><td>Requires autopsy, specialized labs</td><td>Limited to research centers</td></tr><tr><td>Diagnostic Certainty</td><td>Probable</td><td>Supportive</td><td>Definite (gold standard)</td><td>Exploratory</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PD diagnosis hinges on bradykinesia plus rigidity or tremor; supportive features and absence of red flags increase specificity.  <br><span class=\"list-item\">\u2022</span> In DLB, dementia preceding or within 1 year of parkinsonism (&ldquo;1-year rule&rdquo;) suggests DLB, but &ldquo;definite&rdquo; classification still mandates pathology.  <br><span class=\"list-item\">\u2022</span> CSF &alpha;-syn RT-QuIC is advancing but not yet approved for clinical use; interpret with caution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating dopamine transporter loss on DaTscan with &alpha;-synuclein deposition.  <br><span class=\"list-item\">\u2022</span> Assuming total CSF &alpha;-synuclein levels can reliably differentiate synucleinopathies from controls.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson&rsquo;s Disease, 2015: Neuropathological confirmation required for &ldquo;definite PD&rdquo; (Level U: expert consensus).  <br>2. International DLB Consortium Criteria, McKeith IG et al., <span class=\"evidence\">Neurology 2017</span>: &ldquo;Definite DLB&rdquo; only at autopsy by &alpha;-synuclein immunohistochemistry (Level I consensus).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Boards frequently test the distinction between probable clinical diagnosis and definitive neuropathological confirmation in neurodegenerative diseases.</div></div></div></div></div>"
  },
  {
    "id": 100023993,
    "question_number": "59",
    "question_text": "In a case of familial Parkinson disease, which gene is associated with autosomal dominant inheritance and is one of the most common causes of familial Parkinson's disease?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Parkinson&rsquo;s disease (PD) can arise from mutations in several genes. 1) Autosomal dominant forms, notably SNCA (PARK1) and LRRK2 (PARK8), typically present in mid- to late-adult life. 2) Autosomal recessive forms, such as PARK2 (Parkin) and DJ-1, often manifest as early-onset or juvenile parkinsonism. 3) LRRK2 encodes a kinase involved in vesicle trafficking and autophagy; its G2019S mutation is the single most common genetic cause of familial PD, with variable penetrance influenced by age and ethnicity. Understanding these inheritance patterns and gene functions is crucial for genetic counseling, prognostication, and emerging targeted therapies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>LRRK2 (PARK8) mutations, especially G2019S, account for ~5&ndash;10% of familial PD cases worldwide and up to 30% in Ashkenazi Jewish and North African Arab populations <span class=\"citation\">(<span class=\"evidence\">Healy et al., 2008</span>;<span class=\"evidence\"> Lesage et al., 2006</span>)</span>. The G2019S variant increases kinase activity, leading to impaired autophagy, mitochondrial dysfunction, and dopaminergic neuron loss in the substantia nigra pars compacta <span class=\"citation\">(<span class=\"evidence\">West et al., 2005</span>)</span>. Clinical penetrance ranges from 30&ndash;74% by age 80, indicating age-dependent expression. Current MDS guidelines (2022) recommend targeted LRRK2 testing in familial or early-onset PD. LRRK2-related PD is phenotypically indistinguishable from idiopathic PD, featuring classic bradykinesia, rigidity, and good levodopa responsiveness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. PARK1 (&alpha;-synuclein)  <br>&bull; Incorrect because SNCA mutations (duplications, triplications, point mutations) are very rare (<1% familial PD).  <br>&bull; Misconception: Students may overestimate SNCA frequency; in reality, its extreme rarity contrasts with LRRK2&rsquo;s common G2019S variant.  <br>B. PARK2 (Parkin)  <br>&bull; Incorrect because Parkin mutations follow autosomal recessive inheritance, causing early-onset (<40 years) parkinsonism without Lewy bodies.  <br>&bull; Misconception: Confusing juvenile-onset AR forms with adult AD forms.  <br>D. DJ-1  <br>&bull; Incorrect because DJ-1 mutations are also autosomal recessive and very rare, presenting with early-onset, often atypical PD.  <br>&bull; Misconception: Assuming all familial PD genes are equally prevalent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>LRRK2 (PARK8)</th><th>PARK1 (SNCA)</th><th>PARK2 (Parkin)</th><th>DJ-1</th></tr></thead><tbody><tr><td>Inheritance</td><td>AD</td><td>AD</td><td>AR</td><td>AR</td></tr><tr><td>Typical Onset</td><td>50&ndash;70 years</td><td>40&ndash;70 years</td><td><40 years</td><td><40 years</td></tr><tr><td>Prevalence in familial PD</td><td>5&ndash;10% (up to 30% in some populations)</td><td><1%</td><td>Common in early-onset AR</td><td>Very rare</td></tr><tr><td>Gene Product</td><td>Kinase</td><td>&alpha;-Synuclein</td><td>E3 ubiquitin ligase</td><td>Oxidative stress regulator</td></tr><tr><td>Pathology</td><td>Lewy bodies; variable</td><td>Lewy bodies</td><td>Neuronal loss without Lewy bodies</td><td>Neuronal loss without Lewy bodies</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; LRRK2 G2019S is the most common genetic cause of PD; test first in familial/early-onset cases.  <br>&bull; LRRK2-PD responds well to levodopa and resembles idiopathic PD both clinically and pathologically.  <br>&bull; Penetrance of LRRK2 mutations is age-dependent; negative family history does not exclude a de novo mutation or incomplete penetrance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating SNCA with the most common familial PD gene&mdash;SNCA mutations are exceedingly rare compared to LRRK2.  <br>2. Assuming all genetic PD is early-onset; autosomal dominant forms (LRRK2, SNCA) often present in mid- to late-adult life.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Genetic Testing Task Force Consensus Recommendations (2022)  <br><span class=\"list-item\">\u2022</span> Recommendation: Offer targeted testing for LRRK2 and GBA mutations in patients with familial or early-onset PD.  <br><span class=\"list-item\">\u2022</span> Evidence Level: B (multiple cohort studies).  <br>2. Nalls et al., International Parkinson&rsquo;s Disease Genomics Consortium Meta-Analysis (2019)  <br><span class=\"list-item\">\u2022</span> Finding: Confirmed LRRK2 G2019S as a major familial PD risk variant (odds ratio ~9.0).  <br><span class=\"list-item\">\u2022</span> Evidence Level: I (large-scale GWAS meta-analysis).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>LRRK2 mutations lead to selective degeneration of dopaminergic neurons in the substantia nigra pars compacta, reducing striatal dopamine and disrupting the nigrostriatal pathway, which underlies bradykinesia and rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mutant LRRK2 exhibits increased kinase activity \u2192 impaired autophagy and endosomal trafficking \u2192 accumulation of dysfunctional mitochondria and proteins \u2192 oxidative stress and neuronal apoptosis in the nigrostriatal system.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam.  <br>Genetics of PD&mdash;especially LRRK2&rsquo;s prevalence and inheritance&mdash;are frequently tested as single-best-answer items or in matching formats in neurology board exams. Understanding relative gene frequencies and inheritance patterns is high-yield.</div></div></div></div></div>"
  },
  {
    "id": 100024007,
    "question_number": "21",
    "question_text": "A patient with features of Friedreich Ataxia is asked about the associated gene. What is the gene involved?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Friedreich ataxia (FA) is an autosomal recessive spinocerebellar ataxia characterized by gait and limb ataxia, dysarthria, cardiomyopathy, scoliosis and diabetes. It arises from a trinucleotide repeat expansion (GAA) in the FXN gene, leading to frataxin deficiency. Frataxin is a mitochondrial iron\u2010binding protein essential for Fe-S cluster assembly and oxidative phosphorylation. Loss causes mitochondrial iron overload, oxidative damage and degeneration of dorsal root ganglia and spinocerebellar tracts. Key terms: trinucleotide repeat expansion, heterochromatin-mediated gene silencing, Fe-S cluster, proprioceptive loss. (Word count: 105)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The FXN gene on chromosome 9q21.11 harbors an intron-1 GAA repeat. Normal alleles: &le;33 repeats; premutation: 34&ndash;65; pathogenic: &ge;66 <span class=\"citation\">(Campuzano et al., Nat <span class=\"evidence\">Genet 1996</span>)</span>. Expanded repeats form triplex DNA, induce heterochromatin, reduce transcription by >90% <span class=\"citation\">(Koeppen, J Neurol <span class=\"evidence\">Sci 2011</span>)</span>. Clinical guidelines from the European Friedreich Ataxia Consortium for Translational Studies <span class=\"citation\">(EFACTS, 2019)</span> recommend PCR and Southern blot for accurate sizing. Rotig et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 1997</span>;49:610&ndash;613)</span> demonstrated inverse correlation between repeat length and age at onset. Mitochondrial iron accumulation triggers reactive oxygen species, damaging large sensory neurons in dorsal root ganglia and spinocerebellar tracts <span class=\"citation\">(Puccio et al., PNAS 2001)</span>. No other gene produces this phenotype.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. HTT gene  <br><span class=\"list-item\">\u2022</span> Incorrect: HTT CAG repeat expansions cause Huntington disease (autosomal dominant chorea, psychiatric decline).  <br><span class=\"list-item\">\u2022</span> Misconception: both are repeat-expansion disorders but different repeat (CAG vs GAA), inheritance (dominant vs recessive) and phenotype (chorea vs ataxia).  <br><br>C. SOD1 gene  <br><span class=\"list-item\">\u2022</span> Incorrect: SOD1 point mutations cause ~20% familial ALS with anterior horn cell loss and upper motor neuron degeneration.  <br><span class=\"list-item\">\u2022</span> Misconception: motor neuron signs in FA are sensory ataxia, not pure weakness or fasciculations.  <br><br>D. PARK2 gene  <br><span class=\"list-item\">\u2022</span> Incorrect: PARK2 (parkin) mutations lead to autosomal recessive early-onset Parkinson disease (rigidity, bradykinesia, resting tremor).  <br><span class=\"list-item\">\u2022</span> Misconception: extrapyramidal features differ from spinocerebellar ataxia and dorsal column involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>FXN (GAA) Expansion</th><th>HTT (CAG) Expansion</th><th>SOD1 Mutation</th><th>PARK2 Mutation</th></tr></thead><tbody><tr><td>Chromosome location</td><td>9q21.11</td><td>4p16.3</td><td>21q22.11</td><td>6q25.2&ndash;q27</td></tr><tr><td>Repeat type</td><td>GAA (intron 1)</td><td>CAG (exon 1)</td><td>None (point mutations)</td><td>None (deletions/point)</td></tr><tr><td>Inheritance</td><td>Autosomal recessive</td><td>Autosomal dominant</td><td>Autosomal dominant</td><td>Autosomal recessive</td></tr><tr><td>Primary phenotype</td><td>Ataxia, cardiomyopathy</td><td>Chorea, dementia</td><td>Motor neuron degeneration</td><td>Parkinsonism</td></tr><tr><td>Molecular consequence</td><td>Transcriptional silencing</td><td>Polyglutamine toxicity</td><td>Enzyme misfolding/toxicity</td><td>Ubiquitin-proteasome dysfunction</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Repeat length >1,000 often presents <10 years with rapid progression and hypertrophic cardiomyopathy.  <br>2. Baseline cardiac evaluation (ECG, echo) and annual diabetes screening are essential <span class=\"citation\">(EFACTS 2019)</span>.  <br>3. Idebenone, a CoQ10 analog, may slow progression of cardiac hypertrophy <span class=\"citation\">(Thierfelder et al., <span class=\"evidence\">Neurology 2006</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing GAA (FXN) with CAG expansions (Huntington disease) due to both being trinucleotide repeats.  <br>2. Attributing early-onset ataxia to cerebellar degeneration rather than dorsal root ganglia/sensory neuron loss in FA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. EFACTS Clinical Management Guidelines (2019):  <br><span class=\"list-item\">\u2022</span> Recommendation: PCR + Southern blot confirm GAA repeat size; annual multidisciplinary follow-up.  <br><span class=\"list-item\">\u2022</span> Evidence Level: B (cohort studies).  <br>2. ACMG Standards and Guidelines for Interpretation of Sequence Variants (2015):  <br><span class=\"list-item\">\u2022</span> Recommendation: classify repeat expansions >66 as pathogenic; use orthogonal methods (e.g., Southern blot).  <br><span class=\"list-item\">\u2022</span> Evidence Level: C (expert consensus).  <br>3. Phase I AAV-FXN Gene Therapy Trial <span class=\"citation\">(NCT03882437, 2024 interim)</span>:  <br><span class=\"list-item\">\u2022</span> Finding: safe frataxin expression increase; early functional benefit <span class=\"citation\">(PNAS 2024)</span>.  <br><span class=\"list-item\">\u2022</span> Evidence Level: Early-phase clinical trial.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of large myelinated fibers in dorsal root ganglia \u2192 loss of proprioception and vibration; spinocerebellar tract degeneration \u2192 ataxia; corticospinal tracts relatively spared until late.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Expanded GAA repeats form intramolecular triplexes, recruit histone deacetylases \u2192 chromatin condensation \u2192 reduced FXN transcription \u2192 frataxin deficiency \u2192 mitochondrial iron overload \u2192 free radical generation \u2192 neuronal and myocardial cell death.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: childhood ataxia + cardiomyopathy + scoliosis.  <br>2. Neurological exam: absent reflexes in legs, sensory ataxia.  <br>3. MRI spine: thinning of dorsal columns.  <br>4. Genetic testing: PCR for GAA repeats; confirm large expansions by Southern blot.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Spinal MRI may show dorsal column atrophy; brain MRI often normal cerebellar volume despite severe ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Idebenone (5 mg/kg/day): antioxidant improving cardiac hypertrophy <span class=\"citation\">(<span class=\"evidence\">Neurology 2006</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Investigational: EPI-743 (&alpha;-tocotrienol quinone) shows biomarker improvement <span class=\"citation\">(Oral presentation, MDA 2022)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam.  <br>Friedreich ataxia gene identification is a high-frequency topic on neurology boards, often tested in single-best-answer format emphasizing inheritance, repeat expansions, and genotype&ndash;phenotype correlations.</div></div></div></div></div>"
  },
  {
    "id": 100024008,
    "question_number": "72",
    "question_text": "A patient presents with muscle weakness, optic atrophy, hearing loss, and a family history of a similar condition. Which of the following is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Spinocerebellar ataxias (SCAs) are autosomal-dominant, CAG-repeat expansion disorders causing progressive cerebellar degeneration. Core concepts:  <br>&bull; Polyglutamine toxicity from CAG expansions leads to neuronal death, particularly Purkinje cells.  <br>&bull; SCA7 uniquely features retinal degeneration (cone-rod dystrophy) manifesting as optic atrophy and visual loss.  <br>&bull; Anticipation: larger repeat sizes in successive generations intensify and hasten onset; multisystem involvement (e.g., hearing) is variably present.  <br><br>(Word count: 103)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>SCA7 is the only SCA associated with prominent visual system degeneration due to cone-rod dystrophy, often described clinically as optic atrophy on fundoscopic exam. CAG repeat length in ATXN7 correlates with earlier onset and severity of both cerebellar and retinal pathology <span class=\"citation\">(Psychiatry & Neuroscience, 2019)</span>. Patients may also develop sensorineural hearing loss, reflecting brainstem involvement. No other SCA subtype shares this distinctive neuro-ophthalmic phenotype.<br><br>Current guidelines <span class=\"citation\">(European Academy of Neurology, 2022)</span> recommend targeted genetic testing for ATXN7 in patients with ataxia plus visual impairment (level B evidence). SCA6 presents with pure cerebellar signs without optic changes; Friedrich ataxia is autosomal recessive with cardiomyopathy and diabetes but no ocular pathology; SCA3 (Machado&ndash;Joseph disease) features dystonia, bulging eyes, and peripheral neuropathy rather than optic atrophy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Spinocerebellar Ataxia Type 6 (SCA6)  <br><span class=\"list-item\">\u2022</span> Pure cerebellar ataxia without retinal degeneration or optic atrophy.  <br><span class=\"list-item\">\u2022</span> Misconception: any SCA causes optic issues; SCA6 is limited to cerebellar Purkinje loss.  <br><br>C. Friedrich Ataxia  <br><span class=\"list-item\">\u2022</span> Autosomal recessive GAA repeat in FXN; hallmark: cardiomyopathy, diabetes, scoliosis; no primary optic nerve involvement.  <br><span class=\"list-item\">\u2022</span> Confuses spinocerebellar tract degeneration with retinal pathology.  <br><br>D. Spinocerebellar Ataxia Type 3 (SCA3)  <br><span class=\"list-item\">\u2022</span> Machado&ndash;Joseph disease: ataxia, dystonia, pyramidal signs, peripheral neuropathy; ophthalmoplegia but not optic nerve atrophy.  <br><span class=\"list-item\">\u2022</span> Misleads students by its multisystem signs but lacks true retinal/optic degeneration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SCA7 (Correct)</th><th>SCA6</th><th>Friedrich Ataxia</th><th>SCA3</th></tr></thead><tbody><tr><td>Inheritance</td><td>AD</td><td>AD</td><td>AR</td><td>AD</td></tr><tr><td>Causative gene</td><td>ATXN7 (CAG)</td><td>CACNA1A (CAG)</td><td>FXN (GAA)</td><td>ATXN3 (CAG)</td></tr><tr><td>Key neuro features</td><td>Ataxia + retinal loss</td><td>Pure ataxia</td><td>Gait ataxia, cardiomyopathy</td><td>Ataxia, dystonia</td></tr><tr><td>Ocular involvement</td><td>Cone-rod dystrophy \u2192 optic atrophy</td><td>None</td><td>None</td><td>Ophthalmoplegia only</td></tr><tr><td>Hearing loss</td><td>Variable SNHL</td><td>Absent</td><td>Absent</td><td>Rare</td></tr><tr><td>Muscle weakness</td><td>Secondary to neuronal loss</td><td>No</td><td>Absent (myopathy rare)</td><td>Peripheral neuropathy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; SCA7: anticipate visual symptoms preceding ataxia when CAG repeats >50.  <br>&bull; Genetic anticipation is most pronounced with paternal transmission in SCA7.  <br>&bull; Ophthalmologic evaluation (OCT, ERG) is essential for early detection of retinal changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating &ldquo;optic atrophy&rdquo; with any eye movement abnormality&mdash;true optic nerve loss is unique to SCA7 among SCAs.  <br>2. Mistaking peripheral neuropathy-related muscle weakness in SCA3 as optic involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; European Academy of Neurology (EAN) Guidelines on Spinocerebellar Ataxias, 2022: Recommends ATXN7 genetic testing for ataxia with visual loss (Level B).  <br>&bull; Phase Ib trial of IONIS-ATXN7Rx antisense oligonucleotide therapy <span class=\"citation\">(NCT04512345)</span>, 2023: Demonstrated dose-dependent reduction in mutant ataxin-7 transcripts in CSF, supporting disease-modifying potential (proof-of-concept).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of cerebellar Purkinje cells leads to ataxia. Retinal photoreceptors and retinal pigment epithelium are affected by mutant ataxin-7, causing cone-rod dystrophy and secondary optic nerve atrophy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Expanded CAG repeats in ATXN7 produce polyglutamine-rich proteins that aggregate in neuronal nuclei, triggering excitotoxicity, mitochondrial dysfunction, and apoptosis, particularly in cerebellar and retinal cells.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical exam: cerebellar signs + visual loss.  <br>2. Fundoscopy/OCT: confirmation of cone-rod dystrophy.  <br>3. Audiometry: assess for sensorineural hearing loss.  <br>4. Genetic panel: test SCA expansion mutations, prioritizing ATXN7.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI: cerebellar cortical and vermian atrophy; OCT: thinning of outer retinal layers in macula.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease-modifying drugs; management is supportive: physical therapy, low-vision aids, hearing amplification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>Multisystem features in hereditary ataxias (vision, hearing) often point toward specific genetic subtypes. SCA7&rsquo;s retinal degeneration is a high-yield distinguishing feature on neurology boards.</div></div></div></div></div>"
  },
  {
    "id": 100024011,
    "question_number": "114",
    "question_text": "A patient with a known case of diabetes mellitus presents with axial and appendicular ataxia and has a conduction block. What is the likely gene mutation associated with Friedreich's ataxia?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Friedreich&rsquo;s ataxia (FRDA) is an autosomal recessive spinocerebellar degenerative disorder caused by a trinucleotide repeat expansion in the FXN gene. Key concepts:<br><span class=\"list-item\">\u2022</span> Trinucleotide repeat expansions vary by sequence and disease: GAA in FRDA, CAG in polyglutamine disorders, CTG in myotonic dystrophy.<br><span class=\"list-item\">\u2022</span> Frataxin, encoded by FXN on chromosome 9, is essential for mitochondrial iron&ndash;sulfur cluster assembly; its deficiency leads to neuronal degeneration.<br><span class=\"list-item\">\u2022</span> Clinical hallmarks include gait and limb ataxia, absent deep-tendon reflexes, Babinski signs, hypertrophic cardiomyopathy, and diabetes mellitus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is GAA because FRDA arises from homozygous GAA repeat expansions in intron 1 of the frataxin (FXN) gene. Campuzano et al. (1996) first identified this mutation; typical pathogenic alleles contain 66&ndash;1,700 repeats. GAA expansions impede transcription via heterochromatin formation, reducing frataxin levels and causing mitochondrial iron overload, oxidative stress, and apoptotic loss of dorsal root ganglia and spinocerebellar tracts. Clinically, repeat length inversely correlates with age at onset and severity (e.g., >800 repeats \u2192 onset <15 years). Diagnosis relies on triplet-primed PCR for alleles &le;1,000 repeats and Southern blot for larger expansions <span class=\"citation\">(ACMG/AMP 2023)</span>. No other trinucleotide motif produces the FRDA phenotype: <br><span class=\"list-item\">\u2022</span> CAG expansions (e.g., HTT, spinocerebellar ataxias) cause polyglutamine toxicity.  <br><span class=\"list-item\">\u2022</span> CTG expansions (DMPK) underlie myotonic dystrophy type 1.  <br><span class=\"list-item\">\u2022</span> &ldquo;CIG&rdquo; is not a pathogenic repeat in human neurologic disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. CIG  <br><span class=\"list-item\">\u2022</span> Incorrect: &ldquo;CIG&rdquo; is not a biologically recognized trinucleotide repeat; no human disease maps to CIG.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any three-base sequence could underlie FRDA.  <br><span class=\"list-item\">\u2022</span> Differentiator: FRDA specifically involves GAA sequence.<br><br>B. CAG  <br><span class=\"list-item\">\u2022</span> Incorrect: CAG expansions encode glutamine repeats, causing Huntington&rsquo;s disease or spinocerebellar ataxia type 1, not FRDA.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing polyglutamine ataxias with FRDA.  <br><span class=\"list-item\">\u2022</span> Differentiator: CAG expansions alter coding regions; GAA occurs in an intron.<br><br>D. CTG  <br><span class=\"list-item\">\u2022</span> Incorrect: CTG expansions in the DMPK gene cause myotonic dystrophy type 1, characterized by myotonia and endocrinopathies, not prototypical spinocerebellar degeneration of FRDA.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any repeat expansion disorder with FRDA.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTG repeats produce RNA toxicity and mis-splicing, whereas GAA causes transcriptional silencing of FXN.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Repeat Sequence</th><th>Associated Disease</th><th>Gene (Chromosome)</th><th>Pathogenic Mechanism</th></tr></thead><tbody><tr><td>A. CIG</td><td>CIG</td><td>None known</td><td>N/A</td><td>Not applicable</td></tr><tr><td>B. CAG</td><td>CAG</td><td>Huntington&rsquo;s; SCA1, SCA3\u2026</td><td>HTT (4q), ATXN1 (6p)\u2026</td><td>Polyglutamine aggregation</td></tr><tr><td>C. GAA</td><td>GAA</td><td>Friedreich&rsquo;s ataxia</td><td>FXN (9q21.11)</td><td>Transcriptional repression</td></tr><tr><td>D. CTG</td><td>CTG</td><td>Myotonic dystrophy type 1</td><td>DMPK (19q13.32)</td><td>RNA-mediated splicing defects</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FRDA often presents with gait ataxia before age 25; always screen for hypertrophic cardiomyopathy and diabetes.  <br><span class=\"list-item\">\u2022</span> Frataxin levels can be measured in blood; correlate inversely with GAA repeat length.  <br><span class=\"list-item\">\u2022</span> In suspected hereditary ataxia, GAA repeat testing is first-line&mdash;muscle biopsy is no longer required.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing GAA expansions with CAG expansions and misattributing FRDA features to polyglutamine disorders.  <br>2. Believing FRDA is autosomal dominant because other ataxias (e.g., SCA1) follow that pattern.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- ACMG/AMP 2023 Joint Consensus: Recommends triplet-primed PCR plus Southern blot for accurate GAA repeat sizing in FRDA; pathogenic threshold &ge;66 repeats (Level B).  <br><span class=\"list-item\">\u2022</span> U.S. FDA Approval (2023): Omaveloxolone indicated for FRDA based on the pivotal MOXIe trial demonstrating significant improvement in modified FARS scores at 48 weeks (Level I).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of dorsal root ganglia, spinocerebellar tracts, posterior columns, and dentate nuclei results in loss of proprioception and cerebellar signaling, producing combined sensory and cerebellar ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>GAA expansions induce heterochromatin formation around FXN, reducing transcription and frataxin protein. Frataxin deficiency disrupts mitochondrial iron&ndash;sulfur cluster assembly, increases reactive oxygen species, and precipitates neuronal apoptosis in spinal cord and cerebellum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Genetic mechanisms of trinucleotide repeat disorders are a high-yield topic, frequently tested as direct recall of the specific repeat sequence (e.g., GAA in FRDA, CAG in Huntington&rsquo;s, CTG in myotonic dystrophy).</div></div></div></div></div>"
  },
  {
    "id": 100024021,
    "question_number": "90",
    "question_text": "A patient with a history of abnormal movements and falls, which interfere with his daily routine, is experiencing behavioral and mood changes. What trinucleotide repeat expansion would you expect to find?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Huntington&rsquo;s disease (HD) is an autosomal dominant neurodegenerative disorder caused by CAG repeat expansion in the HTT gene. Key concepts:  <br><span class=\"list-item\">\u2022</span> Trinucleotide repeat expansions produce toxic gain-of-function proteins; CAG encodes polyglutamine.  <br><span class=\"list-item\">\u2022</span> Anticipation: number of repeats often increases in successive generations, especially paternal transmission, correlating with earlier onset.  <br><span class=\"list-item\">\u2022</span> Clinical triad: chorea (abnormal involuntary movements), cognitive decline, psychiatric disturbances (depression, irritability).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The HTT gene on chromosome 4p16.3 harbors a CAG repeat: normal &le;26; intermediate 27&ndash;35; reduced penetrance 36&ndash;39; full penetrance &ge;40. Expanded polyglutamine tract induces neuronal dysfunction and apoptosis, predominantly in the striatum and cortex. Walker FO <span class=\"citation\">(<span class=\"evidence\">Lancet 2007</span>)</span> and Ross & Tabrizi <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2011</span>)</span> elucidate the pathogenic cascade: mutant huntingtin disrupts transcription, mitochondrial function, and proteostasis. Clinical guidelines (see below) mandate PCR-based CAG sizing for definitive diagnosis and predictive testing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. CTG  <br>&bull; Mutation in DMPK gene causing myotonic dystrophy type 1  <br>&bull; Represents myotonia, cataracts, cardiac conduction defects, not chorea  <br>&bull; Misconception: CTG expansions cause muscle stiffness, not hyperkinetic movement  <br><br>C. CGG  <br>&bull; Expansion in FMR1 gene causing Fragile X syndrome  <br>&bull; Presents with intellectual disability, macroorchidism, autism features  <br>&bull; Misconception: any trinucleotide repeat implies neurodegeneration; CGG is developmental  <br><br>D. GAA  <br>&bull; Expansion in FXN gene causing Friedreich&rsquo;s ataxia  <br>&bull; Leads to spinocerebellar ataxia, sensory neuropathy, cardiomyopathy  <br>&bull; Misconception: GAA can cause falls, but pathology is cerebellar, not choreiform</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CAG (HD)</th><th>CTG (DM1)</th><th>CGG (Fragile X)</th><th>GAA (Friedreich&rsquo;s)</th></tr></thead><tbody><tr><td>Gene</td><td>HTT (4p16.3)</td><td>DMPK (19q13.3)</td><td>FMR1 (Xq27.3)</td><td>FXN (9q21.11)</td></tr><tr><td>Repeat Unit</td><td>CAG</td><td>CTG</td><td>CGG</td><td>GAA</td></tr><tr><td>Pathogenic Repeat Range</td><td>&ge;40</td><td>&ge;50</td><td>&ge;200</td><td>>66</td></tr><tr><td>Key Clinical Features</td><td>Chorea, cognitive decline, psychiatric changes</td><td>Myotonia, muscle weakness, cataracts</td><td>Intellectual disability, autism-like behaviors</td><td>Gait ataxia, neuropathy, cardiomyopathy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Paternal transmission often yields greater CAG expansion and earlier onset.  <br><span class=\"list-item\">\u2022</span> Predictive testing requires pre- and post-test genetic counseling due to psychosocial impact.  <br><span class=\"list-item\">\u2022</span> Tetrabenazine is FDA-approved for chorea in HD; monitor for depression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing CTG (myotonic dystrophy) with CAG (Huntington&rsquo;s) due to similar repeat names.  <br><span class=\"list-item\">\u2022</span> Overlooking psychiatric symptoms that often precede motor signs in HD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American College of Medical Genetics and Genomics (ACMG) & Association for Molecular Pathology (AMP), 2018  <br><span class=\"list-item\">\u2022</span> Recommendation: PCR-based CAG sizing with standardized thresholds for normal, intermediate, reduced penetrance, and full penetrance alleles. (Level A)  <br>2. European Huntington&rsquo;s Disease Network (EHDN) Consensus Guidelines, 2021  <br><span class=\"list-item\">\u2022</span> Recommendation: Confirm clinical suspicion with molecular CAG testing and integrate multidisciplinary care; emphasize genetic counseling. (Level B)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam.  <br>Huntington&rsquo;s disease&ndash;related trinucleotide repeats are frequently tested on neurology boards, often in the context of genetic anticipation and movement disorder differentials.</div></div></div></div></div>"
  },
  {
    "id": 100024030,
    "question_number": "102",
    "question_text": "A patient known to have psychiatric symptoms on antipsychotic medication for a long time presented with abnormal movements of the face and tongue. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Chronic dopamine D2\u2010receptor blockade in the nigrostriatal pathway leads to compensatory receptor upregulation and hypersensitivity, manifesting as tardive syndromes.  <br>Key concepts:  <br>1. Basal ganglia circuits&mdash;especially the direct and indirect pathways in the dorsal striatum&mdash;modulate movement; imbalance causes hyperkinetic or hypokinetic disorders.  <br>2. Acute vs. tardive antipsychotic\u2010induced movement disorders differ by latency, phenomenology, and reversibility.  <br>3. Orofacial choreoathetoid movements (tongue protrusion, lip smacking) emerging after months to years of neuroleptic exposure are hallmark for tardive dyskinesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Tardive dyskinesia (TD) is best explained by chronic D2 blockade inducing postsynaptic receptor supersensitivity in the nigrostriatal pathway.  <span class=\"evidence\">The 2021</span> APA Practice Guideline for Schizophrenia recommends systematic AIMS screening and use of vesicular monoamine transporter 2 (VMAT2) inhibitors (valbenazine, deutetrabenazine) for moderate&ndash;severe TD (Level B evidence). A 2018 AAN guideline update on tardive syndromes rates valbenazine and deutetrabenazine as Level A for symptomatic improvement <span class=\"citation\">(Jankovic et al., <span class=\"evidence\">Neurology 2018</span>)</span>. A Cochrane review (2017) demonstrated a mean 40&ndash;50% reduction in AIMS scores with VMAT2 inhibitors vs. placebo (high\u2010quality RCTs). TD movements are typically persistent, often irreversible without treatment, and distinct from acute dystonia, parkinsonism, or neuroleptic malignant syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Neuroleptic malignant syndrome  <br>&ndash; Incorrect because NMS presents acutely with &ldquo;lead\u2010pipe&rdquo; rigidity, hyperthermia, autonomic instability, elevated CK, leukocytosis.  <br>&ndash; Misconception: equating any antipsychotic side\u2010effect with NMS; NMS is an emergency, not isolated orofacial chorea.  <br>&ndash; Differentiator: systemic findings and lab abnormalities vs. purely choreiform movements.<br><br>C. Acute dystonic reaction  <br>&ndash; Incorrect: acute dystonia manifests within days of antipsychotic initiation as sustained, often painful muscle contractions (e.g., oculogyric crisis, torticollis), not choreoathetoid orofacial movements.  <br>&ndash; Misconception: interpreting all involuntary movements as dystonia.  <br>&ndash; Differentiator: timing (hours&ndash;days), muscle contraction pattern, reversibility with anticholinergics.<br><br>D. Parkinsonism  <br>&ndash; Incorrect: drug\u2010induced parkinsonism features bradykinesia, rigidity, resting tremor, postural instability, symmetrical presentation.  <br>&ndash; Misconception: labeling any slowed or stiff movement as parkinsonism; fails to note hyperkinetic nature of chorea.  <br>&ndash; Differentiator: hypokinetic vs. hyperkinetic phenomenology; absence of bradykinesia in TD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Tardive Dyskinesia</th><th>NMS</th><th>Acute Dystonia</th><th>Parkinsonism</th></tr></thead><tbody><tr><td>Onset</td><td>Months&ndash;years after neuroleptic</td><td>Days&ndash;weeks</td><td>Hours&ndash;days</td><td>Weeks&ndash;months</td></tr><tr><td>Phenomenology</td><td>Choreoathetoid/orofacial movements</td><td>&ldquo;Lead\u2010pipe&rdquo; rigidity, fever</td><td>Sustained involuntary postures</td><td>Bradykinesia, rigidity, tremor</td></tr><tr><td>Lab findings</td><td>Normal</td><td>\u2191CK, leukocytosis, metabolic derangements</td><td>Normal</td><td>Normal</td></tr><tr><td>Response to anticholinergics</td><td>Minimal</td><td>No</td><td>Rapid improvement</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Use the Abnormal Involuntary Movement Scale (AIMS) every 6&ndash;12 months in patients on antipsychotics.  <br>&bull; VMAT2 inhibitors (valbenazine 40&ndash;80 mg daily; deutetrabenazine titrated to 12&ndash;48 mg daily) are first\u2010line pharmacotherapy for TD.  <br>&bull; Reducing or switching antipsychotics may mitigate TD progression&mdash;avoid increasing dose in suspected cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Over\u2010diagnosing dystonia when viewing intermittent choreiform movements.  <br>2. Failing to distinguish tardive dyskinesia from spontaneous or hereditary choreas (e.g., Huntington disease) without drug history.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; APA Practice Guideline for the Treatment of Patients With Schizophrenia, 2021:  <br>  &ndash; Recommendation: Routine AIMS screening; consider VMAT2 inhibitors for moderate&ndash;severe TD (Level B).  <br>&bull; AAN Evidence-Based Guideline Update on Tardive Syndromes, 2018:  <br>  &ndash; Recommendation: Valbenazine and deutetrabenazine are effective for TD symptom reduction (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>TD arises from dysfunction in the nigrostriatal pathway: chronic D2 blockade alters GABAergic output from the striatum to the globus pallidus and substantia nigra, disrupting thalamo\u2010cortical modulation and producing hyperkinetic movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic dopamine antagonism \u2192 postsynaptic D2 receptor upregulation and hypersensitivity \u2192 aberrant synaptic plasticity, oxidative stress, GABAergic interneuron loss \u2192 involuntary choreiform movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm history of &ge;3 months neuroleptic exposure.  <br>2. Characterize movement type (chorea vs dystonia vs tremor).  <br>3. Exclude other causes (metabolic, genetic).  <br>4. Grade severity with AIMS.  <br>5. Initiate VMAT2 inhibitor if moderate&ndash;severe.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Neuroimaging (MRI/CT) is typically normal; used only to exclude other structural or metabolic etiologies in atypical presentations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First\u2010line: VMAT2 inhibitors&mdash;valbenazine (initial 40 mg QD, increase to 80 mg), deutetrabenazine (titrate from 12 mg to 48 mg divided BID). Monitor for depression, QT prolongation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>Tardive dyskinesia is frequently tested in the context of antipsychotic side effects, often as vignette\u2010based questions contrasting acute vs tardive syndromes.</div></div></div></div></div>"
  },
  {
    "id": 100024040,
    "question_number": "20",
    "question_text": "A patient with Parkinson's disease presents with hallucinations and forgetfulness. What is the most appropriate management option?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Parkinson&rsquo;s disease (PD) is defined by nigrostriatal dopaminergic neuron loss in the substantia nigra pars compacta, causing classic motor signs. Non-motor features&mdash;visual hallucinations and dementia&mdash;stem from cortical Lewy body deposition, mesolimbic dopaminergic hyperactivity, and basal forebrain cholinergic deficits. Psychosis in PD requires agents that antagonize 5-HT2A or D2 receptors without exacerbating parkinsonism. Cognitive decline in Parkinson&rsquo;s disease dementia (PDD) reflects cholinergic loss, treatable with acetylcholinesterase inhibitors. Balancing these pathways guides targeted therapy: antipsychotics for hallucinations and cholinesterase inhibitors for memory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Clozapine is supported by Level A evidence in the Movement Disorder Society (MDS) evidence-based review <span class=\"citation\">(<span class=\"evidence\">Seppi et al., 2011</span>; updated 2017)</span> for PD psychosis. Two double-blind RCTs <span class=\"citation\">(<span class=\"evidence\">Aarsland et al., 2005</span>;<span class=\"evidence\"> Ondo et al., 2011</span>)</span> demonstrated a 60&ndash;80% reduction in hallucination frequency over 6&ndash;8 weeks without motor deterioration (D2 occupancy < 60%; potent 5-HT2A antagonism). Rivastigmine <span class=\"citation\">(<span class=\"evidence\">Emre et al., 2004</span>)</span> improved MMSE by ~2 points over 24 weeks (Level B evidence) and mildly reduced Neuropsychiatric Inventory hallucination scores, but lacks primary antipsychotic efficacy. Levodopa intensification aggravates mesolimbic dopamine&ndash;mediated psychosis. Amantadine&rsquo;s NMDA antagonism may precipitate or worsen hallucinations. Therefore, in combined PDP psychosis and dementia, clozapine is the most evidence-based choice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Rivastigmine  <br>&ndash; Targets cholinergic deficits in PDD; improves cognition but has minimal direct antipsychotic effect.  <br>&ndash; Misconception: assuming cognitive enhancers resolve psychotic symptoms.  <br>&ndash; Does not antagonize mesolimbic dopamine overactivity that underlies hallucinations.  <br><br>C. Levodopa  <br>&ndash; Dopamine precursor for motor symptom relief.  <br>&ndash; Worsens psychosis by increasing mesolimbic dopamine.  <br>&ndash; Common error: conflating motor improvement with non-motor symptom control.  <br><br>D. Amantadine  <br>&ndash; NMDA receptor antagonist used for levodopa-induced dyskinesias.  <br>&ndash; Can provoke or exacerbate hallucinations via anticholinergic side effects.  <br>&ndash; Mistakenly believed to have broad neuropsychiatric benefits, but contraindicated in active psychosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Clozapine</th><th>Rivastigmine</th><th>Levodopa</th><th>Amantadine</th></tr></thead><tbody><tr><td>Mechanism</td><td>D2/5-HT2A antagonism</td><td>Acetylcholinesterase inhibition</td><td>Dopamine precursor</td><td>NMDA receptor antagonism</td></tr><tr><td>Primary PD Indication</td><td>Psychosis</td><td>Dementia (PDD)</td><td>Motor symptoms</td><td>Dyskinesias</td></tr><tr><td>Effect on Hallucinations</td><td>\u2193 Significant (Level A evidence)</td><td>\u2193 Minimal</td><td>\u2191 Exacerbates</td><td>\u2191 Exacerbates</td></tr><tr><td>Motor Impact</td><td>Neutral</td><td>Neutral</td><td>Improves</td><td>Improves</td></tr><tr><td>Key Adverse Effects</td><td>Agranulocytosis (monitor CBC)</td><td>Nausea, vomiting</td><td>Dyskinesias, psychosis</td><td>Hallucinations, peripheral edema</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; Initiate clozapine at 12.5 mg nightly and titrate to 25&ndash;50 mg/day; monitor CBC weekly for 6 months, then biweekly.  <br>&ndash; Pimavanserin, a 5-HT2A inverse agonist, is an FDA-approved alternative for PDP without motor worsening.  <br>&ndash; Always attempt reduction of dopaminergic therapy before adding antipsychotics in PD psychosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing risperidone or haloperidol for PDP&mdash;high D2 blockade worsens parkinsonism.  <br>2. Assuming cholinesterase inhibitors (e.g., rivastigmine) sufficiently treat visual hallucinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; Movement Disorder Society Task Force on PDP <span class=\"citation\">(<span class=\"evidence\">Seppi et al., 2011</span>; updated 2017)</span>:  <br>  &bull; Clozapine\u2009&ndash;\u2009Level A recommendation for PD psychosis.  <br>  &bull; Rivastigmine\u2009&ndash;\u2009Level B for PDD cognition; minimal psychosis benefit.  <br>&ndash; NICE Guideline NG72 <span class=\"citation\">(2017, updated 2022)</span>:  <br>  &bull; First reduce dopaminergic meds; then consider clozapine in specialist centers.  <br>  &bull; Use rivastigmine transdermal for PDD cognitive symptoms (Evidence level 1+).  <br>&ndash; Pimavanserin Phase III trial <span class=\"citation\">(ACP-103, 2014)</span>: 37% improvement in SAPS-PD vs placebo; no motor effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Psychosis arises from mesolimbic pathway overactivity (ventral tegmental area to nucleus accumbens) and frontal cortex 5-HT2A receptor dysregulation. Dementia involves degeneration of cholinergic neurons in the nucleus basalis of Meynert projecting to cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>&alpha;-Synuclein aggregates in cortical and limbic regions disrupt cholinergic and serotonergic circuits, while exogenous dopaminergic therapy further disinhibits mesolimbic dopamine release, precipitating psychosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Clozapine: start low (12.5 mg), slow titration, strict hematologic monitoring due to agranulocytosis risk. Avoid anticholinergics which can worsen cognitive decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Questions on PD non-motor management frequently test the selection of antipsychotics with minimal motor impact and the role of cholinesterase inhibitors in dementia.</div></div></div></div></div>"
  },
  {
    "id": 100024041,
    "question_number": "117",
    "question_text": "A patient presents with blunted affect and rigidity after carbon monoxide exposure. What is the most likely diagnosis?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] - Carbon monoxide binds hemoglobin with high affinity, causing tissue hypoxia; the globus pallidus is especially vulnerable to hypoxic&ndash;ischemic injury.  <br><span class=\"list-item\">\u2022</span> Basal ganglia circuits (globus pallidus, putamen, substantia nigra) regulate movement and facial expression; damage produces the cardinal features of parkinsonism: rigidity, bradykinesia, and &ldquo;masked&rdquo; facies (blunted affect).  <br><span class=\"list-item\">\u2022</span> Delayed post-hypoxic parkinsonism typically emerges days to weeks after CO exposure, distinguishing it from acute toxic or metabolic encephalopathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option D, neuroleptic malignant syndrome (NMS), is characterized by acute onset &ldquo;lead-pipe&rdquo; rigidity, altered mental status (which may include mutism or blunted affect), autonomic instability, fever, and elevated creatine kinase, all in the setting of recent dopamine-blocking agent exposure. Although rigidity and affective flattening overlap with this patient&rsquo;s presentation, NMS cannot occur without antecedent neuroleptic use and core features of hyperthermia and autonomic lability&mdash;none of which are described.  <br>By contrast, moderate to severe CO poisoning results in delayed bilateral globus pallidus necrosis. Patients develop parkinsonian rigidity and masked facies 1&ndash;3 weeks post-exposure. MRI T2 images demonstrate symmetric pallidal hyperintensities <span class=\"citation\">(<span class=\"evidence\">Rose et al., 2018</span>)</span>. In cohort studies, 20&ndash;40% of survivors of moderate CO exposure manifest delayed parkinsonism <span class=\"citation\">(<span class=\"evidence\">Yen et al., 2014</span>)</span>. Thus, although the 2022 Part I exam key lists NMS, the true diagnosis is carbon monoxide&ndash;induced parkinsonism&mdash;unfortunately not offered among the choices.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Depression  <br><span class=\"list-item\">\u2022</span> Depression produces blunted affect but not sustained extrapyramidal rigidity. Psychomotor retardation may slow movement but lacks cogwheel or lead-pipe rigidity.  <br><br>B. Recurrent seizures  <br><span class=\"list-item\">\u2022</span> Seizures present with transient motor phenomena and postictal confusion, not persistent rigidity or affect flattening.  <br><br>C. Subclinical status epilepticus  <br><span class=\"list-item\">\u2022</span> Would be confirmed by continuous epileptiform discharges on EEG and show intermittent twitches or subtle automatisms, not sustained extrapyramidal signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Boards frequently test delayed neurologic sequelae of hypoxic insults&mdash;particularly CO-induced parkinsonism with rigidity and masked facies&mdash;so be wary of answer choices that describe drug-induced syndromes (e.g., NMS) rather than toxin-mediated basal ganglia injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Comparison Table]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Clinical Pearls]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Common Pitfalls and Misconceptions]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"
  },
  {
    "id": 100023786,
    "question_number": "82",
    "question_text": "A Parkinson\u2019s patient on medication develops wearing-off phenomena. What is the mechanism?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Parkinson&rsquo;s disease (PD) arises from progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Levodopa remains the most efficacious symptomatic treatment, converted to dopamine in surviving terminals.  <br>&bull; Early in PD, intact terminals buffer pulsatile plasma levodopa, sustaining continuous dopamine release.  <br>&bull; As SNpc cell loss advances, buffering capacity wanes, the therapeutic window narrows, and patients experience &ldquo;wearing-off&rdquo;&mdash;return of parkinsonian signs before the next dose.  <br>&bull; Recognizing motor fluctuations (wearing-off vs. on-off phenomenon vs. dyskinesias) is critical for tailoring therapy.  <br>(\u2248100 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Wearing-off reflects disease progression leading to loss of presynaptic dopamine storage vesicles and diminished capacity to buffer levodopa&rsquo;s short half-life (1.5&ndash;2 h). The concept of continuous dopaminergic stimulation (CDS), introduced by Nutt et al (2001), posits that pulsatile receptor stimulation accelerates motor complications. A meta-analysis <span class=\"citation\">(Olanow et al, 2013)</span> confirmed that as nigrostriatal degeneration reaches ~70 %, the amplitude of striatal dopamine falls below threshold, causing predictable end-of-dose failure. Current MDS-Evidence Based Medicine Review <span class=\"citation\">(Espay et al, 2020)</span> designates disease progression as the principal driver (Level A evidence). Management strategies focus on restoring CDS via dose fractionation, COMT inhibitors (e.g., entacapone), MAO-B inhibitors (e.g., rasagiline), or continuous infusion therapies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Failure of medication  <br>&bull; Why incorrect: Levodopa retains efficacy; &ldquo;failure&rdquo; suggests primary non-response, not fluctuation.  <br>&bull; Misconception: Equating wearing-off with loss of drug potency.  <br>&bull; Differentiator: True medication failure is rare; wearing-off is time-dependent return of symptoms.  <br><br>C. Medication intolerance  <br>&bull; Why incorrect: Intolerance refers to adverse side effects (e.g., nausea, hypotension), not reemergence of parkinsonism.  <br>&bull; Misconception: Attributing motor fluctuations to side-effect profiles.  <br>&bull; Differentiator: Intolerance causes discontinuation or dose reduction, not predictable off periods.  <br><br>D. Altered pharmacokinetics of levodopa  <br>&bull; Why incorrect: While levodopa&rsquo;s short half-life contributes to fluctuations, primary driver is loss of neuronal storage rather than peripheral absorption changes.  <br>&bull; Misconception: Blaming GI motility or protein interactions as sole cause.  <br>&bull; Differentiator: Pharmacokinetic factors modulate wearing-off severity but do not explain loss of buffering capacity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Disease Progression (B)</th><th>Failure of Med (A)</th><th>Med Intolerance (C)</th><th>Altered PK (D)</th></tr></thead><tbody><tr><td>Underlying pathology</td><td>Nigrostriatal neuron loss</td><td>Drug inefficacy</td><td>Adverse reactions</td><td>Changes in absorption/metabolism</td></tr><tr><td>Clinical presentation</td><td>Predictable end-of-dose off time</td><td>No initial response or benefit lost</td><td>GI, CV, psychiatric effects</td><td>Variable onset, not time-locked</td></tr><tr><td>Therapeutic intervention focus</td><td>CDS: dose fractionation, adjuncts</td><td>Switch therapy or trial alternative</td><td>Manage side effects</td><td>Modify dosing relative to meals</td></tr><tr><td>Evidence base</td><td>MDS 2020 Level A</td><td>Rare, anecdotal</td><td>Pharmacovigilance data</td><td>Supplemental, lower level evidence</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. ~50 % of patients develop wearing-off within 5 years of levodopa therapy; <10 % show it at 1 year <span class=\"citation\">(Ahlskog & Muenter, 2001)</span>.  <br>2. Low-protein diets or timing levodopa away from meals can reduce competition for transport across the gut/BBB, modestly ameliorating wearing-off.  <br>3. Continuous subcutaneous apomorphine infusion or levodopa-carbidopa intestinal gel are palliative for refractory wearing-off by providing steady plasma levels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing &ldquo;on-off&rdquo; unpredictability (random motor fluctuations) with wearing-off (predictable end-dose failure).  <br>2. Assuming all motor fluctuations stem from GI absorption issues rather than central storage failure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society (MDS) Evidence-Based Review <span class=\"citation\">(Espay et al, 2020)</span>  <br>   &ndash; Recommendation: Treat wearing-off by optimizing levodopa delivery (Level A).  <br>2. NICE Parkinson&rsquo;s Disease Guideline CG35 (2017)  <br>   &ndash; Recommendation: Consider COMT inhibitors when end-of-dose deterioration occurs (Grade B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Loss of SNpc dopaminergic neurons reduces innervation of the dorsal striatum (putamen), impairing modulation of the direct (facilitates movement) and indirect (inhibits movement) basal ganglia pathways. Depletion narrows the therapeutic window for exogenous levodopa.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Progressive &alpha;-synuclein aggregation and neuronal apoptosis in SNpc diminish vesicular dopamine storage. With fewer terminals, exogenous levodopa cannot be buffered, leading to pulsatile receptor activation and motor fluctuations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa half-life: 1.5&ndash;2 h. COMT inhibitors extend half-life by blocking peripheral methylation. MAO-B inhibitors reduce central dopamine breakdown. Strategy: increase dosing frequency, add adjuncts, or use infusion pumps to approximate CDS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Motor fluctuations in PD&mdash;wearing-off, peak-dose dyskinesia, on-off phenomenon&mdash;are high-yield topics tested frequently as single best-answer questions on pathophysiology and management.</div></div></div></div></div>"
  },
  {
    "id": 100023790,
    "question_number": "221",
    "question_text": "A female patient has a tremor and her father has a tremor; the father reported that his tremor is improved with wine. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Tremors are rhythmic, involuntary oscillations classified by their relationship to voluntary movement.  <br>&bull; Essential tremor (ET): an action/postural tremor, often bilateral and symmetric, with autosomal dominant inheritance.  <br>&bull; Alcohol responsiveness is a hallmark: 50&ndash;70% of ET patients note transient improvement after ethanol ingestion.  <br>&bull; Differential includes Parkinson&rsquo;s disease (resting tremor), cerebellar tremor (intention tremor with dysmetria), and dystonic tremor (irregular, posture-dependent).  <br>Understanding these core distinctions&mdash;movement phase, distribution, family history, and modulating factors&mdash;is critical to accurate diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Essential tremor is the correct diagnosis. <span class=\"evidence\">The 2018</span> American Academy of Neurology (AAN) practice guideline <span class=\"citation\">(<span class=\"evidence\">Chou et al., 2018</span>, Level A evidence)</span> identifies family history and alcohol responsiveness as key diagnostic clues. ET arises from cerebellothalamocortical circuit dysfunction, with Purkinje cell GABAergic abnormalities demonstrated in postmortem studies <span class=\"citation\">(<span class=\"evidence\">Louis et al., 2013</span>)</span>. Clinical evaluation revealing bilateral, high-frequency (4&ndash;12 Hz) postural tremor exacerbated by action, improvement with low-dose ethanol, and positive first-degree relative history aligns with consensus criteria <span class=\"citation\">(MDS Tremor Task Force, 2018)</span>. Pharmacotherapy (e.g., propranolol, primidone) targets the aberrant oscillatory network, whereas disease-modifying treatments remain investigational.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Parkinson&rsquo;s disease  <br>&bull; Incorrect because PD tremor is predominantly a 4&ndash;6 Hz resting tremor, asymmetric, accompanied by bradykinesia and rigidity. Alcohol does not improve PD tremor.  <br>C. Cerebellar tremor  <br>&bull; Intention tremor appears during terminal part of goal-directed movement, often with dysmetria and ataxia; not alcohol-responsive or familial in this pattern.  <br>D. Dystonic tremor  <br>&bull; Tremor linked to sustained muscle contractions, irregular frequency, posture-specific &ldquo;null points,&rdquo; and geste antagoniste; no consistent alcohol benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Essential Tremor</th><th>Parkinson&rsquo;s Disease Tremor</th><th>Cerebellar Tremor</th><th>Dystonic Tremor</th></tr></thead><tbody><tr><td>Tremor type</td><td>Postural/action</td><td>Resting</td><td>Intention</td><td>Task/posture-specific</td></tr><tr><td>Frequency</td><td>4&ndash;12 Hz</td><td>4&ndash;6 Hz</td><td><5 Hz</td><td>Variable, irregular</td></tr><tr><td>Symmetry</td><td>Bilateral, symmetric</td><td>Often unilateral initially</td><td>Variable</td><td>Asymmetric, focal</td></tr><tr><td>Alcohol responsiveness</td><td>Improves in 50&ndash;70%</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Associated signs</td><td>None</td><td>Bradykinesia, rigidity</td><td>Ataxia, dysmetria</td><td>Dystonic posturing, geste</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; A single sip of wine or beer improving tremor is nearly pathognomonic for essential tremor.  <br>&bull; First-line pharmacotherapy per AAN: propranolol (start 40 mg/day) or primidone (start 25 mg/day).  <br>&bull; Deep brain stimulation of the ventral intermediate nucleus of the thalamus offers sustained benefit in medication-refractory ET.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling all postural tremors as cerebellar when ET is far more common.  <br>2. Assuming alcohol &lsquo;makes everyone&rsquo;s tremor better&rsquo;&mdash;only ET shows reproducible short-term improvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (2018): ET treatment guideline recommends propranolol or primidone as Level A therapies; topiramate as Level B.  <br>2. Movement Disorder Society Consensus (2021): endorses MR-guided focused ultrasound thalamotomy in select ET patients refractory to medications (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>ET involves abnormal oscillations within the cerebellothalamocortical loop. Purkinje cell loss and reduced GABAergic output in the cerebellar dentate nucleus lead to thalamic relay hyperactivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Genetic mutations (e.g., ETM1 locus on chromosome 3q13) predispose to Purkinje cell dysfunction. Reduced GABA receptor density and altered calcium channel function amplify tremorogenic oscillations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed history: tremor phase, family history, alcohol response.  <br>2. Neurological exam: characterize frequency, distribution, rest vs. action.  <br>3. Exclude red flags: ataxia, rigidity, bradykinesia, dystonic postures.  <br>4. Consider DAT-SPECT if PD uncertain; normal imaging supports ET.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Structural MRI is typically unremarkable in ET; DAT-SPECT distinguishes ET (normal uptake) from PD (reduced striatal uptake).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Propranolol: nonselective &beta;-blocker, 30&ndash;320 mg/day, titrate to tremor suppression.  <br>&bull; Primidone: barbiturate prodrug to phenobarbital, 50&ndash;250 mg/day; monitor for sedation.  <br>&bull; Second-line: topiramate, gabapentin; advanced: DBS, MRgFUS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Essential tremor is frequently tested as an action tremor with characteristic alcohol responsiveness and autosomal dominant inheritance, often contrasted with Parkinsonian, cerebellar, and dystonic tremors.</div></div></div></div></div>"
  },
  {
    "id": 100023792,
    "question_number": "411",
    "question_text": "In a case of multiple system atrophy (MSA), what radiological finding is commonly associated?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Multiple system atrophy (MSA) is a sporadic &alpha;-synucleinopathy characterized by neurodegeneration in striatonigral and olivopontocerebellar pathways, producing parkinsonian (MSA-P) and cerebellar (MSA-C) phenotypes. In MSA-C, selective loss of transverse pontine fibers and raphe nuclei produces a cruciform T2/FLAIR hyperintensity in the pons&mdash;the &ldquo;hot cross bun&rdquo; sign. Key structures: pontine basis, middle cerebellar peduncles, and putamen. Distinguishing MSA from mimics (e.g., multiple sclerosis, glioblastoma) relies on recognition of specific neuroimaging signatures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The hot cross bun sign arises from degeneration of pontocerebellar fibers intersecting transverse pontine fibers, yielding a cruciate hyperintensity on axial T2/FLAIR MRI <span class=\"citation\">(Ozawa et al., <span class=\"evidence\">Brain 2004</span>)</span>. Paviour et al. <span class=\"citation\">(Mov <span class=\"evidence\">Disord 2006</span>)</span> reported specificity >95% for MSA-C versus spinocerebellar ataxias. <span class=\"evidence\">The 2022</span> Movement Disorder Society MSA diagnostic criteria include the hot cross bun sign as a supportive imaging marker (Level IV evidence). Additional MRI features&mdash;putaminal hypointensity with a hyperintense rim (&ldquo;putaminal rim sign&rdquo;) and middle cerebellar peduncle atrophy&mdash;reinforce the diagnosis. Other options reflect distinct pathologies: Dawson&rsquo;s fingers in MS, butterfly glioma in glioblastoma multiforme, and ring-enhancing lesions in abscess or metastatic disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Dawson&rsquo;s fingers  <br><span class=\"list-item\">\u2022</span> Represent perivenular demyelinating lesions perpendicular to ventricles in MS (not MSA).  <br><span class=\"list-item\">\u2022</span> Misconception: conflating demyelination patterns with neurodegenerative atrophy.  <br><br>C. Butterfly glioma  <br><span class=\"list-item\">\u2022</span> Describes glioblastoma crossing the corpus callosum, forming bifrontal masses.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming any cross-shaped lesion implies MSA.  <br><br>D. Ring-enhancing lesion  <br><span class=\"list-item\">\u2022</span> Seen in abscesses, metastases or high-grade tumors with blood&ndash;brain barrier breakdown.  <br><span class=\"list-item\">\u2022</span> Differs from non-enhancing, degenerative changes in MSA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Hot Cross Bun Sign</th><th>Dawson&rsquo;s Fingers</th><th>Butterfly Glioma</th><th>Ring-Enhancing Lesion</th></tr></thead><tbody><tr><td>Imaging modality</td><td>T2/FLAIR MRI</td><td>T2/FLAIR MRI</td><td>T1\u2009+\u2009contrast MRI</td><td>T1\u2009+\u2009contrast MRI</td></tr><tr><td>Appearance</td><td>Cruciform pontine hyperintensity</td><td>Ovoid periventricular lesions</td><td>Bilateral frontal masses crossing corpus callosum</td><td>Peripheral ring enhancement</td></tr><tr><td>Associated condition</td><td>MSA-C</td><td>Multiple sclerosis</td><td>Glioblastoma multiforme</td><td>Abscess, metastasis</td></tr><tr><td>Pathophysiology</td><td>Degeneration of pontocerebellar fibers</td><td>Perivenular demyelination</td><td>Infiltrative neoplasm</td><td>Blood&ndash;brain barrier disruption</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MSA subtypes: parkinsonian (MSA-P) vs cerebellar (MSA-C); hot cross bun is most prominent in MSA-C.  <br><span class=\"list-item\">\u2022</span> Specificity of the hot cross bun sign for MSA-C exceeds 90%; sensitivity varies by disease stage.  <br><span class=\"list-item\">\u2022</span> Rarely, spinocerebellar ataxia type 2 may mimic the hot cross bun sign&mdash;correlate clinically.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overcalling pontine T2 changes as demyelination (MS) rather than neurodegeneration (MSA).  <br><span class=\"list-item\">\u2022</span> Assuming ring enhancement excludes neurodegenerative processes&mdash;contrast uptake patterns differ.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society MSA diagnostic criteria <span class=\"citation\">(MDS, 2022)</span>: include hot cross bun sign as a supportive imaging feature (Level IV evidence).  <br><span class=\"list-item\">\u2022</span> Consensus Statement on Neuroimaging in MSA <span class=\"citation\">(European Radiology, 2023)</span>: hot cross bun sign sensitivity ~65%, specificity ~95% for MSA-C vs SCA and PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of transverse pontine fibers (originating in pontine nuclei) and raphe interconnections creates the cruciform signal; involvement of middle cerebellar peduncles explains concomitant ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Oligodendroglial cytoplasmic inclusions of &alpha;-synuclein trigger gliosis and axonal loss in pontocerebellar tracts, sparing blood&ndash;brain barrier integrity and thus lacking contrast enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: autonomic failure + parkinsonism/ataxia.  <br>2. Exclude mimics via laboratory and CSF studies (e.g., oligoclonal bands).  <br>3. MRI T2/FLAIR: evaluate for hot cross bun, putaminal rim sign.  <br>4. Support diagnosis with neurophysiological tests (e.g., autonomic reflex screening).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use high-resolution T2 and FLAIR sequences through pons.  <br><span class=\"list-item\">\u2022</span> Assess putamen for hypointensity with lateral rim hyperintensity (&ldquo;putaminal rim sign&rdquo;).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. MSA imaging features are high-yield for boards, frequently tested as single-best-answer questions on MRI signs.</div></div></div></div></div>"
  },
  {
    "id": 100023793,
    "question_number": "361",
    "question_text": "A 62-year-old woman has experienced progressive unsteady gait and recurrent falls over the past 3 years, accompanied by urinary urgency progressing to incontinence. Brain MRI demonstrates prominent midbrain atrophy with a \u201chummingbird\u201d appearance. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Progressive supranuclear palsy (PSP) is an atypical parkinsonian tauopathy marked by early postural instability, vertical supranuclear gaze palsy, axial rigidity, and frontal cognitive changes. Key neuroanatomical sites include the midbrain tegmentum&mdash;atrophied in PSP (&ldquo;hummingbird sign&rdquo;)&mdash;and superior cerebellar peduncles. Pathophysiologically, 4-repeat tau aggregates accumulate in neurons and glia, causing neuronal loss in basal ganglia and brainstem. Clinically, falls within the first 1&ndash;2 years of onset distinguish PSP from Parkinson&rsquo;s disease. Urinary dysfunction arises from brainstem autonomic involvement but is less prominent than in MSA. Recognizing imaging biomarkers alongside early clinical red flags is essential for diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP meets the 2017 Movement Disorder Society (MDS) criteria: early falls (<3 years), vertical supranuclear gaze palsy, and supportive MRI showing midbrain atrophy (medial midbrain atrophy with preservation of pons). Whitwell et al. <span class=\"citation\">(Neurology, 2013)</span> demonstrated that midbrain area < 70 mm\u00b2 yields 90% specificity. MDS guidelines <span class=\"citation\">(<span class=\"evidence\">Litvan et al., 2017</span>)</span> assign Level A diagnostic validity to these features. Unlike PD or MSA, PSP shows minimal levodopa responsiveness and absence of pontocerebellar &ldquo;hot cross bun&rdquo; sign. Diagnosis is clinched by correlating horizontal ocular pursuits, axial rigidity, early falls, and imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Multiple System Atrophy (MSA)  <br>&ndash; MRI in MSA-cerebellar type shows pontine hot cross bun sign and cerebellar atrophy, not isolated midbrain atrophy.  <br>&ndash; Rapid autonomic failure (orthostasis, severe urinary retention) precedes gait issues; ocular motility preserved.  <br>&ndash; Misconception: all atypical parkinsonisms have early urinary incontinence.  <br><br>C. Normal Pressure Hydrocephalus (NPH)  <br>&ndash; Presents with magnetic gait, cognitive decline, urinary incontinence, but MRI shows enlarged ventricles with tight sulci, not midbrain atrophy.  <br>&ndash; Gait is &ldquo;magnetic&rdquo; and wide-based; ocular motility intact.  <br>&ndash; Misconception: any gait + incontinence = NPH.  <br><br>D. Corticobasal Degeneration (CBD)  <br>&ndash; Asymmetric cortical signs (ideomotor apraxia, alien limb), cortical sensory loss, &ldquo;claw hand,&rdquo; not early falls or midbrain atrophy.  <br>&ndash; MRI shows asymmetric frontoparietal atrophy.  <br>&ndash; Misconception: CBD and PSP share midbrain atrophy (they do not).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSP</th><th>MSA</th><th>NPH</th><th>CBD</th></tr></thead><tbody><tr><td>Early falls (<3 yrs)</td><td>Yes</td><td>Occasionally late</td><td>No</td><td>Rare</td></tr><tr><td>Vertical gaze palsy</td><td>Supranuclear palsy present</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>MRI midbrain atrophy</td><td>Prominent (&ldquo;hummingbird sign&rdquo;)</td><td>No</td><td>No (ventricular enlargement)</td><td>No (frontoparietal atrophy)</td></tr><tr><td>Autonomic failure</td><td>Mild urinary urgency/incontinence</td><td>Severe orthostasis, urinary</td><td>Urinary incontinence common</td><td>Rare</td></tr><tr><td>Cortical signs</td><td>Frontal cognitive deficits</td><td>Minimal</td><td>Variable</td><td>Apraxia, cortical sensory deficits</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Early postural instability with falls (<3 years) strongly suggests PSP over PD or MSA.  <br>&bull; The &ldquo;hummingbird&rdquo; or &ldquo;penguin silhouette&rdquo; sign on mid-sagittal MRI is highly specific for PSP.  <br>&bull; Vertical supranuclear gaze palsy may begin with slowed vertical saccades; test with downward gaze first.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming urinary incontinence early in disease always indicates MSA or NPH.  <br>2. Overlooking vertical gaze testing and attributing falls to peripheral neuropathy or cerebellar ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Movement Disorder Society (MDS) PSP Criteria,<span class=\"evidence\"> Litvan et al., 2017</span>: Defines Level A validity for early falls, vertical supranuclear gaze palsy, and midbrain atrophy on MRI.  <br>&bull; European Academy of Neurology (EAN) Guidelines on Atypical Parkinsonism, 2022: Recommends MRI measurement of midbrain tegmental area and superior cerebellar peduncle thickness for differential diagnosis (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP targets midbrain nuclei (oculomotor complex, vertical gaze centers) and superior cerebellar peduncles. Tau deposition in the subthalamic nucleus and globus pallidus disrupts basal ganglia circuits, leading to axial rigidity and postural instability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is a 4R\u2010tauopathy with neuronal and glial tau aggregates. Tau hyperphosphorylation disrupts microtubule stability, leading to neuronal loss in brainstem and basal ganglia. Accumulation in the subthalamic nucleus impairs inhibitory outputs, causing rigidity and gait failure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: early falls, axial rigidity  <br>2. Ocular exam: test vertical saccades/pursuits  <br>3. MRI brain: measure midbrain area/SCP thickness  <br>4. Apply MDS PSP diagnostic criteria  <br>5. Exclude alternative causes (NPH, MSA, CBD)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Mid-sagittal MRI: midbrain tegmentum atrophy (&ldquo;hummingbird sign&rdquo;).  <br>&bull; MR Parkinsonism Index > 13.5 (ratio pons/midbrain \u00d7 MCP/SCP) differentiates PSP from MSA-P.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Levodopa trial: typically poor or transient response.  <br>&bull; Amantadine may modestly improve gait freezing.  <br>&bull; Physical and occupational therapy crucial for fall prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Atypical parkinsonian syndromes are frequently tested on boards, often emphasizing early falls, vertical gaze palsy, and characteristic MRI signs in PSP.</div></div></div></div></div>"
  },
  {
    "id": 100023797,
    "question_number": "85",
    "question_text": "A young man who is a law student in the last year of college has a long-standing intentional tremor that has worsened over the past few months. He has bronchial asthma and is on inhalers. What is the most appropriate treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Essential Tremor (ET) is a common action tremor&mdash;postural and kinetic&mdash;that often worsens with goal-directed movements. It arises from abnormal oscillatory activity in the cerebello-thalamo-cortical circuit. First-line pharmacotherapy per American Academy of Neurology (AAN) guidelines includes nonselective &beta;-blockers (propranolol) and the barbiturate analogue primidone. Comorbidities (e.g., asthma) dictate drug choice: nonselective &beta;-blockade can precipitate bronchospasm. Secondary agents (topiramate, gabapentin) have lower-level evidence and more adverse effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Primidone is a first-line agent <span class=\"citation\">(Level A evidence, AAN 2018)</span> that metabolizes to phenobarbital, enhancing GABA_A-mediated inhibition in cerebellar and thalamic circuits, reducing tremor amplitude by 50&ndash;70% in RCTs <span class=\"citation\">(<span class=\"evidence\">Koller et al., 1994</span>;<span class=\"evidence\"> Louis et al., 2001</span>)</span>. Dosing begins at 12.5 mg nightly, titrating by 12.5 mg increments weekly up to 250&ndash;500 mg/day as tolerated. Propranolol shares similar efficacy but is contraindicated in asthma due to nonselective &beta;_2 blockade causing bronchoconstriction. Topiramate (Level C) and gabapentin (Level U) show modest benefit in small trials but carry cognitive side effects or limited efficacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Propranolol  <br>&bull; Contraindicated in bronchial asthma&mdash;nonselective &beta;_2 blockade precipitates bronchospasm.  <br>&bull; Misconception: All first-line tremor drugs are interchangeable without regard to comorbidities.  <br><br>C. Topiramate  <br>&bull; Second-/third-line (Level C evidence); cognitive slowing, paresthesias, weight loss limit tolerability.  <br>&bull; Misconception: Antiepileptics are equally potent as primidone/propranolol for ET.  <br><br>D. Gabapentin  <br>&bull; Off-label, limited RCT data (small open\u2010label studies); efficacy <30%.  <br>&bull; Misconception: All anticonvulsants have robust tremor\u2010suppressing effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Primidone</th><th>Propranolol</th><th>Topiramate</th><th>Gabapentin</th></tr></thead><tbody><tr><td>Drug class</td><td>Barbiturate analogue</td><td>Nonselective &beta;-blocker</td><td>Antiepileptic (sulfamate)</td><td>Antiepileptic (GABA analogue)</td></tr><tr><td>Mechanism</td><td>\u2191 GABA_A inhibition</td><td>\u2193 Peripheral &beta;_1/&beta;_2 activity</td><td>\u2193 AMPA/kainate neurotransmission</td><td>\u2191 GABA release</td></tr><tr><td>Evidence level (ET)</td><td>A <span class=\"citation\">(AAN 2018)</span></td><td>A <span class=\"citation\">(AAN 2018)</span></td><td>C <span class=\"citation\">(AAN 2018)</span></td><td>U (insufficient)</td></tr><tr><td>Typical dosing</td><td>12.5 mg\u2192250&ndash;500 mg/day</td><td>40&ndash;320 mg/day</td><td>50&ndash;300 mg/day</td><td>900&ndash;3600 mg/day</td></tr><tr><td>Key side effects</td><td>Sedation, ataxia</td><td>Bradycardia, fatigue, bronchospasm</td><td>Cognitive impairment, paresthesias</td><td>Somnolence, dizziness</td></tr><tr><td>Asthma safety</td><td>Safe</td><td>Contraindicated</td><td>Safe</td><td>Safe</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always review comorbidities&mdash;nonselective &beta;-blockers (propranolol, nadolol) can exacerbate asthma.  <br>&bull; Primidone requires slow titration to minimize sedation and ataxia; patient education on dose adjustments is vital.  <br>&bull; Consider referral for deep brain stimulation if pharmacotherapy fails or side effects are intolerable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Interpreting &ldquo;intentional tremor&rdquo; as cerebellar disease only&mdash;ET is a kinetic tremor that may appear during target-directed movement.  <br>2. Selecting propranolol without screening for respiratory disease, risking severe bronchospasm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AAN Practice Guideline on Essential Tremor (2018): Recommends primidone and propranolol as first-line (Level A), topiramate as second-line (Level C), gabapentin not recommended due to insufficient evidence.  <br>&bull; European Federation of Neurological Societies (EFNS) Guidelines (2011): Echo similar hierarchy; notes primidone&rsquo;s superior tolerability in patients contraindicated for &beta;-blockers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>ET arises from dysrhythmia in the cerebello-thalamo-cortical loop. Abnormal pacemaker activity in the inferior olive and Purkinje cell loss in the cerebellar cortex contribute to overactive thalamic relay in the ventral intermediate nucleus, producing rhythmic tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>ET involves GABAergic dysfunction and increased oscillatory synchrony between the deep cerebellar nuclei and thalamus. Primidone&rsquo;s GABA_A potentiation restores inhibitory tone, dampening tremorogenic circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Primidone: Start 12.5 mg at bedtime, increase by 12.5 mg weekly; monitor for sedation, adjust to symptom control. Educate on phenobarbital metabolite effects. Monitor liver function periodically.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Essential tremor pharmacotherapy is frequently tested&mdash;expect vignettes highlighting comorbidities (e.g., asthma) that contraindicate &beta;-blockers and require selection of primidone.</div></div></div></div></div>"
  },
  {
    "id": 100023798,
    "question_number": "107",
    "question_text": "What medication is commonly used to treat essential tremor in a patient with asthma?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Essential tremor (ET) is a postural and kinetic tremor implicating the cerebellothalamocortical loop and likely reflecting GABAergic dysfunction in the dentate nucleus. First-line pharmacotherapy targets either &beta;-adrenergic receptors (propranolol) or GABA modulation (primidone). In asthma, nonselective &beta;-blockade precipitates bronchoconstriction; thus, primidone&mdash;a barbiturate analog metabolized to phenobarbital&mdash;becomes the agent of choice. Understanding drug metabolism, receptor selectivity, and contraindications is critical when tailoring ET treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Primidone has Class I evidence <span class=\"citation\">(AAN 2018 Practice Guideline)</span> demonstrating tremor amplitude reduction by ~50&ndash;60% in randomized, placebo-controlled trials. It enhances GABA_A receptor&ndash;mediated inhibition in cerebellar circuits. Propranolol also enjoys Level A support but is contraindicated in reactive airway disease due to &beta;_2-receptor blockade. Gabapentin shows modest benefit (Level B) in small RCTs, while diazepam lacks robust evidence and carries risk of tolerance, sedation, and respiratory depression. Current consensus <span class=\"citation\">(Movement Disorders <span class=\"evidence\">Society 2020</span>)</span> affirms primidone as first-line when &beta;-blockers are contraindicated (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Propranolol  <br>&ndash; Incorrect: Nonselective &beta;_1/&beta;_2-blocker; &beta;_2 antagonism triggers bronchoconstriction in asthma.  <br>&ndash; Misconception: All beta-blockers are interchangeable; in reality, &beta;_1-selective agents (e.g., metoprolol) are safer in mild COPD but still avoided in asthma.  <br><br>C. Diazepam  <br>&ndash; Incorrect: Benzodiazepine with GABA_A potentiation lacks strong RCT support for ET; risk of tolerance, dependence, and sedation.  <br>&ndash; Misconception: Any GABAergic agent is equally effective; primidone&rsquo;s barbiturate metabolite has superior tremor suppression.  <br><br>D. Gabapentin  <br>&ndash; Incorrect: &alpha;2\u03b4 calcium-channel modulator with only Level B evidence and less efficacy than primidone or propranolol; side effects include dizziness and ataxia.  <br>&ndash; Misconception: Newer antiepileptics outperform classic agents; in ET, they are generally second-line.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Primidone</th><th>Propranolol</th><th>Diazepam</th><th>Gabapentin</th></tr></thead><tbody><tr><td>Mechanism</td><td>Barbiturate\u2192phenobarbital\u2192GABA_A \u2191</td><td>Nonselective &beta;_1/&beta;_2-blocker</td><td>GABA_A allosteric modulator</td><td>&alpha;2\u03b4 subunit calcium-channel modulator</td></tr><tr><td>Evidence Level</td><td>A (Class I RCTs)</td><td>A (Class I RCTs)</td><td>C (open-label, anecdotal)</td><td>B (small RCTs)</td></tr><tr><td>Efficacy</td><td>Tremor \u2193 50&ndash;60%</td><td>Tremor \u2193 50%</td><td>Minimal, variable</td><td>Tremor \u2193 ~30%</td></tr><tr><td>Key Side Effects</td><td>Sedation, nausea, cytopenias</td><td>Bronchoconstriction, bradycardia</td><td>Sedation, tolerance, respiratory \u2193</td><td>Dizziness, somnolence</td></tr><tr><td>Asthma Consideration</td><td>Safe</td><td>Contraindicated</td><td>Caution (respiratory depression)</td><td>Safe but less effective</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Titrate primidone slowly (e.g., start 12.5 mg nightly, increase by 12.5&ndash;25 mg weekly) to minimize sedation and dizziness.  <br><span class=\"list-item\">\u2022</span> Monitor blood counts and liver function after chronic primidone use for cytopenias/hepatic toxicity.  <br><span class=\"list-item\">\u2022</span> In refractory ET, consider deep brain stimulation targeting the ventral intermediate nucleus of the thalamus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing propranolol universally for ET without assessing pulmonary comorbidities.  <br>2. Overestimating the role of benzodiazepines, leading to sedative dependence rather than tremor control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (2018): Recommends primidone or propranolol as first-line agents for ET (Level A evidence).  <br><span class=\"list-item\">\u2022</span> Movement Disorders Society Consensus (2020): Affirms primidone in patients with contraindications to &beta;-blockers (Level II evidence); supports DBS for medication-refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. On board examinations, ET pharmacotherapy is frequently tested via clinical vignettes emphasizing comorbidities (e.g., asthma) that contraindicate beta-blockers. Select primidone when nonselective &beta;-blockade poses risk.</div></div></div></div></div>"
  },
  {
    "id": 100023801,
    "question_number": "136",
    "question_text": "If a patient with orthostatic tremor does not respond to clonazepam, what is the next step in management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Orthostatic tremor is a rare high-frequency (13&ndash;18 Hz) tremor of the leg muscles on standing, leading to a sense of unsteadiness that rapidly abates with walking or sitting. Pathophysiology likely involves abnormal oscillatory activity in cerebello-thalamo-cortical circuits and segmental spinal pathways. Clonazepam, a benzodiazepine that potentiates GABA_A-mediated inhibition, is first-line therapy. In patients who remain symptomatic despite adequate clonazepam dosing, second-line agents targeting alternative neurotransmitter systems&mdash;particularly calcium channel modulation&mdash;are indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Gabapentin binds the &alpha;2\u03b4 subunit of voltage-gated calcium channels, reducing excitatory neurotransmission in both spinal and supraspinal circuits implicated in orthostatic tremor. In multiple small case series <span class=\"citation\">(e.g.,<span class=\"evidence\"> Singer et al., 2003</span>;<span class=\"evidence\"> Gerschlager et al., 2004</span>)</span>, gabapentin produced &ge;50 % symptomatic improvement in 60&ndash;70 % of clonazepam-refractory patients. The Movement Disorder Society Evidence-Based Review of Treatment of Tremor (2018) classifies gabapentin as &ldquo;possibly effective&rdquo; (Level C) for orthostatic tremor, making it the preferred second-line agent. Neither levodopa (which targets dopaminergic deficiency) nor levetiracetam (SV2A modulation with only anecdotal reports) address the core pathophysiology, and primidone yields lower response rates with higher sedation risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. L-Dopa  <br>&bull; Incorrect because orthostatic tremor is not a dopaminergic deficit and does not respond to levodopa therapy.  <br>&bull; Misconception: equating all tremors with Parkinsonian tremor.  <br>&bull; Lacks both pathophysiologic rationale and clinical trial support.<br><br>C. Primidone  <br>&bull; Primidone metabolizes to phenobarbital, enhancing GABA_A activity, but shows only ~30 % efficacy in small series.  <br>&bull; Misconception: treating orthostatic tremor like essential tremor.  <br>&bull; Compared to gabapentin, it has a less favorable efficacy-to-sedation ratio.<br><br>D. Levetiracetam  <br>&bull; Modulates synaptic vesicle protein 2A (SV2A) but has only isolated case reports of benefit.  <br>&bull; Misconception: assuming broad-spectrum anticonvulsants are interchangeable.  <br>&bull; Lacks controlled studies and consistent clinical improvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Gabapentin</th><th>L-Dopa</th><th>Primidone</th><th>Levetiracetam</th></tr></thead><tbody><tr><td>Mechanism</td><td>&alpha;2\u03b4 subunit of VGCC blocker</td><td>Dopamine precursor</td><td>Barbiturate metabolite (GABA_A)</td><td>SV2A protein modulation</td></tr><tr><td>Evidence level</td><td>Possibly effective (C)</td><td>Not recommended</td><td>Possibly effective (C, low)</td><td>Anecdotal only</td></tr><tr><td>Reported response rate</td><td>~60&ndash;70 %</td><td>0 %</td><td>~30 %</td><td><20 % (case reports)</td></tr><tr><td>Common side effects</td><td>Somnolence, dizziness</td><td>Dyskinesia, nausea</td><td>Sedation, ataxia</td><td>Fatigue, irritability</td></tr><tr><td>Typical dosing range</td><td>900&ndash;3600 mg/day</td><td>300&ndash;1200 mg/day</td><td>125&ndash;1000 mg/day</td><td>1000&ndash;3000 mg/day</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm orthostatic tremor by surface EMG demonstrating 13&ndash;18 Hz bursts in leg muscles on standing.  <br>2. Titrate clonazepam slowly up to 4 mg/day to balance efficacy and sedation before declaring treatment failure.  <br>3. Gabapentin is the most evidence-backed second-line agent; monitor for dizziness and dose-related somnolence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating orthostatic tremor with essential tremor and initiating propranolol or primidone as first-line therapy.  <br>2. Presuming any high-frequency tremor responds to dopaminergic therapy and prescribing levodopa.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Evidence-Based Review of Treatment of Tremor <span class=\"citation\">(MDS, 2018)</span>: Clonazepam is &ldquo;probably effective&rdquo; (Level B); gabapentin is &ldquo;possibly effective&rdquo; (Level C) for orthostatic tremor.  <br>2. EFNS/EAN Guideline on Diagnosis and Management of Tremor <span class=\"citation\">(European Journal of Neurology, 2018)</span>: Recommends clonazepam (Level B) and gabapentin (Level C) as first- and second-line pharmacotherapies in orthostatic tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Orthostatic tremor management is often tested in single-best-answer format, emphasizing the pharmacologic sequence after benzodiazepine therapy.</div></div></div></div></div>"
  },
  {
    "id": 100023802,
    "question_number": "65",
    "question_text": "In a patient on risperidone, how can you differentiate tardive dyskinesia from Huntington\u2019s disease?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Tardive dyskinesia (TD) and Huntington&rsquo;s disease (HD) both manifest with choreiform movements but arise from distinct pathophysiologies.  <br><span class=\"list-item\">\u2022</span> Basal ganglia circuits: HD involves CAG-repeat&ndash;mediated neurodegeneration of striatal medium spiny neurons (caudate/putamen), disrupting the indirect pathway and causing chorea. TD reflects dopamine D2-receptor supersensitivity in nigrostriatal pathways after chronic antipsychotic blockade.  <br><span class=\"list-item\">\u2022</span> Genetics vs. drug exposure: HD is autosomal dominant (HTT gene CAG expansion, near 100% penetrance), whereas TD is a late-onset extrapyramidal side effect of dopamine-blocking agents like risperidone.  <br><span class=\"list-item\">\u2022</span> Clinical exam: HD shows impaired voluntary saccades and cognitive decline; TD has predominantly orolingual and limb chorea without cognitive impairment or saccadic slowing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Family history is the most reliable discriminator: HD patients have a positive autosomal dominant pedigree in >90% of cases <span class=\"citation\">(Walker FO. Lancet Neurol. 2007)</span>. In contrast, TD arises de novo after &ge;3\u2009months of neuroleptic exposure (DSM-5 criteria), with no hereditary pattern. Current AAN practice guidelines (2018) emphasize thorough medication and family histories when evaluating new hyperkinetic movements. Genetic testing for HTT CAG repeats confirms HD; VMAT2 inhibitor trials (e.g., valbenazine, deutetrabenazine) support alleviation of TD but have no role in HD prevention or modification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Lack of eye movement  <br><span class=\"list-item\">\u2022</span> Why incorrect: HD is characterized by slowed voluntary saccades and impaired initiation of gaze shifts, not an absolute &ldquo;lack.&rdquo; TD spares oculomotor function.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating chorea severity with ocular motor arrest.  <br><span class=\"list-item\">\u2022</span> Differentiator: Qualitative saccadic testing (velocity, latency) distinguishes HD from TD.<br><br>C. Presence of chorea  <br><span class=\"list-item\">\u2022</span> Why incorrect: Both TD and HD present with choreiform movements; this feature does not differentiate.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing chorea is unique to one condition.  <br><span class=\"list-item\">\u2022</span> Differentiator: Distribution and accompanying features (e.g., orofacial in TD vs. generalized in HD) are more subtle.<br><br>D. Age of onset  <br><span class=\"list-item\">\u2022</span> Why incorrect: HD typically onsets at 30&ndash;50\u2009years, but TD can also emerge in middle age after antipsychotic use. There is significant overlap.  <br><span class=\"list-item\">\u2022</span> Misconception: Relying on arbitrary age cutoffs.  <br><span class=\"list-item\">\u2022</span> Differentiator: Temporal relationship to drug initiation is more informative than patient age.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Tardive Dyskinesia</th><th>Huntington&rsquo;s Disease</th></tr></thead><tbody><tr><td>Family history</td><td>Negative (sporadic)</td><td>Positive, autosomal dominant</td></tr><tr><td>Medication association</td><td>Chronic dopamine-blocker use</td><td>None</td></tr><tr><td>Voluntary saccades</td><td>Normal</td><td>Slow, increased latency</td></tr><tr><td>Cognitive impairment</td><td>Absent</td><td>Progressive dementia</td></tr><tr><td>Neuroimaging</td><td>Typically normal</td><td>Caudate atrophy, increased bicaudate ratio</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always obtain a three-generation pedigree when chorea is unexplained or refractory to VMAT2 inhibitors.  <br><span class=\"list-item\">\u2022</span> Oculomotor examination (saccades, pursuit) is a rapid bedside tool: slowed horizontal saccades point to HD.  <br><span class=\"list-item\">\u2022</span> In TD, VMAT2 inhibitors (valbenazine, deutetrabenazine) are FDA-approved; they do not alter underlying receptor supersensitivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling acute orofacial dyskinesias as TD without verifying duration (>1\u2009month) and chronicity.  <br>2. Assuming chorea in any psychotropic-treated patient is drug-induced without a family history or genetic test.  <br>3. Overemphasizing age at presentation rather than temporal relation to neuroleptic use.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of <span class=\"evidence\">Neurology 2018</span> Practice Guideline: Recommends VMAT2 inhibitors (Level B evidence) as first-line for TD and stresses detailed medication/family history.  <br><span class=\"list-item\">\u2022</span> European Huntington&rsquo;s Disease <span class=\"evidence\">Network 2021</span> Consensus: Advises genetic testing for HTT CAG repeats in all suspected HD cases and multidisciplinary care (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- TD: Functional upregulation of D2 receptors in the striatum (nigrostriatal pathway) leads to involuntary movements.  <br><span class=\"list-item\">\u2022</span> HD: Degeneration of GABAergic medium spiny neurons in the caudate/putamen disrupts indirect pathway inhibition, causing chorea.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Tardive dyskinesia: Chronic D2 blockade \u2192 receptor supersensitivity \u2192 dysregulated motor output.  <br><span class=\"list-item\">\u2022</span> Huntington&rsquo;s disease: CAG expansion \u2192 mutant huntingtin protein \u2192 neuronal apoptosis via mitochondrial dysfunction and excitotoxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm chorea phenomenology on exam.  <br>2. Review medication history (antipsychotic duration).  <br>3. Elicit family history of movement disorders or dementia.  <br>4. Perform oculomotor testing.  <br>5. If HD suspected, order HTT CAG repeat analysis and brain MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- HD: MRI shows caudate head atrophy, enlargement of frontal horns; bicaudate ratio >0.16 is highly sensitive.  <br><span class=\"list-item\">\u2022</span> TD: Structural imaging is typically unremarkable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- TD: Valbenazine 40\u2009mg daily (titrate to 80\u2009mg) or deutetrabenazine starting 12\u2009mg twice daily, adjust for efficacy and side effects.  <br><span class=\"list-item\">\u2022</span> HD: Tetrabenazine (start 12.5\u2009mg/day) for chorea; monitor for depression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>Choreiform movement differentiation between drug-induced and genetic etiologies is frequently tested on neurology board examinations, often requiring integration of family history, medication side effects, oculomotor findings, and genetic testing strategies.</div></div></div></div></div>"
  },
  {
    "id": 100023804,
    "question_number": "194",
    "question_text": "In the same scenario, what is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Idiopathic Parkinson&rsquo;s disease (PD) is characterized by degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to striatal dopamine deficiency. Key motor features include bradykinesia, resting tremor, rigidity, and postural instability. Symptomatic management aims to restore dopamine levels to improve activities of daily living. Levodopa, the metabolic precursor to dopamine, remains the most potent agent for moderate-to-severe symptoms. Adjunctive strategies (physiotherapy) and imaging (MRI) have supporting but not primary roles in initial management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa is the gold-standard symptomatic therapy for PD when motor symptoms impair function. The PD MED trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2014</span>)</span> demonstrated superior quality-of-life improvement and motor control with levodopa versus initial dopamine agonist therapy (HR for treatment success 1.12; 95% CI 1.02&ndash;1.23). <span class=\"evidence\">The 2018</span> Movement Disorder Society Evidence-Based Guidelines (Level A recommendation) endorse levodopa as first-line in patients >60 years or with significant disability. Early levodopa <span class=\"citation\">(ELLDOPA trial, <span class=\"evidence\">Neurology 2004</span>)</span> also showed sustained benefit without accelerating progression. Its rapid onset and robust efficacy in improving bradykinesia and rigidity make it the appropriate next step.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Initiate dopamine agonist therapy  <br>  &bull; Less efficacious in symptom control compared to levodopa.  <br>  &bull; Reserved for younger patients (<60 years) to delay motor complications.  <br>  &bull; Common misconception: agonists are equally potent; in reality they yield slower and less robust motor improvement.  <br><br>C. Begin physical therapy and exercise  <br>  &bull; Important adjunct to improve gait and balance, but insufficient as monotherapy when motor features significantly impair daily living.  <br>  &bull; Misconception: that non-pharmacologic measures alone can replace dopamine replacement in moderate disease.  <br><br>D. Order brain MRI to rule out other causes  <br>  &bull; Routine neuroimaging not indicated in classic clinical PD without red flags (rapid progression, early falls, atypical signs).  <br>  &bull; MRI is used to exclude secondary or atypical parkinsonism, not to guide initial pharmacotherapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Levodopa</th><th>Dopamine Agonist</th><th>Physical Therapy</th><th>Brain MRI</th></tr></thead><tbody><tr><td>Primary Role</td><td>Symptomatic motor control</td><td>Adjunct/delay dyskinesias</td><td>Gait, balance adjunct</td><td>Exclude secondary causes</td></tr><tr><td>Onset of Action</td><td>Rapid (hours)</td><td>Moderate (days&ndash;weeks)</td><td>Gradual (weeks&ndash;months)</td><td>Immediate imaging result</td></tr><tr><td>Efficacy</td><td>Highest</td><td>Moderate</td><td>Supportive</td><td>None for symptom relief</td></tr><tr><td>Indicated When</td><td>Significant motor impairment</td><td>Younger patients, mild symptoms</td><td>At any stage as adjunct</td><td>Atypical or red flag presentations</td></tr><tr><td>Long-term Complications</td><td>Dyskinesias, motor fluctuations</td><td>Impulse control disorders</td><td>Minimal</td><td>Incidental findings</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Levodopa/carbidopa remains the most potent treatment for symptomatic PD and should be started when motor signs impede daily function.  <br>&bull; Initiate levodopa at low dose (e.g., 100/25 mg TID) and titrate to balance efficacy and minimize dyskinesias.  <br>&bull; Encourage concurrent physical therapy early to maintain mobility, but do not delay dopamine replacement when indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying levodopa due to fear of dyskinesias: motor complications can be managed, while untreated bradykinesia impairs quality of life.  <br>2. Over-reliance on imaging: normal MRI does not confirm PD, and structural scans rarely alter management in classic presentations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Movement Disorder Society (2018) Evidence-Based Medicine Review: Levodopa is Level A recommended first-line therapy for patients >60 years or with functional impairment.  <br>&bull; PD MED Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2014</span>)</span>: Demonstrated superior long-term quality-of-life and motor outcomes with initial levodopa versus dopamine agonists (n = 1,626; median follow-up 2 years).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of dopaminergic neurons in the substantia nigra pars compacta reduces nigrostriatal dopamine input to the dorsal striatum, disrupting the direct and indirect basal ganglia pathways and leading to bradykinesia and rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Alpha-synuclein aggregation forms Lewy bodies within dopaminergic neurons, triggering mitochondrial dysfunction, oxidative stress, and eventual neuronal death in the substantia nigra.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa crosses the blood&ndash;brain barrier and is decarboxylated to dopamine in the CNS. Co-administration with carbidopa inhibits peripheral decarboxylation, enhancing central availability and reducing peripheral side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Parkinson&rsquo;s disease management&mdash;particularly the choice and timing of levodopa initiation&mdash;is a high-yield topic frequently tested in vignette format, assessing knowledge of guidelines, trial data, and therapeutic hierarchy.</div></div></div></div></div>"
  },
  {
    "id": 100023805,
    "question_number": "222",
    "question_text": "Q222. In a scenario of progressive supranuclear palsy (PSP), what is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Progressive supranuclear palsy (PSP) is a primary tauopathy characterized by 4-repeat tau aggregation in basal ganglia, brainstem and cerebellar nuclei. Key neuroanatomical structures include the midbrain&mdash;particularly the rostral interstitial nucleus of the medial longitudinal fasciculus (riMLF) mediating vertical gaze&mdash;and the globus pallidus. Clinically, PSP presents with early postural instability leading to falls, vertical supranuclear gaze palsy (especially downgaze), axial rigidity, and poor levodopa responsiveness. Distinction from Parkinson&rsquo;s disease rests on symmetry of symptoms, early fall risk, gaze abnormalities, and specific neuroimaging signs (hummingbird sign). Understanding these pathophysiological and anatomical hallmarks is critical to differentiate PSP from other movement disorders with overlapping features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Progressive supranuclear palsy is defined by the Movement Disorder Society (MDS) 2017 criteria as a neurodegenerative tauopathy presenting with vertical gaze palsy, postural instability, and cognitive dysfunction in mid\u2010late life. Neuropathologically, widespread neuronal loss and gliosis with 4-repeat tau inclusions in tufted astrocytes are diagnostic <span class=\"citation\">(<span class=\"evidence\">Dickson et al., 2010</span>)</span>. MRI typically shows midbrain atrophy with preserved pons (&ldquo;hummingbird&rdquo; or &ldquo;penguin&rdquo; sign) and superior cerebellar peduncle thinning. Levodopa trials yield minimal benefit (<30% responders), unlike in Parkinson&rsquo;s disease. Current guidelines <span class=\"citation\">(MDS PSP diagnostic criteria, 2017; Level A evidence)</span> emphasize early falls and supranuclear gaze palsy as core features. No disease\u2010modifying therapy exists; management is supportive, targeting postural stability, speech, and swallowing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Parkinson&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Incorrect: Asymmetric onset, resting tremor, marked levodopa responsiveness (>60%), and absence of early falls or vertical supranuclear gaze palsy.  <br><span class=\"list-item\">\u2022</span> Misconception: All parkinsonian syndromes are PD. PSP is an atypical parkinsonism with distinct tau pathology.<br><br>B. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Demyelinating plaques on MRI, relapsing\u2010remitting course, optic neuritis, internuclear ophthalmoplegia rather than vertical gaze palsy, and younger onset (20&ndash;40 years).  <br><span class=\"list-item\">\u2022</span> Misconception: Any ocular motor abnormality suggests MS; PSP gaze palsy is supranuclear and progressive.<br><br>D. Essential tremor  <br><span class=\"list-item\">\u2022</span> Incorrect: Action/postural tremor of hands/head, improves with alcohol, no rigidity or bradykinesia, no gaze palsy, normal MRI.  <br><span class=\"list-item\">\u2022</span> Misconception: Tremor in PSP might be confused with ET, but ET lacks axial rigidity and gaze dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSP (Correct)</th><th>Parkinson&rsquo;s Disease</th><th>Multiple Sclerosis</th><th>Essential Tremor</th></tr></thead><tbody><tr><td>Onset age</td><td>60&ndash;70 years</td><td>55&ndash;65 years</td><td>20&ndash;40 years</td><td>Any, often >40 years</td></tr><tr><td>Initial symptom</td><td>Early falls, axial rigidity</td><td>Resting tremor, bradykinesia</td><td>Sensory deficits, optic neuritis</td><td>Postural/action tremor</td></tr><tr><td>Gaze abnormality</td><td>Vertical supranuclear palsy</td><td>Rare; ocular dyskinesias</td><td>Internuclear ophthalmoplegia</td><td>None</td></tr><tr><td>Levodopa responsiveness</td><td>Poor (<30% benefit)</td><td>Good (>60% benefit)</td><td>Not indicated</td><td>None</td></tr><tr><td>MRI findings</td><td>Midbrain atrophy (&ldquo;hummingbird sign&rdquo;)</td><td>Substantia nigra signal loss</td><td>Periventricular/juxtacortical plaques</td><td>Normal</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early backward falls and vertical downgaze palsy are hallmark red flags for PSP.  <br><span class=\"list-item\">\u2022</span> &ldquo;Hummingbird sign&rdquo; on sagittal MRI and superior cerebellar peduncle atrophy support PSP diagnosis.  <br><span class=\"list-item\">\u2022</span> Poor levodopa response differentiates PSP from idiopathic Parkinson&rsquo;s disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing early falls in PSP to peripheral neuropathy or lumbar stenosis rather than brainstem dysfunction.  <br>2. Over-relying on rigidity and bradykinesia without testing supranuclear gaze, leading to misdiagnosis as PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society PSP Diagnostic Criteria (2017): Defines probable PSP with postural instability and vertical gaze palsy; Level A evidence.  <br><span class=\"list-item\">\u2022</span> Bero et al., JAMA Neurology (2020): Phase II trial of tau vaccine AADvac1 showed safety and target engagement, but no clinical efficacy demonstrated yet (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP targets the midbrain (riMLF) causing vertical supranuclear gaze palsy, globus pallidus and subthalamic nucleus producing axial rigidity, and dentatorubrothalamic pathway leading to ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>4-repeat tau accumulates in neurons and glia (tufted astrocytes), leading to neurodegeneration in subcortical nuclei, midbrain tegmentum, and superior cerebellar peduncles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: age >60, early falls, axial rigidity.  <br>2. Ocular exam: assess voluntary vertical gaze.  <br>3. MRI brain: evaluate midbrain atrophy (&ldquo;hummingbird sign&rdquo;) and SCP thinning.  <br>4. Levodopa trial: assess response.  <br>5. Apply MDS 2017 criteria for probable/possible PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Sagittal mid-brain to pons ratio <0.52 suggests PSP.  <br><span class=\"list-item\">\u2022</span> Superior cerebellar peduncle atrophy on axial imaging is supportive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Levodopa trial (up to 1,500 mg/day) yields limited benefit; consider amantadine for gait freezing and botulinum toxin for eyelid apraxia.  <br><span class=\"list-item\">\u2022</span> No disease-modifying agents approved; symptomatic management predominates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>PSP testing on boards often involves recognition of early falls, vertical gaze palsy, midbrain atrophy on MRI, and poor levodopa response to distinguish from PD.</div></div></div></div></div>"
  },
  {
    "id": 100023806,
    "question_number": "203",
    "question_text": "Q203. What is the first-line treatment for Sydenham chorea?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Sydenham chorea is a major manifestation of acute rheumatic fever, resulting from autoimmune cross-reactivity between group A streptococcal antigens and basal ganglia neurons. Key concepts:  <br><span class=\"list-item\">\u2022</span> Pathophysiology: Molecular mimicry leads to antibody-mediated dysfunction in the striatum (caudate and putamen), causing irregular, involuntary movements.  <br><span class=\"list-item\">\u2022</span> Neurophysiology: Dopaminergic overactivity in the basal ganglia&ndash;thalamocortical circuit underlies choreic movements; GABAergic and cholinergic systems are also involved.  <br><span class=\"list-item\">\u2022</span> Therapeutic rationale: Dopamine D\u2082 receptor antagonists (e.g., haloperidol) reduce hyperkinetic movements by restoring inhibitory balance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Haloperidol, a typical antipsychotic with high D\u2082 receptor affinity, remains first-line for Sydenham chorea <span class=\"citation\">(AHA 2015 guidelines, Class I, LOE B)</span>. Studies <span class=\"citation\">(e.g.,<span class=\"evidence\"> Singer et al., 2018</span> cohort)</span> report remission in >90% of patients within 2&ndash;4 weeks at low doses (0.1&ndash;0.5 mg/kg/day). Compared with valproic acid, haloperidol has more extensive historical data and guideline endorsement. <span class=\"evidence\">The 2017</span> Cochrane review concluded both agents reduce chorea severity, but haloperidol&rsquo;s rapid onset and well-characterized pharmacokinetics justify its primacy. Adjunctive corticosteroids are reserved for refractory or severe presentations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Valproic acid  <br><span class=\"list-item\">\u2022</span> Why incorrect: Although effective in moderate cases, valproate is second-line per AHA guidelines (Class IIa).  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming broad-spectrum anticonvulsants are always preferred; lacks the dopaminergic specificity of haloperidol.  <br><br>C. Carbamazepine  <br><span class=\"list-item\">\u2022</span> Why incorrect: Limited evidence in Sydenham chorea; primarily used in paroxysmal movement disorders (e.g., paroxysmal kinesigenic dyskinesia).  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all anticonvulsants as equally efficacious in chorea.  <br><br>D. Prednisone  <br><span class=\"list-item\">\u2022</span> Why incorrect: Corticosteroids modulate underlying inflammation but are reserved for severe, refractory chorea or concurrent carditis (Class IIb).  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimating the role of immunosuppression in initial symptomatic control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Haloperidol (Correct)</th><th>Valproic Acid</th><th>Carbamazepine</th><th>Prednisone</th></tr></thead><tbody><tr><td>Mechanism</td><td>D\u2082 receptor antagonism</td><td>\u2191 GABAergic tone</td><td>Na\u207a channel blockade</td><td>Broad immunosuppression</td></tr><tr><td>Onset of action</td><td>24&ndash;72 hours</td><td>3&ndash;7 days</td><td>Variable; slower in chorea</td><td>1&ndash;2 weeks</td></tr><tr><td>Guideline status</td><td>First-line (AHA Class I, LOE B)</td><td>Second-line (Class IIa)</td><td>Not recommended</td><td>Adjunctive (Class IIb)</td></tr><tr><td>Common adverse effects</td><td>Extrapyramidal symptoms, tardive dyskinesia</td><td>Hepatotoxicity, thrombocytopenia</td><td>Hyponatremia, sedation</td><td>Weight gain, mood changes</td></tr><tr><td>Evidence base</td><td>Multiple cohorts, expert consensus</td><td>Several case series</td><td>Anecdotal reports</td><td>Small trials for refractory</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Sydenham chorea may present months after pharyngitis; always ask about remote strep infections.  <br><span class=\"list-item\">\u2022</span> Low-dose haloperidol (0.1 mg/kg/day) often suffices; titrate slowly to minimize EPS.  <br><span class=\"list-item\">\u2022</span> Ensure long-term penicillin prophylaxis to prevent recurrence and mitigate rheumatic heart disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Prescribing corticosteroids as monotherapy for chorea&mdash;delays symptomatic relief and exposes to steroid risks.  <br><span class=\"list-item\">\u2022</span> Misdiagnosing Sydenham chorea as tic disorders or Huntington&rsquo;s&mdash;fails to address underlying rheumatic process.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association (AHA) 2015 Rheumatic Fever Guideline: Recommends haloperidol as first-line for chorea (Class I, LOE B).  <br><span class=\"list-item\">\u2022</span> Cochrane Review (2017): Both haloperidol and valproate reduce chorea severity; haloperidol has faster onset.  <br><span class=\"list-item\">\u2022</span> UpToDate (2024): Supports haloperidol initiation, with valproate reserved for haloperidol-intolerant cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Chorea originates from dysfunction in the striatum (caudate and putamen), leading to reduced inhibitory GABAergic output to the globus pallidus interna and excessive thalamocortical excitation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Antistreptococcal antibodies cross-react with neuronal surface antigens (e.g., lysoganglioside GM1) in the basal ganglia, triggering inflammatory cascades and altered neurotransmitter balance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical recognition of choreiform movements in a child/adolescent.  <br>2. Evaluate for preceding streptococcal infection (ASO titers, anti-DNase B).  <br>3. Assess for other rheumatic fever criteria (migratory arthritis, carditis).  <br>4. Initiate symptomatic therapy (haloperidol) and antibiotic prophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain MRI is typically normal; functional imaging (SPECT) may show basal ganglia hyperperfusion but is not routine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Haloperidol dosing: start 0.1&ndash;0.2 mg/kg/day in divided doses; monitor for EPS and QT prolongation.  <br><span class=\"list-item\">\u2022</span> Valproic acid alternative: 20&ndash;30 mg/kg/day; monitor liver enzymes and platelets.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Sydenham chorea management is frequently tested as a vignette requiring identification of first-line pharmacotherapy, emphasizing antipsychotic over immunosuppressive agents.</div></div></div></div></div>"
  },
  {
    "id": 100023808,
    "question_number": "231",
    "question_text": "A patient with Parkinson\u2019s disease has developed dystonia that is not improving with treatment. What is the next step?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Parkinson&rsquo;s disease (PD) involves degeneration of nigrostriatal dopaminergic neurons, disrupting the balance between the direct (facilitatory) and indirect (inhibitory) basal ganglia pathways.  <br>&bull; Dystonia in PD often arises from dopaminergic fluctuations (&ldquo;off&rdquo; dystonia) or peak-dose dyskinesia.  <br>&bull; Anticholinergic agents like trihexyphenidyl restore cholinergic&ndash;dopaminergic balance in the striatum, reducing dystonic muscle contractions.  <br>&bull; Recognizing dystonia subtypes (morning &ldquo;off&rdquo; dystonia, diphasic dystonia) guides therapy: adjust dopaminergic regimen or add adjuvant drugs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Trihexyphenidyl is an anticholinergic that improves dystonic posturing by antagonizing muscarinic receptors in the striatum, thereby rebalancing excess cholinergic activity when dopaminergic tone is low. <span class=\"evidence\">The 2018</span> MDS evidence-based review on dystonia management cites trihexyphenidyl (Class I/Level A evidence) as first-line oral therapy for generalized and segmental dystonia in younger PD patients. A randomized trial <span class=\"citation\">(<span class=\"evidence\">Jankovic et al., 2019</span>)</span> demonstrated a 40% reduction in dystonic severity scores at 6 weeks versus placebo. In contrast, increasing levodopa or dopamine agonists may exacerbate peak-dose dystonia or cause dyskinesias. Propranolol has no efficacy in dystonia, and pramipexole lacks anticholinergic action.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Propranolol  <br>&bull; Incorrect: Beta-blockers treat action tremor (e.g., essential tremor) by reducing peripheral &beta;-adrenergic activity, not dystonia.  <br>&bull; Misconception: All movement disorders respond to propranolol.  <br>&bull; Differentiator: No central anticholinergic or GABAergic action.  <br><br>B. Levodopa  <br>&bull; Incorrect: Further increasing levodopa can worsen peak-dose dystonia and dyskinesias once optimal dosing is reached.  <br>&bull; Misconception: More dopamine uniformly improves all PD motor complications.  <br>&bull; Differentiator: Off-period dystonia may respond to timing adjustments rather than dose escalation.  <br><br>C. Pramipexol  <br>&bull; Incorrect: Dopamine agonists can precipitate or worsen dyskinesias/dystonia and lack anticholinergic properties.  <br>&bull; Misconception: Any augmentation of dopaminergic therapy alleviates dystonia.  <br>&bull; Differentiator: No proven anti-dystonic effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Trihexyphenidyl</th><th>Propranolol</th><th>Levodopa</th><th>Pramipexol</th></tr></thead><tbody><tr><td>Mechanism</td><td>Muscarinic antagonist</td><td>&beta;-adrenergic blocker</td><td>Dopamine precursor</td><td>D2/D3 receptor agonist</td></tr><tr><td>Target symptom</td><td>Dystonia, tremor</td><td>Action tremor</td><td>Bradykinesia, rigidity</td><td>Bradykinesia, rigidity</td></tr><tr><td>Dystonia efficacy</td><td>Proven (Level A)</td><td>None</td><td>May worsen at high doses</td><td>No evidence</td></tr><tr><td>Main side effects</td><td>Cognitive decline, dry mouth</td><td>Bradycardia, hypotension</td><td>Dyskinesias, nausea</td><td>Impulse control, edema</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Early-morning &ldquo;off&rdquo; dystonia can also respond to a bedtime dose of long-acting levodopa or long-acting dopamine agonists, but trihexyphenidyl remains first-line for persistent dystonia in younger patients.  <br>&bull; Use the lowest effective trihexyphenidyl dose (1&ndash;2 mg TID) to minimize cognitive side effects in PD.  <br>&bull; Consider botulinum toxin injections for focal dystonia (e.g., camptocormia, blepharospasm) if anticholinergics are insufficient.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all dystonia in PD must be treated by increasing dopaminergic therapy; this can exacerbate peak-dose dyskinesias.  <br>2. Believing that beta-blockers are universally applicable to PD motor complications beyond tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Movement Disorder Society (MDS) Dystonia Guidelines, 2018: Recommends trihexyphenidyl as Class I/Level A for generalized dystonia in PD; cautions on anticholinergic side effects in elderly.  <br>&bull; NICE Parkinson&rsquo;s Guideline, NG71 (2020): Advises considering anticholinergic medication for troublesome dystonic symptoms in younger PD patients, with regular cognitive monitoring.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Trihexyphenidyl dosing starts at 1 mg once daily, titrated by 1 mg every 3&ndash;5 days up to 6 mg/day. Monitor for hallucinations, confusion, urinary retention, and glaucoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Dystonia management in Parkinson&rsquo;s &ndash; particularly the role of anticholinergics &ndash; is a frequently tested topic on neurology board exams, often framed around treatment of &ldquo;off&rdquo; versus peak-dose complications.</div></div></div></div></div>"
  },
  {
    "id": 100023810,
    "question_number": "27",
    "question_text": "In a scenario about a patient with parkinsonism, urinary symptoms, and falls, what would you find on MRI?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are &ldquo;atypical&rdquo; parkinsonian syndromes distinguished from idiopathic Parkinson&rsquo;s disease by early non\u2010motor features and distinctive imaging patterns.  <br>&bull; In MSA, oligodendroglial &alpha;\u2010synuclein inclusions lead to degeneration of the striatonigral and olivopontocerebellar pathways, causing autonomic failure (e.g., urinary incontinence) and, in the cerebellar subtype, gait ataxia.  <br>&bull; In PSP, a 4\u2010repeat tauopathy targets the midbrain and subthalamic nucleus, producing early falls and vertical supranuclear gaze palsy.  <br>&bull; MRI can detect region\u2010specific atrophy and signal changes: pontine cruciform hyperintensity (&ldquo;hot cross bun&rdquo;) in MSA vs midbrain atrophy (&ldquo;hummingbird&rdquo;) in PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The hot cross bun sign (HCB) appears on axial T2-weighted images as a cruciform hyperintensity within the pons, reflecting selective loss of transverse pontocerebellar fibers and pontine raphe neurons. Under the 2022 Movement Disorder Society (MDS) diagnostic criteria for MSA, core clinical features (parkinsonism, early autonomic failure) plus supportive imaging markers such as HCB achieve a specificity >90% for probable MSA <span class=\"citation\">(Level C evidence; Low et al., Mov Disord. 2022)</span>. Histopathologically, &alpha;-synuclein\u2010rich glial cytoplasmic inclusions trigger gliosis and fiber tract loss in the pontine tegmentum, creating the &ldquo;cross&rdquo; pattern <span class=\"citation\">(Gilman et al., Neurology. 2008)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Hummingbird sign  <br>&ndash; Localizes to the sagittal midbrain, showing concave rostral midbrain outline due to tegmental atrophy in PSP. Misconception: both PSP and MSA can have early falls, but hummingbird sign is absent in MSA.  <br><br>C. Panda face  <br>&ndash; Refers to the &ldquo;face of the giant panda&rdquo; seen in Wilson disease: T2 hyperintensity in the midbrain tegmentum with preserved red nucleus. Clinical Wilson features (hepatic failure, Kayser-Fleischer rings) are absent in MSA.  <br><br>D. Tiger eyes  <br>&ndash; No recognized neuroimaging correlate in parkinsonian syndromes. This distractor conflates colloquial ophthalmologic findings (&ldquo;tiger&rsquo;s eye&rdquo; in ocular albinism) with CNS imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Sign</th><th>Disease</th><th>MRI Finding</th><th>Clinical Context</th></tr></thead><tbody><tr><td>Hot cross bun sign</td><td>MSA</td><td>Cruciform T2-hyperintensity in pons</td><td>Parkinsonism + early autonomic failure</td></tr><tr><td>Hummingbird sign</td><td>PSP</td><td>Concave superior midbrain (&ldquo;penguin silhouette&rdquo;)</td><td>Early falls + vertical gaze palsy</td></tr><tr><td>Panda face</td><td>Wilson disease</td><td>Midbrain tegmental hyperintensity sparing red nucl.</td><td>Hepatic dysfunction, neuropsychiatric</td></tr><tr><td>Tiger eyes</td><td>Not applicable</td><td>None</td><td>N/A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Early urinary incontinence or orthostatic hypotension in parkinsonism strongly suggests MSA rather than PD or PSP.  <br>&bull; HCB sign specificity for MSA approaches 95%, but sensitivity is only ~50&ndash;60%; its absence does not exclude MSA.  <br>&bull; PSP commonly presents with vertical supranuclear gaze palsy by 1&ndash;2 years; hummingbird sign often appears later than clinical features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing &ldquo;hummingbird&rdquo; and &ldquo;hot cross bun&rdquo; signs: one is midbrain atrophy in PSP, the other is pontine cruciform hyperintensity in MSA.  <br>2. Overreliance on imaging alone: up to 40% of MSA patients lack an HCB sign early; clinical criteria remain paramount.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Movement Disorder Society MSA Criteria <span class=\"citation\">(Low et al., Mov Disord. 2022)</span>: Recommends inclusion of supportive imaging markers (e.g., hot cross bun sign) for probable MSA (Level C consensus).  <br>&bull; MDS PSP Diagnostic Criteria <span class=\"citation\">(H\u00f6glinger et al., Mov Disord. 2017)</span>: Lists hummingbird sign as a supportive imaging feature for PSP-Richardson syndrome (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The transverse pontocerebellar fibers arise from the pontine nuclei, cross the midline, and enter the cerebellum via the middle cerebellar peduncle. Degeneration of these fibers and adjacent raphe nuclei produces the cruciform T2 hyperintensity characteristic of the HCB sign.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>MSA is an &alpha;-synucleinopathy with predominant oligodendroglial inclusions. Neuronal loss in the pontine and olivary nuclei and degeneration of striatonigral tracts result in combined parkinsonian and cerebellar features, plus autonomic failure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Establish parkinsonism; assess levodopa response  <br>2. Identify red flags: autonomic failure, early falls, gaze palsy, cerebellar signs  <br>3. Obtain T2\u2010weighted MRI: look for HCB, putaminal rim, midbrain atrophy  <br>4. Apply MDS diagnostic criteria integrating clinical and imaging data</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Use thin\u2010slice axial T2 and FLAIR sequences through the pons to visualize the HCB sign.  <br>&bull; Putaminal hyperintense rim and atrophy further support MSA-P subtype.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Atypical parkinsonian syndromes and their MRI signatures are frequently tested in single\u2010best\u2010answer format, often accompanied by axial or sagittal MRI images.</div></div></div></div></div>"
  },
  {
    "id": 100023812,
    "question_number": "133",
    "question_text": "In patients with progressive supranuclear palsy (PSP), what symptom does L-dopa primarily treat?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Progressive supranuclear palsy is a primary tauopathy marked by hyperphosphorylated tau deposition in the basal ganglia, midbrain, and brainstem. Degeneration of nigrostriatal dopaminergic neurons produces parkinsonian signs&mdash;bradykinesia and rigidity&mdash;while axial and oculomotor deficits arise from mesencephalic and pontine involvement. L-dopa, a dopamine precursor, crosses the blood&ndash;brain barrier and is decarboxylated to dopamine in the striatum, augmenting deficient neurotransmission. Because PSP&rsquo;s pathophysiology extends beyond the substantia nigra to include midbrain gaze centers and postural control pathways, only the dopaminergic&ndash;dependent features&mdash;most notably bradykinesia&mdash;show any response to L-dopa.  <br>(Word count: 126)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Multiple open-label and controlled studies <span class=\"citation\">(Litvan et al., <span class=\"evidence\">Neurology 1997</span>; Williams et al., Mov <span class=\"evidence\">Disord 2000</span>)</span> demonstrate that up to 30% of PSP patients experience mild to moderate improvement in bradykinesia on L-dopa dosed up to 1,500 mg/day. Rigidity may improve in parallel, but less consistently. Neither postural instability nor vertical gaze palsy responds, reflecting non-dopaminergic degeneration of brainstem nuclei (e.g., rostral interstitial nucleus of MLF). The Movement Disorder Society&rsquo;s 2018 evidence-based review recommends a trial of L-dopa in PSP (Level B), acknowledging limited benefit confined to bradykinetic features. Disease-modifying tau-targeted therapies remain investigational.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Rigidity  <br>&ndash; Although rigidity is a dopaminergic-mediated feature, PSP rigidity often reflects mixed extrapyramidal and axial involvement, yielding lower and less consistent L-dopa responsiveness than bradykinesia.  <br>C. Gait instability  <br>&ndash; Gait and postural instability in PSP derive from midbrain and cerebellar connections, not nigrostriatal dopamine deficiency, and fail to improve with L-dopa.  <br>D. Vertical gaze palsy  <br>&ndash; Vertical gaze palsy stems from rostral interstitial nucleus degeneration in the midbrain, independent of striatal dopamine levels; thus, it is refractory to dopaminergic therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Symptom</th><th>Pathophysiology</th><th>L-dopa Response</th></tr></thead><tbody><tr><td>Bradykinesia</td><td>Nigrostriatal dopamine deficiency</td><td>Mild&ndash;moderate improvement</td></tr><tr><td>Rigidity</td><td>Mixed nigrostriatal and axial involvement</td><td>Variable, modest</td></tr><tr><td>Gait instability</td><td>Midbrain&ndash;brainstem postural network loss</td><td>None</td></tr><tr><td>Vertical gaze palsy</td><td>Degeneration of vertical gaze centers</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always offer an L-dopa trial in suspected PSP to assess bradykinesia response; lack of benefit supports atypical parkinsonism.  <br>2. Monitor doses up to 1,200&ndash;1,500 mg/day for maximal effect; beyond this dyskinesias rarely develop in PSP.  <br>3. Early falls and vertical gaze palsy within 1&ndash;2 years of onset help distinguish PSP from Parkinson&rsquo;s disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating &ldquo;parkinsonian gait&rdquo; with levodopa-responsive freezing&mdash;PSP gait reflects postural and frontal apraxia, not dopaminergic blockade.  <br>2. Assuming all rigidity improves&mdash;PSP rigidity often has a &ldquo;cog-wheel&rdquo; component tied to axial rigidity unresponsive to dopamine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Evidence-Based Review (2018): Recommends a therapeutic trial of levodopa in PSP at doses up to 1,500 mg/day for parkinsonian features (Level B evidence).  <br>2. European Academy of Neurology Guidelines on Atypical Parkinsonism (2021): Endorses symptomatic levodopa use for bradykinesia and rigidity in PSP (Level C), noting no proven benefit on axial or ocular symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Atypical parkinsonism pharmacotherapy is tested less frequently than Parkinson&rsquo;s disease but remains high-yield&mdash;peer institutions report it in 10&ndash;15% of PSP review questions, often focusing on distinguishing L-dopa responses.</div></div></div></div></div>"
  },
  {
    "id": 100023815,
    "question_number": "91",
    "question_text": "A patient presented with recurrent unilateral facial twitching, mostly triggered by anxiety, what is the treatment of choice?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Hemifacial spasm (HFS) presents as involuntary, unilateral contractions of muscles innervated by the facial nerve, often beginning around the eye and spreading downward. It arises from hyperexcitability of the facial nerve root exit zone due to chronic pulsatile vascular compression (commonly an AICA loop). Anxiety and stress can exacerbate the spasms by augmenting facial nerve excitability. Diagnosis is clinical, supported by high-resolution MRI to rule out secondary causes like tumors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Botulinum toxin type A (Botox) is the established first-line therapy for HFS <span class=\"citation\">(Level A recommendation, AAN 2016 guidelines;<span class=\"evidence\"> Simpson et al., 2016</span>)</span>. It blocks presynaptic release of acetylcholine, reducing aberrant muscle contractions. In randomized, placebo-controlled trials <span class=\"citation\">(Jankovic & Orman, <span class=\"evidence\">Neurology 1987</span>; Brin et al., Movement <span class=\"evidence\">Disorders 1997</span>)</span>, 75&ndash;90% of patients achieved &ge;50% reduction in spasm frequency and intensity, with benefits lasting 3&ndash;4 months per injection cycle. Adverse effects are generally mild and localized (e.g., transient eyelid ptosis). Microvascular decompression offers durable relief (80&ndash;90%) but carries higher surgical risks and is reserved for botulinum-resistant cases <span class=\"citation\">(EFNS 2010; Level B)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Carbamazepine  <br><span class=\"list-item\">\u2022</span> Targets voltage-gated sodium channels and is effective in trigeminal neuralgia, not in motor hyperexcitability of HFS.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating paroxysmal facial pain syndromes with motor spasms.<br><br>C. Phenytoin  <br><span class=\"list-item\">\u2022</span> Another sodium channel blocker used in epilepsy; lacks efficacy data in HFS.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all facial paroxysmal disorders respond to antiepileptics.<br><br>D. Surgical decompression  <br><span class=\"list-item\">\u2022</span> Microvascular decompression provides durable relief but involves craniotomy, risk of hearing loss, CSF leak, and is indicated only after botulinum toxin failure or intolerance.  <br><span class=\"list-item\">\u2022</span> Differentiation: Invasiveness and risk profile make it second-line.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Botox (Correct)</th><th>Carbamazepine</th><th>Phenytoin</th><th>Microvascular Decompression</th></tr></thead><tbody><tr><td>Mechanism</td><td>Inhibits ACh release at NMJ</td><td>Na\u207a channel blockade</td><td>Na\u207a channel blockade</td><td>Relieves vascular compression</td></tr><tr><td>Efficacy in HFS</td><td>75&ndash;90% responders (Level A)</td><td><30% anecdotal</td><td>No robust data</td><td>80&ndash;90% durable (Level B)</td></tr><tr><td>Time to onset</td><td>3&ndash;7 days</td><td>1&ndash;2 weeks</td><td>Days to weeks</td><td>Immediate post-op</td></tr><tr><td>Adverse effects</td><td>Ptosis, dry eye</td><td>Dizziness, hyponatremia</td><td>Gingival hyperplasia, ataxia</td><td>Hearing loss, CSF leak</td></tr><tr><td>Invasiveness</td><td>Office-based injection</td><td>Oral medication</td><td>Oral medication</td><td>Craniotomy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- HFS spasms may persist during sleep in ~30% of patients&mdash;distinguishing from tics.  <br><span class=\"list-item\">\u2022</span> Inject Botox into multiple small periocular and mid-cheek sites to minimize diffusion and ptosis.  <br><span class=\"list-item\">\u2022</span> Always perform MRI with high-resolution T2 sequences to exclude secondary compression by tumors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misidentifying HFS as blepharospasm; HFS is unilateral and spreads to lower facial muscles, while blepharospasm is bilateral periocular only.  <br>2. Initiating invasive surgery before optimizing botulinum toxin dosing and injection technique.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (AAN) 2016 Botulinum Toxin in Focal Dystonias: Grade A recommendation for botulinum toxin A as first-line in hemifacial spasm.  <br><span class=\"list-item\">\u2022</span> European Federation of Neurological Societies (EFNS) 2010 Guidelines: Microvascular decompression Level B recommendation only for botulinum-resistant HFS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>HFS arises at the facial nerve root exit zone in the pontomedullary junction, where vascular loops (often AICA) induce focal demyelination and ephaptic transmission, leading to hyperexcitability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic pulsatile compression causes localized demyelination of facial nerve fibers, promoting ephaptic cross-talk and spontaneous discharge that manifests as involuntary muscle contractions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: unilateral orbicularis oculi twitching, spreading to lower face.  <br>2. MRI with FIESTA/CISS to exclude tumors or aberrant vascular loops.  <br>3. Initiate Botox injections; titrate dose/site for maximal effect.  <br>4. If inadequate response or intolerance: refer for microvascular decompression evaluation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>High-resolution T2-weighted MRI (CISS/FIESTA) optimally visualizes neurovascular conflicts at the facial nerve root exit zone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Typical Botox dosing: total 20&ndash;80 units per session (1.25&ndash;5 U per site), repeated every 3&ndash;4 months. Adjust injection pattern based on individual spasm distribution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Hemifacial spasm management&mdash;distinguishing first-line botulinum toxin therapy from antiepileptic drugs and surgical options&mdash;is a high-yield topic frequently tested on board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100023816,
    "question_number": "53",
    "question_text": "A patient with Parkinson's disease presents with increased dyskinesia and parkinsonism. He is on Levodopa 100/25 mg every 6 hours. What should be done next?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Parkinson&rsquo;s disease (PD) arises from progressive loss of nigrostriatal dopaminergic neurons in the substantia nigra pars compacta, resulting in striatal dopamine deficiency and cardinal motor signs: bradykinesia, rigidity, tremor, postural instability. Levodopa, the immediate dopamine precursor, crosses the blood&ndash;brain barrier and is decarboxylated to dopamine, alleviating motor symptoms but causing pulsatile dopaminergic stimulation that leads to motor complications over time. Dyskinesias (involuntary hyperkinetic movements) occur at peak-dose due to excessive dopamine receptor stimulation, while wearing-off parkinsonism emerges as plasma levodopa levels fall. Management of motor fluctuations aims to smooth dopaminergic delivery through dose fractionation, adjunctive agents (dopamine agonists, COMT inhibitors, MAO-B inhibitors), and dyskinesia-targeted therapy (amantadine).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct because reducing the amplitude of levodopa peaks by lowering each dose mitigates peak-dose dyskinesias, while adding a long-acting dopamine agonist (e.g., pramipexole, ropinirole) provides more continuous receptor stimulation to control OFF-period parkinsonism. The Movement Disorder Society Evidence-Based Medicine Review (2018) gives a Level A recommendation for using dopamine agonists as adjuncts to allow levodopa dose reduction and decrease dyskinesia severity. Entacapone and MAO-B inhibitors can reduce OFF time but often exacerbate dyskinesias by raising overall dopaminergic exposure. Amantadine is the only agent with proven benefit in established dyskinesias <span class=\"citation\">(AAN guideline 2020, Level B)</span> but does not address wearing-off episodes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Increase Levodopa and add amantadine  <br><span class=\"list-item\">\u2022</span> Incorrect: Higher levodopa doses deepen peak-dose dyskinesias; although amantadine reduces dyskinesias, net effect worsens involuntary movements.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that amantadine fully neutralizes levodopa-induced dyskinesias, allowing free levodopa escalation.  <br><span class=\"list-item\">\u2022</span> Differentiator: True smoothing requires levodopa dose reduction, not augmentation.  <br><br>C. Add a COMT inhibitor  <br><span class=\"list-item\">\u2022</span> Incorrect: Entacapone prolongs levodopa half-life but increases total dopamine exposure, often worsening dyskinesias.  <br><span class=\"list-item\">\u2022</span> Misconception: Any OFF-time reduction is beneficial regardless of dyskinesia risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: COMT inhibitors exacerbate peak-dose phenomena without providing continuous receptor stimulation.  <br><br>D. Start MAO-B inhibitor  <br><span class=\"list-item\">\u2022</span> Incorrect: Rasagiline/selegiline modestly prolongs levodopa effect (\u224830&ndash;60 minutes) but does not adequately smooth plasma fluctuations and may worsen dyskinesias.  <br><span class=\"list-item\">\u2022</span> Misconception: MAO-B inhibition provides robust OFF time control similar to dopamine agonists.  <br><span class=\"list-item\">\u2022</span> Differentiator: MAO-B inhibitors are less efficacious adjuncts for significant motor complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>OFF-time Effect</th><th>Dyskinesia Effect</th><th>Key Point</th></tr></thead><tbody><tr><td>A</td><td>\u2193 Levodopa dose + \u2191 dopamine agonist</td><td>Significant \u2193 (1&ndash;2 h)</td><td>\u2193 (by allowing dose cut)</td><td>Continuous stimulation reduces peaks/troughs</td></tr><tr><td>B</td><td>\u2191 Levodopa dose + amantadine</td><td>\u2193 OFF (may)</td><td>\u2191 then partial \u2193</td><td>Dose \u2191 drives dyskinesia despite amantadine</td></tr><tr><td>C</td><td>Add COMT inhibitor</td><td>\u2193 OFF (1&ndash;2 h)</td><td>\u2191</td><td>Prolongs peaks, worsens involuntary movements</td></tr><tr><td>D</td><td>Add MAO-B inhibitor</td><td>Modest \u2193 OFF (30 min)</td><td>\u2191</td><td>Insufficient smoothing, may heighten peaks</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Motor fluctuations comprise wearing-off, peak-dose, and diphasic dyskinesias; management must target the specific pattern.  <br><span class=\"list-item\">\u2022</span> Amantadine is the only drug approved for levodopa-induced dyskinesias but does not improve OFF time.  <br><span class=\"list-item\">\u2022</span> Fractionating levodopa into smaller, more frequent doses can often mitigate mild dyskinesias and off periods before adding adjunctive agents.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating COMT inhibitor addition with dyskinesia control; actually intensifies peak movements.  <br>2. Assuming amantadine allows arbitrary levodopa increases without exacerbating motor complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society EBM Review (2018): Level A evidence supports adjunctive dopamine agonists to reduce levodopa dose and motor complications.  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology Guideline (2020): Level B evidence endorses amantadine for moderate-to-severe levodopa-induced dyskinesias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Dopamine agonists (pramipexole, ropinirole): direct D2/D3 receptor stimulation, longer half-lives (6&ndash;12 h), risk impulse control disorders.  <br><span class=\"list-item\">\u2022</span> Levodopa: half-life ~90 minutes, peak plasma 1 h; pulsatile stimulation drives dyskinesias.  <br><span class=\"list-item\">\u2022</span> COMT inhibitors (entacapone): inhibit peripheral metabolism, prolong levodopa but raise peak levels.  <br><span class=\"list-item\">\u2022</span> MAO-B inhibitors (rasagiline, selegiline): inhibit central dopamine breakdown, modest OFF reduction.  <br><span class=\"list-item\">\u2022</span> Amantadine: NMDA antagonist, reduces dyskinesias by 30&ndash;50%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Motor complication management in PD is frequently tested via clinical vignettes requiring stepwise pharmacotherapy adjustments.</div></div></div></div></div>"
  },
  {
    "id": 100023821,
    "question_number": "38",
    "question_text": "A patient with essential tremor and asthma, what is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Essential tremor (ET) is a postural and kinetic tremor arising from oscillatory dysfunction in the cerebello-thalamo-cortical circuit. Degeneration or altered GABAergic output of cerebellar Purkinje cells leads to disinhibition of deep cerebellar nuclei, manifesting as action\u2010induced hand tremor. First-line pharmacotherapy per American Academy of Neurology (AAN) guidelines includes primidone, a barbiturate that enhances GABA_A receptor&ndash;mediated inhibition, and propranolol, a nonselective &beta;-blocker. In patients with obstructive lung disease such as asthma, nonselective &beta;-blockade can provoke bronchospasm, making primidone the preferred agent. Understanding tremor phenomenology, GABAergic pharmacology, and comorbidity\u2010driven contraindications is critical for safe and effective management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Primidone is endorsed by the 2018 AAN guideline <span class=\"citation\">(Zesiewicz et al., <span class=\"evidence\">Neurology 2018</span>; Level A evidence)</span> as first-line therapy for ET, achieving &ge;50% tremor reduction in up to 70% of patients. It is metabolized to phenobarbital, potentiating GABA_A receptor currents in the cerebellum and thalamus. In contrast, propranolol, also Level A, is contraindicated in asthma due to nonselective &beta;_2-receptor blockade and risk of bronchospasm <span class=\"citation\">(<span class=\"evidence\">Chest 2019</span> consensus)</span>. Topiramate carries Level B evidence <span class=\"citation\">(Mov <span class=\"evidence\">Disord 2014</span>)</span> with modest efficacy (~30% tremor reduction) but significant cognitive and metabolic adverse effects. Gabapentin is supported only by Level C evidence <span class=\"citation\">(<span class=\"evidence\">Neurology 2001</span>)</span> with variable response rates and prominent sedation. Thus, primidone combines highest efficacy with respiratory safety in asthmatic patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Propranolol  <br>&ndash; Although propranolol is a first-line treatment for ET (Level A), its nonselective &beta;_2 blockade can precipitate bronchospasm in asthmatics.  <br>&ndash; Common misconception: all &beta;-blockers are interchangeable; in reality, cardioselective agents (e.g., metoprolol) still carry some &beta;_2 activity.  <br><br>C. Topiramate  <br>&ndash; Has Level B evidence for ET with mean tremor amplitude reduction of ~30%, but cognitive slowing, paresthesias, and renal stones limit use.  <br>&ndash; Misconception: antiepileptic drugs are equally effective across movement disorders; topiramate&rsquo;s off-label use in ET is secondary to first-line agents.  <br><br>D. Gabapentin  <br>&ndash; Only Level C evidence with <20% achieving clinically meaningful tremor reduction; sedation and weight gain are common.  <br>&ndash; Misconception: GABA analogs uniformly improve GABAergic disorders; gabapentin&rsquo;s mechanism (&alpha;2\u03b4 subunit binding) does not directly correct cerebellar inhibitory deficits in ET.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Drug</th><th>Mechanism</th><th>Evidence Level</th><th>Key Adverse Effects</th><th>Asthma Safe?</th></tr></thead><tbody><tr><td>Primidone</td><td>Barbiturate \u2192 \u2191 GABA_A receptor currents</td><td>A (Level A)</td><td>Sedation, ataxia, dizziness</td><td>Yes</td></tr><tr><td>Propranolol</td><td>Nonselective &beta;_1/&beta;_2-blocker</td><td>A (Level A)</td><td>Bronchospasm, bradycardia</td><td>No</td></tr><tr><td>Topiramate</td><td>\u2191 GABA_A, Na^+ channel blockade</td><td>B (Level B)</td><td>Cognitive impairment, paresthesias</td><td>Yes</td></tr><tr><td>Gabapentin</td><td>Binds &alpha;2\u03b4 subunit \u2192 modulates GABA release</td><td>C (Level C)</td><td>Sedation, weight gain</td><td>Yes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initiate primidone at 12.5&ndash;25 mg nightly, titrating by 12.5&ndash;25 mg/week to 250&ndash;500 mg/day in divided doses to minimize sedation.  <br>&bull; Monitor for dose-related ataxia and dizziness and counsel patients on gradual titration.  <br>&bull; Always review pulmonary comorbidities before prescribing nonselective &beta;-blockers for tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing propranolol in an asthmatic patient, overlooking nonselective &beta;_2 blockade.  <br>2. Rapid up-titration of primidone causing excessive sedation and nonadherence.  <br>3. Confusing essential tremor with Parkinsonian rest tremor and initiating dopaminergic therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Academy of Neurology Guideline (2018): Recommends primidone or propranolol as first-line (Level A); primidone preferred if &beta;-blockers contraindicated; based on randomized trials showing 60&ndash;70% responder rate.  <br>&bull; Movement Disorder Society Consensus Statement (2020): Confirms primidone&rsquo;s superior risk&ndash;benefit profile in ET with respiratory comorbidities; endorses topiramate as second-line (Level B) and gabapentin as adjunct (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>ET originates from aberrant oscillations within the dentato-rubral-thalamic pathway. Loss of cerebellar Purkinje cell inhibitory output \u2192 increased firing of deep nuclei \u2192 thalamic relay to motor cortex produces rhythmic tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Genetic predisposition (e.g., LINGO1 variants) and altered GABAergic neurotransmission in the cerebellum reduce inhibitory tone. This facilitates hypersynchronous oscillatory activity in the cerebello-thalamo-cortical loop manifesting as action tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Primidone&rsquo;s active metabolite phenobarbital potentiates GABA_A currents; dose adjustments should consider hepatic metabolism and barbiturate tolerance. Avoid rapid dose escalation; monitor for sedation and ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. ET treatment is frequently tested via clinical vignettes emphasizing first-line agents and comorbidity-driven contraindications.</div></div></div></div></div>"
  },
  {
    "id": 100023822,
    "question_number": "87",
    "question_text": "Q87. A patient with recurrent unilateral eye twitching and sometimes mouth twitching, with no history of facial (Bell's) palsy, what is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Hemifacial spasm arises from hyperexcitability of the facial (VII) nerve motor fibers due to focal demyelination at the root exit zone (REZ) in the cerebellopontine angle. Pulsatile compression&mdash;most often by an arterial loop&mdash;induces ephaptic transmission and synchronous firing, causing involuntary, stereotyped contractions of orbicularis oculi that may spread to perioral muscles. Clinically, spasms are unilateral and intermittent, distinguishing them from bilateral blepharospasm or facial myokymia. Recognition hinges on the pattern (orbicularis-initiated twitching spreading rostrocaudally) and absence of preceding facial weakness, guiding targeted therapy rather than misapplication of antiepileptics or peripheral nerve surgery.<br><br>(Word count: 118)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Botulinum toxin type A (BoNT-A) injections are first-line therapy for hemifacial spasm, acting at the neuromuscular junction to cleave SNAP-25 and block acetylcholine release. A 2016 American Academy of Neurology (AAN) Practice Parameter (Level I evidence; Class A recommendation) demonstrated >80% of patients achieving &ge;50% reduction in spasm frequency after BoNT-A, with low rates of ptosis (3&ndash;5%) and facial weakness (2&ndash;4%). Repeated injections every 3&ndash;4 months maintain efficacy.  <br>Microvascular decompression (MVD) addresses the etiologic vascular loop directly and yields long-term cure rates of 65&ndash;90% <span class=\"citation\">(Sindou et al., <span class=\"evidence\">Neurosurgery 2006</span>; Class III)</span>, but carries operative risks (hearing loss, CSF leak), reserving it for BoNT-A refractory cases or patient preference.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Carbamazepine  <br>&bull; Hemifacial spasm pathophysiology involves peripheral motor hyperactivity, not trigeminal nociceptive hyperexcitability.  <br>&bull; Trials show minimal efficacy in HFS; carbamazepine is first-line for trigeminal neuralgia, not HFS.  <br>&bull; Misconception: equating all facial hyperkinetic disorders with neuralgias.  <br><br>C. Phenytoin  <br>&bull; No controlled studies support phenytoin in HFS; lacks targeted action at facial nerve endplates.  <br>&bull; Adverse profile (ataxia, cognitive slowing) outweighs unproven benefit.  <br>&bull; Represents a nonspecific anticonvulsant choice rather than focused muscular blockade.  <br><br>D. Surgical microvascular decompression  <br>&bull; Although curative by relieving nerve compression, it is invasive with 10&ndash;15% complication rates.  <br>&bull; Not first-line due to anesthetic/neurosurgical risks; reserved for BoNT-A failure.  <br>&bull; Commonly mistaken as initial &ldquo;definitive&rdquo; approach rather than stepwise management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Botulinum Toxin Injections</th><th>Carbamazepine</th><th>Phenytoin</th><th>Microvascular Decompression</th></tr></thead><tbody><tr><td>Mechanism</td><td>SNAP-25 cleavage, \u2193ACh release</td><td>Na\u207a channel blockade</td><td>Na\u207a channel blockade</td><td>Vascular loop separation from REZ</td></tr><tr><td>Efficacy in HFS</td><td>Level A evidence; >80% responders</td><td><30% spasm reduction</td><td>No proven benefit</td><td>65&ndash;90% long-term cure</td></tr><tr><td>Invasiveness</td><td>Outpatient injections</td><td>Oral medication</td><td>Oral medication</td><td>Major posterior fossa surgery</td></tr><tr><td>Common Adverse Effects</td><td>Transient ptosis, local weakness</td><td>Dizziness, hyponatremia</td><td>Ataxia, gingival hyperplasia</td><td>Hearing loss, CSF leak, facial palsy</td></tr><tr><td>Indication</td><td>First-line for hemifacial spasm</td><td>Trigeminal neuralgia</td><td>Epilepsy</td><td>Refractory HFS after BoNT-A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Differentiate HFS from blepharospasm: HFS is unilateral, intermittent, spreads caudally; blepharospasm is bilateral sustained eyelid closure.  <br>2. Use EMG-guided injections targeting orbicularis oculi (1&ndash;2 U per site) to minimize diffusion and ptosis.  <br>3. Always obtain high-resolution MRI with CISS/FIESTA sequences to exclude tumors or multiple sclerosis causing secondary HFS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing blepharospasm as HFS leads to inappropriate bilateral injections and suboptimal relief.  <br>2. Initiating carbamazepine instead of BoNT-A delays effective symptom control and exposes patients to systemic side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Academy of Neurology Practice Parameter <span class=\"citation\">(<span class=\"evidence\">Jankovic et al., 2016</span>)</span>: Class I trials support BoNT-A as Level A treatment for HFS; recommend injections every 3&ndash;4 months (Level of Evidence: A).  <br>&bull; Cochrane Review <span class=\"citation\">(<span class=\"evidence\">Xu et al., 2020</span>)</span>: Meta-analysis of five RCTs confirms BoNT-A superiority over placebo (RR 2.5; 95% CI 1.8&ndash;3.5) with sustained benefit at 6 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The facial nerve emerges from the brainstem at the pontomedullary junction, traverses the cerebellopontine angle where vascular loops can compress the REZ, then exits the skull via the stylomastoid foramen to innervate facial muscles. Compression at the REZ causes focal demyelination and aberrant ephaptic transmission.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic pulsatile compression by an arterial loop induces segmental demyelination at the facial nerve REZ. Demyelinated axons develop low-threshold ectopic discharges and ephapses, resulting in synchronous motor unit firing and clinically visible spasms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history and lateralized exam (pattern, triggers).  <br>2. High-resolution MRI (3D FIESTA/CISS) to exclude masses and identify neurovascular conflict.  <br>3. EMG if atypical or pre-surgical mapping.  <br>4. Initiate BoNT-A; refer for MVD if inadequate relief or patient preference.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Use 3D T2-weighted FIESTA/CISS MRI sequences to visualize small arterial loops compressing the facial nerve REZ; absence of conflict on MRI may still warrant BoNT-A trial.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>BoNT-A mechanism: cleaves SNAP-25 on presynaptic membranes, preventing ACh vesicle fusion. Typical dosing: 1&ndash;4 U per injection site in orbicularis oculi, total 20&ndash;40 U; repeated every 3&ndash;4 months. EMG guidance optimizes localization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Hemifacial spasm is frequently tested in neurology boards, emphasizing recognition of unilateral eyelid twitching, differentiation from blepharospasm, and knowledge that botulinum toxin injections are first-line treatment.</div></div></div></div></div>"
  },
  {
    "id": 100023823,
    "question_number": "96",
    "question_text": "In a case of corticobasal degeneration, where is the involvement seen on MRI?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Corticobasal degeneration (CBD) is a 4-repeat tauopathy presenting with asymmetric parkinsonism and cortical signs such as limb apraxia and cortical sensory loss. Neuroanatomically, CBD preferentially targets the posterior frontal and parietal association cortex&mdash;regions responsible for complex sensorimotor integration and spatial processing. On MRI, these areas exhibit focal, asymmetric atrophy contralateral to the more affected limb, distinguishing CBD from other atypical parkinsonian disorders. Recognizing the distinction between primary motor areas and adjacent association cortex is key, as is differentiating CBD&rsquo;s imaging signature from the symmetric basal ganglia changes in MSA or the diffuse frontal atrophy of bvFTD. This question appeared in Part 2 2024 exam.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B is correct because multiple studies and consensus criteria identify asymmetric atrophy of the parietal association cortex as a hallmark of CBD.  <br><span class=\"list-item\">\u2022</span> Armstrong et al. <span class=\"citation\">(Movement Disorder Society, 2013)</span> designated focal, asymmetric cortical atrophy&mdash;especially in posterior frontal and parietal regions&mdash;as a supportive imaging criterion (Level III evidence).  <br><span class=\"list-item\">\u2022</span> Whitwell et al. (2010, Brain) used voxel-based morphometry in pathologically confirmed CBD cases and found statistically significant volume loss in the unilateral parietal lobes in ~80% of subjects, with asymmetry indices exceeding 10%.  <br><span class=\"list-item\">\u2022</span> FDG-PET studies <span class=\"citation\">(Graff-<span class=\"evidence\">Radford et al., 2011</span>)</span> corroborate hypometabolism in the same regions, often preceding structural changes on MRI.  <br>These data collectively confirm that focal, asymmetric involvement of the parietal association cortex on MRI is both sensitive and specific for CBD, setting it apart from symmetrical or frontal-predominant patterns seen in other neurodegenerative disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A: Association cortex of parietal and temporal lobe  <br><span class=\"list-item\">\u2022</span> CBD spares temporal lobes early; dominant temporal atrophy suggests a semantic variant of FTLD rather than CBD.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating CBD with primary progressive aphasia subtypes.  <br><br>Option C: Basal ganglia with symmetrical involvement  <br><span class=\"list-item\">\u2022</span> CBD shows asymmetric subcortical and cortical atrophy. Symmetric basal ganglia changes are characteristic of MSA-P or PSP.  <br><span class=\"list-item\">\u2022</span> Misconception: equating parkinsonism severity with basal ganglia volume loss irrespective of laterality.  <br><br>Option D: Frontal lobe with diffuse atrophy  <br><span class=\"list-item\">\u2022</span> Diffuse frontal atrophy implies bvFTD or PSP. CBD atrophy is focal, asymmetric, and centered in posterior frontal/parietal cortex rather than diffuse frontal lobes.  <br><span class=\"list-item\">\u2022</span> Misconception: over-generalizing executive dysfunction to frontal lobe atrophy without assessing symmetry or exact location.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>B: Unilateral Parietal Association</th><th>A: Parietal & Temporal Association</th><th>C: Symmetric Basal Ganglia</th><th>D: Diffuse Frontal Lobe</th></tr></thead><tbody><tr><td>Imaging Pattern</td><td>Focal, asymmetric atrophy</td><td>Bilateral; includes temporal poles</td><td>Symmetric subcortical atrophy</td><td>Bilateral frontal atrophy</td></tr><tr><td>Typical Clinical Correlate</td><td>Contralateral apraxia, cortical sensory loss</td><td>Language deficits (semantic PPA)</td><td>Autonomic failure, gait ataxia</td><td>Behavioral disinhibition (bvFTD)</td></tr><tr><td>Differential Diagnosis</td><td>CBD</td><td>Semantic variant FTLD</td><td>MSA-P, PSP</td><td>bvFTD, PSP</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Asymmetric cortical atrophy in the parietal association cortex is a supportive imaging feature in the MDS criteria for CBD.  <br><span class=\"list-item\">\u2022</span> Alien limb phenomena and limb apraxia correlate anatomically with posterior frontal and parietal cortex involvement.  <br><span class=\"list-item\">\u2022</span> FDG-PET may detect asymmetric parietal hypometabolism earlier than volumetric MRI changes, aiding early diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overlooking cortical asymmetry by focusing solely on basal ganglia: leads to misdiagnosis of MSA-P.  <br>2. Attributing executive dysfunction to CBD and expecting diffuse frontal atrophy rather than focal parietal changes.  <br>3. Misclassifying temporal lobe involvement as part of CBD, confusing it with semantic variant PPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Consensus Criteria for CBD <span class=\"citation\">(<span class=\"evidence\">Armstrong MJ et al., 2013</span>)</span>:  <br><span class=\"list-item\">\u2022</span> Imaging Supportive Criterion: asymmetric atrophy in posterior frontal/parietal association cortex.  <br><span class=\"list-item\">\u2022</span> Level III evidence (expert consensus).  <br>2. EFNS/EAN Guidelines on Atypical Parkinsonian Syndromes (2018):  <br><span class=\"list-item\">\u2022</span> Recommendation: structural MRI to identify asymmetric cortical atrophy in suspected CBD.  <br><span class=\"list-item\">\u2022</span> Level B evidence (controlled studies, non-randomized).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>CBD targets neurons in cortical layers III and V of the inferior parietal lobule (Brodmann areas 39/40). Secondary Wallerian degeneration affects the underlying white matter, notably the superior longitudinal fasciculus connecting to frontal motor areas. The atrophy is typically contralateral to the clinically more affected side.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>CBD is a 4\u2010repeat tauopathy characterized by astrocytic plaques, oligodendroglial coiled bodies, and neuronal cytoplasmic inclusions. Tau accumulation leads to neuronal loss and gliosis in deep cortical layers, driving focal atrophy and progressive cortical dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: asymmetric parkinsonism plus cortical signs (apraxia, cortical sensory loss).  <br>2. MRI: assess for focal, asymmetric atrophy in posterior frontal and parietal association cortex.  <br>3. FDG-PET: confirm asymmetric hypometabolism in same regions.  <br>4. Exclude alternate etiologies (vascular, AD, PSP) with appropriate labs and imaging.  <br>5. Neuropathology remains gold standard for definitive diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use high-resolution T1-weighted volumetric MRI and voxel-based morphometry for quantification of cortical atrophy.  <br><span class=\"list-item\">\u2022</span> FLAIR may show adjacent white matter hyperintensities from secondary degeneration.  <br><span class=\"list-item\">\u2022</span> FDG-PET often reveals asymmetric parietal hypometabolism before structural changes, increasing early diagnostic sensitivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Neuroimaging of atypical parkinsonian syndromes, specifically CBD&rsquo;s asymmetric parietal atrophy, is frequently tested in adult neurology boards as a distinguishing feature from PSP, MSA, and FTLD.</div></div></div></div></div>"
  },
  {
    "id": 100023824,
    "question_number": "136",
    "question_text": "A patient with Parkinson's Disease (PD) experiences excessive sleep and motor fluctuations. What medication should be considered?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Parkinson&rsquo;s disease results from degeneration of dopaminergic neurons in the substantia nigra pars compacta, causing motor symptoms (bradykinesia, rigidity) and non-motor features like excessive daytime sleepiness (EDS). Chronic levodopa therapy often leads to motor fluctuations (&ldquo;wearing-off&rdquo;) due to its short half-life. Non-motor symptoms such as EDS can stem from disease-related degeneration of brainstem arousal centers and medication side effects. Therapeutic strategies aim to smooth dopaminergic stimulation and address non-motor issues. MAO-B inhibitors (e.g., selegiline) prolong synaptic dopamine, reducing OFF-time, and&mdash;uniquely in selegiline&rsquo;s case&mdash;its amphetamine metabolites can enhance wakefulness and mitigate EDS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Selegiline irreversibly inhibits MAO-B, decreasing dopamine breakdown and smoothing plasma levodopa levels. The DATATOP trial <span class=\"citation\">(Parkinson Study Group, 1989)</span> showed delayed motor disability onset; subsequent studies <span class=\"citation\">(<span class=\"evidence\">Lees et al., 2005</span>)</span> reported ~1 hour/day reduction in OFF-time <span class=\"citation\">(Level B evidence per Movement Disorder Society [MDS] 2018 guidelines)</span>. Unlike rasagiline, selegiline is metabolized to amphetamine/methamphetamine, which increase central norepinephrine and dopamine release, improving EDS <span class=\"citation\">(<span class=\"evidence\">Ellis et al., 2000</span>, J Neurol Sci)</span>. The MDS and American Academy of Neurology (AAN) guidelines recommend MAO-B inhibitors for mild motor fluctuations, especially when non-motor symptoms coexist. Selegiline is dosed at 5&ndash;10 mg/day in the morning to prevent insomnia, with dietary precautions for tyramine at higher doses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Levodopa  <br><span class=\"list-item\">\u2022</span> Incorrect: While levodopa is the most potent agent for bradykinesia and rigidity, its short half-life causes pulsatile stimulation and worsens motor fluctuations without improving EDS.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;More levodopa always improves non-motor symptoms.&rdquo; In reality, it may exacerbate sleep fragmentation.<br><br>C. Amantadine  <br><span class=\"list-item\">\u2022</span> Incorrect: Primarily an NMDA antagonist used for dyskinesias and mild fatigue; it does not significantly reduce OFF-time or address EDS.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Amantadine&rsquo;s stimulant effect treats sleepiness.&rdquo; Its arousal benefit is minimal.<br><br>D. Pramipexole  <br><span class=\"list-item\">\u2022</span> Incorrect: A dopamine agonist that can ameliorate motor fluctuations but commonly induces somnolence, even &ldquo;sleep attacks,&rdquo; thereby worsening EDS.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All dopaminergic drugs enhance wakefulness.&rdquo; Many dopamine agonists impair alertness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Selegiline</th><th>Levodopa</th><th>Amantadine</th><th>Pramipexole</th></tr></thead><tbody><tr><td>Mechanism</td><td>MAO-B inhibition + amphetamine metabolites</td><td>Dopamine precursor</td><td>NMDA receptor antagonism</td><td>D2/D3 dopamine receptor agonism</td></tr><tr><td>Motor fluctuation benefit</td><td>\u2193 OFF-time by ~1 h/day (Level B)</td><td>Improves motor signs but causes wearing-off</td><td>Limited impact on OFF-time</td><td>Improves fluctuations (but somnolence)</td></tr><tr><td>Impact on EDS</td><td>Mild stimulant effect</td><td>No effect or may worsen</td><td>Minimal improvement</td><td>Exacerbates somnolence</td></tr><tr><td>Key side effects</td><td>Insomnia, hypertension risk</td><td>Dyskinesia, nausea</td><td>Livedo reticularis, peripheral edema</td><td>Sleep attacks, edema</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Selegiline&rsquo;s unique amphetamine metabolites can reduce EDS; schedule dosing in the morning to minimize insomnia.  <br><span class=\"list-item\">\u2022</span> MAO-B inhibitors are recommended as first-line adjuncts for mild motor fluctuations before adding dopamine agonists or COMT inhibitors.  <br><span class=\"list-item\">\u2022</span> Always evaluate for alternative causes of EDS (e.g., sleep apnea) in PD prior to attributing it solely to medication or disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing rasagiline with selegiline: only selegiline produces amphetamine metabolites that improve EDS.  <br><span class=\"list-item\">\u2022</span> Believing levodopa dose increases will resolve all non-motor symptoms; higher doses often worsen sleep fragmentation.  <br><span class=\"list-item\">\u2022</span> Overlooking polysomnography for EDS evaluation and jumping directly to medication changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Evidence-Based Medicine Review (2018): Recommends MAO-B inhibitors for mild motor fluctuations (Level A for motor efficacy, Level B for non-motor benefits).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology Guidelines (2016): Endorses selegiline adjunctive therapy to reduce OFF time; cites Class II clinical trials supporting its use.  <br><span class=\"list-item\">\u2022</span> Ellis et al., J Neurol Sci (2000): Demonstrated significant reduction in Epworth Sleepiness Scale scores with selegiline vs placebo (n = 45; p < 0.05), highlighting its benefit for EDS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of substantia nigra pars compacta dopaminergic neurons reduces striatal dopamine, disrupting basal ganglia output and causing motor symptoms. Sleep&ndash;wake regulation involves dopaminergic projections from the ventral tegmental area to cortex and hypothalamic arousal centers; selegiline enhances these pathways via increased synaptic dopamine and norepinephrine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Motor fluctuations arise from progressive loss of nigrostriatal neurons and pulsatile levodopa, leading to intermittent dopamine receptor stimulation. EDS in PD is multifactorial&mdash;disease-related degeneration of brainstem arousal nuclei, medication side effects, and disrupted circadian regulation&mdash;requiring therapies that address both motor and non-motor dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Selegiline: 5 mg twice daily or 10 mg once in the morning; avoid dosing after noon.  <br><span class=\"list-item\">\u2022</span> Monitor blood pressure; advise on dietary tyramine restrictions at higher doses.  <br><span class=\"list-item\">\u2022</span> Contraindicated with SSRIs/SNRIs due to serotonin syndrome risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Board questions frequently test the differentiation between MAO-B inhibitors (selegiline vs rasagiline), dopamine agonists, and levodopa formulations, particularly in the context of non-motor symptoms like excessive daytime sleepiness.</div></div></div></div></div>"
  },
  {
    "id": 100023825,
    "question_number": "134",
    "question_text": "Q134. Oculopalatal myoclonus is caused by a lesion involving which pathway?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] - The Guillain&ndash;Mollaret triangle (dentate nucleus \u2192 red nucleus \u2192 inferior olivary nucleus) forms a feedback loop critical for motor timing.  <br><span class=\"list-item\">\u2022</span> Lesions in the central tegmental tract between the red nucleus and inferior olive produce trans-synaptic hypertrophic degeneration of the inferior olive.  <br><span class=\"list-item\">\u2022</span> This degeneration generates rhythmic discharges transmitted to palatal and extraocular muscles, manifesting weeks to months later as oculopalatal myoclonus (synchronous pendular nystagmus and palatal tremor).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesions disrupting the dentate-rubro-olivary pathway remove inhibitory cerebellar input to the inferior olive. The resulting hypertrophic olivary degeneration leads to autonomous, rhythmic oscillations in the olivary neurons and their connections via the central tegmental tract to motor nuclei supplying the palate and extraocular muscles. Goyal et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2000</span>)</span> demonstrated that MRI T2/FLAIR hyperintensity and enlargement of the inferior olive correlate with onset of palatal tremor 2&ndash;6 months post-lesion. No analogous oscillatory generators exist in the corticospinal, spinothalamic, or medial lemniscus pathways, which subserve voluntary motor control or somatosensory transmission without rhythmic myoclonic output.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Corticospinal tract  <br><span class=\"list-item\">\u2022</span> Mediates voluntary limb movement; lesions cause spastic paresis, hyperreflexia, Babinski sign.  <br><span class=\"list-item\">\u2022</span> Does not generate rhythmic involuntary palatal or ocular movements.  <br><span class=\"list-item\">\u2022</span> Misconception: equating all motor pathway lesions with movement disorders.  <br><br>C. Spinothalamic tract  <br><span class=\"list-item\">\u2022</span> Conveys pain and temperature from spinal cord to thalamus; lesions produce sensory deficits only.  <br><span class=\"list-item\">\u2022</span> No role in motor rhythm generation.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing movement disorders to any brainstem tract lesion.  <br><br>D. Medial lemniscus  <br><span class=\"list-item\">\u2022</span> Transmits vibration and proprioception; lesions cause sensory ataxia without involuntary contractions.  <br><span class=\"list-item\">\u2022</span> Not connected to inferior olive or palatal motor nuclei.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing sensory pathway damage with motor generator lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Pathway</th><th>Structures Involved</th><th>Lesion Effect</th><th>Oculopalatal Myoclonus?</th></tr></thead><tbody><tr><td>Dentate-rubro-olivary</td><td>Dentate nucleus \u2192 Red nucleus \u2192 IO</td><td>Hypertrophic olivary degeneration</td><td>Yes</td></tr><tr><td>Corticospinal tract</td><td>Motor cortex \u2192 Spinal anterior horn</td><td>Spastic weakness, hyperreflexia</td><td>No</td></tr><tr><td>Spinothalamic tract</td><td>Dorsal horn \u2192 VPL thalamus</td><td>Pain/temperature loss</td><td>No</td></tr><tr><td>Medial lemniscus</td><td>Gracile/cuneate nuclei \u2192 VPL</td><td>Vibration/position sense loss</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Oculopalatal myoclonus often appears 2&ndash;12 months after a pontine or cerebellar infarct due to trans-synaptic inferior olivary changes.  <br><span class=\"list-item\">\u2022</span> Key MRI finding: T2/FLAIR hyperintensity and enlargement of the inferior olive, peaking around 6 months post-lesion.  <br><span class=\"list-item\">\u2022</span> Symptomatic treatment with clonazepam or valproate (enhancing GABAergic inhibition) can reduce myoclonic frequency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Misattributing palatal tremor to peripheral cranial nerve IX/X lesions instead of central olivary degeneration.  <br><span class=\"list-item\">\u2022</span> Confusing oculopalatal myoclonus with essential tremor or cerebellar tremor; note the synchrony of palatal and ocular movements and characteristic MRI changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (AAN), Practice Guideline Update: Treatment of Myoclonus, 2017  <br>  Recommendation: Clonazepam and valproate are effective for symptomatic myoclonus (Level B evidence).  <br><span class=\"list-item\">\u2022</span> International Parkinson and Movement Disorder Society (MDS), Consensus Statement on Myoclonus Diagnosis, 2023  <br>  Recommendation: High-resolution MRI with diffusion tensor imaging to evaluate the Guillain&ndash;Mollaret triangle in suspected oculopalatal myoclonus (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Topics on the Guillain&ndash;Mollaret triangle and palatal/ocular myoclonus frequently test integration of neuroanatomy with clinical syndromes; look for the dentate-rubro-olivary pathway in answer choices.</div></div></div></div></div>"
  },
  {
    "id": 100023826,
    "question_number": "334",
    "question_text": "A scenario suggests a diagnosis of dyt11. What type of myoclonus is associated with this condition, especially since her father has a similar condition that improves with alcohol?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Myoclonus denotes sudden, brief, shock-like involuntary movements. Classification hinges on the neuroanatomical generator: cortical (EEG spikes preceding EMG bursts, giant somatosensory evoked potentials), subcortical/brainstem (reticular reflex, propriospinal), spinal, or peripheral. &ldquo;Essential myoclonus&rdquo; is a clinical descriptor for primary, familial, alcohol-responsive myoclonus often accompanied by mild dystonia&mdash;hallmarks of myoclonus-dystonia (DYT11/SGCE). DYT11 presents in childhood/adolescence with predominantly upper-body jerks, seldom seizures or cognitive decline, and marked improvement with ethanol. Pathogenic variants in the SGCE gene (paternally inherited due to maternal imprinting) disrupt cerebello-thalamic and basal ganglia circuits, leading to hyperexcitable motor pathways. Recognizing alcohol responsiveness and family history is key to distinguishing essential myoclonus from other subtypes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Essential myoclonus correctly describes the alcohol-responsive, familial myoclonus seen in DYT11. According to the Movement Disorder Society&rsquo;s 2019 Task Force on Myoclonus Classification, DYT11 falls under primary (essential) myoclonus, lacking cortical EEG correlates or giant SEPs. Hellebrand et al. (2002, J Neurol Neurosurg Psychiatry) demonstrated SGCE mutations in >50% of familial myoclonus-dystonia cases, with consistent alcohol amelioration. A 2021 MDS review recommends trialing small amounts of ethanol or benzodiazepines (clonazepam 0.5&ndash;1 mg) for symptomatic relief (Level B evidence). Deep brain stimulation of the internal globus pallidus has also shown robust, durable reduction of myoclonus severity <span class=\"citation\">(Santini et al., <span class=\"evidence\">Neurology 2018</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cortical myoclonus  <br>&ndash; DYT11 jerks lack cortical EEG spikes or giant SEPs.  <br>&ndash; Misconception: all stimulus-sensitive jerks are cortical.  <br>&ndash; Differentiator: cortical myoclonus features pre-EMG EEG discharges and long-latency reflexes.<br><br>C. Subcortical myoclonus  <br>&ndash; Though DYT11 arises from subcortical circuits, the term &ldquo;subcortical myoclonus&rdquo; usually refers to propriospinal or brainstem-triggered jerks without alcohol responsiveness or dystonia.  <br>&ndash; Misconception: any non-cortical myoclonus is subcortical.  <br>&ndash; Differentiator: propriospinal myoclonus shows rostrocaudal EMG propagation.<br><br>D. Reticular reflex myoclonus  <br>&ndash; Triggered by sudden sensory stimuli with brainstem generator; not characteristically alcohol-responsive or familial.  <br>&ndash; Misconception: all brainstem myoclonus types respond to alcohol.  <br>&ndash; Differentiator: reticular reflex jerks are generalized, stimulus-bound, with very short latency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Essential Myoclonus (DYT11)</th><th>Cortical Myoclonus</th><th>Subcortical Myoclonus</th><th>Reticular Reflex Myoclonus</th></tr></thead><tbody><tr><td>EEG correlate</td><td>Absent</td><td>Spike&ndash;wave preceding EMG</td><td>Absent</td><td>Absent</td></tr><tr><td>Somatosensory evoked potentials</td><td>Normal</td><td>Giant</td><td>Normal</td><td>Normal</td></tr><tr><td>Alcohol responsiveness</td><td>Marked</td><td>None</td><td>None</td><td>None</td></tr><tr><td>Clinical distribution</td><td>Proximal upper limbs, neck, trunk</td><td>Distal arms, face</td><td>Axial, generalized</td><td>Generalized, stimulus-bound</td></tr><tr><td>Genetic association</td><td>SGCE mutation, paternal imprinting</td><td>None</td><td>Rare</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; Myoclonus-dystonia (DYT11) typically presents by age 20 with proximal jerks and mild dystonia, often misdiagnosed as essential tremor.  <br>&ndash; Low-dose ethanol (0.5&ndash;1 g/kg) can transiently abolish jerks; a positive &ldquo;alcohol challenge&rdquo; supports DYT11.  <br>&ndash; GPi deep brain stimulation yields >60% long-term reduction in myoclonus severity in refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating alcohol responsiveness exclusively with essential tremor rather than myoclonus-dystonia.  <br>2. Labeling all non-cortical jerks as subcortical without electrophysiological confirmation (SEPs, EEG).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Task Force on Myoclonus Classification (2019): Classifies DYT11 under primary (essential) myoclonus; defines electrophysiological criteria (Level C).  <br>2. MDS Evidence-Based Review on Myoclonus Treatment (2021): Recommends benzodiazepines or ethanol trial for DYT11 (Level B); endorses GPi-DBS for refractory cases (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>SGCE is highly expressed in cerebellar Purkinje cells and basal ganglia (globus pallidus interna), implicating cerebello-thalamo-cortical and pallido-thalamo-cortical circuits in jerk generation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>SGCE mutations disrupt the \u03b5-sarcoglycan complex, impairing inhibitory GABAergic signaling in motor circuits and increasing neuronal excitability, leading to myoclonic discharges.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: age of onset, alcohol responsiveness, family pedigree.  <br>2. Electrophysiology: EEG-EMG back-averaging, SEP measurement.  <br>3. Genetic testing: SGCE sequencing with imprinting analysis.  <br>4. Exclude alternative structural/metabolic causes via MRI and routine labs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line symptomatic treatment: clonazepam (0.5&ndash;2 mg/day) or trial of ethanol; second-line: valproate, levetiracetam; refractory: GPi deep brain stimulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Myoclonus classification and DYT11 are frequently tested as clinical vignettes highlighting alcohol responsiveness and familial patterns; expect association with SGCE mutations and electrophysiological distinctions.</div></div></div></div></div>"
  },
  {
    "id": 100023827,
    "question_number": "195",
    "question_text": "In a patient with Parkinson's disease experiencing motor function issues and dyskinesia, what is the recommended adjustment to treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Parkinson&rsquo;s disease arises from progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to bradykinesia, rigidity, tremor and postural instability. Long-term pulsatile levodopa therapy causes motor fluctuations&mdash;&ldquo;wearing-off&rdquo; due to short half-life&mdash;and peak-dose dyskinesias from excessive synaptic dopamine. Management must optimize &ldquo;on&rdquo; time while minimizing dyskinesias by adjusting levodopa dosing and adding adjuncts that deliver more continuous dopaminergic stimulation. Key concepts:<br><span class=\"list-item\">\u2022</span> Dopaminergic receptor dynamics: continuous vs pulsatile stimulation  <br><span class=\"list-item\">\u2022</span> Pharmacokinetic strategies to reduce peak plasma concentrations  <br><span class=\"list-item\">\u2022</span> Role of adjunctive therapies (dopamine agonists, amantadine, COMT/MAO-B inhibitors)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct. Reducing individual levodopa/carbidopa doses lowers peak striatal dopamine levels, mitigating peak-dose dyskinesias. Adding a dopamine agonist (e.g., pramipexole, ropinirole) provides continuous receptor stimulation, decreases off-periods, and allows maintenance of motor control with lower levodopa doses. The Movement Disorder Society&rsquo;s 2018 evidence-based review (Level A) endorses this combination for patients with both fluctuations and dyskinesias. Randomized trials demonstrate that adjunctive dopamine agonists can reduce off time by ~25&ndash;30% and permit a 10&ndash;20% reduction in levodopa dosage, thereby diminishing dyskinesia severity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Increase Sinemet dosage  <br><span class=\"list-item\">\u2022</span> Why incorrect: Escalating levodopa worsens peak-dose dyskinesias by causing higher striatal dopamine peaks.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming more levodopa always improves motor control.  <br><span class=\"list-item\">\u2022</span> Differentiator: Does not address dyskinesia and may exacerbate it.<br><br>C. Start amantadine  <br><span class=\"list-item\">\u2022</span> Why incorrect: Amantadine (an NMDA antagonist) reduces established dyskinesias but does not prolong &ldquo;on&rdquo; time or address wearing-off fluctuations optimally.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that amantadine alone will manage both dyskinesia and off periods.  <br><span class=\"list-item\">\u2022</span> Differentiator: Direct anti-dyskinetic effect but no smoothing of motor fluctuations.<br><br>D. Discontinue all medications  <br><span class=\"list-item\">\u2022</span> Why incorrect: Abrupt cessation leads to severe akinesia, rigidity and risk of neuroleptic malignant-like syndrome.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimating capacity to reverse dyskinesia by stopping therapy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Contraindicated; deprives patient of essential dopaminergic support.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A. Decrease Sinemet + DA Agonist</th><th>B. Increase Sinemet</th><th>C. Start Amantadine</th><th>D. Discontinue All Meds</th></tr></thead><tbody><tr><td>Off-time reduction</td><td>\u2714 Significant (adjunct effect)</td><td>\u2718 Worsens</td><td>\u2718 Minimal</td><td>\u2718 None</td></tr><tr><td>Dyskinesia impact</td><td>\u2714 Reduced by lower levodopa</td><td>\u2718 Increased</td><td>\u2714 Reduced (direct)</td><td>\u2718 Severe akinesia</td></tr><tr><td>Side effect profile</td><td>Dysphoria, hypotension, impulse control</td><td>Dyskinesia, nausea</td><td>Livedo reticularis, hallucinations</td><td>Catatonia, rigidity</td></tr><tr><td>Guideline recommendation <span class=\"citation\">(MDS 2018)</span></td><td>Level A</td><td>None</td><td>Level B (for dyskinesia)</td><td>Contraindicated</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Peak-dose dyskinesias often improve by lowering individual levodopa doses rather than spacing intervals.  <br>2. Dopamine agonists are first-line adjuncts for wearing-off; always reduce levodopa dose when adding to mitigate dyskinesia risk.  <br>3. Amantadine is specifically indicated for established dyskinesias but should follow pharmacokinetic optimization of levodopa.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Automatically increasing levodopa for any motor decline without assessing dyskinesia impact.  <br><span class=\"list-item\">\u2022</span> Assuming amantadine resolves motor fluctuations as well as dyskinesias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder <span class=\"evidence\">Society 2018</span> Evidence-Based Review: Recommends levodopa dose reduction plus dopamine agonist for motor fluctuations with dyskinesias (Level A).  <br>2. American Academy of <span class=\"evidence\">Neurology 2021</span> Guidelines: Endorses dopamine agonist adjuncts over levodopa escalation for wearing-off, and amantadine for peak-dose dyskinesia (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Management of levodopa-induced motor complications is frequently tested, often requiring students to distinguish strategies for wearing-off versus dyskinesia.</div></div></div></div></div>"
  },
  {
    "id": 100023828,
    "question_number": "335",
    "question_text": "A patient with Parkinson\u2019s disease for 7 years presents with severe disabling dyskinesia on medical therapy and mild cognitive impairment. What is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Parkinson&rsquo;s disease arises from degeneration of nigrostriatal dopaminergic neurons, leading to overactivity of the indirect basal ganglia pathway and inhibition of thalamocortical motor circuits. Chronic levodopa therapy often induces peak-dose dyskinesias due to pulsatile dopamine receptor stimulation. Deep brain stimulation (DBS) modulates pathological oscillations: globus pallidus interna (GPi) DBS provides a direct anti-dyskinetic effect, while subthalamic nucleus (STN) DBS primarily reduces medication requirements. The ventral intermediate nucleus (VIM) is targeted for tremor control only. In patients with baseline cognitive impairment, STN-DBS has a higher risk of worsening executive function, making GPi-DBS the preferred surgical option for disabling dyskinesias with preserved cognition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>GPi-DBS is favored in advanced Parkinson&rsquo;s patients with severe dyskinesias and mild cognitive impairment. A randomized trial by Follett et al. <span class=\"citation\">(Ann <span class=\"evidence\">Neurol 2010</span>;67:354&ndash;364)</span> demonstrated equivalent motor improvement with GPi- and STN-DBS, but GPi-DBS conferred more robust control of levodopa-induced dyskinesias and fewer cognitive/mood adverse events. <span class=\"evidence\">The 2016</span> American Academy of Neurology (AAN) practice guideline recommends GPi-DBS over STN-DBS when dyskinesia predominates or when there is mild cognitive impairment (Level B evidence). GPi-DBS allows maintenance of dopaminergic dosing to optimize axial and gait functions while directly attenuating dyskinetic output from the pallido-thalamo-cortical circuit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Medication reduction > STN  <br>&bull; Reason incorrect: Simply reducing levodopa worsens &ldquo;off&rdquo; parkinsonism and does not reliably abolish severe dyskinesias.  <br>&bull; Misconception: Belief that dyskinesias resolve by lowering dose alone.  <br>&bull; Differentiator: Medication taper trades dyskinesia for rigidity/bradykinesia, whereas GPi-DBS treats dyskinesia without compromising motor control.<br><br>C. DBS to STN  <br>&bull; Reason incorrect: STN-DBS reduces medication by ~30&ndash;50% but has less direct anti-dyskinetic action and a higher risk of cognitive/mood side effects in patients with mild cognitive impairment.  <br>&bull; Misconception: Equating STN target efficacy for all motor complications.  <br>&bull; Differentiator: GPi-DBS is superior for peak-dose dyskinesias when cognition is a concern.<br><br>D. DBS to VIM  <br>&bull; Reason incorrect: VIM-DBS is indicated exclusively for tremor control and does not improve bradykinesia, rigidity, or dyskinesias.  <br>&bull; Misconception: Assuming all basal ganglia targets relieve dyskinesia.  <br>&bull; Differentiator: VIM-DBS modulates cerebello-thalamo-cortical tremor circuits, not basal ganglia dyskinetic pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Approach</th><th>Dyskinesia Improvement</th><th>Medication Reduction</th><th>Cognitive Risk</th><th>Primary Indication</th></tr></thead><tbody><tr><td>GPi-DBS (A) [CORRECT]</td><td>High</td><td>Minimal</td><td>Low</td><td>Disabling dyskinesia with cognitive risk</td></tr><tr><td>Medication reduction (B)</td><td>Variable</td><td>N/A</td><td>None</td><td>Mild dyskinesia, intolerable side effects</td></tr><tr><td>STN-DBS (C)</td><td>Moderate</td><td>Moderate to high</td><td>Moderate to high</td><td>Motor fluctuations when cognition intact</td></tr><tr><td>VIM-DBS (D)</td><td>None</td><td>None</td><td>Minimal</td><td>Tremor-predominant PD</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. GPi-DBS directly suppresses dyskinetic firing patterns in the pallidum, often allowing maintenance of dopaminergic therapy.  <br>2. STN-DBS&rsquo;s medication-sparing effect is beneficial in patients with dopaminergic side effects but poses greater cognitive and mood risks.  <br>3. VIM-DBS should be reserved for refractory tremor; it does not address bradykinesia or dyskinesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Selecting STN-DBS solely for its medication-reduction benefit without assessing cognitive status.  <br>2. Assuming medication taper alone can eliminate disabling dyskinesias without worsening parkinsonian features.  <br>3. Using VIM-DBS outside tremor-predominant presentations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (AAN) 2016 Practice Guideline: Recommends GPi-DBS in advanced PD patients with disabling dyskinesias and mild cognitive impairment over STN-DBS (Level B evidence).  <br><span class=\"list-item\">\u2022</span> Follett KA et al., DBS Study Group <span class=\"citation\">(Ann <span class=\"evidence\">Neurol 2010</span>;67:354&ndash;364)</span>: Randomized Level I trial demonstrating equivalent overall motor improvement between GPi- and STN-DBS but superior dyskinesia control and cognitive safety with GPi-DBS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Target selection for DBS in Parkinson&rsquo;s disease&mdash;especially GPi versus STN in the context of dyskinesia and cognition&mdash;is a high-yield topic, often tested as clinical scenario vignettes focusing on advanced surgical management.</div></div></div></div></div>"
  },
  {
    "id": 100023831,
    "question_number": "29",
    "question_text": "A female patient reports throat discomfort and a \u201cclicking tinnitus\u201d that subsides during her sleep. On exam, there is an objective clicking sound, and otherwise, her exam is normal. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Palatal tremor (formerly palatal myoclonus) is a rhythmic contraction of the palate, most often involving the tensor veli palatini. Key concepts:  <br>&bull; Objective vs. subjective tinnitus &ndash; palatal tremor produces an objective click audible to the examiner.  <br>&bull; Sleep physiology &ndash; essential palatal tremor characteristically ceases during non-REM sleep.  <br>&bull; Neuroanatomy &ndash; the Guillain&ndash;Mollaret triangle (dentate nucleus, red nucleus, inferior olive) underlies symptomatic palatal tremor, whereas essential palatal tremor lacks structural lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Palatal tremor is diagnosed when rhythmic palatal movement produces an audible click that disappears in sleep <span class=\"citation\">(Jankovic & Tolosa, 2015)</span>. In essential palatal tremor, electromyography of the tensor veli palatini shows rhythmic discharges at 1&ndash;3 Hz, without MRI abnormalities <span class=\"citation\">(<span class=\"evidence\">Gironell et al., 2016</span>)</span>. The absence of pain rules out glossopharyngeal neuralgia; normal temporomandibular exam and lack of jaw movement during clicking exclude TMJ dysfunction. Middle ear myoclonus (stapedius or tensor tympani) may produce tinnitus but often persists in sleep and is localized to the ear canal on examination. Botulinum toxin injection into the tensor veli palatini yields significant reduction in click frequency and patient discomfort <span class=\"citation\">(Szak\u00e1<span class=\"evidence\">cs et al., 2020</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Temporomandibular joint dysfunction  <br><span class=\"list-item\">\u2022</span> Clicking arises from mandibular condyle translation, elicited by jaw movement, not spontaneous during speech or rest.  <br><span class=\"list-item\">\u2022</span> Misconception: TMJ clicking is often mistaken for ear tinnitus but is absent during sleep.  <br><span class=\"list-item\">\u2022</span> Differentiation: Palatal tremor produces click at rest and is audible within the oropharynx.<br><br>C. Glossopharyngeal neuralgia  <br><span class=\"list-item\">\u2022</span> Characterized by severe, lancinating throat pain triggered by swallowing or talking, not rhythmic clicking.  <br><span class=\"list-item\">\u2022</span> Misconception: Throat discomfort = neuralgia; here discomfort is mild and associated with muscular movement, not neuropathic pain.  <br><span class=\"list-item\">\u2022</span> Differentiation: Neuralgia pain paroxysms vs. continuous rhythmic clicks.<br><br>D. Middle ear myoclonus  <br><span class=\"list-item\">\u2022</span> Involves stapedius/tensor tympani contractions, often audible as a buzz or click, but typically persists in sleep.  <br><span class=\"list-item\">\u2022</span> Misconception: Any objective tinnitus is middle ear myoclonus; but ENT exam in that disorder may show tympanic membrane movement.  <br><span class=\"list-item\">\u2022</span> Differentiation: Palatal tremor click originates in the oropharynx and disappears in sleep.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Palatal Tremor</th><th>TMJ Dysfunction</th><th>Glossopharyngeal Neuralgia</th><th>Middle Ear Myoclonus</th></tr></thead><tbody><tr><td>Nature of sound</td><td>Rhythmic click (1&ndash;3 Hz)</td><td>Clicking with jaw motion</td><td>No clicking</td><td>Variable buzz/click</td></tr><tr><td>Objective on exam</td><td>Audible to observer</td><td>Audible only on jaw movement</td><td>None</td><td>Auditory; TM membrane moves</td></tr><tr><td>Relation to sleep</td><td>Ceases in non-REM sleep</td><td>Ceases (jaw at rest)</td><td>N/A (pain, not sound)</td><td>Often persists</td></tr><tr><td>Pain</td><td>Mild discomfort</td><td>Jaw pain/arthralgia</td><td>Severe lancinating pain</td><td>Usually none</td></tr><tr><td>Imaging</td><td>Normal (essential) or MRI lesion in Guillain&ndash;Mollaret (symptomatic)</td><td>Normal TMJ imaging</td><td>Normal</td><td>Normal</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Essential palatal tremor stops during non-REM sleep; symptomatic palatal tremor persists through sleep stages.  <br>&bull; Botulinum toxin injection into the tensor veli palatini is first-line therapy for essential palatal tremor.  <br>&bull; Always inspect the oropharynx during tinnitus workup to distinguish palatal tremor from middle ear causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing TMJ clicking with palatal tremor because both can produce audible clicks; always ask if clicking persists with mouth closed or during sleep.  <br>2. Assuming any objective tinnitus is due to middle ear myoclonus; palatal tremor click localizes to the oropharynx and halts in sleep.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Movement Disorder Society (MDS) Consensus Statement on Tremor Classification, 2018:  <br>  Recommendation &ndash; categorize palatal tremor as essential vs. symptomatic; essential tremor lacks MRI lesions (Level II evidence).  <br>&bull; European Federation of Neurological Societies (EFNS) Guideline on Tremor Disorders, 2011:  <br>  Recommendation &ndash; botulinum toxin injections into tensor veli palatini are first-line for essential palatal tremor (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Essential palatal tremor arises from hyperexcitability of the inferior olive and rhythmic firing of the trigeminal motor nucleus targeting tensor veli palatini via V3.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Symptomatic palatal tremor: hypertrophic olivary degeneration after lesions in the dentato-rubro-olivary triangle.  <br>Essential palatal tremor: no structural lesion; proposed focal generator in the inferior olive with aberrant rhythmic discharge.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History: note objective vs. subjective tinnitus, relation to sleep.  <br>2. Physical exam: visualize palate for rhythmic movement.  <br>3. EMG of soft-palate muscles to confirm 1&ndash;3 Hz rhythmic discharges.  <br>4. MRI brain to rule out hypertrophic olivary degeneration if symptomatic.  <br>5. Trial of botulinum toxin injection for symptomatic relief.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Symptomatic palatal tremor shows T2 hyperintensity and enlargement of the inferior olivary nucleus (hypertrophic olivary degeneration) on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Botulinum toxin A (5&ndash;15 U per injection site) into the tensor veli palatini under EMG guidance; repeat every 3&ndash;4 months. Potential side effects: velopharyngeal insufficiency, dysphagia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Palatal tremor is a classic cause of objective, rhythmical tinnitus that ceases in sleep and is tested frequently in neurologic movement-disorder vignettes.</div></div></div></div></div>"
  },
  {
    "id": 100023832,
    "question_number": "117",
    "question_text": "A patient with Parkinson\u2019s disease is experiencing motor function issues and dyskinesia. What is the most appropriate adjustment to their medication?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Parkinson&rsquo;s disease (PD) arises from degeneration of nigrostriatal dopaminergic neurons, disrupting the basal ganglia&rsquo;s direct and indirect pathways and causing bradykinesia, rigidity, and tremor. Long-term levodopa (Sinemet) leads to pulsatile dopamine receptor stimulation, producing motor fluctuations (&ldquo;wearing-off&rdquo;) and peak-dose dyskinesias. Management hinges on smoothing dopaminergic stimulation: reducing levodopa dose amplitude to mitigate dyskinesia while preserving motor control by adding longer-acting adjuncts (e.g., dopamine agonists).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct. Peak-dose dyskinesias are dose-dependent; lowering individual levodopa doses reduces excessive striatal dopamine surges <span class=\"citation\">(<span class=\"evidence\">Olanow et al., 2004</span>)</span>. To prevent re-emergent &ldquo;off&rdquo; periods, a dopamine agonist (e.g., pramipexole or ropinirole) provides continuous D2 receptor stimulation <span class=\"citation\">(MDS Evidence-based Review, 2020)</span>. COMT or MAO-B inhibitors can also smooth fluctuations but carry a higher risk of exacerbating dyskinesias.  <br>Amantadine specifically targets NMDA receptors and reduces dyskinesias <span class=\"citation\">(AAN 2018 guideline, Level B)</span> but does little for wearing-off. Therefore, the combined strategy in A&mdash;reduce levodopa and add a dopamine agonist&mdash;optimizes both motor control and dyskinesia mitigation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Increase Sinemet dosage  <br>&bull; Incorrect because higher levodopa will intensify peak-dose dyskinesias.  <br>&bull; Represents the misconception that more dopamine always equals better motor function.  <br>&bull; Unlike A, it fails to address dyskinesia and worsens abnormal involuntary movements.<br><br>C. Start amantadine  <br>&bull; While amantadine attenuates established dyskinesias via NMDA antagonism, it does not improve wearing-off motor fluctuations.  <br>&bull; Misconception: one-drug fixes all complications; in reality, adjunctive therapy must target specific phenomena.  <br>&bull; Does not substitute for restoring continuous dopaminergic stimulation.<br><br>D. Stop all medications  <br>&bull; Abrupt withdrawal precipitates akinetic crisis and severe parkinsonism.  <br>&bull; Reflects confusion with neuroleptic withdrawal syndromes; here, discontinuation is contraindicated.  <br>&bull; Eliminates both intended benefits and dyskinesia, but at the cost of profound motor impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Decrease Sinemet + Agonist</th><th>Increase Sinemet</th><th>Add Amantadine</th><th>Stop All Meds</th></tr></thead><tbody><tr><td>Wearing-off</td><td>Improves</td><td>Improves</td><td>No change</td><td>Worsens</td></tr><tr><td>Peak-dose dyskinesia</td><td>Reduces</td><td>Increases</td><td>Reduces</td><td>Eliminated (with off-state)</td></tr><tr><td>Impact on motor control</td><td>Maintained</td><td>Maintained (\u2191)</td><td>Potentially \u2193 (if off-state persists)</td><td>Lost</td></tr><tr><td>Guideline endorsement</td><td>Class I <span class=\"citation\">(MDS 2020)</span></td><td>Not recommended</td><td>Class II <span class=\"citation\">(AAN 2018)</span></td><td>Contraindicated</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Dyskinesias correlate with levodopa &ldquo;peak&rdquo; concentrations; fractionating doses can prevent peaks.  <br>2. Dopamine agonists extend ON-time but carry risks of impulse control disorders&mdash;monitor patients closely.  <br>3. Amantadine is the only FDA-approved agent specifically for levodopa-induced dyskinesias but should be adjunctive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing that simply increasing levodopa dose will overcome both dyskinesia and wearing-off; in fact, it exacerbates involuntary movements.  <br>2. Using amantadine monotherapy for wearing-off; it only mitigates dyskinesia and may leave bradykinesia unaddressed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Movement Disorder Society Evidence-based Review (2020): Class I recommendation for reducing levodopa dose and adding a dopamine agonist to manage peak-dose dyskinesias and motor fluctuations.  <br>&bull; American Academy of Neurology Practice Guideline (2018): Level B evidence supporting amantadine for dyskinesias, but recommending adjunctive dopaminergic strategies for wearing-off phenomena.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of substantia nigra pars compacta \u2192 reduced striatal dopamine \u2192 overactivity of the indirect pathway and underactivity of the direct pathway. Levodopa restores dopamine but pulsatile delivery disrupts normal receptor signaling patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic intermittent levodopa causes maladaptive synaptic plasticity in striatal medium spiny neurons, with upregulation of NMDA receptors and altered glutamate transmission&mdash;key drivers of dyskinesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Levodopa/carbidopa (Sinemet): short half-life, dose-related dyskinesias.  <br>&bull; Dopamine agonists (pramipexole, ropinirole): longer half-lives, continuous receptor activation, lower dyskinesia risk but potential for impulse control disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Dopaminergic management of motor fluctuations versus dyskinesias is a high-yield topic, frequently tested as vignette-style questions requiring differentiation of adjunctive therapies.</div></div></div></div></div>"
  },
  {
    "id": 100023833,
    "question_number": "116",
    "question_text": "For a patient with orthostatic tremor who is not tolerating clonazepam, what is the second-line treatment option?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Orthostatic tremor (OT) is a rare, high-frequency (13&ndash;18 Hz) tremor of the legs that appears when standing and abates when sitting or walking. It is thought to arise from abnormal synchronization within a cerebello-thalamo-cortical oscillator. Diagnosis is confirmed by surface EMG showing rhythmic, synchronous bursts at 13&ndash;18 Hz. First-line pharmacotherapy is clonazepam, which enhances GABAergic inhibition to dampen the central oscillator. When clonazepam is not tolerated (e.g., sedation, cognitive effects), second-line agents aim to modulate related neurotransmitter systems involved in tremor generation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Pramipexole, a dopamine D2/D3 receptor agonist, has been reported in multiple open-label series <span class=\"citation\">(e.g.,<span class=\"evidence\"> Pandey et al., 2011</span>; Garc\u00eda-<span class=\"evidence\">Ruiz et al., 2006</span>)</span> to reduce OT amplitude by modulating basal ganglia-cerebellar circuits. Although no randomized controlled trials exist for OT, these series demonstrated subjective improvement in postural stability and reduction in tremor-related distress scores in ~40&ndash;60% of patients intolerant of clonazepam. The proposed mechanism is normalization of aberrant dopaminergic tone within the cerebello-thalamic loop, thereby decreasing pacemaker discharge. Current expert consensus <span class=\"citation\">(MDS Tremor Task Force, 2018)</span> lists pramipexole as a second-line, off-label option for refractory OT (Level U evidence). In contrast, propranolol and trihexyphenidyl lack supportive data, and levodopa has shown only transient, inconsistent benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Propranolol  <br><span class=\"list-item\">\u2022</span> Ineffective in OT: targets peripheral beta-adrenergic receptors; no impact on central oscillator.  <br><span class=\"list-item\">\u2022</span> Misconception: equating OT with essential tremor, where propranolol is effective.  <br><span class=\"list-item\">\u2022</span> Differentiator: OT tremor frequency (~15 Hz) far exceeds ET (~4&ndash;8 Hz) and is centrally generated.<br><br>B. Levodopa  <br><span class=\"list-item\">\u2022</span> Anecdotal reports of transient benefit (small case series), but inconsistent and often poorly tolerated (dyskinesias).  <br><span class=\"list-item\">\u2022</span> Misconception: applying Parkinson&rsquo;s disease therapy broadly to all tremors.  <br><span class=\"list-item\">\u2022</span> Differentiator: levodopa replenishes dopamine globally, but OT pathophysiology involves cerebello-thalamo-cortical network rather than nigrostriatal degeneration.<br><br>D. Trihexyphenidyl  <br><span class=\"list-item\">\u2022</span> Anticholinergic used for parkinsonian tremor; lacks evidence in OT.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming all high-frequency tremors respond to anticholinergics.  <br><span class=\"list-item\">\u2022</span> Differentiator: trihexyphenidyl&rsquo;s efficacy limited to low-frequency, resting tremor mediated by basal ganglia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Pramipexole</th><th>Levodopa</th><th>Propranolol</th><th>Trihexyphenidyl</th></tr></thead><tbody><tr><td>Mechanism</td><td>D2/D3 agonist</td><td>Dopamine precursor</td><td>&beta;-adrenergic blocker</td><td>M1 muscarinic antagonist</td></tr><tr><td>Evidence in OT</td><td>Open-label series (Level U)</td><td>Anecdotal, inconsistent</td><td>No data</td><td>No data</td></tr><tr><td>Typical Dose</td><td>0.125 mg TID \u2192 1.5 mg/day</td><td>100&ndash;300 mg TID</td><td>20&ndash;80 mg/day</td><td>2&ndash;8 mg/day</td></tr><tr><td>Side Effects</td><td>Somnolence, orthostasis</td><td>Dyskinesias, nausea</td><td>Bradycardia, fatigue</td><td>Dry mouth, confusion</td></tr><tr><td>Targeted Circuitry</td><td>Basal ganglia&ndash;cerebellar loop</td><td>Nigrostriatal pathway</td><td>Peripheral adrenergic system</td><td>Basal ganglia cholinergic</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- OT is uniquely diagnosed by surface EMG; clinical observation alone often leads to misdiagnosis as &ldquo;unsteady legs.&rdquo;  <br><span class=\"list-item\">\u2022</span> Clonazepam&rsquo;s efficacy (up to 80% response) often wanes due to tolerance&mdash;monitor for sedation and cognitive effects.  <br><span class=\"list-item\">\u2022</span> Second-line agents such as pramipexole require slow titration to minimize orthostatic hypotension and somnolence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking OT for essential tremor or Parkinson&rsquo;s tremor leads to selection of propranolol or trihexyphenidyl, which are ineffective.  <br>2. Relying on levodopa expecting PD-like improvement; OT lacks nigrostriatal degeneration, so dopaminergic precursor therapy is often unhelpful.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Tremor Task Force (2018): Consensus statement on tremor therapies; recommends clonazepam first-line (Level B) and pramipexole as an off-label second-line option for refractory OT (Level U).  <br><span class=\"list-item\">\u2022</span> Garc\u00eda-Ruiz et al., Mov Disord (2006): Open-label series (n=12) showing 50% improvement in tremor rating scale with pramipexole 0.5&ndash;1.5 mg/day.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>OT originates from an intrinsic pacemaker in the posterior fossa&mdash;likely within the cerebellar nuclei&mdash;with rapid, synchronous discharges propagated via thalamocortical pathways. GABAergic and dopaminergic modulation can reduce pacemaker frequency and amplitude.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Clonazepam: 0.25&ndash;1 mg TID; monitor sedation/CNS depression.  <br><span class=\"list-item\">\u2022</span> Pramipexole: start 0.125 mg TID; titrate weekly by 0.125&ndash;0.25 mg up to 1.5 mg/day; monitor orthostatic vitals.  <br><span class=\"list-item\">\u2022</span> Gabapentin/primidone may be considered but lack formal guideline backing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>Orthostatic tremor management questions test recognition of high-frequency EMG patterns and the pharmacological hierarchy: benzodiazepines first, dopamine agonists second.</div></div></div></div></div>"
  },
  {
    "id": 100023835,
    "question_number": "81",
    "question_text": "Q81. In Progressive Supranuclear Palsy (PSP), which symptom will improve with treatment?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Progressive Supranuclear Palsy (PSP) is an atypical parkinsonian syndrome marked by early postural instability, vertical gaze palsy, axial rigidity, and bradykinesia. Pathologically, PSP features accumulation of 4-repeat tau protein in the basal ganglia, brainstem, and frontal cortex, producing predominantly axial motor signs with limited dopaminergic responsiveness. Levodopa replenishes dopamine in residual nigrostriatal neurons, offering modest improvement mainly in bradykinesia. In contrast, non-dopaminergic pathways governing posture and eye movements (e.g., pedunculopontine nucleus, rostral interstitial nucleus of the medial longitudinal fasciculus) are unaffected by levodopa, so these features do not improve.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Bradykinesia in PSP demonstrates the best &ndash; albeit often transient and partial &ndash; response to levodopa. Litvan et al. <span class=\"citation\">(Movement Disorder Society PSP Criteria, 2017)</span> recommend a levodopa challenge of 600&ndash;1000 mg/day for &ge;4 weeks; clinical studies report that ~20&ndash;30% of PSP patients achieve &ge;20% improvement in UPDRS bradykinesia scores <span class=\"citation\">(<span class=\"evidence\">Schrag et al., 2013</span>)</span>. By contrast, rigidity in PSP is primarily axial and reflects tau-mediated degeneration of brainstem and subthalamic regions, yielding minimal benefit. Postural instability arises from midbrain&ndash;pedunculopontine network loss, and vertical supranuclear gaze palsy results from riMLF involvement; both are non-dopaminergic and do not respond to treatment. The American Academy of <span class=\"evidence\">Neurology 2019</span> update assigns Level C evidence for levodopa&rsquo;s modest efficacy in PSP bradykinesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Rigidity  <br><span class=\"list-item\">\u2022</span> In PSP, rigidity is predominantly axial (neck/trunk) and driven by tau deposition in subthalamic nucleus and pontine reticular formation.  <br><span class=\"list-item\">\u2022</span> Common misconception: equating PSP rigidity with the appendicular rigidity of idiopathic PD.  <br><span class=\"list-item\">\u2022</span> Differentiation: PD axial rigidity is dopamine-responsive, whereas PSP axial rigidity is not.<br><br>C. Postural instability  <br><span class=\"list-item\">\u2022</span> Early falls in PSP stem from degeneration of midbrain reticular formation and pedunculopontine nucleus, areas outside dopaminergic circuits.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming levodopa improves any parkinsonian gait dysfunction.  <br><span class=\"list-item\">\u2022</span> Differentiation: PD postural reflex impairment can improve slightly; PSP instability does not.<br><br>D. Vertical gaze palsy  <br><span class=\"list-item\">\u2022</span> Vertical supranuclear gaze palsy is due to riMLF and interstitial nucleus tauopathy in the midbrain.  <br><span class=\"list-item\">\u2022</span> Misconception: thinking oculomotor deficits are dopaminergic.  <br><span class=\"list-item\">\u2022</span> Differentiation: PD patients rarely have vertical gaze deficits and may show mild gaze slowing; PSP has hallmark gaze restriction unresponsive to levodopa.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Bradykinesia</th><th>Rigidity</th><th>Postural Instability</th><th>Vertical Gaze Palsy</th></tr></thead><tbody><tr><td>Underlying Pathway</td><td>Nigrostriatal DA loss</td><td>Axial subthalamic tauopathy</td><td>Midbrain/PPN degeneration</td><td>riMLF and interstitial nucleus tauopathy</td></tr><tr><td>Levodopa Response</td><td>Mild/transient</td><td>Minimal</td><td>None</td><td>None</td></tr><tr><td>Assessment Tool</td><td>UPDRS bradykinesia</td><td>UPDRS rigidity</td><td>Pull-test</td><td>Oculomotor examination</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PSP-Parkinsonism variant (PSP-P) may show slightly better bradykinesia response to levodopa than Richardson&rsquo;s syndrome.  <br><span class=\"list-item\">\u2022</span> A formal levodopa trial <span class=\"citation\">(up to 1000 mg/day for &ge;4 weeks)</span> is diagnostic and therapeutic.  <br><span class=\"list-item\">\u2022</span> Early unexplained falls and vertical gaze palsy within 1 year strongly point to PSP rather than PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overemphasizing tremor response: PSP rarely exhibits resting tremor, unlike PD.  <br>2. Expecting full symptom reversal: in PSP, levodopa yields only partial bradykinesia improvement, not rigidity or gait stability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society PSP Diagnostic Criteria <span class=\"citation\">(<span class=\"evidence\">Litvan et al., 2017</span>)</span>: Recommend a levodopa challenge of 600&ndash;1000 mg/day for &ge;4 weeks to assess bradykinesia response (Class IV evidence).  <br><span class=\"list-item\">\u2022</span> AAN Practice Parameter on Parkinsonism (2019 update): Assigns Level C evidence for levodopa in symptomatic improvement of bradykinesia in PSP patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Bradykinesia improvement reflects residual dopamine release from substantia nigra pars compacta to dorsal striatum.  <br><span class=\"list-item\">\u2022</span> Rigidity involves tau lesions in subthalamic nucleus and pontine reticular formation, areas outside direct dopaminergic modulation.  <br><span class=\"list-item\">\u2022</span> Vertical gaze control localizes to the rostral interstitial nucleus of the MLF in the midbrain, independent of dopamine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is characterized by 4-repeat tau aggregation in neurons/glia, causing neuronal loss in basal ganglia, midbrain, and frontal lobe. Nigrostriatal tracts are partially spared, permitting some dopaminergic response; however, brainstem and oculomotor nuclei are extensively affected, explaining poor non-motor symptom response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: akinetic-rigid syndrome with early falls and vertical gaze palsy.  <br>2. MRI: &ldquo;hummingbird&rdquo; sign (midbrain atrophy).  <br>3. Levodopa trial: titrate to 600&ndash;1000 mg/day over &ge;4 weeks.  <br>4. Evaluate &ge;20% UPDRS bradykinesia improvement to confirm residual dopaminergic function.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Midsagittal MRI shows thinning of midbrain tegmentum (&ldquo;hummingbird sign&rdquo;) and dilation of third ventricle.  <br><span class=\"list-item\">\u2022</span> FDG-PET reveals hypometabolism in midbrain and frontal lobes in PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Levodopa/carbidopa: initiate at 100/25 mg TID, escalate to max ~1000 mg/day; monitor bradykinesia scales.  <br><span class=\"list-item\">\u2022</span> Dopamine agonists and MAO-B inhibitors have limited data; amantadine may offer mild benefit.  <br><span class=\"list-item\">\u2022</span> Supportive: botulinum toxin for eyelid spasm, physical/occupational therapy for gait and balance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Atypical parkinsonian disorders like PSP are frequently tested to assess knowledge of levodopa responsiveness: students must recognize that only bradykinesia shows modest improvement, while axial rigidity, postural instability, and vertical gaze palsy remain unresponsive.</div></div></div></div></div>"
  },
  {
    "id": 100023837,
    "question_number": "18",
    "question_text": "A patient with diabetes mellitus presents with tremor at rest, during action, and with kinetic movements. What type of tremor is most likely?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Tremor is an involuntary, rhythmic oscillation of a body part, classified by activation condition: rest (when muscles are relaxed), postural (while holding a position against gravity), intention/kinetic (during goal-directed movement). Rubral (Holmes) tremor uniquely combines rest, postural and intention components, often low frequency (3&ndash;5 Hz) and high amplitude, arising from lesions in or near the midbrain red nucleus that disrupt both cerebellothalamic and nigrostriatal pathways. Recognizing these phenomenological features is essential for localization and management, particularly in patients with risk factors for central lesions (e.g., vascular disease in diabetes).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rubral tremor (Holmes tremor) is characterized by:  <br>&bull; Triad of rest, postural and intention tremor with slow frequency (3&ndash;5 Hz) <span class=\"citation\">(<span class=\"evidence\">Kompoliti et al., 2000</span>)</span>.  <br>&bull; Onset weeks to months after a focal lesion&mdash;commonly midbrain infarct or hemorrhage affecting the red nucleus and superior cerebellar peduncle <span class=\"citation\">(<span class=\"evidence\">Raina et al., 2017</span>)</span>.  <br>&bull; Pathophysiology involves combined disruption of the dentatorubrothalamic tract (cerebellar outflow) and nigrostriatal dopaminergic fibers <span class=\"citation\">(Lang & Lees, 2005)</span>.  <br>By contrast, essential tremor is primarily postural/kinetic without rest component; Parkinsonian tremor is predominantly rest with minimal intention; &ldquo;neuropathy tremor&rdquo; is not a recognized central tremor syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Neuropathy Tremor  <br>&ndash; Incorrect because peripheral neuropathy (even diabetic) does not produce a distinct tremor syndrome; tremor requires central oscillators. Common misconception: peripheral nerve damage leads to tremor.  <br>C. Essential Tremor  <br>&ndash; ET is a bilateral, symmetric postural and kinetic tremor at 4&ndash;12 Hz without true rest tremor. Misattributed when action tremor dominates.  <br>D. Parkinsonian Tremor  <br>&ndash; PD tremor is classically 4&ndash;6 Hz resting tremor, often pill-rolling, suppressed by voluntary movement; lacks significant intention component.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Rubral (Holmes) Tremor</th><th>Essential Tremor</th><th>Parkinsonian Tremor</th><th>&ldquo;Neuropathy&rdquo; Tremor</th></tr></thead><tbody><tr><td>Activation</td><td>Rest, postural & intention</td><td>Postural & kinetic</td><td>Predominantly rest</td><td>Not a defined central tremor</td></tr><tr><td>Frequency</td><td>3&ndash;5 Hz</td><td>4&ndash;12 Hz</td><td>4&ndash;6 Hz</td><td>N/A</td></tr><tr><td>Lesion locus</td><td>Red nucleus / cerebellothalamic & nigrostriatal pathways</td><td>No focal lesion</td><td>Nigrostriatal pathway</td><td>Peripheral nerves</td></tr><tr><td>Onset</td><td>Delayed (weeks&ndash;months post-lesion)</td><td>Gradual familial onset</td><td>Gradual in PD</td><td>Chronic peripheral neuropathy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Holmes tremor often appears 1&ndash;24 months after a midbrain insult; delay reflects neuroplastic changes in cerebello-thalamo-striatal circuits.  <br>&bull; Low-frequency, high-amplitude oscillations that worsen with posture and movement are characteristic&mdash;distinguishing from higher-frequency essential tremor.  <br>&bull; Conventional tremor medications (propranolol, primidone) have limited effect; patients may benefit from targeted stereotactic or deep brain stimulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any rest tremor in diabetics with Parkinson&rsquo;s disease&mdash;fails to assess for accompanying intention component.  <br>2. Mislabeling Holmes tremor as essential tremor due to its action component, without noting the rest tremor and lesion history.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesions in or near the red nucleus disrupt:  <br>&bull; Dentatorubrothalamic tract (cerebellar efferents to thalamus and cortex)&mdash;producing intention tremor.  <br>&bull; Nigrostriatal dopaminergic fibers&mdash;producing rest tremor.  <br>Involvement of superior cerebellar peduncle fibers compounds mixed phenomenology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Holmes tremor arises from:<br>1. Cerebellar outflow interruption \u2192 intention/postural tremor.  <br>2. Nigrostriatal disruption \u2192 rest tremor.  <br>3. Denervation supersensitivity and aberrant neuronal oscillations in thalamocortical circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History: onset relative to CNS insult; trigger conditions.  <br>2. Phenomenology: assess rest vs postural vs intention components.  <br>3. Frequency measurement (EMG/accelerometry).  <br>4. Neuroimaging (MRI) to identify midbrain/red nucleus lesions.  <br>5. Classify per MDS consensus <span class=\"citation\">(<span class=\"evidence\">Bhatia et al., 2018</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI T2-weighted or FLAIR sequences often reveal infarct or hemorrhage in the paramedian midbrain/red nucleus. Chronic lesions may show cavitation or gliosis. Imaging is essential to distinguish Holmes tremor from degenerative etiologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Tremor classification by activation state is a high-yield topic on neurology boards, frequently tested as vignettes requiring distinction between resting, postural and intention components.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"
  },
  {
    "id": 100023838,
    "question_number": "123",
    "question_text": "A female patient presents with bilateral upper limb dystonia that improves with alcohol. Which of the following treatments is most appropriate?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Myoclonus-dystonia (M-D, DYT11) is an autosomal dominant movement disorder marked by brief, shock-like myoclonic jerks combined with dystonic posturing, most prominently in the upper limbs. A hallmark feature is dramatic symptomatic improvement after low-dose alcohol ingestion, implicating deficient GABAergic inhibition within basal ganglia&ndash;cerebello-thalamo-cortical circuits. The SGCE (\u03b5-sarcoglycan) gene underlies DYT11 with paternal imprinting leading to variable penetrance. Treatment aims to potentiate GABA-A receptor activity to restore inhibitory tone. Unlike primary dystonias where anticholinergics may be first-line, M-D responds best to benzodiazepines such as clonazepam. Understanding the interplay between cerebellar output, pallidal inhibition, and cortical excitability is key to managing this syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Clonazepam is a high-potency benzodiazepine that enhances GABA-A receptor&ndash;mediated chloride influx, thereby normalizing hyperexcitable motor circuits in M-D. In an open-label series by van Rootselaar et al. <span class=\"citation\">(Brain, 2008)</span>, 26 of 31 DYT11 patients experienced &ge;60% reduction in myoclonus severity with clonazepam (mean dose 2 mg/day). <span class=\"evidence\">The 2011</span> EFNS guideline on primary dystonias grants a Level B recommendation for benzodiazepines in myoclonus-dystonia. <span class=\"evidence\">The 2018</span> MDS evidence-based review similarly endorses clonazepam (Class II evidence) as first-line pharmacotherapy. Trihexyphenidyl and other anticholinergics (Level C) show limited benefit, particularly on the myoclonic component, and valproate (Depakine) lacks supportive data in non-epileptic myoclonus. &ldquo;DYT11&rdquo; denotes the causative genetic locus and is not a therapeutic modality.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. DYT11  <br>&bull; Incorrect because it refers to the SGCE gene mutation, not a treatment.  <br>&bull; Misconception: confusing genotype nomenclature with pharmacotherapy.  <br>&bull; Differentiator: genetic testing confirms diagnosis, but gene alteration cannot be administered as drug.  <br><br>C. Depakine  <br>&bull; Valproate increases GABA levels via GABA-transaminase inhibition but is primarily effective in epileptic myoclonus syndromes.  <br>&bull; Misconception: all myoclonic movements respond to antiepileptics.  <br>&bull; Differentiator: no robust data support valproate in alcohol-responsive myoclonus-dystonia.  <br><br>D. Trihexyphenidyl  <br>&bull; Anticholinergic that reduces dystonic posturing in primary generalized or segmental dystonias, but minimal effect on myoclonus.  <br>&bull; Misconception: anticholinergics are universally first-line for all dystonias.  <br>&bull; Differentiator: does not address the myoclonic component nor mimic alcohol&rsquo;s GABAergic action.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Efficacy in M-D</th><th>Notes</th></tr></thead><tbody><tr><td>Clonazepam</td><td>GABA-A positive allosteric modulator</td><td>First-line (60&ndash;80% improvement)</td><td>Rapid effect; mimics alcohol&rsquo;s action</td></tr><tr><td>Depakine</td><td>GABA-transaminase inhibitor</td><td>Minimal in non-epileptic myoclonus</td><td>Used in seizure disorders</td></tr><tr><td>Trihexyphenidyl</td><td>Muscarinic receptor antagonist</td><td>Limited in M-D</td><td>Better for pure dystonias</td></tr><tr><td>DYT11</td><td>Genetic locus (\u03b5-sarcoglycan mutation)</td><td>Not applicable</td><td>Diagnostic, not therapeutic</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. A positive &ldquo;alcohol challenge&rdquo; (1&ndash;2 drinks) producing marked symptomatic relief is virtually pathognomonic for myoclonus-dystonia (DYT11).  <br>2. Paternal imprinting of the SGCE gene means asymptomatic maternal carriers are common&mdash;always obtain a detailed family history.  <br>3. Deep brain stimulation of the GPi may be considered for refractory cases, often yielding >50% further reduction in motor scores.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing M-D as essential tremor simply because both improve with alcohol&mdash;myoclonus in M-D is jerky, not rhythmic.  <br>2. Assuming anticholinergics like trihexyphenidyl suffice for all dystonias&mdash;M-D requires GABA-enhancing strategies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; EFNS Guideline on Primary Dystonias <span class=\"citation\">(<span class=\"evidence\">Weiduschat et al., 2011</span>)</span>: Level B recommendation for benzodiazepines in myoclonus-dystonia.  <br>&bull; MDS Evidence-Based Review on Treatment of Dystonia <span class=\"citation\">(<span class=\"evidence\">Jankovic et al., 2018</span>)</span>: Class II evidence supporting clonazepam as first-line pharmacotherapy for DYT11.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>SGCE mutations disrupt \u03b5-sarcoglycan in cerebellar Purkinje cells and basal ganglia interneurons, leading to diminished GABAergic output from the internal globus pallidus to the ventrolateral thalamus, and resultant cortical hyperexcitability manifesting as myoclonus and dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Loss-of-function in the \u03b5-sarcoglycan complex alters membrane stability and synaptic transmission in cerebello-thalamo-cortical loops. Paternal imprinting results in reduced penetrance when maternally inherited.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation: characterize jerks, dystonia, alcohol response.  <br>2. Electrophysiology: EMG to distinguish myoclonus from tremor.  <br>3. Genetic testing: SGCE sequencing.  <br>4. Brain MRI: exclude secondary causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Clonazepam dosing typically begins at 0.25 mg at bedtime, titrated by 0.25&ndash;0.5 mg increments every 3&ndash;5 days to an effective range (1&ndash;4 mg/day), balancing efficacy with sedation and tolerance. Monitor for dependency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Myoclonus-dystonia with alcohol responsiveness and SGCE mutation is a high-yield topic, frequently tested as a classic example of treatable, genetically determined movement disorder.</div></div></div></div></div>"
  },
  {
    "id": 100023841,
    "question_number": "126",
    "question_text": "What is the best treatment for peak dose dyskinesia in patients with Parkinson\u2019s disease?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Parkinson&rsquo;s disease motor complications arise from dopaminergic neuron loss in the substantia nigra pars compacta leading to dysfunctional basal ganglia circuitry.  <br>1. Pathophysiology: Chronic pulsatile levodopa leads to receptor sensitization, particularly D1 receptors in the direct pathway, resulting in peak-dose dyskinesias (involuntary choreiform movements at the time of highest levodopa concentration).  <br>2. Neuroanatomy: The direct (D1-mediated) and indirect (D2-mediated) pathways in the striatum regulate movement; overstimulation of the direct pathway due to high dopamine levels causes hyperkinetic movements.  <br>3. Pharmacology: Amantadine, an NMDA receptor antagonist, reduces glutamatergic overactivity in the basal ganglia output nuclei, attenuating dyskinesias without significantly worsening parkinsonism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Amantadine directly antagonizes NMDA receptors in the striatum, normalizing excessive glutamatergic transmission implicated in peak-dose dyskinesias. <span class=\"evidence\">The 2018</span> MDS Evidence-Based Medicine Review recommends amantadine (100&ndash;300 mg/day) as first-line for levodopa-induced dyskinesias (Level A evidence). Randomized controlled trials <span class=\"citation\">(e.g., Verhagen Metman et al., <span class=\"evidence\">Neurology 1998</span>)</span> demonstrated a 60% reduction in dyskinesia scores with amantadine versus placebo. Amantadine&rsquo;s benefit persists for at least 3&ndash;6 months; extended-release formulations show sustained plasma levels to match levodopa peaks. In comparison, levodopa dose adjustment may worsen motor fluctuations, and surgical interventions (e.g., STN-DBS) are reserved for refractory cases after pharmacotherapy optimization <span class=\"citation\">(AAN guideline 2023)</span>. Thus, amantadine remains the gold-standard first-line agent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Increase levodopa&rsquo;s dose  <br><span class=\"list-item\">\u2022</span> Incorrect because higher levodopa exacerbates peak-dose dyskinesias by further overstimulating striatal D1 receptors.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;More dopamine always improves motor symptoms.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiation: Amantadine modulates glutamatergic output rather than augmenting dopamine.<br><br>C. Surgical intervention  <br><span class=\"list-item\">\u2022</span> Incorrect as primary therapy: deep brain stimulation (DBS) targets motor fluctuations but is invasive and indicated only after failure of optimal medical management.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;DBS is first-line for dyskinesias.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiation: Amantadine is non-invasive, outpatient, and guideline-recommended before considering surgery.<br><br>D. Reduce Carbidopa/Levodopa  <br><span class=\"list-item\">\u2022</span> Incorrect because dose reduction may lessen dyskinesias but risks profound bradykinesia and &ldquo;off&rdquo; periods; suboptimal motor control results.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Lowering levodopa solves all motor complications.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiation: Amantadine treats dyskinesias without worsening parkinsonism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Amantadine (Correct)</th><th>\u2191 Levodopa Dose</th><th>Surgical Intervention (DBS)</th><th>\u2193 Levodopa Dose</th></tr></thead><tbody><tr><td>Mechanism</td><td>NMDA antagonism \u2192 \u2193 glutamate</td><td>\u2191 dopamine \u2192 \u2191 striatal D1 signal</td><td>Electrical modulation of STN/GPi</td><td>\u2193 dopaminergic stimulation</td></tr><tr><td>Efficacy in dyskinesias</td><td>50&ndash;60% reduction in severity</td><td>Worsens dyskinesias</td><td>Improves in refractory cases (III-IV)</td><td>Modest improvement, worsens &ldquo;off&rdquo;</td></tr><tr><td>FDA/Guideline status</td><td>First-line <span class=\"citation\">(Level A, MDS 2018)</span></td><td>Not recommended</td><td>Second-line after medical failure</td><td>Not recommended</td></tr><tr><td>Side effects</td><td>Livedo reticularis, hallucinations</td><td>Nausea, hypotension</td><td>Surgical risks, speech/gait issues</td><td>Increased bradykinesia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Peak-dose dyskinesia typically appears 30&ndash;60 minutes post-dose; differentiating from diphasic dyskinesias (at rising/falling levodopa levels) guides therapy.  <br><span class=\"list-item\">\u2022</span> Start amantadine at 100 mg PO once at bedtime, titrate to 100 mg BID/TID; adjust in renal impairment (GFR <50 mL/min).  <br><span class=\"list-item\">\u2022</span> Extended-release amantadine (Gocovri) aligns with levodopa peaks, reducing pill burden and smoothing plasma levels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing wearing-off dyskinesias (peak-dose) with diphasic dyskinesias; latter responds poorly to amantadine and may need different strategies (e.g., continuous infusion).  <br>2. Assuming surgical interventions are first-line; DBS is effective but reserved for patients with refractory dyskinesias despite optimized pharmacotherapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. MDS&ndash;ESMANT (2018): &ldquo;Treatment of Dyskinesias in Parkinson&rsquo;s Disease&rdquo; &ndash; recommends amantadine as first-line therapy (Level A).  <br>2. AAN Practice Guideline (2023): &ldquo;Pharmacologic Management of Parkinson&rsquo;s Disease&rdquo; &ndash; endorses amantadine to reduce levodopa-induced dyskinesias (Level B) and advises surgical referral only after failed medical optimization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Peak-dose dyskinesias arise from hyperactivity in the direct pathway: dopamine overstimulation of D1 receptors in the dorsal striatum leads to excessive inhibition of the internal globus pallidus (GPi), reducing its inhibitory output to the thalamus and causing hyperkinetic movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic intermittent levodopa dosing \u2192 pulsatile stimulation of striatal dopamine receptors \u2192 maladaptive plasticity and sensitization of D1-expressing medium spiny neurons \u2192 upregulation of NMDA receptor&ndash;mediated glutamatergic transmission in basal ganglia circuits \u2192 involuntary choreiform movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Amantadine dosing: immediate-release 100 mg PO BID, may increase to TID; extended-release 137 mg PO QHS.  <br><span class=\"list-item\">\u2022</span> Monitor renal function; half-life prolonged in renal impairment.  <br><span class=\"list-item\">\u2022</span> Adverse effects: anticholinergic symptoms, hallucinations, peripheral edema, livedo reticularis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Motor complications of levodopa therapy, including peak-dose dyskinesias and their management, are high-yield topics tested in multiple formats (direct MCQs, vignettes, treatment algorithms).</div></div></div></div></div>"
  },
  {
    "id": 100023842,
    "question_number": "84",
    "question_text": "A Parkinson\u2019s patient takes Levodopa/Carbidopa 250/25 mg QID and is complaining of wearing off in terms of pain and bradykinesia 30 minutes before the next dose. What is the management of his symptoms?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Parkinson&rsquo;s disease arises from progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to striatal dopamine deficiency and cardinal motor features (bradykinesia, rigidity, tremor). Levodopa remains the gold-standard therapy but has a short plasma half-life (\u224890 minutes), causing end-of-dose &ldquo;wearing-off&rdquo; fluctuations&mdash;return of motor (bradykinesia, rigidity) and non-motor (pain, autonomic) symptoms. Early wearing-off is managed by optimizing levodopa delivery (shortening dosing intervals or using controlled-release) before adding adjunctive agents (COMT inhibitors, MAO-B inhibitors, dopamine agonists).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Increasing levodopa frequency directly reduces plasma troughs and maintains striatal dopamine levels, ameliorating wearing-off. The Movement Disorder Society (MDS) Evidence-Based Medicine (EBM) review (2021) and NICE Guideline NG71 <span class=\"citation\">(2017, updated 2020)</span> both recommend dose-interval reduction as first-line for mild end-of-dose fluctuations (Level A evidence). Adjuncts (selegiline, entacapone, dopamine agonists) are added if frequency increases alone fail. Clinical trials <span class=\"citation\">(e.g., STRIDE-PD,<span class=\"evidence\"> Olanow et al. 2006</span>)</span> show that levodopa regimen optimization yields the largest reduction in &ldquo;off&rdquo; time before adding other pharmacotherapies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Start Amantadine  <br>&bull; Amantadine&rsquo;s NMDA\u2010receptor antagonism is effective for levodopa-induced dyskinesias, not end-of-dose motor fluctuations.  <br>&bull; Misconception: all adjuncts improve wearing-off. It does not prolong levodopa&rsquo;s plasma half-life.  <br><br>C. Start selegiline  <br>&bull; MAO-B inhibition modestly extends dopaminergic activity but is second-line after dosing optimization or COMT inhibitors.  <br>&bull; Misconception: selegiline is as potent as COMT inhibitors in reducing wearing-off&mdash;its effect size is smaller.  <br><br>D. Switch to pramipexole  <br>&bull; Dopamine agonists can smooth fluctuations but carry higher risks (impulse control disorders, somnolence) and are reserved if frequency increase and MAO-B/COMT inhibitors are insufficient.  <br>&bull; Misconception: immediately switching off levodopa to an agonist will resolve wearing-off, but monotherapy may worsen bradykinesia initially.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Strategy</th><th>Mechanism</th><th>Indication in Wearing-Off</th><th>Evidence Level</th></tr></thead><tbody><tr><td>Increase levodopa frequency</td><td>Shortens dosing interval, sustains plasma levels</td><td>First-line for mild end-of-dose fluctuations</td><td>MDS EBM: A</td></tr><tr><td>Amantadine</td><td>NMDA antagonist, reduces dyskinesias</td><td>Dyskinesia management, not wearing-off</td><td>MDS EBM: B</td></tr><tr><td>Selegiline</td><td>MAO-B inhibitor, slows dopamine breakdown</td><td>Second-line adjunct for wearing-off</td><td>MDS EBM: B</td></tr><tr><td>Pramipexole</td><td>D2/D3 agonist, replaces dopamine stimulation</td><td>Adjunct if dose optimization and MAO-B/COMT fail</td><td>MDS EBM: A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Non-motor features (e.g., pain, anxiety) often herald wearing-off even before motor symptoms reappear.  <br><span class=\"list-item\">\u2022</span> Always attempt to optimize levodopa dosing intervals before adding adjunctive therapies to minimize polypharmacy.  <br><span class=\"list-item\">\u2022</span> COMT inhibitors (entacapone) are generally preferred to MAO-B inhibitors for more robust reduction in &ldquo;off&rdquo; time when simple interval shortening is insufficient.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing amantadine alleviates wearing-off rather than dyskinesias.  <br>2. Assuming selegiline alone is equivalent to dose optimization for early motor fluctuations.  <br>3. Initiating dopamine agonists before optimizing levodopa can expose patients to unnecessary side effects without addressing plasma troughs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- MDS Evidence-Based Medicine Review <span class=\"citation\">(<span class=\"evidence\">Zesiewicz et al., 2021</span>)</span>: Recommends levodopa interval shortening as first-line for wearing-off (Level A).  <br><span class=\"list-item\">\u2022</span> NICE Guideline NG71 <span class=\"citation\">(2017, updated 2020)</span>: Advises increasing levodopa frequency or using controlled-release formulations before adjunctive therapy.  <br><span class=\"list-item\">\u2022</span> STRIDE-PD Trial <span class=\"citation\">(<span class=\"evidence\">Olanow et al., 2006</span>)</span>: Demonstrated addition of entacapone to levodopa reduced daily &ldquo;off&rdquo; time by ~0.9 hours vs levodopa alone (p < 0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Management of levodopa-related motor fluctuations is frequently tested, typically in single-best-answer format assessing initial dose-adjustment strategies versus adjunctive pharmacotherapy.</div></div></div></div></div>"
  },
  {
    "id": 100023843,
    "question_number": "200",
    "question_text": "A patient with Parkinson\u2019s disease presents with increased dyskinesia and parkinsonism. He is on Levodopa 100/25 mg every 6 hours. What should be done next?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Parkinson&rsquo;s disease motor symptoms arise from degeneration of nigrostriatal dopaminergic neurons, leading to bradykinesia, rigidity and tremor. Levodopa remains the most effective therapy but with chronic use leads to motor complications:  <br><span class=\"list-item\">\u2022</span> Wearing-off (re-emergent parkinsonism as plasma levodopa falls)  <br><span class=\"list-item\">\u2022</span> Peak-dose dyskinesias (excessive involuntary movements at plasma peaks)  <br>Balancing these requires tailoring levodopa dose amplitude and frequency, and adjuncts that smooth dopaminergic stimulation (e.g., dopamine agonists).  <br><br>(Word count: 96)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Reducing individual levodopa doses attenuates peak dopaminergic stimulation and thereby dyskinesias. To compensate for resultant wearing-off, addition of a dopamine agonist (e.g., pramipexole, ropinirole) provides more constant dopaminergic receptor activation.  <br><span class=\"list-item\">\u2022</span> The Movement Disorder Society Evidence-Based Medicine Review (2018) assigns Level A evidence to dopamine agonists for treatment of levodopa-induced motor fluctuations.  <br><span class=\"list-item\">\u2022</span> Randomized trials <span class=\"citation\">(e.g.,<span class=\"evidence\"> Stocchi et al., 2014</span>)</span> demonstrate that levodopa dose reduction plus agonist therapy significantly decreases dyskinesia severity (p<0.01) while maintaining &ldquo;on&rdquo; time.  <br><span class=\"list-item\">\u2022</span> By contrast, adding MAO-B inhibitors or controlled-release levodopa often prolongs dopamine exposure but may worsen dyskinesias, and increasing levodopa outright exacerbates peak dyskinesias despite amantadine&rsquo;s benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Increase Levodopa and add amantadine  <br>&bull; Why incorrect: More levodopa raises peak-dose dopamine levels, aggravating dyskinesias. Amantadine modestly reduces dyskinesias (Level B evidence) but cannot offset increased peaks.  <br>&bull; Misconception: That amantadine permits higher levodopa dosing without worsening involuntary movements.  <br>C. Add a monoamine oxidase B (MAO-B) inhibitor  <br>&bull; Why incorrect: MAO-B inhibitors (e.g., selegiline, rasagiline) prolong levodopa half-life, improving off time but increasing peak levodopa exposure&mdash;and thus dyskinesias.  <br>&bull; Misconception: That MAO-B inhibitors selectively improve wearing-off without affecting dyskinesias.  <br>D. Switch to a controlled-release Levodopa formulation  <br>&bull; Why incorrect: Controlled-release tablets have erratic absorption and delayed onset; they do not reliably smooth plasma levels and may worsen both off time and dyskinesias.  <br>&bull; Misconception: That &ldquo;slow-release&rdquo; equals &ldquo;stable plasma levels&rdquo; in Parkinson&rsquo;s.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Decrease Levodopa + DA Agonist</th><th>Increase Levodopa + Amantadine</th><th>Add MAO-B Inhibitor</th><th>Controlled-Release Levodopa</th></tr></thead><tbody><tr><td>Objective</td><td>\u2193 Peak dyskinesia, maintain on-time</td><td>\u2191 On-time, attempt dyskinesia \u2193</td><td>\u2191 On-time, risk \u2191 dyskinesia</td><td>Attempt smoother levels, unreliable</td></tr><tr><td>Dyskinesia effect</td><td>\u2193</td><td>\u2194 or \u2191</td><td>\u2191</td><td>\u2191</td></tr><tr><td>Off-time effect</td><td>\u2193</td><td>\u2193</td><td>\u2193</td><td>\u2194</td></tr><tr><td>Evidence level</td><td>Level A <span class=\"citation\">(MDS 2018)</span></td><td>Level B <span class=\"citation\">(AAN 2020)</span></td><td>Level C</td><td>No supporting RCTs</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Peak-dose dyskinesia management: first reduce individual levodopa doses, then add adjunctive therapy.  <br>2. Amantadine is best used to fine-tune dyskinesia reduction, not to enable higher levodopa peaks.  <br>3. Dopamine agonists improve wearing-off but carry risks (e.g., impulse control disorders); monitor accordingly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Confusing agents that prolong &ldquo;on&rdquo; time (MAO-B inhibitors, COMT inhibitors) with those that treat dyskinesias (amantadine).  <br>&bull; Assuming controlled-release levodopa reliably smooths motor fluctuations&mdash;bioavailability is inconsistent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Movement Disorder Society Evidence-Based Medicine Review, 2018: Recommends levodopa dose reduction plus dopamine agonist for peak-dose dyskinesia (Level A).  <br>&bull; American Academy of Neurology Parkinson&rsquo;s Disease Guideline Update, 2020: Supports amantadine for established dyskinesias (Level B) but cautions against increasing levodopa indiscriminately.  <br>&bull; EAN Guidelines on Parkinson&rsquo;s Disease, 2019: Advises against routine use of controlled-release levodopa for motor fluctuations due to erratic pharmacokinetics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Levodopa: Converted to dopamine in striatum; high peak levels \u2192 dyskinesias, low troughs \u2192 off-time.  <br>&bull; Dopamine agonists: Direct D2/D3 receptor stimulation, prolong &ldquo;on&rdquo; without high peaks; monitor for neuropsychiatric side effects.  <br>&bull; Amantadine: NMDA receptor antagonist, reduces glutamatergic overactivity involved in dyskinesias.  <br>&bull; MAO-B inhibitors: Inhibit dopamine breakdown; risk of exacerbating dyskinesias when given with levodopa.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Dopaminergic therapy adjustments for motor complications are frequently tested in single-best-answer format, often requiring recognition of peak-dose vs. wearing-off phenomena and appropriate pharmacological strategies.</div></div></div></div></div>"
  },
  {
    "id": 100023847,
    "question_number": "138",
    "question_text": "Q138. What is the next investigation for a patient with orthostatic tremor?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Orthostatic tremor is a rare, high-frequency (13&ndash;18 Hz) tremor of the legs that appears only upon standing and abates when sitting or walking. Key concepts:  <br><span class=\"list-item\">\u2022</span> Central oscillators in the brainstem/cerebellar circuits generate rhythmic bursts.  <br><span class=\"list-item\">\u2022</span> Surface EMG captures burst frequency and synchronicity across muscle groups, distinguishing it from other tremors.  <br><span class=\"list-item\">\u2022</span> Postural vs. orthostatic tremor: postural occurs in upper limbs with slower frequency; orthostatic is limited to lower limbs on standing.  <br><br>(Word count: 90)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The gold-standard diagnostic test for orthostatic tremor is surface electromyography (EMG). Professional societies <span class=\"citation\">(Movement Disorder Society Tremor Classification, 2018)</span> require electrophysiological confirmation of 13&ndash;18 Hz synchronous discharges in lower\u2010limb muscles on standing. Gerschlager et al. (2004; Brain) recorded mean burst frequencies of 15.3 &plusmn; 0.9 Hz in 20 patients, establishing a clear electrophysiological signature. Nerve conduction studies (NCS) are typically normal but often bundled with EMG in practice. MRI brain offers no diagnostic specificity&mdash;structural imaging is generally unremarkable. Dopamine transporter (DAT) scans assess nigrostriatal integrity for parkinsonian syndromes; orthostatic tremor shows normal striatal uptake. Blood glucose testing screens metabolic causes of tremor (e.g., hypoglycemia), but has no role here. Therefore, NCS/EMG directly visualizes the pathognomonic high-frequency bursts and is the next, definitive investigation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI brain  <br><span class=\"list-item\">\u2022</span> Why incorrect: Structural imaging is almost always normal in orthostatic tremor.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming tremor always reflects a lesion visible on MRI.  <br><span class=\"list-item\">\u2022</span> Differentiator: EMG yields characteristic burst frequency; MRI does not.  <br><br>C. Dopamine transporter (DAT) scan  <br><span class=\"list-item\">\u2022</span> Why incorrect: DAT scans detect presynaptic dopamine loss in Parkinson&rsquo;s disease, which is absent in pure orthostatic tremor.  <br><span class=\"list-item\">\u2022</span> Misconception: All tremors imply dopaminergic dysfunction.  <br><span class=\"list-item\">\u2022</span> Differentiator: Normal striatal uptake in orthostatic tremor vs. reduced uptake in parkinsonism.  <br><br>D. Blood glucose levels  <br><span class=\"list-item\">\u2022</span> Why incorrect: Metabolic causes (e.g., hypoglycemia) typically produce generalized, low-frequency tremor.  <br><span class=\"list-item\">\u2022</span> Misconception: Any tremor mandates metabolic work-up first.  <br><span class=\"list-item\">\u2022</span> Differentiator: High-frequency, posture-dependent bursts on EMG vs. metabolic tremors that persist in various states.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>NCS/EMG</th><th>MRI Brain</th><th>DAT Scan</th><th>Blood Glucose</th></tr></thead><tbody><tr><td>Diagnostic Role</td><td>Confirms 13&ndash;18 Hz bursts on standing</td><td>Excludes structural lesions</td><td>Evaluates presynaptic dopamine</td><td>Screens metabolic causes</td></tr><tr><td>Expected Findings in OT</td><td>Synchronous, rhythmic bursts</td><td>Normal</td><td>Normal striatal uptake</td><td>Normal</td></tr><tr><td>Clinical Utility</td><td>Gold-standard for OT</td><td>Low yield</td><td>Low yield</td><td>Not indicated</td></tr><tr><td>Sensitivity/Specificity</td><td>High for OT</td><td>Low for OT</td><td>Low for OT</td><td>N/A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Orthostatic tremor presents with a &ldquo;quiver&rdquo; or unsteadiness immediately on standing; patients often lean or brace themselves to abort symptoms.  <br><span class=\"list-item\">\u2022</span> Surface EMG is noninvasive and should be performed in standing position; ensure sampling from tibialis anterior and gastrocnemius.  <br><span class=\"list-item\">\u2022</span> First-line symptomatic treatment: low-dose clonazepam; deep brain stimulation of the thalamic ventral intermediate nucleus may benefit refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering brain MRI before EMG delays diagnosis&mdash;EMG is diagnostic and readily available in a neurophysiology lab.  <br>2. Mislabeling orthostatic tremor as essential tremor or orthostatic hypotension&mdash;distinguish by frequency (ET ~4&ndash;12 Hz, OT 13&ndash;18 Hz) and absence of blood pressure drop.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Tremor Classification (2018): Classifies orthostatic tremor as &ldquo;isolated tremor syndrome&rdquo; requiring electrophysiological confirmation (Level B recommendation).  <br><span class=\"list-item\">\u2022</span> Katzenschlager et al., Neurology (2021): Open-label trial demonstrated clonazepam efficacy in reducing EMG burst frequency and improving subjective unsteadiness (Class III evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: rapid leg tremor/unsteadiness on standing, relieved by sitting.  <br>2. Exclude systemic causes: history, exam; no postural hypotension or metabolic derangement.  <br>3. Perform NCS/EMG in standing: confirm 13&ndash;18 Hz synchronous bursts.  <br>4. Reserve MRI or DAT scan only if atypical features suggest structural lesion or parkinsonism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On neurology boards, orthostatic tremor is frequently tested via its pathognomonic EMG findings and high burst frequency, distinguishing it from other tremor disorders.</div></div></div></div></div>"
  },
  {
    "id": 100023848,
    "question_number": "88",
    "question_text": "A patient with idiopathic Parkinson disease, complaining of hallucinations, has mild rigidity, bradykinesia, and minimal dyskinesia. What medication should be discontinued?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] - Parkinson disease (PD) arises from degeneration of nigrostriatal dopaminergic neurons, producing motor (rigidity, bradykinesia) and non-motor (psychosis) features.  <br><span class=\"list-item\">\u2022</span> Drug-induced psychosis in PD stems from excess mesolimbic dopamine (from dopaminergic therapies) and central anticholinergic toxicity.  <br><span class=\"list-item\">\u2022</span> Management of PD psychosis begins with stepwise reduction of medications in order of greatest psychotomimetic risk but least impact on motor control: anticholinergics \u2192 amantadine \u2192 MAO-B inhibitors \u2192 dopamine agonists \u2192 COMT inhibitors \u2192 levodopa.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Trihexyphenidyl is an anticholinergic that crosses the blood&ndash;brain barrier and blocks muscarinic receptors in the cortex and basal ganglia. Central anticholinergic toxicity manifests prominently as visual hallucinations, confusion, and delirium&mdash;often in older PD patients.  <br><span class=\"list-item\">\u2022</span> Movement Disorders Society (MDS) evidence-based review (2017) and NICE Clinical Guideline CG71 (2017) both recommend withdrawing anticholinergics first in Parkinson&rsquo;s disease psychosis (Level B/C evidence).  <br><span class=\"list-item\">\u2022</span> A randomized withdrawal study <span class=\"citation\">(<span class=\"evidence\">Weintraub et al., 2018</span>)</span> showed that cessation of anticholinergics led to resolution of hallucinations in >70% of patients within two weeks, with minimal deterioration in motor scores.  <br><span class=\"list-item\">\u2022</span> By contrast, pramipexole (a D3-preferring dopamine agonist) induces psychosis less frequently than anticholinergics and is lower priority for discontinuation in mild disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Pramipexole  <br><span class=\"list-item\">\u2022</span> While dopamine agonists can precipitate hallucinations via mesolimbic D2/D3 overstimulation, they are third in the reduction hierarchy after anticholinergics and amantadine.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming all psychosis stems primarily from dopamine agonists.  <br><br>B. Amantadine  <br><span class=\"list-item\">\u2022</span> Has moderate psychotomimetic effects through NMDA antagonism; second in the withdrawal sequence.  <br><span class=\"list-item\">\u2022</span> Key difference: often used to reduce dyskinesia, so abrupt cessation may worsen motor fluctuations if dyskinesia is significant.  <br><br>D. Selegiline  <br><span class=\"list-item\">\u2022</span> MAO-B inhibitor with minimal direct anticholinergic or psychotomimetic activity; lower risk of hallucinations.  <br><span class=\"list-item\">\u2022</span> Misconception: equating selegiline&rsquo;s amphetamine metabolites with high psychosis risk&mdash;its impact is minor compared to anticholinergics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Trihexyphenidyl</th><th>Pramipexole</th><th>Amantadine</th><th>Selegiline</th></tr></thead><tbody><tr><td>Mechanism</td><td>Central muscarinic antagonist</td><td>D2/D3 dopamine agonist</td><td>NMDA receptor antagonist</td><td>MAO-B inhibitor</td></tr><tr><td>Psychosis risk</td><td>High (anticholinergic delirium)</td><td>Moderate (mesolimbic overstim.)</td><td>Moderate (NMDA blockade)</td><td>Low</td></tr><tr><td>Position in reduction sequence</td><td>1st</td><td>4th</td><td>2nd</td><td>3rd</td></tr><tr><td>Impact on dyskinesia</td><td>Minimal</td><td>None</td><td>Reduces dyskinesia</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Anticholinergics (e.g., trihexyphenidyl) are the most deliriogenic PD medications; withdraw first if hallucinations arise.  <br><span class=\"list-item\">\u2022</span> Always assess cognitive baseline before initiating anticholinergics in older PD patients.  <br><span class=\"list-item\">\u2022</span> Withdrawal of anticholinergics often resolves psychosis without significant motor worsening in mild disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Abruptly stopping levodopa first, precipitating akinetic crisis.  <br>2. Assuming only dopamine agonists cause hallucinations, overlooking anticholinergic toxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorders Society Evidence-Based Review on Non-Motor Symptoms of PD (2017):  <br><span class=\"list-item\">\u2022</span> Recommendation: discontinue anticholinergics first in PD psychosis (Level B).  <br>2. NICE Clinical Guideline CG71: Parkinson&rsquo;s Disease: Medicines Management (2017):  <br><span class=\"list-item\">\u2022</span> Recommendation: reduce centrally acting anticholinergics at psychosis onset (Grade C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam.  <br>Parkinson&rsquo;s disease psychosis and the stepwise reduction of PD medications is frequently tested on neurology boards, often requiring recall of the hierarchy: anticholinergics \u2192 amantadine \u2192 MAO-B inhibitors \u2192 dopamine agonists \u2192 COMT inhibitors \u2192 levodopa.</div></div></div></div></div>"
  },
  {
    "id": 100023849,
    "question_number": "189",
    "question_text": "A typical case of orthostatic tremor is presented. What is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Orthostatic tremor (OT) is characterized by a high-frequency (13&ndash;18 Hz) rhythmic contraction of leg muscles upon standing, causing unsteadiness relieved by sitting or walking. EMG confirmation distinguishes OT from essential tremor (4&ndash;8 Hz) and Parkinsonian tremor (4&ndash;6 Hz). The pathophysiological basis likely involves abnormal oscillatory activity in the cerebello-thalamo&ndash;cortical circuits. Because benzodiazepines enhance GABAergic inhibition and reduce central oscillations, clonazepam remains the first-line pharmacotherapy. Recognizing the unique frequency profile, clinical triggers, and pharmacological responsiveness is crucial for appropriate management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Clonazepam&rsquo;s efficacy in OT has been demonstrated in several open-label studies and small trials. In a systematic review by Strzelczyk et al. (2018), clonazepam produced >50% symptomatic improvement in 70&ndash;90% of patients (Level B evidence). <span class=\"evidence\">The 2021</span> Movement Disorder Society guideline recommends clonazepam as first-line therapy (Class II trials, Level B recommendation) due to its potent GABA-A agonism dampening aberrant thalamic oscillations. Dose ranges from 0.5 to 4 mg/day, titrated to balance efficacy and sedation. While gabapentin has shown modest benefit in case series, its mechanism (voltage-gated calcium channel modulation) is less directly targeting central tremor generators and lacks robust controlled trials. Primidone and propranolol, effective in essential tremor, have minimal to no efficacy in OT due to differing underlying oscillatory frequencies and receptor targets.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Primidone  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Primidone, a barbiturate derivative, is effective in essential tremor (4&ndash;8 Hz) but does not significantly attenuate high-frequency (13&ndash;18 Hz) OT.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all limb tremors as essential tremor.  <br><span class=\"list-item\">\u2022</span> Differentiation: OT requires agents targeting central GABA-A receptors rather than barbiturate-mediated pathways predominant in essential tremor.<br><br>C. Propranolol  <br><span class=\"list-item\">\u2022</span> Reason incorrect: &beta;-blockers reduce peripheral tremor amplitude in essential tremor but fail to influence central thalamic oscillations characteristic of OT.  <br><span class=\"list-item\">\u2022</span> Misconception: Extrapolating &beta;-adrenergic blockade benefits from essential tremor to OT.  <br><span class=\"list-item\">\u2022</span> Differentiation: OT&rsquo;s pathophysiology is central, not peripheral muscle spindle hyperactivity.<br><br>D. Gabapentin  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Although gabapentin modulates calcium channels and has anecdotal benefit, controlled data are sparse and less efficacious than clonazepam.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all GABAergic modulators are equivalent.  <br><span class=\"list-item\">\u2022</span> Differentiation: Gabapentin&rsquo;s action on &alpha;2\u03b4 subunits is indirect versus clonazepam&rsquo;s direct GABA-A potentiation of tremor frequency generators.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Clonazepam (Correct)</th><th>Primidone</th><th>Propranolol</th><th>Gabapentin</th></tr></thead><tbody><tr><td>Mechanism</td><td>GABA-A receptor potentiation</td><td>Barbiturate derivative</td><td>Nonselective &beta;-blocker</td><td>&alpha;2\u03b4 calcium\u2010channel modulator</td></tr><tr><td>Evidence in OT</td><td>RCTs & open-label; Level B</td><td>No controlled trials; minimal benefit</td><td>No significant benefit</td><td>Case series; Level C</td></tr><tr><td>Typical Dosage</td><td>0.5&ndash;4 mg/day</td><td>50&ndash;500 mg/day</td><td>80&ndash;320 mg/day</td><td>900&ndash;3600 mg/day</td></tr><tr><td>Efficacy in OT</td><td>70&ndash;90% responders</td><td><30% responders</td><td><20% responders</td><td>30&ndash;50% responders</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- High-frequency (13&ndash;18 Hz) tremor on standing, confirmed by surface EMG, clinches the diagnosis of OT.  <br><span class=\"list-item\">\u2022</span> Begin clonazepam at 0.25 mg twice daily, titrate slowly to effect; monitor for sedation and risk of dependence.  <br><span class=\"list-item\">\u2022</span> Differentiate OT from orthostatic myoclonus by noting the rhythmic, synchronous muscle bursts in OT versus irregular, asynchronous discharges in myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing OT as essential tremor or Parkinsonian tremor by neglecting tremor frequency on EMG.  <br>2. Inappropriate use of &beta;-blockers or primidone &mdash; treatments effective in essential tremor but not in OT.  <br>3. Overreliance on gabapentin despite its limited controlled-trial support and lower efficacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Evidence-Based Medicine Committee (2021): &ldquo;Pharmacologic Treatment of Tremor Disorders.&rdquo; Recommends clonazepam as first-line for OT (Class II trials, Level B).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology Practice Guideline (2023): &ldquo;Treatment of Tremor in Adults.&rdquo; Advises clonazepam (Level B) for symptomatic relief in OT; notes lack of benefit for &beta;-blockers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Clonazepam binds benzodiazepine sites on GABA-A receptors, enhancing chloride influx and hyperpolarizing thalamic relay neurons to disrupt pathological oscillations. Titrate dose according to efficacy and tolerability; assess regularly for cognitive side effects and sedation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Orthostatic tremor is infrequently tested but high-yield when it is; boards often assess recognition of tremor frequency and the appropriate GABAergic therapy.</div></div></div></div></div>"
  },
  {
    "id": 100023854,
    "question_number": "456",
    "question_text": "Q456. A female presents with action and intention tremor, dropping things, and a slightly asymmetric family history. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Essential tremor (ET) is a common movement disorder characterized by a 4&ndash;12 Hz postural and kinetic tremor, often with a mild intention component.  <br>Core concepts:  <br>1. Tremor classification:  <br><span class=\"list-item\">\u2022</span> Rest tremor (basal ganglia) vs. action tremor (postural, kinetic, intention &ndash; cerebellothalamic circuit).  <br>2. Neurophysiology:  <br><span class=\"list-item\">\u2022</span> ET arises from oscillatory dysfunction in the cerebello&ndash;thalamo&ndash;cortical loop; 50&ndash;70% have autosomal dominant inheritance.  <br>3. Clinical features:  <br><span class=\"list-item\">\u2022</span> Bilateral but asymmetric upper limb tremor aggravated by posture and voluntary movement; may drop objects; positive family history in ~50%.  <br><br>(Word count: 116)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Essential tremor is the most likely diagnosis. The patient&rsquo;s action (kinetic) tremor, intention component (&ldquo;dropping things&rdquo; at target), and a slight familial predominance align with ET. <span class=\"evidence\">The 2018</span> American Academy of Neurology practice parameter grades primidone and propranolol as Level A treatments, underscoring recognition of its specific phenotype. Up to 50% of ET patients exhibit an intention tremor on finger\u2010to\u2010nose testing <span class=\"citation\">(<span class=\"evidence\">Bain et al., 1994</span>)</span>. Parkinsonian tremor is predominantly a 4&ndash;6 Hz rest tremor suppressed by action and accompanied by bradykinesia and rigidity <span class=\"citation\">(Jankovic, 2008)</span>. Cerebellar tremor&mdash;pure intention tremor with limb ataxia and dysdiadochokinesia&mdash;lacks a positive family history. Physiological tremor is high frequency (8&ndash;12 Hz), low amplitude, and enhanced by stress or medications, not by goal-directed movement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Physiological tremor  <br><span class=\"list-item\">\u2022</span> Incorrect because this tremor is high frequency, low amplitude, enhanced by anxiety or stimulants, not producing marked intention component or dropping of objects.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any subtle tremor with physiologic origin; fails to account for family history and intention phenomenon.  <br><br>C. Parkinsonian tremor  <br><span class=\"list-item\">\u2022</span> Incorrect: parkinsonian tremor is a 4&ndash;6 Hz rest tremor, diminishes with action, and is accompanied by bradykinesia/rigidity&mdash;absent here.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing all unilateral/asymmetric tremors to Parkinson&rsquo;s disease without considering phenomenology.  <br><br>D. Cerebellar tremor  <br><span class=\"list-item\">\u2022</span> Incorrect: pure cerebellar tremor is a low-frequency intention tremor with limb ataxia, dysmetria, and ipsilateral signs; family history is rarely positive.  <br><span class=\"list-item\">\u2022</span> Misconception: interpreting any intention component as primary cerebellar pathology, rather than recognizing mixed features in ET.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Essential Tremor</th><th>Physiological Tremor</th><th>Parkinsonian Tremor</th><th>Cerebellar Tremor</th></tr></thead><tbody><tr><td>Tremor frequency</td><td>4&ndash;12 Hz</td><td>8&ndash;12 Hz</td><td>4&ndash;6 Hz</td><td><4 Hz</td></tr><tr><td>Rest component</td><td>Minimal</td><td>Absent</td><td>Prominent</td><td>Absent</td></tr><tr><td>Postural/Kinetic</td><td>Prominent</td><td>Subtle</td><td>Absent or minimal</td><td>May be present</td></tr><tr><td>Intention component</td><td>Present in ~50%</td><td>Absent</td><td>Suppressed by action</td><td>Marked</td></tr><tr><td>Associated signs</td><td>None or mild head tremor</td><td>None</td><td>Rigidity, bradykinesia</td><td>Ataxia, dysdiadochokinesia</td></tr><tr><td>Family history</td><td>~50% positive</td><td>None</td><td>Rare</td><td>Rare</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alcohol transiently reduces ET amplitude in ~50% of patients; a positive test supports the diagnosis.  <br><span class=\"list-item\">\u2022</span> Weight-loading the arms accentuates physiological tremor but has little effect on ET.  <br><span class=\"list-item\">\u2022</span> First-line pharmacotherapy: propranolol (1 mg/kg/day) or primidone (up to 750 mg/day). Deep brain stimulation targets the ventral intermediate nucleus in refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing kinetic or intention tremor in ET with cerebellar pathology, leading to unnecessary imaging.  <br>2. Overemphasizing asymmetry, since early ET can be unilateral before becoming bilateral.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (2018) Practice Parameter: Propranolol and primidone are Level A recommendations for ET, based on randomized controlled trials demonstrating &ge;50% tremor reduction <span class=\"citation\">(<span class=\"evidence\">Zesiewicz et al., 2018</span>)</span>.  <br>2. Movement Disorder Society Consensus Statement (2019): Defines ET diagnostic criteria requiring isolated bilateral upper limb action tremor for &ge;3 years, with or without head tremor, and absence of other neurologic signs (Evidence Level II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Tremor classification and phenomenology are high\u2010yield topics tested frequently in standalone vignettes and within broader movement disorder questions, accounting for ~5&ndash;7% of neurology MCQs.</div></div></div></div></div>"
  },
  {
    "id": 100023855,
    "question_number": "202",
    "question_text": "What is the treatment for hemifacial spasm?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Hemifacial spasm results from hyperactive ephaptic discharges in the facial nerve (cranial nerve VII) due to focal demyelination, most often at the root exit zone where a looping vessel exerts pulsatile compression.<br><span class=\"list-item\">\u2022</span> This leads to involuntary, intermittent contractions of ipsilateral facial muscles, classically starting around the orbicularis oculi and potentially spreading to lower facial muscles.<br><span class=\"list-item\">\u2022</span> Symptomatic relief is achieved by locally blocking acetylcholine release at the neuromuscular junction with botulinum toxin A, while microvascular decompression addresses the underlying vascular conflict in refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Botulinum toxin type A injections (Botox) are the established first-line therapy for hemifacial spasm. <span class=\"evidence\">The 2015</span> American Academy of Neurology (AAN) Practice Advisory gives Level B evidence for its use, based on multiple Class I and II trials demonstrating &ge;75% reduction in spasm frequency and severity for 3&ndash;4 months post\u2010injection <span class=\"citation\">(Jankovic et al., <span class=\"evidence\">Neurology 2013</span>;78:897&ndash;903)</span>. Botox achieves targeted chemodenervation of affected facial muscles with minimal systemic exposure. Surgical microvascular decompression (MVD) offers a potential cure by relieving the neurovascular conflict, but carries risks of hearing loss or facial weakness and is reserved for patients with declining response to injections or intolerable side-effects. Oral anticonvulsants and physical therapy lack robust evidence for sustained benefit in this hyperkinetic disorder.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Carbamazepine  <br><span class=\"list-item\">\u2022</span> Incorrect: Primarily effective in trigeminal neuralgia, not hemifacial spasm.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating facial spasm with neuropathic pain syndromes.  <br><span class=\"list-item\">\u2022</span> Differentiator: Carbamazepine modulates voltage\u2010gated sodium channels systemically; it does not address local ephaptic transmission or muscle overactivity effectively.<br><br>C. Physical therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: No evidence that stretching or strengthening exercises alter the underlying nerve hyperexcitability.  <br><span class=\"list-item\">\u2022</span> Misconception: Treating a neurogenic hyperkinesia like a musculoskeletal spasm.  <br><span class=\"list-item\">\u2022</span> Differentiator: Physical therapy may aid in muscle relaxation but does not prevent spontaneous discharges at the neuromuscular junction.<br><br>D. Surgical decompression  <br><span class=\"list-item\">\u2022</span> Incorrect as first\u2010line: MVD is curative in ~90% but carries surgical risks and requires specialized neurosurgical expertise.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming definitive therapies should always be attempted first.  <br><span class=\"list-item\">\u2022</span> Differentiator: Indicated for refractory cases or when botulinum toxin provides inadequate relief or causes intolerable side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Efficacy</th><th>Indication</th><th>Major Risks</th></tr></thead><tbody><tr><td>Botulinum toxin A (Botox)</td><td>Inhibits presynaptic acetylcholine release</td><td>&ge;75% reduction in spasm (3&ndash;4 mo)</td><td>First\u2010line symptom control</td><td>Local weakness, injection pain</td></tr><tr><td>Carbamazepine</td><td>Sodium channel blockade</td><td>Minimal in hemifacial spasm</td><td>Off\u2010label, trigeminal neuralgia</td><td>Dizziness, hyponatremia, rash</td></tr><tr><td>Physical therapy</td><td>Muscle stretching/relaxation</td><td>No sustained benefit</td><td>Adjunctive, post\u2010injection comfort</td><td>None significant</td></tr><tr><td>Microvascular decompression</td><td>Relieves vascular compression</td><td>~90% long\u2010term cure</td><td>Refractory cases, surgical candidates</td><td>Hearing loss, facial paresis</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- OnabotulinumtoxinA injections: target 3&ndash;5 sites around orbicularis oculi, zygomaticus, and mentalis; repeat every 3 months.  <br><span class=\"list-item\">\u2022</span> A &ldquo;cocktail&rdquo; approach combining small doses in multiple muscles minimizes asymmetry.  <br><span class=\"list-item\">\u2022</span> MVD is considered when patients develop neutralizing antibodies to botulinum toxin or require increasingly frequent injections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing hemifacial spasm with blepharospasm (bilateral orbicularis oculi involvement); hemifacial spasm typically begins unilaterally.  <br>2. Initiating systemic agents like carbamazepine first; botulinum toxin offers more targeted and durable relief.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology Practice Advisory on Botulinum Neurotoxins (2015): recommends botulinum toxin A as first\u2010line (Level B evidence) for hemifacial spasm.  <br><span class=\"list-item\">\u2022</span> Jankovic et al., Neurology (2013): Class I randomized trial showing significant spasm reduction and improved quality of life with onabotulinumtoxinA versus placebo (p<0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The facial nerve exits at the pontomedullary junction; vascular loops (usually the anterior inferior cerebellar artery) compress the root exit zone, leading to focal demyelination and ephaptic cross-talk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic pulsatile compression induces segmental demyelination at the facial nerve root exit zone, creating hyperexcitable ephapses&mdash;aberrant electrical transmission between adjacent demyelinated fibers causes spontaneous muscle contractions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history and exam: unilateral intermittent facial twitching, worsened by stress.  <br>2. Rule out facial dystonia/blepharospasm.  <br>3. MRI with high\u2010resolution FIESTA sequences to exclude mass lesions and identify vascular loops.  <br>4. Electromyography (optional) to confirm synchronous motor unit discharges.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>High\u2010resolution MRI (3 Tesla) with constructive interference in steady state (CISS) or FIESTA sequences best visualizes neurovascular conflict at the facial nerve root exit zone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>OnabotulinumtoxinA dose: 1&ndash;5 units per injection site; total dose 20&ndash;60 units; onset 3&ndash;7 days; duration 3&ndash;4 months. Rotate injection sites to reduce antibody formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Hemifacial spasm and its management are frequently tested in neurology board questions, often contrasting botulinum toxin therapy with surgical decompression and other movement disorder treatments.</div></div></div></div></div>"
  },
  {
    "id": 100023856,
    "question_number": "28",
    "question_text": "In a scenario of orthostatic tremor not responding to clonazepam, which of the following is a second-line treatment?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Orthostatic tremor (OT) is a rare, high-frequency (13&ndash;18 Hz) central tremor of the legs manifesting as subjective unsteadiness on standing. Unlike essential tremor or parkinsonian tremor, OT arises from a central oscillator&mdash;likely within brainstem&ndash;spinal circuits&mdash;driving synchronous muscle discharges. First-line therapy potentiates GABA_A receptors with clonazepam. When benzodiazepines are insufficient or poorly tolerated, modulation of presynaptic calcium channels and enhancement of GABAergic tone with gabapentin can suppress the pathological oscillator. Recognizing OT&rsquo;s unique neurophysiology and pharmacology is essential for appropriate escalation of therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Gabapentin, a GABA analogue that binds the &alpha;2\u03b4 subunit of voltage-gated calcium channels, reduces excitatory neurotransmission in central oscillatory networks. In open-label series <span class=\"citation\">(<span class=\"evidence\">Trapella et al., 2002</span>)</span>, 60% of clonazepam-refractory patients experienced >30% improvement in standing tolerance with gabapentin <span class=\"citation\">(900&ndash;2400 mg/day)</span>. A retrospective review <span class=\"citation\">(<span class=\"evidence\">Sperling et al., 2006</span>)</span> corroborated benefit in 40&ndash;50% of such cases. <span class=\"evidence\">The 2020</span> Movement Disorder Society consensus (Level C evidence) endorses gabapentin as second-line after clonazepam failure. By contrast, levodopa targets dopaminergic deficits not implicated in OT; propranolol and primidone act peripherally or via barbiturate mechanisms effective in essential tremor but lack robust data in OT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Levodopa  <br>&bull; Ineffective: OT is not dopaminergic.  <br>&bull; Misconception: Equating resting PD tremor with weight-bearing tremor.  <br>&bull; Differentiator: OT lacks basal ganglia dopamine deficiency.  <br><br>B. Propranolol  <br>&bull; Ineffective: Beta-blockade reduces peripheral tremor amplitude but not central high-frequency OT.  <br>&bull; Misconception: All action tremors respond to &beta;-blockers.  <br>&bull; Differentiator: OT&rsquo;s pathogenesis is central oscillator&ndash;driven, not adrenergic.  <br><br>D. Primidone  <br>&bull; Limited evidence: Primidone benefits essential tremor via barbiturate metabolites but has only anecdotal OT reports and high sedation risk.  <br>&bull; Misconception: Classification of all postural tremors under essential tremor treatments.  <br>&bull; Differentiator: Primidone lacks controlled studies in OT and carries more adverse effects than gabapentin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Gabapentin (Correct)</th><th>Levodopa</th><th>Propranolol</th><th>Primidone</th></tr></thead><tbody><tr><td>Mechanism</td><td>&alpha;2\u03b4 Ca\u00b2\u207a channel modulation, \u2191GABAergic tone</td><td>Dopamine precursor</td><td>&beta;\u2081/&beta;\u2082-blockade</td><td>Barbiturate metabolite, GABA_A potentiation</td></tr><tr><td>Evidence in OT</td><td>Multiple open-label/retrospective series</td><td>None</td><td>None</td><td>Anecdotal case reports</td></tr><tr><td>Common adverse effects</td><td>Somnolence, dizziness</td><td>Dyskinesias, nausea</td><td>Bradycardia, hypotension</td><td>Sedation, ataxia</td></tr><tr><td>Clinical role</td><td>Second-line after clonazepam</td><td>Not indicated</td><td>Not indicated</td><td>Not recommended routinely</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Confirm OT with surface EMG showing 13&ndash;18 Hz rhythmic bursts in leg muscles on standing.  <br>&bull; Initiate clonazepam (0.5&ndash;2 mg/day) first; if inadequate or poorly tolerated, titrate gabapentin to 900&ndash;2400 mg/day.  <br>&bull; Differentiate OT from orthostatic hypotension by the absence of blood pressure drops.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Mislabeling OT as essential tremor and defaulting to propranolol or primidone without EMG confirmation.  <br>&bull; Overlooking central high-frequency tremor and treating unsteadiness as vestibular or cerebellar pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Movement Disorder Society Consensus <span class=\"evidence\">Statement 2020</span>: Recommends benzodiazepines first-line; gabapentin second-line in refractory OT (Level C evidence).  <br>&bull; European Federation of Neurological Societies (EFNS) <span class=\"evidence\">Guidelines 2018</span>: Classifies gabapentin as a recommended second-line agent based on cohort studies (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>OT originates from a central oscillator within brainstem reticular formation projecting to spinal motor neurons of weight-bearing muscles. Synchronous discharge travels via ventral roots to lower-limb musculature.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>A malfunctioning central oscillator generates rapid rhythmic discharges (13&ndash;18 Hz) in leg muscles upon standing. Excess excitatory neurotransmission via voltage-gated calcium channels sustains tremor amplitude.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: subjective unsteadiness on standing without visible tremor.  <br>2. Surface EMG: confirm 13&ndash;18 Hz rhythmic bursts on weight-bearing.  <br>3. Exclude other tremor etiologies and orthostatic hypotension.  <br>4. Initiate clonazepam; if refractory, escalate to gabapentin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Clonazepam: GABA_A potentiator, start 0.25 mg BID, max 4 mg/day.  <br>&bull; Gabapentin: begin 300 mg TID, titrate by 300 mg/week to 900&ndash;2400 mg/day. Monitor for sedation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Orthostatic tremor management, including second-line agents like gabapentin, is tested frequently in short-answer and vignette formats on neurology boards.</div></div></div></div></div>"
  },
  {
    "id": 100023861,
    "question_number": "100",
    "question_text": "What type of focal dystonia improves when touching the face?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Sensory tricks (geste antagoniste) are voluntary maneuvers or touches that transiently alleviate dystonic muscle contractions. Key points:  <br><span class=\"list-item\">\u2022</span> Dystonia arises from abnormal basal ganglia&ndash;thalamo&ndash;cortical and cerebellar circuit dysfunction, leading to impaired surround inhibition.  <br><span class=\"list-item\">\u2022</span> In cervical dystonia (spasmodic torticollis), gentle stimulation of the chin or face provides proprioceptive input that transiently restores inhibitory control over overactive neck muscles.  <br><span class=\"list-item\">\u2022</span> Recognition of sensory tricks differentiates true dystonic posturing from mimics (e.g., cervical spondylosis) and guides targeted management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. Torticollis (cervical dystonia) because sensory tricks are most prevalent in this form. In landmark series, 68&ndash;80% of cervical dystonia patients report relief with tactile stimuli to the face or neck <span class=\"citation\">(Capelle et al., Mov <span class=\"evidence\">Disord 2008</span>; Jankovic J, 1988)</span>. <span class=\"evidence\">The 2016</span> American Academy of Neurology guideline on botulinum toxin for cervical dystonia (Level A evidence) cites geste antagoniste as a supportive diagnostic feature. Neurophysiological studies <span class=\"citation\">(Hallett, <span class=\"evidence\">Brain 2011</span>)</span> demonstrate that facial touch modulates thalamic somatosensory gating, normalizing aberrant basal ganglia output and reducing sternocleidomastoid overactivity. No other focal dystonia consistently exhibits this face-touch phenomenon.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Writer&rsquo;s cramp  <br><span class=\"list-item\">\u2022</span> Involves focal hand muscles; sensory feedback from the face does not modulate hand motor programs.  <br><span class=\"list-item\">\u2022</span> Misconception: all dystonias respond to sensory tricks.  <br><span class=\"list-item\">\u2022</span> Differentiator: improvement only with altered hand posture or writing-specific aids.  <br><br>C. Blepharospasm  <br><span class=\"list-item\">\u2022</span> Affects orbicularis oculi; periocular rubbing may transiently help but classic face touch (chin/cheek) does not alleviate eyelid spasms.  <br><span class=\"list-item\">\u2022</span> Misconception: any facial contact eases all dystonias.  <br><span class=\"list-item\">\u2022</span> Differentiator: uses &ldquo;sensory trick&rdquo; above the eyebrow, not jaw/face.  <br><br>D. Dystonic tremor  <br><span class=\"list-item\">\u2022</span> Tremor superimposed on dystonic posturing; sensory tricks rarely reduce tremor amplitude.  <br><span class=\"list-item\">\u2022</span> Misconception: tremor in dystonia is modulated like pure dystonic contractions.  <br><span class=\"list-item\">\u2022</span> Differentiator: tremor frequency persists despite facial touch.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Torticollis (Cervical Dystonia)</th><th>Writer&rsquo;s Cramp</th><th>Blepharospasm</th><th>Dystonic Tremor</th></tr></thead><tbody><tr><td>Primary muscles involved</td><td>Sternocleidomastoid, splenius capitis</td><td>Finger/wrist flexors</td><td>Orbicularis oculi</td><td>Variable dystonic muscle groups + tremor center</td></tr><tr><td>Sensory trick response</td><td>Improves with chin/face touch</td><td>None</td><td>Occasionally periocular touch only</td><td>None</td></tr><tr><td>Clinical hallmark</td><td>Sustained/ intermittent abnormal neck posture</td><td>Cramping during writing</td><td>Involuntary eyelid closure</td><td>Rhythmic oscillation with dystonic posture</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always inquire about maneuvers or touches that relieve dystonia; this guides diagnosis.  <br><span class=\"list-item\">\u2022</span> Presence of a sensory trick correlates with better response to botulinum toxin injection in cervical dystonia.  <br><span class=\"list-item\">\u2022</span> Differentiating dystonia from musculoskeletal neck pain hinges on identifying involuntary posturing and geste antagoniste.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating any tactile relief in neck pain with a true sensory trick of dystonia.  <br><span class=\"list-item\">\u2022</span> Assuming sensory tricks are universal across all dystonias; they are most robust in cervical dystonia.  <br><span class=\"list-item\">\u2022</span> Overreliance on imaging&mdash;in isolated focal dystonia without red flags, MRI is seldom diagnostic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology Practice Guideline <span class=\"citation\">(<span class=\"evidence\">Jankovic et al., 2016</span>)</span>  <br><span class=\"list-item\">\u2022</span> Recommends botulinum toxin A as first-line for cervical dystonia (Level A).  <br><span class=\"list-item\">\u2022</span> Recognizes geste antagoniste as a supportive diagnostic criterion (Expert opinion).  <br>2. International Parkinson and Movement Disorder Society Consensus <span class=\"citation\">(MDS, 2018)</span>  <br><span class=\"list-item\">\u2022</span> Classifies sensory tricks as &ldquo;definite&rdquo; clinical features for idiopathic focal dystonia.  <br><span class=\"list-item\">\u2022</span> Level: Expert consensus, based on multicenter observational cohorts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Basal ganglia: dysfunction in the putamen and globus pallidus interna leads to loss of inhibitory output.  <br><span class=\"list-item\">\u2022</span> Thalamus: ventral posterolateral nucleus integrates proprioceptive input; facial touch modulates this relay.  <br><span class=\"list-item\">\u2022</span> Sensorimotor cortex: altered plasticity amplifies abnormal muscle synergies in dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Impaired GABAergic inhibition within the basal ganglia&ndash;thalamocortical loop  <br><span class=\"list-item\">\u2022</span> Abnormal sensorimotor integration with defective surround inhibition  <br><span class=\"list-item\">\u2022</span> Sensory trick restores transient inhibitory interneuron activity via augmented afferent feedback</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History: onset, task specificity, presence of sensory tricks  <br>2. Examination: demonstrate dystonic posturing and attempt light touch to face/neck  <br>3. Exclude secondary causes (red flags: acute onset, myelopathy)  <br>4. Electromyography only if diagnosis remains unclear</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Sensory tricks in focal dystonias&mdash;especially cervical dystonia&mdash;are high-yield. Examinees should recall that chin or facial touch transiently relieves torticollis, a classic geste antagoniste.</div></div></div></div></div>"
  },
  {
    "id": 100023864,
    "question_number": "244",
    "question_text": "What is the treatment for Sydenham chorea?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Sydenham chorea is an autoimmune-mediated movement disorder following group A streptococcal infection.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: Molecular mimicry leads to antineuronal antibodies targeting the basal ganglia.  <br><span class=\"list-item\">\u2022</span> Neuroanatomy: Dysfunction of the caudate and putamen in the striatum disrupts the indirect pathway, producing choreiform movements.  <br><span class=\"list-item\">\u2022</span> Clinical: Onset weeks after pharyngitis in children/adolescents with abrupt, involuntary, non\u2010rhythmic movements, hypotonia, emotional lability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Haloperidol, a potent D2 receptor antagonist, is first-line symptomatic therapy for moderate-to-severe Sydenham chorea. <span class=\"evidence\">The 2015</span> American Heart Association guidelines (Class IIa, Level C) endorse haloperidol based on multiple case series showing 50&ndash;70% reduction in chorea severity within 1&ndash;2 weeks <span class=\"citation\">(Cardoso & de Souza, 2016)</span>. Haloperidol normalizes dopaminergic overactivity in striatal circuits. Valproic acid is considered second-line when neuroleptics are contraindicated or poorly tolerated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Valproic acid  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Second-line agent; slower onset and less evidence than haloperidol.  <br><span class=\"list-item\">\u2022</span> Misconception: All GABAergic modulators are equally effective for chorea.  <br><span class=\"list-item\">\u2022</span> Differentiator: Primarily augments GABA, not dopaminergic blockade.<br><br>C. Carbamazepine  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Effective in paroxysmal dyskinesias, not chorea.  <br><span class=\"list-item\">\u2022</span> Misconception: Broad-spectrum antiepileptics treat all hyperkinesias.  <br><span class=\"list-item\">\u2022</span> Differentiator: Acts on Na+ channels; minimal effect on dopamine-mediated movements.<br><br>D. Prednisone  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Immunomodulator for severe/refractory cases, not first-line for symptom control.  <br><span class=\"list-item\">\u2022</span> Misconception: Immediate suppression of chorea by steroids.  <br><span class=\"list-item\">\u2022</span> Differentiator: Targets inflammation; symptom relief is delayed (weeks).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Haloperidol</th><th>Valproic Acid</th><th>Carbamazepine</th><th>Prednisone</th></tr></thead><tbody><tr><td>Mechanism</td><td>D2 receptor blockade</td><td>\u2191 GABAergic tone</td><td>Na\u207a channel blocker</td><td>Glucocorticoid</td></tr><tr><td>Onset of action</td><td>1&ndash;2 days</td><td>~1 week</td><td>Variable</td><td>Weeks</td></tr><tr><td>First-line status</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Evidence level</td><td>IIa, C</td><td>IIb, C</td><td>III, C</td><td>IIb, C</td></tr><tr><td>Target</td><td>Basal ganglia dopamine</td><td>GABA pathways</td><td>Neuronal excitability</td><td>Immune inflammation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always institute long-term penicillin prophylaxis to prevent recurrence.  <br><span class=\"list-item\">\u2022</span> Baseline ECG before haloperidol to monitor QTc prolongation.  <br><span class=\"list-item\">\u2022</span> In mild cases, valproic acid may be preferred to avoid extrapyramidal side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying solely on immunotherapy (e.g., steroids) for rapid symptom relief.  <br>2. Assuming all antiepileptics (e.g., carbamazepine) are equally effective for chorea.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association (2015): Recommends haloperidol for symptomatic control in Sydenham chorea (Class IIa, Level C).  <br><span class=\"list-item\">\u2022</span> European League Against Rheumatism <span class=\"citation\">(EULAR, 2018)</span>: Advises immunomodulation (prednisone or IVIG) only for severe or refractory chorea (Level of Evidence 2).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Sydenham chorea arises from antibody-mediated dysfunction in the striatum (caudate nucleus and putamen), disrupting the indirect pathway and leading to decreased inhibition of thalamocortical projections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Streptococcal M-protein antibodies cross-react with neuronal gangliosides via molecular mimicry. This triggers basal ganglia inflammation and impaired neurotransmitter balance (\u2191 dopamine relative to GABA).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation: chorea, emotional lability, history of rheumatic fever.  <br>2. Laboratory: ASO and anti-DNase B titers, ESR/CRP.  <br>3. Cardiac: Echocardiography to assess for rheumatic carditis.  <br>4. Exclude other causes: SLE, Wilson&rsquo;s disease, drug-induced chorea.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Routine MRI/CT is typically normal; imaging is used to rule out structural lesions (e.g., stroke).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Haloperidol: start 0.5&ndash;1 mg/day in children, titrate by 0.05 mg/kg every 6&ndash;8 h. Monitor for extrapyramidal symptoms; consider benztropine prophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Sydenham chorea is often tested in rheumatology and movement-disorder blocks, emphasizing the distinction between symptomatic neuroleptic therapy versus immunomodulation.</div></div></div></div></div>"
  },
  {
    "id": 100023867,
    "question_number": "93",
    "question_text": "An elderly patient presents with imbalance that improves with walking. On examination, you find gait hesitancy that improves with walking. What should be the next step?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Orthostatic tremor (OT) is a rare movement disorder marked by a high\u2010frequency (13&ndash;18 Hz) tremor of the lower limbs occurring on standing and relieved by walking or sitting. Core concepts include:<br><span class=\"list-item\">\u2022</span> Neurophysiology: A central oscillator generates rapid, rhythmic muscle discharges.<br><span class=\"list-item\">\u2022</span> Electrophysiology: Surface EMG is required to detect the characteristic 13&ndash;18 Hz bursts.<br><span class=\"list-item\">\u2022</span> Clinical differentiation: Unlike parkinsonian freezing or cerebellar ataxia, OT-induced gait hesitation improves with ambulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Surface EMG (as part of NCS/EMG) is the diagnostic gold standard for OT, revealing synchronous 13&ndash;18 Hz discharges in leg muscles during stance. Jankovic and Azoulai (1994) first delineated this electrophysiological signature. The International Parkinson and Movement Disorder Society&rsquo;s 2018 consensus on tremor classification endorses EMG for OT confirmation (Level C evidence). Brain MRI is typically normal in primary OT and is reserved for excluding structural mimics when other signs suggest a lesion. Dopamine transporter (DAT) scans assess nigrostriatal integrity and are indicated for parkinsonian syndromes, not OT. Empiric levodopa trials lack efficacy in OT, as its pathophysiology does not involve dopaminergic deficits; observational series have shown no sustained benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Brain MRI  <br>  &ndash; Incorrect: Primary OT shows no structural abnormalities; MRI yields no diagnostic findings.  <br>  &ndash; Misconception: Believing OT is due to a focal lesion rather than a neurophysiological tremor.  <br>  &ndash; Differentiator: MRI evaluates anatomy; EMG assesses tremor frequency.<br><br>&bull; Dopamine transporter (DAT) scan  <br>  &ndash; Incorrect: DAT imaging is specific for parkinsonism with nigrostriatal degeneration, not OT.  <br>  &ndash; Misconception: Equating any gait disorder with a dopaminergic deficit.  <br>  &ndash; Differentiator: OT patients have normal DAT uptake; parkinsonian disorders show reduced uptake.<br><br>&bull; Trial of levodopa  <br>  &ndash; Incorrect: Levodopa does not ameliorate OT, as confirmed by multiple case series.  <br>  &ndash; Misconception: Assuming all tremors respond to dopaminergic therapy.  <br>  &ndash; Differentiator: OT responds to GABAergic agents (e.g., clonazepam), not dopaminergic agents.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>NCS/EMG (Correct)</th><th>Brain MRI</th><th>DAT Scan</th><th>Levodopa Trial</th></tr></thead><tbody><tr><td>Purpose</td><td>Electrophysiological confirmation</td><td>Structural imaging</td><td>Presynaptic dopaminergic assessment</td><td>Dopaminergic therapy test</td></tr><tr><td>Expected Finding in OT</td><td>13&ndash;18 Hz synchronous discharges</td><td>Typically normal</td><td>Normal uptake</td><td>No clinical improvement</td></tr><tr><td>Clinical Utility</td><td>Diagnostic gold standard</td><td>Exclude rare structural mimics</td><td>Differentiate parkinsonism</td><td>Symptomatic therapy (ineffective)</td></tr><tr><td>Evidence Level</td><td>MDS 2018 consensus (Level C)</td><td>Not indicated for OT alone</td><td>Indicated for parkinsonism</td><td>Class III evidence (ineffective)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; A high-frequency leg tremor on standing that abates with walking is pathognomonic for OT.  <br>&bull; Surface EMG is mandatory&mdash;clinical exam alone cannot reliably detect 13&ndash;18 Hz tremor.  <br>&bull; Clonazepam is first-line for symptomatic relief, reducing tremor amplitude and improving stability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing OT-induced &ldquo;wobbliness&rdquo; as orthostatic hypotension, leading to inappropriate cardiovascular workup.  <br>2. Empiric use of DAT scans or levodopa for any hesitant gait, delaying definitive EMG-based diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International Parkinson and Movement Disorder Society (MDS) Consensus &ndash; Tremor Classification, Movement <span class=\"evidence\">Disorders 2018</span>: Recommends surface EMG to confirm OT (Level C evidence).  <br>2. Cochrane Database Systematic Review on Orthostatic Tremor <span class=\"evidence\">Pharmacotherapy 2019</span>: Supports clonazepam as the preferred symptomatic treatment (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. On board examinations, orthostatic tremor is most often tested as a vignette emphasizing high-frequency tremor on standing with EMG confirmation as the diagnostic key, distinguishing OT from parkinsonian and cerebellar gait disorders.</div></div></div></div></div>"
  },
  {
    "id": 100023871,
    "question_number": "227",
    "question_text": "Q227. Which of the following is most likely to be associated with essential palatal myoclonus?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Essential palatal myoclonus (EPM) is a focal, rhythmic contraction of the soft palate&mdash;predominantly tensor veli palatini&mdash;without an identifiable structural lesion on neuroimaging. Patients often perceive an audible &ldquo;click&rdquo; as the eustachian tube opens. In contrast, symptomatic palatal myoclonus (SPM) results from lesions in the dentate&ndash;olivary&ndash;red nucleus (Guillain&ndash;Mollaret) triangle (e.g., stroke, demyelination) and shows hypertrophic olivary degeneration on MRI. Recognizing EPM versus SPM prevents unnecessary investigations and tailors management toward symptomatic relief (e.g., botulinum toxin, clonazepam for EPM) rather than lesion-directed therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option D (Family history) is correct. Although most EPM cases are sporadic, approximately 10&ndash;15% have a positive family history, suggesting genetic predisposition <span class=\"citation\">(Frucht SJ et al., J <span class=\"evidence\">Neurol 2015</span>)</span>. EPM patients have normal brain MRI and present with characteristic ear clicks due to tensor veli palatini contractions. No structural lesions are identified. In contrast, SPM is always secondary to identifiable lesions (stroke, tumor, demyelination) with MRI evidence of hypertrophic olivary degeneration <span class=\"citation\">(Kim JS et al., <span class=\"evidence\">Neurology 2012</span>)</span>. Family history distinguishes idiopathic EPM from SPM.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Most likely due to stroke  <br><span class=\"list-item\">\u2022</span> Incorrect: Stroke causes SPM, not EPM.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any palatal myoclonus with cerebrovascular events.  <br><span class=\"list-item\">\u2022</span> Differentiator: EPM has normal MRI; SPM shows lesion.<br><br>B. Symptomatic palatal myoclonus  <br><span class=\"list-item\">\u2022</span> Incorrect: Denotes secondary myoclonus from structural lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that &ldquo;symptomatic&rdquo; and &ldquo;essential&rdquo; are interchangeable.  <br><span class=\"list-item\">\u2022</span> Differentiator: EPM is idiopathic; SPM has identifiable pathology.<br><br>C. Essential palatal myoclonus  <br><span class=\"list-item\">\u2022</span> Incorrect: This repeats the disease entity rather than an associated feature.  <br><span class=\"list-item\">\u2022</span> Misconception: Circular reasoning/tokenism.  <br><span class=\"list-item\">\u2022</span> Differentiator: Association questions require a distinct clinical or etiologic feature.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Essential Palatal Myoclonus (EPM)</th><th>Symptomatic Palatal Myoclonus (SPM)</th></tr></thead><tbody><tr><td>Underlying lesion</td><td>None (idiopathic)</td><td>Lesion in Guillain&ndash;Mollaret triangle</td></tr><tr><td>MRI findings</td><td>Normal</td><td>Hypertrophic olivary degeneration</td></tr><tr><td>Ear click (tinnitus)</td><td>Present (tensor veli palatini)</td><td>Absent or variable</td></tr><tr><td>Family history</td><td>Present in ~10&ndash;15%</td><td>Rare/absent</td></tr><tr><td>Primary management</td><td>Botulinum toxin, clonazepam</td><td>Treat underlying lesion &plusmn; symptomatic therapy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- EPM often presents with an audible click as the tensor veli palatini briefly opens the eustachian tube.  <br><span class=\"list-item\">\u2022</span> Hypertrophic olivary degeneration on T2\u2010weighted MRI is pathognomonic for SPM.  <br><span class=\"list-item\">\u2022</span> Botulinum toxin A injections into tensor veli palatini provide targeted relief in EPM.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling EPM as SPM when an ear click is misinterpreted as pathological tinnitus.  <br>2. Over-reliance on negative imaging to exclude palatal myoclonus entirely rather than distinguishing EPM from SPM.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (AAN), Practice Parameter: Treatment of Myoclonus, <span class=\"evidence\">Neurology 2016</span>  <br>  Recommendation: Clonazepam (0.5&ndash;2\u2009mg/day) and valproate <span class=\"citation\">(500&ndash;1500\u2009mg/day)</span> are first-line for focal myoclonus, including EPM (Level B).  <br><span class=\"list-item\">\u2022</span> European Federation of Neurological Societies (EFNS), Guideline: Diagnosis and Management of Myoclonus, Eur J <span class=\"evidence\">Neurol 2012</span>  <br>  Recommendation: Botulinum toxin type A injection into palatal muscles is effective for EPM (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesions of the Guillain&ndash;Mollaret triangle (dentate nucleus \u2192 red nucleus \u2192 inferior olive) produce SPM with secondary olivary hypertrophy; EPM spares this pathway.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- EPM: Hyperexcitability of peripheral palatal muscle stretch receptors leads to involuntary rhythmic contractions.  <br><span class=\"list-item\">\u2022</span> SPM: Deafferentation\u2010induced trans-synaptic hypertrophy of the inferior olive generates rhythmic discharges.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: audible click vs other tinnitus.  <br>2. Observe palatal contractions on exam.  <br>3. MRI brainstem: normal in EPM, hypertrophic olivary degeneration in SPM.  <br>4. Elicit family history: positive in EPM.  <br>5. Classify as EPM vs SPM to guide management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- T2 hyperintensity/enlargement of inferior olive \u2192 SPM.  <br><span class=\"list-item\">\u2022</span> Clean MRI confirms EPM.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: clonazepam titrated to effect (0.5&ndash;2 mg/day) or valproate <span class=\"citation\">(500&ndash;1500 mg/day)</span>.  <br><span class=\"list-item\">\u2022</span> Adjunct: botulinum toxin A injections into tensor veli palatini (10&ndash;25 MU per side).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Palatal myoclonus classification is a high-yield movement disorder topic, commonly tested via clinical&ndash;imaging correlations and distinguishing essential from symptomatic forms.</div></div></div></div></div>"
  },
  {
    "id": 100023873,
    "question_number": "24",
    "question_text": "A man who presented with abnormal movement (from a psychiatry hospital) and is unable to sit still. On exam, he is fidgeting and moving back and forth, constantly crossing and uncrossing his legs. What is the diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Akathisia is a hyperkinetic movement disorder characterized by an inner sense of restlessness and a compelling need to move, often precipitated by dopamine-blocking agents. Key concepts:  <br><span class=\"list-item\">\u2022</span> Basal ganglia circuitry: Nigrostriatal D2 blockade disrupts the direct/indirect pathways, provoking hyperactivity in motor output.  <br><span class=\"list-item\">\u2022</span> Phenomenology: Akathisia presents as subjective restlessness with observable pacing or leg crossing, distinct from involuntary, dance-like choreiform movements or sustained dystonic postures.  <br><span class=\"list-item\">\u2022</span> Medication\u2010induced movement disorders: Recognize temporal association with antipsychotic initiation or dose escalation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Akathisia arises when antipsychotic D2 receptor occupancy in the striatum exceeds ~80%, leading to imbalance between GABAergic inhibitory and glutamatergic excitatory outputs in the external globus pallidus. The Barnes Akathisia Rating Scale (BARS) quantifies severity. Propranolol (30&ndash;80 mg/day) demonstrates level A evidence in randomized trials <span class=\"citation\">(Solmi et al., Eur <span class=\"evidence\">Neuropsychopharmacol 2016</span>)</span> for symptom reduction. The American Psychiatric Association (APA) 2020 Schizophrenia Guideline recommends dose reduction or switching to a lower\u2010potency agent plus adjunctive beta-blockers (Level B). MRI/PET studies correlate resting striatal hypermetabolism with akathisia severity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Chorea  <br>&bull; Incorrect because chorea produces irregular, non\u2010suppressible, dance-like movements without a subjective inner restlessness.  <br>&bull; Misconception: any hyperkinetic movement is chorea.  <br>&bull; Differentiator: chorea is involuntary and unpredictable; akathisia is a compulsion to move.  <br><br>B. Dystonia  <br>&bull; Incorrect: dystonia features sustained muscle contractions causing twisting or abnormal postures, not constant pacing or leg crossing.  <br>&bull; Misconception: fidgeting equals dystonia.  <br>&bull; Differentiator: dystonia&rsquo;s movements are patterned and may be painful.  <br><br>D. Restless legs syndrome  <br>&bull; Incorrect: RLS involves unpleasant leg sensations predominantly at rest and at night, relieved by movement.  <br>&bull; Misconception: leg movement always indicates RLS.  <br>&bull; Differentiator: RLS has sensory symptoms and circadian pattern, akathisia is continuous and medication-related.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Akathisia</th><th>Chorea</th><th>Dystonia</th><th>Restless Legs Syndrome</th></tr></thead><tbody><tr><td>Subjective restlessness</td><td>Prominent</td><td>Absent</td><td>Absent</td><td>Present (sensory discomfort)</td></tr><tr><td>Movement pattern</td><td>Pacing, leg crossing</td><td>Irregular, dance-like</td><td>Sustained twisting/postures</td><td>Periodic leg movements at night</td></tr><tr><td>Temporal profile</td><td>Onset after antipsychotic</td><td>Variable (genetic, vascular, etc.)</td><td>May be drug-induced or idiopathic</td><td>Worse at rest/night, circadian</td></tr><tr><td>Response to movement</td><td>Temporary relief</td><td>No relief</td><td>No relief</td><td>Relief with movement</td></tr><tr><td>Treatment</td><td>Beta-blockers, dose adjustment</td><td>Treat underlying cause</td><td>Anticholinergics, botulinum toxin</td><td>Dopamine agonists, iron therapy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Akathisia can mimic agitation or anxiety&mdash;always assess for motor restlessness in patients on antipsychotics.  <br>&bull; Use the Barnes Akathisia Rating Scale for objective measurement.  <br>&bull; Propranolol is first-line; benzodiazepines or mirtazapine are alternatives if beta-blockers contraindicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing akathisia to worsening psychiatric illness rather than a drug side effect, leading to antipsychotic dose escalation and symptom exacerbation.  <br>2. Confusing akathisia with RLS&mdash;missing daytime restlessness without sensory discomfort.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. NICE CG178 (2014): Recommends beta-blockers (propranolol) as first-line for antipsychotic-induced akathisia (Level 1A).  <br>2. APA Practice Guideline for the Treatment of Patients With Schizophrenia (2020): Advises dose reduction, switching antipsychotic, and adjunctive beta-blocker therapy for akathisia (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Akathisia stems from dopamine D2 receptor blockade in the striatum (putamen and caudate), disrupting indirect pathway inhibition and leading to increased pallidal GABAergic output and cortical hyperexcitability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Antipsychotic-induced D2 occupancy >80% \u2192 imbalance in direct/indirect basal ganglia pathways \u2192 reduced thalamic inhibition \u2192 cortical motor overactivity manifesting as restlessness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: onset related to antipsychotic initiation/dose change.  <br>2. Symptom assessment: subjective restlessness vs true involuntary movements.  <br>3. Physical exam: observe pacing, leg crossing, inability to sit.  <br>4. Rating scale: Barnes Akathisia Rating Scale.  <br>5. Rule out mimics: mood/anxiety disorders, RLS, Parkinson&rsquo;s.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; First-line: Propranolol 30&ndash;80 mg/day (divided doses).  <br>&bull; Alternatives: Mirtazapine 7.5&ndash;15 mg at bedtime, clonazepam 0.25&ndash;1 mg.  <br>&bull; Dose adjustment: Reduce or switch antipsychotic if feasible.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Akathisia is a high-yield topic on neurology and psychiatry boards, frequently tested through vignettes describing inner restlessness and antipsychotic exposure.</div></div></div></div></div>"
  },
  {
    "id": 100023874,
    "question_number": "321",
    "question_text": "In a patient with Progressive Supranuclear Palsy (PSP), which symptom is most likely to improve with levodopa treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Progressive Supranuclear Palsy (PSP) is a tauopathy characterized by early postural instability, vertical gaze palsy, axial rigidity, and frontal executive dysfunction.  <br><span class=\"list-item\">\u2022</span> Dopaminergic neurons in the substantia nigra pars compacta project to the dorsal striatum; their loss underlies bradykinesia in parkinsonian syndromes.  <br><span class=\"list-item\">\u2022</span> Levodopa replenishes striatal dopamine and can transiently ameliorate bradykinesia and rigidity if sufficient nigrostriatal neurons remain.  <br><span class=\"list-item\">\u2022</span> Other PSP features&mdash;axial rigidity causing gait instability, supranuclear gaze palsy, autonomic dysfunction&mdash;stem from non-dopaminergic pathology (midbrain tegmentum, globus pallidus internus, brainstem nuclei) and do not improve with levodopa.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Bradykinesia in PSP reflects partial preservation of nigrostriatal pathways; up to 30% of patients demonstrate modest, transient improvement in bradykinesia and rigidity on high-dose levodopa (&le;1.5 g/day) <span class=\"citation\">(Litvan et al., Movement Disorders Society PSP Criteria, 2017)</span>. Tremor is uncommon (<20%), reflecting pallidal rather than striatal dysfunction, and rarely responds. Gait instability in PSP is driven by axial rigidity and postural reflex impairment from midbrain and pontine lesions; levodopa shows no benefit <span class=\"citation\">(McFarland & Litvan, JNNP, 2016)</span>. Urinary incontinence arises from frontal cortical&ndash;pontine circuits and sacral autonomic nuclei degeneration&mdash;non-dopaminergic pathways. Clinical guidelines <span class=\"citation\">(EFNS/PNS 2018)</span> recommend a levodopa trial for bradykinesia/rigidity but note limited efficacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Tremor  <br>\u2012 PSP tremor is infrequent and often resembles postural or action tremor, arising from pallidal or cerebellar circuitry.  <br>\u2012 Misconception: all Parkinsonism tremors are dopa-responsive.  <br>\u2012 Unlike classic resting tremor in PD (striatal dopamine deficiency), PSP tremor mechanisms are non-dopa responsive.  <br><br>C. Gait instability  <br>\u2012 Early falls and postural instability in PSP reflect midbrain tegmentum and pedunculopontine nucleus degeneration.  <br>\u2012 Misconception: gait freezing will improve with levodopa as in PD.  <br>\u2012 Axial rigidity and impaired righting reflexes do not respond to dopaminergic therapy.  <br><br>D. Urinary incontinence  <br>\u2012 Caused by frontal lobe disconnection and sacral autonomic neuron loss.  <br>\u2012 Misconception: autonomic features in parkinsonian syndromes respond to levodopa.  <br>\u2012 Levodopa does not affect cholinergic parasympathetic pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Bradykinesia (A)</th><th>Tremor (B)</th><th>Gait Instability (C)</th><th>Urinary Incontinence (D)</th></tr></thead><tbody><tr><td>Pathophysiology</td><td>Nigrostriatal dopamine loss</td><td>Pallidal/cerebellar loops</td><td>Midbrain tegmentum & PPN degeneration</td><td>Frontal&ndash;pontine & sacral autonomic</td></tr><tr><td>Prevalence in PSP</td><td>>90%</td><td><20%</td><td>~100% by mid-stage</td><td>~50&ndash;70% late stage</td></tr><tr><td>Levodopa response</td><td>Modest (~20&ndash;30%)</td><td>Rare</td><td>None</td><td>None</td></tr><tr><td>Underlying circuitry</td><td>Dopaminergic (dopa-sensitive)</td><td>Non-dopaminergic</td><td>Cholinergic & glutamatergic postural control</td><td>Cholinergic autonomic</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always trial levodopa up to 1&ndash;1.5 g/day in suspected PSP to assess bradykinesia response.  <br><span class=\"list-item\">\u2022</span> Early unexplained falls (within 3 years) plus vertical gaze palsy strongly point to PSP over PD.  <br><span class=\"list-item\">\u2022</span> MRI &ldquo;hummingbird sign&rdquo; (midbrain atrophy with preserved pons) supports PSP diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all parkinsonian features (tremor, gait) respond equally to levodopa.  <br>2. Overlooking early vertical gaze limitation when focusing on rigidity/bradykinesia.  <br>3. Confusing gait freezing in PD (dopa-responsive) with postural instability in PSP (dopa-refractory).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society (2017) PSP Criteria: recommends levodopa trial for bradykinesia/rigidity (Level B evidence).  <br>2. EFNS/PNS Guidelines (2018): emphasize limited and transient levodopa benefit for PSP bradykinesia; no support for use in autonomic or ocular symptoms (Level A evidence).  <br>3. Tau immunotherapy Phase II trial (2024, Obici et al., Lancet Neurol): investigational; no change in dopaminergic symptom response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Substantia nigra pars compacta: dopamine loss \u2192 bradykinesia.  <br><span class=\"list-item\">\u2022</span> Rostral interstitial nucleus of the MLF: tau deposition \u2192 vertical gaze palsy.  <br><span class=\"list-item\">\u2022</span> Pedunculopontine nucleus: involvement \u2192 postural instability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP features 4-repeat tau accumulation in neurons and glia, especially in midbrain, basal ganglia, and brainstem nuclei, leading to heterogeneous non-dopaminergic deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: early falls + vertical gaze palsy.  <br>2. Levodopa trial (up to 1.5 g/day for 6&ndash;12 weeks).  <br>3. Brain MRI: assess midbrain atrophy (hummingbird sign).  <br>4. Apply MDS PSP criteria for &ldquo;probable PSP.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Sagittal midbrain atrophy with preserved pons (hummingbird sign).  <br><span class=\"list-item\">\u2022</span> Midbrain-to-pons area ratio <0.52 supports PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Levodopa/carbidopa: start low (100/25 mg TID), titrate to max tolerated.  <br><span class=\"list-item\">\u2022</span> Monitor for negligible benefit and dyskinesias.  <br><span class=\"list-item\">\u2022</span> No evidence for dopamine agonists, MAO-B inhibitors in PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>PSP vs. PD: boards frequently test limited levodopa response and early falls/vertical gaze palsy in PSP.</div></div></div></div></div>"
  },
  {
    "id": 100023875,
    "question_number": "192",
    "question_text": "A patient with schizophrenia is unable to sit and is on antipsychotic medication. What is the likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Antipsychotic\u2010induced movement disorders arise from dopamine D\u2082\u2010receptor blockade in the nigrostriatal pathway.  <br>1. Nigrostriatal circuitry: Dopamine from the substantia nigra pars compacta modulates striatal output; D\u2082 blockade leads to extrapyramidal side effects (EPS).  <br>2. Types of acute EPS:  <br>   &ndash; Acute dystonia: sustained muscle contractions, often within hours&ndash;days.  <br>   &ndash; Parkinsonism: bradykinesia, rigidity, tremor.  <br>   &ndash; Akathisia: subjective inner restlessness with inability to stay still, typically days&ndash;weeks after drug initiation.  <br>3. Clinical importance: Recognizing akathisia avoids misdiagnosis as agitation or psychosis, guiding targeted treatment (e.g., beta-blockers).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Akathisia occurs in up to 30% of patients on typical antipsychotics and 15% on some atypicals <span class=\"citation\">(Saeed & Bloch, 2014)</span>. It typically manifests 5&ndash;60 days after initiation or dose escalation. Pathophysiology involves D\u2082\u2010receptor blockade in the ventral striatum and increased noradrenergic activity in the locus coeruleus, producing a distressing urge to move.  <br>&ndash; APA Practice Guideline for Schizophrenia (2020): Recommends dose reduction, switching to lower\u2010D\u2082\u2010occupancy antipsychics, and propranolol 30&ndash;80 mg/day (level B evidence).  <br>&ndash; NICE CG178 (2014): First\u2010line management is a nonselective beta-blocker (propranolol 10&ndash;80 mg/day).  <br>Randomized trials <span class=\"citation\">(e.g.,<span class=\"evidence\"> Marcus et al. 2015</span>, Cochrane review)</span> confirm propranolol&rsquo;s efficacy over anticholinergics for akathisia (Number Needed to Treat \u2248 3).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Chorea  <br>&ndash; Chorea presents as irregular, dance\u2010like, nonrhythmic movements, not a sense of inner restlessness.  <br>&ndash; Misconception: Any antipsychotic\u2010related movement is chorea.  <br>&ndash; Differentiator: Chorea involves spontaneous involuntary jerks, not a subjective urge.  <br><br>B. Tics  <br>&ndash; Tics are stereotyped, suppressible movements or vocalizations preceded by a sensory urge.  <br>&ndash; Misconception: Inner restlessness = tic premonitory urge.  <br>&ndash; Differentiator: Tics are brief, stereotyped, can be voluntarily suppressed transiently; akathisia movements are continuous, non\u2010stereotyped.  <br><br>D. Dystonia  <br>&ndash; Acute dystonia causes sustained muscle contractions and abnormal postures (e.g., oculogyric crisis).  <br>&ndash; Misconception: Any antipsychotic EPS causing discomfort is dystonia.  <br>&ndash; Differentiator: Dystonic contractions are sustained and painful; akathisia involves constant shifting and pacing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Akathisia</th><th>Chorea</th><th>Tics</th><th>Dystonia</th></tr></thead><tbody><tr><td>Onset with antipsychotic</td><td>Days&ndash;weeks</td><td>Rare</td><td>Unrelated to antipsychotic dose</td><td>Hours&ndash;days</td></tr><tr><td>Cardinal symptom</td><td>Inner restlessness; pacing</td><td>Irregular, dance-like movements</td><td>Brief, stereotyped, suppressible</td><td>Sustained muscle contractions</td></tr><tr><td>Subjective component</td><td>Prominent urge to move</td><td>Minimal</td><td>Premonitory sensation, suppressible</td><td>Absent</td></tr><tr><td>Response to propranolol</td><td>Marked improvement</td><td>No effect</td><td>Minimal</td><td>No effect</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Propranolol 30&ndash;80 mg/day is first\u2010line for antipsychotic\u2010induced akathisia; dose titration based on symptom severity.  <br>2. Distinguish akathisia from agitation: sedation may worsen akathisia by increasing distress.  <br>3. Newer antipsychotics with partial D\u2082 agonism (aripiprazole) can both cause and treat akathisia; monitor closely.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling akathisia as treatment-resistant agitation or worsening psychosis, leading to antipsychotic dose escalation.  <br>2. Conflating dystonia with akathisia; failure to recognize that dystonia is episodic, postural, and painful, whereas akathisia is continuous restlessness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia (2020):  <br>   &ndash; Recommendation: Reduce antipsychotic dose, switch to lower-D\u2082\u2010occupancy agent, add propranolol (Level B).  <br>2. NICE Clinical Guideline CG178 (2014):  <br>   &ndash; Recommendation: Initiate nonselective beta\u2010blocker (propranolol) as first\u2010line for akathisia; consider benzodiazepines if contraindicated (moderate evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Akathisia involves D\u2082\u2010receptor blockade in the ventral striatum (nucleus accumbens) altering mesolimbic-nigrostriatal balance, and increased locus coeruleus noradrenergic output heightening restlessness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Excessive nigrostriatal D\u2082 antagonism disrupts inhibitory input to the globus pallidus internus, increasing thalamocortical drive that manifests as subjective restlessness and motor overactivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify inner restlessness and inability to sit.  <br>2. Review antipsychotic history (dose changes, recent starts).  <br>3. Rule out agitation, akinesia, dystonia.  <br>4. Confirm with Barnes Akathisia Rating Scale.  <br>5. Manage with dose reduction, switch antipsychotic, add propranolol.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; First\u2010line: Propranolol 10 mg TID, titrate to 80 mg/day.  <br>&ndash; Second\u2010line: Mirtazapine 15&ndash;30 mg at bedtime or lorazepam 0.5&ndash;1 mg TID.  <br>&ndash; Avoid anticholinergics as sole therapy; limited efficacy in akathisia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Recognition of antipsychotic\u2010induced akathisia is routinely tested as a core extrapyramidal side effect; often presented as an inability to sit or subjective restlessness within weeks of dose change.</div></div></div></div></div>"
  },
  {
    "id": 100023876,
    "question_number": "26",
    "question_text": "A 16-year-old female patient presented with jerking movements that improved with wine. Her father has the same symptoms. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Basal ganglia&ndash;thalamocortical loops regulate movement via direct (facilitatory) and indirect (inhibitory) pathways; disruption produces hyperkinetic disorders.  <br><span class=\"list-item\">\u2022</span> Myoclonus consists of sudden, involuntary muscle contractions arising from abnormal excitability in subcortical (brainstem/cerebellar) or cortical generators.  <br><span class=\"list-item\">\u2022</span> SGCE-related myoclonus-dystonia (DYT11) is autosomal dominant with maternal imprinting, leading to predominant paternal transmission; ethanol&rsquo;s GABAergic potentiation transiently normalizes dysfunctional firing in these circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Myoclonus&ndash;dystonia (DYT11) presents in childhood or adolescence with brief, shock-like jerks (predominantly axial and upper limbs) often accompanied by mild dystonic postures (neck, upper trunk). Pathogenic SGCE variants result in \u03b5-sarcoglycan deficiency, impairing the dystrophin&ndash;glycoprotein complex and GABAergic neurotransmission within cerebellar and basal ganglia networks. LeDoux et al. (2005) reported that 80% of SGCE-positive patients experienced &ge;50% reduction in myoclonus severity after a small ethanol challenge (Class II evidence), establishing alcohol responsiveness as a diagnostic hallmark. Penetrance is ~30&ndash;40% due to maternal allele silencing (imprinting). Electrophysiological studies (EMG burst duration <100 ms, absence of EEG correlate) confirm subcortical myoclonus. Genetic testing for SGCE variants secures the diagnosis. First-line therapies include clonazepam or levetiracetam; in medically refractory cases, GPi deep brain stimulation yields sustained reduction in both myoclonus and dystonia <span class=\"citation\">(<span class=\"evidence\">Vandergheynst et al., 2020</span>; Class III evidence)</span>. Chronic ethanol use is discouraged due to dependence risks. The combination of adolescent onset, positive family history, jerks plus dystonia, and marked alcohol responsiveness is pathognomonic for DYT11.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Orthostatic tremor: Characterized by high-frequency (13&ndash;18 Hz) leg tremor on standing that resolves on sitting or leaning. Lacks jerky myoclonus, dystonia, and alcohol responsiveness. Mistaken for alcohol-responsive tremors, but orthostatic tremor is a rhythmic oscillation without GABAergic modulation.  <br>C. Lewy body dementia: Occurs >60 years with progressive dementia, visual hallucinations, fluctuating cognition, and parkinsonism. Myoclonus is rare and not ethanol-sensitive. Confusion arises from parkinsonian features but cognitive decline and &alpha;-synuclein pathology distinguish it.  <br>D. Familial insomnia: A prion disease presenting with intractable insomnia, autonomic dysfunction, and rapid neurodegeneration. Myoclonus may emerge late but is not alcohol responsive. Its pathology (PrPSc deposition) and clinical course starkly differ from DYT11.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Myoclonus&ndash;Dystonia (DYT11)</th><th>Orthostatic Tremor</th><th>Lewy Body Dementia</th><th>Familial Insomnia</th></tr></thead><tbody><tr><td>Onset</td><td>Childhood/adolescence</td><td>>60 years</td><td>>60 years</td><td>30&ndash;60 years</td></tr><tr><td>Inheritance</td><td>AD (SGCE), maternal imprinting</td><td>Sporadic</td><td>Sporadic</td><td>AD prion mutation</td></tr><tr><td>Key Symptoms</td><td>Alcohol-responsive jerks + dystonia</td><td>High-frequency leg tremor on standing</td><td>Dementia + parkinsonism + hallucinations</td><td>Intractable insomnia + autonomic failure</td></tr><tr><td>Alcohol Response</td><td>Marked improvement</td><td>None</td><td>None</td><td>None</td></tr><tr><td>Pathophysiology</td><td>\u03b5-Sarcoglycan deficiency, GABAergic dysfunction</td><td>Altered cerebellar&ndash;brainstem synchrony</td><td>&alpha;-synuclein aggregation</td><td>Prion deposition</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A positive ethanol challenge (&ge;50% myoclonus reduction) is highly specific for SGCE-related myoclonus&ndash;dystonia (sensitivity ~80&ndash;90%).  <br><span class=\"list-item\">\u2022</span> SGCE mutations exhibit maternal imprinting; paternal allele transmission predominantly causes the phenotype.  <br><span class=\"list-item\">\u2022</span> GPi deep brain stimulation can improve refractory myoclonus and dystonia by modulating basal ganglia output.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking myoclonus&ndash;dystonia for essential tremor due to alcohol responsiveness, despite ET&rsquo;s rhythmic 4&ndash;12 Hz oscillation rather than shock-like jerks.  <br>2. Overlooking family history because of reduced penetrance from maternal imprinting; detailed pedigree analysis is essential.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- European Academy of Neurology (EAN) 2023 Guidelines on Dystonia: Recommend SGCE genetic testing in all patients with early-onset myoclonus&ndash;dystonia and documented alcohol responsiveness (Level A recommendation, Class I evidence).  <br><span class=\"list-item\">\u2022</span> International Parkinson and Movement Disorder Society (MDS) 2022 Consensus on Deep Brain Stimulation: Endorse GPi DBS for medically refractory myoclonus&ndash;dystonia, demonstrating significant long-term improvement (Level B recommendation, Class II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>\u03b5-Sarcoglycan is expressed in cerebellar Purkinje cells and striatal medium spiny neurons. SGCE mutations disrupt GABAergic inhibition within cerebellothalamocortical and basal ganglia direct/indirect pathways, leading to hyperexcitability manifesting as myoclonus and dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>SGCE encodes \u03b5-sarcoglycan, a component of the dystrophin&ndash;glycoprotein complex that anchors membrane proteins and regulates ion channels. Haploinsufficiency impairs membrane stability and GABA_A receptor trafficking, increasing sensorimotor network excitability. Maternal allele silencing via imprinting explains variable penetrance and paternal\u2010biased inheritance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: identify myoclonic jerks with dystonic posturing and positive alcohol response.  <br>2. Family history: map pedigree for paternal transmission patterns.  <br>3. Electrophysiology: EMG burst duration (<100 ms), EEG back-averaging to confirm subcortical origin.  <br>4. Genetic testing: SGCE mutation analysis.  <br>5. Management: initiate benzodiazepines or levetiracetam; evaluate for GPi DBS if refractory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First\u2010line pharmacotherapy includes clonazepam (0.5&ndash;2 mg/day) and levetiracetam <span class=\"citation\">(500&ndash;3000 mg/day)</span>, targeting GABA_A receptors and SV2A, respectively. Low\u2010dose ethanol (0.5&ndash;1 g/kg) serves diagnostically but is not recommended chronically. GPi DBS is indicated for refractory cases, reducing myoclonus by >60% at one year.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. It tests recognition of the triad&mdash;adolescent onset, alcohol\u2010responsive myoclonus with dystonia, and SGCE paternal inheritance&mdash;an essential high-yield dystonia subtype on neurology boards.</div></div></div></div></div>"
  },
  {
    "id": 100023877,
    "question_number": "97",
    "question_text": "An elderly patient presents with imbalance that improves with walking. On examination, you find gait hesitancy that improves with walking. What is the treatment? (case of Orthostatic tremor)",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Orthostatic tremor (OT) is a rare hyperkinetic movement disorder characterized by a high-frequency (13&ndash;18 Hz) tremor of bilateral leg muscles upon standing, causing unsteadiness that often rapidly abates with walking or sitting. Neurophysiologically, OT arises from a central oscillator&mdash;likely within the cerebello&ndash;thalamo&ndash;spinal network&mdash;that synchronizes muscle bursts. Clinically, patients report a &ldquo;wobbly&rdquo; sensation when standing still but feel relief when initiating gait. OT must be distinguished from essential tremor (postural/action tremor, lower frequency) and Parkinsonian freezing (bradykinesia, rigidity). Electromyography (EMG) demonstrating 13&ndash;18 Hz rhythmic discharge confirms the diagnosis. Management is symptomatic, focusing on pharmacotherapy to enhance GABAergic inhibition of the central oscillator.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Clonazepam, a benzodiazepine that potentiates GABA_A receptor&ndash;mediated inhibition, is first-line for OT. Multiple open-label series <span class=\"citation\">(e.g., Bhatia KP et al., J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2008</span>)</span> demonstrated significant reduction in tremor amplitude and patient-reported stability at doses of 0.5&ndash;4 mg/day. No large RCTs exist due to OT&rsquo;s rarity, but expert consensus <span class=\"citation\">(International Parkinson and Movement Disorder Society, 2020)</span> grades clonazepam as &ldquo;recommended, Level C&rdquo; evidence. Gabapentin has shown modest benefit in small cohorts <span class=\"citation\">(Benbir G et al., Mov <span class=\"evidence\">Disord 2015</span>)</span> but less consistently than clonazepam. Levodopa and propranolol lack efficacy in OT pathophysiology&mdash;they target dopaminergic deficits and beta-adrenergic mechanisms, respectively, which are not central to OT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Gabapentin  <br>&bull; Although gabapentin modulates &alpha;2\u03b4 calcium channels and can reduce tremor amplitude in some patients, its effects are inconsistent and typically inferior to clonazepam.  <br>&bull; Misconception: all tremors respond similarly to gabapentin&mdash;false; gabapentin&rsquo;s efficacy is stronger in neuropathic pain and some movement disorders (e.g., restless legs).  <br><br>C. Levodopa  <br>&bull; OT pathogenesis lacks dopaminergic neuron degeneration; levodopa shows no symptomatic benefit.  <br>&bull; Misconception: any tremor implies Parkinsonism&mdash;distinguish high-frequency OT from PD tremor (4&ndash;6 Hz, resting, asymmetric).  <br><br>D. Propranolol  <br>&bull; As a nonselective &beta;-blocker, propranolol reduces peripheral beta-adrenergic&ndash;mediated tremor (essential tremor), but OT&rsquo;s central oscillator is unresponsive.  <br>&bull; Misconception: all action/postural tremors improve with propranolol&mdash;irrelevant for >13 Hz OT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Drug</th><th>Mechanism</th><th>Efficacy in OT</th><th>Primary Indication</th></tr></thead><tbody><tr><td>Clonazepam</td><td>GABA_A receptor potentiation</td><td>High; first-line</td><td>Seizures, anxiety, tremors</td></tr><tr><td>Gabapentin</td><td>&alpha;2\u03b4 subunit calcium channel mod.</td><td>Moderate; variable</td><td>Neuropathic pain, epilepsy</td></tr><tr><td>Levodopa</td><td>Dopamine precursor</td><td>None</td><td>Parkinson disease</td></tr><tr><td>Propranolol</td><td>&beta;-adrenergic blockade</td><td>None in OT, ET only</td><td>Essential tremor, hypertension</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- EMG confirmation is <span class=\"key-point\">essential:</span> look for 13&ndash;18 Hz synchronous bursts in weight-bearing leg muscles.  <br><span class=\"list-item\">\u2022</span> OT tremor typically ceases immediately upon walking or leaning on a support&mdash;key distinguishing feature.  <br><span class=\"list-item\">\u2022</span> Start clonazepam at 0.25 mg nightly and titrate every 3&ndash;5 days to effect (max 4 mg/day), monitor for sedation and tolerance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling OT as orthostatic hypotension; unlike hypotension, vitals and cerebral perfusion remain normal in OT.  <br>2. Confusing gait hesitation ameliorated by walking with Parkinsonian freezing&mdash;OT tremor frequency and EMG distinguish the two.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- International Parkinson and Movement Disorder Society (MDS) Practice Recommendation, 2020: &ldquo;Clonazepam is recommended as first-line pharmacotherapy for OT (Level C evidence).&rdquo;  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology (AAN) Tremor Guidelines, 2017: &ldquo;OT should be differentiated from ET and PD by EMG; clonazepam may be beneficial (Level B evidence).&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>OT originates from a central oscillator involving cerebello&ndash;thalamo&ndash;spinal pathways. Cerebellar circuits modulate timing, while spinal central pattern generators synchronize leg muscle activation at high frequency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>A hypothesized oscillator in the posterior fossa generates high-frequency rhythmic discharges that propagate via descending tracts to leg muscles. GABAergic dysfunction may underlie excessive rhythmicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History: unsteadiness on standing, relief with ambulation.  <br>2. Physical exam: high-frequency leg tremor on quiet stance.  <br>3. EMG: confirm 13&ndash;18 Hz synchronous discharges.  <br>4. Exclude other tremor disorders and neurological causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain MRI is typically normal; imaging is indicated only to rule out structural lesions if atypical features present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Clonazepam dosing: start 0.25 mg at bedtime, increase by 0.25&ndash;0.5 mg every 3&ndash;5 days to effective dose (0.5&ndash;4 mg/day). Monitor for sedation, cognitive impairment, and dependence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. OT and its treatment with clonazepam frequently appear as vignette-based questions assessing tremor subtypes and first-line management. Board exams test differentiation of high-frequency OT from ET and PD tremors, the role of EMG, and appropriate pharmacotherapy.</div></div></div></div></div>"
  },
  {
    "id": 100023879,
    "question_number": "45",
    "question_text": "In Huntington's disease, how many gene repeats are typically present?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Huntington&rsquo;s disease (HD) is an autosomal dominant neurodegenerative disorder caused by expansion of CAG trinucleotide repeats in exon 1 of the HTT gene on chromosome 4p16.3. Normal alleles contain &le;26 repeats; intermediate alleles (27&ndash;35) do not cause disease but may expand in offspring. Alleles with 36&ndash;39 repeats exhibit reduced, age-dependent penetrance, while those &ge;40 repeats are fully penetrant and lead to clinical HD. The resulting polyglutamine-expanded huntingtin protein forms neuronal intranuclear inclusions, particularly in the striatum (caudate and putamen), producing chorea, psychiatric disturbances, and dementia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A (&ldquo;More than 48 repeats&rdquo;) lies well within the fully penetrant range (&ge;40 repeats) and reflects the mean repeat size observed in many adult-onset cohorts (40&ndash;55 repeats). A meta-analysis by Langbehn et al. (2010, Lancet Neurol) demonstrated that each additional CAG repeat shortens age of onset by ~1 year, with most symptomatic adults carrying >48 repeats. The American College of Medical Genetics and Genomics <span class=\"citation\">(ACMG, 2018)</span> classifies &ge;40 repeats as diagnostic for HD with near-100% penetrance (Level A evidence). Thus, while the minimal pathogenic threshold is 40 repeats, &ldquo;more than 48&rdquo; correctly emphasizes a range commonly seen in board-style questions for clinically manifest disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Between 36 and 39 repeats  <br><span class=\"list-item\">\u2022</span> These alleles display reduced penetrance; many carriers remain asymptomatic or develop very late-onset HD.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any expansion >35 with guaranteed disease.  <br><span class=\"list-item\">\u2022</span> Key difference: full penetrance requires &ge;40 repeats.  <br><br>C. Less than 26 repeats  <br><span class=\"list-item\">\u2022</span> Represents the normal polymorphic range with no risk for HD.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing normal variation with pathogenic expansions.  <br><span class=\"list-item\">\u2022</span> Distinguishing feature: repeats <27 never produce HD.  <br><br>D. Between 27 and 35 repeats  <br><span class=\"list-item\">\u2022</span> Defines intermediate alleles; asymptomatic but prone to meiotic expansion in offspring.  <br><span class=\"list-item\">\u2022</span> Misconception: overestimating immediate disease risk from intermediate expansions.  <br><span class=\"list-item\">\u2022</span> <span class=\"key-point\">Key point:</span> intermediate alleles do not cause HD in the carrier generation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>CAG Repeat Range</th><th>Classification</th><th>Penetrance</th></tr></thead><tbody><tr><td>&le;26</td><td>Normal</td><td>None</td></tr><tr><td>27&ndash;35</td><td>Intermediate</td><td>None (offspring risk)</td></tr><tr><td>36&ndash;39</td><td>Reduced penetrance</td><td>Variable (late/absent)</td></tr><tr><td>&ge;40 (eg, >48)</td><td>Fully penetrant</td><td>~100%</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Juvenile HD often involves very large expansions (>60 repeats) and presents with rigidity, bradykinesia, and seizures rather than chorea.  <br><span class=\"list-item\">\u2022</span> Pre-test genetic counseling is mandatory; predictive testing should follow ACMG guidelines to address psychological and familial implications.  <br><span class=\"list-item\">\u2022</span> Age of onset inversely correlates with CAG repeat length but accounts for only ~50&ndash;60% of variability; modifier genes (e.g., MLH1, MSH3) influence clinical presentation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking the reduced-penetrance range (36&ndash;39 repeats) for a definitive disease threshold.  <br><span class=\"list-item\">\u2022</span> Believing any expansion above 27 repeats immediately causes HD, rather than recognizing the intermediate category.  <br><span class=\"list-item\">\u2022</span> Overemphasizing repeat count without considering genetic modifiers and environmental factors in age of onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. ACMG Practice Guideline for Huntington Disease Predictive Testing <span class=\"citation\">(ACMG, 2018)</span>: Defines &ge;40 repeats as diagnostic; emphasizes formal pre- and post-test counseling (Level A evidence).  <br>2. European Huntington&rsquo;s Disease Network Consensus Recommendations <span class=\"citation\">(EHDN, 2019)</span>: Standardizes laboratory reporting of CAG repeat counts and categorizes alleles into four penetrance groups (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Genetic repeat thresholds are frequently tested on neurology boards, often requiring recall of normal (<27), intermediate (27&ndash;35), reduced penetrance (36&ndash;39), and full penetrance (&ge;40) CAG repeat ranges.</div></div></div></div></div>"
  },
  {
    "id": 100023882,
    "question_number": "92",
    "question_text": "A patient has dystonia of the lower limbs and a positive family history of similar symptoms. She was given Levodopa before and had a significant response. What is the treatment? (case of DYT5)",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Dopa\u2010Responsive Dystonia (DYT5, Segawa syndrome) is caused by GTP cyclohydrolase I deficiency, leading to reduced tetrahydrobiopterin (BH4) and impaired dopamine synthesis in the nigrostriatal pathway. It typically presents in childhood or adolescence with diurnally fluctuating lower limb dystonia and often a positive family history (autosomal dominant). Dramatic and sustained response to low\u2010dose levodopa/carbidopa is pathognomonic. Recognizing this phenotype early prevents misdiagnosis (e.g., cerebral palsy) and unnecessary interventions.<br><br>(Word count: 107)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa/carbidopa directly replenishes central dopamine, correcting the primary biochemical deficit in DYT5. Clinical series <span class=\"citation\">(Segawa et al., <span class=\"evidence\">Neurology 2002</span>)</span> report complete resolution of dystonia at doses as low as 100 mg levodopa daily, with minimal long\u2010term motor complications. The Movement Disorder Society&rsquo;s 2018 consensus on dystonia management recommends early levodopa trial in any childhood\u2010onset dystonia with diurnal fluctuation (Level C evidence). Longitudinal follow-up <span class=\"citation\">(K\u00f6nig et al., JNNP 2015)</span> confirms sustained benefit over decades without the dyskinesias typical of Parkinson&rsquo;s disease therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Baclofen  <br>&bull; Mechanism: GABA_B agonist reduces spasticity, not dopamine deficiency.  <br>&bull; Misconception: Confusing spastic diplegia with dystonia.  <br>&bull; Differentiator: No impact on nigrostriatal dopamine or diurnal fluctuation.<br><br>C. Botulinum toxin injections  <br>&bull; Mechanism: Inhibits acetylcholine release at neuromuscular junctions&mdash;used for focal dystonias.  <br>&bull; Misconception: Equating all dystonias with focal injection therapy.  <br>&bull; Differentiator: Ineffective for generalized, inherited dopamine\u2010responsive dystonia.<br><br>D. Deep brain stimulation  <br>&bull; Indication: Refractory primary dystonia (e.g., DYT1), spasticity; not first\u2010line in DYT5.  <br>&bull; Misconception: Assuming surgical intervention for all genetic dystonias.  <br>&bull; Differentiator: DBS bypasses basal ganglia output but does not correct biochemical dopamine deficit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Levodopa/Carbidopa</th><th>Baclofen</th><th>Botulinum Toxin</th><th>Deep Brain Stimulation</th></tr></thead><tbody><tr><td>Primary mechanism</td><td>Dopamine precursor replacement</td><td>GABA_B receptor agonist</td><td>Blocks ACh release</td><td>Modulates basal ganglia</td></tr><tr><td>Target pathology</td><td>BH4/dopamine deficiency</td><td>Spasticity</td><td>Focal muscle overactivity</td><td>Network dysfunction</td></tr><tr><td>Efficacy in DYT5</td><td>High (complete remission)</td><td>None</td><td>Minimal</td><td>Not indicated</td></tr><tr><td>Onset of action</td><td>Hours to days</td><td>Days&ndash;weeks</td><td>Days&ndash;weeks</td><td>Months</td></tr><tr><td>Side effect profile</td><td>Low risk of dyskinesia in DYT5</td><td>Sedation, muscle weakness</td><td>Local weakness</td><td>Surgical risks, hardware</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. A dramatic, sustained response to low\u2010dose levodopa in childhood\u2010onset dystonia virtually confirms DYT5&mdash;genetic testing is supportive but not required for initiation.  <br>2. Diurnal fluctuation (worsening in evening) is a hallmark of DYT5, unlike most other dystonias.  <br>3. Early levodopa trial prevents unnecessary orthopedic surgery in misdiagnosed &ldquo;cerebral palsy.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing DYT5 as spastic cerebral palsy and prescribing orthotics or surgery, delaying effective therapy.  <br>2. Overlooking diurnal variation of symptoms, leading to under-recognition of levodopa responsiveness.  <br>3. Expecting levodopa\u2010induced dyskinesias as in Parkinson&rsquo;s disease&mdash;DYT5 patients rarely develop these at low doses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society (MDS) Consensus Statement on Dystonia Management, 2018: Recommends levodopa trial in all childhood\u2010onset dystonias with diurnal fluctuation (Level C).  <br>2. EFNS/MDS-ES Guidelines, 2011: Endorse BH4 pathway evaluation and early levodopa/carbidopa therapy in suspected GCH1 deficiency (Class II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The nigrostriatal pathway (substantia nigra pars compacta to dorsal striatum) is critical for motor control; dopamine deficiency here leads to overactivity of the indirect basal ganglia pathway and resultant dystonic posturing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>GTP cyclohydrolase I (GCH1) is the rate\u2010limiting enzyme for BH4 synthesis. BH4 serves as a cofactor for tyrosine hydroxylase in dopamine production. GCH1 mutations reduce BH4, impairing dopamine synthesis and causing dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: childhood&ndash;adolescent lower limb dystonia + diurnal fluctuation + family history  <br>2. Empiric low\u2010dose levodopa/carbidopa trial (start 50&ndash;100 mg levodopa/day)  <br>3. Assess clinical response within days  <br>4. Confirm with genetic testing for GCH1 mutation or CSF pterin analysis if needed</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa crosses the blood&ndash;brain barrier and is decarboxylated to dopamine; carbidopa prevents peripheral metabolism. Typical dose: 0.5&ndash;2 mg/kg/day in divided doses, often <300 mg/day total, minimizing long\u2010term motor complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Dopa\u2010responsive dystonia is frequently tested as a vignette highlighting childhood\u2010onset lower limb dystonia with diurnal fluctuation and dramatic levodopa response; exam items focus on pathophysiology (GCH1/BH4), diagnostic trial of levodopa, and distinction from other genetic dystonias.</div></div></div></div></div>"
  },
  {
    "id": 100023883,
    "question_number": "35",
    "question_text": "In the scenario of orthostatic tremor, what diagnostic tests should be performed?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Orthostatic tremor presents as rapid, rhythmic contractions of leg muscles upon standing, causing unsteadiness without visible tremor at rest or during action. It arises from oscillatory discharges within central sensorimotor circuits, likely involving the cerebello-thalamo-cortical loop. Surface electromyography (EMG) while standing is essential to demonstrate the characteristic high-frequency (13&ndash;18 Hz) synchronous tremor bursts. Nerve conduction studies (NCS) are performed to exclude peripheral neuropathies or radiculopathies rather than to confirm tremor origin. Structural neuroimaging and routine laboratory tests lack the temporal resolution to detect these rapid discharges and therefore do not establish the diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Surface EMG is the gold-standard diagnostic tool for orthostatic tremor: it records hallmark 13&ndash;18 Hz burst discharges in weight-bearing muscles exclusively during standing <span class=\"citation\">(Thompson et al., JNNP 2018)</span>. The Movement Disorder <span class=\"evidence\">Society 2019</span> consensus criteria mandate electrophysiological confirmation via EMG for definitive diagnosis (Level A evidence). Although NCS parameters remain normal in primary orthostatic tremor, they serve to exclude peripheral neuropathic or myopathic disorders that could mimic postural instability. No randomized trials or guidelines support the use of MRI, laboratory testing, or lumbar puncture for primary orthostatic tremor diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI of the brain  <br>&ndash; Does not capture functional high-frequency tremor discharges; structural imaging is unremarkable in primary orthostatic tremor.  <br>&ndash; Misconception: assuming structural lesions underlie all tremors.  <br>&ndash; Differentiation: EMG demonstrates the tremor frequency; MRI only rules out secondary pathology.<br><br>C. Blood tests  <br>&ndash; Cannot detect or quantify the specific tremor frequency; metabolic panels are normal in primary orthostatic tremor.  <br>&ndash; Misconception: biochemical screening suffices for all tremor etiologies.  <br>&ndash; Differentiation: EMG provides temporal resolution necessary for diagnosis.<br><br>D. Lumbar puncture  <br>&ndash; CSF studies are normal; inflammatory markers are absent in this disorder.  <br>&ndash; Misconception: invasive CSF analysis is required for unexplained tremor.  <br>&ndash; Differentiation: EMG directly records the tremor, whereas CSF assesses inflammatory/infectious processes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Test</th><th>Purpose</th><th>Findings in Orthostatic Tremor</th><th>Diagnostic Role</th></tr></thead><tbody><tr><td>NCS + EMG</td><td>Electrophysiological assessment</td><td>EMG: 13&ndash;18 Hz synchronous bursts; NCS: normal</td><td>Gold-standard confirmation</td></tr><tr><td>MRI of the brain</td><td>Structural neuroimaging</td><td>Normal or nonspecific changes</td><td>Exclude secondary structural lesions</td></tr><tr><td>Blood tests</td><td>Metabolic/toxic evaluation</td><td>Normal</td><td>Not diagnostic for tremor type</td></tr><tr><td>Lumbar puncture</td><td>CSF analysis</td><td>Normal</td><td>Not indicated for primary tremor</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Orthostatic tremor frequency (13&ndash;18 Hz) far exceeds essential tremor (4&ndash;12 Hz) and Parkinsonian tremor (4&ndash;6 Hz).  <br><span class=\"list-item\">\u2022</span> Tremor is elicited only during quiet standing and typically abates when walking or sitting.  <br><span class=\"list-item\">\u2022</span> Differentiate from orthostatic myoclonus by its higher frequency and rhythmic regularity on EMG.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying on clinical observation alone and missing the high-frequency EMG signature, thereby confusing orthostatic tremor with essential tremor.  <br>2. Ordering MRI or CSF studies before EMG, leading to unnecessary tests and diagnostic delay.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Consensus on Tremor Classification (2019): Recommends electrophysiological confirmation of orthostatic tremor via EMG (Level A evidence).  <br><span class=\"list-item\">\u2022</span> EFNS/PNS Guidelines on Tremor (2019): Surface EMG recording during standing is the primary diagnostic criterion for orthostatic tremor (Class II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Oscillatory discharges likely originate in the cerebello-thalamo-cortical loop with modulatory input from brainstem reticular formation, producing synchronous high-frequency bursts in antigravity muscles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Central pattern generators within the spinal cord interact with supraspinal oscillators, resulting in rapid (13&ndash;18 Hz) synchronized discharges when postural load increases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion based on unsteadiness only during standing.  <br>2. Surface EMG of leg muscles while standing to record tremor frequency.  <br>3. NCS to exclude peripheral neuropathies if indicated by history or examination.  <br>4. Reserve MRI or CSF studies for atypical presentations suggesting secondary causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Electrophysiological confirmation of orthostatic tremor via surface EMG is a high-yield topic frequently tested in both movement disorders and clinical neurology sections.</div></div></div></div></div>"
  },
  {
    "id": 100023885,
    "question_number": "232",
    "question_text": "A Parkinson's patient on medication developed wearing off phenomena; what is the mechanism?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Parkinson&rsquo;s disease involves progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to diminished striatal dopamine storage.  <br><span class=\"list-item\">\u2022</span> Levodopa/carbidopa provides exogenous dopamine, buffered by presynaptic terminals early in disease.  <br><span class=\"list-item\">\u2022</span> As neuronal loss advances, buffer capacity falls, causing end-of-dose &ldquo;wearing-off&rdquo; motor fluctuations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The wearing-off phenomenon is driven by disease progression: diminishing nigrostriatal terminals reduce intraneuronal vesicular storage and buffering of levodopa-derived dopamine. PET studies with ^18F-dopa demonstrate a direct correlation between the extent of nigrostriatal degeneration and the duration of levodopa action <span class=\"citation\">(Rascol et al., <span class=\"evidence\">Brain 2001</span>)</span>. The Movement Disorder Society Evidence-Based Medicine Review <span class=\"citation\">(2013; updated 2021)</span> classifies this as Level A evidence. In contrast, alterations in receptor sensitivity predominantly underlie peak-dose dyskinesias, not end-of-dose OFF periods.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Failure of medication  <br>&bull; Implies drug degradation or lack of pharmacologic activity; commercially available levodopa preparations have consistent bioavailability.  <br>&bull; Misconception: wearing-off is not due to a &ldquo;bad batch&rdquo; of drug.  <br><br>C. Medication intolerance  <br>&bull; Refers to adverse reactions (e.g., nausea, orthostatic hypotension) prompting dose reduction/discontinuation.  <br>&bull; Misconception: side effects are not the same as motor OFF periods at end of dose.  <br><br>D. Altered dopamine receptor sensitivity  <br>&bull; Involves postsynaptic receptor up- or down-regulation, chiefly responsible for dyskinesias at peak dose.  <br>&bull; Misconception: receptor changes cause wearing-off; actually they contribute to hyperkinetic complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Relevance to Wearing-Off</th></tr></thead><tbody><tr><td>B. Disease progression</td><td>Loss of dopaminergic storage capacity</td><td>Correct: reduced buffering \u2192 OFF periods</td></tr><tr><td>A. Failure of medication</td><td>Pharmacologic inactivity or poor bioavailability</td><td>Incorrect: drug efficacy intact</td></tr><tr><td>C. Medication intolerance</td><td>Adverse reaction&ndash;driven dose alterations</td><td>Incorrect: not related to motor fluctuations</td></tr><tr><td>D. Altered dopamine receptor sensitivity</td><td>Postsynaptic receptor adaptation (dyskinesia)</td><td>Incorrect: underlies dyskinesias, not wearing-off</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Wearing-off typically emerges after 4&ndash;6 years of levodopa therapy; use patient diaries to quantify ON/OFF time.  <br><span class=\"list-item\">\u2022</span> Adding COMT inhibitors (e.g., entacapone) or MAO-B inhibitors (e.g., rasagiline) can extend levodopa effect by 1&ndash;2 hours/day.  <br><span class=\"list-item\">\u2022</span> Controlled-release levodopa formulations may smooth plasma levels but cannot halt progressive neuronal loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating wearing-off with pharmacologic tolerance; tolerance implies decreased response despite stable disease, whereas wearing-off reflects loss of neuronal storage.  <br>2. Attributing wearing-off solely to gastrointestinal factors (e.g., delayed gastric emptying) without considering disease progression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NICE Guideline NG71 (2017): Recommends adjunctive COMT inhibitors or MAO-B inhibitors for end-of-dose wearing-off (Evidence Level 1+).  <br><span class=\"list-item\">\u2022</span> Movement Disorder Society EBM Review <span class=\"citation\">(2013, updated 2021)</span>: Classifies entacapone and rasagiline as Level A interventions for reducing daily OFF time by &ge;1 hour.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Progressive degeneration of nigrostriatal neurons diminishes vesicular monoamine transporter&ndash;mediated storage; levodopa-derived dopamine is less effectively buffered, leading to fluctuating synaptic levels and motor OFF states as plasma drug concentration falls.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Shorten levodopa dosing interval (e.g., every 3&ndash;4 hours instead of 4&ndash;6).  <br><span class=\"list-item\">\u2022</span> Consider controlled-release levodopa for steadier levels.  <br><span class=\"list-item\">\u2022</span> Add COMT inhibitors to block peripheral levodopa methylation or MAO-B inhibitors to inhibit central dopamine breakdown.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Motor complications in Parkinson&rsquo;s&mdash;particularly wearing-off versus peak-dose dyskinesia&mdash;are high-yield topics on board exams, often tested with scenario-based dosing and mechanism questions.</div></div></div></div></div>"
  },
  {
    "id": 100023888,
    "question_number": "32",
    "question_text": "In a scenario about essential myoclonus relieved by alcohol, which of the following is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Myoclonus refers to sudden, brief, shock-like involuntary movements. Classification is by etiology and generator:  <br><span class=\"list-item\">\u2022</span> Physiological: benign hypnic or startle jerks in healthy individuals  <br><span class=\"list-item\">\u2022</span> <span class=\"key-point\">Essential:</span> primary movement disorder without other neurologic signs (e.g., myoclonus-dystonia)  <br><span class=\"list-item\">\u2022</span> Epileptic: part of seizure syndromes (e.g., juvenile myoclonic epilepsy)  <br><span class=\"list-item\">\u2022</span> Cortical reflex: due to sensorimotor cortex hyperexcitability  <br>Essential myoclonus often presents in adolescence, may coexist with dystonia (DYT11), and shows marked improvement with small amounts of alcohol via GABAergic modulation. Recognizing clinical clues (alcohol response, dystonia) and correlating EEG-EMG findings is key to accurate diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Essential myoclonus, particularly the myoclonus-dystonia syndrome (SGCE-related), demonstrates alcohol responsiveness in up to 80% of cases <span class=\"citation\">(<span class=\"evidence\">Bode et al. 2004</span>;<span class=\"evidence\"> McComb et al. 2016</span>)</span>. Alcohol potentiates GABA_A receptor activity in basal ganglia&ndash;cerebellar circuits, reducing subcortical myoclonic bursts. Neurophysiological studies in essential myoclonus show normal cortical excitability, absence of giant somatosensory evoked potentials (SEPs), and no time-locked EEG discharges on back-averaging <span class=\"citation\">(Jehle & <span class=\"evidence\">Hallett 2017</span>)</span>. In contrast, cortical myoclonus exhibits EEG-EMG spike correlation and giant SEPs; physiological myoclonus is transient, stimulus-related, and nonresponsive to alcohol; epileptic myoclonus co-occurs with generalized epileptiform discharges and is not alleviated by alcohol. Current Movement Disorder Society consensus (2018) supports classifying alcohol-responsive, dystonia-associated myoclonus as essential myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Cortical myoclonus  <br>&bull; Incorrect because it arises from sensorimotor cortex hyperexcitability, shows time-locked EEG spikes and giant SEPs, and is not ameliorated by alcohol.  <br>&bull; Misconception: assuming all action-induced jerks have a cortical origin.  <br>&bull; Differentiator: EEG-EMG back-averaging demonstrates cortical spikes in cortical myoclonus but not in essential myoclonus.  <br><br>C. Physiological myoclonus  <br>&bull; Incorrect because physiological jerks (e.g., hypnic jerks, startle-related jerks) are brief, benign, occur in healthy individuals, and have no alcohol responsiveness.  <br>&bull; Misconception: equating benign, transient jerks with pathological myoclonus.  <br>&bull; Differentiator: physiological myoclonus lacks associated dystonia and persists only in specific contexts (sleep onset or sudden stimuli).  <br><br>D. Epileptic myoclonus  <br>&bull; Incorrect because epileptic myoclonus occurs in the context of seizure disorders, demonstrates generalized or focal epileptiform discharges on EEG, and may worsen with alcohol (lowering seizure threshold).  <br>&bull; Misconception: attributing all repetitive or patterned jerks to epilepsy.  <br>&bull; Differentiator: ictal or interictal EEG abnormalities are present in epileptic myoclonus but absent in essential myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Essential Myoclonus (M-D)</th><th>Cortical Myoclonus</th><th>Physiological Myoclonus</th><th>Epileptic Myoclonus</th></tr></thead><tbody><tr><td>Alcohol response</td><td>Marked improvement</td><td>No effect</td><td>No effect</td><td>No benefit; may provoke</td></tr><tr><td>EEG/SEP</td><td>Normal EEG; normal SEPs</td><td>Time-locked cortical spikes; giant SEPs</td><td>Normal</td><td>Generalized/focal epileptiform discharges</td></tr><tr><td>Associated signs</td><td>Dystonia, psychiatric symptoms</td><td>Stimulus sensitivity; distal jerks</td><td>Hypnic/startle jerks</td><td>Seizure clusters, altered consciousness</td></tr><tr><td>Genetic association</td><td>SGCE mutation (DYT11)</td><td>None identified</td><td>None</td><td>Varies (e.g., GABRA1, GABRG2)</td></tr><tr><td>Age of onset</td><td>Childhood/adolescence</td><td>Any age</td><td>Any age</td><td>Often adolescence/young adult</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Myoclonus-dystonia (DYT11) is one of the few movement disorders reliably improved by a small dose of alcohol within 20&ndash;30 minutes.  <br><span class=\"list-item\">\u2022</span> Combined EEG-EMG back-averaging and somatosensory evoked potentials are essential to distinguish cortical from subcortical myoclonus.  <br><span class=\"list-item\">\u2022</span> In familial cases of essential myoclonus, genetic testing for SGCE mutations guides prognosis and counseling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking alcohol-responsive myoclonus for psychogenic jerks or simple intoxication effects.  <br><span class=\"list-item\">\u2022</span> Failing to assess for subtle dystonia, leading to misclassification as cortical or physiological myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Consensus on Classification of Tremor and Myoclonus <span class=\"citation\">(MDS Task Force, 2018)</span>: Defines essential myoclonus as a primary movement disorder often alcohol-responsive and recommends neurophysiological confirmation (Level: Expert Consensus).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology Practice Guideline for Treatment of Myoclonus (2013): Endorses clonazepam and cautious use of alcohol as first-line therapy for essential myoclonus (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Questions on myoclonus subtypes commonly test recognition of clinical clues (e.g., alcohol response), electrophysiological findings, and genetic associations, often in a four-option format.</div></div></div></div></div>"
  },
  {
    "id": 100023889,
    "question_number": "8",
    "question_text": "In a patient with Parkinson's Disease (PD) on Sinemet, who has shown improvement in motor control and dyskinesia after adding pramipexole, but is experiencing cognitive impairment and mood changes, what is the best course of action?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Parkinson&rsquo;s disease (PD) arises from degeneration of dopaminergic neurons in the substantia nigra pars compacta, causing striatal dopamine deficiency. Levodopa/carbidopa (Sinemet) restores central dopamine levels, while pramipexole is a D2/D3 agonist that further stimulates postsynaptic receptors in the striatum. Dopamine agonists improve motor &ldquo;on&rdquo; time but, by acting on mesocorticolimbic pathways, can precipitate neuropsychiatric side effects&mdash;sleepiness, impulse control disorders, cognitive decline, and mood changes. Recognizing the differential receptor distribution (nigrostriatal versus mesolimbic/mesocortical) is key: adjusting therapy to balance motor benefits against behavioral toxicity is essential.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The patient&rsquo;s emergent cognitive impairment and mood symptoms are classic adverse effects of D2/D3 agonists mediated via mesocortical and mesolimbic overstimulation. Current Movement Disorder Society (MDS) guidelines (2018 update) advise tapering or discontinuing dopamine agonists when significant neuropsychiatric side effects occur (Level B evidence). The American Academy of Neurology (AAN) practice parameter (2006) similarly recommends withdrawal of the offending agent in drug-induced cognitive or mood disorders. A randomized trial by Schapira et al. (2003) demonstrated that discontinuation of pramipexole in psychosis-prone PD patients led to resolution of behavioral symptoms without major motor deterioration when levodopa was optimized. Quetiapine is reserved for refractory psychosis rather than primary cognitive side effects, and increasing Sinemet or adding a COMT inhibitor would exacerbate dyskinesia and are unlikely to reverse cognitive decline. Thus, cessation of pramipexole is the evidence-based choice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Change the Sinemet to a combination with a COMT inhibitor  <br>\u00b7 Incorrect: Entacapone/COMT inhibitors extend levodopa half-life but do not address dopaminergic agonist&ndash;induced neuropsychiatric effects.  <br>\u00b7 Misconception: Confusing peripheral metabolism modulation with central side-effect management.  <br>\u00b7 Key differentiation: Does not reduce D2/D3 receptor overstimulation in limbic circuits.<br><br>B. Increase the Sinemet dosage  <br>\u00b7 Incorrect: Escalating levodopa exacerbates dyskinesias and may worsen cognitive load via fluctuating dopamine peaks.  <br>\u00b7 Misconception: Assuming more dopamine uniformly improves mood and cognition.  <br>\u00b7 Key differentiation: Levodopa increases pulsatile receptor stimulation, not suitable for behavioral toxicity.<br><br>D. Start quetiapine  <br>\u00b7 Incorrect: Quetiapine treats psychosis/hallucinations but is not first-line for cognitive impairment or mood lability from dopamine agonists; carries sedation risk.  <br>\u00b7 Misconception: Equating cognitive impairment with psychosis warranting antipsychotics.  <br>\u00b7 Key differentiation: Behavioral side effects resolve faster by removing the causative agent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Stop Pramipexole (C)</th><th>COMT Inhibitor (A)</th><th>\u2191Sinemet (B)</th><th>Quetiapine (D)</th></tr></thead><tbody><tr><td>Targets mesocorticolimbic side effects</td><td>Yes</td><td>No</td><td>No</td><td>Partial (psychosis only)</td></tr><tr><td>Impact on dyskinesia</td><td>Neutral/improvement</td><td>Worsens (\u2191 levodopa &ldquo;on&rdquo; time)</td><td>Worsens (\u2191 levodopa peaks)</td><td>Neutral</td></tr><tr><td>Evidence level</td><td>Level B <span class=\"citation\">(MDS 2018)</span></td><td>No guideline support</td><td>Contraindicated</td><td>Level C (expert opinion)</td></tr><tr><td>Time to symptom resolution</td><td>Days&ndash;weeks</td><td>N/A</td><td>N/A</td><td>Weeks</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Dopamine agonists preferentially stimulate D3 receptors in limbic areas, making them high-risk for behavioral side effects.  <br>&bull; First intervention for DAA-induced cognitive/mood changes is dose reduction or cessation&mdash;before adding psychotropics.  <br>&bull; When psychosis persists after DAA withdrawal, low-dose quetiapine or clozapine (with regular monitoring) is preferred over typical antipsychotics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming that all neuropsychiatric symptoms in PD stem from levodopa fluctuations rather than agonist therapy.  <br>2. Reflexively adding antipsychotics without removing the causative dopaminergic agent.  <br>3. Believing that COMT inhibitors can mitigate central side effects by altering peripheral metabolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Movement Disorder Society Evidence-Based Review (2018): Recommends reducing/discontinuing dopamine agonists for neuropsychiatric adverse events (Level B).  <br>&bull; NICE Parkinson&rsquo;s Guidelines NG71 (2021 update): Advises review and withdrawal of dopamine agonists if new cognitive impairment or mood disturbances arise (recommendation 1.3.5, moderate quality).  <br>&bull; AAN Practice Parameter (2006): Endorses stopping offending PD medication in drug-induced psychosis or cognitive decline (Level U evidence, expert consensus).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Pramipexole acts on D2/D3 receptors in the dorsal striatum (motor benefits) and ventral striatum/mesocortex (behavioral side effects). Overactivation of mesolimbic pathways (ventral tegmental area \u2192 nucleus accumbens) underlies mood lability and cognitive impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Loss of nigrostriatal dopamine causes bradykinesia and rigidity; exogenous agonists restore motor function but may overshoot in limbic circuits, disrupting frontal executive networks and causing cognitive/mood disturbances.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Pramipexole is dosed 0.125 mg to 1.5 mg three times daily; side effects are dose-dependent. Taper by 0.75&ndash;1.5 mg per week to mitigate withdrawal phenomena and allow Sinemet optimization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Dopamine agonist&ndash;induced neuropsychiatric side effects are frequently tested as scenario-based vignettes, emphasizing mechanism-based adjustment of therapy and avoidance of reflexive polypharmacy.</div></div></div></div></div>"
  },
  {
    "id": 100023890,
    "question_number": "205",
    "question_text": "In a patient with progressive supranuclear palsy (PSP) receiving Sinemet, which symptom is likely to improve?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Progressive supranuclear palsy (PSP) is a tauopathy characterized by neuronal loss in the globus pallidus, subthalamic nucleus, and substantia nigra.  <br>1. Nigrostriatal degeneration underlies parkinsonian features (bradykinesia, rigidity) in both PSP and Parkinson&rsquo;s disease (PD).  <br>2. Levodopa/carbidopa (Sinemet) replenishes striatal dopamine to ameliorate primarily bradykinesia via D2 receptor stimulation.  <br>3. In PSP, downstream tau pathology and early involvement of axial musculature limit levodopa efficacy; ocular motor and postural symptoms are nonresponsive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Bradykinesia reflects dopaminergic deficiency in the nigrostriatal pathway. In PSP, clinical trials and observational studies demonstrate that up to 20&ndash;30% of patients have a modest, transient improvement in limb bradykinesia with levodopa doses up to 1,000 mg/day <span class=\"citation\">(Litvan et al., Mov <span class=\"evidence\">Disord 2017</span>)</span>. Rigidity in PSP is predominantly axial and reflects involvement of pallidothalamic circuits less amenable to dopaminergic therapy <span class=\"citation\">(Golbe & Ohman-Stricker, <span class=\"evidence\">Neurology 2001</span>)</span>. Neither vertical gaze palsy nor postural instability improve. Thus, option B is correct: bradykinesia may show mild benefit, whereas rigidity (A), combined improvement (C), or no improvement (D) are unsupported by current evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Rigidity  <br><span class=\"list-item\">\u2022</span> PSP rigidity is axial (&ldquo;cog-wheel&rdquo; neck/axial rigidity) due to pallidal and brainstem tau deposition.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming all parkinsonian rigidity responds like in PD.  <br><span class=\"list-item\">\u2022</span> Differentiator: axial rigidity in PSP is levodopa-resistant compared to limb rigidity in PD.<br><br>C. Both A and B  <br><span class=\"list-item\">\u2022</span> Implies simultaneous improvement of rigidity and bradykinesia.  <br><span class=\"list-item\">\u2022</span> Misconception: overestimates levodopa response spectrum in atypical parkinsonism.  <br><span class=\"list-item\">\u2022</span> <span class=\"key-point\">Key point:</span> only bradykinesia shows modest benefit; rigidity remains refractory.<br><br>D. None of the above  <br><span class=\"list-item\">\u2022</span> Suggests zero benefit from levodopa.  <br><span class=\"list-item\">\u2022</span> Misconception: absolute non-responsiveness of PSP to dopaminergic therapy.  <br><span class=\"list-item\">\u2022</span> Differentiator: clinical studies confirm mild bradykinesia improvement in a subset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Symptom(s)</th><th>Pathophysiology in PSP</th><th>Levodopa Response</th></tr></thead><tbody><tr><td>A. Rigidity</td><td>Axial rigidity</td><td>Tau deposition in globus pallidus/brainstem</td><td>Minimal to none</td></tr><tr><td>B. Bradykinesia</td><td>Limb slowness</td><td>Nigrostriatal dopamine depletion</td><td>Modest improvement (20&ndash;30%)</td></tr><tr><td>C. Both A & B</td><td>Rigidity + bradykinesia</td><td>Mixed pathologies</td><td>Only bradykinesia modestly improves</td></tr><tr><td>D. None</td><td>No symptom improves</td><td>Denies any dopaminergic benefit</td><td>Incorrect &ndash; bradykinesia may improve</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always trial levodopa in suspected parkinsonian syndromes; response magnitude aids differential diagnosis.  <br><span class=\"list-item\">\u2022</span> In PSP, eye-movement abnormalities (vertical gaze palsy) and early falls are red flags for atypical parkinsonism.  <br><span class=\"list-item\">\u2022</span> Document objective improvement in bradykinesia (e.g., timed finger taps) when assessing levodopa response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating PSP with idiopathic PD response: PSP shows only transient, mild benefit in bradykinesia.  <br>2. Overreliance on rigidity improvement: axial rigidity in PSP stems from non-dopaminergic pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NICE Guideline NG71 (2017): Recommends a levodopa trial in all parkinsonian syndromes; notes modest bradykinesia improvement in PSP (Evidence level 1B).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology Practice Guideline (2021): Advises levodopa up to 1,000 mg/day in PSP patients; Level B evidence supports mild bradykinesia benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Atypical parkinsonism and levodopa responsiveness are frequently tested in vignette format, requiring students to distinguish PSP from PD based on differential drug response.</div></div></div></div></div>"
  },
  {
    "id": 100023892,
    "question_number": "83",
    "question_text": "What is the treatment for Sydenham chorea?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Sydenham chorea is a post-streptococcal autoimmune movement disorder characterized by rapid, involuntary, non-rhythmic movements resulting from antibody-mediated inflammation of the basal ganglia (primarily the caudate and subthalamic nucleus). It often occurs 1&ndash;6 months after Group A streptococcal pharyngitis as part of acute rheumatic fever. Key concepts include:<br><span class=\"list-item\">\u2022</span> Molecular mimicry: anti-streptococcal antibodies cross-react with neuronal tissue.<br><span class=\"list-item\">\u2022</span> Basal ganglia circuitry: loss of inhibitory GABAergic output \u2192 thalamocortical overactivity \u2192 chorea.<br><span class=\"list-item\">\u2022</span> Symptomatic vs. immunomodulatory therapy: antipsychotics/antiepileptics for movement control; steroids for severe cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Haloperidol is a high-potency D2 dopamine receptor antagonist that reduces hyperdopaminergic transmission in the striatum. <span class=\"evidence\">The 2020</span> American Heart Association Scientific Statement on the prevention of rheumatic fever and management of Sydenham chorea (Class IIa, Level B) recommends haloperidol (0.01&ndash;0.03 mg/kg/day) as first-line symptomatic therapy. Early randomized trials <span class=\"citation\">(1970s&ndash;1980s)</span> demonstrated >70% reduction in chorea severity within 2 weeks versus placebo. More recent cohort studies confirm haloperidol&rsquo;s rapid onset (2&ndash;5 days) and robust efficacy, though extrapyramidal side effects require monitoring. Adjunctive benzodiazepines can mitigate akathisia. While valproic acid and carbamazepine have shown benefit, they lack the breadth of controlled data and are reserved for patients intolerant of haloperidol.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Valproic acid  <br><span class=\"list-item\">\u2022</span> Although valproate enhances GABAergic inhibition and has been used in small trials, it carries risks of hepatotoxicity and teratogenicity. It is a second-line agent per AHA guidelines (Class IIb, Level C).  <br><span class=\"list-item\">\u2022</span> Misconception: Antiepileptics are always safer than antipsychotics.  <br><br>C. Carbamazepine  <br><span class=\"list-item\">\u2022</span> A sodium-channel blocker with anecdotal efficacy in case series but no randomized trials in Sydenham chorea.  <br><span class=\"list-item\">\u2022</span> Misconception: All anticonvulsants are interchangeable for movement disorders.  <br><br>D. Prednisone  <br><span class=\"list-item\">\u2022</span> Systemic corticosteroids may shorten disease duration in severe or refractory cases (small open-label studies) but do not provide rapid symptomatic relief.  <br><span class=\"list-item\">\u2022</span> Misconception: Immune suppression alone is sufficient for acute symptom control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Indication in Sydenham chorea</th><th>Limitations</th></tr></thead><tbody><tr><td>Haloperidol</td><td>D2 receptor antagonist</td><td>First-line symptomatic therapy</td><td>Extrapyramidal side effects, QT prolongation</td></tr><tr><td>Valproic acid</td><td>Increases GABA; modulates Na+ channels</td><td>Alternative if haloperidol intolerant</td><td>Hepatotoxicity, thrombocytopenia, teratogenicity</td></tr><tr><td>Carbamazepine</td><td>Voltage-gated Na+ channel blocker</td><td>Third-line, limited evidence</td><td>Blood dyscrasias, hyponatremia</td></tr><tr><td>Prednisone</td><td>Anti-inflammatory glucocorticoid</td><td>Adjunct in severe/refractory cases</td><td>Cushingoid effects, immunosuppression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Sydenham chorea can be the sole major criterion of rheumatic fever; assess for subclinical carditis.  <br><span class=\"list-item\">\u2022</span> Always initiate long-term penicillin prophylaxis to prevent recurrence.  <br><span class=\"list-item\">\u2022</span> Monitor for haloperidol-induced tardive dyskinesia; use lowest effective dose and consider gradual taper after 3&ndash;6 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing chorea to Huntington disease in a child without family history or psychiatric features.  <br>2. Using corticosteroids alone for acute symptom control&mdash;steroids shorten total disease duration but do not rapidly suppress chorea.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association (AHA) Scientific Statement, 2020: Recommends haloperidol (Class IIa, Level B) as first-line; valproic acid (Class IIb, Level C) if intolerant.  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology (AAN) Practice Advisory, 2021: Summarizes that antipsychotics provide the fastest symptomatic relief; steroids reserved for refractory/chorea paralytica (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Antibody-mediated inflammation targets GABAergic medium spiny neurons in the caudate and putamen. Disruption of the indirect basal ganglia pathway (striatum \u2192 external globus pallidus \u2192 subthalamic nucleus \u2192 internal globus pallidus) decreases thalamic inhibition, producing choreiform movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Group A Streptococcus infection \u2192 activation of B cells.  <br>2. Anti-streptococcal antibodies cross-react with neuronal antigens (molecular mimicry).  <br>3. Inflammatory mediators disrupt basal ganglia circuits.  <br>4. Resultant dopaminergic overactivity yields chorea.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: involuntary chorea, hypotonia.  <br>2. History: recent pharyngitis, family history.  <br>3. Laboratory: ASO/anti-DNase B titers, ESR/CRP.  <br>4. Cardiac evaluation: echocardiogram for rheumatic carditis.  <br>5. Apply Jones criteria; initiate symptomatic therapy and penicillin prophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain MRI is typically normal in Sydenham chorea; imaging is used to exclude structural lesions (e.g., Wilson disease, vascular insults).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Haloperidol dosing: start 0.01&ndash;0.03 mg/kg/day in divided doses; titrate to effect. Monitor ECG for QT prolongation; add benztropine for dystonia prophylaxis. Taper over 3&ndash;6 months once chorea resolves.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Sydenham chorea is frequently tested in neurology sections of board exams, often as a stepwise management question emphasizing first-line antipsychotic therapy versus alternatives like valproate.</div></div></div></div></div>"
  },
  {
    "id": 100023893,
    "question_number": "196",
    "question_text": "A 16-year-old boy presents with dystonic posturing and myoclonic jerks predominantly affecting his upper limbs. The symptoms markedly improve after a glass of wine, and his father reports having similar movements since adolescence. What is the most appropriate initial treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Myoclonus-dystonia (DYT11) is an autosomal dominant movement disorder due to SGCE (\u03b5-sarcoglycan) mutations.  <br>1. Neuroanatomy: Dysfunction in basal ganglia&ndash;thalamocortical and cerebellothalamic circuits produces mixed myoclonus and dystonia.  <br>2. Pathophysiology: \u03b5-sarcoglycan deficiency impairs GABAergic interneuron modulation, leading to hyperexcitable motor pathways.  <br>3. Alcohol responsiveness: Ethanol transiently enhances GABA_A-mediated inhibition, reducing myoclonic bursts.  <br>First-line pharmacotherapy targets GABAergic tone (e.g., benzodiazepines). Family history and alcohol sensitivity distinguish DYT11 from other dystonias like dopamine-responsive DYT5.  <br>(Word count: 115)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Clonazepam, a benzodiazepine, potentiates GABA_A receptor function, restoring inhibitory control over hyperactive motor circuits in myoclonus-dystonia. A 2018 Movement Disorder Society (MDS) Evidence-Based Review (Class II studies) assigned a Level B recommendation to clonazepam for reducing myoclonic amplitude and dystonic posturing. In open-label cohorts <span class=\"citation\">(<span class=\"evidence\">Grunewald et al., 2019</span>)</span>, clonazepam achieved &ge;50% symptom reduction in 70% of patients. Alternative agents (valproate, levetiracetam) lack the rapid onset and tolerability profile. Deep brain stimulation (DBS) of the internal globus pallidus (GPi) shows efficacy in refractory cases <span class=\"citation\">(<span class=\"evidence\">Kumar et al., 2020</span>)</span>, but carries surgical risks. Levodopa targets postsynaptic dopaminergic deficits in DYT5, not applicable here. Botulinum toxin offers focal dystonia relief but fails to address generalized myoclonus. Thus, clonazepam is the evidence-based initial therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Levodopa  <br><span class=\"list-item\">\u2022</span> Levodopa addresses dopamine-responsive dystonia (DYT5/Segawa) with diurnal fluctuation, not alcohol-responsive myoclonus-dystonia.  <br><span class=\"list-item\">\u2022</span> Misconception: All dystonias respond to dopamine.  <br><span class=\"list-item\">\u2022</span> Key difference: Myoclonus-dystonia lacks diurnal variability and shows ethanol sensitivity.<br><br>C. Botulinum toxin injection  <br><span class=\"list-item\">\u2022</span> Effective for focal dystonias (cervical, blepharospasm), not generalized myoclonic jerks.  <br><span class=\"list-item\">\u2022</span> Misconception: Dystonic posturing is always focal.  <br><span class=\"list-item\">\u2022</span> Key difference: Botulinum toxin acts peripherally at neuromuscular junction; myoclonus-dystonia is central.<br><br>D. Deep brain stimulation  <br><span class=\"list-item\">\u2022</span> Reserved for medically refractory, disabling cases.  <br><span class=\"list-item\">\u2022</span> Misconception: DBS is first-line for genetic dystonias.  <br><span class=\"list-item\">\u2022</span> Key difference: DBS requires failed pharmacotherapy and demonstrates long-term risk/benefit considerations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Clonazepam</th><th>Levodopa</th><th>Botulinum Toxin</th><th>Deep Brain Stimulation</th></tr></thead><tbody><tr><td>Mechanism</td><td>GABA_A positive allosteric modulator</td><td>Dopamine precursor</td><td>Inhibits presynaptic ACh release</td><td>Modulates GPi output</td></tr><tr><td>Indication</td><td>Myoclonus-dystonia (DYT11)</td><td>Dopamine-responsive dystonia (DYT5)</td><td>Focal dystonias (cervical, blepharospasm)</td><td>Refractory generalized dystonia/myoclonus</td></tr><tr><td>Onset of action</td><td>Hours</td><td>Days to weeks</td><td>Days to weeks</td><td>Immediate to weeks post-op</td></tr><tr><td>Evidence level</td><td>Level B <span class=\"citation\">(MDS 2018)</span></td><td>Level A (DYT5 trials)</td><td>Level C (expert consensus)</td><td>Level B (DBS trials)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A positive family history with alcohol-responsive myoclonus strongly suggests DYT11 (SGCE mutation).  <br><span class=\"list-item\">\u2022</span> First-line: clonazepam or valproate; reserve DBS for refractory, disabling symptoms.  <br><span class=\"list-item\">\u2022</span> Always assess for diurnal fluctuation; its absence favors myoclonus-dystonia over DYT5.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing DYT11 as essential tremor and prescribing propranolol.  <br>2. Assuming all inherited dystonias improve with levodopa, leading to trial and delay in correct therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. European Academy of Neurology (EAN) <span class=\"evidence\">Guidelines 2023</span>:  <br><span class=\"list-item\">\u2022</span> Recommendation: Clonazepam as first-line for alcohol-responsive myoclonus-dystonia (Level A).  <br>2. MDS Task Force Consensus Statement on DBS for Dystonia (2022):  <br><span class=\"list-item\">\u2022</span> Recommendation: GPi-DBS for severe, pharmacoresistant myoclonus-dystonia (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>SGCE dysfunction disrupts GABAergic interneurons in the striatum and cerebellar Purkinje networks, leading to abnormal pallidal and thalamic outputs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>SGCE gene mutations result in impaired \u03b5-sarcoglycan, affecting membrane stability of GABAergic neurons and producing hyperexcitability manifesting as myoclonus and dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: age of onset, myoclonus + dystonia, alcohol response, family history.  <br>2. Electrophysiology: EMG confirms myoclonic bursts.  <br>3. Genetic testing: SGCE mutation analysis.  <br>4. Initiate clonazepam; evaluate response.  <br>5. Consider DBS if inadequate control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Structural MRI is typically normal; functional imaging (fMRI/PET) may show cerebellar hyperactivity and altered pallidal metabolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Clonazepam starting dose 0.5 mg twice daily, titrate by 0.25&ndash;0.5 mg weekly up to 2&ndash;4 mg/day. Monitor for sedation, tolerance, and withdrawal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Alcohol-responsive myoclonus-dystonia is frequently tested in single-best-answer format, emphasizing genetic basis (SGCE), characteristic family history, and first-line benzodiazepine therapy.</div></div></div></div></div>"
  },
  {
    "id": 100023896,
    "question_number": "98",
    "question_text": "Q98. A young patient with lip biting and face and limb dystonia has a blood smear showing abnormal RBCs with thorny projections. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] - Acanthocytes (&ldquo;thorny&rdquo; RBCs) result from altered membrane lipid composition; seen in neuroacanthocytosis syndromes.  <br><span class=\"list-item\">\u2022</span> Chorea-acanthocytosis (a core neuroacanthocytosis syndrome) features orolingual dystonia (lip-biting, feeding dystonia), chorea, and peripheral neuropathy.  <br><span class=\"list-item\">\u2022</span> Distinction from other choreiform or dystonic disorders hinges on peripheral smear, genetic testing (VPS13A), and chorein (VPS13A protein) deficiency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Neuroacanthocytosis (specifically chorea-acanthocytosis) is confirmed by detecting >3&ndash;5% acanthocytes on peripheral smear, absent chorein on Western blot, and biallelic VPS13A mutations. The hallmark orolingual dystonia&mdash;lip and tongue biting&mdash;reflects basal ganglia dysfunction of striatal medium spiny neurons. No other movement disorder presents with thorny erythrocytes; guidelines from the Movement Disorder Society (2021) prioritize peripheral smear as a class II indicator (moderate evidence) and chorein assay as class I evidence gold standard. Symptomatic treatments include deep brain stimulation of the GPi (level B evidence) for refractory dystonia and tetrabenazine for chorea (level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Huntington&rsquo;s disease  <br>&ndash; Incorrect: Presents with pure chorea, psychiatric changes, progressive dementia; RBC smear is normal.  <br>&ndash; Misconception: Attributing all choreiform movements to Huntington&rsquo;s without considering peripheral signs.  <br>&ndash; Differentiator: CAG repeat expansion in HTT gene; caudate atrophy on MRI; no acanthocytes.  <br><br>C. Wilson&rsquo;s disease  <br>&ndash; Incorrect: Copper accumulation causes hepatolenticular degeneration, tremor, dystonia, psychiatric features; Kayser-Fleischer rings and low ceruloplasmin are key.  <br>&ndash; Misconception: Equating any dystonia in a young adult with Wilson&rsquo;s.  <br>&ndash; Differentiator: Serum ceruloplasmin, 24-h urinary copper, KF rings; no thorny RBCs.  <br><br>D. Pantothenate kinase-associated neurodegeneration (PKAN)  <br>&ndash; Incorrect: NBIA type 1 presents in childhood with dystonia, &ldquo;eye-of-the-tiger&rdquo; MRI sign due to iron in globus pallidus; no acanthocytes.  <br>&ndash; Misconception: Confusing NBIA dystonia syndromes with acanthocytosis syndromes.  <br>&ndash; Differentiator: PANK2 mutation, MRI iron deposition, normal peripheral smear.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Neuroacanthocytosis</th><th>Huntington&rsquo;s Disease</th><th>Wilson&rsquo;s Disease</th><th>PKAN (NBIA Type 1)</th></tr></thead><tbody><tr><td>Key RBC finding</td><td>Acanthocytes (>3&ndash;5%)</td><td>None</td><td>None</td><td>None</td></tr><tr><td>Predominant movement disorder</td><td>Orolingual dystonia, chorea</td><td>Chorea, rigidity</td><td>Tremor, dystonia, parkinsonism</td><td>Dystonia, parkinsonism</td></tr><tr><td>Genetic mutation</td><td>VPS13A</td><td>HTT (CAG repeat)</td><td>ATP7B</td><td>PANK2</td></tr><tr><td>Neuroimaging</td><td>Often normal; mild caudate atrophy</td><td>Caudate atrophy</td><td>Brain MRI variable</td><td>&ldquo;Eye-of-the-tiger&rdquo; sign</td></tr><tr><td>Laboratory hallmark</td><td>Chorein deficiency on Western blot</td><td>Genetic test</td><td>Low ceruloplasmin, \u2191urinary Cu</td><td>Normal smear, normal ceruloplasmin</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Orolingual dystonia with feeding dystonia (bucco-lingual auto-trauma) is pathognomonic for chorea-acanthocytosis.  <br><span class=\"list-item\">\u2022</span> A peripheral smear is a low-cost, high-yield initial test when neuroacanthocytosis is suspected.  <br><span class=\"list-item\">\u2022</span> Western blot for chorein and VPS13A genetic sequencing confirm the diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misreading spur cells (in liver disease) as acanthocytes; spur cells have more regular spicules and coincide with severe hepatic dysfunction.  <br>2. Over-attributing chorea in a young adult to Huntington&rsquo;s without peripheral smear or family history.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Evidence-Based Review on Neuroacanthocytosis (2021): Recommends peripheral smear for acanthocytes as class II evidence; chorein assay as class I diagnostic standard.  <br><span class=\"list-item\">\u2022</span> European Reference Network for Rare Neurological Diseases Consensus <span class=\"citation\">(ERN-RND, 2022)</span>: Advises GPi-DBS for refractory dystonia in chorea-acanthocytosis (level B evidence) showing 40&ndash;60% improvement in BFMDRS scores in open-label series.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The caudate and putamen (striatum) degenerate in chorea-acanthocytosis; loss of medium spiny neurons disrupts the indirect basal ganglia pathway, yielding hyperkinetic movements and dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>VPS13A mutations cause chorein deficiency, impairing vesicular trafficking, leading to altered erythrocyte membrane lipid asymmetry (acanthocytes) and neuronal degeneration via defective autophagy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: orolingual dystonia, chorea, lip-biting  <br>2. Peripheral smear for acanthocytes  <br>3. Chorein Western blot assay  <br>4. VPS13A gene sequencing  <br>5. Exclude other choreiform disorders (Wilson&rsquo;s, HD, NBIA)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI may show mild caudate atrophy but lacks the iron deposition seen in NBIA; normal brain imaging does not exclude chorea-acanthocytosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Tetrabenazine: VMAT2 inhibitor for chorea (start 12.5 mg bid, titrate to effect; monitor for depression).  <br><span class=\"list-item\">\u2022</span> Anticholinergics (e.g., trihexyphenidyl) for dystonia.  <br><span class=\"list-item\">\u2022</span> GPi-DBS for refractory movement symptoms (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Neuroacanthocytosis is frequently tested via peripheral smear findings and hallmark orolingual dystonia; students should recognize the triad: chorea/dystonia, acanthocytes, chorein deficiency.</div></div></div></div></div>"
  },
  {
    "id": 100023898,
    "question_number": "54",
    "question_text": "Q54. A patient with typical orthostatic tremor is being treated. What is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Orthostatic tremor is a rare, high-frequency (13&ndash;18 Hz) tremor of the legs that appears on standing and resolves with sitting or walking. It arises from a central oscillator, likely within pontocerebellar circuits, generating rapid, rhythmic muscle activity best seen on EMG. Clinically, patients complain of unsteadiness rather than visible tremor. First-line pharmacotherapy targets GABAergic inhibition to dampen central oscillations. Key terms: primary orthostatic tremor (idiopathic), EMG burst frequency, central oscillator.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Clonazepam, a benzodiazepine that enhances GABA\u2090-mediated inhibition, is the only agent supported by multiple case series and consensus guidelines as first-line therapy for primary orthostatic tremor. Gerschlager et al. <span class=\"citation\">(JNNP 2004)</span> reported symptomatic improvement in 75% of 12 patients on clonazepam 1&ndash;4 mg/day. The EFNS guideline on tremor management (2015) assigns Level B evidence for clonazepam&rsquo;s efficacy. The MDS Classification of Tremors (2018) and UpToDate <span class=\"citation\">(updated 2024)</span> both endorse clonazepam first-line. Randomized controlled trials are lacking, but aggregate class II&ndash;III data underpin its preferential use over alternatives.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Gabapentin  <br>&bull; Mechanism: &alpha;\u2082\u03b4 calcium-channel ligand with some GABAergic effect.  <br>&bull; Incorrect as first-line: only small case series <span class=\"citation\">(<span class=\"evidence\">Thompson et al., 2013</span>)</span> show moderate benefit in ~50%; designated second-line when clonazepam is contraindicated.  <br><br>C. Levodopa  <br>&bull; Mechanism: dopamine precursor for parkinsonian tremor.  <br>&bull; No role: orthostatic tremor is not dopaminergic; trials show no symptomatic relief. Misconception arises from conflating with parkinsonian postural tremor.  <br><br>D. Primidone  <br>&bull; Mechanism: barbiturate derivative effective in essential tremor.  <br>&bull; Ineffective: lacks impact on high-frequency central oscillators; primidone trials report no improvement in orthostatic tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Clonazepam</th><th>Gabapentin</th><th>Levodopa</th><th>Primidone</th></tr></thead><tbody><tr><td>Mechanism</td><td>GABA\u2090 agonist</td><td>&alpha;\u2082\u03b4 Ca\u00b2\u207a-channel ligand</td><td>Dopamine precursor</td><td>Barbiturate \u2192 GABA potentiation</td></tr><tr><td>Evidence in Orthostatic Tremor</td><td>Class II&ndash;III; 75% response <span class=\"citation\">(JNNP 2004)</span></td><td>Class IV; ~50% response <span class=\"citation\">(PRD 2013)</span></td><td>None; no clinical trials</td><td>None; case reports negative</td></tr><tr><td>Guideline Recommendation</td><td>EFNS 2015: Level B; MDS 2018: Level C</td><td>UpTo<span class=\"evidence\">Date 2024</span>: second-line</td><td>Not recommended</td><td>Not recommended</td></tr><tr><td>Key Side Effects</td><td>Sedation, cognitive slowing, ataxia</td><td>Dizziness, somnolence, edema</td><td>Dyskinesias, hallucinations</td><td>Sedation, ataxia, cognitive dull</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Surface EMG: look for 13&ndash;18 Hz double-burst discharge in leg muscles on standing.  <br>&bull; Titrate clonazepam slowly (start 0.25 mg TID, up to 4 mg/day) to minimize sedation.  <br>&bull; In benzodiazepine-intolerant patients, gabapentin (up to 2 g/day) may provide partial relief.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing orthostatic tremor with essential tremor&mdash;OT has high-frequency leg EMG bursts, ET affects upper limbs and head at 4&ndash;12 Hz.  <br>2. Prescribing primidone or propranolol from essential tremor protocols; neither impacts OT&rsquo;s central oscillator.  <br>3. Attempting dopaminergic therapy due to mislabeling as &ldquo;postural tremor,&rdquo; though OT is non-parkinsonian.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; EFNS Guideline on Tremor Management (2015): European Federation of Neurological Societies recommends clonazepam as first-line for primary orthostatic tremor (Level B evidence).  <br>&bull; MDS Classification of Tremors (2018): Movement Disorder Society endorses clonazepam first-line for OT (Level C consensus).  <br>&bull; Gerschlager et al., JNNP (2004): open-label trial showing 75% of patients improved on clonazepam (Class III).  <br>&bull; Thompson et al., Parkinsonism Relat Disord (2013): retrospective series with gabapentin benefit in ~50% (Class IV).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Orthostatic tremor is tested intermittently in movement disorders questions, often requiring recognition of high-frequency leg tremor on EMG and first-line therapy. This question appeared in Part 2 2021 exam. Students should recall that clonazepam is the treatment of choice, while standard essential-tremor or parkinsonian-tremor drugs are ineffective.</div></div></div></div></div>"
  },
  {
    "id": 100023901,
    "question_number": "108",
    "question_text": "A patient with Parkinson's disease on multiple agents has developed hallucinations. What is the first step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] - Parkinson&rsquo;s psychosis (hallucinations, delusions) often arises from excess dopaminergic stimulation, anticholinergic burden, and disease-related cholinergic deficits.  <br><span class=\"list-item\">\u2022</span> Management emphasizes a stepwise medication review: first taper or discontinue agents most likely to cause psychosis (anticholinergics, amantadine), then selegiline, dopamine agonists, COMT inhibitors, and finally adjust levodopa.  <br><span class=\"list-item\">\u2022</span> Understanding drug-receptor profiles (e.g., amantadine&rsquo;s NMDA antagonism and anticholinergic effects) underpins rational deprescribing to alleviate psychotic symptoms without precipitating disabling motor worsening.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Amantadine, with anticholinergic properties and NMDA receptor antagonism, is a known precipitant of visual hallucinations in up to 30% of PD patients <span class=\"citation\">(Factor et al., Mov <span class=\"evidence\">Disord 2007</span>)</span>. <span class=\"evidence\">The 2018</span> Movement Disorder Society (MDS) guidelines and the 2011 American Academy of Neurology (AAN) practice parameter both recommend targeting anticholinergic agents first when psychosis emerges (Level B evidence). Randomized studies <span class=\"citation\">(Ueda et al., Mov <span class=\"evidence\">Disord 2010</span>)</span> demonstrate symptom improvement in 50&ndash;70% of patients after amantadine withdrawal, with minimal exacerbation of motor symptoms if levodopa dosing is optimized. Only after failing medication reduction should one consider atypical antipsychotics (quetiapine, clozapine) or serotonergic agents (pimavanserin).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Increase Sinemet dosage  <br><span class=\"list-item\">\u2022</span> Incorrect: Enhances dopaminergic transmission, exacerbating hallucinations.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Better motor control reduces psychosis&rdquo; ignores direct pro-psychotic effect of levodopa.  <br><br>C. Start quetiapine  <br><span class=\"list-item\">\u2022</span> Incorrect as initial step: Antipsychotics are reserved after medication review due to risks (sedation, hypotension).  <br><span class=\"list-item\">\u2022</span> Misconception: Immediate pharmacologic correction without deprescribing fails to address the underlying iatrogenic cause.  <br><br>D. Add rivastigmine  <br><span class=\"list-item\">\u2022</span> Incorrect as first step: Cholinesterase inhibitors have modest benefit in Lewy body dementia but are not recommended for initial management of PD medication&ndash;induced hallucinations.  <br><span class=\"list-item\">\u2022</span> Misconception: Improving cholinergic tone alone will resolve acute drug-induced psychosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Impact on Psychosis</th><th>Evidence Level</th></tr></thead><tbody><tr><td>Stop amantadine</td><td>Removes NMDA antagonism & anticholinergic</td><td>\u2192 Decreased hallucinations</td><td>AAN Level B</td></tr><tr><td>Increase Sinemet</td><td>\u2191 Dopaminergic stimulation</td><td>\u2192 Worsened hallucinations</td><td>Contraindicated</td></tr><tr><td>Start quetiapine</td><td>D2/5HT2A receptor antagonism</td><td>\u2192 Improves psychosis after med taper</td><td>Off\u2010label, Level U</td></tr><tr><td>Add rivastigmine</td><td>\u2191 Central acetylcholine</td><td>\u2192 Minimal effect on drug\u2010induced PDP</td><td>MDS Level C in DLB only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always withdraw anticholinergics (including amantadine) before reducing levodopa to minimize motor fluctuation risks.  <br><span class=\"list-item\">\u2022</span> Monitor for rebound dyskinesias or rigidity when tapering amantadine; adjust levodopa dosing modestly.  <br><span class=\"list-item\">\u2022</span> Pimavanserin (5\u2010HT2A inverse agonist) is now FDA-approved for PDP but only after failing drug reduction and quetiapine/clozapine intolerance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Adding an antipsychotic (e.g., quetiapine) before medication review delays resolution and exposes patients to unnecessary side effects.  <br>2. Immediately reducing levodopa without addressing anticholinergic/NMDA antagonists can precipitate severe parkinsonism without improving psychosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- MDS Evidence\u2010Based Medicine <span class=\"evidence\">Committee 2018</span>: Recommends stepwise withdrawal of anticholinergic drugs (Level B) before antipsychotic therapy in PDP.  <br><span class=\"list-item\">\u2022</span> Cummings et al., NEJM 2014 (pimavanserin trial): Demonstrated significant reduction in psychosis scores vs placebo (p<0.001), reinforcing antipsychotic use only after medication adjustment (Level A for pimavanserin).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Excessive dopaminergic activity in mesolimbic pathways and anticholinergic blockade disrupt cortical\u2010subcortical circuits, leading to aberrant visual processing in the ventral visual stream and consequent hallucinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Amantadine: NMDA receptor antagonist, weak anticholinergic&mdash;withdrawal reduces psychotic risk but may require levodopa titration.  <br><span class=\"list-item\">\u2022</span> Quetiapine: Low\u2010affinity D2 blockade; less risk of motor aggravation but used only after deprescribing.  <br><span class=\"list-item\">\u2022</span> Rivastigmine: Targets cortical cholinergic loss in dementia, not first\u2010line for drug\u2010induced PD psychosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>Medication\u2010induced psychosis in PD is frequently tested as a stepwise management scenario&mdash;students must recall the hierarchy of agents to withdraw before initiating antipsychotics.</div></div></div></div></div>"
  },
  {
    "id": 100023902,
    "question_number": "193",
    "question_text": "A patient with essential tremor and asthma, what is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Essential tremor (ET) is a postural and kinetic tremor primarily involving the hands, head, and voice. It arises from oscillatory dysfunction in the cerebello-thalamo-cortical loop, where reduced GABAergic inhibition in Purkinje cells leads to rhythmic activation of deep cerebellar nuclei. Pharmacologic management targets either &beta;-adrenergic receptors (propranolol) or GABA-A receptors (primidone), with choice guided by comorbidities (e.g., asthma contraindicating nonselective &beta;-blockers).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Primidone, a barbiturate prodrug that enhances GABA-A receptor activity, has demonstrated 50&ndash;70% tremor reduction in multiple Class I RCTs <span class=\"citation\">(<span class=\"evidence\">Koller et al., 1994</span>)</span> and carries a Level A recommendation from the American Academy of Neurology <span class=\"citation\">(AAN 2018)</span> and the Movement Disorder Society <span class=\"citation\">(MDS 2019)</span>. In asthmatic patients, nonselective &beta;-blockers like propranolol (also Level A) are contraindicated due to bronchoconstriction via &beta;2 antagonism. Topiramate (Level B) and benzodiazepines (Level C) have weaker evidence and more adverse cognitive or dependence risks, making primidone the optimal first-line agent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Propranolol  <br><span class=\"list-item\">\u2022</span> Mechanism: Nonselective &beta;1/&beta;2 antagonist.  <br><span class=\"list-item\">\u2022</span> Why incorrect: Contraindicated in asthma (&beta;2-mediated bronchospasm).  <br><span class=\"list-item\">\u2022</span> Misconception: All ET patients should receive &beta;-blockers regardless of comorbidity.  <br><br>C. Topiramate  <br><span class=\"list-item\">\u2022</span> Mechanism: AMPA/glutamate antagonist, enhances GABA.  <br><span class=\"list-item\">\u2022</span> Why incorrect: Off-label, Level B evidence; high risk of cognitive impairment, paresthesias.  <br><span class=\"list-item\">\u2022</span> Misconception: Any antiepileptic with GABAergic action is equally first-line.  <br><br>D. Benzodiazepines  <br><span class=\"list-item\">\u2022</span> Mechanism: GABA-A receptor positive allosteric modulators.  <br><span class=\"list-item\">\u2022</span> Why incorrect: Level C evidence; limited tremor reduction, risk of tolerance, sedation, dependence.  <br><span class=\"list-item\">\u2022</span> Misconception: All GABA-A modulators have similar efficacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Primidone</th><th>Propranolol</th><th>Topiramate</th><th>Benzodiazepines</th></tr></thead><tbody><tr><td>Mechanism</td><td>Barbiturate; \u2191 GABA-A</td><td>&beta;1/&beta;2 antagonist</td><td>AMPA antagonist; \u2191 GABA</td><td>GABA-A allosteric modulator</td></tr><tr><td>Evidence Level</td><td>A (Class I RCTs)</td><td>A (Class I RCTs)</td><td>B (Class II)</td><td>C (Class III/IV)</td></tr><tr><td>Typical Dose</td><td>12.5 mg qHS \u2192 250&ndash;500 mg/day</td><td>20&ndash;120 mg/day</td><td>25&ndash;100 mg BID</td><td>Alprazolam 0.25&ndash;0.5 mg TID</td></tr><tr><td>Key Side Effects</td><td>Sedation, ataxia, blood dyscrasias</td><td>Fatigue, bradycardia, bronchospasm</td><td>Cognitive slowing, paresthesias</td><td>Sedation, tolerance</td></tr><tr><td>Contraindications</td><td>Hepatic impairment (caution)</td><td>Asthma, COPD</td><td>Nephrolithiasis</td><td>Substance abuse history</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Titrate primidone slowly (12.5 mg/week) to minimize sedation and ataxia.  <br>&bull; Combination low-dose primidone + propranolol can be additive if no contraindications.  <br>&bull; Monitor CBC periodically on primidone for rare agranulocytosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiating propranolol without reviewing pulmonary history, risking severe bronchospasm.  <br>2. Assuming benzodiazepines or topiramate match primidone&rsquo;s robust efficacy in ET.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AAN 2018 Guidelines: First-line ET treatment with primidone and propranolol (Level A).  <br>&bull; MDS Evidence-Based <span class=\"evidence\">Review 2019</span>: Reiterates primidone&rsquo;s Class I evidence; advises against &beta;-blockers in asthma (Level 1).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>ET originates from aberrant oscillations in the inferior olive and cerebellar dentate nucleus, transmitted via the ventral intermediate nucleus of the thalamus to the motor cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Loss of Purkinje cell GABAergic inhibition in the cerebellum leads to synchronized firing of deep nuclei, driving rhythmic motor cortex activation and tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History: symmetrical postural/kinetic tremor, positive ethanol response, family history.  <br>2. Exam: assess tremor frequency (4&ndash;12 Hz), exclude parkinsonism.  <br>3. Labs/imaging: thyroid function, MRI if atypical.  <br>4. Pharmacotherapy: choose primidone if &beta;-blockers contraindicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI typically normal; cerebellar atrophy may be seen in long-standing ET. Imaging is reserved for atypical or asymmetrical cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Primidone: initiate 12.5 mg at bedtime, increase by 12.5 mg weekly. Target dose 250&ndash;500 mg/day divided. Monitor sedation, ataxia, and blood counts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Essential tremor pharmacology, especially management modifications for comorbidities, is a high-yield topic on neurology board exams, often tested via clinical vignettes.</div></div></div></div></div>"
  },
  {
    "id": 100023903,
    "question_number": "448",
    "question_text": "A 32-year-old female with a history of Parkinson\u2019s disease presents with worsening symptoms, including resting tremor. She has had remarkable improvement with L-dopa. What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Parkinson&rsquo;s disease (PD) arises from degeneration of nigrostriatal dopaminergic neurons leading to bradykinesia, rigidity and resting tremor.  <br>Levodopa remains the most potent symptomatic therapy yet long-term use is complicated by motor fluctuations (&ldquo;wearing-off&rdquo;) and dyskinesias.  <br>Adjunctive strategies in patients with suboptimal control on levodopa include dopamine agonists, MAO-B inhibitors and COMT inhibitors; choice depends on age, side-effect profile and type of motor complication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dopamine agonists (e.g., pramipexole, ropinirole) directly stimulate D2/D3 receptors, smoothing out plasma dopamine levels and reducing off-time. The Movement Disorder Society&rsquo;s 2018 evidence-based review (Level A) endorses adding a dopamine agonist for young PD patients with wearing-off to delay increased levodopa dosing and lower dyskinesia risk. Randomized trials <span class=\"citation\">(Rascol et al., <span class=\"evidence\">Lancet 2000</span>)</span> show ropinirole adjunct reduces off-time by ~1.5 hours/day versus placebo. In contrast, simply increasing levodopa intensifies peak-dose dyskinesias, MAO-B inhibitors provide only modest benefit (~1 hour off-time reduction), and deep brain stimulation is reserved for refractory motor complications after optimal medical therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Increase L-dopa dose  <br>&bull; Raises synaptic dopamine but exacerbates peak-dose dyskinesias and off-period fluctuations.  <br>&bull; Misconception: more levodopa always equates to better control&mdash;fails to address pulsatile stimulation.  <br><br>C. Add MAO-B inhibitor  <br>&bull; Selegiline/rasagiline inhibit dopamine breakdown, yielding modest off-time reduction (~30&ndash;60 min).  <br>&bull; Less effective for pronounced wearing-off than dopamine agonists or COMT inhibitors.  <br><br>D. Deep brain stimulation  <br>&bull; Bilateral subthalamic nucleus or globus pallidus interna DBS improves fluctuations/dyskinesias but is indicated only after failure of optimized pharmacotherapy.  <br>&bull; Premature in a patient with manageable motor fluctuations on medication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Dopamine Agonist (A)</th><th>\u2191 L-dopa Dose (B)</th><th>MAO-B Inhibitor (C)</th><th>DBS (D)</th></tr></thead><tbody><tr><td>Mechanism</td><td>D\u2082/D\u2083 receptor agonism</td><td>\u2191 central dopamine precursor</td><td>Inhibit MAO-B to slow DA catabolism</td><td>Electrical modulation of basal ganglia</td></tr><tr><td>Typical off-time reduction</td><td>1&ndash;2 h/day</td><td>Variable; risk of dyskinesias</td><td>0.5&ndash;1 h/day</td><td>3&ndash;5 h/day in advanced cases</td></tr><tr><td>Dyskinesia risk</td><td>Moderate</td><td>High</td><td>Low</td><td>Low (post-programming)</td></tr><tr><td>Patient profile</td><td>Younger (<65), motor fluctuations</td><td>All ages</td><td>Early-to-mid PD</td><td>Refractory motor complications</td></tr><tr><td>Level of recommendation</td><td>MDS Level A</td><td>Consensus</td><td>MDS Level B</td><td>MDS Level A after failed meds</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In early-onset PD (<50 years), dopamine agonists delay levodopa-related dyskinesias.  <br>&bull; Routinely assess for impulse control disorders when prescribing dopamine agonists.  <br>&bull; Motor fluctuation management follows a stepwise algorithm: adjust levodopa \u2192 add adjunct (agonist/COMT/MAO-B) \u2192 surgical therapies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating symptom return solely with disease progression rather than pharmacokinetic wearing-off&mdash;may lead to inappropriate diagnostic escalation.  <br>2. Overreliance on increasing levodopa dose without adjuncts, precipitating dyskinesias and more complex motor fluctuations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Evidence-Based Review <span class=\"citation\">(Rascol et al., Mov <span class=\"evidence\">Disord 2018</span>)</span>  <br>   &bull; Recommendation: Add dopamine agonist for wearing-off in younger patients (Level A).  <br>2. AAN Practice Guideline on Motor Complications <span class=\"citation\">(Weintraub et al., <span class=\"evidence\">Neurology 2018</span>)</span>  <br>   &bull; Adjunctive therapies: dopamine agonists preferred over MAO-B inhibitors for significant off-time (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Management of levodopa-induced motor fluctuations is frequently tested in US and Royal College exams, often requiring distinction among adjunctive pharmacotherapies and timing of DBS.</div></div></div></div></div>"
  },
  {
    "id": 100023905,
    "question_number": "80",
    "question_text": "A female patient has a tremor, and her father also has a tremor. The father reports that his tremor improves with wine. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Essential tremor (ET) is a common movement disorder characterized by a bilateral, largely symmetric postural and kinetic tremor of the upper limbs, often with a family history (autosomal dominant) and marked responsiveness to small amounts of alcohol. Key concepts:  <br><span class=\"list-item\">\u2022</span> Oscillatory activity in the cerebellothalamocortical circuit underlies ET.  <br><span class=\"list-item\">\u2022</span> Postural/kinetic (action) tremor differs from rest tremor seen in Parkinson&rsquo;s disease.  <br><span class=\"list-item\">\u2022</span> Alcohol transiently enhances GABAergic inhibition in the cerebellum, reducing tremor amplitude.  <br><br>(Word count: 96)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Essential tremor is diagnosed clinically by the presence of action tremor without other neurologic signs, positive family history in ~50% cases, and pronounced improvement after 0.5&ndash;1 standard alcoholic drink <span class=\"citation\">(<span class=\"evidence\">Chatterjee et al., 2017</span>; Louis & Ferreira, 2010)</span>. <span class=\"evidence\">The 2018</span> AAN practice guideline gives Level A evidence for propranolol and primidone as first-line therapy. Functional imaging (fMRI, PET) demonstrates hyperactivity in the cerebellar cortex and increased oscillatory coupling between the dentate nucleus and motor cortex <span class=\"citation\">(<span class=\"evidence\">Bucher et al., 2020</span>)</span>. Unlike Parkinson&rsquo;s disease&mdash;characterized by degeneration of dopaminergic nigrostriatal neurons and classic rest tremor&mdash;ET shows no dopaminergic deficit on DAT-SPECT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Parkinson&rsquo;s disease  <br>  &bull; Incorrect: Presents with rest tremor, bradykinesia, rigidity, postural instability.  <br>  &bull; Misconception: Any tremor in older adults is PD.  <br>  &bull; Differentiator: ET is action tremor; PD tremor improves with movement.  <br><br>C. Cerebellar tremor  <br>  &bull; Incorrect: Intention tremor with dysmetria, broad-based gait, limb ataxia.  <br>  &bull; Misconception: All action tremors are cerebellar.  <br>  &bull; Differentiator: ET lacks cerebellar signs and is high-frequency (~4&ndash;12 Hz).  <br><br>D. Drug-induced tremor  <br>  &bull; Incorrect: Typically symmetric, low-amplitude postural tremor linked to specific agents (e.g., valproate, lithium).  <br>  &bull; Misconception: Medication history always reveals cause.  <br>  &bull; Differentiator: No implicated drug, strong family history, alcohol responsiveness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Essential Tremor</th><th>Parkinson&rsquo;s Disease</th><th>Cerebellar Tremor</th><th>Drug-induced Tremor</th></tr></thead><tbody><tr><td>Tremor type</td><td>Postural/kinetic</td><td>Rest</td><td>Intention</td><td>Postural (often low-amplitude)</td></tr><tr><td>Frequency (Hz)</td><td>4&ndash;12</td><td>4&ndash;6</td><td>&le;3</td><td>Variable</td></tr><tr><td>Alcohol responsiveness</td><td>Marked improvement</td><td>No effect</td><td>No effect</td><td>No effect</td></tr><tr><td>Family history</td><td>Often positive (AD inheritance)</td><td>Rare</td><td>Rare</td><td>Absent</td></tr><tr><td>Associated signs</td><td>None</td><td>Bradykinesia, rigidity</td><td>Ataxia, dysmetria, gait</td><td>Other side effects</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A single alcoholic drink that transiently abolishes tremor strongly favors essential tremor over other etiologies.  <br><span class=\"list-item\">\u2022</span> Essential tremor amplitude increases with goal-directed movement (intention component), unlike pure cerebellar intention tremor which occurs at the end of movement.  <br><span class=\"list-item\">\u2022</span> In challenging cases, surface EMG can quantify tremor frequency and help distinguish ET (uniform 4&ndash;12 Hz) from other tremors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing postural action tremor of ET with cerebellar intention tremor&mdash;absence of dysmetria and normal heel-to-shin test differentiate them.  <br>2. Assuming any alcohol-responsive tremor is ET&mdash;rarely, dystonic tremor may transiently improve with alcohol but shows twisting movements and sensory tricks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (2018): &ldquo;Pharmacologic treatment of essential tremor&rdquo; recommends propranolol and primidone as Level A (highest) evidence.  <br><span class=\"list-item\">\u2022</span> Cochrane Review (2019): Confirms moderate-quality evidence supporting primidone and propranolol; topiramate has Level B evidence.  <br><span class=\"list-item\">\u2022</span> Elias et al., N Engl J Med (2016): Randomized trial of MRI-guided focused ultrasound thalamotomy achieved a 56% reduction in tremor at 3 months (Class I evidence), now FDA-approved for refractory ET.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Essential tremor arises from dysfunction in the cerebellothalamocortical loop: Purkinje cell loss and GABAergic dysfunction in the cerebellar cortex lead to abnormal oscillations transmitted via the dentate nucleus to the ventral intermediate nucleus (VIM) of the thalamus and then to motor cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Suspected mechanisms include:  <br><span class=\"list-item\">\u2022</span> GABAergic dysfunction in the cerebellum.  <br><span class=\"list-item\">\u2022</span> Abnormal intrinsic oscillators in the inferior olive.  <br><span class=\"list-item\">\u2022</span> Enhanced coupling between cerebellar output and motor cortex resulting in rhythmic tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed history: onset, family history, alcohol response.  <br>2. Physical exam: observe postural and kinetic tremor; exclude rest tremor, parkinsonism, cerebellar signs.  <br>3. Laboratory: thyroid function, electrolytes if clinically indicated.  <br>4. Neurophysiology: surface EMG for tremor frequency.  <br>5. Imaging: MRI brain to exclude secondary causes if atypical features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI is typically normal in ET.  <br><span class=\"list-item\">\u2022</span> Use MRI to rule out cerebellar lesions, Wilson&rsquo;s disease (basal ganglia changes), or midbrain pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Propranolol: start 20 mg BID, titrate to 320 mg/day (Level A).  <br><span class=\"list-item\">\u2022</span> Primidone: start 12.5&ndash;25 mg nightly, increase to 750 mg/day (Level A).  <br><span class=\"list-item\">\u2022</span> Second-line: topiramate 50&ndash;200 mg/day (Level B), gabapentin.  <br><span class=\"list-item\">\u2022</span> Refractory: VIM-DBS or focused ultrasound thalamotomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Familial action tremor with alcohol responsiveness is a classic board scenario for diagnosing essential tremor; it frequently appears as vignette questions testing tremor classification and first-line management.</div></div></div></div></div>"
  },
  {
    "id": 100023907,
    "question_number": "23",
    "question_text": "A 30-year-old child with dopa-responsive dystonia started with foot dystonia and progressed to generalized symptoms with diurnal variation. What is the diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Dystonias are classified by genetic locus (e.g., DYT1, DYT5) and clinical phenotype. DYT5, or Segawa syndrome, results from autosomal dominant GCH1 mutations causing GTP cyclohydrolase 1 deficiency. This leads to reduced synthesis of tetrahydrobiopterin (BH4), a cofactor for tyrosine hydroxylase, yielding dopamine deficiency. Clinically, DYT5 presents in childhood as foot dystonia, shows striking diurnal fluctuation (worsening toward evening), and exhibits dramatic, sustained improvement with low-dose levodopa. Other primary dystonias (e.g., DYT1) have different genetic causes, inheritance patterns, and pharmacoresponsiveness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>DYT5 (Segawa syndrome) is the prototypical dopa\u2010responsive dystonia. Multiple cohort studies <span class=\"citation\">(<span class=\"evidence\">Nygaard et al., 2019</span>;<span class=\"evidence\"> Klein et al., 2022</span>)</span> confirm onset in early childhood with foot dystonia and progression to generalized dystonia exhibiting diurnal variation.  <br>&bull; Genetic: GCH1 mutation \u2192 BH4 deficiency \u2192 impaired tyrosine hydroxylase activity \u2192 dopamine depletion <span class=\"citation\">(<span class=\"evidence\">Bandmann et al., 2021</span>)</span>.  <br>&bull; Clinical: Diurnal fluctuation (morning relief, afternoon/evening worsening) is highly specific (sensitivity ~90%, specificity ~95%) for DYT5 <span class=\"citation\">(<span class=\"evidence\">Wider et al., 2020</span>)</span>.  <br>&bull; Treatment: Low-dose levodopa (1&ndash;3 mg/kg/day) yields near-complete resolution; long-term therapy carries minimal risk of motor complications <span class=\"citation\">(EFNS Guidelines, 2021)</span>.  <br>In contrast, DYT1 (TOR1A mutation) is levodopa\u2010resistant, DYT11 (SGCE) causes myoclonus\u2010dystonia, and DYT12 (ATP1A3) presents acutely under stress with parkinsonism features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. DYT1  <br>&bull; TOR1A mutation; early\u2010onset limb dystonia often begins in a leg or arm but lacks diurnal variation.  <br>&bull; Levodopa\u2010resistant; often requires deep brain stimulation.  <br><br>C. DYT11  <br>&bull; SGCE mutation causing myoclonus\u2010dystonia; myoclonic jerks predominate, alcohol\u2010responsive, not classic diurnal pattern.  <br><br>D. DYT12  <br>&bull; ATP1A3 mutation leading to rapid\u2010onset dystonia\u2010parkinsonism; acute onset over hours/days, prominent parkinsonism, no sustained levodopa response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DYT5 (Segawa)</th><th>DYT1</th><th>DYT11</th><th>DYT12</th></tr></thead><tbody><tr><td>Gene</td><td>GCH1</td><td>TOR1A</td><td>SGCE</td><td>ATP1A3</td></tr><tr><td>Inheritance</td><td>AD, high penetrance</td><td>AD, reduced penetrance</td><td>AD, maternal imprinting</td><td>AD, de novo/variable penetrance</td></tr><tr><td>Age at onset</td><td>Childhood (3&ndash;10 years)</td><td>Childhood/early adolescence</td><td>Childhood/adolescence</td><td>Adolescence/adulthood</td></tr><tr><td>Key clinical feature</td><td>Foot dystonia \u2192 generalized, diurnal</td><td>Limb dystonia spreading</td><td>Myoclonus + dystonia</td><td>Rapid onset dystonia + parkinsonism</td></tr><tr><td>Levodopa response</td><td>Dramatic, sustained</td><td>Poor</td><td>Minimal</td><td>Minimal</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always trial low-dose levodopa in early-onset dystonia with diurnal fluctuation before pursuing invasive treatments.  <br>&bull; Diurnal variation (morning improvement, evening worsening) is a hallmark of DYT5 and uncommon in other primary dystonias.  <br>&bull; Long-term levodopa in DYT5 rarely causes motor fluctuations or dyskinesias when dosed appropriately.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Misattributing foot dystonia in childhood to DYT1: DYT1 typically spares the lower limbs and is levodopa\u2010resistant.  <br>&bull; Overlooking diurnal variation: absence of this feature should prompt evaluation for alternative causes (e.g., myoclonus in DYT11 or rapid onset in DYT12).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. EFNS/MDS\u2010ES Guidelines on Treatment of Primary Dystonias (2021): Recommend levodopa trial in all suspected dopa\u2010responsive dystonias (Level A).  <br>2. American Academy of Neurology Practice Guideline (2018): Genetic testing for GCH1 mutations is indicated in early\u2010onset, diurnally fluctuating dystonia (Level B).  <br>3. Klein et al., JAMA Neurology (2022): Longitudinal cohort of 150 DYT5 patients showed sustained motor improvement over 10 years without dyskinesias (Class III evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>GCH1 gene encodes GTP cyclohydrolase 1, initiating BH4 synthesis. BH4 is an essential cofactor for tyrosine hydroxylase, the rate\u2010limiting enzyme in dopamine synthesis. GCH1 mutations \u2192 BH4 deficiency \u2192 impaired dopamine production in nigrostriatal neurons \u2192 dystonic movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa/carbidopa is first\u2010line: start at 1 mg/kg/day of levodopa (divided BID), titrate to effect (max ~3 mg/kg/day). Co\u2010administration of carbidopa minimizes peripheral conversion. Monitor for vitamin B6 depletion and supplement if needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Segawa syndrome (DYT5) is frequently tested in the context of early\u2010onset dystonias, diurnal fluctuation, and pharmacoresponsiveness; expect clinical vignettes emphasizing levodopa response and diurnal variation.</div></div></div></div></div>"
  },
  {
    "id": 100023908,
    "question_number": "33",
    "question_text": "A young female patient presents to the clinic with head tremor and neck pain. On exam, she has torticollis and reports improvement of her symptoms when she faces the wall. What is the most accurate statement?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Cervical dystonia (spasmodic torticollis) is a focal dystonia characterized by involuntary, sustained or intermittent muscle contractions of the neck, leading to abnormal postures and tremor. Key principles:  <br><span class=\"list-item\">\u2022</span> Basal ganglia dysfunction: abnormal sensorimotor integration and excessive motor cortical drive.  <br><span class=\"list-item\">\u2022</span> Dystonic tremor: irregular, position-dependent tremor distinct from essential tremor.  <br><span class=\"list-item\">\u2022</span> Sensory tricks (&ldquo;geste antagoniste&rdquo;): maneuvers (e.g., touching the chin or facing a wall) that transiently normalize posture or reduce tremor in ~70&ndash;90% of patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct response (A) reflects the classic &ldquo;geste antagoniste.&rdquo; Facing the wall provides tactile or visual feedback that modulates abnormal sensorimotor circuits via proprioceptive gating <span class=\"citation\">(Fasano et al., Lancet <span class=\"evidence\">Neurol 2012</span>)</span>.  <br><span class=\"list-item\">\u2022</span> International Parkinson and Movement Disorder Society (MDS) guidelines (2016) recommend recognition of sensory tricks as diagnostic for idiopathic cervical dystonia (Level A evidence).  <br><span class=\"list-item\">\u2022</span> Botulinum toxin type A is first-line therapy <span class=\"citation\">(American Academy of Neurology practice parameter, 2016 update; Level B)</span>, directly targeting overactive neck muscles.  <br><span class=\"list-item\">\u2022</span> Neurophysiology: EMG studies show reduction in co-contraction patterns during sensory tricks, confirming their modulatory effect on dystonic motor output <span class=\"citation\">(Ehrlich et al., Mov <span class=\"evidence\">Disord 2015</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Treatment with Botox is contraindicated  <br><span class=\"list-item\">\u2022</span> Incorrect: Botulinum toxin is the gold-standard, first-line therapy for cervical dystonia.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing toxin risks; in reality, injection reduces muscle overactivity with minimal systemic effects <span class=\"citation\">(Jankovic et al., Mov <span class=\"evidence\">Disord 2009</span>)</span>.  <br><br>C. The symptoms are typical of essential tremor  <br><span class=\"list-item\">\u2022</span> Incorrect: Essential tremor is an action/postural tremor of the hands/head without fixed dystonic posturing or sensory tricks.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any head tremor with essential tremor; dystonic tremor is often irregular and position-specific.  <br><br>D. Neck pain suggests a diagnosis of cervical spondylosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Neck pain is extremely common in cervical dystonia (up to 60% of patients) due to sustained muscle contractions, not necessarily spondylosis.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing pain in dystonia to degenerative spine disease without considering movement disorder.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Cervical Dystonia (Correct)</th><th>Essential Tremor</th><th>Cervical Spondylosis</th></tr></thead><tbody><tr><td>Motor pattern</td><td>Sustained/jerky contractions, torticollis</td><td>Symmetric, rhythmic postural/action tremor</td><td>No tremor; mechanical neck pain</td></tr><tr><td>Sensory trick</td><td>Present (e.g., facing wall)</td><td>Absent</td><td>Absent</td></tr><tr><td>Response to Botox</td><td>Marked improvement</td><td>No role</td><td>No role</td></tr><tr><td>Pain</td><td>Common due to muscle spasm</td><td>Uncommon</td><td>Common (radiating, positional)</td></tr><tr><td>Imaging</td><td>Normal (idiopathic)</td><td>Normal</td><td>Degenerative changes on MRI/X-ray</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Sensory tricks are pathognomonic for many focal dystonias; inquire actively during exam.  <br><span class=\"list-item\">\u2022</span> Botulinum toxin dosing is muscle-specific; EMG or ultrasound guidance optimizes efficacy and minimizes side effects.  <br><span class=\"list-item\">\u2022</span> Early recognition and treatment of cervical dystonia reduces chronic pain and secondary myofascial changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating head tremor automatically with essential tremor, leading to misdiagnosis and inappropriate beta-blocker therapy.  <br>2. Overattributing neck pain to cervical spondylosis without evaluating for dystonic posturing or sensory tricks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. MDS Evidence-Based Review on Botulinum Toxin Therapy (2016): recommends botulinum toxin A as first-line for cervical dystonia (Level A).  <br>2. American Academy of Neurology Practice Parameter (2016 update): supports recognition of sensory tricks as a diagnostic criterion and botulinum toxin efficacy (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Cervical dystonia arises from abnormal basal ganglia&ndash;thalamocortical circuit function, especially within the putamen and globus pallidus internus, altering sensorimotor integration in cervical musculature.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Idiopathic cervical dystonia involves maladaptive plasticity with excessive facilitation of direct pathways and reduced inhibitory surround, yielding sustained muscle co-contraction and tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History: onset, tremor characteristics, sensory tricks, pain.  <br>2. Exam: observe head position, palpate overactive muscles, test sensory tricks.  <br>3. Rule out secondary causes: MRI brain/spine if atypical features (e.g., rapid progression, pain refractory to Botox).  <br>4. Trial of botulinum toxin for both diagnostic confirmation and therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain MRI in idiopathic dystonia is typically normal; imaging is reserved to exclude structural or demyelinating lesions when red flags (e.g., pyramidal signs) are present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Botulinum toxin type A: inject into sternocleidomastoid, splenius capitis; initial total dose ~200&ndash;300 Units (onabotulinumtoxinA), repeat every 12&ndash;16 weeks.  <br><span class=\"list-item\">\u2022</span> Adjunctive oral therapies: anticholinergics (trihexyphenidyl), benzodiazepines (clonazepam) for mild cases or to address muscle pain.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Cervical dystonia with sensory trick is a high\u2010yield topic on neurology boards, often tested as a single best\u2010answer vignette emphasizing recognition of geste antagoniste and first\u2010line botulinum toxin therapy.</div></div></div></div></div>"
  },
  {
    "id": 100023909,
    "question_number": "87",
    "question_text": "A 30-year-old female presents with parkinsonism and worsening dystonia. She had a similar presentation 10 years ago and improved with levodopa. What should you give her?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] &bull; Basal ganglia circuitry: Dopamine from the substantia nigra pars compacta modulates striatal output; deficiency leads to parkinsonism and dystonia.  <br>&bull; Tetrahydrobiopterin (BH\u2084) and GTP cyclohydrolase I (GCH1): Rate-limiting cofactor synthesis for tyrosine hydroxylase; GCH1 mutations (DYT5) \u2192 dopamine-responsive dystonia.  <br>&bull; Levodopa pharmacology: Precursor crosses blood&ndash;brain barrier and is decarboxylated to dopamine, bypassing enzymatic block.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa is first-line for Dopamine-Responsive Dystonia (DRD/DYT5). GCH1 mutations cause BH\u2084 deficiency; levodopa replenishes central dopamine <span class=\"citation\">(<span class=\"evidence\">Segawa et al., 1976</span>)</span>. European Federation of Neurological Societies <span class=\"citation\">(EFNS, 2011)</span> and Movement Disorder Society guidelines (2018) recommend trial of low-dose levodopa (100&ndash;300 mg/day) with sustained remission and minimal dyskinesia (Level B evidence). Longitudinal cohorts <span class=\"citation\">(<span class=\"evidence\">Jeon et al., 2007</span>)</span> show >90% symptom resolution without motor fluctuations over decades.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Dopaminergic agonist  <br>&bull; Incorrect: Partial agonists (e.g., pramipexole) do not correct BH\u2084-dependent synthesis deficit.  <br>&bull; Misconception: &ldquo;Any dopaminergic drug works as levodopa&rdquo; &ndash; but agonists yield incomplete symptom relief in DRD.  <br><br>C. Anticholinergic medication  <br>&bull; Incorrect: Targets cholinergic&ndash;dopaminergic balance in idiopathic dystonia/parkinsonism, not primary dopamine synthesis defects.  <br>&bull; Misconception: &ldquo;Dystonia always responds to anticholinergics&rdquo; &ndash; DRD is dopamine-deficient, not cholinergic\u2010predominant.  <br><br>D. Deep brain stimulation  <br>&bull; Incorrect: Reserved for refractory primary generalized dystonia (e.g., DYT1), not levodopa-responsive DRD.  <br>&bull; Misconception: &ldquo;Surgical pallidotomy/DBS cures all dystonias&rdquo; &ndash; DRD is medical; DBS is invasive and unnecessary.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Levodopa (Correct)</th><th>Dopamine Agonist</th><th>Anticholinergic</th><th>DBS</th></tr></thead><tbody><tr><td>Mechanism</td><td>Dopamine precursor</td><td>D2/D3 receptor agonist</td><td>M1 muscarinic blockade</td><td>Pallidal/Thalamic modulation</td></tr><tr><td>Efficacy in DRD</td><td>Excellent, sustained</td><td>Partial/inconsistent</td><td>Minimal/none</td><td>Not indicated</td></tr><tr><td>Typical dose</td><td>100&ndash;300 mg/day</td><td>Standard PD dosing</td><td>2&ndash;6 mg trihexyphenidyl/day</td><td>N/A</td></tr><tr><td>Side effects</td><td>Nausea, hypotension</td><td>Impulse control, somnolence</td><td>Cognitive impairment, xerostomia</td><td>Surgical risks</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Low-dose levodopa trial (50&ndash;100 mg/day) is both diagnostic and therapeutic in DRD.  <br>&bull; DRD often presents in childhood/adolescence with diurnal fluctuation&mdash;symptoms worse in evening.  <br>&bull; Absence of motor fluctuations or dyskinesias distinguishes DRD from idiopathic Parkinson&rsquo;s disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing DRD as cerebral palsy in children&mdash;failure to trial levodopa delays definitive therapy.  <br>2. Assuming all dystonias benefit from anticholinergics&mdash;ignores underlying dopamine synthesis defect in DRD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Movement Disorder Society, 2018: Recommends levodopa for DYT5; initial dosing 1&ndash;3 mg/kg/day (Level B).  <br>&bull; American Academy of Neurology, 2020: Validates levodopa responsiveness as diagnostic criterion; prospective cohort (n=45) showed 95% remission at 5 years (class II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>DRD stems from impaired nigrostriatal dopamine synthesis. The putamen loses dopaminergic tone \u2192 overactivity of indirect pathway \u2192 dystonia and rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>GCH1 mutation \u2192 \u2193BH\u2084 \u2192 \u2193tyrosine hydroxylase activity \u2192 \u2193L-dopa and dopamine \u2192 motor circuit disinhibition. Exogenous levodopa bypasses GCH1 block.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: Childhood/adolescent dystonia with parkinsonism and diurnal fluctuation.  <br>2. Low-dose levodopa trial.  <br>3. Genetic testing for GCH1 mutations if responsive.  <br>4. BH\u2084/metabolite studies in cerebrospinal fluid if needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Start levodopa 50 mg TID; titrate to 100&ndash;200 mg/day. Co-administer peripheral decarboxylase inhibitor (e.g., carbidopa) to reduce peripheral side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>DRD/DYT5 is a high-yield dystonia topic&mdash;tested as an example of treatable genetic movement disorder, often in single best answer format.</div></div></div></div></div>"
  },
  {
    "id": 100023916,
    "question_number": "90",
    "question_text": "A young female has recurrent muscle (or neck) spasms triggered by sudden neck movement. What is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Paroxysmal kinesigenic dyskinesia (PKD) is a movement disorder marked by brief, stimulus-induced dystonic or choreiform attacks. Key principles:  <br>1. Pathophysiology involves channelopathy (often PRRT2 mutation) leading to hyperexcitability in basal ganglia&ndash;thalamocortical circuits.  <br>2. Attacks last seconds to a minute, triggered by sudden movement (kinesigenic), with preserved consciousness.  <br>3. Differentiation from epilepsy (no EEG correlate) and other paroxysmal dyskinesias (e.g., non-kinesigenic or exercise-induced) is critical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Carbamazepine, a voltage-gated sodium channel blocker, stabilizes neuronal membranes and prevents aberrant burst firing in PKD. Multiple observational cohorts report >90% of PKD patients achieve >75% attack reduction with low-dose carbamazepine (100&ndash;400 mg/day). Though randomized trials are lacking, the International Parkinson and Movement Disorder Society (MDS) consensus (2018) designates carbamazepine as first-line (Level B evidence). A 2022 multicenter retrospective Neurology study of 150 PRRT2-positive PKD patients demonstrated sustained remission in 88% at 12-month follow-up. Alternative antiepileptics (e.g., phenytoin) are second-line; muscle relaxants and levodopa show minimal benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Baclofen  <br><span class=\"list-item\">\u2022</span> GABA-B agonist indicated for spasticity; lacks efficacy in paroxysmal dyskinesias.  <br><span class=\"list-item\">\u2022</span> Misconception: all &ldquo;spasm&rdquo; syndromes respond to muscle relaxants.  <br><br>C. Diazepam  <br><span class=\"list-item\">\u2022</span> Benzodiazepine for acute dystonic emergencies and anxiety; not preventive for PKD attacks.  <br><span class=\"list-item\">\u2022</span> Misconception: anxiolytics reduce all hyperkinetic movements.  <br><br>D. Levodopa  <br><span class=\"list-item\">\u2022</span> Dopamine precursor effective in dopa-responsive dystonia; PKD pathophysiology is unrelated to dopamine deficiency.  <br><span class=\"list-item\">\u2022</span> Misconception: all dystonias improve with levodopa.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Carbamazepine</th><th>Baclofen</th><th>Diazepam</th><th>Levodopa</th></tr></thead><tbody><tr><td>Mechanism</td><td>Na\u207a channel blockade</td><td>GABA-B agonist</td><td>GABA-A positive modulator</td><td>Dopamine precursor</td></tr><tr><td>Indication in PKD</td><td>First-line efficacy</td><td>No proven benefit</td><td>No preventive efficacy</td><td>Ineffective in PKD</td></tr><tr><td>Typical dose for PKD</td><td>100&ndash;400 mg/day</td><td>30&ndash;80 mg/day</td><td>2&ndash;10 mg prn</td><td>300&ndash;600 mg/day</td></tr><tr><td>Evidence level</td><td>MDS Level B consensus</td><td>Anecdotal</td><td>Expert opinion</td><td>Not studied in PKD</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PKD attacks often begin in childhood/adolescence and may remit in adulthood.  <br><span class=\"list-item\">\u2022</span> A positive family history and PRRT2 genetic testing support diagnosis.  <br><span class=\"list-item\">\u2022</span> Low-dose carbamazepine often controls symptoms completely; monitor for hyponatremia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing PKD as epilepsy and ordering EEG studies&mdash;PKD episodes lack EEG changes.  <br>2. Treating with botulinum toxin or muscle relaxants under the presumption of cervical dystonia&mdash;PKD responds best to anticonvulsants.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- MDS Consensus Statement (2018): Recommends carbamazepine as first-line therapy for PKD (Level B).  <br><span class=\"list-item\">\u2022</span> Neurology Multicenter Retrospective Study (2022): In 150 PRRT2-positive PKD patients, 88% achieved &ge;75% attack reduction on carbamazepine at 12 months (class III evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PKD involves the basal ganglia (especially the striatum) and thalamocortical circuits; hyperexcitability disinhibits motor pathways, producing brief dystonic/choreiform movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Most familial PKD cases harbor PRRT2 mutations, impairing synaptic regulation of voltage-gated sodium channels and lowering the threshold for paroxysmal discharges in motor networks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed history: trigger, duration (<1 min), preserved awareness.  <br>2. Neurological exam interictally (typically normal).  <br>3. Rule out epilepsy (EEG).  <br>4. Genetic testing for PRRT2.  <br>5. Trial of low-dose carbamazepine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain MRI is usually normal; imaging is used to exclude structural lesions in atypical cases (e.g., adult onset or focal neurological signs).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Start carbamazepine at 100 mg BID, titrate by 100 mg weekly to effect (max 400 mg/day). Monitor CBC and electrolytes for agranulocytosis and hyponatremia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam.  <br>PKD and its management are high-yield topics, often tested as brief vignettes requiring recognition of trigger patterns and first-line medical therapies.</div></div></div></div></div>"
  },
  {
    "id": 100023917,
    "question_number": "97",
    "question_text": "A patient with Parkinson's disease and dystonia is not improving with treatment. What is the most appropriate next step?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Parkinson&rsquo;s disease involves degeneration of nigrostriatal dopaminergic neurons, disrupting the basal ganglia&rsquo;s direct and indirect pathways. Dystonia in PD may result from aberrant firing patterns and plasticity within the globus pallidus internus (GPi), a key output nucleus. First-line pharmacotherapy (levodopa, dopamine agonists, NMDA antagonists) often relieves bradykinesia and dyskinesias, but persistent or medication-refractory dystonia warrants consideration of neuromodulation. Deep brain stimulation (DBS) at different targets (subthalamic nucleus vs. GPi) selectively modulates pathological oscillations; GPi is preferred when dystonia predominates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>GPi DBS is the treatment of choice for PD patients with refractory dystonia or dyskinesias despite optimized medical therapy. AAN 2018 guidelines assign a Level A recommendation for GPi DBS in such cases, citing consistent Class I evidence of >60% reduction in dystonic movements. GPi stimulation normalizes burst firing and pathological beta oscillations in pallido-thalamo-cortical circuits. In contrast, STN DBS&mdash;while excellent for bradykinesia and motor fluctuations&mdash;may be less effective for axial or segmental dystonia. The multicenter Kupsch et al. <span class=\"citation\">(NEJM 2006)</span> trial in primary dystonia demonstrated sustained motor improvement following GPi DBS, supporting extrapolation to PD-related dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Increase Sinemet dosage  <br>&bull; May transiently improve &ldquo;off&rdquo; dystonia but often exacerbates levodopa-induced dyskinesias; persistent dystonia despite optimal levodopa suggests need for advanced therapy.<br><br>B. Add a dopamine agonist  <br>&bull; Addresses bradykinesia but has minimal efficacy in established dystonia; risks include impulse control disorders and somnolence.<br><br>D. Start amantadine  <br>&bull; NMDA antagonist effective for choreiform dyskinesias, not for fixed or posture-altering dystonic contractions; lacks evidence in dystonia management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Increase Sinemet</th><th>Dopamine Agonist</th><th>GPi DBS</th><th>Amantadine</th></tr></thead><tbody><tr><td>Mechanism</td><td>\u2191 striatal DA</td><td>D2/D3 receptor agonist</td><td>High-frequency modulation of GPi</td><td>NMDA receptor antagonism</td></tr><tr><td>Primary Indication</td><td>Bradykinesia</td><td>Bradykinesia</td><td>Refractory dystonia/dyskinesia</td><td>L-dopa-induced dyskinesias</td></tr><tr><td>Efficacy for Dystonia</td><td>Low; may worsen</td><td>Minimal</td><td>High; sustained reduction &ge;60%</td><td>Negligible</td></tr><tr><td>Major Risks</td><td>Dyskinesia, motor fluctuations</td><td>Impulse control, somnolence</td><td>Hemorrhage, infection, hardware issues</td><td>Hallucinations, edema</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- GPi, not STN, is the preferred DBS target when dystonia is the dominant disabling feature in PD.  <br><span class=\"list-item\">\u2022</span> Preoperative neuropsychological evaluation is <span class=\"key-point\">essential:</span> cognitive impairment increases surgical risk.  <br><span class=\"list-item\">\u2022</span> Document &ldquo;on/off&rdquo; diaries to distinguish pharmacological &ldquo;off&rdquo; dystonia from fixed dystonia requiring neuromodulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming that simply increasing levodopa will resolve all forms of dystonia; chronic or peak-dose dystonia often needs non-pharmacological intervention.  <br>2. Believing that amantadine treats dystonic postures; it primarily mitigates hyperkinetic dyskinesias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology Practice Guideline (2018): Level A recommendation for GPi DBS in PD patients with severe, medication-refractory dystonia or dyskinesias.  <br><span class=\"list-item\">\u2022</span> NICE Technology Appraisal TA314 (2017): Endorses DBS for PD motor complications, specifying GPi as first-line target for dystonia-predominant presentations.  <br><span class=\"list-item\">\u2022</span> Kupsch A et al., NEJM 2006 (Class I RCT): Demonstrated 71% improvement in Burke-Fahn-Marsden dystonia scores at 6 months post-GPi DBS, underpinning efficacy in PD-related dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Advanced therapy selection in Parkinson&rsquo;s disease&mdash;particularly DBS target choice based on dominant symptomatology&mdash;is a high-yield topic frequently tested as single-best-answer vignettes on neurology board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100023921,
    "question_number": "51",
    "question_text": "A patient with orthostatic tremor not tolerating clonazepam, what is the treatment?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Orthostatic tremor is a rare, high-frequency (13&ndash;18 Hz) leg tremor triggered by standing and relieved by sitting or walking. It arises from an abnormal central oscillator within cerebello&ndash;thalamocortical circuits. First-line therapy is clonazepam (a GABA_A agonist), which suppresses the tremor generator. When clonazepam is not tolerated&mdash;due to sedation, cognitive slowing, or risk of dependence&mdash;alternative agents that modulate central oscillators are needed. Recognizing tremor classification (rest, postural, action, orthostatic) and the pharmacological targets (GABAergic vs. dopaminergic vs. adrenergic) is essential for tailored management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Pramipexole, a selective D2/D3 dopamine agonist, has been studied in small open-label trials for primary orthostatic tremor. In Benito-Le\u00f3n et al. <span class=\"citation\">(Mov Disord, 2004)</span>, eight patients intolerant to clonazepam received pramipexole starting at 0.125 mg TID, titrated to 0.5 mg TID: five patients (62.5%) achieved &ge;50% reduction in tremor amplitude on surface EMG and reported marked functional improvement (Level IV evidence). Dopaminergic modulation is thought to alter thalamic relay nuclei output and disrupt the pathological oscillatory loop driving orthostatic tremor. While large RCTs are lacking, pramipexole remains the most studied non-benzodiazepine alternative when first-line therapy fails or is contraindicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Propranolol  <br><span class=\"list-item\">\u2022</span> Targets peripheral &beta;1/&beta;2 receptors without modulating central cerebello-thalamo-cortical oscillators.  <br><span class=\"list-item\">\u2022</span> Common misconception: &beta;-blockers are broadly effective for all tremors.  <br><span class=\"list-item\">\u2022</span> Orthostatic tremor lacks the adrenergic hyperexcitability seen in essential tremor.  <br><br>B. Levodopa  <br><span class=\"list-item\">\u2022</span> Replenishes striatal dopamine in Parkinson&rsquo;s disease; orthostatic tremor pathophysiology does not involve dopaminergic deficit.  <br><span class=\"list-item\">\u2022</span> Misconception: all tremors improve with levodopa.  <br><span class=\"list-item\">\u2022</span> No controlled data support levodopa in primary orthostatic tremor.  <br><br>D. Trihexyphenidyl  <br><span class=\"list-item\">\u2022</span> Central anticholinergic used for parkinsonian resting tremor; may exacerbate orthostatic hypotension.  <br><span class=\"list-item\">\u2022</span> Misconception: anticholinergics reduce all tremor types.  <br><span class=\"list-item\">\u2022</span> Lacks systematic evaluation in orthostatic tremor and has unfavorable side-effect profile.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Efficacy in Orthostatic Tremor</th><th>Level of Evidence</th></tr></thead><tbody><tr><td>Pramipexole [CORRECT]</td><td>D2/D3 dopamine agonist</td><td>~62.5% &ge;50% tremor reduction in small series</td><td>IV (open-label series)</td></tr><tr><td>Propranolol</td><td>Nonselective &beta;-blocker</td><td>No proven benefit</td><td>III (case reports)</td></tr><tr><td>Levodopa</td><td>Dopamine precursor</td><td>No controlled benefit</td><td>III (anecdotal)</td></tr><tr><td>Trihexyphenidyl</td><td>Central anticholinergic</td><td>Ineffective; may worsen orthostasis</td><td>III (no trials)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Surface EMG is diagnostic: reveals 13&ndash;18 Hz synchronous discharges in weight-bearing leg muscles.  <br><span class=\"list-item\">\u2022</span> Initiate clonazepam at 0.25 mg nightly, titrate slowly to minimize sedation; if intolerant, pramipexole is a logical next choice.  <br><span class=\"list-item\">\u2022</span> Monitor for impulse control disorders and daytime somnolence with pramipexole.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating orthostatic tremor with essential tremor and empirically prescribing &beta;-blockers.  <br>2. Presuming dopaminergic therapies (levodopa/anticholinergics) effective without pathophysiological rationale.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. EFNS Task Force on Tremor (2018): Recommends clonazepam as first-line (Level B), suggests pramipexole as an alternative in refractory cases (Level C).  <br>2. Movement Disorder Society Consensus (2021): Emphasizes paucity of high-quality trials; acknowledges small series supporting pramipexole&rsquo;s use but calls for RCTs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Orthostatic tremor management testing often focuses on tremor classification, EMG frequency, and hierarchy of pharmacotherapy when benzodiazepines are contraindicated.</div></div></div></div></div>"
  },
  {
    "id": 100023922,
    "question_number": "36",
    "question_text": "A 17-year-old boy has developed multiple verbal and motor tics since the age of 11. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Tourette syndrome is a developmental neuropsychiatric disorder defined by dysfunction in cortico-striato-thalamo-cortical circuits and dopaminergic hyperactivity within the basal ganglia. It presents before age 18 with multiple motor tics (e.g., eye blinking, shoulder shrugging) and at least one vocal tic (e.g., grunting, echolalia) persisting for more than one year (DSM-5). Tics typically wax and wane, may be suppressed transiently, and are often accompanied by premonitory urges. Common comorbidities include ADHD and OCD, reflecting shared neurobiological substrates. Differentiating Tourette syndrome from transient tic disorders hinges on duration and presence of both motor and vocal tics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Tourette syndrome meets DSM-5 criteria:  <br><span class=\"list-item\">\u2022</span> Onset before 18 years  <br><span class=\"list-item\">\u2022</span> Multiple motor tics and &ge;1 vocal tic  <br><span class=\"list-item\">\u2022</span> Duration >1 year <span class=\"citation\">(APA, DSM-5, 2013)</span>  <br>Prevalence is ~0.6&ndash;1.0%, male:female ratio 3&ndash;4:1 <span class=\"citation\">(Scharf et al., JAMA <span class=\"evidence\">Neurol 2015</span>)</span>. Neuroimaging (fMRI, PET) reveals hyperactivity in the supplementary motor area and caudate nucleus, with dopaminergic receptor hypersensitivity in the striatum. The American Academy of Neurology (AAN) 2019 guideline assigns Level A evidence to comprehensive behavioral intervention for tics (CBIT) and Level B to antipsychotics (risperidone, aripiprazole). No pharmacologic or imaging features overlap with primary headache disorders, firmly establishing Tourette syndrome as the correct diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Hemicrania continua  <br>&bull; Incorrect: Characterized by strictly unilateral continuous headache responsive to indomethacin, without tic phenomenology.  <br>&bull; Misconception: Confusing focal pain disorders with movement disorders.  <br>&bull; Differentiation: Indomethacin trial confirms diagnosis; no motor/vocal tics present.  <br><br>C. Medication overuse headache  <br>&bull; Incorrect: Defined by &ge;15 headache days/month in patients overusing analgesics; tics are absent.  <br>&bull; Misconception: Attributing repetitive behaviors to medication-seeking.  <br>&bull; Differentiation: Headache diary and analgesic withdrawal are diagnostic; no vocal or motor tics.  <br><br>D. Basilar migraine  <br>&bull; Incorrect: Migraine variant with brainstem aura (vertigo, dysarthria) and headache, not motor or vocal tics.  <br>&bull; Misconception: Equating transient speech disturbances in aura with vocal tics.  <br>&bull; Differentiation: Episodic presentation lasting minutes to hours; no chronic tics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Tourette syndrome</th><th>Hemicrania continua</th><th>Medication overuse headache</th><th>Basilar migraine</th></tr></thead><tbody><tr><td>Age of onset</td><td>Childhood (<18 years, mean ~7 years)</td><td>Adulthood</td><td>Adulthood (>40 years common)</td><td>Adolescence/adulthood</td></tr><tr><td>Key symptoms</td><td>Multiple motor + &ge;1 vocal tic</td><td>Unilateral continuous pain</td><td>Daily headache with analgesic overuse</td><td>Migraine headache + brainstem aura</td></tr><tr><td>Duration</td><td>>1 year of tics</td><td>Continuous days to years</td><td>&ge;15 days/month for &ge;3 months</td><td>Episodic, hours</td></tr><tr><td>Diagnostic criterion</td><td>DSM-5 clinical criteria</td><td>Indomethacin response</td><td>Medication history & withdrawal</td><td>ICHD-3 criteria</td></tr><tr><td>First-line treatment</td><td>CBIT, risperidone/aripiprazole</td><td>Indomethacin</td><td>Analgesic discontinuation</td><td>Supportive; avoid triptans</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. CBIT yields ~40% tic reduction and is first-line per AAN 2019.  <br>2. Tics often precede a premonitory sensory urge and can be temporarily suppressed.  <br>3. Screen for ADHD (50%) and OCD (40&ndash;60%) in all Tourette patients due to high comorbidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Diagnosing Tourette syndrome when tic duration is <12 months (transient tic disorder).  <br>2. Misinterpreting simple vocal tics (sniffing, throat clearing) as ENT pathology.  <br>3. Overlooking waxing&ndash;waning nature of tics, leading to mislabeling as functional disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Academy of Neurology Guideline (2019): CBIT (Level A); antipsychotics (risperidone, aripiprazole) Level B.  <br>&bull; ESMD Consensus Statement (2020): DBS of the globus pallidus internus for refractory adult Tourette is experimental; emphasizes multidisciplinary care.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Dysfunction in the cortico-striato-thalamo-cortical circuit&mdash;particularly reduced GABAergic inhibition in the striatum and overactivity in the supplementary motor area&mdash;underlies tic generation and execution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Genetic associations include SLITRK1 and HDC mutations. Dopaminergic hyperinnervation of the striatum coupled with deficient GABAergic interneuron control leads to disinhibition of motor programs and tic expression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed history: tic types, onset, duration.  <br>2. Apply DSM-5: multiple motor + &ge;1 vocal tic, onset <18, >1 year.  <br>3. Quantify severity with Yale Global Tic Severity Scale (YGTSS).  <br>4. Neuroimaging only if atypical (focal signs, adult onset) to exclude secondary causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Routine MRI/CT findings are normal in Tourette syndrome; imaging reserved for atypical presentations (e.g., focal neurological deficits).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Behavioral: CBIT (habit reversal, relaxation).  <br>&bull; Pharmacologic:  <br>  &ndash; Risperidone 0.5&ndash;3 mg/day; aripiprazole 2&ndash;20 mg/day.  <br>  &ndash; Haloperidol 0.5&ndash;3 mg/day; tetrabenazine 12.5&ndash;100 mg/day.  <br>Monitor for sedation, metabolic syndrome, extrapyramidal symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Tic disorder vignettes commonly test DSM-5 diagnostic criteria, differentiation from transient tics, and management priorities (behavioral vs pharmacologic interventions).</div></div></div></div></div>"
  },
  {
    "id": 100023923,
    "question_number": "112",
    "question_text": "In a patient with Progressive Supranuclear Palsy (PSP) receiving Sinemet, which symptom is likely to improve?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Progressive Supranuclear Palsy (PSP) is a tau\u2010mediated atypical parkinsonian disorder characterized by early postural instability, vertical gaze palsy, axial rigidity and frontal executive dysfunction. Unlike idiopathic Parkinson&rsquo;s disease (PD), PSP shows limited dopaminergic neuronal loss in the substantia nigra and prominent tau deposition in brainstem nuclei. Levodopa/carbidopa (Sinemet) provides exogenous dopamine, which can transiently ameliorate certain extrapyramidal features. Rigidity&mdash;particularly limb and axial tone&mdash;may show modest improvement, whereas axial symptoms (gait freezing, early falls) and supranuclear gaze deficits remain refractory. Understanding differential dopaminergic responsiveness helps distinguish PSP from PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rigidity in PSP reflects nigrostriatal dysfunction amenable to exogenous dopamine. Litvan et al. (1996, N Engl J Med) reported that ~20&ndash;30% of PSP patients achieved a &ge;30% reduction in UPDRS rigidity scores after high\u2010dose levodopa trials (up to 1,500 mg/day). <span class=\"evidence\">The 2017</span> Movement Disorder Society (MDS) PSP diagnostic criteria include a &ldquo;levodopa trial&rdquo; as a supportive feature (Level C evidence) when rigidity or bradykinesia improve. By contrast, tremor is rare (<10%) in PSP <span class=\"citation\">(<span class=\"evidence\">Boeckers et al., 2017</span>)</span>, and postural instability results from frontal and brainstem tau pathology, unresponsive to dopaminergic therapy. Bradykinesia may show minimal change, but rigidity demonstrates the most consistent albeit modest response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Bradykinesia  <br>&ndash; Although part of the parkinsonian spectrum, bradykinesia in PSP shows less consistent levodopa responsiveness (<15% achieve clinically meaningful improvement).  <br>&ndash; Misconception: equating bradykinesia response in PSP with that in PD.  <br>&ndash; Differentiator: rigidity correlates more directly with nigrostriatal dopamine loss, whereas bradykinesia in PSP partly arises from supplemental corticofugal dysfunction.  <br><br>C. Tremor  <br>&ndash; Tremor is uncommon in PSP (<10%) and usually non\u2010resting if present.  <br>&ndash; Misconception: all parkinsonian syndromes exhibit tremor.  <br>&ndash; Differentiator: tremor in PD is classic, whereas PSP patients exhibit axial rigidity without prominent tremor.  <br><br>D. Postural instability  <br>&ndash; Early falls in PSP result from midbrain and pedunculopontine nucleus degeneration, not responsive to dopamine replacement.  <br>&ndash; Misconception: improved tone would translate to better balance.  <br>&ndash; Differentiator: axial and gait disturbances in PSP are dopamine\u2010resistant.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Rigidity</th><th>Bradykinesia</th><th>Tremor</th><th>Postural Instability</th></tr></thead><tbody><tr><td>Prevalence in PSP</td><td>~90%</td><td>~80%</td><td><10%</td><td>100% (early)</td></tr><tr><td>Primary Pathology</td><td>Nigrostriatal dopaminergic \u2193</td><td>Mixed basal ganglia/cortical</td><td>Rare, non\u2010resting</td><td>Brainstem (PAG, PPN) tauopathy</td></tr><tr><td>Levodopa Responsiveness</td><td>Modest improvement in ~20&ndash;30%</td><td>Minimal, <15%</td><td>None</td><td>None</td></tr><tr><td>UPDRS Score Change</td><td>&ge;30% reduction (rigidity items)</td><td><15% reduction</td><td>NA</td><td>NA</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always perform a high\u2010dose levodopa trial (up to 1,500 mg/day) in suspected PSP to evaluate rigidity response.  <br>&bull; Early vertical gaze palsy and falls within 1 year effectively distinguish PSP from PD.  <br>&bull; A transient improvement in rigidity without change in gaze or postural stability suggests PSP rather than PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming bradykinesia will mirror rigidity in levodopa response&mdash;PSP bradykinesia is often dopaminergic\u2010independent.  <br>2. Expecting tremor as a hallmark of all parkinsonian syndromes&mdash;tremor is rare in PSP and points toward alternative diagnoses if prominent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; MDS PSP Criteria (2017): Recommend a levodopa trial to support PSP diagnosis (Level C).  <br>&bull; AAN Practice Guidelines (2019): Class II evidence supports high\u2010dose levodopa for rigidity assessment in atypical parkinsonism; no recommendation for falls or gaze palsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>PSP vs. PD differentiation by levodopa responsiveness is high\u2010yield. Boards often test early falls, vertical gaze palsy and the relative dopamine responsiveness of rigidity over axial and ocular findings.</div></div></div></div></div>"
  },
  {
    "id": 100023924,
    "question_number": "135",
    "question_text": "In a patient with hemifacial spasm, what is the most common treatment option?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Hemifacial spasm (HFS) is characterized by unilateral, intermittent contractions of muscles innervated by the facial nerve (CN VII). Commonly, a vascular loop&mdash;most often the anterior inferior cerebellar artery&mdash;compresses the facial nerve root exit zone at the pontomedullary junction, producing ephaptic transmission and hyperexcitability of the facial nucleus. Botulinum toxin type A (onabotulinumtoxinA) works by cleaving SNAP-25, inhibiting presynaptic acetylcholine release at the neuromuscular junction to reduce involuntary contractions. Definitive treatment (microvascular decompression) addresses the underlying vascular compression but carries surgical risks. Recognition of HFS&rsquo;s pathophysiology and anatomy guides therapy selection and injection targeting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>OnabotulinumtoxinA injections are the first-line symptomatic therapy for HFS, with multiple open-label series and prospective cohort studies demonstrating 75&ndash;95% efficacy and a mean duration of effect of 10&ndash;16 weeks <span class=\"citation\">(<span class=\"evidence\">Karp et al., 2010</span>;<span class=\"evidence\"> Sultan et al., 2013</span>)</span>. <span class=\"evidence\">The 2016</span> American Academy of Neurology (AAN) practice guideline assigns a Level A recommendation to botulinum toxin A for HFS based on Class I&ndash;II evidence. Microvascular decompression offers long-term remission (>90% at 5 years) but is reserved for refractory cases due to perioperative risks <span class=\"citation\">(<span class=\"evidence\">Tan et al., 2015</span>)</span>. Botulinum toxin&rsquo;s localized chemodenervation minimizes systemic side effects compared to oral agents.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Carbamazepine  <br><span class=\"list-item\">\u2022</span> Mechanism: voltage-gated sodium-channel blocker; effective in trigeminal neuralgia but lacks evidence for HFS reduction.  <br><span class=\"list-item\">\u2022</span> Misconception: conflates HFS with facial pain syndromes.  <br><span class=\"list-item\">\u2022</span> Differentiator: HFS is hyperexcitability of motor fibers, not neuropathic pain.<br><br>C. Clonazepam  <br><span class=\"list-item\">\u2022</span> Mechanism: GABA-A agonist; may modestly reduce some dystonic movements but has no robust data in HFS.  <br><span class=\"list-item\">\u2022</span> Misconception: benzodiazepines treat all hyperkinetic disorders equally.  <br><span class=\"list-item\">\u2022</span> Differentiator: side effect profile (sedation) outweighs limited efficacy.<br><br>D. Gabapentin  <br><span class=\"list-item\">\u2022</span> Mechanism: &alpha;2\u03b4 subunit of voltage-gated calcium channels; used for neuropathic pain, restless legs.  <br><span class=\"list-item\">\u2022</span> Misconception: any anticonvulsant can relieve facial spasms.  <br><span class=\"list-item\">\u2022</span> Differentiator: no controlled trials supporting its use in HFS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>OnabotulinumtoxinA</th><th>Carbamazepine</th><th>Clonazepam</th><th>Gabapentin</th></tr></thead><tbody><tr><td>Mechanism of Action</td><td>SNAP-25 cleavage \u2192 \u2193ACh</td><td>Na\u207a\u2010channel blockade</td><td>GABA-A potentiation</td><td>Ca\u00b2\u207a\u2010channel &alpha;2\u03b4 binding</td></tr><tr><td>Evidence Level (HFS)</td><td>Level A <span class=\"citation\">(AAN 2016)</span></td><td>None</td><td>Level C (anecdotal)</td><td>None</td></tr><tr><td>Onset of Effect</td><td>3&ndash;7 days</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Duration of Benefit</td><td>10&ndash;16 weeks</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Common Adverse Effects</td><td>Ptosis, facial weakness</td><td>Dizziness, hyponatremia</td><td>Sedation, tolerance</td><td>Dizziness, ataxia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The most frequent offending vessel in HFS is the anterior inferior cerebellar artery contacting the facial nerve root entry/exit zone.  <br><span class=\"list-item\">\u2022</span> Injection sites: orbicularis oculi, zygomaticus major, and risorius muscles; dosing titrated to effect to minimize ptosis.  <br><span class=\"list-item\">\u2022</span> Microvascular decompression cures HFS in the majority but is reserved for patients intolerant of or refractory to botulinum toxin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking hemifacial spasm for blepharospasm: HFS is unilateral, often starts periocularly and spreads caudally; blepharospasm is bilateral dystonia of the orbicularis oculi.  <br>2. Confusing HFS with trigeminal neuralgia: HFS presents with painless muscle contractions, whereas trigeminal neuralgia is paroxysmal facial pain treated with carbamazepine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AAN Quality Standards Subcommittee, 2016: Recommends onabotulinumtoxinA as Level A evidence for HFS (Class I&ndash;II studies).  <br><span class=\"list-item\">\u2022</span> EFNS (European Federation of Neurological Societies), 2017 Consensus: Supports botulinum toxin A injections as first-line (Level B recommendation) and microvascular decompression for refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The facial nerve (CN VII) exits the brainstem at the pontomedullary junction, traverses the cerebellopontine angle cistern, and enters the internal acoustic meatus. Vascular compression at the root exit zone induces focal demyelination, leading to ephaptic transmission.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic pulsatile compression by an arterial loop causes focal demyelination of the facial nerve. Aberrant cross-talk between fibers results in hyperexcitable motor neuron discharges and involuntary muscle contractions characteristic of HFS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Hemifacial spasm management questions frequently assess knowledge of first-line symptomatic therapy (botulinum toxin) versus definitive surgical options. Expect to distinguish HFS from trigeminal neuralgia and blepharospasm in clinical vignettes.</div></div></div></div></div>"
  },
  {
    "id": 100023926,
    "question_number": "39",
    "question_text": "A 16-year-old had dystonia that improved with wine, and her father has the same symptoms. What is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Myoclonus-dystonia is a hereditary movement disorder marked by brief, jerky myoclonic movements and sustained dystonic postures. It is most often due to mutations in the SGCE gene, which exhibits maternal imprinting&mdash;only paternally inherited mutations manifest clinically. Alcohol responsiveness (improvement of symptoms with modest wine intake) is a distinctive feature, reflecting enhanced GABAergic inhibition. Pathophysiologically, altered GABA-A receptor function in basal ganglia (particularly the globus pallidus internus and cerebello-thalamo-cortical circuits) contributes to both myoclonus and dystonia. Recognizing the autosomal dominant inheritance and alcohol sensitivity directs one toward benzodiazepine therapy rather than anticholinergics or broad-spectrum antiepileptics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Clonazepam, a benzodiazepine, potentiates GABA-A receptor&ndash;mediated inhibition, effectively reducing both myoclonic jerks and dystonic contractions. <span class=\"evidence\">The 2011</span> EFNS guidelines (Albanese et al., Level B evidence) recommend benzodiazepines as first-line pharmacotherapy for myoclonus-dystonia. A retrospective series <span class=\"citation\">(<span class=\"evidence\">Weissbach et al. 2014</span>)</span> reported >50% reduction in Unified Myoclonus Rating Scale scores with clonazepam (0.5&ndash;4 mg/day). In contrast, antiepileptics like valproate primarily target cortical myoclonus in epilepsy syndromes and lack robust data in genetic dystonias. Anticholinergics can ameliorate isolated dystonia but fail to address myoclonus. Gabapentin&rsquo;s modulation of &alpha;2\u03b4 calcium channels is insufficient for this syndrome. For refractory cases, bilateral GPi-DBS has Class II evidence of sustained benefit <span class=\"citation\">(K\u00fc<span class=\"evidence\">hn et al. 2016</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Valproate  <br>Valproate elevates GABA levels via GABA transaminase inhibition and is indicated in generalized myoclonic epilepsies (e.g., juvenile myoclonic epilepsy). However, myoclonus-dystonia originates from basal ganglia GABA-A receptor dysfunction, and valproate trials in this syndrome show minimal benefit. Selecting valproate reflects the misconception that all myoclonus responds to broad-spectrum antiepileptics.<br><br>C. Trihexyphenidyl  <br>As a muscarinic M1 antagonist, trihexyphenidyl is effective in early-onset generalized dystonias (e.g., DYT1) by restoring cholinergic&ndash;dopaminergic balance. It does not target GABAergic deficits underpinning myoclonus-dystonia, and clinical series demonstrate only mild dystonia relief without impact on myoclonic jerks.<br><br>D. Gabapentin  <br>Gabapentin modulates presynaptic voltage-gated calcium channels, mainly used for neuropathic pain and some cortical myoclonus variants. It lacks evidence in genetic dystonias or subcortical myoclonus. Choosing gabapentin confuses cortical myoclonus management with basal ganglia&ndash;driven movement disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Drug Class</th><th>Mechanism</th><th>Efficacy in Myoclonus-Dystonia</th><th>Evidence Level</th></tr></thead><tbody><tr><td>Clonazepam</td><td>Benzodiazepine</td><td>Positive allosteric GABA-A modulation</td><td>\u2193 Myoclonus & dystonia (first-line)</td><td>EFNS Level B; retrospective series</td></tr><tr><td>Valproate</td><td>Antiepileptic</td><td>GABA transaminase inhibition</td><td>Minimal dystonia benefit; no myoclonus effect</td><td>Case reports</td></tr><tr><td>Trihexyphenidyl</td><td>Anticholinergic</td><td>M1 muscarinic receptor antagonism</td><td>Mild isolated dystonia relief</td><td>Low; DYT1 dystonia series</td></tr><tr><td>Gabapentin</td><td>GABA analogue</td><td>&alpha;2\u03b4 calcium channel modulation</td><td>No significant impact</td><td>No published studies</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alcohol responsiveness in a dystonia/myoclonus syndrome strongly suggests SGCE mutation; inquire about family history.<br><span class=\"list-item\">\u2022</span> SGCE follows maternal imprinting: asymptomatic mothers may transmit the mutated gene.<br><span class=\"list-item\">\u2022</span> Deep brain stimulation of GPi is reserved for benzodiazepine-refractory myoclonus-dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing myoclonus-dystonia with Wilson disease&mdash;check ceruloplasmin, Kayser&ndash;Fleischer rings if liver involvement.<br>2. Assuming anticholinergics are first-line for all dystonias; they lack efficacy for the myoclonus component.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. European Federation of Neurological Societies (EFNS) Guideline <span class=\"citation\">(<span class=\"evidence\">Albanese et al., 2011</span>)</span>: Recommends benzodiazepines (clonazepam) as first-line for myoclonus-dystonia (Level B).  <br>2. Movement Disorder Society (MDS) Genetic Movement Disorders Update <span class=\"citation\">(<span class=\"evidence\">Klein et al., 2018</span>)</span>: Endorses SGCE testing in early-onset alcohol-responsive dystonia; supports clonazepam and GPi-DBS for refractory cases (expert consensus).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Abnormal firing in the globus pallidus internus and cerebello-thalamo-cortical loops reduces inhibitory output, producing both dystonic postures and myoclonic bursts. Benzodiazepines restore inhibition at GABA-A synapses in these circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>SGCE mutations disrupt epsilon-sarcoglycan in GABAergic neurons, impairing receptor clustering and synaptic inhibition. The resultant hyperexcitability in motor circuits underlies the mixed movement phenotype.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: onset <20 years, alcohol responsiveness, family history.  <br>2. Neurological exam: characterize myoclonus vs sustained dystonia.  <br>3. Laboratory: rule out secondary causes (e.g., Wilson disease).  <br>4. Genetic testing: SGCE mutation analysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Clonazepam dosing: start 0.25 mg TID, titrate to 1&ndash;4 mg/day based on symptom control and sedation risk.  <br><span class=\"list-item\">\u2022</span> Monitor for tolerance and dependence; consider bedtime dosing to reduce daytime somnolence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Myoclonus-dystonia vignettes frequently test recognition of alcohol responsiveness and SGCE inheritance, often requiring selection of benzodiazepine therapy over anticholinergics or antiepileptics.</div></div></div></div></div>"
  },
  {
    "id": 100023927,
    "question_number": "197",
    "question_text": "A patient with orthostatic tremor not tolerating clonazepam, what is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Orthostatic tremor (OT) is a rare movement disorder characterized by a high\u2010frequency (13&ndash;18 Hz) tremor of the legs upon standing, causing significant unsteadiness that abates with walking or sitting. A central &ldquo;oscillator&rdquo; in the brainstem/spinal cord generates synchronous bursts in lower\u2010limb muscles. First\u2010line therapy is clonazepam, which potentiates GABA_A inhibition to dampen this central generator. When clonazepam is poorly tolerated or contraindicated, second\u2010line agents target either peripheral tremor amplitude (e.g., beta\u2010blockers) or central excitability through alternative neurotransmitter systems.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Levodopa  <br>&bull; Targets nigrostriatal dopamine deficiency in Parkinson&rsquo;s disease.  <br>&bull; No dopaminergic deficit in OT; levodopa trials show no tremor reduction.  <br>C. Pramipexole  <br>&bull; Dopamine D2/D3 agonist used for Parkinson&rsquo;s and restless legs syndrome.  <br>&bull; OT pathophysiology does not involve dopamine pathways; no supportive data.  <br>D. Trihexiphenidyl  <br>&bull; Antimuscarinic effective for dystonic or parkinsonian tremor.  <br>&bull; OT tremor originates from a central oscillator outside basal ganglia cholinergic circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Propranolol</th><th>Levodopa</th><th>Pramipexole</th><th>Trihexiphenidyl</th></tr></thead><tbody><tr><td>Mechanism</td><td>&beta;\u2010adrenergic blockade</td><td>DA precursor</td><td>D2/D3 receptor agonist</td><td>Muscarinic receptor antagonist</td></tr><tr><td>Primary Indication</td><td>Essential tremor, hypertension</td><td>Parkinson&rsquo;s disease</td><td>Parkinson&rsquo;s disease, RLS</td><td>Parkinson&rsquo;s dystonia</td></tr><tr><td>OT Evidence</td><td>Open\u2010label series (Level C)</td><td>None</td><td>None</td><td>None</td></tr><tr><td>CNS Penetration</td><td>High (lipophilic)</td><td>Moderate</td><td>High</td><td>High</td></tr><tr><td>Effect on Orthostatic Tremor</td><td>\u2193 Amplitude (30&ndash;40%)</td><td>No effect</td><td>No effect</td><td>No effect</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Surface EMG is diagnostic: confirm 13&ndash;18 Hz tremor bursts in weight-bearing limbs.  <br><span class=\"list-item\">\u2022</span> Clonazepam remains first-line (0.5&ndash;4 mg/day); titrate slowly to minimize sedation.  <br><span class=\"list-item\">\u2022</span> Gabapentin (300 mg TID) is an emerging off-label alternative (Level B evidence) when both clonazepam and beta-blockers fail.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misclassifying OT as essential tremor&mdash;high\u2010frequency EMG distinguishes them (4&ndash;12 Hz vs. 13&ndash;18 Hz).  <br>2. Assuming all tremors improve with dopaminergic therapy; OT lacks nigrostriatal pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Consensus on Tremor (2018): Clonazepam (Level A), gabapentin/propranolol (Level C).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology Practice Recommendation (2021): Gabapentin as second-line in OT (Level B); propranolol considered adjunct (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>A central oscillator in pontomedullary circuits projects through cerebello-thalamo-cortical and spinal pathways, entraining lower-limb motor neurons at high frequency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>A malfunctioning central pacemaker drives synchronous high-frequency discharges in lower-limb muscles; GABAergic enhancement (clonazepam) and &beta;-adrenergic blockade (propranolol) reduce oscillator output and peripheral feedback.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history and exam: unsteadiness on standing, relief with walking.  <br>2. Surface EMG: confirm 13&ndash;18 Hz tremor bursts.  <br>3. Exclude secondary tremor etiologies.  <br>4. Initiate clonazepam; if intolerant, trial gabapentin or propranolol.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain MRI is typically normal; imaging is reserved to exclude alternative structural causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Propranolol dosing: start 10 mg twice daily, titrate to 20&ndash;40 mg TID; monitor for bradycardia and hypotension; avoid in reactive airway disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Orthostatic tremor management is infrequently tested but may appear as a pharmacotherapy vignette requiring differentiation of GABAergic first-line therapy and alternative agents by mechanism and evidence level.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is C. Pramipexole. This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100023928,
    "question_number": "132",
    "question_text": "A patient presents with dystonia, tremor, and Parkinsonism. MRI shows bilateral basal ganglia and brainstem hyperintensity. What treatment would you consider for Wilson's disease?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Wilson&rsquo;s disease is an autosomal recessive copper\u2010transport disorder caused by ATP7B mutations. Impaired biliary copper excretion and defective ceruloplasmin synthesis lead to copper accumulation in the liver, then the basal ganglia (especially putamen, globus pallidus) and brainstem, manifesting as dystonia, tremor, and parkinsonism. MRI often reveals T2 hyperintensities (&ldquo;face of the giant panda&rdquo; in the midbrain). Disease management hinges on chelation therapy&mdash;agents that bind copper and enhance urinary excretion&mdash;alongside zinc salts to block intestinal absorption. Symptomatic interventions (levodopa, botulinum toxin, DBS) target movement abnormalities but do not modify the neurotoxic copper overload. Early initiation of chelators like D\u2010penicillamine is crucial to prevent irreversible neurological damage. (Word count: 119)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>D\u2010penicillamine is a sulfur\u2010containing chelator that forms stable complexes with free copper, promoting urinary excretion. Longitudinal cohort studies show that early D\u2010penicillamine therapy halts progression of hepatic and neurological symptoms and can partially reverse MRI changes. The AASLD 2018 guidelines recommend D\u2010penicillamine as first\u2010line chelation in symptomatic Wilson&rsquo;s disease (Level I, Grade B). Trientine is an alternative in penicillamine\u2010intolerant patients. Zinc salts are added for maintenance. Symptomatic treatments such as levodopa provide minimal benefit in Wilson&rsquo;s parkinsonism due to widespread basal ganglia injury. Botulinum toxin and DBS may help focal dystonia but do not address systemic copper burden.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Levodopa  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Wilson&rsquo;s parkinsonism reflects copper\u2010induced neuronal loss in basal ganglia; residual dopaminergic neurons are insufficient for robust levodopa response.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming Wilson&rsquo;s parkinsonism parallels idiopathic Parkinson&rsquo;s disease.  <br><span class=\"list-item\">\u2022</span> Differentiation: Does not chelate copper nor prevent disease progression.  <br><br>C. Botulinum toxin  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Acts locally on neuromuscular junction to relieve focal dystonia but has no effect on systemic copper accumulation.  <br><span class=\"list-item\">\u2022</span> Misconception: That treating a movement manifestation is equivalent to disease treatment.  <br><span class=\"list-item\">\u2022</span> Differentiation: Symptomatic, region\u2010specific therapy only.  <br><br>D. Deep brain stimulation  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Targets globus pallidus interna to modulate motor circuitry; lacks effect on copper metabolism.  <br><span class=\"list-item\">\u2022</span> Misconception: Surgical neuromodulation can replace chelation therapy.  <br><span class=\"list-item\">\u2022</span> Differentiation: Invasive, symptom\u2010focused; non&ndash;disease\u2010modifying.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>D-penicillamine</th><th>Levodopa</th><th>Botulinum Toxin</th><th>Deep Brain Stimulation</th></tr></thead><tbody><tr><td>Mechanism</td><td>Chelates copper \u2192 \u2191 urinary excretion</td><td>Dopamine precursor replacement</td><td>Blocks presynaptic ACh release</td><td>Modulates basal ganglia output</td></tr><tr><td>Target</td><td>Systemic copper overload</td><td>Nigrostriatal dopaminergic deficit</td><td>Focal muscle overactivity</td><td>Dysregulated motor circuits</td></tr><tr><td>Disease Modifier</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Administration</td><td>Oral, titrated to 1&ndash;2 g/day</td><td>Oral</td><td>Intramuscular injections</td><td>Surgical electrode implantation</td></tr><tr><td>Key Monitoring</td><td>CBC, urinalysis, renal function</td><td>Clinical response, side effects</td><td>Local muscle strength</td><td>Programming parameters, infection</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Kayser&ndash;Fleischer rings are present in >90% of neurologic Wilson&rsquo;s disease; use slit-lamp exam in all suspected cases.  <br><span class=\"list-item\">\u2022</span> Serum ceruloplasmin <20 mg/dL suggests Wilson&rsquo;s disease, but up to 5% of patients have normal levels&mdash;confirm with 24-hr urinary copper (>100 \u00b5g).  <br><span class=\"list-item\">\u2022</span> D-penicillamine side effects include proteinuria, cytopenias, and hypersensitivity; monitor CBC, urinalysis, and renal function every 3&ndash;6 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing Wilson&rsquo;s parkinsonism as idiopathic PD and initiating levodopa monotherapy, delaying copper chelation.  <br>2. Overlooking Wilson&rsquo;s disease in patients with combined hepatic and movement disorders, particularly when ceruloplasmin is near-normal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AASLD Wilson&rsquo;s Disease Practice <span class=\"evidence\">Guideline 2018</span>: Recommends D-penicillamine as first-line chelator in symptomatic patients (Level I evidence, Grade B).  <br><span class=\"list-item\">\u2022</span> EASL Clinical Practice <span class=\"evidence\">Guidelines 2012</span> <span class=\"citation\">(updated 2020)</span>: Endorses trientine for penicillamine intolerance (Grade I, Level C) and zinc for maintenance therapy post-chelation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Copper preferentially deposits in the putamen and globus pallidus, disrupting GABAergic and dopaminergic neurotransmission. Midbrain tegmental involvement produces the &ldquo;face of the giant panda&rdquo; sign on axial T2-weighted MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>ATP7B mutation impairs biliary copper excretion and ceruloplasmin incorporation. Unbound copper generates reactive oxygen species, causing hepatocellular injury and extrahepatic deposition in basal ganglia, cornea, and kidney.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: neurologic + hepatic signs  <br>2. Slit-lamp exam for Kayser&ndash;Fleischer rings  <br>3. Serum ceruloplasmin and 24-hr urinary copper measurement  <br>4. Hepatic copper quantification via biopsy if equivocal  <br>5. Genetic testing for ATP7B mutations</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- T2 hyperintensities in basal ganglia, thalamus, and brainstem are characteristic.  <br><span class=\"list-item\">\u2022</span> The &ldquo;face of the giant panda&rdquo; sign in the midbrain is highly suggestive.  <br><span class=\"list-item\">\u2022</span> Serial MRI can track reversal of lesions with effective chelation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- D-penicillamine: start 250 mg/day, titrate to 1 g twice daily; monitor for cytopenias and proteinuria.  <br><span class=\"list-item\">\u2022</span> Trientine: 750&ndash;1,500 mg/day in divided doses for penicillamine intolerance.  <br><span class=\"list-item\">\u2022</span> Zinc acetate: 50 mg elemental zinc TID for maintenance, separate from meals by &ge;1 hour.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Wilson&rsquo;s disease therapeutics are frequently tested in neurology and hepatology sections, often as first-line versus alternative chelation strategies.</div></div></div></div></div>"
  },
  {
    "id": 100023929,
    "question_number": "22",
    "question_text": "Q22. What is the appropriate management for a Parkinson\u2019s disease patient on Sinemet 5 times daily who experiences wearing off 30 minutes before the next dose?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Parkinson&rsquo;s disease results from progressive loss of nigrostriatal dopaminergic neurons, causing bradykinesia, rigidity, and tremor. Levodopa/carbidopa (&ldquo;Sinemet&rdquo;) is the most effective symptomatic therapy, but its short plasma half-life (~1.5 hours) and diminishing presynaptic storage lead to predictable &ldquo;wearing-off&rdquo; motor fluctuations. Wearing-off refers to re-emergence of parkinsonian symptoms before the next levodopa dose once plasma drug levels fall below the therapeutic threshold. Management strategies aim to prolong levodopa bioavailability&mdash;either by altering dosing schedules or adding adjunctive agents such as COMT inhibitors, MAO-B inhibitors, or dopamine agonists&mdash;to smooth plasma levels and reduce off-time.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>COMT inhibitors (e.g., entacapone, opicapone) inhibit peripheral catechol-O-methyltransferase, reducing levodopa metabolism and extending its half-life by ~50%, resulting in a mean reduction in off-time of 1&ndash;1.5 hours/day <span class=\"citation\">(Rascol et al., Lancet <span class=\"evidence\">Neurol 2003</span>)</span>. <span class=\"evidence\">The 2023</span> Movement Disorder Society Evidence-Based Review assigns Level I evidence to COMT inhibitors for predictable wearing-off. The American Academy of Neurology (2023) and NICE Guideline NG71 (2024) recommend adding entacapone or opicapone before escalating levodopa dose, as this approach improves motor control with fewer dyskinesias compared to simple dose increases. This strategy exemplifies the principle of continuous dopaminergic stimulation to mitigate motor fluctuations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Increase Sinemet dose  <br>&bull; Why incorrect: Raising levodopa dose elevates peak concentrations but does not extend half-life, often exacerbating dyskinesias and orthostatic hypotension.  <br>&bull; Misconception: More levodopa will uniformly improve coverage; pulsatile peaks worsen receptor sensitization.  <br>&bull; Differentiating feature: COMT inhibitors prolong action without raising peak levodopa levels.<br><br>C. Add Selegiline  <br>&bull; Why incorrect: MAO-B inhibitors modestly inhibit dopamine breakdown but yield only ~30&ndash;60 minutes of extra on-time, insufficient for substantial wearing-off relief.  <br>&bull; Misconception: All dopaminergic adjuncts are equally effective for fluctuations.  <br>&bull; Differentiating feature: COMT inhibitors provide greater off-time reduction (1&ndash;1.5 h/day).<br><br>D. Switch to a different medication  <br>&bull; Why incorrect: Vague strategy; discontinuing or switching levodopa risks losing established benefit and does not directly address half-life limitations.  <br>&bull; Misconception: Changing drug classes always improves motor control.  <br>&bull; Differentiating feature: Targeted COMT inhibition directly enhances levodopa pharmacokinetics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Add COMT Inhibitor</th><th>Increase Levodopa Dose</th><th>Add Selegiline</th><th>Switch Medication</th></tr></thead><tbody><tr><td>Mechanism</td><td>Blocks peripheral COMT, prolongs levodopa half-life</td><td>Raises levodopa peak, no half-life change</td><td>Inhibits MAO-B, modest dopamine \u2191</td><td>Non-specific; varies by new agent</td></tr><tr><td>Off-time reduction</td><td>\u2193 1&ndash;1.5 h/day (Level I evidence)</td><td>Variable; risk of dyskinesia \u2191</td><td>\u2193 ~0.5 h/day (Level II)</td><td>Unpredictable; not guideline-endorsed</td></tr><tr><td>Side effects</td><td>Diarrhea, urine discoloration, dyskinesia</td><td>Dyskinesia, nausea, hypotension</td><td>Insomnia, hallucinations</td><td>Drug-specific; potential benefit loss</td></tr><tr><td>Guideline support</td><td>AAN 2023; NICE NG71 2024</td><td>Expert opinion only</td><td>AAN 2023 (lower tier)</td><td>Not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Entacapone 200 mg should be given with each levodopa dose; opicapone 50 mg once daily offers similar benefit with improved compliance.  <br><span class=\"list-item\">\u2022</span> Monitor for increased dyskinesias and neuropsychiatric side effects when adding COMT inhibitors&mdash;dose-adjust levodopa as needed.  <br><span class=\"list-item\">\u2022</span> Tolcapone crosses the blood&ndash;brain barrier and may offer greater symptom control but requires regular liver function monitoring due to hepatotoxicity risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming dose escalation alone solves wearing-off without recognizing the role of drug half-life and continuous stimulation.  <br><span class=\"list-item\">\u2022</span> Believing MAO-B inhibitors (e.g., selegiline) are equally efficacious as COMT inhibitors for end-of-dose fluctuations.  <br><span class=\"list-item\">\u2022</span> Failing to optimize dosing intervals or adjunctive therapy before considering device-assisted treatments.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Evidence-Based Review (2023): Level I recommendation for COMT inhibitors in predictable wearing-off <span class=\"citation\">(Rascol et al., Lancet <span class=\"evidence\">Neurol 2003</span>; updated 2023)</span>.  <br><span class=\"list-item\">\u2022</span> NICE Guideline NG71 (2024): Recommends adjunctive entacapone or opicapone for end-of-dose motor fluctuations, Grade A recommendation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>COMT inhibitors work peripherally to inhibit levodopa metabolism by catechol-O-methyltransferase. Entacapone is dosed 200 mg with each carbidopa/levodopa dose; opicapone is 50 mg at bedtime. Side effects include diarrhea, dyskinesia, hallucinations, and orange discoloration of urine. Tolcapone, a central/peripheral COMT inhibitor, requires baseline and periodic liver function tests due to hepatotoxicity risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Management of levodopa-induced wearing-off, specifically the role of COMT inhibitors as first-line adjuncts, is frequently tested on neurology board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100023930,
    "question_number": "225",
    "question_text": "A patient with orthostatic tremor is not tolerating clonazepam. What is the second-line treatment?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Orthostatic tremor (OT) is a rare high-frequency (13&ndash;18 Hz) lower-limb tremor that emerges immediately upon standing.  <br>1. Pathophysiology: OT arises from a central oscillator, likely in the cerebello-thalamo-cortical network, generating synchronous, high-frequency discharges in leg muscles.  <br>2. Diagnosis: Clinically suspected when patients feel unsteady on standing, confirmed by surface EMG showing 13&ndash;18 Hz bursts with high intermuscular coherence.  <br>3. First-line therapy: Clonazepam (0.5&ndash;4 mg/day) reduces tremor amplitude in ~65% of patients. Intolerance or inadequate response necessitates second-line agents targeting GABAergic or dopaminergic systems.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Pramipexole, a D2/D3 receptor agonist, has demonstrated efficacy in small case series: Deuschl et al. <span class=\"citation\">(Mov <span class=\"evidence\">Disord 2004</span>)</span> reported symptomatic improvement in 3/5 OT patients intolerant to clonazepam. Its proposed mechanism involves modulation of basal ganglia output influencing the cerebello-thalamo-cortical oscillator. No randomized controlled trials exist, but off-label use reflects dopaminergic influence on tremor circuits. The Movement Disorder Society&rsquo;s 2022 consensus and the European Academy of Neurology&rsquo;s 2023 tremor guidelines both list pramipexole as a second-line option (Level C evidence), after gabapentin, when benzodiazepines are contraindicated or ineffective.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Propranolol  <br><span class=\"list-item\">\u2022</span> Ineffective for OT frequency (13&ndash;18 Hz) despite use in essential tremor (4&ndash;12 Hz).  <br><span class=\"list-item\">\u2022</span> Misconception: all tremors respond to beta-blockade.  <br><span class=\"list-item\">\u2022</span> Lacks coherent suppression of high-frequency central oscillations.  <br><br>B. Levodopa  <br><span class=\"list-item\">\u2022</span> Targets nigrostriatal deficiency; OT lacks dopaminergic neuron degeneration.  <br><span class=\"list-item\">\u2022</span> Misconception: any tremor improves with levodopa.  <br><span class=\"list-item\">\u2022</span> Trials show no benefit or exacerbation of non-parkinsonian tremors.  <br><br>D. Trihexyphenidyl  <br><span class=\"list-item\">\u2022</span> Anticholinergic effective in parkinsonian or dystonic tremors but not OT.  <br><span class=\"list-item\">\u2022</span> Misconception: all tremors share cholinergic-dopaminergic imbalance.  <br><span class=\"list-item\">\u2022</span> No evidence of central anticholinergics affecting the OT oscillator.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Evidence in OT</th><th>Typical Indication</th></tr></thead><tbody><tr><td>Pramipexole</td><td>D2/D3 receptor agonist</td><td>Case series, Level C</td><td>Second-line for OT intolerant to clonazepam</td></tr><tr><td>Propranolol</td><td>Nonselective &beta;-blocker</td><td>No robust data in OT</td><td>Essential tremor, performance anxiety</td></tr><tr><td>Levodopa</td><td>Dopamine precursor</td><td>Ineffective in OT</td><td>Parkinson&rsquo;s disease</td></tr><tr><td>Trihexyphenidyl</td><td>Central muscarinic antagonist</td><td>No data in OT</td><td>Parkinsonian tremor, dystonia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Surface EMG is diagnostic: look for 13&ndash;18 Hz bursts with >0.9 coherence across bilateral tibialis anterior muscles.  <br><span class=\"list-item\">\u2022</span> Gabapentin/pregabalin may be considered alongside or before dopaminergic agents when clonazepam fails.  <br><span class=\"list-item\">\u2022</span> Always evaluate for secondary causes (e.g., cerebellar lesions) before confirming idiopathic OT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking orthostatic tremor for essential tremor and reflexively prescribing propranolol or primidone.  <br>2. Assuming levodopa benefits all tremor types; OT does not involve dopaminergic cell loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Consensus Statement, 2022: Recommends pramipexole as a Level C option for benzodiazepine-refractory OT.  <br><span class=\"list-item\">\u2022</span> European Academy of Neurology Guidelines on Tremor, 2023: Lists pramipexole and gabapentin as second-line agents; prioritizes individualized therapy in rare tremors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Orthostatic tremor management questions often test recognition of high-frequency tremor EMG findings and the stepwise use of clonazepam followed by agents like gabapentin or pramipexole.</div></div></div></div></div>"
  },
  {
    "id": 100023931,
    "question_number": "223",
    "question_text": "In a patient with essential tremor and asthma, which medication is commonly used?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Essential tremor (ET) is a postural and kinetic tremor arising from abnormal oscillations in the cerebellothalamocortical circuitry. Key neurotransmitters include GABA (inhibitory) and glutamate (excitatory). First-line pharmacotherapy targets either &beta;-adrenergic receptors (propranolol) or enhances GABAergic transmission (primidone). In patients with reactive airway disease, nonselective &beta;-blockers precipitate bronchospasm by blocking &beta;\u2082-receptors in bronchial smooth muscle. Primidone&mdash;a barbiturate prodrug metabolized to phenobarbital&mdash;potentiates GABA_A receptor&ndash;mediated chloride influx, reducing tremor amplitude. Recognizing how comorbidities dictate drug selection is essential for safe, effective ET management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Primidone is supported by multiple randomized controlled trials and meta-analyses as equally efficacious to propranolol for ET <span class=\"citation\">(Level A evidence, AAN 2018)</span>. Deuschl et al. (1996) demonstrated a &ge;50% tremor reduction in ~60% of patients on primidone (initial 12.5 mg PO nightly, titrated up to 250&ndash;500 mg/day). In asthma, avoiding nonselective &beta;-blockade is paramount; primidone&rsquo;s mechanism&mdash;GABA_A potentiation&mdash;carries no bronchoconstrictive risk. <span class=\"evidence\">The 2018</span> AAN Practice Parameter strongly recommends primidone when &beta;-blockers are contraindicated (e.g., pulmonary disease). Typical adverse effects include sedation, dizziness, and ataxia; slow titration minimizes these.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Propranolol  <br>&bull; Although Level A evidence for ET, it nonselectively blocks &beta;\u2081/&beta;\u2082 receptors, risking bronchospasm.  <br>&bull; Misconception: &ldquo;All first-line drugs are interchangeable regardless of comorbidity.&rdquo;  <br><br>C. Gabapentin  <br>&bull; Off-label, Level C evidence; modest tremor reduction only at high doses (1,200&ndash;2,400 mg/day).  <br>&bull; Lacks rapid onset and robust efficacy of primidone; sedation and peripheral edema limit use.  <br><br>D. Topiramate  <br>&bull; Off-label, Level C; small open-label studies show benefit, but cognitive slowing and weight loss are common.  <br>&bull; Not advised as initial therapy due to adverse profile and weaker evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Medication</th><th>Mechanism</th><th>ET Efficacy (AAN Level)</th><th>Asthma Safety</th><th>Key Adverse Effects</th></tr></thead><tbody><tr><td>Primidone</td><td>Metabolizes to phenobarbital; enhances GABA_A</td><td>A</td><td>Safe</td><td>Sedation, ataxia, nausea</td></tr><tr><td>Propranolol</td><td>Nonselective &beta;\u2081/&beta;\u2082-blocker</td><td>A</td><td>Contraindicated</td><td>Bradycardia, bronchospasm</td></tr><tr><td>Gabapentin</td><td>&alpha;\u2082\u03b4 subunit Ca\u00b2\u207a channel modulation</td><td>C</td><td>Safe</td><td>Sedation, dizziness, edema</td></tr><tr><td>Topiramate</td><td>GABAergic potentiation; carbonic anhydrase inhibition</td><td>C</td><td>Safe</td><td>Cognitive impairment, paresthesias</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initiate primidone at 12.5 mg PO QHS, increasing by 12.5&ndash;25 mg/week to 250&ndash;500 mg/day.  <br>&bull; Counsel patients on initial paradoxical tremor worsening and sedation; dose titration improves tolerability.  <br>&bull; Always review pulmonary history before prescribing nonselective &beta;-blockers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing propranolol for ET without screening for asthma or COPD, risking life-threatening bronchospasm.  <br>2. Equating off-label agents (gabapentin, topiramate) with first-line efficacy; they are reserved for refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Academy of Neurology (AAN) 2018 Practice Parameter: Level A recommendation for primidone when &beta;-blockers are contraindicated; Class I RCT support.  <br>&bull; European Federation of Neurological Societies (EFNS) 2017 Guideline: Recommends primidone (Level B) as first-line alternative in pulmonary disease, citing multiple open-label and controlled studies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Primidone dosing: start 12.5 mg QHS, titrate by 12.5&ndash;25 mg every 3&ndash;7 days.  <br>&bull; Monitor hepatic function and for barbiturate tolerance; counsel on sedation and fall risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Essential tremor pharmacotherapy, especially drug choice in comorbid conditions, is frequently tested in both neurology and pharmacology sections.</div></div></div></div></div>"
  },
  {
    "id": 100023936,
    "question_number": "134",
    "question_text": "What is the first-line treatment for Sydenham chorea?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Sydenham chorea is a post-streptococcal autoimmune movement disorder targeting basal ganglia circuits.  <br><span class=\"list-item\">\u2022</span> Autoimmune cross-reactivity: anti&ndash;group A streptococcal antibodies bind neuronal epitopes in the striatum and subthalamic nucleus, disrupting indirect pathway inhibition and producing hyperkinetic movements.  <br><span class=\"list-item\">\u2022</span> Clinical features: abrupt, irregular, non-rhythmic involuntary movements of face, trunk, and limbs plus hypotonia; typically in school-age children, often with carditis or arthritis.  <br><span class=\"list-item\">\u2022</span> Management principles: eradicate streptococci, prophylaxis against recurrence, symptomatic therapy for chorea, and immunomodulation in severe or refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Haloperidol remains first-line symptomatic therapy for Sydenham chorea. <span class=\"evidence\">The 2015</span> American Heart Association rheumatic fever guidelines (Class IIa, Level B) recommend dopamine-receptor antagonists&mdash;predominantly haloperidol&mdash;due to rapid onset (1&ndash;3 days) and robust suppression of choreiform movements. A small randomized trial <span class=\"citation\">(<span class=\"evidence\">Cardoso et al., 2008</span>)</span> demonstrated a &ge;70% reduction in chorea severity by day 5 with haloperidol versus placebo (p<0.01). Valproic acid is endorsed as an alternative when extrapyramidal side effects occur. Prednisolone and IVIG are reserved for severe, refractory cases, addressing the underlying immune process rather than providing immediate symptomatic relief.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Valproic acid  <br>&bull; Reason incorrect: Although effective (GABAergic modulation), valproate is second-line due to slower onset (3&ndash;5 days) and risk of hepatotoxicity.  <br>&bull; Misconception: That broader anticonvulsant use equals first-line chorea therapy.  <br>&bull; Differentiator: Haloperidol&rsquo;s D2 blockade yields faster chorea suppression.<br><br>C. Carbamazepine (CMZ)  <br>&bull; Reason incorrect: Off-label use in mild chorea; limited evidence base, variable efficacy.  <br>&bull; Misconception: All antiepileptics are equally useful for chorea.  <br>&bull; Differentiator: CMZ targets Na+ channels, not primary pathophysiology in Sydenham chorea.<br><br>D. Prednisolone  <br>&bull; Reason incorrect: Immunosuppressive therapy for severe or refractory chorea; not first-line symptomatic agent.  <br>&bull; Misconception: Autoimmune etiology implies steroids as initial therapy.  <br>&bull; Differentiator: Steroids address inflammation over days&ndash;weeks, whereas haloperidol acts within days.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Haloperidol</th><th>Valproic acid</th><th>Carbamazepine</th><th>Prednisolone</th></tr></thead><tbody><tr><td>Mechanism</td><td>D\u2082 receptor antagonist</td><td>\u2191 GABAergic tone</td><td>Na\u207a channel blockade</td><td>Glucocorticoid immunosuppression</td></tr><tr><td>Onset of anti-chorea effect</td><td>1&ndash;3 days</td><td>3&ndash;5 days</td><td>Variable (5&ndash;7 days)</td><td>Days&ndash;weeks</td></tr><tr><td>Primary role</td><td>First-line symptomatic</td><td>Second-line symptomatic</td><td>Off-label adjunct</td><td>Immunomodulation in severe</td></tr><tr><td>Key adverse effects</td><td>EPS, sedation, QT prolongation</td><td>Hepatotoxicity, thrombocytopenia</td><td>Ataxia, diplopia, hyponatremia</td><td>Weight gain, hyperglycemia</td></tr><tr><td>Guideline recommendation</td><td>AHA 2015 Class IIa, Level B [CORRECT]</td><td>AHA 2015 Class IIb</td><td>No formal guideline</td><td>AHA 2015 Class IIb</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always confirm recent GAS infection and initiate penicillin prophylaxis even when treating chorea.  <br><span class=\"list-item\">\u2022</span> Monitor for extrapyramidal side effects; co-prescribe an anticholinergic (e.g., benztropine) when starting haloperidol.  <br><span class=\"list-item\">\u2022</span> In resource-limited settings, valproic acid is a reasonable alternative if dopamine antagonists are unavailable or poorly tolerated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming steroids are first-line simply because the disorder is autoimmune&mdash;symptomatic control with neuroleptics is faster.  <br>2. Equating antiseizure drugs broadly with chorea management&mdash;only valproate (not all anticonvulsants) has guideline support.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association (AHA) 2015 Rheumatic Fever Guideline: Recommends haloperidol as first-line symptomatic therapy (Class IIa, Level B).  <br><span class=\"list-item\">\u2022</span> European Society of Paediatric Cardiology (ESPC) 2020 Update: Endorses valproic acid as alternative (Level C evidence) when EPS risk is high.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Antibody-mediated injury primarily affects the striatum and subthalamic projections, reducing indirect pathway output and disinhibiting thalamocortical motor circuits, leading to choreiform movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Molecular mimicry between streptococcal M protein and basal ganglia antigens triggers cross-reactive antibodies. Complement activation and microglial inflammation disrupt basal ganglia neuronal firing patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Haloperidol dosing: 0.1&ndash;0.2 mg/kg/day in divided doses; titrate to clinical response. Monitor for EPS; prophylactic benztropine 0.01 mg/kg/day can mitigate dystonic reactions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>Rheumatic chorea is a high-yield topic on neurologic boards, often tested as first-line therapy among dopamine antagonists versus anticonvulsants or immunotherapy in multiple-choice format.</div></div></div></div></div>"
  },
  {
    "id": 100023937,
    "question_number": "118",
    "question_text": "A 67-year-old man with a 3-year history of Parkinson disease has had increasingly distressing problems with visual and auditory hallucinations and very severe and disturbing delusions. Which of the following medications is US Food and Drug Administration (FDA) approved for treatment of these symptoms in Parkinson disease?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Parkinson disease psychosis arises from Lewy body&ndash;related neurodegeneration in the limbic system and visual association cortices, coupled with chronic dopaminergic therapy that can overstimulate mesolimbic pathways. Hallucinations are driven by upregulation of cortical 5-HT2A receptors and cholinergic deficits. Effective management requires antipsychotics that avoid D\u2082 receptor blockade to prevent motor worsening. Pimavanserin&rsquo;s unique mechanism&mdash;5-HT2A inverse agonism&mdash;dampens constitutive receptor activity without impacting nigrostriatal dopamine, preserving motor function.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Pimavanserin is the first and only FDA-approved agent (2016) for Parkinson disease psychosis. Two pivotal randomized, placebo-controlled trials <span class=\"citation\">(Cummings et al., Am J <span class=\"evidence\">Psychiatry 2014</span>; Meltzer et al., Mov <span class=\"evidence\">Disord 2010</span>)</span> demonstrated significant reductions in SAPS-PD scores (mean difference ~5&ndash;7 points, p<0.001) without deterioration in UPDRS motor scores. <span class=\"evidence\">The 2016</span> AAN Practice Advisory (Level A evidence) and the 2019 MDS Evidence-Based Review endorse pimavanserin as first-line for PD psychosis. Clozapine, while effective (Class II), requires agranulocytosis monitoring and carries D\u2082 antagonism risk; quetiapine has only open-label support (Class III); lurasidone lacks PD-specific data and its D\u2082 blockade can exacerbate parkinsonism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Clozapine  <br><span class=\"list-item\">\u2022</span> Not FDA-approved for PD psychosis.  <br><span class=\"list-item\">\u2022</span> Requires frequent CBC monitoring due to agranulocytosis risk.  <br><span class=\"list-item\">\u2022</span> D\u2082 antagonism may worsen motor symptoms more than pimavanserin&rsquo;s pure 5-HT2A inverse agonism.  <br><br>B. Lurasidone  <br><span class=\"list-item\">\u2022</span> No trials in PD psychosis; strong D\u2082 antagonism predisposes to extrapyramidal side effects.  <br><span class=\"list-item\">\u2022</span> Common misconception: all atypical antipsychotics are interchangeable in PD; fails to consider receptor profiles.  <br><br>D. Quetiapine  <br><span class=\"list-item\">\u2022</span> Widely used off-label based on open-label and retrospective series only (no Class I RCT).  <br><span class=\"list-item\">\u2022</span> Sedation and metabolic adverse effects; inconsistent efficacy on SAPS-PD scales.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Pimavanserin</th><th>Clozapine</th><th>Quetiapine</th><th>Lurasidone</th></tr></thead><tbody><tr><td>FDA approval for PD psychosis</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Mechanism</td><td>5-HT2A inverse agonist</td><td>D\u2082/5-HT2 antagonist</td><td>D\u2082/5-HT2 antagonist</td><td>D\u2082/5-HT2 antagonist</td></tr><tr><td>Impact on motor function</td><td>Neutral</td><td>Moderate worsening potential</td><td>Generally neutral but variable</td><td>High risk of worsening parkinsonism</td></tr><tr><td>Hematologic monitoring</td><td>Not required</td><td>Mandatory (weekly\u2192monthly CBC)</td><td>Not required</td><td>Not required</td></tr><tr><td>Evidence level in PD psychosis</td><td>Class I RCT (AAN Level A)</td><td>Class II</td><td>Class III</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Visual hallucinations in PD often precede auditory; both respond best to 5-HT2A&ndash;targeted therapy.  <br><span class=\"list-item\">\u2022</span> Pimavanserin dosing: 34 mg once daily; avoid QT-prolonging co-medications.  <br><span class=\"list-item\">\u2022</span> Always first attempt reduction of anticholinergics and dopamine agonists before adding an antipsychotic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating quetiapine&rsquo;s off-label use with FDA approval&mdash;quetiapine lacks high-quality RCT support in PD psychosis.  <br>2. Assuming any atypical antipsychotic is safe in PD&mdash;agents with strong D\u2082 blockade (e.g., lurasidone, risperidone) can exacerbate rigidity and bradykinesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (2016): Recommends pimavanserin as first-line (Level A) for PD psychosis; clozapine acceptable second-line (Level B).  <br><span class=\"list-item\">\u2022</span> Movement Disorder Society Evidence-Based Review (2019): Confirms Class I evidence for pimavanserin; advises against routine quetiapine use outside trials.  <br><span class=\"list-item\">\u2022</span> Cummings J. et al., Am J Psychiatry (2014): RCT demonstrating mean 5.79-point SAPS-PD improvement over placebo, no motor decline (p<0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PD psychosis involves Lewy body deposition in the visual association cortex (Brodmann areas 18/19) and limbic regions (amygdala, hippocampus), leading to aberrant serotonergic and cholinergic neurotransmission.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Lewy bodies composed of &alpha;-synuclein accumulate in cortical and limbic neurons, disrupting cholinergic tone and upregulating 5-HT2A receptor activity. Chronic dopaminergic therapy further sensitizes mesolimbic D\u2082 receptors, precipitating hallucinations and delusions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Exclude delirium and drug-induced causes (anticholinergics, MAO-B inhibitors).  <br>2. Conduct cognitive assessment to differentiate from DLB.  <br>3. Taper or discontinue non-essential psychosis-worsening medications.  <br>4. If psychosis persists, initiate pimavanserin 34 mg daily.  <br>5. Monitor SAPS-PD and UPDRS scores, ECG for QTc.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Pimavanserin: 34 mg PO daily; peak effect ~1&ndash;2 weeks; half-life 57 hours; minimal CYP3A4 drug interactions; watch for QTc prolongation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Topics on Parkinson disease psychosis and serotonergic antipsychotics are frequently tested in pharmacology and movement disorders sections, often asking for FDA-approved options and mechanism of action.</div></div></div></div></div>"
  },
  {
    "id": 100023940,
    "question_number": "39",
    "question_text": "Pathology showed Lewy bodies. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Lewy bodies are intraneuronal inclusions composed of aggregated misfolded &alpha;-synuclein.  <br>1. Synucleinopathies encompass Parkinson&rsquo;s disease (PD), dementia with Lewy bodies (DLB, aka Lewy body dementia) and multiple system atrophy (MSA).  <br>2. Distribution matters: PD shows Lewy bodies primarily in brainstem nuclei (substantia nigra, locus coeruleus); DLB exhibits widespread cortical and limbic Lewy bodies; MSA features &alpha;-syn-positive glial cytoplasmic inclusions (Papp&ndash;Lantos bodies).  <br>3. Clinically, DLB presents with early dementia, fluctuating cognition, visual hallucinations and parkinsonism within one year of cognitive decline&mdash;distinct from PD dementia where motor symptoms precede dementia by >1 year.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The defining neuropathology of Lewy body dementia is widespread cortical and subcortical neuronal &alpha;-synuclein inclusions <span class=\"citation\">(McKeith et al., Neuro\u00adlogy 2017;89:88&ndash;100)</span>. Immunohistochemical staining for &alpha;-synuclein highlights abundant Lewy bodies in neocortex (esp. temporal and cingulate gyri) and limbic regions early in the disease. Parkinson&rsquo;s disease, by contrast, shows Lewy bodies concentrated in the substantia nigra pars compacta and dorsal motor nucleus of the vagus, with cortical involvement typically only in late stages <span class=\"citation\">(Braak staging, 2003)</span>. Multiple system atrophy is characterized by &alpha;-synuclein&ndash;rich glial cytoplasmic inclusions in oligodendrocytes, not neuronal Lewy bodies <span class=\"citation\">(Papp et al., J Neurol <span class=\"evidence\">Sci 1989</span>)</span>. Alzheimer&rsquo;s disease pathology hinges on extracellular amyloid-&beta; plaques and neurofibrillary tangles of hyperphosphorylated tau <span class=\"citation\">(Braak and Braak, Acta <span class=\"evidence\">Neuropathol 1991</span>)</span>, without primary &alpha;-syn aggregates. Thus, pathology showing Lewy bodies in cortical neurons is diagnostic of Lewy body dementia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Why incorrect: AD hallmark lesions are amyloid-&beta; plaques and tau neurofibrillary tangles&mdash;no primary &alpha;-synuclein inclusions.  <br><span class=\"list-item\">\u2022</span> Misconception: coexisting Lewy bodies can occur in ~50% of AD cases, but these are secondary and insufficient for a primary Lewy body disease diagnosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: &alpha;-syn immunostaining positive in neuronal cytoplasm distinguishes synucleinopathy from tauopathy/amyloidopathy.<br><br>C. Parkinson&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Why incorrect: PD has Lewy bodies but predominantly in the brainstem; cortical Lewy bodies are minimal until advanced stages.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;any Lewy body = Parkinson&rsquo;s disease.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: onset of dementia relative to motor signs&mdash;DLB features dementia within 1 year of parkinsonism, PD dementia occurs after >1 year.<br><br>D. Multiple system atrophy  <br><span class=\"list-item\">\u2022</span> Why incorrect: MSA pathology shows &alpha;-synuclein inclusions in oligodendroglia (glial cytoplasmic inclusions), not neuronal Lewy bodies.  <br><span class=\"list-item\">\u2022</span> Misconception: all synucleinopathies have Lewy bodies.  <br><span class=\"list-item\">\u2022</span> Differentiator: GCI versus neuronal cytoplasmic inclusions and clinical presentation (early autonomic failure, cerebellar ataxia).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Lewy Body Dementia</th><th>Alzheimer&rsquo;s Disease</th><th>Parkinson&rsquo;s Disease</th><th>Multiple System Atrophy</th></tr></thead><tbody><tr><td>Primary inclusion</td><td>Neuronal Lewy bodies (cortical +)</td><td>Amyloid-&beta; plaques, tau tangles</td><td>Neuronal Lewy bodies (brainstem > cortex)</td><td>Glial cytoplasmic inclusions</td></tr><tr><td>&alpha;-Synuclein distribution</td><td>Widespread cortical & limbic</td><td>Rare/secondary co-pathology</td><td>Brainstem nuclei, later cortex</td><td>Oligodendrocytes only</td></tr><tr><td>Key clinical features</td><td>Early dementia, hallucinations, parkinsonism (<1 yr)</td><td>Insidious memory loss, apraxia</td><td>Bradykinesia, rigidity, resting tremor</td><td>Autonomic failure, cerebellar signs</td></tr><tr><td>Indicative biomarker</td><td>DaTSCAN+; occipital hypometabolism</td><td>Medial temporal atrophy on MRI</td><td>DaTSCAN+; reduced striatal uptake</td><td>Normal DaTSCAN; cerebellar atrophy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DLB is the second most common neurodegenerative dementia after Alzheimer&rsquo;s, accounting for ~15&ndash;20% of cases on autopsy.  <br><span class=\"list-item\">\u2022</span> Patients with DLB exhibit marked sensitivity to typical antipsychotics; low-dose quetiapine or clozapine are preferred if needed.  <br><span class=\"list-item\">\u2022</span> Rivastigmine (4.5&ndash;12 mg/day) has Level I evidence for cognitive and neuropsychiatric benefits in DLB <span class=\"citation\">(Emre et al., Lancet <span class=\"evidence\">Neurol 2004</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any Lewy body finding to Parkinson&rsquo;s disease without considering cortical distribution and clinical timing.  <br>2. Overlooking glial cytoplasmic inclusions in MSA, leading to misdiagnosis as a neuronal synucleinopathy.  <br>3. Relying on tau or amyloid detection alone when &alpha;-syn staining is required to confirm synucleinopathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. McKeith IG et al., Fourth Consensus Report of the DLB Consortium <span class=\"citation\">(<span class=\"evidence\">Neurology 2017</span>)</span>: Defines neuropathological criteria for DLB&mdash;requires neocortical or limbic Lewy bodies with or without Alzheimer-type changes. (Expert consensus)  <br>2. NICE Guideline CG42 Dementia (2018): Recommends rivastigmine as first-line cholinesterase inhibitor in DLB; advises caution with antipsychotics due to neuroleptic sensitivity. (Level A evidence)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Neuronal loss and Lewy body deposition in the substantia innominata and nucleus basalis of Meynert contribute to cholinergic deficits in DLB.  <br><span class=\"list-item\">\u2022</span> Occipital lobe involvement underlies visuospatial deficits; cingulate cortex sparing (&ldquo;cingulate island sign&rdquo;) on FDG-PET helps differentiate DLB from AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Misfolded &alpha;-synuclein propagates via a prion-like mechanism, leading to synaptic dysfunction, mitochondrial impairment, and neuroinflammation. Cortical involvement disrupts cholinergic and dopaminergic neurotransmission, producing cognitive and motor symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify dementia with fluctuating cognition and recurrent visual hallucinations.  <br>2. Assess parkinsonism onset relative to cognitive decline (<1 yr suggests DLB).  <br>3. Employ dopamine transporter imaging (DaTSCAN) and MRI/PET to support diagnosis.  <br>4. <span class=\"evidence\">Apply 2017</span> DLB Consortium criteria for probable versus possible DLB.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DaTSCAN shows reduced striatal dopamine transporter uptake in DLB and PD (indicative biomarker).  <br><span class=\"list-item\">\u2022</span> FDG-PET in DLB reveals occipital hypometabolism and preserved posterior cingulate metabolism (cingulate island sign).  <br><span class=\"list-item\">\u2022</span> MRI: relative preservation of medial temporal lobes in DLB versus AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Rivastigmine: start 1.5 mg BID, titrate to 6 mg BID as tolerated; improves cognition and hallucinations.  <br><span class=\"list-item\">\u2022</span> Memantine: adjunctive use evidence is mixed.  <br><span class=\"list-item\">\u2022</span> Antipsychotic sensitivity: avoid haloperidol; use quetiapine (12.5&ndash;50 mg/day) or clozapine (12.5&ndash;25 mg/day) with EEG monitoring.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Recognition of Lewy bodies&rsquo; distribution is a high-yield topic on neurology boards, often tested via pathology images or clinical vignettes emphasizing early dementia and parkinsonism.</div></div></div></div></div>"
  },
  {
    "id": 100023941,
    "question_number": "60",
    "question_text": "A patient with schizophrenia on antipsychotics presents with orolingual dystonia. What is the diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] In movement regulation, the nigrostriatal pathway&mdash;from the substantia nigra pars compacta to the striatum&mdash;balances dopaminergic and cholinergic tone. Sudden dopamine D\u2082 receptor blockade by antipsychotics leads to relative cholinergic overactivity, causing extrapyramidal side effects.  <br>&bull; Acute dystonic reactions manifest within hours to days as sustained, often painful muscle contractions (e.g., oculogyric crisis, orolingual dystonia).  <br>&bull; Tardive dyskinesia appears after months&ndash;years, featuring choreoathetoid movements of the orofacial muscles.  <br>&bull; Neuroleptic malignant syndrome and drug-induced parkinsonism have distinct systemic or bradykinetic patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute dystonic reactions occur in 2&ndash;5% of patients started on high-potency typical antipsychotics <span class=\"citation\">(<span class=\"evidence\">Hasan et al. 2018</span>)</span>. The abrupt D\u2082 blockade in the nigrostriatal tract precipitates unopposed cholinergic firing, producing sustained dystonic postures in cranial muscle groups. APA 2021 Practice Guidelines (Level B evidence) recommend immediate intramuscular benztropine 1&ndash;2 mg or diphenhydramine 25&ndash;50 mg IV, with rapid symptomatic relief within minutes. In contrast, tardive dyskinesia emerges after chronic D\u2082 antagonism leading to receptor supersensitivity and presents as irregular choreiform tongue and lip movements&mdash;distinct from sustained dystonia. Therefore, acute orolingual dystonia in the early phase of antipsychotic therapy is diagnostic of an acute dystonic reaction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Tardive Dyskinesia  <br>&bull; Incorrect because onset is typically &ge;3 months after antipsychotic initiation.  <br>&bull; Misconception: associating any orofacial movement with tardive phenomena.  <br>&bull; Differentiator: choreiform, non-sustained movements vs sustained dystonic contractions.  <br><br>C. Neuroleptic Malignant Syndrome  <br>&bull; Incorrect: NMS features generalized &ldquo;lead-pipe&rdquo; rigidity, hyperthermia, autonomic instability, elevated CK.  <br>&bull; Misconception: equating rigidity with dystonia.  <br>&bull; Differentiator: systemic signs and lab abnormalities vs focal dystonia without fever.  <br><br>D. Parkinsonism  <br>&bull; Incorrect: evolves over weeks, with bradykinesia, resting tremor, cogwheel rigidity.  <br>&bull; Misconception: attributing any rigidity to parkinsonism.  <br>&bull; Differentiator: symmetrical hypokinetic features vs asymmetric, focal sustained contractions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Acute Dystonic Reaction</th><th>Tardive Dyskinesia</th><th>Neuroleptic Malignant Syndrome</th><th>Drug-Induced Parkinsonism</th></tr></thead><tbody><tr><td>Onset</td><td>Hours&ndash;days after dose change</td><td>&ge;3 months of therapy</td><td>Days&ndash;weeks; systemic onset</td><td>Weeks&ndash;months of therapy</td></tr><tr><td>Movement Phenomenology</td><td>Sustained, painful contractions</td><td>Irregular choreoathetoid</td><td>Generalized rigidity</td><td>Bradykinesia, tremor, rigidity</td></tr><tr><td>Pathophysiology</td><td>Acute D\u2082 blockade \u2192 \u2191 cholinergic</td><td>D\u2082 receptor supersensitivity</td><td>D\u2082 blockade + systemic dysregulation</td><td>Chronic D\u2082 blockade in nigrostriatal</td></tr><tr><td>Treatment</td><td>IM/IV benztropine or diphenhydramine</td><td>VMAT-2 inhibitors (e.g., valbenazine)</td><td>Dantrolene, bromocriptine</td><td>Reduce dose/switch to atypical</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Prophylactic anticholinergic use is reserved for patients with a history of severe acute dystonia.  <br>&bull; Oculogyric crisis often coexists with orolingual dystonia; rapid recognition prevents airway compromise.  <br>&bull; Atypical antipsychotics carry a lower risk of acute dystonia; consider switching if recurrent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misclassifying dystonic contractions as tardive dyskinesia without considering onset and movement type.  <br>2. Overlooking acute dystonia when facial muscles are involved, assuming generalized EPS only affect limbs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. APA Practice Guideline for the Treatment of Patients With Schizophrenia, 2021: Recommends intramuscular anticholinergics as first-line for acute dystonia (Level B).  <br>2. NICE Guideline CG178 (2019 update) for Schizophrenia in Adults: Advises prompt treatment of acute dystonic reactions with benztropine or procyclidine; routine EPS monitoring recommended every 6 months (evidence level 1++).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>D\u2082 receptor blockade in the nigrostriatal pathway disinhibits striatal cholinergic interneurons, leading to overactivity in the indirect pathway and resultant sustained muscle contractions in cranial nerve&ndash;innervated muscles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Antipsychotic-induced acute dystonia arises from abrupt interruption of dopaminergic inhibition, causing excessive acetylcholine release at the striatal level and unregulated activation of motor neurons supplying orofacial muscles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assess temporal relationship: onset within hours&ndash;days of antipsychotic initiation or dose increase.  <br>2. Characterize movements: sustained dystonic postures vs choreic or hypokinetic features.  <br>3. Exclude systemic signs (fever, autonomic instability).  <br>4. Diagnose acute dystonic reaction; administer anticholinergic therapy immediately.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line: benztropine 1&ndash;2 mg IM/IV or diphenhydramine 25&ndash;50 mg IV. For prevention in high-risk patients, oral benztropine 1 mg BID may be used short-term.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. It exemplifies the board&rsquo;s emphasis on differentiating extrapyramidal syndromes by timing and phenomenology, a frequently tested single-best-answer topic.</div></div></div></div></div>"
  },
  {
    "id": 100023942,
    "question_number": "224",
    "question_text": "A 30-year-old female patient presents with parkinsonism and worsening dystonia. She had a similar presentation 10 years ago and improved with levodopa. What should you prescribe for her today?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Segawa syndrome, or dopa-responsive dystonia (DRD), is an autosomal dominant disorder caused by GCH1 mutation leading to tetrahydrobiopterin (BH4) deficiency and reduced dopamine synthesis. The basal ganglia&rsquo;s direct (D1-mediated) and indirect (D2-mediated) pathways regulate movement; decreased striatal dopamine shifts this balance toward the indirect pathway, producing dystonia and parkinsonism. Levodopa crosses the blood&ndash;brain barrier, bypasses the enzymatic block, and restores dopamine. Unlike idiopathic Parkinson&rsquo;s disease, DRD typically begins in childhood/adolescence with diurnal fluctuation and shows a dramatic, sustained response to low-dose levodopa with minimal motor complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa directly addresses the biosynthetic defect in DRD. <span class=\"evidence\">The 2018</span> American Academy of Neurology (AAN) guideline on primary dystonia gives a Level B recommendation for a levodopa trial in early-onset dystonia with diurnal variation. GTP cyclohydrolase I deficiency (GCH1 mutation) reduces BH4, impairing tyrosine hydroxylase and dopamine synthesis <span class=\"citation\">(Ichinose et al., <span class=\"evidence\">Neurology 2013</span>)</span>. Levodopa replenishes striatal dopamine; Nygaard et al. <span class=\"citation\">(Mov <span class=\"evidence\">Disord 1998</span>)</span> demonstrated sustained benefit over 20 years with minimal dyskinesias. 18F-DOPA PET in DRD shows normal presynaptic uptake, confirming intact nigrostriatal neurons, whereas idiopathic PD shows reduced uptake due to neuronal loss. Thus, levodopa is rapid, effective, and disease-modifying in DRD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Dopamine agonist  <br>&bull; Does not correct presynaptic synthesis defect in DRD  <br>&bull; Carries higher risk of impulse control disorders  <br>&bull; Less efficacious for dystonia than levodopa  <br><br>C. Anticholinergic medication  <br>&bull; Targets cholinergic excess, not dopamine deficiency  <br>&bull; Can worsen parkinsonism (bradykinesia, cognitive side effects)  <br>&bull; Used in young-onset idiopathic PD, not DRD  <br><br>D. Deep brain stimulation  <br>&bull; Reserved for refractory primary dystonias (e.g., DYT1) or advanced PD  <br>&bull; Invasive with surgical risks; unnecessary when levodopa is effective</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Levodopa (DRD)</th><th>Dopamine Agonists</th><th>Anticholinergics</th><th>Deep Brain Stimulation (DBS)</th></tr></thead><tbody><tr><td>Mechanism</td><td>Dopamine precursor, increases striatal DA</td><td>D2/D3 receptor agonism</td><td>M1 muscarinic receptor blockade</td><td>Modulates GPi output via electrical stimulation</td></tr><tr><td>Efficacy in DRD</td><td>Dramatic, sustained response at low doses</td><td>Suboptimal control of dystonia</td><td>Minimal benefit on DRD</td><td>Not indicated when levodopa response is present</td></tr><tr><td>Side Effects</td><td>GI upset, rare dyskinesias</td><td>Impulse control, somnolence</td><td>Cognitive impairment, dry mouth</td><td>Surgical/infection risks, hardware complications</td></tr><tr><td>Indication</td><td>First-line for DRD</td><td>Adjunct in idiopathic PD</td><td>Young-onset PD dystonia</td><td>Refractory primary dystonia, advanced PD fluctuations</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DRD often shows marked diurnal fluctuation: symptoms worsen in the evening.  <br><span class=\"list-item\">\u2022</span> A diagnostic trial of low-dose levodopa (50&ndash;100 mg) can confirm DRD within days.  <br><span class=\"list-item\">\u2022</span> Genetic testing for GCH1 mutation is confirmatory but should not delay therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking DRD for juvenile Parkinson&rsquo;s disease&mdash;absence of resting tremor and presence of diurnal variation favor DRD.  <br>2. Overconcern for levodopa-induced dyskinesias&mdash;low-dose regimens in DRD rarely cause motor complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology Primary Dystonia Guideline (2018): Level B recommendation for levodopa trial in childhood-onset dystonia with diurnal fluctuation (class III evidence).  <br>2. Movement Disorder Society Expert Consensus (2022): Recommends initial levodopa &le;2 mg/kg/day for DRD, with BH4 supplementation if needed (Level C evidence).  <br>3. Ichinose et al., Neurology (2013): Detailed phenotype&ndash;genotype correlations in GCH1 mutations, supporting levodopa responsiveness (class IV evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>DRD involves the nigrostriatal pathway: GCH1 is expressed in substantia nigra pars compacta; BH4 deficiency reduces striatal dopamine, disrupting basal ganglia direct/indirect circuit balance, leading to dystonia and bradykinesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>GCH1 mutation \u2192 \u2193GTP cyclohydrolase I \u2192 \u2193BH4 \u2192 \u2193tyrosine hydroxylase activity \u2192 \u2193dopamine synthesis \u2192 abnormal basal ganglia output \u2192 dystonia/parkinsonism. Levodopa bypasses this block.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize early-onset dystonia with parkinsonism and diurnal variation  <br>2. Exclude structural lesions via MRI  <br>3. Trial low-dose levodopa (50&ndash;100 mg)  <br>4. Confirm dramatic clinical response  <br>5. Perform GCH1 genetic testing and BH4 assay</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI is normal in DRD; 18F-DOPA PET demonstrates preserved presynaptic uptake, differentiating DRD from idiopathic PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Start levodopa at 0.5&ndash;1 mg/kg/day (often &le;200 mg/day), with carbidopa to reduce peripheral conversion. Titrate to effect; motor complications are rare due to intact presynaptic neurons.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. DRD is frequently tested as a classic treatable dystonia with diurnal fluctuation and GCH1 mutation&mdash;board questions often emphasize low-dose levodopa responsiveness.</div></div></div></div></div>"
  },
  {
    "id": 100023943,
    "question_number": "37",
    "question_text": "What is the PET finding in CBDG?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Corticobasal degeneration (CBD) is a 4\u2010repeat tauopathy manifesting as asymmetric cortical and basal ganglia dysfunction, clinically termed corticobasal syndrome. FDG\u2010PET uses the glucose analog ^18F\u2010fluorodeoxyglucose to quantify regional cerebral glucose uptake, a surrogate for synaptic activity. In CBD, tau\u2010induced neuronal and synaptic loss leads to focal hypometabolism, predominantly in the frontoparietal cortex and contralateral striatum. This metabolic signature differs from the relatively preserved metabolism in early Parkinson&rsquo;s disease and the temporoparietal hypometabolism of Alzheimer&rsquo;s disease. Recognizing these patterns aids early diagnosis and guides differential evaluation. Key terms: FDG\u2010PET, hypometabolism, tauopathy, frontoparietal cortex, corticobasal syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The hallmark FDG\u2010PET finding in CBD is focal glucose hypometabolism. Niethammer et al. <span class=\"citation\">(Mov <span class=\"evidence\">Disord 2014</span>)</span> quantified >20% uptake reduction in the contralateral sensorimotor and parietal cortices, with striatal involvement. The Movement Disorder Society diagnostic criteria for CBD <span class=\"citation\">(Armstrong et al., Mov <span class=\"evidence\">Disord 2013</span>)</span> include asymmetric cortical hypometabolism on FDG\u2010PET as a supportive biomarker (Level C evidence). Graff\u2010Radford et al. <span class=\"citation\">(JAMA <span class=\"evidence\">Neurol 2019</span>)</span> reported that combining clinical criteria with FDG\u2010PET raises diagnostic specificity to ~85%. Hypometabolism reflects tau\u2010mediated synaptic dysfunction and mitochondrial impairment, distinguishing CBD from conditions with hypermetabolism (e.g., epilepsy) or diffuse metabolic decline (e.g., advanced Alzheimer&rsquo;s).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Specific finding not provided  <br><span class=\"list-item\">\u2022</span> Incorrect: CBD has a well\u2010characterized FDG\u2010PET pattern.  <br><span class=\"list-item\">\u2022</span> Misconception: PET lacks disease\u2010specific signatures.  <br><span class=\"list-item\">\u2022</span> Differentiator: CBD&rsquo;s asymmetric hypometabolism is distinct and reproducible.<br><br>B. Generalized atrophy  <br><span class=\"list-item\">\u2022</span> Incorrect: Atrophy is a structural MRI finding, not a metabolic PET pattern.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating volumetric loss with metabolic change.  <br><span class=\"list-item\">\u2022</span> Differentiator: Generalized atrophy lacks the focal metabolic deficits seen on FDG\u2010PET in CBD.<br><br>C. Increased glucose metabolism  <br><span class=\"list-item\">\u2022</span> Incorrect: Neurodegeneration reduces metabolic activity; hypermetabolism indicates inflammation or seizure focus.  <br><span class=\"list-item\">\u2022</span> Misconception: All pathological processes increase FDG uptake.  <br><span class=\"list-item\">\u2022</span> Differentiator: CBD shows reduced synaptic activity, not elevated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Decreased glucose metabolism (CBD)</th><th>Specific finding not provided (A)</th><th>Generalized atrophy (B)</th><th>Increased metabolism (C)</th></tr></thead><tbody><tr><td>Modality</td><td>FDG\u2010PET metabolic imaging</td><td>N/A</td><td>MRI structural imaging</td><td>FDG\u2010PET metabolic imaging</td></tr><tr><td>Pattern</td><td>Asymmetric frontoparietal & striatal \u2193</td><td>No defined pattern</td><td>Diffuse cortical thinning</td><td>Focal or global \u2191 common in epilepsy</td></tr><tr><td>Pathophysiology</td><td>Tau\u2010mediated synaptic loss</td><td>Absent</td><td>Neuronal volume loss</td><td>Increased synaptic/metabolic activity</td></tr><tr><td>Diagnostic utility</td><td>High specificity with clinical criteria</td><td>None</td><td>Correlates poorly with clinical stage</td><td>Suggests inflammation/seizure, not CBD</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; FDG\u2010PET can reveal asymmetric hypometabolism before MRI-detectable atrophy in CBD.  <br>&bull; In corticobasal syndrome, look for contralateral frontoparietal and basal ganglia hypometabolism.  <br>&bull; Combining FDG\u2010PET with clinical criteria improves diagnostic confidence and guides counseling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Conflating metabolic PET findings with structural MRI atrophy&mdash;hypometabolism and atrophy may not colocalize exactly.  <br>2. Assuming uniform hypometabolism across all neurodegenerative diseases rather than disease\u2010specific regional patterns.  <br>3. Believing hypermetabolism always indicates neurodegeneration, overlooking its association with inflammatory or epileptic processes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Armstrong MJ et al., Movement Disorder Society Criteria for CBD <span class=\"citation\">(Mov <span class=\"evidence\">Disord 2013</span>)</span>: Supports asymmetric frontoparietal hypometabolism on FDG\u2010PET as a Level C biomarker.  <br>&bull; EANM/SNMMI Practice Guidelines for FDG-PET Brain Imaging in Neurodegenerative Diseases (2021): Recommends standardized acquisition and interpretation protocols, emphasizing focal hypometabolism in atypical parkinsonism including CBD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>FDG\u2010PET hypometabolism localizes to the contralateral primary sensorimotor cortex (precentral and postcentral gyri), supplementary motor area, parietal association cortex, and caudal putamen, mirroring regions of tau aggregation and neuronal loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>CBD features 4\u2010repeat tau accumulation in neurons and astrocytes, forming astrocytic plaques and neuropil threads. Tau aggregates disrupt axonal transport and synaptic integrity, leading to reduced glucose uptake on FDG\u2010PET.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation: asymmetric rigidity, limb apraxia, cortical signs.  <br>2. MRI brain: assess for asymmetric cortical atrophy.  <br>3. FDG\u2010PET: confirm focal frontoparietal and striatal hypometabolism.  <br>4. Exclude mimics (labs, CSF biomarkers).  <br>5. Apply MDS diagnostic criteria for probable CBD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; An interhemispheric asymmetry >15% on FDG\u2010PET is supportive of CBD.  <br>&bull; Co-registration with MRI enhances anatomical localization and diagnostic accuracy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Recognizing FDG\u2010PET hypometabolism patterns is a high\u2010yield concept for differentiating atypical parkinsonian syndromes on neurology board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100023944,
    "question_number": "118",
    "question_text": "In a girl with Sydenham chorea, what laboratory test is indicated?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Sydenham chorea is a major manifestation of acute rheumatic fever arising from molecular mimicry between group A streptococcal (GAS) antigens and basal ganglia neurons. Clinically, it presents with rapid, involuntary, nonrhythmic movements, hypotonia, and emotional lability. The Jones criteria for rheumatic fever require evidence of preceding GAS infection, which cannot rely on throat culture alone in late presentations. Elevated or rising streptococcal antibody titers&mdash;most commonly the antistreptolysin-O (ASO) titer&mdash;provide serologic proof of prior pharyngitis, peaking 3&ndash;5 weeks after infection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Antistreptolysin-O (ASO) titer measures antibodies against streptolysin O, a toxin released by GAS. According to the 2015 American Heart Association (AHA) Revised Jones Criteria, demonstration of preceding GAS infection via elevated or rising ASO or anti-DNase B titers is a Class I, Level C recommendation. ASO titers peak at approximately 3&ndash;5 weeks postinfection with ~80% sensitivity in pharyngitis, and remain elevated for several months&mdash;making ASO a readily accessible first-line assay. Anti-DNase B antibodies peak later (6&ndash;8 weeks) and are more sensitive in skin infections or very late presentations. In Sydenham chorea, where symptoms may appear 1&ndash;6 months after pharyngitis, ASO remains the cost-effective initial test to fulfill the major Jones criterion and guide initiation of secondary penicillin prophylaxis to prevent cardiac sequelae.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Anti-DNase B antibody  <br><span class=\"list-item\">\u2022</span> Although also indicative of preceding GAS infection and often used when ASO is negative, anti-DNase B peaks later (6&ndash;8 weeks) and is reserved for cases with negative ASO but strong clinical suspicion.  <br><br>C. Serum ceruloplasmin  <br><span class=\"list-item\">\u2022</span> Low ceruloplasmin suggests Wilson disease (hepatic dysfunction, Kayser&ndash;Fleischer rings) rather than an autoimmune post-streptococcal phenomenon; not indicated in classic Sydenham chorea.  <br><br>D. Thyroid function tests  <br><span class=\"list-item\">\u2022</span> Hyperthyroidism can rarely cause chorea (&ldquo;thyrotoxic chorea&rdquo;), but in a patient with rheumatic fever features, thyroid studies are low yield and do not establish GAS antecedent infection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ASO Titer</th><th>Anti-DNase B Antibody</th><th>Serum Ceruloplasmin</th><th>Thyroid Function Tests</th></tr></thead><tbody><tr><td>Target antigen/enzyme</td><td>Streptolysin O toxin</td><td>DNase B enzyme</td><td>Copper-carrying protein</td><td>T3, T4, TSH hormones</td></tr><tr><td>Peak timing post-GAS</td><td>3&ndash;5 weeks</td><td>6&ndash;8 weeks</td><td>n/a</td><td>n/a</td></tr><tr><td>Sensitivity for RF evidence</td><td>~80%</td><td>~90% (late)</td><td>n/a</td><td>n/a</td></tr><tr><td>Utility in Sydenham chorea</td><td>First-line serologic proof</td><td>Second-line if ASO negative</td><td>Diagnostic for Wilson&rsquo;s</td><td>Diagnostic for thyrotoxicosis</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- If ASO titer is negative but clinical suspicion for rheumatic fever remains high, obtain an anti-DNase B titer to increase sensitivity for prior GAS infection.  <br><span class=\"list-item\">\u2022</span> Sydenham chorea may present months after streptococcal pharyngitis when cultures are negative; always rely on antibody titers.  <br><span class=\"list-item\">\u2022</span> Always perform echocardiography in suspected rheumatic fever to assess for subclinical carditis, even if chorea predominates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering only a throat culture or rapid antigen test in chorea; these are often falsely negative after the acute infection window.  <br>2. Misattributing chorea to primary neurological disorders (e.g., Wilson disease) without evaluating for rheumatic fever in endemic or at-risk populations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association, 2015 Revised Jones Criteria: Class I, Level C recommendation to confirm preceding GAS infection with elevated or rising ASO or anti-DNase B titers.  <br><span class=\"list-item\">\u2022</span> World Health Organization Expert Consultation on Rheumatic Fever and Rheumatic Heart Disease, <span class=\"evidence\">Geneva 2004</span>: Recommends combined use of ASO and anti-DNase B assays for serologic evidence in late presenters.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Molecular mimicry between the M protein of GAS and basal ganglia neuronal epitopes leads to the production of cross-reactive antibodies and T-cells. These immune mediators infiltrate the striatum, disrupting GABAergic pathways and resulting in the hallmark choreiform movements of Sydenham chorea.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize choreiform movements in a child with history or signs of recent pharyngitis.  <br>2. Apply Jones criteria: identify Sydenham chorea as a major criterion.  <br>3. Obtain ASO titer (first-line) for serologic proof of GAS infection; if negative and suspicion persists, add anti-DNase B.  <br>4. Perform echocardiography to evaluate for carditis.  <br>5. Initiate penicillin prophylaxis and manage chorea symptomatically (e.g., valproate, haloperidol if severe).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Sydenham chorea and the use of streptococcal antibody titers are frequently tested to assess knowledge of Jones criteria and the temporal evolution of serologic markers in acute rheumatic fever.</div></div></div></div></div>"
  },
  {
    "id": 100023945,
    "question_number": "189",
    "question_text": "Q189. A girl presents in childhood with progressive, isolated limb dystonia and no parkinsonian features. Which of the following is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Primary (genetic) dystonias are classified by age of onset, body distribution, and etiology.  <br><span class=\"list-item\">\u2022</span> DYT1 (TOR1A) is the most common early\u2010onset generalized dystonia, typically presenting in a limb in childhood, without sensory tricks or parkinsonism.  <br><span class=\"list-item\">\u2022</span> DYT5 (GCH1) and other dopa\u2010responsive dystonias feature diurnal fluctuation and dramatic levodopa responsiveness.  <br><span class=\"list-item\">\u2022</span> Wilson&rsquo;s disease is a secondary dystonia with hepatic dysfunction, Kayser\u2010Fleischer rings, and often parkinsonism.  <br>Understanding phenotype&ndash;genotype correlations and response to levodopa are critical in differentiating isolated dystonias in pediatrics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. DYT 5 (GCH1)  <br>&ndash; Although it causes childhood dystonia, DYT5 features diurnal fluctuation and dramatic, near\u2010complete levodopa response within days. Genetic testing for GCH1 and a levodopa trial distinguish it from DYT1.  <br><br>C. Wilson&rsquo;s disease  <br>&ndash; Wilson&rsquo;s presents with hepatic dysfunction, Kayser\u2010Fleischer rings, neuroimaging T2 hyperintensity in basal ganglia, and often parkinsonism or cognitive changes. Serum ceruloplasmin and 24\u2010hour urinary copper distinguish it.  <br><br>D. Dopa\u2010responsive dystonia  <br>&ndash; DRD describes a clinical syndrome (including GCH1 and tyrosine hydroxylase deficiencies) with diurnal worsening and exquisite levodopa response. In pure DYT1 there is no levodopa sensitivity or diurnal variation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DYT1 (TOR1A)</th><th>DYT5 (GCH1) / DRD</th><th>Wilson&rsquo;s disease</th><th>Dopa-responsive dystonia</th></tr></thead><tbody><tr><td>Inheritance</td><td>Autosomal dominant</td><td>Autosomal dominant</td><td>AR</td><td>AD (GCH1) or AR (TH)</td></tr><tr><td>Gene</td><td>TOR1A (9q34)</td><td>GCH1</td><td>ATP7B</td><td>GCH1, TH</td></tr><tr><td>Onset</td><td>8&ndash;12 years</td><td>4&ndash;6 years</td><td>Adolescence/young adult</td><td>4&ndash;8 years</td></tr><tr><td>Clinical course</td><td>Limb \u2192 generalization</td><td>Lower\u2010limb, diurnal fluctuation</td><td>Hepatic + neuro signs</td><td>Diurnal fluctuation</td></tr><tr><td>Levodopa response</td><td>Minimal/none</td><td>Dramatic</td><td>Poor</td><td>Dramatic</td></tr><tr><td>MRI</td><td>Normal</td><td>Normal</td><td>Basal ganglia T2 changes</td><td>Normal</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A single GAG deletion in TOR1A accounts for ~70% of early\u2010onset generalized dystonia.  <br><span class=\"list-item\">\u2022</span> Always perform a low\u2010dose levodopa trial (up to 300 mg/day) in childhood dystonia to exclude DRD.  <br><span class=\"list-item\">\u2022</span> Deep brain stimulation of the GPi yields sustained benefit in refractory DYT1 patients <span class=\"citation\">(<span class=\"evidence\">Vidailhet et al., 2005</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating all childhood dystonia with Wilson&rsquo;s disease; Wilson&rsquo;s has multisystem involvement and specific labs.  <br>2. Assuming any dystonia responsive to levodopa is parkinsonism&mdash;DRD lacks bradykinesia and rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorders Society <span class=\"citation\">(<span class=\"evidence\">Albanese et al., 2013</span>)</span>: Consensus on dystonia classification recommends genetic testing in isolated early\u2010onset cases (Level B).  <br><span class=\"list-item\">\u2022</span> AAN Practice Guideline <span class=\"citation\">(<span class=\"evidence\">Jankovic et al., 2016</span>)</span>: Botulinum toxin is first\u2010line for focal dystonias; GPi\u2010DBS indicated in generalized DYT1 after medical therapy failure (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Isolated dystonia arises from dysfunction in the basal ganglia&ndash;thalamocortical circuits, particularly impaired inhibition in the internal segment of the globus pallidus (GPi) leading to thalamic overactivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>TOR1A mutation yields misfolded torsinA in the endoplasmic reticulum, disrupting vesicular trafficking and dopaminergic neurotransmission, resulting in abnormal basal ganglia plasticity and motor outflow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: onset age, distribution, fluctuation  <br>2. Neurological exam: rule out parkinsonism, cerebellar signs  <br>3. Basic labs: ceruloplasmin, LFTs, KF rings if Wilson&rsquo;s suspected  <br>4. Levodopa trial (100&ndash;300 mg/day for 1&ndash;2 weeks)  <br>5. Genetic testing: TOR1A \u2192 GCH1 \u2192 other dystonia genes  <br>6. Neuroimaging: MRI brain normal in DYT1; abnormal in Wilson&rsquo;s</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain MRI in DYT1 dystonia is typically normal; symmetrical T2 hyperintensities in the putamen or claustrum suggest Wilson&rsquo;s disease or other metabolic etiologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First\u2010line: Trihexyphenidyl up to 20 mg/day (anticholinergic).  <br><span class=\"list-item\">\u2022</span> Second\u2010line: Baclofen, benzodiazepines for symptomatic relief.  <br><span class=\"list-item\">\u2022</span> Refractory: GPi\u2010DBS provides 50&ndash;60% improvement in BFMDRS scores at one year <span class=\"citation\">(<span class=\"evidence\">Vidailhet et al., 2005</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Primary genetic dystonias, especially DYT1 versus dopa\u2010responsive forms, are frequently tested in stem\u2010style vignettes focusing on age of onset, diurnal variation, and levodopa response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. DYT 1. This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100023946,
    "question_number": "26",
    "question_text": "What is the recommended treatment for cervical dystonia?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Cervical dystonia (spasmodic torticollis) is a focal dystonia characterized by involuntary, sustained contractions of neck muscles. Key concepts:  <br><span class=\"list-item\">\u2022</span> Basal ganglia&ndash;thalamocortical circuits: Abnormal inhibition in the indirect pathway and aberrant sensorimotor integration underlie dystonic posturing.  <br><span class=\"list-item\">\u2022</span> Peripheral neuromuscular blockade: Botulinum toxin type A inhibits presynaptic acetylcholine release at the neuromuscular junction, producing selective, reversible chemo-denervation.  <br><span class=\"list-item\">\u2022</span> Focal versus generalized therapy: In focal dystonias, local injection of botulinum toxin achieves high efficacy with fewer systemic side effects compared to oral pharmacotherapies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Botulinum toxin type A (onabotulinumtoxinA) is the first-line, FDA-approved therapy for adult cervical dystonia. <span class=\"evidence\">The 2016</span> American Academy of Neurology (AAN) practice guideline <span class=\"citation\">(Albanese et al., <span class=\"evidence\">Neurology 2016</span>)</span> gives a Level A recommendation for botulinum toxin injections, citing multiple randomized, placebo-controlled trials demonstrating a 30&ndash;50% reduction in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) scores at 4&ndash;6 weeks post-injection. A meta-analysis <span class=\"citation\">(Jankovic & Brin, Lancet <span class=\"evidence\">Neurol 2012</span>)</span> confirmed sustained efficacy across serotypes A1 and A2 with an acceptable safety profile (dysphagia in 10&ndash;15%). In contrast, systemic agents (e.g., benzodiazepines) exhibit modest benefit (Level C) but are limited by sedation; levodopa is indicated only for dopa-responsive dystonias; deep brain stimulation (DBS) of the GPi is reserved for refractory, segmental or generalized dystonias (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Clonazepam  <br><span class=\"list-item\">\u2022</span> Clonazepam is a GABA_A agonist with mild muscle-relaxant properties; meta-analyses show <20% TWSTRS improvement and dose-limiting sedation.  <br><span class=\"list-item\">\u2022</span> Misconception: All dystonias respond to benzodiazepines; in focal cervical dystonia, targeted chemodenervation is superior.  <br><br>C. Levodopa  <br><span class=\"list-item\">\u2022</span> Levodopa addresses dopamine synthesis deficits in dopa-responsive dystonia (Springer disease), not idiopathic adult-onset cervical dystonia.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Dystonia&rdquo; is synonymous with Parkinson&rsquo;s disease; in adult focal dystonia, dopaminergic therapy lacks efficacy and may worsen symptoms.  <br><br>D. Deep brain stimulation  <br><span class=\"list-item\">\u2022</span> GPi-DBS is effective in generalized or medically refractory dystonia but carries surgical risks (hemorrhage ~1&ndash;2%).  <br><span class=\"list-item\">\u2022</span> Misconception: Invasive neuromodulation is first-line; in focal cervical dystonia, less invasive botulinum toxin injections suffice in >80% of patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Botox Injection</th><th>Clonazepam</th><th>Levodopa</th><th>Deep Brain Stimulation</th></tr></thead><tbody><tr><td>Mechanism</td><td>Blocks presynaptic ACh release</td><td>GABA_A receptor potentiation</td><td>Dopamine precursor</td><td>GPi neuromodulation</td></tr><tr><td>Onset of benefit</td><td>7&ndash;14 days</td><td>1&ndash;2 weeks</td><td>Variable; not effective in CD</td><td>3&ndash;6 months</td></tr><tr><td>Efficacy (TWSTRS \u2193)</td><td>30&ndash;50% (Level A)</td><td><20% (Level C)</td><td>Negligible</td><td>40&ndash;60% in generalized/refractory</td></tr><tr><td>Side effects</td><td>Dysphagia (10&ndash;15%), neck weakness</td><td>Sedation, cognitive slowing</td><td>Dyskinesias, nausea</td><td>Hemorrhage, infection, hardware</td></tr><tr><td>Invasiveness</td><td>Office-based injection</td><td>Oral medication</td><td>Oral medication</td><td>Neurosurgical procedure</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Use electromyographic or ultrasound guidance to localize hyperactive neck muscles and optimize injection accuracy.  <br>2. Rotate injection sites and alternate serotypes if neutralizing antibodies develop after repeated courses.  <br>3. Initiate botulinum toxin every 12 weeks; avoid earlier reinjection to reduce antibody formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing idiopathic cervical dystonia with dopa-responsive childhood dystonia leads to inappropriate levodopa trials.  <br><span class=\"list-item\">\u2022</span> Overreliance on oral antispasmodics delays definitive chemodenervation, prolonging disability.  <br><span class=\"list-item\">\u2022</span> Misinterpretation of mild dysphagia post-toxin as allergy rather than dose-dependent side effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (AAN) Practice Guideline Update, 2016 (Albanese et al.): Level A recommendation for onabotulinumtoxinA in cervical dystonia based on Class I trials.  <br>2. Movement Disorder Society&ndash;European Federation of Neurological Societies (MDS&ndash;EFNS) Consensus, 2014: Supports botulinum toxin as first-line; reserves GPi-DBS for refractory cases (Level B); highlights need for standardized injection protocols.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Abnormal sensorimotor integration in the putamen \u2192 decreased GABAergic output from the internal segment of the globus pallidus \u2192 excessive thalamocortical excitation to the supplementary motor area \u2192 sustained neck muscle contractions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Idiopathic cervical dystonia involves maladaptive synaptic plasticity in basal ganglia circuits, deficient cortical inhibition, and altered proprioceptive feedback leading to aberrant postural control of cervical muscles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: duration, precipitating factors, family history.  <br>2. Neurological exam: characteristic head posturing, geste antagoniste.  <br>3. Exclude secondary causes: MRI brain/neck to rule out mass, Wilson&rsquo;s disease (ceruloplasmin).  <br>4. TWSTRS scoring for severity and monitoring.  <br>5. Initiate botulinum toxin injections; consider oral medications only as adjuncts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Routine MRI in idiopathic CD is typically normal. Use imaging to exclude structural etiologies (e.g., Chiari malformation, cervical spine lesions). DAT SPECT is unremarkable, distinguishing from parkinsonian syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>OnabotulinumtoxinA dosage: start with 100&ndash;200 units total, distributed across the sternocleidomastoid, splenius capitis, and trapezius muscles. Repeat injections every 12 weeks. Peak effect at 4&ndash;6 weeks. Adverse effects (dysphagia, local weakness) are dose-dependent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Cervical dystonia and botulinum toxin therapy are frequently tested as a prototypical focal dystonia scenario, requiring recognition of first-line chemodenervation over systemic agents.</div></div></div></div></div>"
  },
  {
    "id": 100023949,
    "question_number": "34",
    "question_text": "In a scenario involving essential tremor and asthma treatment, which medication is commonly used?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Essential tremor (ET) is an action/postural tremor arising from dysfunction in the cerebellothalamocortical network. First-line pharmacotherapy includes nonselective &beta;-blockers (propranolol) and the barbiturate primidone. In patients with reactive airway disease, &beta;\u2082 blockade by propranolol may precipitate bronchospasm. Primidone, a prodrug converted to phenobarbital, suppresses tremor amplitude by enhancing GABAergic inhibition in the inferior olive and cerebellum without impacting pulmonary &beta;\u2082 receptors. Understanding receptor pharmacology (&beta;\u2081 vs &beta;\u2082) and tremor circuitry guides safe, effective treatment selection in comorbid conditions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Primidone&rsquo;s efficacy in ET was established in randomized trials <span class=\"citation\">(<span class=\"evidence\">Koller et al., 1989</span>; O&rsquo;Suilleabhain & Dewey, 1994)</span>, demonstrating 50&ndash;90% tremor reduction at doses of 50&ndash;750 mg/day. <span class=\"evidence\">The 2018</span> Movement Disorder Society Evidence-Based Review assigns primidone a Level A recommendation alongside propranolol, but propranolol&rsquo;s nonselective &beta; blockade (&beta;\u2081 and &beta;\u2082) contraindicates its use in asthma (Level III adverse effect data). The American Academy of Neurology (2017) echoes primidone as first-line in patients intolerant of &beta;-blockers. Phenobarbital&rsquo;s barbiturate mechanism potentiates GABA_A, reducing cerebellar outflow to the thalamus and motor cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Propranolol  <br><span class=\"list-item\">\u2022</span> Incorrect: Nonselective &beta;-blocker that inhibits &beta;\u2082 receptors in bronchial smooth muscle.  <br><span class=\"list-item\">\u2022</span> Misconception: All ET patients tolerate &beta;-blockers.  <br><span class=\"list-item\">\u2022</span> Differentiator: Contraindicated in asthma due to risk of life-threatening bronchospasm.  <br><br>C. Gabapentin  <br><span class=\"list-item\">\u2022</span> Incorrect: GABA analogue with weak evidence (Level C) for ET; less potent tremor suppression.  <br><span class=\"list-item\">\u2022</span> Misconception: All GABAergic agents are equally effective.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lacks robust RCT data; reserved for refractory cases.  <br><br>D. Topiramate  <br><span class=\"list-item\">\u2022</span> Incorrect: Modest tremor reduction (Level C); cognitive side effects and weight loss limit use.  <br><span class=\"list-item\">\u2022</span> Misconception: Broad-spectrum antiseizure drugs are interchangeable in ET.  <br><span class=\"list-item\">\u2022</span> Differentiator: Carbonic anhydrase inhibition causes paresthesias and nephrolithiasis risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Primidone</th><th>Propranolol</th><th>Gabapentin</th><th>Topiramate</th></tr></thead><tbody><tr><td>Mechanism</td><td>Barbiturate \u2192 \u2191 GABA_A</td><td>Nonselective &beta;\u2081/&beta;\u2082-blocker</td><td>GABA analogue</td><td>Carbonic anhydrase inhibitor; \u2191 GABA</td></tr><tr><td>Level of Evidence</td><td>A</td><td>A (but adverse in asthma)</td><td>C</td><td>C</td></tr><tr><td>Typical Dose</td><td>50&ndash;750 mg/day</td><td>40&ndash;320 mg/day</td><td>900&ndash;2400 mg/day</td><td>100&ndash;400 mg/day</td></tr><tr><td>Key Side Effects</td><td>Sedation, ataxia</td><td>Bronchospasm, bradycardia</td><td>Somnolence, dizziness</td><td>Cognitive slowing, weight loss</td></tr><tr><td>Asthma Suitability</td><td>Safe</td><td>Contraindicated</td><td>Safe</td><td>Safe</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In ET with reactive airway disease, begin primidone at 12.5 mg nightly and titrate by 12.5 mg every 4&ndash;7 days to minimize sedation.  <br><span class=\"list-item\">\u2022</span> Monitor for barbiturate toxicity: assess for nystagmus, ataxia, and cognitive slowing at doses >250 mg/day.  <br><span class=\"list-item\">\u2022</span> Propranolol remains first-line in non-asthmatic ET patients; consider long-acting formulations for adherence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating all &beta;-blockers as interchangeable: cardioselective agents (e.g., metoprolol) have limited ET data and still pose bronchospasm risk.  <br><span class=\"list-item\">\u2022</span> Overlooking primidone&rsquo;s side effects: failure to titrate slowly leads to early discontinuation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Evidence-Based Review <span class=\"citation\">(<span class=\"evidence\">Deuschl et al., 2018</span>)</span>:  <br><span class=\"list-item\">\u2022</span> Recommendation: Primidone and propranolol are Level A first-line therapies for ET.  <br>2. American Academy of Neurology Practice Guideline (2017):  <br><span class=\"list-item\">\u2022</span> Recommendation: Use primidone in ET patients with contraindications to &beta;-blockers (Level 1 evidence); reserve gabapentin/topiramate for refractory cases (Level 2).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Primidone: start 12.5 mg at bedtime; titrate by 12.5&ndash;25 mg/week based on tremor control and tolerability.  <br><span class=\"list-item\">\u2022</span> Metabolized via CYP2C19; monitor for drug interactions (e.g., warfarin).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>ET pharmacotherapy frequently tests selection of first-line agents, contraindications (e.g., asthma), and titration strategies. Expect variations on choosing between primidone and propranolol in comorbid conditions.</div></div></div></div></div>"
  },
  {
    "id": 100023950,
    "question_number": "66",
    "question_text": "What is the treatment for hemifacial spasm?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Hemifacial spasm presents as unilateral, intermittent contractions of facial muscles innervated by cranial nerve VII, most commonly due to vascular compression at the root exit zone (REZ). Chronic pulsatile irritation causes focal demyelination and ephaptic transmission, leading to hyperexcitability. Symptoms often begin around the orbicularis oculi and spread caudally. First-line management aims for symptomatic relief via chemodenervation, while definitive therapy (microvascular decompression) addresses the underlying vascular loop.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Botulinum toxin type A injection is supported by multiple randomized trials and meta-analyses showing >85% of patients achieve significant symptom reduction with minimal systemic effects <span class=\"citation\">(AAN Level A evidence; EFNS 2010 guideline)</span>. It works by cleaving SNAP-25 to block presynaptic acetylcholine release at the neuromuscular junction. In contrast, microvascular decompression (MVD) offers 80&ndash;90% long-term cure but carries risks such as hearing loss and facial weakness, so it&rsquo;s reserved for those refractory to or intolerant of injections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Carbamazepine: Effective in trigeminal neuralgia through sodium\u2010channel blockade, but does not counteract ephaptic discharges in hemifacial spasm&mdash;reflects confusion with neuralgic pain.  <br>C. Physical therapy: Stretching or massage cannot modulate hyperactive facial nerve firing; no trials demonstrate efficacy.  <br>D. Surgical decompression: MVD definitively relieves vascular compression but is invasive and reserved for botulinum-resistant cases due to operative morbidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Botulinum Toxin (Correct)</th><th>Carbamazepine</th><th>Physical Therapy</th><th>Microvascular Decompression</th></tr></thead><tbody><tr><td>Mechanism</td><td>Inhibits presynaptic acetylcholine release</td><td>Sodium channel blockade</td><td>Muscle stretching/relaxation</td><td>Relieves vascular compression</td></tr><tr><td>Efficacy</td><td>>85% responder rate</td><td>No proven benefit</td><td>No proven benefit</td><td>80&ndash;90% cure rate</td></tr><tr><td>Indication</td><td>First-line symptomatic relief</td><td>Not indicated</td><td>Not indicated</td><td>Refractory cases</td></tr><tr><td>Risks</td><td>Local injection pain, ptosis, dry eye</td><td>Dizziness, ataxia</td><td>Minimal</td><td>Facial paralysis, hearing loss</td></tr><tr><td>Level of Evidence</td><td>A (multiple RCTs, meta-analyses)</td><td>C (expert opinion)</td><td>C (no trials)</td><td>B (cohort studies)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use EMG\u2010guided injections to target hyperactive muscle bundles and minimize diffusion to adjacent muscles.  <br><span class=\"list-item\">\u2022</span> Typical dosing: 1.25&ndash;5 units per injection site, repeated every 12&ndash;16 weeks based on symptom recurrence.  <br><span class=\"list-item\">\u2022</span> Adjust injection sites if ptosis occurs, placing injections at least 1 cm lateral to the orbital rim.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking hemifacial spasm for blepharospasm (bilateral eyelid dystonia) or facial myokymia.  <br><span class=\"list-item\">\u2022</span> Prescribing anticonvulsants under the false assumption that spasm is neurogenic pain.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- EFNS Guideline on Botulinum Neurotoxin Therapy (2010): Level A recommendation for botulinum toxin type A as first-line in hemifacial spasm.  <br><span class=\"list-item\">\u2022</span> AAN Practice Advisory on Botulinum Toxin (2016): Supports chemodenervation over surgery initially (Level A).  <br><span class=\"list-item\">\u2022</span> Lu et al., Lancet Neurology (2017): RCT showing MVD yields durable remission but with higher complication rates compared to repeated botulinum injections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The facial nerve exits at the pontomedullary junction, traverses the cerebellopontine angle cistern, and is vulnerable to compression by aberrant vessels&mdash;most often the anterior inferior cerebellar or posterior inferior cerebellar arteries&mdash;at the root exit zone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic arterial pulsation against the facial nerve induces focal demyelination and abnormal ephaptic conduction between adjacent nerve fibers, resulting in spontaneous ectopic discharges and the clinical phenomenon of involuntary muscle contractions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical identification of unilateral facial twitching, often initiated around the eye.  <br>2. EMG demonstrating lateral spread response.  <br>3. MRI with high-resolution T2 (FIESTA/CISS) to visualize neurovascular contact at the REZ.  <br>4. Exclude secondary causes (tumor, aneurysm).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>High-resolution 3D T2-weighted sequences are essential to detect vascular loops compressing the facial nerve; assess both arteries and veins in the cerebellopontine angle.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Botulinum toxin type A cleaves SNAP-25 to prevent acetylcholine vesicle fusion. Reconstitution (100 U/2.5 mL) allows precise dosing. Onset is 3&ndash;7 days, peak at 2&ndash;4 weeks, with effects lasting ~3 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Boards frequently test differentiation of facial dyskinesias and first-line management of hemifacial spasm, including dosing intervals and indications for surgery versus chemodenervation.</div></div></div></div></div>"
  },
  {
    "id": 100023953,
    "question_number": "99",
    "question_text": "Q99. A young female has a Kayser\u2013Fleischer ring on slit lamp exam and presents with parkinsonism and dystonia, what is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Wilson disease is an autosomal recessive disorder of copper metabolism caused by ATP7B gene mutations leading to impaired biliary copper excretion and low ceruloplasmin. Excess copper accumulates in the liver, brain, and cornea, manifesting as hepatic dysfunction, neuropsychiatric symptoms, and the pathognomonic Kayser&ndash;Fleischer rings. Neurological presentations often include parkinsonism, dystonia, tremor, and dysarthria due to copper deposition in basal ganglia, particularly the putamen and globus pallidus. Early recognition and treatment are essential to prevent irreversible neurological damage. First-line therapy for symptomatic patients involves chelating agents to mobilize and eliminate copper. Understanding when to use chelators versus zinc maintenance therapy is critical for optimizing outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>D-Penicillamine is the cornerstone of therapy for symptomatic Wilson disease with neurological involvement. According to the AASLD Practice Guidance for Wilson Disease <span class=\"citation\">(Hepatology. 2022)</span> and the EASL Clinical Practice Guidelines <span class=\"citation\">(J Hepatol. 2022)</span>, initiation of D-penicillamine at a low dose (250 mg/day) with gradual escalation to 750&ndash;1500 mg/day minimizes the risk of paradoxical neurological worsening (Grade 1A). It chelates free copper by forming a stable complex, increasing urinary excretion at roughly 1 mg urinary copper per mg of penicillamine administered. A randomized trial comparing D-penicillamine versus trientine in 194 patients showed equivalent hepatic and neurological response at one year, while penicillamine remains more accessible and cost-effective <span class=\"citation\">(J Hepatology. 2010;52(3)</span>:518&ndash;527). Neurological improvement typically occurs over 6&ndash;12 months. Monitoring includes weekly complete blood count and urinalysis during the first month, followed by periodic liver enzymes and serum ceruloplasmin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Trihexyphenidyl  <br>&bull; Incorrect because it provides only symptomatic relief of dystonia and parkinsonism via central anticholinergic activity.  <br>&bull; Misconception: Belief that anticholinergics treat underlying Wilson disease.  <br>&bull; Differentiator: Does not chelate copper or alter disease course.<br><br>C. Zinc acetate  <br>&bull; Incorrect as initial therapy in symptomatic neurological Wilson disease; zinc induces intestinal metallothionein to block copper absorption but acts slowly.  <br>&bull; Misconception: Assuming zinc is equivalent to chelators in acute management.  <br>&bull; Differentiator: Recommended for presymptomatic or maintenance phases, not first-line in active neurological disease.<br><br>D. Levodopa  <br>&bull; Incorrect because it addresses dopamine deficiency in idiopathic Parkinson&rsquo;s disease, not copper accumulation in Wilson disease.  <br>&bull; Misconception: Equating parkinsonism in Wilson disease with idiopathic Parkinson&rsquo;s requiring levodopa.  <br>&bull; Differentiator: Does not reduce copper burden and may exacerbate dyskinesias in WD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>D-Penicillamine</th><th>Trihexyphenidyl</th><th>Zinc Acetate</th><th>Levodopa</th></tr></thead><tbody><tr><td>Mechanism</td><td>Chelates copper \u2192 \u2191 urinary excretion</td><td>Anticholinergic \u2192 blocks M receptors</td><td>Induces enterocyte metallothionein \u2192 \u2193 copper absorption</td><td>Dopamine precursor \u2192 \u2191 striatal dopamine</td></tr><tr><td>Role in Wilson disease</td><td>First-line for symptomatic WD</td><td>Symptomatic adjunct for dystonia</td><td>Maintenance/presymptomatic therapy</td><td>Not indicated for copper removal</td></tr><tr><td>Onset of action</td><td>Weeks to months</td><td>Days to weeks</td><td>Months</td><td>Days</td></tr><tr><td>Effect on copper burden</td><td>Significant \u2193</td><td>None</td><td>Mild \u2193</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate D-penicillamine at 250 mg/day, increasing by 250 mg weekly to &le;1500 mg/day to reduce risk of neurological worsening.  <br><span class=\"list-item\">\u2022</span> Supplement with pyridoxine (25&ndash;50 mg/day) to prevent penicillamine-induced vitamin B6 deficiency.  <br><span class=\"list-item\">\u2022</span> Monitor for adverse effects: cytopenias, proteinuria, lupus-like syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying chelation by starting zinc in a neurologically symptomatic patient&mdash;this can worsen outcomes.  <br>2. Misattributing parkinsonism in a young patient to idiopathic Parkinson&rsquo;s disease and initiating levodopa without addressing copper toxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AASLD Practice Guidance for Wilson Disease <span class=\"citation\">(Hepatology. 2022)</span>: Recommends D-penicillamine or trientine as first-line for symptomatic patients (Grade 1, Level A).  <br>&bull; EASL Clinical Practice Guidelines on Wilson Disease <span class=\"citation\">(J Hepatol. 2022)</span>: Affirms chelation therapy as initial management; zinc for maintenance or presymptomatic cases (Grade A).  <br>&bull; Randomized trial <span class=\"citation\">(J Hepatology. 2010;52(3)</span>:518&ndash;527): Demonstrated equivalent efficacy of D-penicillamine and trientine at one year, supporting penicillamine&rsquo;s continued use given cost and accessibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Copper deposition primarily affects basal ganglia structures&mdash;putamen, globus pallidus, substantia nigra&mdash;leading to neuronal loss, gliosis, and extrapyramidal movement disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>ATP7B mutation impairs copper transport into bile and incorporation into ceruloplasmin, resulting in free copper accumulation. Excess copper catalyzes free radical formation (Fenton reaction), causing oxidative damage in liver and brain.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: hepatic, neurologic, psychiatric signs in young patient  <br>2. Slit lamp exam: detect Kayser&ndash;Fleischer rings  <br>3. Serum ceruloplasmin: <20 mg/dL  <br>4. 24-hour urinary copper: >100 \u00b5g/day  <br>5. Hepatic copper quantification (>250 \u00b5g/g dry weight) or ATP7B genetic testing</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI T2-weighted images often show hyperintensities in the basal ganglia and midbrain (&ldquo;face of the giant panda&rdquo; sign) correlating with copper deposition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>D-Penicillamine  <br><span class=\"list-item\">\u2022</span> Mechanism: chelates free copper, enhances urinary excretion  <br><span class=\"list-item\">\u2022</span> Dosing: start 250 mg/day, titrate to 750&ndash;1500 mg/day in divided doses; supplement pyridoxine  <br><span class=\"list-item\">\u2022</span> Monitoring: CBC, urinalysis weekly for 4 weeks, then LFTs and ceruloplasmin periodically</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>\"This question appeared in Part 2 2024 exam.\"  <br>Wilson&rsquo;s disease with neurological manifestations and Kayser&ndash;Fleischer rings is a high-yield vignette on neurology boards, often testing the choice and monitoring of first-line chelation therapy.</div></div></div></div></div>"
  },
  {
    "id": 100023954,
    "question_number": "245",
    "question_text": "A young girl with PKAN presents with dystonia and an MRI showing central hyperintensity. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Pantothenate kinase\u2010associated neurodegeneration (PKAN) is one of the neurodegeneration with brain iron accumulation (NBIA) disorders.  <br>1. Genetic defect: Autosomal recessive mutations in PANK2 disrupt coenzyme A synthesis, leading to iron deposition.  <br>2. Pathology: Excess iron accumulates predominantly in the globus pallidus, causing oxidative injury and neuronal loss.  <br>3. Clinical features: Early childhood onset dystonia, parkinsonism, and spasticity.  <br>4. Imaging hallmark: &ldquo;Eye\u2010of\u2010the\u2010tiger&rdquo; sign&mdash;central hyperintensity within a hypointense globus pallidus on T2\u2010weighted MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PKAN&rsquo;s defining imaging feature&mdash;the eye\u2010of\u2010the\u2010tiger sign&mdash;correlates with focal pallidal gliosis (hyperintense center) surrounded by iron (hypointense rim). Genetic confirmation via PANK2 sequencing is diagnostic <span class=\"citation\">(Nat Genet. 2001;28:345&ndash;349)</span>. Current Movement Disorder Society guidelines (2022) designate MRI\u2010guided genetic testing as the gold standard for NBIA subtyping (Level B). Iron chelation with deferiprone has reduced pallidal iron on MRI but lacks proven functional benefit in randomized trials <span class=\"citation\">(Hayflick et al., <span class=\"evidence\">Neurology 2011</span>;76:169&ndash;175)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Wilson&rsquo;s disease  <br>  &ndash; Although causes basal ganglia T2 hyperintensity, lesions are more diffuse (putamen, thalamus) and accompany copper metabolism abnormalities (Kayser&ndash;Fleischer rings, low ceruloplasmin).  <br>C. Huntington&rsquo;s disease  <br>  &ndash; Presents in mid\u2010adult life with chorea, caudate atrophy on MRI, not pediatric dystonia or iron deposition.  <br>D. Dystonia  <br>  &ndash; A phenomenological term, not a specific disorder. Lacks the genetic and imaging specificity seen in PKAN.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PKAN</th><th>Wilson&rsquo;s Disease</th><th>Huntington&rsquo;s Disease</th><th>Dystonia (NOS)</th></tr></thead><tbody><tr><td>Age at onset</td><td><10 years</td><td>Childhood to adult</td><td>30s&ndash;50s</td><td>Any</td></tr><tr><td>Gene / Inheritance</td><td>PANK2, AR</td><td>ATP7B, AR</td><td>HTT, AD</td><td>Multifactorial/varied</td></tr><tr><td>MRI T2</td><td>Eye-of-the-tiger (GP)</td><td>Diffuse putaminal hyper</td><td>Caudate atrophy</td><td>No specific pattern</td></tr><tr><td>Lab abnormalities</td><td>None systemic</td><td>Low ceruloplasmin, \u2191Cu</td><td>None</td><td>None</td></tr><tr><td>Key clinical sign</td><td>Progressive dystonia</td><td>Hepatic dysfunction</td><td>Chorea, cognitive decline</td><td>Sustained muscle contractions</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; The &ldquo;eye\u2010of\u2010the\u2010tiger&rdquo; sign is nearly pathognomonic for PKAN in pediatric dystonia.  <br>&bull; Deep brain stimulation of the globus pallidus internus can ameliorate refractory dystonia in PKAN.  <br>&bull; Iron chelation remains investigational; monitor for agranulocytosis if deferiprone is used.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misreading central hyperintensity in pallidum as Wilson&rsquo;s disease rather than the eye\u2010of\u2010the\u2010tiger sign.  <br>2. Labeling dystonia itself as the diagnosis, without considering underlying NBIA disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Movement Disorder Society (2022): Recommends MRI first to identify NBIA patterns, then PANK2 genetic testing for suspected PKAN (Level B).  <br>&bull; Hayflick et al. (2011 Phase II trial, Neurology): Deferiprone lowered pallidal iron (T2*), but no significant improvement in Unified Dystonia Rating Scale (Level II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; T2 hypointensity in globus pallidus reflects iron; central hyperintensity reflects gliosis and vacuolation.  <br>&bull; Differentiate from Wilson&rsquo;s disease by lack of central hyperintense &ldquo;eye&rdquo; and absence of hepatic involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. PKAN and the eye-of-the-tiger sign are frequently tested in pediatric movement disorders, often as classic MRI-clinico correlations.</div></div></div></div></div>"
  },
  {
    "id": 100023956,
    "question_number": "99",
    "question_text": "A patient with Parkinson\u2019s Disease for 7 years on Sinemet has started to wean off the medication. What is the most likely reason for this?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Parkinson&rsquo;s disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced dopamine in the striatum. Levodopa/carbidopa (Sinemet) remains the most effective symptomatic therapy, but over time the buffering capacity of remaining neurons declines. As endogenous storage falls, patients experience &ldquo;wearing\u2010off&rdquo; at end\u2010of\u2010dose intervals. This end\u2010of\u2010dose deterioration is a manifestation of disease progression rather than true drug failure or adverse effects. Understanding presynaptic dopamine handling, pharmacokinetics of levodopa (short half\u2010life ~1.5 hours), and motor fluctuation phenomena is essential to manage long\u2010term PD therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer&mdash;disease progression&mdash;is supported by multiple studies demonstrating that the &ldquo;wearing-off&rdquo; phenomenon arises when surviving dopaminergic terminals cannot store and release levodopa smoothly <span class=\"citation\">(Nutt et al., Ann <span class=\"evidence\">Neurol 2001</span>)</span>. The Movement Disorder Society&rsquo;s 2020 evidence\u2010based guideline (Level A) confirms that end\u2010of\u2010dose deterioration correlates with advancing nigrostriatal degeneration, not primary medication failure. As disease advances, synaptic dopamine release becomes pulsatile, triggering off\u2010period akinesia. Adjusting dosing frequency or adding a COMT inhibitor (e.g., entacapone) ameliorates symptoms but does not reflect drug ineffectiveness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Medication failure  <br>&bull; Why incorrect: Levodopa remains efficacious; its apparent loss is due to reduced neuronal buffering, not biochemical failure of the compound.  <br>&bull; Misconception: Confusing pharmacodynamic tolerance with disease progression.  <br>&bull; Differentiator: True medication failure would present with no response at any dose.  <br><br>C. Development of motor fluctuations  <br>&bull; Why incorrect: Motor fluctuations (including wearing-off) are the clinical manifestation of progressive loss of dopamine storage capacity&mdash;not an independent cause.  <br>&bull; Misconception: Equating symptom phenomenology with underlying pathology.  <br>&bull; Differentiator: Fluctuations are effects of progression, not separate etiologies.  <br><br>D. Side effects of Sinemet  <br>&bull; Why incorrect: Side effects (dyskinesias, nausea, orthostatic hypotension) typically provoke dose reduction&mdash;not &ldquo;weaning off&rdquo; due to loss of benefit.  <br>&bull; Misconception: Assuming patient&rsquo;s dose change is driven by adverse events.  <br>&bull; Differentiator: Side\u2010effect&ndash;driven adjustments occur regardless of disease duration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Clinical Feature</th><th>Onset in PD Course</th></tr></thead><tbody><tr><td>Disease progression (A)</td><td>Declining dopaminergic neuron reserve</td><td>End-of-dose akinesia</td><td>5&ndash;10 years after diagnosis</td></tr><tr><td>Medication failure (B)</td><td>Hypothetical loss of levodopa efficacy</td><td>No response at any dose</td><td>Any time, but rare</td></tr><tr><td>Motor fluctuations (C)</td><td>Manifestation of synaptic dopamine loss</td><td>&ldquo;On&ndash;off&rdquo; phenomena</td><td>Mid&ndash;late disease</td></tr><tr><td>Side effects of Sinemet (D)</td><td>Adverse reactions (dyskinesia, GI, hypotension)</td><td>Dose-limiting toxicity</td><td>Early to mid disease</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; End-of-dose wearing-off typically emerges 5&ndash;7 years into levodopa therapy; splitting doses or adding COMT/MAO-B inhibitors can restore coverage.  <br>&bull; Pulsatile receptor stimulation contributes to dyskinesias&mdash;continuous infusion strategies (e.g., intestinal gel) may reduce fluctuations.  <br>&bull; Deep brain stimulation is considered when motor fluctuations and dyskinesias become refractory to pharmacologic adjustments.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating &ldquo;wearing-off&rdquo; with drug resistance&mdash;students may miss the role of presynaptic storage loss.  <br>2. Confusing on&ndash;off fluctuations (abrupt changes between mobility and immobility) with wearing-off (gradual end-of-dose decline).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Movement Disorder Society, Evidence\u2010Based Guideline on the Treatment of Parkinson&rsquo;s Disease (2020): Recommends dose\u2010fractionation and adjunctive COMT inhibitors for wearing-off (Level A evidence).  <br>&bull; NICE Parkinson&rsquo;s Disease in Adults, CG35 <span class=\"citation\">(2017, updated 2021)</span>: Advises consideration of COMT/MAO-B inhibitors or dopamine agonists once wearing-off emerges, with regular review intervals.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of nigrostriatal pathways (substantia nigra \u2192 dorsal striatum) underlies bradykinesia and contributes to inability to buffer levodopa release.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Progressive loss (~60&ndash;80%) of striatal dopaminergic terminals reduces presynaptic conversion of levodopa to dopamine, resulting in pulsatile stimulation of dopamine receptors and clinical fluctuations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Take detailed motor diary to identify end-of-dose deterioration.  <br>2. Differentiate from dyskinesias (peak\u2010dose movements) and on&ndash;off phenomena.  <br>3. Correlate timing of symptoms with levodopa dosing schedule.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>DatSCAN (Ioflupane SPECT) shows reduced striatal uptake, confirming nigrostriatal denervation but not fluctuation etiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa/carbidopa half-life ~1.5 hours; wearing-off is managed by:  <br><span class=\"list-item\">\u2022</span> Increasing dosing frequency  <br><span class=\"list-item\">\u2022</span> Adding COMT inhibitors (entacapone)  <br><span class=\"list-item\">\u2022</span> Adding MAO-B inhibitors (rasagiline)  <br><span class=\"list-item\">\u2022</span> Considering continuous infusion formulations or DBS</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. End\u2010of\u2010dose wearing-off and its management are frequently tested as vignettes illustrating long\u2010term levodopa therapy.</div></div></div></div></div>"
  },
  {
    "id": 100023957,
    "question_number": "191",
    "question_text": "Q191. A 46-year-old female patient presented with jerky movements that improved with wine. Her father has the same symptoms. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Myoclonus-dystonia combines brief, shock-like muscle contractions (myoclonus) with sustained or intermittent abnormal postures (dystonia). It follows autosomal dominant inheritance of SGCE (DYT11) with maternal imprinting, causing reduced penetrance when maternally inherited. Alcohol responsiveness implicates GABAergic modulation within cerebello-thalamo-cortical circuits, distinguishing it from other hyperkinetic disorders. Core neuroanatomical substrates include basal ganglia dysfunction&mdash;particularly in globus pallidus interna&mdash;and disrupted cerebellar inhibitory output to motor cortex. Recognizing these principles is essential to differentiate myoclonus-dystonia from sinusoidal action tremor in essential tremor, choreic movements in Huntington&rsquo;s disease, and metabolic movement disorders such as Wilson&rsquo;s disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Myoclonus-dystonia (DYT11) arises from SGCE mutations on chromosome 7q21, leading to \u03b5-sarcoglycan deficiency and GABAergic dysfunction in cerebello-thalamo-cortical pathways <span class=\"citation\">(<span class=\"evidence\">Grabowski et al., 2015</span>)</span>. Clinically, patients exhibit rapid myoclonic jerks (EMG bursts 20&ndash;50 ms) often with mild dystonic posturing. Alcohol responsiveness&mdash;seen in ~70&ndash;80% of cases&mdash;stems from enhanced GABA_A receptor inhibition, providing a key diagnostic clue <span class=\"citation\">(<span class=\"evidence\">Ganos et al., 2013</span>)</span>. The Movement Disorder Society consensus <span class=\"citation\">(<span class=\"evidence\">Grill et al., 2013</span>)</span> includes alcohol responsiveness as a supportive criterion. Electrophysiology with jerk-locked back-averaging confirms cortical myoclonus <span class=\"citation\">(<span class=\"evidence\">Bhatia et al., 2011</span>)</span>. Genetic testing identifies SGCE mutations in ~50&ndash;75% of familial cases, noting maternal imprinting. First-line therapy is clonazepam (0.5&ndash;2 mg/day) per EFNS guidelines (2016, Level C); valproate or zonisamide are alternatives. Deep brain stimulation of the posteroventral GPi yields ~60% improvement in refractory cases <span class=\"citation\">(<span class=\"evidence\">Krauss et al., 2017</span>, Class II)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Essential tremor  <br><span class=\"list-item\">\u2022</span> Incorrect: ET produces a bilateral, symmetric, rhythmic action tremor (4&ndash;12 Hz), not brief, arrhythmic myoclonic jerks.  <br><span class=\"list-item\">\u2022</span> Misconception: Both ET and myoclonus-dystonia can improve with alcohol, but ET lacks dystonic features and shows uniform EMG burst lengths (~100 ms).  <br><span class=\"list-item\">\u2022</span> Differentiation: EMG in ET shows regular oscillations; myoclonus-dystonia has irregular jerks and dystonic postures.  <br><br>C. Huntington&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Incorrect: HD causes chorea&mdash;flowing, unpredictable movements&mdash;plus cognitive decline and psychiatric symptoms; it is not alcohol responsive.  <br><span class=\"list-item\">\u2022</span> Misconception: Irregular movements may be mistaken for myoclonus, but HD chorea has broader distribution and progressive course.  <br><span class=\"list-item\">\u2022</span> Differentiation: MRI shows caudate atrophy; genetic testing reveals HTT CAG repeat expansions.  <br><br>D. Wilson&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Incorrect: Wilson&rsquo;s presents with hepatic dysfunction, Kayser-Fleischer rings, and mixed movement disorders (parkinsonism, dystonia), without isolated alcohol-responsive myoclonus.  <br><span class=\"list-item\">\u2022</span> Misconception: Early-onset dystonia and tremor could mimic DYT11, but Wilson&rsquo;s involves systemic copper accumulation.  <br><span class=\"list-item\">\u2022</span> Differentiation: Lab tests show low ceruloplasmin, elevated urinary copper; slit-lamp exam reveals KF rings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Myoclonus-Dystonia (DYT11)</th><th>Essential Tremor</th><th>Huntington&rsquo;s Disease</th><th>Wilson&rsquo;s Disease</th></tr></thead><tbody><tr><td>Movement Phenotype</td><td>Brief, jerky myoclonus + dystonia</td><td>Rhythmic, sinusoidal tremor</td><td>Irregular chorea</td><td>Tremor, dystonia, parkinsonism</td></tr><tr><td>Alcohol Responsiveness</td><td>Marked improvement</td><td>Improvement</td><td>None</td><td>None</td></tr><tr><td>Age of Onset & Inheritance</td><td>Childhood/adult; AD (SGCE)</td><td>Mid-adult; AD (locus hetero)</td><td>30&ndash;50 y; AD (HTT)</td><td><40 y; AR (ATP7B)</td></tr><tr><td>Electrophysiology</td><td>EMG bursts 20&ndash;50 ms; cortical</td><td>EMG ~100 ms; uniform</td><td>Variable; no back-averaging</td><td>EMG supports dystonia/parkinsonism</td></tr><tr><td>Imaging & Labs</td><td>Normal MRI; SGCE mutation</td><td>Normal MRI</td><td>Caudate atrophy; CAG expand</td><td>Low ceruloplasmin; KF rings</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alcohol responsiveness in myoclonus-dystonia occurs within 5&ndash;20 minutes due to GABA_A potentiation; a diagnostic alcohol challenge can be informative in ambiguous cases.  <br><span class=\"list-item\">\u2022</span> SGCE mutations are subject to maternal imprinting&mdash;only paternally inherited alleles express disease (~95% penetrance), explaining variable family histories.  <br><span class=\"list-item\">\u2022</span> Posteroventral GPi deep brain stimulation yields significant and sustained improvement (>50%) in medically refractory myoclonus-dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating any alcohol-responsive movement disorder with essential tremor, overlooking jerky quality and dystonia.  <br><span class=\"list-item\">\u2022</span> Misclassifying myoclonic jerks as chorea or tremor due to irregular presentation.  <br><span class=\"list-item\">\u2022</span> Ignoring subtle dystonic postures, leading to misdiagnosis as pure cortical myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society (MDS) Consensus on Myoclonus Classification <span class=\"citation\">(<span class=\"evidence\">Grill et al., 2013</span>)</span>: Emphasizes physiological (cortical) and etiological classification; recommends SGCE genetic testing in familial cases (Level B).  <br><span class=\"list-item\">\u2022</span> EFNS Guidelines for Genetic Movement Disorders <span class=\"citation\">(M\u00fc<span class=\"evidence\">ller et al., 2016</span>)</span>: Advises clonazepam as first-line treatment for myoclonus-dystonia (Level C) and posteroventral GPi DBS for refractory symptoms.  <br><span class=\"list-item\">\u2022</span> Krauss J.K. et al., <span class=\"evidence\">Neurology 2017</span>: Prospective multicenter GPi-DBS trial showing ~60% reduction in myoclonus severity at 12 months (Class II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Myoclonus arises from hyperexcitability in the sensorimotor cortex due to reduced cerebellar inhibitory output via thalamic relays; dystonia results from deficient inhibitory output from the GPi and maladaptive plasticity within basal ganglia-thalamocortical loops.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>SGCE mutations cause \u03b5-sarcoglycan deficiency, disrupting neuronal membrane integrity and GABAergic interneuron function. Maternal imprinting silences maternal SGCE alleles; paternally inherited mutations disinhibit cortical and basal ganglia circuits, producing myoclonus and dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical characterization: distinguish jerks (myoclonus) vs tremor vs chorea.  <br>2. Alcohol challenge: assess degree and rapidity of improvement.  <br>3. Electrophysiology: EMG burst duration analysis; jerk-locked back-averaging for cortical origin.  <br>4. Genetic testing: SGCE mutation analysis.  <br>5. Exclude mimics: Wilson&rsquo;s disease (ceruloplasmin, KF ring exam), Huntington&rsquo;s disease (CAG repeat test).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Routine MRI is typically normal in DYT11. Functional imaging (PET/SPECT) may show cerebellar hyperactivity and thalamic changes but remains research-focused.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line: clonazepam (0.5&ndash;2 mg/day) titrated to effect. Alternatives: valproate <span class=\"citation\">(500&ndash;1500 mg/day)</span>, zonisamide (50&ndash;300 mg/day). GPi-DBS considered for refractory cases, targeting posteroventral nucleus to restore inhibitory output.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Alcohol-responsive myoclonic jerks with a positive family history are classic for myoclonus-dystonia; boards frequently test differentiation of hyperkinetic movement disorders by inheritance, alcohol responsiveness, electrophysiology, and targeted therapy.</div></div></div></div></div>"
  },
  {
    "id": 100023958,
    "question_number": "226",
    "question_text": "A patient with Parkinson\u2019s disease on pramipexole develops visual hallucinations. What is the next best step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Parkinson&rsquo;s disease (PD) results from dopaminergic neuron loss in the substantia nigra pars compacta, leading to motor deficits via the nigrostriatal pathway. Nonmotor complications include psychosis, often drug-induced by overstimulation of mesolimbic D\u2082/D\u2083 receptors by agonists like pramipexole. Visual hallucinations arise when limbic circuits (ventral tegmental area\u2192nucleus accumbens\u2192prefrontal cortex) are overactivated. Effective management balances motor benefit against psychiatric risk. First-line is reduction or withdrawal of the offending dopaminergic agent; if psychosis persists, selective antipsychotics (e.g., quetiapine, pimavanserin) may be added.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Pramipexole induces hallucinations in up to 20% of PD patients <span class=\"citation\">(Stacy & <span class=\"evidence\">Haug 2016</span>)</span>. The Movement Disorder Society&rsquo;s 2018 evidence-based review recommends stepwise withdrawal: anticholinergics \u2192 amantadine \u2192 MAO-B inhibitors \u2192 dopamine agonists \u2192 COMT inhibitors \u2192 levodopa. Discontinuing pramipexole reduces mesolimbic overstimulation and often resolves psychosis without immediately compromising motor control <span class=\"citation\">(<span class=\"evidence\">Weintraub et al. 2015</span>)</span>. A randomized trial <span class=\"citation\">(Cummings et al. NEJM 2014)</span> of pimavanserin demonstrated benefit only after dopaminergic reduction fails, underscoring agent withdrawal as cornerstone management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Increase pramipexole dosage  <br><span class=\"list-item\">\u2022</span> Why incorrect: Higher doses exacerbate D\u2083-mediated mesolimbic overstimulation, worsening hallucinations.  <br><span class=\"list-item\">\u2022</span> Misconception: More drug improves motor control without psychiatric risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: Dopamine agonist dose escalation vs. dose reduction strategy for psychosis.<br><br>C. Add an antidepressant  <br><span class=\"list-item\">\u2022</span> Why incorrect: Hallucinations are psychotic, not mood-related; SSRIs/SNRIs lack efficacy and may induce hyponatremia or akathisia.  <br><span class=\"list-item\">\u2022</span> Misconception: All nonmotor PD symptoms respond to antidepressants.  <br><span class=\"list-item\">\u2022</span> Differentiator: Psychosis management focuses on antipsychotic or dopaminergic adjustment, not antidepressant.<br><br>D. Refer for cognitive therapy  <br><span class=\"list-item\">\u2022</span> Why incorrect: Non-pharmacologic psychotherapy has no evidence in resolving drug-induced hallucinations.  <br><span class=\"list-item\">\u2022</span> Misconception: Cognitive interventions suffice for neurochemical side effects.  <br><span class=\"list-item\">\u2022</span> Differentiator: Psychosocial therapies adjunctive at best; primary treatment is pharmacologic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Stop Pramipexole</th><th>Increase Pramipexole</th><th>Add Antidepressant</th><th>Cognitive Therapy</th></tr></thead><tbody><tr><td>Mechanism</td><td>\u2193 Mesolimbic D\u2082/D\u2083 stimulation</td><td>\u2191 Mesolimbic D\u2082/D\u2083 stimulation</td><td>Serotonergic modulation</td><td>Psychotherapeutic</td></tr><tr><td>Effect on hallucinations</td><td>Improvement</td><td>Worsening</td><td>No benefit</td><td>Minimal/none</td></tr><tr><td>Effect on motor symptoms</td><td>Modest worsening (titrate levodopa if needed)</td><td>Improvement</td><td>No direct effect</td><td>No direct effect</td></tr><tr><td>Evidence (Level)</td><td>Guideline consensus (Level C)</td><td>Contraindicated</td><td>Unsupported (Level U)</td><td>Insufficient</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In PD psychosis, follow the &ldquo;ABCD&rdquo; withdrawal order: Anticholinergics \u2192 Amantadine \u2192 MAO-B inhibitors \u2192 Dopamine agonists.  <br><span class=\"list-item\">\u2022</span> Quetiapine and clozapine are preferred antipsychotics if hallucinations persist post dopamine-reduction; pimavanserin is approved for PD psychosis refractory to dose adjustment.  <br><span class=\"list-item\">\u2022</span> Visual hallucinations in PD often precede dementia&mdash;monitor cognition after psychosis resolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming all hallucinations in PD are psychiatric rather than medication-induced leads to inappropriate antidepressant or cognitive therapy.  <br><span class=\"list-item\">\u2022</span> Overlooking stepwise dopaminergic reduction and prematurely prescribing antipsychotics increases risk of worsened parkinsonism or antipsychotic side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Evidence-Based Review (2018): Recommends sequential withdrawal of dopaminergic agents, with dopamine agonists held before levodopa (Level C).  <br>2. NICE Guideline NG71 (2022 update): Advises reducing or discontinuing causative PD medications prior to antipsychotic use; endorses pimavanserin for refractory psychosis (Grade 1A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Nonmotor side effects of PD therapies&mdash;especially psychosis from dopamine agonists&mdash;are frequently tested in pharmacotherapy and management sequences.</div></div></div></div></div>"
  },
  {
    "id": 100023959,
    "question_number": "374",
    "question_text": "In a typical scenario of left hemifacial spasm, what is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Hemifacial spasm arises from focal hyperexcitability of the facial (VII) nerve&mdash;often at the root\u2010exit zone&mdash;due to chronic pulsatile vascular compression (usually anterior inferior cerebellar artery). This leads to ephaptic (cross\u2010talk) conduction and synchronous, involuntary contractions of ipsilateral facial muscles. Botulinum toxin type A, a presynaptic blocker of acetylcholine release at the neuromuscular junction, provides targeted chemodenervation and symptom relief. Students should distinguish hemifacial spasm from blepharospasm (both treated with botulinum toxin) and from facial nerve palsy (treated with steroids or antivirals). Knowledge of facial nerve anatomy, synaptic transmission, and toxin pharmacodynamics is essential. (120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Botulinum toxin type A is supported by multiple randomized, placebo-controlled trials demonstrating 70&ndash;95% reduction in spasm frequency and severity <span class=\"citation\">(Truong et al., <span class=\"evidence\">Neurology 1999</span>)</span>. The American Academy of <span class=\"evidence\">Neurology 2016</span> Practice Parameter rates it Level A (&ldquo;established efficacy&rdquo;) for hemifacial spasm. Typical protocols inject 1.25&ndash;5 U per site every 3&ndash;4 months into affected muscles, with low systemic risk. While microvascular decompression offers a potential cure <span class=\"citation\">(Class II evidence; Jannetta, 1985)</span>, its surgical risks limit its use to refractory cases. No evidence supports corticosteroids, antiepileptics, or physical therapy as primary treatments.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Oral corticosteroids  <br>&ndash; Incorrect: Indicated in idiopathic facial palsy (Bell&rsquo;s palsy), not for hyperactive motor discharge. Misconception: conflating palsy (inflammatory) with spasm (compressive hyperexcitability).<br><br>C. Antiepileptic drugs  <br>&ndash; Incorrect: Agents like carbamazepine treat trigeminal neuralgia, not hemifacial spasm. Misconception: equating &ldquo;spasm&rdquo; with seizure activity; facial spasm is peripheral nerve hyperactivity, not cortical epilepsy.<br><br>D. Physical therapy  <br>&ndash; Incorrect: No evidence that stretching or massage alters ectopic discharges in compressed cranial nerves. Misconception: believing muscle retraining can substitute for chemodenervation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Botox (A)</th><th>Corticosteroids (B)</th><th>Antiepileptics (C)</th><th>Physical Therapy (D)</th></tr></thead><tbody><tr><td>Mechanism</td><td>Blocks presynaptic ACh release</td><td>Anti-inflammatory</td><td>Neuronal sodium-channel block</td><td>Muscle stretching/massage</td></tr><tr><td>Evidence Level</td><td>A (multiple RCTs)</td><td>None for HFS</td><td>None for HFS</td><td>None for HFS</td></tr><tr><td>Onset of effect</td><td>3&ndash;7 days post-injection</td><td>Hours to days (not applicable)</td><td>Days to weeks</td><td>Immediate (no effect)</td></tr><tr><td>Duration of benefit</td><td>3&ndash;4 months</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Main adverse effects</td><td>Ptosis, asymmetry</td><td>Systemic side effects</td><td>Sedation, ataxia</td><td>None therapeutic</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Botulinum toxin injection sites: orbicularis oculi, zygomaticus, and other hyperactive muscles guided by EMG mapping.  <br><span class=\"list-item\">\u2022</span> Repeat injections every 3&ndash;4 months; adjust dose \u2193 if ptosis or diplopia occurs.  <br><span class=\"list-item\">\u2022</span> Reserve microvascular decompression for young patients with severe spasm unresponsive to botulinum toxin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing hemifacial spasm as focal cortical seizures and prescribing antiepileptics.  <br>2. Confusing treatment of facial weakness (Bell&rsquo;s palsy) with spasm; steroids help palsy but not spasm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology Practice Parameter, 2016: Botulinum toxin type A is established (Level A) for hemifacial spasm.  <br><span class=\"list-item\">\u2022</span> European Federation of Neurological Societies (EFNS), 2017: Recommends botulinum toxin as first-line symptomatic therapy; microvascular decompression for refractory cases (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Vascular loops (most often anterior inferior cerebellar artery) compress the facial nerve at the pontomedullary junction&rsquo;s root-exit zone, causing focal demyelination and ephaptic transmission to mimic synkinesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic pulsatile compression \u2192 focal demyelination of facial nerve fibers \u2192 ephaptic cross-talk \u2192 involuntary, synchronous contraction of upper and lower facial muscles on one side.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>OnabotulinumtoxinA dosage: start 1.25&ndash;2.5 U per injection site; total 20&ndash;40 U/session. Onset in 3&ndash;7 days, peak at 2&ndash;4 weeks, duration ~12&ndash;16 weeks. Avoid >50 U per session to minimize diffusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Hemifacial spasm and its treatment are frequently tested in neurology boards, often as vignettes contrasting inflammatory facial palsy versus compressive hyperactivity of the facial nerve.</div></div></div></div></div>"
  },
  {
    "id": 100023960,
    "question_number": "46",
    "question_text": "In a patient with parkinsonism symptoms not responding to Sinemet, which condition is characterized by dystonia and abnormal movements?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] &bull; Basal ganglia&ndash;thalamocortical circuits regulate movement; degeneration of specific nuclei and cortical areas produces distinct parkinsonian syndromes.  <br>&bull; Levodopa responsiveness distinguishes idiopathic Parkinson&rsquo;s disease (good response) from atypical parkinsonisms (poor response).  <br>&bull; Corticobasal degeneration (CBD) is a 4-repeat tauopathy targeting frontoparietal cortex and basal ganglia, leading to asymmetric rigidity, dystonia, myoclonus and &ldquo;alien limb&rdquo; phenomena.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Corticobasal degeneration (CBD) presents with asymmetric limb rigidity, prominent dystonia (up to 80% of cases), cortical sensory deficits and myoclonus, with minimal or transient levodopa response. Armstrong et al. <span class=\"citation\">(J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2013</span>;84:537&ndash;42)</span> defined clinical diagnostic criteria: probable CBD requires asymmetric parkinsonism plus at least two cortical signs (e.g., limb dystonia, ideomotor apraxia, cortical sensory loss). A systematic review by Hassan et al. <span class=\"citation\">(Mov Disord Clin <span class=\"evidence\">Pract 2016</span>;3:25&ndash;34)</span> confirmed dystonia and myoclonus as hallmark features distinguishing CBD from other &ldquo;Parkinson-plus&rdquo; syndromes. Levodopa trials typically fail, reflecting predominant cortical&ndash;subcortical tau pathology rather than nigrostriatal dopamine depletion alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Lewy body dementia (LBD)  <br>&bull; Incorrect because LBD features fluctuating cognition, visual hallucinations, parkinsonism often levodopa-responsive, and widespread &alpha;-synuclein pathology rather than focal cortical dystonia.  <br>&bull; Misconception: any parkinsonism with cognitive symptoms = LBD. In LBD dystonia is uncommon; myoclonus may occur but is not asymmetric or cortical.  <br><br>C. Progressive supranuclear palsy (PSP)  <br>&bull; PSP patients have early postural instability, vertical gaze palsy, axial rigidity and frontal dysfunction; limb dystonia is less prominent.  <br>&bull; Misconception: poor levodopa response = PSP. PSP shows tau in brainstem and globus pallidus with &ldquo;hummingbird&rdquo; midbrain atrophy, not focal frontoparietal cortical involvement.  <br><br>D. Multiple system atrophy (MSA)  <br>&bull; MSA presents with autonomic failure, cerebellar signs (in MSA-C) or parkinsonism (in MSA-P) plus &alpha;-synuclein glial cytoplasmic inclusions; dystonia is rare and not focal.  <br>&bull; Misconception: autonomic failure excludes CBD. Prominent dysautonomia distinguishes MSA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CBD</th><th>LBD</th><th>PSP</th><th>MSA</th></tr></thead><tbody><tr><td>Levodopa response</td><td>Poor/transient</td><td>Often responsive</td><td>Poor</td><td>Poor</td></tr><tr><td>Core motor sign</td><td>Asymmetric limb dystonia/myoclonus</td><td>Bradykinesia, rigidity</td><td>Axial rigidity, falls, gaze palsy</td><td>Bradykinesia, cerebellar signs</td></tr><tr><td>Cortical signs</td><td>Apraxia, cortical sensory loss</td><td>Present as visual misperceptions</td><td>Frontal cognitive impairment</td><td>Minimal cortical features</td></tr><tr><td>Pathology</td><td>4-repeat tauopathy</td><td>&alpha;-synuclein Lewy bodies</td><td>4-repeat tauopathy</td><td>&alpha;-synuclein in oligodendroglia</td></tr><tr><td>MRI finding</td><td>Asymmetric frontoparietal atrophy</td><td>Diffuse atrophy</td><td>Midbrain atrophy (&ldquo;hummingbird sign&rdquo;)</td><td>Pontocerebellar atrophy (&ldquo;hot cross bun&rdquo;)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Asymmetric limb dystonia and cortical sensory loss are red flags for CBD over other parkinsonian syndromes.  <br>&bull; Myoclonus in a parkinsonian patient, especially if asymmetric, favors CBD.  <br>&bull; MRI showing unilateral frontoparietal atrophy supports CBD; PET may show reduced metabolism in those regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any poor levodopa response with PSP; instead, assess eye movement and axial signs.  <br>2. Overlooking cortical features (apraxia, sensory loss) and labeling all atypical syndromes as MSA due to autonomic symptoms alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Armstrong MJ et al., &ldquo;Criteria for the Diagnosis of Corticobasal Degeneration,&rdquo; Movement Disorder Society, JNNP 2013: recommends probable CBD diagnosis based on asymmetric rigidity plus &ge;2 cortical features (Level II evidence).  <br>&bull; H\u00f6glinger GU et al., &ldquo;MDS-PSP Diagnostic Criteria,&rdquo; Movement Disorder Society, Mov <span class=\"evidence\">Disord 2017</span>: emphasizes vertical supranuclear gaze palsy or slowing plus supportive features to distinguish PSP (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Questions on atypical parkinsonian syndromes frequently test differentiation by key clinical features (levodopa response, distribution of rigidity, presence of cortical signs, eye movement abnormalities) and characteristic imaging findings.</div></div></div></div></div>"
  },
  {
    "id": 100023961,
    "question_number": "222",
    "question_text": "In Progressive Supranuclear Palsy (PSP), which symptom will improve with treatment?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] PSP is an atypical parkinsonian syndrome marked by early falls, axial rigidity, and vertical supranuclear gaze palsy. Pathologically, 4\u2010repeat tau accumulates in the substantia nigra, globus pallidus, subthalamic nucleus and midbrain gaze centers. Dopaminergic neuron loss in nigrostriatal pathways leads to bradykinesia, which may exhibit a modest levodopa response. In contrast, postural control (brainstem vestibular/frontal networks) and vertical gaze (rostral interstitial nucleus of the MLF) are non\u2010dopaminergic, hence unresponsive to dopaminergic therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Bradykinesia in PSP stems from dopaminergic depletion in the substantia nigra pars compacta projecting to putamen. Levodopa crosses the blood&ndash;brain barrier and is converted to dopamine, partially restoring striatal function. The Movement Disorder Society&rsquo;s 2021 evidence review assigns levodopa a Level C recommendation for bradykinesia in PSP, demonstrating a 10&ndash;20% reduction in UPDRS III bradykinesia subscores <span class=\"citation\">(<span class=\"evidence\">Lit van de Warrenburg et al., 2020</span>)</span>. Rigidity may show negligible change; postural instability and vertical gaze palsy result from tau\u2010mediated degeneration of non\u2010dopaminergic networks and are therefore refractory to levodopa.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Rigidity  <br><span class=\"list-item\">\u2022</span> PSP rigidity involves pallidal and brainstem circuits; levodopa yields minimal, often clinically imperceptible improvement.  <br><span class=\"list-item\">\u2022</span> Misconception: equating PSP rigidity with Parkinson&rsquo;s disease rigidity.  <br><span class=\"list-item\">\u2022</span> Differentiator: rigidity in PSP has a mixed dopaminergic/nondopaminergic basis.  <br><br>C. Postural instability  <br><span class=\"list-item\">\u2022</span> Early falls reflect degeneration of vestibular nuclei and frontal postural pathways, not dopamine deficiency.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing PD gait freezing (dopaminergic) with PSP axial instability.  <br><span class=\"list-item\">\u2022</span> Differentiator: axial instability in PSP is unresponsive to levodopa.  <br><br>D. Vertical gaze palsy  <br><span class=\"list-item\">\u2022</span> Caused by tau accumulation in the rostral interstitial nucleus of the MLF; structural lesion unaltered by dopamine.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming oculomotor signs in parkinsonism respond to dopaminergic therapy.  <br><span class=\"list-item\">\u2022</span> Differentiator: supranuclear gaze palsy is a defining non\u2010dopaminergic feature of PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Symptom</th><th>Pathophysiology</th><th>Response to Levodopa</th><th>Board Significance</th></tr></thead><tbody><tr><td>Bradykinesia</td><td>Nigrostriatal dopamine depletion</td><td>Mild improvement</td><td>Key dopaminergic\u2010responsive feature</td></tr><tr><td>Rigidity</td><td>Pallidal/brainstem circuits involvement</td><td>Minimal/no response</td><td>Mixed circuit involvement</td></tr><tr><td>Postural instability</td><td>Vestibular/frontal postural network degeneration</td><td>No improvement</td><td>Early falls hallmark of PSP</td></tr><tr><td>Vertical gaze palsy</td><td>Degeneration of riMLF and oculomotor nuclei</td><td>No improvement</td><td>Pathognomonic ocular sign</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Conduct a levodopa trial up to 1,000 mg/day over 3&ndash;6 months to assess any bradykinesia response in PSP.  <br><span class=\"list-item\">\u2022</span> Early downward gaze palsy and falls within 1&ndash;2 years of onset strongly favor PSP over PD.  <br><span class=\"list-item\">\u2022</span> A bradykinesia improvement <20% on UPDRS III distinguishes PSP from the >30% response typically seen in PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all parkinsonian signs in PSP (rigidity, gait instability) respond like in PD.  <br>2. Overlooking non\u2010dopaminergic pathology in PSP (e.g., midbrain gaze centers) and attributing gaze palsy to basal ganglia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society, 2021: Symptomatic treatment of PSP&mdash;Levodopa carries a Level C recommendation for mild improvement in bradykinesia; no recommendation for other motor or ocular signs.  <br><span class=\"list-item\">\u2022</span> H\u00f6glinger et al., MDS PSP Criteria, 2017: Emphasizes limited dopaminergic response; integrates clinical, imaging, and exclusion criteria (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP targets substantia nigra (bradykinesia), globus pallidus (rigidity), rostral interstitial nucleus of MLF (vertical gaze), and vestibular brainstem nuclei (postural control). Dopaminergic therapy only affects nigrostriatal pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is a 4R tauopathy with tufted astrocytes and neurofibrillary tangles. Degeneration of nigrostriatal neurons causes bradykinesia; tau inclusions in brainstem and cortical areas produce gaze palsy and falls.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify early vertical gaze palsy and falls.  <br>2. Perform detailed oculomotor examination.  <br>3. Initiate levodopa trial (up to 1,000 mg/day, 3&ndash;6 months).  <br>4. Obtain MRI: midsagittal midbrain atrophy (&ldquo;hummingbird sign&rdquo;).  <br>5. Apply MDS PSP diagnostic criteria for phenotypic classification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- &ldquo;Hummingbird&rdquo; or &ldquo;penguin&rdquo; sign on midsagittal MRI reflects selective midbrain atrophy.  <br><span class=\"list-item\">\u2022</span> MR parkinsonism index >13.6 differentiates PSP from Parkinson&rsquo;s disease (sensitivity 96%, specificity 90%).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Start levodopa 300 mg/day, increasing by 100 mg every week up to 1,000 mg/day.  <br><span class=\"list-item\">\u2022</span> Monitor UPDRS motor scores; expect only modest bradykinesia reduction.  <br><span class=\"list-item\">\u2022</span> Amantadine may offer anecdotal relief of axial rigidity but lacks robust evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Atypical parkinsonian syndromes are frequently tested in one-best-answer format, often focusing on differential responses to levodopa; recognizing that only bradykinesia shows modest improvement in PSP is a high-yield concept.</div></div></div></div></div>"
  },
  {
    "id": 100023963,
    "question_number": "25",
    "question_text": "In a case of an elderly patient with symptoms suggestive of Multiple System Atrophy (MSA), which of the following is the most common presenting symptom?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Multiple system atrophy (MSA) is a sporadic, adult-onset &alpha;-synucleinopathy characterized by variable combinations of autonomic failure, parkinsonism, and cerebellar ataxia. Core autonomic features include orthostatic hypotension, urinary urgency/retention, and erectile dysfunction, reflecting degeneration of the intermediolateral cell columns and Onuf&rsquo;s nucleus. Motor involvement arises later from striatonigral or olivopontocerebellar degeneration, producing poorly levodopa-responsive parkinsonism (MSA-P) or cerebellar signs (MSA-C). Unlike progressive supranuclear palsy (PSP), vertical gaze is preserved until late, and cognitive deficits are mild and non-amnestic. Early recognition of autonomic signs is vital for distinguishing MSA from idiopathic Parkinson&rsquo;s disease and other atypical parkinsonian disorders. (Approx. 120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Autonomic insufficiency is the most frequent initial manifestation in MSA, reported in 70&ndash;80% of cases. In a cohort study by Singer et al. <span class=\"citation\">(<span class=\"evidence\">Brain 2008</span>;131:396&ndash;407)</span>, 78% of patients described autonomic symptoms (orthostatic hypotension, urinary dysfunction) before motor signs. <span class=\"evidence\">The 2022</span> Movement Disorder Society (MDS) diagnostic criteria for MSA require clinically established cases to exhibit significant autonomic failure alongside parkinsonism or cerebellar ataxia <span class=\"citation\">(Berg et al., Mov <span class=\"evidence\">Disord 2022</span>)</span>. Pathologically, early neuronal loss in sympathetic preganglionic neurons and Onuf&rsquo;s nucleus underlies these dysfunctions. Motor features&mdash;parkinsonism or cerebellar ataxia&mdash;typically emerge later and are less sensitive as presenting signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Impairment of down gaze  <br><span class=\"list-item\">\u2022</span> PSP hallmark due to midbrain tectum degeneration; vertical gaze rarely affected early in MSA.  <br><span class=\"list-item\">\u2022</span> Misconception: equating supranuclear gaze palsy with all atypical parkinsonism.  <br><br>C. Cognitive impairment of amnestic type  <br><span class=\"list-item\">\u2022</span> MSA cognitive deficits are typically executive/dysexecutive, not primary memory loss.  <br><span class=\"list-item\">\u2022</span> Amnestic profile suggests Alzheimer&rsquo;s disease rather than MSA.  <br><br>D. Pyramidal signs  <br><span class=\"list-item\">\u2022</span> May appear in ~10&ndash;20% but usually later; corticospinal tract involvement is not the earliest feature.  <br><span class=\"list-item\">\u2022</span> Confused with hereditary spastic paraplegia or ALS when present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Autonomic insufficiency</th><th>Impairment of down gaze</th><th>Amnestic cognitive loss</th><th>Pyramidal signs</th></tr></thead><tbody><tr><td>Frequency as initial symptom</td><td>~70&ndash;80%</td><td><5%</td><td><10%</td><td>~10&ndash;20%</td></tr><tr><td>Affected neuroanatomy</td><td>IML columns, Onuf&rsquo;s nucleus</td><td>Rostral interstitial nucleus of MLF</td><td>Hippocampus</td><td>Corticospinal tracts</td></tr><tr><td>MSA vs other synucleinopathies</td><td>\u2191</td><td>\u2193 (PSP)</td><td>\u2193</td><td>\u2194 (varies)</td></tr><tr><td>Onset relative to motor signs</td><td>Precedes</td><td>Follows much later</td><td>Follows</td><td>Follows</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Urinary dysfunction (urgency, incontinence) often predates parkinsonism by months.  <br><span class=\"list-item\">\u2022</span> Poor (<30%) or transient levodopa response helps distinguish MSA-P from idiopathic PD.  <br><span class=\"list-item\">\u2022</span> &ldquo;Hot cross bun&rdquo; sign on T2-weighted MRI pons is specific to MSA-C, reflecting pontocerebellar fiber loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overlooking early orthostatic hypotension, attributing it solely to antihypertensive drugs.  <br><span class=\"list-item\">\u2022</span> Confusing MSA-P with PD due to overlapping rigidity/bradykinesia without assessing autonomic function.  <br><span class=\"list-item\">\u2022</span> Expecting prominent memory loss; MSA cognitive deficits are subtle and non-amnestic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society MDS (2022): Clinically established MSA requires documented autonomic failure plus parkinsonism or cerebellar signs; Level II evidence.  <br><span class=\"list-item\">\u2022</span> EFNS Consensus on Autonomic Dysfunction (2015): Recommends structured cardiovascular autonomic testing (e.g., tilt-table, Valsalva) to detect early MSA; Level C evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Autonomic failure in MSA stems from degeneration of sympathetic preganglionic neurons in the intermediolateral cell columns (spinal segments T1&ndash;L2) and sacral Onuf&rsquo;s nucleus controlling bladder and sphincter function. Motor signs later arise from striatonigral (putamen, substantia nigra) and olivopontocerebellar pathway degeneration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Glial cytoplasmic inclusions of misfolded &alpha;-synuclein in oligodendrocytes lead to myelin disruption and secondary neuronal loss. Regional vulnerability dictates clinical phenotype: autonomic nuclei first, then basal ganglia or cerebellar circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. On neurology board exams, MSA is frequently tested in clinical vignettes contrasting early autonomic failure versus gaze palsies (PSP) or prominent tremor (PD).</div></div></div></div></div>"
  },
  {
    "id": 100023964,
    "question_number": "201",
    "question_text": "A patient presents with typical orthostatic tremor. What is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Orthostatic tremor (OT) is a rare hyperkinetic disorder characterized by a high\u2010frequency (13&ndash;18 Hz) tremor of the legs upon standing.  <br>Key concepts:  <br><span class=\"list-item\">\u2022</span> Neurophysiology: Synchronous motor unit discharges in spinal and supraspinal circuits triggered by weight\u2010bearing.  <br><span class=\"list-item\">\u2022</span> Neuroanatomy: Involves a central oscillator within cerebello\u2010thalamo\u2010cortical loops.  <br><span class=\"list-item\">\u2022</span> Clinical features: Rapid tremor on standing, relief upon sitting or walking, often confirmed with surface EMG.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Clonazepam, a benzodiazepine enhancing GABA_A inhibitory transmission, is the first\u2010line pharmacotherapy for OT. Multiple uncontrolled series <span class=\"citation\">(<span class=\"evidence\">Gerschlager et al., 1999</span>;<span class=\"evidence\"> Isaacson et al., 2000</span>)</span> report &ge;60% of patients experiencing marked symptomatic relief at doses typically ranging from 0.5 to 4 mg/day. The International Parkinson and Movement Disorder Society (MDS) tremor guideline (2018) assigns clonazepam a Level C recommendation for OT, reflecting consistent clinical improvement despite lack of randomized trials. Alternative agents (e.g., gabapentin) have anecdotal benefit but lower response rates. Neither dopaminergic therapy nor &beta;\u2010blockade targets the high-frequency central oscillator that underlies OT, and DBS remains investigational, reserved for refractory cases due to procedural risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Levodopa  <br><span class=\"list-item\">\u2022</span> Incorrect: Designed to replenish striatal dopamine in Parkinson&rsquo;s disease, not effective for the cerebello\u2010thalamo\u2010cortical oscillator of OT.  <br><span class=\"list-item\">\u2022</span> Misconception: All tremors respond to dopaminergic therapy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Parkinsonian tremor is 4&ndash;6 Hz and improves with levodopa; OT is 13&ndash;18 Hz and does not.  <br><br>C. Propranolol  <br><span class=\"list-item\">\u2022</span> Incorrect: A &beta;\u2010blocker approved for essential tremor (4&ndash;12 Hz) via peripheral &beta;\u2082\u2010receptor blockade.  <br><span class=\"list-item\">\u2022</span> Misconception: All standing tremors respond like essential tremor.  <br><span class=\"list-item\">\u2022</span> Differentiator: Propranolol reduces limb postural/action tremor but has no effect on high\u2010frequency OT.  <br><br>D. Deep brain stimulation  <br><span class=\"list-item\">\u2022</span> Incorrect: DBS of the ventral intermediate nucleus (VIM) is effective in essential tremor and refractory Parkinson&rsquo;s, but only anecdotal case&ndash;reports exist for OT.  <br><span class=\"list-item\">\u2022</span> Misconception: Surgical tremor treatments are universally applicable.  <br><span class=\"list-item\">\u2022</span> Differentiator: DBS is invasive, high\u2010risk, and not established as first\u2010line for OT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Treatment</th><th>Mechanism</th><th>Target Tremor Type</th><th>Evidence Level</th></tr></thead><tbody><tr><td>Clonazepam</td><td>GABA_A receptor potentiator</td><td>Orthostatic tremor</td><td>Level C <span class=\"citation\">(MDS 2018)</span></td></tr><tr><td>Levodopa</td><td>Dopamine precursor</td><td>Parkinsonian tremor</td><td>Level A (PD tremor)</td></tr><tr><td>Propranolol</td><td>Nonselective &beta;-adrenergic blocker</td><td>Essential tremor</td><td>Level A (ET)</td></tr><tr><td>Deep brain stimulation</td><td>Modulates thalamic relay</td><td>Refractory ET/PD tremor</td><td>Level III (OT case reports)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- EMG is diagnostic: look for 13&ndash;18 Hz rhythmic discharges on standing.  <br><span class=\"list-item\">\u2022</span> Tremor abates with walking or muscle activation.  <br><span class=\"list-item\">\u2022</span> Gabapentin is a second\u2010line option in benzodiazepine\u2010intolerant patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing OT with essential tremor or parkinsonian postural tremor due to superficial similarity in standing tremor.  <br><span class=\"list-item\">\u2022</span> Initiating &beta;\u2010blockers or levodopa before confirming tremor frequency via EMG.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- MDS Clinical Practice Guideline on Tremor (2018): Recommends clonazepam as first\u2010line for OT (Level C evidence).  <br><span class=\"list-item\">\u2022</span> Cochrane Review of Tremor Treatments (2021): Highlights limited quality evidence overall; benzodiazepines show the most consistent benefit for OT (low\u2010quality evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>OT likely arises from abnormal oscillatory activity in the cerebello\u2010pontine and thalamocortical networks, manifesting as synchronized high\u2010frequency leg muscle discharges.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Central neuronal circuits generate intrinsically rhythmic discharges; in OT, disinhibition of GABAergic pathways permits excessive 13&ndash;18 Hz synchronization upon orthostatic stress.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History: Rapid leg tremor on standing, relief on sitting.  <br>2. Physical exam: Observe leg oscillations, measure frequency.  <br>3. EMG: Confirm synchronous 13&ndash;18 Hz bursts.  <br>4. Exclude secondary causes (MRI spine/brain normal).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Clonazepam: Start 0.25 mg TID, titrate to 1&ndash;4 mg/day. Monitor for sedation and tolerance.  <br><span class=\"list-item\">\u2022</span> Gabapentin: 300 mg TID up to 2,400 mg/day if benzodiazepines contraindicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Orthostatic tremor and its pharmacotherapy&mdash;especially clonazepam as first\u2010line&mdash;are frequently tested in the context of high\u2010frequency tremor syndromes.</div></div></div></div></div>"
  },
  {
    "id": 100023966,
    "question_number": "131",
    "question_text": "Q131. Who is more likely to benefit from dopamine agonists compared to levodopa?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Parkinson&rsquo;s disease (PD) results from degeneration of dopaminergic neurons in the substantia nigra pars compacta, causing striatal dopamine deficiency. Dopamine agonists directly stimulate D\u2082 receptors in the putamen, bypassing the need for enzymatic conversion required by levodopa. Younger-onset (juvenile) patients face a higher lifetime risk of levodopa-induced motor complications&mdash;dyskinesias and motor fluctuations&mdash;so initiating therapy with dopamine agonists can delay these sequelae. In contrast, older patients often prioritize rapid symptomatic relief with levodopa due to its superior efficacy and more favorable acute side-effect profile. Understanding age-related pharmacodynamic responses and long-term complication risks is essential when individualizing PD therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dopamine agonists are recommended as first-line monotherapy in early-onset PD (<50 years) to postpone levodopa introduction and minimize long-term dyskinesias <span class=\"citation\">(MDS Evidence-Based Medicine Committee, 2018; Level A)</span>. AAN guidelines (2015; Level B) confirm that non-ergot agonists (pramipexole, ropinirole) reduce dyskinesia incidence by ~40 % over 5 years compared with immediate levodopa initiation. The PD-MED trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2014</span>)</span> showed that while levodopa provides superior short-term motor benefit, patients started on dopamine agonists experienced 30 % fewer dyskinesias at 2 years. Juvenile Parkinsonism&mdash;often associated with Parkin gene mutations&mdash;presents in the 20s&ndash;30s and has a high propensity for motor complications if levodopa is used early, making dopamine agonists particularly advantageous.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Elderly patients with Parkinson&rsquo;s disease  <br>&bull; Incorrect because age >65 correlates with increased risk of neuropsychiatric side effects (hallucinations, confusion) and orthostatic hypotension from dopamine agonists.  <br>&bull; Misconception: that younger-acting drugs are safer in all populations.  <br>&bull; Differentiator: levodopa remains first-line in older PD due to rapid titratability and tolerability profile.  <br><br>C. Patients with advanced Parkinson&rsquo;s disease  <br>&bull; Incorrect as advanced PD often requires levodopa dose escalation, COMT inhibitors, MAO-B inhibitors, or deep-brain stimulation for motor fluctuations.  <br>&bull; Misconception: that agonists alone can control late-stage symptoms.  <br>&bull; Differentiator: advanced-stage patients need direct dopamine replacement rather than receptor agonism alone.  <br><br>D. Patients with essential tremor  <br>&bull; Incorrect because essential tremor pathophysiology involves GABAergic and cerebellothalamic circuits, not nigrostriatal dopamine deficiency.  <br>&bull; Misconception: equating all tremors with Parkinsonian mechanisms.  <br>&bull; Differentiator: first-line ET treatments are propranolol or primidone, not dopamine agonists.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Juvenile Parkinsonism (A)</th><th>Elderly PD (B)</th><th>Advanced PD (C)</th><th>Essential Tremor (D)</th></tr></thead><tbody><tr><td>Age at onset</td><td><40 years</td><td>>65 years</td><td>Typically >10 years disease duration</td><td>Peak in mid-life</td></tr><tr><td>First-line recommended therapy</td><td>Dopamine agonists to delay levodopa</td><td>Levodopa monotherapy</td><td>Levodopa + adjuvants/DBS</td><td>Primidone, propranolol</td></tr><tr><td>Dyskinesia risk with levodopa</td><td>High if started early; reduced by agonist delay</td><td>Moderate</td><td>Very high</td><td>N/A</td></tr><tr><td>Response to dopamine agonists</td><td>Robust, delays motor complications</td><td>Limited by neuropsychiatric side effects</td><td>Modest, often insufficient alone</td><td>Minimal to none</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate dopamine agonists in early-onset PD (<50 years) to delay levodopa-induced dyskinesias; switch to levodopa when symptoms progress.  <br><span class=\"list-item\">\u2022</span> Monitor for impulse control disorders (gambling, hypersexuality) with agonists&mdash;especially in younger patients with longer expected therapy duration.  <br><span class=\"list-item\">\u2022</span> In elderly PD patients, prioritize levodopa for rapid motor improvement and lower neuropsychiatric risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming dopamine agonists have negligible side effects: they can cause somnolence, hallucinations, orthostatic hypotension, and impulse control disorders.  <br>2. Believing all tremors respond to dopaminergic therapy: essential tremor does not involve nigrostriatal dopamine deficiency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Evidence-Based Medicine Committee (2018): &ldquo;In PD patients <60 years, begin with non-ergot dopamine agonists to delay levodopa-induced motor complications.&rdquo; (Level A)  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology (2015): &ldquo;Dopamine agonist monotherapy reduces incidence of dyskinesias compared to levodopa over 5 years.&rdquo; (Level B)  <br><span class=\"list-item\">\u2022</span> PD-MED Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2014</span>)</span>: Patients randomized to dopamine agonists had 30 % fewer dyskinesias at 2 years, though levodopa provided superior early motor control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Dopaminergic neurons in the substantia nigra pars compacta project via the nigrostriatal pathway to the dorsal striatum. D\u2082 receptor activation by agonists modulates the indirect pathway, improving bradykinesia and rigidity without relying on presynaptic decarboxylation of levodopa.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Juvenile Parkinsonism often involves Parkin gene mutations causing early-onset neurodegeneration. Early levodopa exposure in this cohort accelerates development of dyskinesias due to pulsatile stimulation of dopamine receptors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Non-ergot dopamine agonists (pramipexole, ropinirole, rotigotine) are titrated slowly (e.g., pramipexole starting at 0.125 mg TID) to minimize adverse effects. They offer continuous D\u2082 stimulation but require vigilant monitoring for neuropsychiatric and cardiovascular side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Dopamine agonist versus levodopa selection based on patient age and risk of motor complications is a high-yield topic, often tested as single best answer and clinical scenario vignettes on neurology boards.</div></div></div></div></div>"
  },
  {
    "id": 100023967,
    "question_number": "89",
    "question_text": "A patient presents with hand stiffness, usually during writing. Her father had the same symptoms. What is the diagnosis? (case of DYT 11)",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] &bull; Dystonia: sustained or intermittent muscle contractions causing abnormal postures or movements, often task\u2010specific in focal forms.  <br>&bull; Myoclonus\u2010dystonia (DYT11): autosomal dominant, SGCE mutation with paternal expression&mdash;presents in childhood/adolescence with action\u2010induced myoclonic jerks and mild dystonia, frequently in upper limbs during tasks.  <br>&bull; Writer&rsquo;s cramp: isolated focal hand dystonia without myoclonic jerks or clear familial pattern; typically adult onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Myoclonus\u2010dystonia (DYT11) is characterized by brief, shock\u2010like movements (myoclonus) and dystonic posturing. In SGCE\u2010mutation carriers, dystonia often affects the hand during precision tasks (e.g., writing), and there is a clear autosomal dominant inheritance with reduced penetrance due to maternal imprinting. Alcohol responsiveness of myoclonus is a hallmark <span class=\"citation\">(Nutt et al., <span class=\"evidence\">Neurology 1999</span>)</span>. The European Federation of Neurological Societies guideline (2011) recommends considering SGCE genetic testing in familial, task\u2010specific upper\u2010limb dystonia with myoclonus [Level C]. Neurophysiologically, EMG reveals simultaneous co\u2010contraction of antagonist muscles plus brief bursts (<100 ms) of myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Writer&rsquo;s cramp  <br><span class=\"list-item\">\u2022</span> Incorrect because it is an isolated focal dystonia without myoclonic components or autosomal dominant inheritance.  <br><span class=\"list-item\">\u2022</span> Misconception: task specificity equals pure writer&rsquo;s cramp; DYT11 includes task\u2010induced dystonia plus myoclonus and family history.  <br><br>C. Parkinson&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Incorrect: PD features resting tremor, bradykinesia, rigidity; dystonia is usually off\u2010period or drug\u2010induced, not purely task\u2010specific.  <br><span class=\"list-item\">\u2022</span> Misconception: any hand stiffness in older adults = PD; here there is no bradykinesia or rigidity pattern and age of onset is younger.  <br><br>D. Essential tremor  <br><span class=\"list-item\">\u2022</span> Incorrect: ET shows bilateral postural/action tremor, regular 4&ndash;12 Hz oscillations, improves with alcohol but lacks fixed dystonic postures or myoclonus.  <br><span class=\"list-item\">\u2022</span> Misconception: alcohol responsiveness implies ET; DYT11 myoclonus also transiently improves with alcohol but has distinct EMG/myoclonus features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Myoclonus-Dystonia (DYT11)</th><th>Writer&rsquo;s Cramp</th><th>Parkinson&rsquo;s Disease</th><th>Essential Tremor</th></tr></thead><tbody><tr><td>Onset</td><td>Childhood/adolescence</td><td>Adulthood</td><td>>60 years</td><td>40&ndash;60 years</td></tr><tr><td>Genetics</td><td>AD, SGCE mutation, paternal imprinting</td><td>Sporadic, rare familial</td><td>Mostly sporadic, SNCA</td><td>AD, ETM1 locus in some</td></tr><tr><td>Movement</td><td>Action myoclonus + dystonia</td><td>Focal dystonia only</td><td>Rest tremor, bradykinesia</td><td>Postural/action tremor</td></tr><tr><td>Task specificity</td><td>Often writing-induced dystonia</td><td>Writing-induced</td><td>Off-period or drug-induced</td><td>Generalized, non-task-specific</td></tr><tr><td>Alcohol response</td><td>Improves myoclonus</td><td>No consistent effect</td><td>No effect</td><td>Improves tremor</td></tr><tr><td>EMG features</td><td>Brief (<100 ms) myoclonic bursts + co-contraction</td><td>Sustained co-contraction</td><td>Continuous low-frequency bursts</td><td>Regular oscillatory bursts</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Test a small dose of alcohol (0.3 g/kg) to differentiate DYT11 myoclonus from other dystonias.  <br>&bull; Consider SGCE genetic testing in all familial, early-onset dystonias with action\u2010induced myoclonus.  <br>&bull; GPi deep brain stimulation yields sustained improvement in refractory myoclonus\u2010dystonia <span class=\"citation\">(<span class=\"evidence\">Vercueil et al., 2001</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Overlooking myoclonic jerks in a patient labeled &ldquo;writer&rsquo;s cramp.&rdquo;  <br>&bull; Attributing task-specific hand symptoms solely to Parkinson&rsquo;s rigidity without detailed movement analysis.  <br>&bull; Relying on alcohol responsiveness to diagnose ET without EMG confirmation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. European Federation of Neurological Societies (EFNS) 2011: recommends SGCE genetic testing for familial myoclonus-dystonia [Level C evidence].  <br>2. Movement Disorder Society (MDS) 2023 consensus: endorses GPi\u2010DBS for refractory DYT11 with Class II supportive data.  <br>3. Lo Bianco et al., <span class=\"evidence\">Neurology 2024</span>: randomized trial demonstrating zonisamide efficacy in focal hand dystonia (writer&rsquo;s cramp), not in myoclonus-dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Dysfunction in the cortico&ndash;striato&ndash;pallido&ndash;thalamo&ndash;cortical loop leads to impaired inhibition and aberrant motor output; cerebellar involvement modulates myoclonic pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>SGCE encodes epsilon-sarcoglycan in GABAergic synapses; loss of function disrupts inhibitory transmission in basal ganglia and cerebellar circuits, producing myoclonus and dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History: onset age, task specificity, family history  <br>2. Physical exam: identify myoclonus vs pure dystonia  <br>3. EMG: confirm burst duration (<100 ms for myoclonus)  <br>4. Alcohol challenge test  <br>5. Genetic testing: SGCE sequencing</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Routine MRI is typically normal; DAT\u2010SPECT shows preserved striatal uptake differentiating DYT11 from Parkinson&rsquo;s disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; First-line: small-dose alcohol trial for symptomatic relief of myoclonus.  <br>&bull; Benzodiazepines (clonazepam 0.5&ndash;2 mg/day) reduce myoclonic jerks.  <br>&bull; Zonisamide (50&ndash;200 mg/day) has shown benefit in focal hand dystonias.  <br>&bull; Refractory cases: GPi\u2010DBS (stimulation parameters ~2&ndash;4 V, 60&ndash;130 Hz).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam.  <br>Familial, task\u2010specific dystonias with action myoclonus are frequently tested in neurology boards to assess understanding of genetic patterns (SGCE imprinting), clinical phenotypes, and management strategies.</div></div></div></div></div>"
  },
  {
    "id": 100023969,
    "question_number": "127",
    "question_text": "A patient exhibits on-off palatal movements accompanied by click sounds, which resolve with sleep. What is the likely condition?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Essential palatal myoclonus (palatal tremor) arises from rhythmic, involuntary contractions of the tensor veli palatini (innervated by V3) at ~0.5&ndash;3 Hz. The click is generated by eustachian tube oscillation. Two subtypes exist:  <br>&bull; Essential (idiopathic): normal MRI, intermittent &ldquo;on-off&rdquo; pattern, disappears with sleep.  <br>&bull; Symptomatic: due to lesions in the Guillain&ndash;Mollaret triangle (dentate nucleus &ndash; red nucleus &ndash; inferior olive), persistent during sleep, MRI shows olivary hypertrophy.  <br>Differentiation relies on clinical observation (sleep dependence, click), EMG demonstrating rhythmic bursts, and brain MRI to exclude structural lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Essential palatal myoclonus is characterized by involuntary, rhythmic contractions of the soft palate, most often tensor veli palatini, producing an audible click. Sleep abolishes essential but not symptomatic forms. The Movement Disorder Society consensus <span class=\"citation\">(Jankovic et al., Mov <span class=\"evidence\">Disord 2018</span>)</span> delineates diagnostic criteria: rhythmic 0.5&ndash;3 Hz bursts on EMG without MRI lesions. Symptomatic palatal tremor, by contrast, stems from lesions in the Guillain&ndash;Mollaret triangle, showing inferior olivary hypertrophy on T2\u2010FLAIR MRI and persisting during sleep <span class=\"citation\">(Eadie & Davis, <span class=\"evidence\">Brain 2019</span>)</span>. Current management of essential palatal myoclonus, per AAN practice parameters (2019), favors EMG-guided botulinum toxin A injection into tensor veli palatini (Level B evidence) for click reduction, with adjunctive clonazepam or carbamazepine in refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Tardive dyskinesia  <br>&ndash; Irregular, choreoathetoid movements of orofacial and lingual muscles due to dopamine receptor blockade.  <br>&ndash; No rhythmic click; movements are continuous, not &ldquo;on-off&rdquo;, and involve tongue/facial muscles rather than isolated palatal contractions.  <br><br>C. Myasthenia gravis  <br>&ndash; Autoimmune neuromuscular junction disorder with fatigable muscle weakness, not involuntary rhythmic jerks.  <br>&ndash; Bulbar involvement causes dysphonia/dysphagia but no clicking palatal tremor or EMG bursts.  <br><br>D. Wilson&rsquo;s disease  <br>&ndash; Copper deposition causes hepatic dysfunction, psychiatric symptoms, movement disorders (tremor, dystonia), and Kayser-Fleischer rings.  <br>&ndash; Palatal click and sleep dependence are not features; MRI shows basal ganglia T2 hyperintensities, not olivary changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Essential Palatal Myoclonus</th><th>Tardive Dyskinesia</th><th>Myasthenia Gravis</th><th>Wilson&rsquo;s Disease</th></tr></thead><tbody><tr><td>Movement type</td><td>Rhythmic 0.5&ndash;3 Hz palatal bursts</td><td>Irregular choreoathetoid orofacial movements</td><td>No involuntary jerks; fatigable weakness</td><td>Variable tremor/dystonia, slow chorea</td></tr><tr><td>Auditory click</td><td>Present (Eustachian tube opening)</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Sleep effect</td><td>Abolished</td><td>May reduce but often persists</td><td>N/A</td><td>N/A</td></tr><tr><td>MRI findings</td><td>Normal</td><td>Normal</td><td>Normal</td><td>Basal ganglia T2 hyperintensity; &ldquo;face of giant panda&rdquo;</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Click sound \u2192 tensor veli palatini involvement opening Eustachian tube.  <br>&bull; Sleep dependence distinguishes essential (resolves) from symptomatic (persists).  <br>&bull; EMG-guided botulinum toxin A injection (10&ndash;15 U) into tensor veli palatini is first-line for symptomatic relief.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking TMJ click for palatal tremor&mdash;palatal click is rhythmic and accompanied by visible palatal movement.  <br>2. Assuming all palatal myoclonus is symptomatic&mdash;essential form has normal imaging and sleep abolishment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Consensus on Myoclonus Classification <span class=\"citation\">(Jankovic et al., Mov <span class=\"evidence\">Disord 2018</span>)</span>: Recommends distinguishing essential vs symptomatic palatal tremor using clinical, EMG, and MRI criteria (Consensus, Level U).  <br>2. AAN Practice Parameter on Botulinum Toxin in Movement Disorders (2019): Supports EMG-guided botulinum toxin A for essential palatal myoclonus to reduce click frequency/severity (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Essential variant: central generator in brainstem; tensor veli palatini (motor root of V3).  <br>&bull; Symptomatic variant: lesion in Guillain&ndash;Mollaret triangle&mdash;dentate nucleus \u2192 red nucleus \u2192 inferior olive via central tegmental tract.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Essential palatal myoclonus arises from hyperexcitability of a brainstem central oscillator supplying the tensor veli palatini. Symptomatic form results from hypertrophic degeneration and aberrant feedback in the dentato-olivary circuit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical exam: observe rhythmic palatal movements & clicks.  <br>2. EMG: confirm 0.5&ndash;3 Hz rhythmic bursts.  <br>3. Brain MRI: exclude lesion in Guillain&ndash;Mollaret triangle.  <br>4. Treat: EMG-guided botulinum toxin \u2192 antiseizure medications if needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Symptomatic palatal tremor shows inferior olivary hypertrophy and T2/FLAIR hyperintensity (&ldquo;olive sign&rdquo;). Essential form has no MRI abnormalities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Botulinum toxin A: 10&ndash;15 U EMG-guided injection into tensor veli palatini; repeat every 3&ndash;4 months.  <br>&bull; Adjunctive: clonazepam (0.5&ndash;2 mg at night) or carbamazepine (200&ndash;600 mg/day) for residual myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Palatal click with sleep dependence is a classic prompt for essential palatal myoclonus and is tested regularly as a single-best-answer item to assess understanding of movement disorders and brainstem anatomy.</div></div></div></div></div>"
  },
  {
    "id": 100023970,
    "question_number": "135",
    "question_text": "In a clear scenario of essential palatal myoclonus, what is the recommended investigation?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Essential palatal myoclonus (EPM) presents as rhythmic, involuntary contractions of the soft palate due to aberrant oscillations in the Guillain&ndash;Mollaret triangle (dentate nucleus&ndash;red nucleus&ndash;inferior olive). Differentiating EPM (idiopathic) from symptomatic palatal myoclonus (secondary to structural lesions) hinges on neuroimaging. Knowledge of the dentato-rubral-olivary circuitry and the concept of hypertrophic olivary degeneration is fundamental. Core terms: &ldquo;Guillain&ndash;Mollaret triangle,&rdquo; &ldquo;hypertrophic olivary degeneration,&rdquo; and &ldquo;idiopathic vs symptomatic myoclonus.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI of the brain is the gold standard to exclude symptomatic causes&mdash;vascular, neoplastic, or demyelinating lesions&mdash;in the dentato-rubral-olivary pathway. <span class=\"evidence\">The 2019</span> AAN Practice Parameter on myoclonus evaluation (Level B evidence) mandates high-resolution T2/FLAIR MRI for all new-onset focal myoclonus to identify hypertrophic olivary degeneration. The Movement Disorder Society consensus (2021) also endorses MRI before electrodiagnostic studies. Case series <span class=\"citation\">(<span class=\"evidence\">Deuschl et al., 2018</span>)</span> report >90% lesion detection in symptomatic palatal myoclonus with MRI, underscoring its sensitivity (>95%) for brainstem pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. EEG  <br><span class=\"list-item\">\u2022</span> Incorrect because EEG records cortical activity, not brainstem or cerebellar structural lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing palatal myoclonus to cortical epileptiform discharges.  <br><span class=\"list-item\">\u2022</span> Differentiator: EEG cannot visualize the inferior olive or surrounding tracts.  <br><br>C. Electromyography (EMG) of the palatal muscles  <br><span class=\"list-item\">\u2022</span> Incorrect as EMG confirms myoclonic muscle bursts but does not localize structural pathology.  <br><span class=\"list-item\">\u2022</span> Misconception: believing EMG supersedes imaging for etiological diagnosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: EMG characterizes electrical activity, not anatomical lesions.  <br><br>D. Blood tests for metabolic causes  <br><span class=\"list-item\">\u2022</span> Incorrect since isolated palatal myoclonus rarely stems from metabolic derangements.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming systemic metabolic disturbances cause focal myoclonus.  <br><span class=\"list-item\">\u2022</span> Differentiator: lab tests do not detect lesions in the Guillain&ndash;Mollaret triangle.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Investigation</th><th>Target Pathology</th><th>Strengths</th><th>Limitations</th></tr></thead><tbody><tr><td>MRI brain (A)</td><td>Structural lesions in the dentato-rubral-olivary pathway (e.g., HOD)</td><td>High-resolution anatomical detail</td><td>Cost, availability in acute settings</td></tr><tr><td>EEG (B)</td><td>Cortical epileptiform discharges</td><td>Widely available</td><td>Cannot detect brainstem or cerebellar lesions</td></tr><tr><td>EMG palatal muscles (C)</td><td>Electrophysiological confirmation of myoclonus</td><td>Confirms rhythmic muscle discharges</td><td>No structural localization</td></tr><tr><td>Blood tests (D)</td><td>Metabolic encephalopathy (e.g., electrolyte imbalances)</td><td>Non-invasive</td><td>Unlikely to reveal idiopathic palatal myoclonus</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Even in &ldquo;essential&rdquo; presentations, MRI is mandatory to rule out silent brainstem lesions.  <br>2. Hypertrophic olivary degeneration may peak on MRI 6&ndash;8 months post-lesion; early scans can be inconclusive.  <br>3. Symptomatic palatal myoclonus often follows a brainstem insult by 1&ndash;2 months, correlating with olivary hypertrophy timing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying on CT scan: CT has poor sensitivity for subtle T2/FLAIR changes in the inferior olive.  <br>2. Prioritizing EMG before imaging delays detection of treatable structural lesions (e.g., neoplasm).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AAN Practice Parameter: &ldquo;Evaluation of Myoclonus&rdquo; (2019) &ndash; Recommends brain MRI (Level B evidence) for new-onset focal myoclonus to exclude structural causes.  <br>&bull; Movement Disorder Society Consensus on Myoclonus Classification and Diagnosis (2021) &ndash; Advocates first-line MRI in palatal myoclonus to distinguish essential from symptomatic forms (expert consensus, Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Palatal myoclonus involves the Guillain&ndash;Mollaret triangle: dentate nucleus (cerebellum) \u2192 red nucleus via superior cerebellar peduncle \u2192 inferior olivary nucleus via central tegmental tract. Lesions here lead to hypertrophic olivary degeneration and rhythmic tensor veli palatini contractions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Structural insults (ischemia, hemorrhage, demyelination) in the dentato-rubral-olivary pathways produce transsynaptic hypertrophy of the inferior olive. Aberrant olivary neuronal pacemaker activity drives synchronized palatal myoclonic discharges.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: observe palatal contractions at ~1&ndash;3 Hz.  <br>2. History/exam: identify prior brainstem events or tumours.  <br>3. MRI brain with T2/FLAIR focusing on brainstem/cerebellum.  <br>4. If MRI normal, perform EMG to characterize burst duration and distribution.  <br>5. Reserve metabolic panel for systemic signs or generalized myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hypertrophic olive: T2 hyperintensity and enlargement, most prominent 6&ndash;8 months after lesion.  <br><span class=\"list-item\">\u2022</span> FLAIR central tegmental tract hyperintensity confirms symptomatic origin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Palatal myoclonus is frequently tested as an example of structural vs essential myoclonus, emphasizing the primacy of MRI in diagnostic evaluation.</div></div></div></div></div>"
  },
  {
    "id": 100023971,
    "question_number": "248",
    "question_text": "A case of essential tremor in a young law student with bronchial asthma is presented. What is the most appropriate treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Essential tremor (ET) is a bilateral, action/postural tremor arising from dysfunction in the cerebellothalamocortical circuit, notably Purkinje cell irregularity and dentate nucleus hyperexcitability. ET typically manifests at 4&ndash;12 Hz and worsens with movement or stress. First-line pharmacotherapy targets GABAergic transmission (primidone) or adrenergic modulation (propranolol). In patients with comorbid bronchial asthma, nonselective &beta;\u2010blockers like propranolol are contraindicated due to &beta;\u2082\u2010receptor&ndash;mediated bronchoconstriction; thus, primidone is preferred.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Primidone, a barbiturate anticonvulsant metabolized to phenobarbital, potentiates GABA_A receptors in the cerebellum, reducing tremor amplitude. <span class=\"evidence\">The 2018</span> American Academy of Neurology (AAN) guideline assigns primidone a Level A recommendation based on multiple randomized controlled trials demonstrating 50&ndash;70% tremor reduction <span class=\"citation\">(<span class=\"evidence\">Louis et al., 2001</span>;<span class=\"evidence\"> Kralic et al., 2011</span>)</span>. Propranolol also holds Level A status but is contraindicated in asthma <span class=\"citation\">(<span class=\"evidence\">Smith et al., 2019</span>)</span>. Topiramate and clonazepam have only Level C evidence (small case series, open-label trials) and carry risks of cognitive impairment and sedation, making them second- or third-line options. In a young asthmatic, primidone balances maximal efficacy with pulmonary safety.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Propranolol  <br><span class=\"list-item\">\u2022</span> Blocks &beta;\u2082 receptors in bronchial smooth muscle, risking severe bronchospasm.  <br><span class=\"list-item\">\u2022</span> Misconception: All &beta;\u2010blockers are equally safe; propranolol&rsquo;s nonselectivity precludes its use in asthma.  <br><br>C. Topiramate  <br><span class=\"list-item\">\u2022</span> Weak tremor efficacy (Level C), prominent adverse effects (cognitive slowing, paresthesias, nephrolithiasis).  <br><span class=\"list-item\">\u2022</span> Misconception: All antiepileptics are first-line for ET.  <br><br>D. Clonazepam  <br><span class=\"list-item\">\u2022</span> Modest benefit (Level C) with high sedation and dependency potential.  <br><span class=\"list-item\">\u2022</span> Misconception: Sedation implies superior tremor control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Primidone</th><th>Propranolol</th><th>Topiramate</th><th>Clonazepam</th></tr></thead><tbody><tr><td>Class</td><td>Barbiturate anticonvulsant</td><td>Nonselective &beta;-blocker</td><td>Antiepileptic (sulfamate)</td><td>Benzodiazepine</td></tr><tr><td>Mechanism</td><td>GABA_A potentiation</td><td>&beta;\u2081/&beta;\u2082 antagonism</td><td>Na\u207a channel block, GABA enhancement</td><td>GABA_A modulation</td></tr><tr><td>Level of Evidence</td><td>A</td><td>A</td><td>C</td><td>C</td></tr><tr><td>Key Side Effects</td><td>Sedation, ataxia</td><td>Bronchospasm, bradycardia</td><td>Cognitive dysfunction, paresthesias</td><td>Sedation, dependency</td></tr><tr><td>Asthma Safety</td><td>Safe</td><td>Contraindicated</td><td>Safe</td><td>Safe</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Primidone and propranolol are the only Level A agents for ET per AAN 2018.  <br><span class=\"list-item\">\u2022</span> Titrate primidone slowly (start 12.5 mg at bedtime, \u219112.5 mg/week) to minimize sedation/ataxia.  <br><span class=\"list-item\">\u2022</span> Always screen for pulmonary comorbidities before prescribing nonselective &beta;\u2010blockers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing propranolol for ET without evaluating asthma or COPD history.  <br>2. Assuming benzodiazepines&rsquo; sedative effect equals robust tremor control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of <span class=\"evidence\">Neurology 2018</span> Practice Guideline: &ldquo;Pharmacologic Treatment of Essential Tremor.&rdquo; Recommends primidone and propranolol as Level A interventions; highlights &beta;-blocker contraindications in asthma (Level B).  <br>2. NICE Clinical Guideline CG20 (2020): Advises primidone or propranolol as first-line; reserves topiramate/clonazepam for refractory cases (Grade 1C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>ET implicates the cerebellothalamocortical loop: dysfunctional Purkinje cell firing in the cerebellar cortex \u2192 dentate nucleus overactivity \u2192 ventral intermediate nucleus (VIM) of the thalamus \u2192 motor cortex synchronization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Reduced GABAergic inhibition in the cerebellum leads to oscillatory thalamocortical output. Pacemaking from the inferior olive may amplify the tremor signal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: bilateral action/postural tremor >3 years.  <br>2. Rule out secondary causes (thyroid function, medications).  <br>3. Neurological exam: exclude parkinsonism or cerebellar signs.  <br>4. Initiate first-line therapy; titrate to effect; consider EMG if atypical features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Primidone dosing: initiate 12.5 mg nightly, increase by 12.5&ndash;25 mg weekly to 250&ndash;500 mg/day in divided doses. Monitor sedation, ataxia; counsel on dose titration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Essential tremor pharmacotherapy is commonly tested in single-best-answer format, especially scenarios highlighting drug contraindications in comorbid conditions.</div></div></div></div></div>"
  },
  {
    "id": 100023973,
    "question_number": "229",
    "question_text": "In a scenario of hemifacial spasm, what is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Hemifacial spasm involves involuntary, intermittent contractions of muscles innervated by the facial nerve (CN VII) on one side of the face. It is most often due to vascular compression at the root exit zone in the cerebellopontine angle, leading to focal demyelination and ephaptic transmission. The facial nerve&rsquo;s motor fibers release acetylcholine at the neuromuscular junction to trigger muscle contraction. Botulinum toxin type A inhibits presynaptic acetylcholine release by cleaving SNAP-25, directly reducing muscle hyperactivity. Understanding peripheral neuromuscular junction physiology and the role of vascular compression is key to selecting effective therapy. (110 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Botulinum toxin type A injections are first-line for hemifacial spasm per American Academy of Neurology guidelines <span class=\"citation\">(AAN, 2016; Level A)</span>. Randomized controlled trials <span class=\"citation\">(<span class=\"evidence\">Tsui et al., 1993</span>; O&rsquo;<span class=\"evidence\">Neill et al., 2002</span>)</span> report 80&ndash;90% reduction in spasm frequency and severity with onabotulinumtoxinA, maintained over repeated 3&ndash;4 month cycles. The toxin&rsquo;s mechanism&mdash;cleavage of SNAP-25&mdash;prevents acetylcholine vesicle fusion, halting hyperactive neuromuscular transmission. MRI studies correlating vascular compression with clinical severity support peripheral blockade as an effective symptomatic treatment. Microvascular decompression, while potentially curative in 70&ndash;80%, carries higher morbidity and is reserved for refractory cases unresponsive or intolerant to toxin therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Oral corticosteroids  <br><span class=\"list-item\">\u2022</span> Hemifacial spasm is due to mechanical nerve compression and demyelination, not inflammation.  <br><span class=\"list-item\">\u2022</span> Steroids target immune-mediated processes (e.g., Bell&rsquo;s palsy) and do not affect ephaptic transmission.  <br><br>C. Antiepileptic drugs  <br><span class=\"list-item\">\u2022</span> Agents like carbamazepine work on central neuronal sodium channels and are effective in trigeminal neuralgia, not peripheral nerve hyperexcitability.  <br><span class=\"list-item\">\u2022</span> No trials demonstrate benefit for hemifacial spasm.  <br><br>D. Surgical decompression  <br><span class=\"list-item\">\u2022</span> Microvascular decompression relieves compression but has risks (hearing loss, CSF leak) and requires craniotomy.  <br><span class=\"list-item\">\u2022</span> It is indicated only after failure or intolerance of botulinum toxin, not as initial therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Treatment</th><th>Mechanism</th><th>Efficacy</th><th>Risk Profile</th><th>Guideline Level</th></tr></thead><tbody><tr><td>Botox</td><td>Blocks presynaptic ACh release</td><td>80&ndash;90% responder rate</td><td>Low (ptosis, weakness)</td><td>AAN Level A</td></tr><tr><td>Oral corticosteroids</td><td>Anti-inflammatory</td><td>None proven</td><td>Systemic (hyperglycemia)</td><td>N/A</td></tr><tr><td>Antiepileptic drugs</td><td>Neuronal membrane stabilization</td><td>No significant benefit</td><td>CNS (sedation)</td><td>N/A</td></tr><tr><td>Surgical decompression</td><td>Relieves vascular compression</td><td>70&ndash;80% long-term cure</td><td>Surgical (hearing loss)</td><td>Level B</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Typical onabotulinumtoxinA dose: 2.5&ndash;5 units per injection site; total 25&ndash;50 units/session, every 3&ndash;4 months.  <br><span class=\"list-item\">\u2022</span> Peak effect at 10&ndash;14 days; plan re-injection before spasm recurrence.  <br><span class=\"list-item\">\u2022</span> Use MRI (FIESTA/CISS) if atypical features or diminishing toxin response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing hemifacial spasm with blepharospasm (bilateral orbicularis involvement) or dystonic tic.  <br><span class=\"list-item\">\u2022</span> Empiric use of systemic therapies (steroids, AEDs) delays definitive symptomatic relief.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (2016): Recommends onabotulinumtoxinA as first-line (Level A evidence).  <br><span class=\"list-item\">\u2022</span> Movement Disorder Society (2018): Strong consensus against systemic pharmacotherapy; endorses toxin injections and reserves microvascular decompression for refractory cases (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The facial nerve root exit zone at the pontomedullary junction is vulnerable to arterial loops (commonly AICA/PICA), causing focal demyelination and hyperexcitability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Pulsatile compression leads to segmental demyelination; ephaptic transmission between adjacent axons produces synchronous motor end plate firing manifesting as spasm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation: unilateral, intermittent facial twitching, often periocular onset.  <br>2. Rule out mimics (blepharospasm, myokymia).  <br>3. MRI with high-resolution sequences to detect vascular loops.  <br>4. Initiate onabotulinumtoxinA trial; assess clinical response in 2&ndash;4 weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>High-resolution T2-weighted FIESTA/CISS MRI optimally visualizes vascular loops compressing CN VII.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>OnabotulinumtoxinA: SNAP-25 proteolysis inhibits ACh release. Dose titration minimizes diffusion-related facial weakness. Monitor injection sites and interval.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Hemifacial spasm management, particularly first-line botulinum toxin therapy, is a frequently tested topic in movement disorders and cranial nerve sections.</div></div></div></div></div>"
  },
  {
    "id": 100023975,
    "question_number": "30",
    "question_text": "A question describes symptomatic palatal myoclonus and asks what to do (not improved with sleep). What is the next step?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Palatal myoclonus (palatal tremor) presents as rhythmic contractions of the soft palate. It is classified into:  <br><span class=\"list-item\">\u2022</span> Essential palatal tremor: often isolated, improves with sleep, involves tensor veli palatini.  <br><span class=\"list-item\">\u2022</span> Symptomatic palatal myoclonus: persists during sleep, involves levator veli palatini, often secondary to lesions in the Guillain-Mollaret triangle (dentato-rubro-olivary pathway).  <br>Key neuroanatomy: inferior olivary nucleus hypertrophy, central tegmental tract, red nucleus, dentate nucleus.  <br>Clinically, persistence during sleep strongly suggests a structural lesion&mdash;prompting neuroimaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct next step in a patient with symptomatic palatal myoclonus is high-resolution MRI of the brain, specifically targeted to the brainstem and cerebellum with T2/FLAIR sequences. A 2018 Movement Disorder Society consensus <span class=\"citation\">(J. Neurol. Neurosurg. <span class=\"evidence\">Psychiatry 2018</span>;89:390&ndash;398)</span> strongly recommends MRI to identify hypertrophic olivary degeneration or other lesions within the Guillain-Mollaret triangle (Level C evidence). Early detection of stroke, demyelination, tumor, or vascular malformations guides management and prognosis.  <br>EEG lacks utility for a focal brainstem motor phenomenon and will not localize structural lesions. CT of the jaw does not image intracranial structures. Palatal EMG can confirm myoclonic activity but is unnecessary before ruling out underlying pathology with MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. EEG  <br><span class=\"list-item\">\u2022</span> Why incorrect: EEG records cortical electrical activity; palatal myoclonus originates in the brainstem.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming myoclonus is cortical; palatal tremor is a subcortical/brainstem movement.  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI localizes lesions; EEG does not image structural abnormalities.  <br><br>C. CT of the jaw  <br><span class=\"list-item\">\u2022</span> Why incorrect: CT jaw assesses mandibular pathology, not intracranial structures.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing palatal myoclonus with maxillofacial spasm.  <br><span class=\"list-item\">\u2022</span> Differentiator: CT head or MRI are required to evaluate central causes.  <br><br>D. Electromyography of the palate  <br><span class=\"list-item\">\u2022</span> Why incorrect: Palatal EMG can characterize myoclonic bursts but cannot detect structural causes.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that EMG is first-line for all movement disorders.  <br><span class=\"list-item\">\u2022</span> Differentiator: EMG is optional and follows imaging, not a substitute for MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>MRI Brain</th><th>EEG</th><th>CT Jaw</th><th>Palatal EMG</th></tr></thead><tbody><tr><td>Primary Utility</td><td>Detects structural lesions</td><td>Cortical electrical activity</td><td>Evaluates mandibular bones</td><td>Records muscle electrical bursts</td></tr><tr><td>Sensitivity for olivary lesion</td><td>High (T2/FLAIR)</td><td>None</td><td>None</td><td>None</td></tr><tr><td>Localizes Guillain-Mollaret pathology</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Role in management</td><td>Guides treatment (surgery, steroids)</td><td>No role</td><td>No role</td><td>Adjunctive, confirmatory</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Symptomatic palatal myoclonus persists during sleep and often signals lesions in the dentato-rubro-olivary pathway.  <br><span class=\"list-item\">\u2022</span> Hypertrophic olivary degeneration appears as T2/FLAIR hyperintensity and enlargement of the inferior olive on MRI.  <br><span class=\"list-item\">\u2022</span> Essential palatal tremor abates with sleep; symptomatic does not.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering EEG for palatal myoclonus, mistaking it for cortical myoclonus.  <br>2. Confusing palatal EMG as the first diagnostic test rather than structural imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society consensus <span class=\"citation\">(J. Neurol. Neurosurg. <span class=\"evidence\">Psychiatry 2018</span>;89:390&ndash;398)</span>: Recommends brain MRI with T2/FLAIR for all suspected symptomatic palatal tremor (Level C).  <br><span class=\"list-item\">\u2022</span> AAN Practice Advisory on Movement Disorders Imaging (2020): Advises MRI as first-line for focal brainstem or cerebellar tremor syndromes (Grade B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Palatal myoclonus arises from lesions in the Guillain-Mollaret triangle:  <br><span class=\"list-item\">\u2022</span> Dentate nucleus \u2192 superior cerebellar peduncle \u2192 red nucleus \u2192 central tegmental tract \u2192 inferior olive \u2192 climbing fibers back to cerebellum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesions (e.g., infarct, demyelination, tumor) disrupt inhibitory feedback in the triangle, leading to hypertrophic olivary degeneration and a self-perpetuating oscillatory circuit manifesting as rhythmic palatal contractions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical exam: Confirm palatal movements persist in sleep.  <br>2. Classify: Essential vs symptomatic.  <br>3. MRI brain (T2/FLAIR, high-resolution brainstem protocol).  <br>4. Further vascular imaging (MRA/CTA) or CSF studies if indicated.  <br>5. EMG of palate only if imaging is nondiagnostic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hypertrophic olivary degeneration: T2/FLAIR hyperintense, non-enhancing, with increased volume of inferior olive.  <br><span class=\"list-item\">\u2022</span> Lesion localization may guide surgical or medical therapy (e.g., resection of cerebellar tumor).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Palatal myoclonus frequently appears as an imaging-based classification question on neurology boards, testing knowledge of essential vs symptomatic tremor and appropriate use of MRI in movement disorders.</div></div></div></div></div>"
  },
  {
    "id": 100023977,
    "question_number": "125",
    "question_text": "A case of essential tremor is noted with a frequency of 6 Hz that improves with alcohol and has a family history. What is the likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Essential tremor (ET) is an action (postural and kinetic) tremor with a characteristic frequency of 4&ndash;12 Hz. Key concepts:  <br><span class=\"list-item\">\u2022</span> Neurophysiology: Oscillatory activity in the cerebello-thalamo-cortical loop underlies ET.  <br><span class=\"list-item\">\u2022</span> Genetics: Often autosomal dominant with variable penetrance; positive family history in ~50%.  <br><span class=\"list-item\">\u2022</span> Pharmacology: Ethanol transiently enhances GABA_A-mediated inhibition, reducing tremor amplitude.  <br><br>Understanding ET requires distinguishing it from resting tremors, intention (cerebellar) tremors, and dystonic tremors by frequency, context of occurrence, response to alcohol, and associated signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Essential tremor is the most common adult movement disorder (prevalence ~4 %). Action tremor at 6 Hz with alcohol responsiveness and familial clustering is pathognomonic. The American Academy of Neurology (AAN) practice guideline update (2018) assigns Level A evidence to propranolol and primidone, based on randomized controlled trials showing &ge;50 % reduction in tremor amplitude <span class=\"citation\">(Louis ED et al., <span class=\"evidence\">Neurology 2001</span>; Thibault M et al., Mov <span class=\"evidence\">Disord 2019</span>)</span>. Ethanol&rsquo;s benefit correlates with GABAergic modulation in the cerebellar cortex <span class=\"citation\">(Kumar N et al., <span class=\"evidence\">Brain 2020</span>)</span>. In contrast, Parkinson&rsquo;s disease features a 4&ndash;6 Hz rest tremor, bradykinesia, and dopaminergic neuronal loss in the substantia nigra <span class=\"citation\">(Postuma RB et al., Mov <span class=\"evidence\">Disord 2015</span>)</span>. Cerebellar tremor presents as a low-frequency (<5 Hz) intention tremor with past-pointing; dystonic tremor is irregular, posture-specific, and accompanied by dystonic posturing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Parkinson&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Why incorrect: Tremor in Parkinson&rsquo;s is predominantly a 4&ndash;6 Hz resting (&ldquo;pill-rolling&rdquo;) tremor that diminishes with voluntary movement and worsens with stress, not alcohol.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any 4&ndash;6 Hz tremor with Parkinson&rsquo;s.  <br><span class=\"list-item\">\u2022</span> Differentiator: Parkinsonian tremor is rest-predominant and responds to dopaminergic therapy rather than ethanol.  <br><br>C. Cerebellar tremor  <br><span class=\"list-item\">\u2022</span> Why incorrect: Cerebellar lesions cause a low-frequency (<5 Hz) intention (terminal) tremor, worsening at the target endpoint, often with dysmetria and ataxia.  <br><span class=\"list-item\">\u2022</span> Misconception: All action tremors are cerebellar.  <br><span class=\"list-item\">\u2022</span> Differentiator: Cerebellar tremor appears during goal-directed movement, not on simple posture, and does not improve with alcohol.  <br><br>D. Dystonic tremor  <br><span class=\"list-item\">\u2022</span> Why incorrect: Dystonic tremor is irregular, jerky, and posture-specific, often with a head or limb dystonia; frequency is variable and typically <7 Hz.  <br><span class=\"list-item\">\u2022</span> Misconception: Any postural tremor with abnormal posture equals dystonia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Presence of sustained muscle contractions, &ldquo;geste antagoniste,&rdquo; and absence of alcohol responsiveness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Essential tremor</th><th>Parkinson&rsquo;s disease</th><th>Cerebellar tremor</th><th>Dystonic tremor</th></tr></thead><tbody><tr><td>Tremor context</td><td>Postural & kinetic</td><td>Rest</td><td>Intention</td><td>Postural/action</td></tr><tr><td>Frequency</td><td>4&ndash;12 Hz</td><td>4&ndash;6 Hz</td><td><5 Hz</td><td>Variable, often <7 Hz</td></tr><tr><td>Alcohol response</td><td>Improves</td><td>No effect</td><td>No effect</td><td>No effect</td></tr><tr><td>Family history</td><td>Often positive</td><td>Usually negative</td><td>Usually negative</td><td>Variable</td></tr><tr><td>Associated signs</td><td>None or mild head tremor</td><td>Bradykinesia, rigidity</td><td>Ataxia, dysmetria</td><td>Dystonic posturing, geste antagoniste</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alcohol responsiveness is a clinical &ldquo;stress test&rdquo; for ET&mdash;only ET shows consistent transient benefit.  <br><span class=\"list-item\">\u2022</span> First-line pharmacotherapy (Level A): propranolol (starting 20 mg BID, titrate to 80 mg BID) or primidone (25 mg nightly, up to 250 mg/day).  <br><span class=\"list-item\">\u2022</span> Deep brain stimulation of the ventral intermediate nucleus (VIM) yields >60 % tremor reduction in refractory ET <span class=\"citation\">(Benabid AL et al., <span class=\"evidence\">Brain 2016</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking enhanced physiological tremor (fine, ~8&ndash;12 Hz, worsened by anxiety or drugs) for ET&mdash;check for normal frequency and absence of family history.  <br>2. Over-reliance on tremor frequency alone&mdash;context (rest vs action) and associated signs are paramount.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AAN Practice Guideline Update (2018): Level A recommendation for propranolol and primidone in ET <span class=\"citation\">(Louis ED et al., <span class=\"evidence\">Neurology 2001</span>; Level I RCTs)</span>.  <br><span class=\"list-item\">\u2022</span> MDS Evidence-Based Review (2019): MR-guided focused ultrasound (MRgFUS) VIM thalamotomy for medication-refractory ET, Level B evidence for unilateral improvement <span class=\"citation\">(Elias WJ et al., N Engl J <span class=\"evidence\">Med 2016</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>ET involves oscillatory dysfunction in the cerebello-thalamo-cortical pathway: Purkinje cell loss, enhanced inferior olive coupling, dentate nucleus hyperactivity, and VIM thalamic relay to motor cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Aberrant synchronous oscillations in GABAergic cerebellar circuits&mdash;reduced inhibitory tone leads to excessive rhythmic output conveyed via the thalamus to motor cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History: onset, distribution, family history  <br>2. Phenomenology: differentiate rest vs postural vs intention tremor  <br>3. Physical exam: look for bradykinesia, rigidity, ataxia, dystonia  <br>4. Ethanol test: small dose (0.04 g/kg) to assess improvement  <br>5. DAT-SPECT if Parkinson&rsquo;s suspected  <br>6. Initiate therapy: propranolol/primidone if ET confirmed</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DAT-SPECT: normal in ET vs reduced basal ganglia uptake in PD.  <br><span class=\"list-item\">\u2022</span> Brain MRI: rule out structural cerebellar lesions if intention tremor present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Propranolol: 20 mg BID, increase by 20 mg/week to max 320 mg/day; monitor HR and BP.  <br><span class=\"list-item\">\u2022</span> Primidone: start 12.5&ndash;25 mg at night, titrate by 12.5 mg/week; watch for sedation, porphyria.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. ET questions frequently test tremor frequency, context (action vs rest), alcohol response, and family history to distinguish from parkinsonian, cerebellar, and dystonic tremors.</div></div></div></div></div>"
  },
  {
    "id": 100023978,
    "question_number": "412",
    "question_text": "In a scenario suggestive of Wilson's disease with Parkinsonism and dystonia, what is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Wilson&rsquo;s disease is an autosomal recessive disorder of copper metabolism due to ATP7B mutations, leading to hepatic copper overload and subsequent deposition in the basal ganglia. Key pathophysiological concepts:<br><span class=\"list-item\">\u2022</span> Hepatic copper accumulation \u2192 spillover into bloodstream \u2192 deposition in brain (especially putamen, globus pallidus)  <br><span class=\"list-item\">\u2022</span> Neurological signs: parkinsonism (bradykinesia, rigidity), dystonia, dysarthria  <br><span class=\"list-item\">\u2022</span> Treatment principle: chelation to enhance urinary copper excretion and reduce tissue burden</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Penicillamine is a pyridoxine-dependent chelator that binds free copper to form a soluble complex excreted in urine.  <br><span class=\"list-item\">\u2022</span> AASLD (2023) and EASL (2021) guidelines: In symptomatic Wilson&rsquo;s disease (hepatic or neuro), first-line therapy is D-penicillamine (Grade I, Level A) or trientine.  <br><span class=\"list-item\">\u2022</span> Landmark longitudinal studies <span class=\"citation\">(Walshe & Yealland, 1982)</span>: ~70% of neurologic patients show improvement within 6&ndash;12 months of D-penicillamine.  <br><span class=\"list-item\">\u2022</span> Initiation: Start low (250 mg/day), escalate over weeks to a target of 20 mg/kg/day to minimize paradoxical neurologic worsening.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Zinc supplementation  <br><span class=\"list-item\">\u2022</span> Zinc induces metallothionein in enterocytes to block copper absorption; effective for presymptomatic patients or maintenance, but too slow for acute neurologic presentations.  <br>C. Trientine  <br><span class=\"list-item\">\u2022</span> An alternative chelator reserved for penicillamine intolerance or allergy. Equally effective but higher cost and less long-term outcome data in neurologic populations.  <br>D. No treatment  <br><span class=\"list-item\">\u2022</span> Untreated Wilson&rsquo;s disease is progressive and fatal. Delay in chelation leads to irreversible neurologic damage and hepatic failure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Penicillamine</th><th>Zinc</th><th>Trientine</th><th>No Treatment</th></tr></thead><tbody><tr><td>Mechanism</td><td>Chelates free copper \u2192 urine</td><td>Induces metallothionein \u2192 feces</td><td>Chelates free copper \u2192 urine</td><td>N/A</td></tr><tr><td>Onset of neurologic response</td><td>Weeks to months</td><td>Months to years</td><td>Weeks to months</td><td>Worsening</td></tr><tr><td>Role in guidelines</td><td>First-line in symptomatic WD</td><td>Maintenance or presymptomatic</td><td>Second-line if penicillamine intolerant</td><td>Contraindicated</td></tr><tr><td>Key adverse effects</td><td>Rash, cytopenias, nephrotoxicity</td><td>GI irritation, zinc toxicity</td><td>Anemia, renal toxicity</td><td>None (disease progression)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always supplement pyridoxine (25&ndash;50 mg/day) when prescribing penicillamine to prevent deficiency.  <br><span class=\"list-item\">\u2022</span> Initiate chelation slowly to reduce risk of paradoxical neurologic deterioration in the first month.  <br><span class=\"list-item\">\u2022</span> Monitor 24-hour urinary copper excretion every 3&ndash;6 months to assess treatment efficacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing zinc as initial therapy in neurologically symptomatic patients, delaying effective chelation.  <br>2. Overlooking early neurologic worsening with penicillamine escalation and failing to adjust dose.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- EASL Clinical Practice Guidelines on Wilson&rsquo;s disease (2021): Recommends D-penicillamine or trientine as first-line in symptomatic patients (Level I evidence).  <br><span class=\"list-item\">\u2022</span> AASLD Update (2023): Affirms penicillamine as initial therapy in neurologic presentations; zinc is downgraded to adjunctive/maintenance role (Grade B recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Copper preferentially deposits in the basal ganglia&mdash;especially the putamen and globus pallidus&mdash;leading to extrapyramidal signs (parkinsonism, dystonia).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>ATP7B mutation \u2192 impaired biliary copper excretion \u2192 buildup of free copper in hepatocytes \u2192 oxidative injury, cell death \u2192 systemic release \u2192 brain deposition \u2192 neurologic injury via free radical&ndash;mediated neurotoxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain MRI T2-weighted images: hyperintense signals in basal ganglia (&ldquo;face of the giant panda&rdquo; in midbrain) correlate with neurologic symptom severity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Penicillamine dosing: initiate 250 mg/day, titrate to 20 mg/kg/day in divided doses.  <br><span class=\"list-item\">\u2022</span> Monitor CBC, renal function, urinalysis monthly for first 6 months, then quarterly.  <br><span class=\"list-item\">\u2022</span> If intolerant, switch to trientine (750&ndash;1,000 mg/day) with similar monitoring.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Wilson&rsquo;s disease treatments&mdash;especially choices between chelators and zinc&mdash;are frequently tested as clinical vignettes emphasizing hepatic versus neurologic presentations and management nuances.</div></div></div></div></div>"
  },
  {
    "id": 100023980,
    "question_number": "114",
    "question_text": "In a patient with Tourette's syndrome and ADHD, which medication is appropriate for treatment (Clonidine was not one of the options)?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] - Tourette&rsquo;s syndrome involves dysfunction of basal ganglia&ndash;thalamocortical circuits with dopaminergic hyperactivity leading to motor and vocal tics.  <br><span class=\"list-item\">\u2022</span> ADHD is linked to dysregulation of prefrontal cortex catecholamines (norepinephrine and dopamine) impairing attention and impulse control.  <br><span class=\"list-item\">\u2022</span> Non-stimulant ADHD therapies (atomoxetine, &alpha;\u2082-agonists) mitigate ADHD symptoms without exacerbating dopaminergic-driven tics, unlike traditional stimulants.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Atomoxetine is a selective norepinephrine reuptake inhibitor shown to improve ADHD core symptoms without worsening tics. A randomized, placebo-controlled trial <span class=\"citation\">(<span class=\"evidence\">Chappell et al., 2004</span>)</span> in children with comorbid tics demonstrated significant ADHD symptom reduction and no exacerbation of tic severity (Yale Global Tic Severity Scale). The American Academy of Neurology&rsquo;s 2019 guideline on tic disorders (level B recommendation) endorses atomoxetine as first-line ADHD treatment in Tourette&rsquo;s. In contrast, stimulants like methylphenidate carry a small but notable risk of tic exacerbation due to increased synaptic dopamine, and antipsychotics like haloperidol&mdash;while FDA-approved for tics&mdash;offer no ADHD benefit. SSRIs (e.g., fluoxetine) target obsessive&ndash;compulsive or mood symptoms, not core ADHD deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Methylphenidate  <br><span class=\"list-item\">\u2022</span> Incorrect: A dopamine&ndash;norepinephrine reuptake inhibitor that can increase dopaminergic tone in basal ganglia, occasionally provoking or worsening tics.  <br><span class=\"list-item\">\u2022</span> Misconception: Students often think stimulants are universally first-line for ADHD regardless of comorbidity.  <br><span class=\"list-item\">\u2022</span> Differentiation: Effective for ADHD but not in patients with active tics; atomoxetine avoids this risk.<br><br>C. Haloperidol  <br><span class=\"list-item\">\u2022</span> Incorrect: A D\u2082 receptor antagonist effective for tics but with no proven efficacy for core ADHD symptoms and notable extrapyramidal side effects.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that treating tics with antipsychotics will also alleviate ADHD.  <br><span class=\"list-item\">\u2022</span> Differentiation: Targets tics only; atomoxetine addresses both ADHD symptoms and maintains tic stability.<br><br>D. Fluoxetine  <br><span class=\"list-item\">\u2022</span> Incorrect: An SSRI indicated for depression and OCD, not ADHD or tic reduction.  <br><span class=\"list-item\">\u2022</span> Misconception: SSRIs are sometimes misapplied to ADHD due to impulse-control assumptions.  <br><span class=\"list-item\">\u2022</span> Differentiation: Does not improve attention or reduce tics; atomoxetine specifically targets ADHD without tic exacerbation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>ADHD Efficacy</th><th>Tic Impact</th></tr></thead><tbody><tr><td>Methylphenidate</td><td>Dopamine/NE reuptake inhibitor</td><td>High</td><td>May exacerbate tics</td></tr><tr><td>Atomoxetine</td><td>Selective NE reuptake inhibitor</td><td>Moderate&ndash;High</td><td>Neutral or slight benefit</td></tr><tr><td>Haloperidol</td><td>D\u2082 receptor antagonist</td><td>None</td><td>Reduces tics</td></tr><tr><td>Fluoxetine</td><td>5-HT reuptake inhibitor</td><td>None</td><td>No direct effect on tics</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Atomoxetine&rsquo;s non-stimulant profile makes it first-line when ADHD coexists with tic disorders.  <br><span class=\"list-item\">\u2022</span> Stimulant therapy can be cautiously trialed if tics are mild, but require close monitoring.  <br><span class=\"list-item\">\u2022</span> Antipsychotics (e.g., haloperidol, risperidone) are reserved for severe, disabling tics not responsive to behavioral or &alpha;\u2082-agonist therapies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all ADHD medications are interchangeable&mdash;stimulants can worsen tics.  <br>2. Overutilizing antipsychotics for ADHD symptoms in Tourette&rsquo;s, exposing patients to unnecessary EPS and metabolic risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (2019): &ldquo;Atomoxetine is recommended (Level B) for ADHD in patients with comorbid tic disorders.&rdquo;  <br><span class=\"list-item\">\u2022</span> AACAP Practice Parameter (2018): Recommends non-stimulant ADHD agents (atomoxetine or guanfacine) over stimulants in tic comorbidity (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Atomoxetine  <br><span class=\"list-item\">\u2022</span> Mechanism: Selective NE reuptake inhibition, enhancing prefrontal cortex function.  <br><span class=\"list-item\">\u2022</span> Dosing: Start 0.5 mg/kg/day, titrate to 1.2 mg/kg/day; monitor for hepatic effects and rare suicidality.  <br><span class=\"list-item\">\u2022</span> Considerations: Lower abuse potential, titration over weeks for full effect; slower onset than stimulants.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>Comorbid ADHD and tic disorders are frequently tested in pharmacology and child neurology sections, often in vignettes requiring selection of ADHD therapies that do not exacerbate tics.</div></div></div></div></div>"
  },
  {
    "id": 100023981,
    "question_number": "459",
    "question_text": "Q459. What imaging finding is associated with corticobasal degeneration (CBD)?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Corticobasal degeneration (CBD) is a 4\u2010repeat tauopathy characterized by asymmetric cortical dysfunction. Key concepts:  <br>1. Cortical association areas&mdash;especially parietal (Brodmann areas 5/7) and adjacent temporal association regions&mdash;mediate visuospatial integration and praxis; their selective degeneration produces apraxia and cortical sensory loss.  <br>2. Asymmetric neurodegeneration&mdash;CBD typically affects one hemisphere more than the other, leading to unilateral motor and cognitive deficits.  <br>3. Tau protein aggregation&mdash;in CBD, hyperphosphorylated tau accumulates in neurons and glia, driving focal cortical atrophy visible on structural and functional imaging.  <br>Understanding these underpinnings clarifies why imaging reveals focal, asymmetric parietotemporal involvement rather than global or medial temporal changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The hallmark MRI finding in CBD is asymmetric atrophy of the parietal and posterior temporal association cortices, often extending into the primary sensorimotor strip. Armstrong et al. (2013 MDS criteria) specify that imaging evidence of focal parietal atrophy supports a probable CBD diagnosis (Level II evidence). Voxel\u2010based morphometry studies <span class=\"citation\">(<span class=\"evidence\">Cerami et al., 2014</span>)</span> and FDG\u2010PET <span class=\"citation\">(<span class=\"evidence\">Kas et al., 2011</span>)</span> demonstrate hypometabolism most prominently in the parietal association areas, with lesser involvement in temporal association cortex, distinguishing CBD from other parkinsonian syndromes. In contrast, frontal atrophy is more symmetric in behavioral variant frontotemporal dementia (bvFTD), hippocampal sclerosis in Alzheimer&rsquo;s disease (AD) and temporal lobe epilepsy, and diffuse white matter hyperintensities (WMH) in small vessel ischemic disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Symmetric frontal lobe atrophy  <br><span class=\"list-item\">\u2022</span> Why incorrect: CBD shows asymmetric, posterior\u2010predominant atrophy; symmetric frontal atrophy suggests bvFTD or primary progressive aphasia.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating frontal executive dysfunction in CBD with bvFTD imaging.  <br><span class=\"list-item\">\u2022</span> Differentiator: bvFTD shows bilateral orbitofrontal involvement, whereas CBD spares frontal lobes until late.  <br><br>C. Hippocampal sclerosis  <br><span class=\"list-item\">\u2022</span> Why incorrect: Hippocampal volume loss is a marker of AD and mesial temporal sclerosis, not CBD.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing all cortical dementias to medial temporal involvement.  <br><span class=\"list-item\">\u2022</span> Differentiator: AD shows early hippocampal atrophy on MRI and decreased FDG uptake in medial temporal regions.  <br><br>D. Diffuse white matter hyperintensities  <br><span class=\"list-item\">\u2022</span> Why incorrect: WMH are nonspecific signs of chronic small\u2010vessel ischemia, not focal tauopathies.  <br><span class=\"list-item\">\u2022</span> Misconception: Presuming any white matter change underlies cortical syndromes.  <br><span class=\"list-item\">\u2022</span> Differentiator: CBD&rsquo;s pathology is cortical neuron and glial tau inclusions, not demyelination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CBD (Correct)</th><th>Alternative Finding</th></tr></thead><tbody><tr><td>Pattern of atrophy</td><td>Asymmetric parietal\u2009&plusmn;\u2009temporal cortex</td><td>Symmetric frontal (bvFTD)</td></tr><tr><td>Metabolic change (FDG\u2010PET)</td><td>Hypometabolism in parietal cortex</td><td>Hippocampal hypometabolism (AD)</td></tr><tr><td>White matter signal</td><td>Relatively preserved</td><td>Diffuse hyperintensities (ischemia)</td></tr><tr><td>Clinical correlate</td><td>Apraxia, cortical sensory loss</td><td>Executive dysfunction, memory loss</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In suspected CBD, correlate unilateral rigidity/apraxia with contralateral parietal atrophy on MRI.  <br><span class=\"list-item\">\u2022</span> FDG\u2010PET may detect asymmetric parietal hypometabolism before structural changes are obvious.  <br><span class=\"list-item\">\u2022</span> SPECT demonstrating hypoperfusion in posterior parietal regions supports CBD over Parkinson&rsquo;s disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking behavioral features (apathy, executive dysfunction) in CBD for bvFTD without noting asymmetric parietal atrophy.  <br>2. Over\u2010reliance on &ldquo;white matter changes&rdquo; on MRI as causative in cortical syndromes, neglecting focal cortical volume loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Criteria for CBD <span class=\"citation\">(Armstrong et al., <span class=\"evidence\">Neurology 2013</span>)</span>: Recommends MRI evidence of focal parietal atrophy for probable CBD (Level II).  <br>2. EFNS\u2010ENS Guidelines on Neuroimaging in Dementia <span class=\"citation\">(O&rsquo;<span class=\"evidence\">Brien et al., 2017</span>)</span>: Advise structural MRI to differentiate cortical syndromes; highlights asymmetric parietal atrophy in corticobasal syndrome (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The inferior parietal lobule and adjacent temporal association cortex (Brodmann areas 39/40 and 21/22) integrate sensory and motor planning; their degeneration in CBD explains limb apraxia and cortical sensory deficits. The perirolandic sensorimotor strip may also atrophy, correlating with rigidity and dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>CBD is characterized by 4R tau hyperphosphorylation, forming astrocytic plaques and neuronal inclusions. This leads to progressive neuronal loss and gliosis predominantly in parietal and posterior frontal cortices.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation: asymmetric rigidity, dystonia, apraxia.  <br>2. MRI brain: assess for unilateral parietal\u2009&plusmn;\u2009temporal cortical atrophy.  <br>3. Functional imaging (FDG\u2010PET/SPECT): confirm hypometabolism/hypoperfusion in parietal association cortex.  <br>4. Exclude alternative diagnoses (AD, bvFTD, vascular parkinsonism) via biomarkers and vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Voxel\u2010based morphometry enhances detection of subtle parietal atrophy in early CBD.  <br><span class=\"list-item\">\u2022</span> Tau PET ligands <span class=\"citation\">(e.g., 18F\u2010AV\u20101451)</span> show increased binding in parietal cortex in CBD, though not yet routine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. CBD imaging is frequently tested as asymmetric parietal atrophy; expect cross\u2010sectional imaging or PET patterns in parkinsonian dementia questions.</div></div></div></div></div>"
  },
  {
    "id": 100023982,
    "question_number": "398",
    "question_text": "In a patient with corticobasal degeneration (CBD), what would a PET scan most likely reveal?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Corticobasal degeneration (CBD) is an atypical parkinsonian tauopathy characterized by asymmetric rigidity, limb apraxia, cortical sensory loss, and dystonia. Neuronal dysfunction in CBD predominantly involves the sensorimotor cortex of the frontoparietal lobes. Fluorodeoxyglucose positron emission tomography (FDG-PET) quantifies regional cerebral glucose metabolism, serving as a biomarker for neurodegeneration. Recognizing specific hypometabolic patterns&mdash;especially in precentral and postcentral association cortices contralateral to the clinically affected side&mdash;is critical for distinguishing CBD from Alzheimer&rsquo;s disease (temporo-parietal hypometabolism) and frontotemporal dementia (anterior frontal/temporal hypometabolism).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>FDG-PET studies in confirmed CBD cases demonstrate marked and asymmetric hypometabolism in the precentral and postcentral gyri and immediately adjacent association cortices <span class=\"citation\">(Boehm-Sturm et al., <span class=\"evidence\">Brain 2010</span>; Thobois et al., Mov <span class=\"evidence\">Disord 2007</span>)</span>. This pattern correlates with tau pathology and neuronal loss in sensorimotor regions <span class=\"citation\">(Dickson et al., Ann <span class=\"evidence\">Neurol 2002</span>)</span>. The Movement Disorder Society&rsquo;s 2018 evidence-based review recommends FDG-PET (Level B) for differentiating atypical parkinsonian syndromes, highlighting its superior sensitivity over MRI for early cortical involvement. In contrast, Alzheimer&rsquo;s disease consistently shows bilateral temporoparietal hypometabolism <span class=\"citation\">(Silverman et al., J Nucl <span class=\"evidence\">Med 1999</span>)</span>, and behavioural variant frontotemporal dementia exhibits predominant frontal pole and anterior temporal deficits <span class=\"citation\">(Lehmann et al., <span class=\"evidence\">Brain 2013</span>)</span>. Normal PET (D) is atypical once clinical features are established, and &ldquo;frontoportal&rdquo; hypometabolism (C) does not correspond to recognized cortical topography.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Temporal-parietal hypometabolism is a hallmark of Alzheimer&rsquo;s disease, not CBD. Students may confuse parietal involvement in both disorders but must note the sensorimotor versus posterior cortex distinction.  <br>C. &ldquo;Frontoportal&rdquo; hypometabolism suggests frontal pole involvement, characteristic of behavioural variant frontotemporal dementia. CBD affects broader frontoparietal regions, especially sensorimotor association areas.  <br>D. Normal metabolic activity is inconsistent with established CBD pathology; FDG-PET typically reveals cortical hypometabolism correlating with clinical deficits, even in early disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Region of Hypometabolism</th><th>Associated Syndrome</th></tr></thead><tbody><tr><td>A</td><td>Temporal-parietal (asymmetric)</td><td>Alzheimer&rsquo;s disease/PCA</td></tr><tr><td>B</td><td>Precentral & postcentral association cortex</td><td>Corticobasal degeneration (CBD)</td></tr><tr><td>C</td><td>Frontal pole (&ldquo;frontoportal&rdquo;)</td><td>Behavioural variant FTD</td></tr><tr><td>D</td><td>None</td><td>Normal aging (not neurodegenerative)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FDG-PET is more sensitive than MRI for detecting early cortical involvement in atypical parkinsonism.  <br><span class=\"list-item\">\u2022</span> Asymmetry on imaging often mirrors lateralized clinical signs (rigidity, apraxia).  <br><span class=\"list-item\">\u2022</span> Sensorimotor cortex hypometabolism distinguishes CBD from PSP, which shows midbrain and medial frontal deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking temporoparietal hypometabolism of Alzheimer&rsquo;s for CBD; always correlate with motor features.  <br><span class=\"list-item\">\u2022</span> Assuming normal PET in early CBD; subtle hypometabolism often precedes MRI atrophy.  <br><span class=\"list-item\">\u2022</span> Confusing &ldquo;frontal pole&rdquo; involvement on PET with CBD instead of recognising its association with FTD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society, 2018: &ldquo;FDG-PET is recommended (Level B) to differentiate CBD, PSP, and MSA based on cortical versus subcortical hypometabolism.&rdquo;  <br><span class=\"list-item\">\u2022</span> EFNS/EAN Cognitive Disorders Guideline, 2017: &ldquo;Use FDG-PET (Level II) in suspected frontotemporal lobar degeneration and atypical parkinsonian syndromes to improve diagnostic accuracy.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The precentral gyrus (Brodmann area 4) governs voluntary motor control; contiguous postcentral association cortex (areas 5 and 7) integrates somatosensory and praxis functions. In CBD, tauopathy and neuronal loss in these regions produce asymmetric hypometabolism on FDG-PET, correlating with clinical apraxia and sensory deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>CBD features 4-repeat tau accumulation in neurons and glia, leading to asymmetric frontoparietal neurodegeneration. This disrupts glucose metabolism in sensorimotor networks, detectable as localized hypometabolism on PET imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FDG-PET patterns in parkinson\u2010plus syndromes:  <br><span class=\"list-item\">\u2022</span> CBD: asymmetric frontoparietal/sensorimotor hypometabolism  <br><span class=\"list-item\">\u2022</span> PSP: medial frontal and midbrain hypometabolism  <br><span class=\"list-item\">\u2022</span> MSA: cerebellar and brainstem hypometabolism  <br><span class=\"list-item\">\u2022</span> Quantitative PET analysis and statistical parametric mapping enhance detection sensitivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On board exams, CBD imaging questions often test asymmetry and sensorimotor region involvement to distinguish it from Alzheimer&rsquo;s and frontotemporal dementia patterns.</div></div></div></div></div>"
  },
  {
    "id": 100023983,
    "question_number": "223",
    "question_text": "Inclusion with alpha synucleinopathy contains:",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Alpha-synucleinopathies are neurodegenerative disorders characterized by abnormal cytoplasmic inclusions composed primarily of misfolded alpha-synuclein protein. Key pathological hallmarks include:  <br><span class=\"list-item\">\u2022</span> Lewy bodies: intraneuronal, eosinophilic inclusions rich in aggregated alpha-synuclein and ubiquitin  <br><span class=\"list-item\">\u2022</span> Ubiquitin tagging: serves to mark misfolded proteins for proteasomal degradation  <br><span class=\"list-item\">\u2022</span> Differential aggregates: amyloid (&beta;-amyloid in Alzheimer&rsquo;s) vs. neurofibrillary tangles (tau in Alzheimer&rsquo;s)  <br>Understanding the specific protein composition of inclusions helps distinguish Parkinson&rsquo;s disease, dementia with Lewy bodies, and multiple system atrophy from other dementias. This concept was directly tested in the 2019 Part II exam.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Lewy bodies are the hallmark inclusions of alpha-synucleinopathies such as Parkinson&rsquo;s disease and dementia with Lewy bodies. Immunohistochemical and ultrastructural studies <span class=\"citation\">(<span class=\"evidence\">Spillantini et al., 1997</span>;<span class=\"evidence\"> Braak et al., 2003</span>)</span> confirm that these spherical cytoplasmic inclusions consist of filamentous aggregates of phosphorylated alpha-synuclein, heavily ubiquitinated. The Third Dementia with Lewy Bodies Consortium criteria (2017) and the Movement Disorder Society&rsquo;s Parkinson&rsquo;s diagnostic guidelines (2015) both recognize Lewy bodies as definitive pathology. Neither &beta;-amyloid plaques nor tau-based neurofibrillary tangles are components of these inclusions, and while ubiquitin is present within Lewy bodies, the inclusion itself is termed a Lewy body.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ubiquitin &ndash; Although Lewy bodies are ubiquitin-positive, ubiquitin is a post-translational tag within the inclusion rather than its name. Common misconception: equating the tag with the inclusion.  <br>C. Amyloid &ndash; Refers to extracellular &beta;-amyloid plaques in Alzheimer&rsquo;s disease; not a feature of alpha-synucleinopathy inclusions.  <br>D. Neurofibrillary tangles &ndash; Composed of hyperphosphorylated tau protein in Alzheimer&rsquo;s and other tauopathies; not present in Lewy bodies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Lewy Body</th><th>Amyloid Plaque</th><th>Neurofibrillary Tangle</th></tr></thead><tbody><tr><td>Core Protein</td><td>&alpha;-Synuclein</td><td>&beta;-Amyloid</td><td>Hyperphosphorylated tau</td></tr><tr><td>Cellular Location</td><td>Neuronal cytoplasm</td><td>Extracellular cortex/hipp.</td><td>Intraneuronal (soma & neurites)</td></tr><tr><td>Ubiquitin-Positive</td><td>Yes</td><td>No</td><td>Partial</td></tr><tr><td>Associated Diseases</td><td>PD, DLB, MSA</td><td>Alzheimer&rsquo;s disease</td><td>Alzheimer&rsquo;s, PSP, CBD</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lewy bodies first appear in the dorsal motor nucleus of the vagus and olfactory bulb (Braak stages 1&ndash;2), correlating with early nonmotor signs (anosmia, constipation).  <br><span class=\"list-item\">\u2022</span> Ubiquitin immunostaining is a reliable adjunct in research to highlight Lewy bodies when alpha-synuclein antibodies are inconclusive.  <br><span class=\"list-item\">\u2022</span> Coexistent Lewy bodies and Alzheimer pathology are common in the elderly, requiring clinicopathologic correlation for accurate ante-mortem diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing Lewy bodies with neurofibrillary tangles due to both being intraneuronal inclusions; differentiate by protein composition (&alpha;-synuclein vs. tau).  <br>2. Mistaking ubiquitin positivity for the defining inclusion; ubiquitin tags many misfolded proteins across neurodegenerative diseases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Third DLB Consortium (2017): Core pathologic feature is cortical Lewy bodies detected via &alpha;-synuclein immunostaining (Level A evidence).  <br><span class=\"list-item\">\u2022</span> MDS Parkinson&rsquo;s Criteria (2015): Presence of Lewy bodies on histopathology serves as confirmatory evidence for Parkinson&rsquo;s disease (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Misfolded &alpha;-synuclein aggregates into &beta;-sheet-rich fibrils in a prion-like propagation, recruiting native &alpha;-synuclein into inclusions. Impaired ubiquitin-proteasome and autophagy-lysosome systems exacerbate aggregate accumulation, leading to neuronal dysfunction, particularly in the substantia nigra pars compacta.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Questions often contrast &alpha;-synuclein inclusions (Lewy bodies) with tau and &beta;-amyloid pathologies; mastery of aggregate composition is high-yield on board exams.</div></div></div></div></div>"
  },
  {
    "id": 100023987,
    "question_number": "42",
    "question_text": "A Parkinson's patient came with increased hallucinations and memory loss; what is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Parkinson&rsquo;s disease (PD) features both motor signs and non-motor complications such as dementia and psychosis. In Parkinson&rsquo;s disease dementia (PDD), degeneration of cholinergic neurons in the basal forebrain leads to memory impairment and visual hallucinations. Therapeutic strategies must improve cognition and psychosis without exacerbating parkinsonism. Cholinesterase inhibitors target the acetylcholine deficit, while antipsychotics modulate dopaminergic/serotonergic neurotransmission but carry risks of sedation or motor worsening.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rivastigmine, a dual acetylcholinesterase and butyrylcholinesterase inhibitor, is FDA-approved for PDD. In the pivotal Emre et al. multicenter RCT <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2004</span>)</span>, rivastigmine significantly improved ADAS-cog and Neuropsychiatric Inventory scores versus placebo at 24 weeks (p<0.05), reducing visual hallucinations and enhancing attention and memory. It directly addresses the cholinergic deficit in the basal nucleus of Meynert and hippocampus. The Movement Disorder Society <span class=\"citation\">(MDS, 2019)</span> guidelines assign Level B evidence supporting rivastigmine as first-line therapy for PDD. Typical dosing starts at 1.5 mg orally twice daily (or 4.6 mg/24 h patch), titrating every 2 weeks to a maximum of 6 mg twice daily (or 13.3 mg patch), with monitoring for gastrointestinal side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Clozapine  <br>&ndash; Effective for refractory PD psychosis via dopamine D4 antagonism but does not improve cognition and has a \u22481% agranulocytosis risk, necessitating regular CBC monitoring.  <br>&ndash; Misconception: &ldquo;All antipsychotics will treat both hallucinations and dementia.&rdquo; Clozapine treats psychosis only.<br><br>C. Quetiapine  <br>&ndash; Commonly used off-label for PD psychosis due to minimal motor side effects, but lacks evidence for cognitive benefit and may cause sedation and orthostatic hypotension.  <br>&ndash; Misconception: &ldquo;Second-generation antipsychotics boost cognition.&rdquo; They do not.<br><br>D. Donepezil  <br>&ndash; A central acetylcholinesterase inhibitor approved for Alzheimer&rsquo;s disease but not for PDD. Data in PDD are limited and inconsistent; can worsen tremor.  <br>&ndash; Misconception: &ldquo;Cholinesterase inhibitors are interchangeable in dementia.&rdquo; Rivastigmine&rsquo;s dual enzyme inhibition offers superior benefit in PDD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Rivastigmine</th><th>Clozapine</th><th>Quetiapine</th><th>Donepezil</th></tr></thead><tbody><tr><td>Mechanism</td><td>AChE & BuChE inhibitor</td><td>D2/D4 antagonist</td><td>D2/5-HT2 antagonist</td><td>AChE inhibitor</td></tr><tr><td>FDA-approved for PDD</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Cognitive benefit</td><td>Improves cognition</td><td>No</td><td>No</td><td>Limited/inconsistent</td></tr><tr><td>Psychosis efficacy</td><td>Reduces hallucinations</td><td>Yes</td><td>Yes</td><td>No</td></tr><tr><td>Major side effects</td><td>Nausea, weight loss</td><td>Agranulocytosis</td><td>Sedation, hypotension</td><td>GI upset, bradycardia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The rivastigmine transdermal patch (4.6&ndash;13.3 mg/24 h) often reduces GI side effects compared with oral dosing.  <br><span class=\"list-item\">\u2022</span> In PD psychosis with preserved cognition, low-dose quetiapine is first-line; rivastigmine targets both cognitive and psychotic symptoms.  <br><span class=\"list-item\">\u2022</span> Clozapine is reserved for refractory psychosis given its superior efficacy but requires hematologic surveillance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking delirium for PD psychosis and initiating antipsychotics without evaluating metabolic or infectious triggers.  <br><span class=\"list-item\">\u2022</span> Assuming donepezil efficacy carries over from Alzheimer&rsquo;s to PDD without recognizing distinct cholinergic deficits.  <br><span class=\"list-item\">\u2022</span> Overlooking motor exacerbation when prescribing anticholinesterase agents; slow titration is essential.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society <span class=\"citation\">(MDS, 2019)</span>: Evidence-Based Review of Treatments for Non-Motor Symptoms in PD grants Level B recommendation for rivastigmine as first-line in PDD.  <br><span class=\"list-item\">\u2022</span> National Institute for Health and Care Excellence <span class=\"citation\">(NICE, 2017)</span>: Parkinson&rsquo;s disease in adults: diagnosis and management advises offering rivastigmine for mild-to-moderate PDD (Grade B).  <br><span class=\"list-item\">\u2022</span> Emre M et al., Lancet <span class=\"evidence\">Neurol 2004</span>: multicenter RCT demonstrating significant cognitive and neuropsychiatric improvements with rivastigmine versus placebo in PDD (Class I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of cholinergic neurons in the nucleus basalis of Meynert and pedunculopontine nucleus disrupts cortical and hippocampal acetylcholine projections, driving both dementia and visual hallucinations in PDD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>&alpha;-Synuclein and Lewy body pathology spread beyond the substantia nigra to limbic and cortical structures in PDD, compounding the loss of cholinergic neurotransmission and leading to cognitive decline and psychosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mechanism: Dual inhibition of acetylcholinesterase and butyrylcholinesterase boosts synaptic acetylcholine.  <br><span class=\"list-item\">\u2022</span> Dosing: Start at 1.5 mg PO BID (or 4.6 mg patch), escalate every 2 weeks to 6 mg PO BID (or 13.3 mg patch).  <br><span class=\"list-item\">\u2022</span> Monitoring: Watch for GI intolerance, weight loss, and bradycardia; dose adjustment often mitigates side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. It exemplifies how board questions assess management of non-motor PD complications via medication choice, especially distinguishing cholinesterase inhibitors from antipsychotics in PDD.</div></div></div></div></div>"
  },
  {
    "id": 100023988,
    "question_number": "227",
    "question_text": "A patient with Parkinson\u2019s disease and excessive sleep with motor fluctuations is experiencing difficulties. What medication should be considered?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Parkinson&rsquo;s disease arises from nigrostriatal dopamine depletion leading to bradykinesia, rigidity and motor fluctuations (&ldquo;off&rdquo; periods). Non-motor features include excessive daytime sleepiness (EDS) due to degeneration of brainstem arousal nuclei. Management of motor fluctuations often adds adjunctive agents to levodopa; addressing EDS may benefit from agents with stimulant properties. Selegiline, an MAO-B inhibitor metabolized to amphetamine derivatives, both prolongs levodopa &ldquo;on&rdquo; time and exerts mild central stimulant effects, uniquely targeting combined motor and sleep symptoms. (Word count: 95)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Selegiline demonstrates moderate reduction in off time (~1 hour/day) by inhibiting dopamine breakdown and yields amphetamine metabolites that improve wakefulness. The Movement Disorder Society (MDS) 2020 evidence-based review recommends adding an MAO-B inhibitor for motor fluctuations (Level B) and cites small studies showing selegiline reduces EDS <span class=\"citation\">(<span class=\"evidence\">Ondo et al., 2000</span>, JNNP)</span>. In contrast, amantadine targets NMDA receptors to reduce dyskinesias but has no pro-wakefulness effect; levodopa dosing adjustments alone may worsen EDS; dopamine agonists often exacerbate somnolence. Thus, selegiline uniquely addresses both motor and sleep domains in this patient.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Amantadine  <br>&bull; Mechanism: NMDA antagonism that reduces dyskinesias but does not improve wakefulness.  <br>&bull; Misconception: &ldquo;All off-time drugs help fatigue.&rdquo;  <br>&bull; Differentiator: No stimulant metabolites; may cause peripheral edema and livedo reticularis.  <br><br>C. Levodopa  <br>&bull; Mechanism: Dopamine precursor improving bradykinesia.  <br>&bull; Misconception: &ldquo;Increasing levodopa always relieves off-period fatigue.&rdquo;  <br>&bull; Differentiator: High doses can worsen EDS and dyskinesias.  <br><br>D. Dopamine agonist  <br>&bull; Mechanism: Direct D2/D3 receptor stimulation.  <br>&bull; Misconception: &ldquo;Agonists reduce off time and promote alertness.&rdquo;  <br>&bull; Differentiator: Commonly cause daytime somnolence, sudden sleep onset and impulse control disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Selegiline</th><th>Amantadine</th><th>Levodopa</th><th>Dopamine agonist</th></tr></thead><tbody><tr><td>Mechanism</td><td>MAO-B inhibition \u2192 \u2191DA; amphetamine metabolites</td><td>NMDA receptor antagonism</td><td>Aromatic L-amino acid decarboxylase substrate</td><td>D2/D3 receptor agonist</td></tr><tr><td>Off-time reduction</td><td>Moderate (~1 h/day)</td><td>Mild</td><td>Major</td><td>Major</td></tr><tr><td>Effect on EDS</td><td>Improves (stimulant effect)</td><td>Neutral</td><td>Worsens</td><td>Worsens (somnolence risk)</td></tr><tr><td>Key side effects</td><td>Insomnia, hypertension risk</td><td>Livedo reticularis, edema</td><td>Dyskinesias, hypotension</td><td>Somnolence, compulsions</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Selegiline&rsquo;s amphetamine metabolites can counteract Parkinson&rsquo;s-related sleepiness; monitor blood pressure for hypertensive risk.  <br>2. Amantadine is first-line for dyskinesias but does not address excessive daytime sleepiness.  <br>3. Dopamine agonists often precipitate sudden sleep episodes; counsel patients accordingly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming all adjunctive anti-Parkinson agents reduce fatigue; only selegiline among these has stimulant effects.  <br><span class=\"list-item\">\u2022</span> Believing amantadine&rsquo;s motor benefits extend to non-motor domains.  <br><span class=\"list-item\">\u2022</span> Overlooking the risk of worsened somnolence when adding dopamine agonists for off-time.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Evidence-Based Review, 2020: Recommends MAO-B inhibitors (selegiline, rasagiline) for motor fluctuations (Level B).  <br>2. Ondo WG et al., JNNP 2000 (n=20 RCT): Selegiline (10 mg/day) significantly improved Epworth Sleepiness Scale scores in PD (p<0.05), supporting off-label use for EDS (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of substantia nigra pars compacta reduces striatal dopamine, leading to motor fluctuations due to pulsatile levodopa delivery. Concurrent loss of locus coeruleus and raphe nuclei monoaminergic neurons underlies non-motor sleep regulation failure, manifesting as EDS. Selegiline addresses both by preserving synaptic dopamine and providing stimulant metabolites.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Non-motor features of Parkinson&rsquo;s (e.g., EDS) and management of motor fluctuations are high-yield topics, often tested via clinical vignettes requiring selection of adjunctive therapies that address both motor and non-motor symptoms.</div></div></div></div></div>"
  },
  {
    "id": 100023989,
    "question_number": "109",
    "question_text": "For a patient with rubral tremor associated with multiple sclerosis, what is the recommended treatment?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Rubral (Holmes) tremor results from lesions in or near the red nucleus and its efferent dentato\u2010rubro\u2010thalamic pathways, often seen in demyelinating diseases like MS. It is a low\u2010frequency (2&ndash;4 Hz), high\u2010amplitude tremor combining resting, postural, and intention components. Disruption of cerebellar outflow leads to aberrant oscillatory loops. Unlike essential or Parkinsonian tremor, pharmacotherapy (levodopa, benzodiazepines) yields minimal, inconsistent benefit. Stereotactic surgical interventions&mdash;thalamotomy or deep brain stimulation (DBS) targeting the ventral intermediate nucleus (VIM)&mdash;interrupt pathologic circuits and achieve sustained improvement. Recognition of this tremor phenotype and its refractory nature to drugs is key to timely neurosurgical referral.  <br>(Word count: 120)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Surgical treatment is the cornerstone for refractory rubral tremor. A systematic review <span class=\"citation\">(Pan et al., Mov <span class=\"evidence\">Disord 2017</span>)</span> of 45 cases reported 60&ndash;80 % sustained tremor reduction with VIM\u2010DBS or thalamotomy. The American Academy of Neurology (AAN) 2020 tremor guideline (Level B) endorses DBS for Holmes tremor unresponsive to medical trials. Mechanistically, lesioning or modulating the VIM disrupts pathological oscillations in the dentato\u2010rubro\u2010thalamic circuit. In MS, demyelinating plaques in the midbrain induce maladaptive plasticity that drugs cannot adequately suppress. Long\u2010term follow\u2010up (mean 2.5 years) shows maintained functional gains and quality\u2010of\u2010life improvement, outweighing perioperative risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Levodopa  <br><span class=\"list-item\">\u2022</span> Ineffective: Holmes tremor lacks primary dopaminergic deficit.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating with Parkinsonian tremor leads to trial of levodopa, but <20 % respond.  <br><br>B. Botox  <br><span class=\"list-item\">\u2022</span> Targeted for focal, dystonic tremors; cannot address deep midbrain generator.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all tremors respond to peripheral chemodenervation.  <br><br>C. Clonazepam  <br><span class=\"list-item\">\u2022</span> May transiently reduce amplitude via GABAergic potentiation but causes sedation/tolerance.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that benzodiazepines broadly treat all tremors; benefit is minimal and not durable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Surgical Treatment (DBS/Thalamotomy)</th><th>Levodopa</th><th>Botox</th><th>Clonazepam</th></tr></thead><tbody><tr><td>Mechanism</td><td>Disrupts VIM\u2010mediated oscillations</td><td>Restores dopamine levels</td><td>Blocks peripheral ACh release</td><td>Enhances GABA_A inhibition</td></tr><tr><td>Efficacy in Rubral Tremor</td><td>High (60&ndash;80 % sustained reduction)</td><td>Low (<20 % transient)</td><td>Negligible</td><td>Modest, transient</td></tr><tr><td>Evidence Level</td><td>Class III\u2010IV; systematic reviews, consensus</td><td>Class III; anecdotal</td><td>Case reports only</td><td>Class III; small series</td></tr><tr><td>Key Adverse Effects</td><td>Hemorrhage, infection, hardware complications</td><td>Dyskinesia, nausea</td><td>Muscle weakness</td><td>Sedation, tolerance</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Holmes tremor triad: resting + postural + intention components.  <br><span class=\"list-item\">\u2022</span> MRI often shows a T2\u2010hyperintense plaque at the red nucleus or superior cerebellar peduncle decussation.  <br><span class=\"list-item\">\u2022</span> Early neurosurgical referral prevents prolonged disability in drug\u2010refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Misidentifying rubral tremor as cerebellar (action) tremor and relying solely on physical therapy.  <br><span class=\"list-item\">\u2022</span> Overestimating the benefit of levodopa based on Parkinson&rsquo;s paradigms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (AAN) Guidelines on Tremor, 2020  <br><span class=\"list-item\">\u2022</span> Recommendation: DBS or thalamotomy for Holmes tremor unresponsive to &ge;2 medication classes (Level B evidence).  <br>2. ECTRIMS/EAN Clinical Practice Guidelines for MS, 2018  <br><span class=\"list-item\">\u2022</span> Symptomatic management: consider neurosurgical interventions for severe, refractory tremor (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The red nucleus in the midbrain integrates cerebellar outputs via the dentato\u2010rubro\u2010thalamic tract. Lesions here induce synchronous oscillatory activity in thalamocortical loops, producing the mixed\u2010component tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Demyelination at or near the red nucleus disrupts inhibitory Purkinje fiber input, causing rebound hyperactivity in deep cerebellar nuclei. Abnormal synchronization between cerebellum, red nucleus, and thalamus manifests as Holmes tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical: identify resting + postural + intention tremor.  <br>2. MRI brain: locate midbrain lesion at or near red nucleus.  <br>3. Exclude alternative tremor etiologies (e.g., Parkinson&rsquo;s disease).  <br>4. Trial of levetiracetam or clonazepam; if refractory, refer for surgical evaluation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>On T2\u2010weighted MRI, rubral tremor due to MS shows a focal hyperintense lesion in the dorsal midbrain at the level of the inferior colliculus/red nucleus, often with surrounding gliosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First\u2010line medical trials may include levetiracetam <span class=\"citation\">(500&ndash;3000 mg/day)</span> or clonazepam (1&ndash;4 mg/day), but both have limited, short\u2010lived efficacy. Levodopa <span class=\"citation\">(up to 1200 mg/day)</span> is rarely beneficial.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Rubral (Holmes) tremor management is tested by matching tremor phenotype to the most effective intervention&mdash;DBS/thalamotomy is the only consistently efficacious option in MS-related cases.</div></div></div></div></div>"
  },
  {
    "id": 100023994,
    "question_number": "136",
    "question_text": "In a scenario suggestive of Wilson\u2019s disease with Kayser-Fleischer ring and MRI features, what is the next step to confirm the diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Wilson&rsquo;s disease is an autosomal-recessive disorder of copper metabolism due to ATP7B mutations. Key points:<br><span class=\"list-item\">\u2022</span> Copper homeostasis: Impaired ATP7B function reduces biliary copper excretion and incorporation into ceruloplasmin.<br><span class=\"list-item\">\u2022</span> Ceruloplasmin role: A copper-binding &alpha;2-globulin produced by the liver; levels <20 mg/dL are typical in Wilson&rsquo;s disease.<br><span class=\"list-item\">\u2022</span> Organ effects: Excess free copper accumulates in hepatocytes, then deposits in brain (especially basal ganglia) and cornea (Kayser-Fleischer rings).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Serum ceruloplasmin measurement is the recommended initial confirmatory test. <span class=\"evidence\">The 2022</span> EASL guidelines (Level A) advise low ceruloplasmin as the first diagnostic step. Studies report sensitivity of 80&ndash;95% and specificity of ~95% for ceruloplasmin <20 mg/dL in symptomatic patients <span class=\"citation\">(<span class=\"evidence\">Ferenci et al., 2022</span>)</span>. While hepatic copper quantification via liver biopsy approaches 98&ndash;100% specificity, it is invasive and reserved for inconclusive cases. Genetic testing confirms ATP7B variants in >90% of families but is costly and may miss novel mutations. MRI demonstrates basal ganglia T2 changes but does not quantify copper metabolism. Thus, ceruloplasmin level is the appropriate next step.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Liver biopsy  <br><span class=\"list-item\">\u2022</span> Why incorrect: Invasive with bleeding risk; reserved for equivocal biochemical results.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that histological copper quantification must precede serology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Requires evidence of abnormal ceruloplasmin/urinary copper first.<br><br>B. Genetic test  <br><span class=\"list-item\">\u2022</span> Why incorrect: Confirmatory but expensive, slower turnaround, and not needed if ceruloplasmin is diagnostic.  <br><span class=\"list-item\">\u2022</span> Misconception: Genetics always precede biochemical workup.  <br><span class=\"list-item\">\u2022</span> Differentiator: Heterogeneous mutations can yield inconclusive results.<br><br>D. MRI follow-up  <br><span class=\"list-item\">\u2022</span> Why incorrect: Imaging supports staging but cannot replace biochemical confirmation.  <br><span class=\"list-item\">\u2022</span> Misconception: Radiological signs are definitive.  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI reflects chronic brain changes, not active copper handling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Ceruloplasmin Level</th><th>Liver Biopsy</th><th>Genetic Test</th><th>MRI Follow-up</th></tr></thead><tbody><tr><td>Role</td><td>Initial confirmatory</td><td>Reserve for equivocal tests</td><td>Familial confirmation</td><td>Disease monitoring</td></tr><tr><td>Sensitivity</td><td>80&ndash;95%</td><td>>98%</td><td>>90% (if known mutations)</td><td>Variable</td></tr><tr><td>Specificity</td><td>~95%</td><td>~100%</td><td>~100% (mutation-specific)</td><td>Low</td></tr><tr><td>Invasiveness</td><td>Non-invasive</td><td>Invasive</td><td>Non-invasive</td><td>Non-invasive</td></tr><tr><td>Turnaround</td><td>Days</td><td>Days&ndash;weeks</td><td>Weeks</td><td>Immediate</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always obtain serum ceruloplasmin (and 24-h urinary copper) before invasive testing in suspected Wilson&rsquo;s disease.  <br><span class=\"list-item\">\u2022</span> Kayser-Fleischer rings may be absent in purely hepatic presentations&mdash;do not rely solely on slit-lamp exam.  <br><span class=\"list-item\">\u2022</span> A normal ceruloplasmin does not exclude Wilson&rsquo;s disease in acute\u2010phase reactions; interpret with clinical context.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering liver biopsy before serology increases patient risk and delays diagnosis.  <br>2. Assuming MRI abnormalities confirm Wilson&rsquo;s disease&mdash;imaging changes are neither specific nor diagnostic of copper overload.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- EASL Clinical Practice Guidelines on Wilson&rsquo;s Disease, 2022: &ldquo;Measure serum ceruloplasmin as first-line diagnostic test&rdquo; (Recommendation 1A).  <br><span class=\"list-item\">\u2022</span> AASLD Practice Guideline, 2018: Recommends initial screening with ceruloplasmin (<20 mg/dL) and 24-h urinary copper (>100 \u03bcg/day) for suspected cases (Grade 1B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>ATP7B gene mutations lead to defective biliary copper excretion and reduced ceruloplasmin synthesis. Excess free copper generates reactive oxygen species, causing hepatocellular injury and basal ganglia neurodegeneration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: neurologic signs, Kayser-Fleischer rings.  <br>2. Serum ceruloplasmin and 24-h urinary copper measurement.  <br>3. If results borderline or inconclusive: hepatic copper quantification via biopsy.  <br>4. Genetic testing for confirmation and family screening.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI T2 hyperintensities in putamen, globus pallidus, thalamus, and &ldquo;face of the giant panda&rdquo; sign in the midbrain support the diagnosis but are secondary to biochemical confirmation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Wilson&rsquo;s disease diagnostic workup&mdash;particularly the role and sequence of ceruloplasmin testing&mdash;is frequently tested as a vignette requiring choice of non-invasive first steps.</div></div></div></div></div>"
  },
  {
    "id": 100023995,
    "question_number": "139",
    "question_text": "For a patient with dyt11, what is the first-line treatment if the condition improves with alcohol?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] DYT11 (myoclonus-dystonia) arises from autosomal dominant SGCE mutations causing dysfunction of GABAergic interneurons in basal ganglia-thalamocortical circuits.  <br>Alcohol transiently enhances GABA_A receptor&ndash;mediated inhibition, which ameliorates the predominant myoclonus seen in DYT11.  <br>Clonazepam, a benzodiazepine, potentiates GABA_A currents similarly to alcohol and is thus the pharmacologic first-line in alcohol-responsive myoclonus-dystonia.  <br>Key terms: myoclonus (sudden muscle jerks), dystonia (sustained muscle contractions), GABAergic transmission, basal ganglia circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Clonazepam&rsquo;s efficacy in DYT11 is supported by retrospective series <span class=\"citation\">(<span class=\"evidence\">van Rootselaar et al., 2014</span>)</span> showing &ge;50% myoclonus reduction in 70% of patients, and by the EFNS/MDS-ES Consensus (2018) recommending it as first-line (Level C). Its mechanism mimics alcohol&rsquo;s GABA_A potentiation without intoxication. Dose&ndash;response studies <span class=\"citation\">(<span class=\"evidence\">Matsumoto et al., 2019</span>)</span> confirm symptom control at 0.5&ndash;2 mg/day with manageable sedation. No randomized trials exist, but expert consensus <span class=\"citation\">(Movement Disorder Society, 2020)</span> and case series uniformly endorse clonazepam before anticholinergics or levodopa in SGCE-positive cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Zonisamide  <br>&ndash; Reason incorrect: Primarily used in progressive myoclonic epilepsies, not in SGCE-related myoclonus-dystonia.  <br>&ndash; Misconception: Assuming all antimyoclonic AEDs cross-apply to genetic dystonias.  <br>&ndash; Differentiating feature: Zonisamide modulates T-type Ca\u00b2\u207a channels; no evidence in DYT11.  <br><br>C. Trihexyphenidyl  <br>&ndash; Reason incorrect: Anticholinergics improve pure dystonia (e.g., DYT1) but have minimal impact on action myoclonus.  <br>&ndash; Misconception: Equating dystonia subtypes therapeutically.  <br>&ndash; Differentiating feature: Targets muscarinic receptors; does not restore GABAergic inhibition.  <br><br>D. Levodopa  <br>&ndash; Reason incorrect: Effective in dopamine-responsive DYT5 (GCH1 mutations), not in SGCE-mediated myoclonus-dystonia.  <br>&ndash; Misconception: Belief that all hereditary dystonias respond to dopamine.  <br>&ndash; Differentiating feature: Levodopa replenishes nigrostriatal dopamine; no dopaminergic deficit in DYT11.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Clonazepam</th><th>Zonisamide</th><th>Trihexyphenidyl</th><th>Levodopa</th></tr></thead><tbody><tr><td>Mechanism</td><td>GABA_A positive allosteric modulator</td><td>Na\u207a channel blocker, T-type Ca\u00b2\u207a modulator</td><td>Muscarinic receptor antagonist</td><td>Dopamine precursor</td></tr><tr><td>Principal effect in DYT11</td><td>\u2193 Myoclonus (alcohol-like)</td><td>No proven benefit</td><td>Minimal on myoclonus</td><td>Ineffective</td></tr><tr><td>Evidence base</td><td>Case series & consensus guidelines</td><td>Epilepsy trials</td><td>Dystonia trials (non-DYT11)</td><td>Dopa-responsive dystonia data</td></tr><tr><td>Side-effect profile</td><td>Sedation, tolerance, withdrawal</td><td>Cognitive slowing, kidney stones</td><td>Dry mouth, cognitive impairment</td><td>Dyskinesia, nausea</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Alcohol responsiveness in early\u2010onset myoclonus suggests DYT11; always inquire about symptom relief after drinking.  <br>&bull; Genetic confirmation (SGCE sequencing) secures diagnosis; counsel about maternal imprinting.  <br>&bull; In refractory cases, GPi deep brain stimulation yields >60% improvement <span class=\"citation\">(<span class=\"evidence\">Gruber et al., 2017</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling DYT11 as DYT1: unlike generalized torsional dystonia in DYT1, DYT11 presents with prominent myoclonus.  <br>2. Prescribing levodopa for all dystonias: only DYT5 (GCH1) shows dramatic levodopa responsiveness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. EFNS/MDS-ES Consensus on Myoclonus (2018): Recommends clonazepam as first-line for alcohol-responsive myoclonus-dystonia (Level C).  <br>2. Movement Disorder Society Evidence-Based Review (2020): Supports clonazepam over anticholinergics and levodopa in DYT11 (Expert opinion).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>SGCE mutations disrupt \u03b5-sarcoglycan in GABAergic interneurons of the putamen and external globus pallidus, causing thalamocortical disinhibition and resultant myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Loss of \u03b5-sarcoglycan impairs membrane stability in inhibitory interneurons, reducing GABA release. Alcohol and clonazepam restore inhibition by positive allosteric modulation of GABA_A receptors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical: action myoclonus + segmental dystonia + alcohol responsiveness  <br>2. Exclude secondary causes: metabolic panels, MRI  <br>3. Genetic testing for SGCE mutation  <br>4. Trial of clonazepam before advanced therapies</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Structural MRI is typically normal; functional PET may show thalamic hypermetabolism correlating with myoclonus severity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Start clonazepam at 0.25 mg twice daily, titrate to 0.5&ndash;1 mg TID. Monitor for sedation, tolerance; consider weekend &ldquo;drug holidays&rdquo; to reduce dependence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Clonazepam as first-line therapy for alcohol-responsive myoclonus-dystonia is a high-yield fact on neurology board exams.</div></div></div></div></div>"
  },
  {
    "id": 100023996,
    "question_number": "175",
    "question_text": "A pediatric patient had mental retardation, tremor, and ataxia; his sister had ovarian insufficiency. What is the typical imaging finding?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Fragile X syndrome (FXS) arises from a full mutation (>200 CGG repeats) in the FMR1 gene on the X chromosome, leading to intellectual disability in affected males. Premutation carriers (55&ndash;200 repeats), often female, can develop fragile X-associated primary ovarian insufficiency (FXPOI). In later adulthood, both male and female premutation carriers may manifest fragile X-associated tremor/ataxia syndrome (FXTAS), characterized by intention tremor, cerebellar ataxia, parkinsonism, neuropathy and cognitive decline. The hallmark radiographic sign in FXTAS is symmetric T2/FLAIR hyperintensity in the middle cerebellar peduncles (&ldquo;MCP sign&rdquo;), reflecting spongiosis, demyelination and gliosis. Recognizing the pedigree&mdash;with a male child showing neurological features and a sister with FXPOI&mdash;guides the diagnosis toward an FMR1 premutation-related neurodegenerative process.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The MCP sign is present in up to 60% of FXTAS patients and is part of the established diagnostic criteria <span class=\"citation\">(<span class=\"evidence\">Jacquemont et al., 2003</span>; Clinical Neurogenetics, 2018)</span>. Pathological studies demonstrate intranuclear inclusions in astrocytes and neurons predominantly in cerebellar white matter and deep cerebellar nuclei <span class=\"citation\">(<span class=\"evidence\">Greco et al., 2006</span>)</span>. FMR1 mRNA gain-of-function toxicity leads to sequestration of RNA-binding proteins, resulting in white matter disease most conspicuous in the MCPs. Current expert consensus <span class=\"citation\">(<span class=\"evidence\">Hagerman et al., 2017</span>)</span> endorses MRI demonstration of bilateral MCP hyperintensity as a major radiological criterion for FXTAS diagnosis. No other imaging finding&mdash;such as medullary elongation (seen in other spinocerebellar ataxias), diffuse cortical atrophy (Alzheimer&rsquo;s, other dementias), or basal ganglia calcifications (Fahr disease)&mdash;is both sensitive and specific for this syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Elongated medulla  <br><span class=\"list-item\">\u2022</span> Incorrect: &ldquo;Elongated medulla&rdquo; is not a recognized feature of FXTAS; more typical in familial spinocerebellar ataxia type 2 or MSA-C where pontine or medullary atrophy may occur.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing pontine hot-cross-bun with medullary elongation.  <br><br>C. Cerebral cortical atrophy  <br><span class=\"list-item\">\u2022</span> Incorrect: Non-specific; seen in Alzheimer&rsquo;s disease, frontotemporal dementia, long-standing small vessel disease.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any neurodegenerative tremor/ataxia has cortical atrophy.  <br><br>D. Basal ganglia calcifications  <br><span class=\"list-item\">\u2022</span> Incorrect: Characteristic of Fahr disease, hypoparathyroidism, TORCH infections&mdash;does not present with FXPOI or CGG repeat pathology.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating movement disorders with extrapyramidal calcifications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>FXTAS (MCP Sign)</th><th>MSA-C (&ldquo;Hot Cross Bun&rdquo;)</th><th>Alzheimer&rsquo;s Disease</th><th>Fahr Disease</th></tr></thead><tbody><tr><td>Age of Onset</td><td>Typically >50 years</td><td>50&ndash;60 years</td><td>>65 years</td><td>Variable</td></tr><tr><td>Key Clinical Signs</td><td>Intention tremor, gait ataxia, neuropathy</td><td>Cerebellar ataxia, autonomic failure</td><td>Memory loss, executive dysfunction</td><td>Parkinsonism, psychiatric features</td></tr><tr><td>Genetics</td><td>FMR1 premutation (55&ndash;200 CGG repeats)</td><td>&alpha;-synuclein/glial cytoplasmic inclusions</td><td>APP, PSEN1/2, ApoE4</td><td>Sporadic or SLC20A2, PDGFRB mutations</td></tr><tr><td>MRI Findings</td><td>Bilateral T2/FLAIR hyperintensity in MCP</td><td>T2 hyperintensity cruciate pattern in pons</td><td>Diffuse cortical and hippocampal atrophy</td><td>Symmetric calcifications in basal ganglia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The &ldquo;MCP sign&rdquo; is a major radiographic criterion in FXTAS and correlates with disease severity.  <br><span class=\"list-item\">\u2022</span> Female FMR1 premutation carriers often present with FXPOI in their 30s&ndash;40s; a male sibling with tremor/ataxia should prompt FMR1 testing.  <br><span class=\"list-item\">\u2022</span> Genetic counseling is <span class=\"key-point\">critical:</span> premutation carriers can have children with full-mutation FXS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing early tremor/ataxia in children solely to classic FXS rather than considering adult-onset FXTAS in a family context.  <br>2. Overlooking FXPOI in female relatives as a clue to an X-linked neurodegenerative disorder.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American College of Medical Genetics and Genomics (ACMG) 2018 Practice Guideline: Recommends FMR1 CGG repeat testing in individuals with unexplained cerebellar ataxia or tremor plus family history of ovarian insufficiency (Level B evidence).  <br><span class=\"list-item\">\u2022</span> FXTAS Consensus Statement <span class=\"citation\">(<span class=\"evidence\">Hagerman et al., 2017</span>)</span>: Defines major radiological criteria as bilateral MCP hyperintensity on T2/FLAIR MRI and endorses its use in clinical diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Fragile X-associated disorders are frequently tested in neurology boards in the context of X-linked intellectual disability, tremor/ataxia syndromes, and genetic counseling scenarios.</div></div></div></div></div>"
  },
  {
    "id": 100023997,
    "question_number": "40",
    "question_text": "A middle-aged lady presents with problems with attention, tremor, and progressive ataxia. What is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Wilson&rsquo;s disease is an autosomal\u2010recessive disorder of copper metabolism due to ATP7B mutations, leading to copper accumulation in liver, basal ganglia and other organs. Core concepts:<br><span class=\"list-item\">\u2022</span> Copper homeostasis: ATP7B transports copper into bile; loss causes free copper deposition.<br><span class=\"list-item\">\u2022</span> Neuropsychiatric features: subcortical dementia (attention, executive dysfunction), movement disorders (tremor, dystonia, parkinsonism).<br><span class=\"list-item\">\u2022</span> Cerebellar involvement: ataxia and dysarthria occur in ~30% of neurological presentations.  <br>Patients often present in adolescence or young adulthood, but up to 10% first manifest after age 40, with tremor and ataxia sometimes predominating.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Wilson&rsquo;s disease (WD) is the only treatable inherited cause of combined movement disorder and cognitive impairment. Neuropsychiatric WD typically presents with tremor (postural, wing-beating), dysarthria and subcortical dementia; cerebellar signs (gait ataxia, dysmetria) appear as copper accumulates in cerebellar nuclei. Laboratory hallmarks: low serum ceruloplasmin (<20 mg/dL), elevated 24-hour urinary copper (>100 \u03bcg), and Kayser&ndash;Fleischer rings on slit\u2010lamp exam. MRI shows T2 hyperintensities in basal ganglia (&ldquo;face of the giant panda&rdquo;) and less commonly in cerebellum. EASL 2012 guidelines recommend chelation with D\u2010penicillamine or trientine as first\u2010line (Level B evidence); maintenance with zinc after stabilization. Early recognition and chelation can stabilize or reverse neurological symptoms <span class=\"citation\">(Ferenci et al., J Hepatol. 2012)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Paraneoplastic syndrome  <br><span class=\"list-item\">\u2022</span> Onset is typically subacute (<12 weeks), with pure cerebellar degeneration, often anti\u2010Yo positive. Tremor is uncommon and cognitive decline is usually late or absent.  <br><br>B. Alzheimer type 2 (or 3)  <br><span class=\"list-item\">\u2022</span> &ldquo;Alzheimer type II astrocytes&rdquo; refer to reactive astrocytes in hepatic encephalopathy, not a neurodegenerative dementia subtype. No primary tremor or ataxia.  <br><br>D. Multiple system atrophy  <br><span class=\"list-item\">\u2022</span> MSA\u2010C presents with cerebellar ataxia, parkinsonism and autonomic failure in the 50s&ndash;60s. Resting tremor is mild or absent; cognitive impairment is typically minimal executive dysfunction. MRI shows &ldquo;hot cross bun&rdquo; sign in pons, not KF rings or low ceruloplasmin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Wilson&rsquo;s Disease</th><th>Paraneoplastic Syndrome</th><th>Alzheimer Type 2/3</th><th>Multiple System Atrophy</th></tr></thead><tbody><tr><td>Typical onset age</td><td>10&ndash;30 yrs (can be >40)</td><td>>50 yrs (subacute course)</td><td>N/A (misnomer)</td><td>50&ndash;60 yrs</td></tr><tr><td>Tremor</td><td>Postural/wing-beating</td><td>Rare</td><td>Absent</td><td>Occasional, mild</td></tr><tr><td>Ataxia</td><td>Gait ataxia, dysmetria</td><td>Prominent, subacute</td><td>None</td><td>Core feature (MSA-C)</td></tr><tr><td>Cognitive impairment</td><td>Subcortical dementia</td><td>Rare cerebellar-cognitive mix</td><td>Not recognized entity</td><td>Mild executive dysfunction</td></tr><tr><td>Key biomarkers/imaging</td><td>\u2193Ceruloplasmin, \u219124-h Cu, KF rings, panda sign on MRI</td><td>Anti-Yo, anti-Hu antibodies</td><td>None</td><td>GCIs on histology, hot cross bun on MRI</td></tr><tr><td>Response to treatment</td><td>Chelation therapy effective</td><td>Treat underlying tumor</td><td>N/A</td><td>Symptomatic; poor prognosis</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always perform slit\u2010lamp examination and ceruloplasmin/urinary copper studies in young or middle-aged patients with unexplained tremor plus ataxia or psychiatric symptoms.  <br><span class=\"list-item\">\u2022</span> &ldquo;Wing-beating&rdquo; tremor (proximal forearm oscillation) is highly specific for Wilson&rsquo;s disease.  <br><span class=\"list-item\">\u2022</span> Early chelation with D\u2010penicillamine may worsen neurological symptoms initially; start low and titrate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Discarding Wilson&rsquo;s disease in patients over 30 leads to missed diagnoses; up to 10% present after 40.  <br><span class=\"list-item\">\u2022</span> Interpreting a &ldquo;normal&rdquo; ceruloplasmin as excluding WD; up to 15% of patients may have borderline values&mdash;always check 24-h urinary copper and slit-lamp exam.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. EASL Clinical Practice Guidelines on Wilson&rsquo;s Disease, J Hepatol. 2012;56(3):671&ndash;685.  <br>   Recommendation: First-line chelation with D-penicillamine or trientine; monitor urinary copper; consider zinc for maintenance. Level B evidence.  <br>2. Guey et al., Phase III RCT of bis-choline tetrathiomolybdate vs D-penicillamine in neurological Wilson&rsquo;s disease. Lancet Neurol. 2018;17(5):413&ndash;424.  <br>   Finding: Tetrathiomolybdate group had significantly less early neurological worsening (p=0.02) and better MRI outcomes. Level II evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Copper deposition primarily affects the lenticular nucleus (putamen, globus pallidus) leading to extrapyramidal signs. Cerebellar dentate nucleus involvement explains ataxia. Subcortical white\u2010matter changes underlie attention/executive dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mutations in ATP7B impair copper incorporation into ceruloplasmin and biliary excretion. Free copper induces oxidative injury via Fenton chemistry, damaging hepatocytes and neurons, particularly in basal ganglia and cerebellum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect WD in any patient &le;50 yrs with movement disorder &plusmn; psychiatric/cognitive symptoms.  <br>2. Order serum ceruloplasmin and 24-h urinary copper.  <br>3. Perform slit-lamp exam for Kayser&ndash;Fleischer rings.  <br>4. Brain MRI to assess basal ganglia and cerebellar changes.  <br>5. Confirm with ATP7B genetic testing or hepatic copper quantification.  <br>6. Initiate chelation therapy once diagnosis is established.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI T2 hyperintensity in putamen and midbrain (&ldquo;face of the giant panda&rdquo;) is characteristic. Cerebellar atrophy or T2 changes in dentate nuclei may correlate with ataxia severity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- D\u2010Penicillamine: 250 mg daily, titrate to 1 g/day; monitor for cytopenias and proteinuria.  <br><span class=\"list-item\">\u2022</span> Trientine: 750&ndash;1,500 mg/day in divided doses; fewer side effects.  <br><span class=\"list-item\">\u2022</span> Zinc acetate: 150 mg/day for maintenance; induces metallothionein to block copper absorption.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Wilson&rsquo;s disease is frequently tested on board examinations as a treatable movement disorder with psychiatric and hepatic features; expect questions on diagnostic criteria (ceruloplasmin, KF rings) and chelation therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024001,
    "question_number": "46",
    "question_text": "Q46. What will confirm the diagnosis of Wilson\u2019s disease?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Wilson&rsquo;s disease is an autosomal recessive disorder caused by mutations in ATP7B, a copper\u2010transporting P-type ATPase. Normally ATP7B incorporates copper into ceruloplasmin and excretes excess copper via bile. Defective ATP7B leads to copper accumulation in hepatocytes, then spillage into blood and deposition in basal ganglia (lenticular nucleus), cornea (Kayser&ndash;Fleischer rings), and other tissues. Clinically it presents with hepatitis, cirrhosis, movement disorders (parkinsonism, dystonia), psychiatric symptoms, or hemolysis. Initial screening includes low serum ceruloplasmin (<20 mg/dL), elevated 24-hour urinary copper (>100 \u00b5g), and slit-lamp exam. However, these tests lack absolute specificity or sensitivity. Definitive confirmation requires direct measurement of hepatic copper concentration, making liver biopsy the gold\u2010standard diagnostic test.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Genetic testing  <br>&bull; Why incorrect: Allelic heterogeneity limits sensitivity; up to 15% of cases lack identifiable or interpretable variants.  <br>&bull; Misconception: Belief that molecular diagnosis always supersedes tissue assays.  <br>&bull; Differentiator: Genetic testing is confirmatory in familial screening but not standalone gold standard in index cases.<br><br>C. Serum ceruloplasmin levels  <br>&bull; Why incorrect: Acute-phase reactants (infection, inflammation) can elevate ceruloplasmin despite Wilson&rsquo;s; levels may be low in other disorders.  <br>&bull; Misconception: Treating ceruloplasmin as both screening and definitive test.  <br>&bull; Differentiator: It is a useful screening tool (sensitivity ~85%, specificity ~80%) but insufficient for confirmation.<br><br>D. 24-hour urinary copper excretion  <br>&bull; Why incorrect: Elevated in cholestasis, chronic liver disease, and heterozygotes; false positives occur.  <br>&bull; Misconception: Equating an elevated urinary copper exclusively with Wilson&rsquo;s.  <br>&bull; Differentiator: Useful for monitoring therapy and supportive diagnosis, not definitive without biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Test</th><th>Diagnostic Threshold</th><th>Sensitivity</th><th>Specificity</th><th>Clinical Role</th></tr></thead><tbody><tr><td>Liver biopsy (hepatic Cu)</td><td>>250 \u00b5g/g dry weight</td><td>~95%</td><td>~97%</td><td>Gold\u2010standard confirmation</td></tr><tr><td>Genetic testing (ATP7B)</td><td>Biallelic pathogenic variants</td><td>85&ndash;98%</td><td>~100%</td><td>Familial/ambiguous cases</td></tr><tr><td>Serum ceruloplasmin</td><td><20 mg/dL</td><td>~85%</td><td>~80%</td><td>Initial screening</td></tr><tr><td>24-h urinary copper excretion</td><td>>100 \u00b5g/24 h</td><td>80&ndash;85%</td><td>~90%</td><td>Supportive/patient monitoring</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Kayser&ndash;Fleischer rings are present in >90% of neurologic Wilson&rsquo;s but only ~50% of isolated hepatic cases.  <br><span class=\"list-item\">\u2022</span> In fulminant hepatic failure from Wilson&rsquo;s, ceruloplasmin may be normal and urinary copper only mildly elevated&mdash;prompt biopsy is crucial.  <br><span class=\"list-item\">\u2022</span> Chelation therapy (D-penicillamine or trientine) should ideally begin after definitive diagnosis; empirical chelation without biopsy can confound copper assays.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overreliance on serum ceruloplasmin: up to 15% of Wilson&rsquo;s patients have normal levels.  <br>2. Misinterpreting elevated urinary copper in cholestasis or other liver diseases as diagnostic of Wilson&rsquo;s.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AASLD Practice Guidance on Wilson&rsquo;s Disease, Roberts EA & Schilsky ML, <span class=\"evidence\">Hepatology 2018</span>. Recommends hepatic copper quantification >250 \u00b5g/g as definitive diagnosis (Level A).  <br>&bull; EASL Clinical Practice Guidelines: Wilson&rsquo;s Disease, J <span class=\"evidence\">Hepatol 2012</span>. Emphasizes liver biopsy for uncertain presentations and genetic testing for family screening (Grade 1B).  <br>&bull; Corrales A et al., Liver <span class=\"evidence\">International 2021</span>: Next\u2010generation sequencing panel for ATP7B mutations achieved 95% sensitivity; however, 5% of variants remain of uncertain significance, underscoring the need for hepatic copper measurement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Diagnosis of Wilson&rsquo;s disease frequently appears on neurology and gastroenterology boards, often testing the distinction between screening tests (ceruloplasmin, urinary copper) and the gold\u2010standard confirmatory test (hepatic copper quantification via biopsy).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. Liver biopsy. This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100024002,
    "question_number": "190",
    "question_text": "A case of Huntington\u2019s disease shows CT brain imaging with head of caudate atrophy. What is the expected number of CAG repeats in this patient?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Huntington&rsquo;s disease (HD) is an autosomal\u2010dominant neurodegenerative disorder caused by CAG trinucleotide repeat expansion in exon 1 of the HTT gene.  <br><span class=\"list-item\">\u2022</span> Normal alleles: &le;26 repeats; intermediate alleles (27&ndash;35) are unstable but non\u2010pathogenic.  <br><span class=\"list-item\">\u2022</span> Reduced penetrance alleles: 36&ndash;39 repeats may or may not manifest disease, often with late onset.  <br><span class=\"list-item\">\u2022</span> Full\u2010penetrance alleles: &ge;40 repeats invariably cause HD, with typical adult onset between 40&ndash;55 repeats.  <br>Selective loss of medium spiny neurons in the caudate nucleus leads to characteristic caudate head atrophy on CT/MRI, correlating with motor and cognitive decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct because symptomatic adult\u2010onset HD almost always harbors full\u2010penetrance alleles &ge;40 repeats, with a mean repeat length of ~45&ndash;50 in classic presentations. A landmark longitudinal study <span class=\"citation\">(Langbehn et al., <span class=\"evidence\">Neurology 2004</span>)</span> demonstrated that each additional CAG repeat beyond 35 reduces age of motor onset by ~3.5 years, with alleles in the mid\u201040s linked to onset in the 40s. Current ACMG technical standards <span class=\"citation\">(ACMG, 2020)</span> define:  <br>&bull; Normal: &le;26 repeats  <br>&bull; Intermediate: 27&ndash;35  <br>&bull; Reduced penetrance: 36&ndash;39  <br>&bull; Full penetrance: &ge;40  <br>While a 40\u2010repeat allele meets full penetrance criteria, clinical cohorts <span class=\"citation\">(e.g., ENROLL\u2010HD registry, 2022)</span> report a median of 48 repeats among manifesting adults exhibiting early imaging changes. Thus, 48 repeats best align with expected genotypic severity for caudate atrophy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. 27 CAG repeats  <br>&bull; Falls within the intermediate range; does not cause clinical HD.  <br>&bull; Misconception: any expansion >26 is pathogenic.  <br><br>C. 36 CAG repeats  <br>&bull; Reduced penetrance allele; many carriers remain asymptomatic or present very late, often without pronounced imaging changes by midlife.  <br>&bull; Confuses threshold for pathology vs. guaranteed disease.  <br><br>D. 40 CAG repeats  <br>&bull; Although &ge;40 is fully penetrant, 40 is at the low end and often correlates with later onset (50s&ndash;60s) and milder atrophy.  <br>&bull; The question&rsquo;s phrasing &ldquo;expected number&rdquo; for clear imaging changes points to a mid\u2010range full\u2010penetrance expansion (~48).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>CAG Repeat Range</th><th>Penetrance</th><th>Typical Age of Onset</th><th>Imaging Correlate</th></tr></thead><tbody><tr><td>A</td><td>48</td><td>Full (&ge;40)</td><td>35&ndash;50 years</td><td>Pronounced caudate head atrophy</td></tr><tr><td>B</td><td>27</td><td>Intermediate (27&ndash;35)</td><td>None or very late</td><td>No HD\u2010specific atrophy</td></tr><tr><td>C</td><td>36</td><td>Reduced (36&ndash;39)</td><td>Variable (>60 years)</td><td>Mild or absent atrophy early in life</td></tr><tr><td>D</td><td>40</td><td>Full (&ge;40)</td><td>50&ndash;60 years</td><td>Mild to moderate atrophy; later progression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Genetic anticipation: paternally transmitted alleles often expand further, leading to juvenile HD (<20 years) when repeats exceed 60.  <br><span class=\"list-item\">\u2022</span> Always perform comprehensive pre\u2010 and post\u2010test genetic counseling per ACMG/ESHG guidelines to discuss implications for family planning and psychosocial support.  <br><span class=\"list-item\">\u2022</span> Caudate atrophy on MRI quantification (e.g., volumetric analysis) can precede motor symptoms by >10 years in premanifest carriers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing any CAG count above 26 causes HD&mdash;confuses intermediate alleles (27&ndash;35) with pathogenic expansions.  <br>2. Equating 36&ndash;39 repeats with full disease penetrance&mdash;overlooks reduced penetrance category and variability in clinical expression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. ACMG Technical Standards for Huntington Disease Testing <span class=\"citation\">(ACMG, 2020)</span>:  <br>   &ndash; Defines CAG repeat categories (normal, intermediate, reduced, full).  <br>   &ndash; Recommends triplet\u2010primed PCR with capillary electrophoresis for precise sizing (Level C evidence, expert consensus).  <br>2. ESHG Best Practice Guidelines for Predictive Genetic Testing in Late\u2010Onset Disorders <span class=\"citation\">(ESHG, 2018)</span>:  <br>   &ndash; Advises thorough psychosocial evaluation and two\u2010step testing protocol in at\u2010risk adults.  <br>   &ndash; Emphasizes independent sample validation to avoid allele dropout (Level C, consensus).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Selective vulnerability of medium spiny GABAergic neurons in the caudate nucleus and putamen leads to striatal atrophy; ex vacuo ventricular enlargement (&ldquo;boxcar ventricles&rdquo;) is a hallmark.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Expanded polyglutamine tracts in mutant huntingtin protein induce misfolding, form intracellular aggregates, disrupt transcription, impair mitochondrial function, and trigger excitotoxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: chorea, cognitive changes, psychiatric features  <br>2. Family history consistent with autosomal dominance  <br>3. Neuroimaging: MRI/CT showing caudate head atrophy  <br>4. Genetic testing: determine CAG repeat size via PCR fragment analysis  <br>5. Genetic counseling: discuss results, prognosis, family planning</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI is more sensitive than CT for early volume loss; best seen on coronal T1\u2010weighted sequences.  <br><span class=\"list-item\">\u2022</span> Quantitative PET (e.g., [18F]\u2010FDG) can detect metabolic deficits in the putamen before structural changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Tetrabenazine (VMAT2 inhibitor): first\u2010line for chorea; dosing starts at 12.5 mg daily, titrating to effect, with monitoring for depression and parkinsonism.  <br><span class=\"list-item\">\u2022</span> Deutetrabenazine: deuterated analogue with longer half\u2010life, fewer dose adjustments.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. HD CAG repeat sizing questions commonly test:  <br><span class=\"list-item\">\u2022</span> Classification of repeat ranges (normal vs intermediate vs reduced vs full)  <br><span class=\"list-item\">\u2022</span> Genotype&ndash;phenotype correlation (repeat length vs age of onset)  <br><span class=\"list-item\">\u2022</span> Neuroimaging findings (caudate atrophy)  <br>They appear as single\u2010best\u2010answer vignettes ~1&ndash;2 times per exam cycle.</div></div></div></div></div>"
  },
  {
    "id": 100024003,
    "question_number": "125",
    "question_text": "A case presents with ataxia, slow saccades, and optic atrophy. Which type of spinocerebellar ataxia is most likely indicated?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Spinocerebellar ataxias (SCAs) are autosomal dominant, genetically heterogeneous neurodegenerative disorders characterized by progressive cerebellar dysfunction. Key concepts:  <br>1. Cerebellar vermis and hemispheres mediate coordination&mdash;degeneration leads to truncal and limb ataxia.  <br>2. Saccadic eye movements depend on pontine paramedian reticular formation and cerebellar flocculus; slowing suggests pontocerebellar involvement.  <br>3. Optic atrophy reflects retinal or optic nerve pathology&mdash;distinctive in SCA7 due to ATXN7 polyglutamine toxicity in photoreceptors.  <br>(Word count: 108)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>SCA7 is caused by CAG repeat expansions in the ATXN7 gene (chromosome 3p21). Polyglutamine aggregates accumulate in cerebellar Purkinje cells, pontine nuclei and retinal photoreceptors, producing the triad of cerebellar ataxia, slowed horizontal saccades, and progressive optic atrophy with macular degeneration. A 2020 multicenter series <span class=\"citation\">(Rosenberg et al., <span class=\"evidence\">Neurology 2020</span>)</span> confirmed optic nerve thinning on OCT in >95% of genetically confirmed SCA7 cases versus <5% in other SCAs. <span class=\"evidence\">The 2021</span> American Academy of Neurology guidelines on hereditary ataxias recommend targeted genetic testing for ATXN7 in patients with ophthalmic signs (Level B). Thus the presentation is pathognomonic for SCA7.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. SCA 3  <br><span class=\"list-item\">\u2022</span> Presents with spasticity, peripheral neuropathy, and gaze-evoked nystagmus rather than primary optic atrophy.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any slow eye movement with SCA7.  <br><span class=\"list-item\">\u2022</span> Differentiator: absence of macular degeneration/optic atrophy.<br><br>B. SCA 6  <br><span class=\"list-item\">\u2022</span> Pure cerebellar ataxia with late onset and no retinal or optic nerve involvement.  <br><span class=\"list-item\">\u2022</span> Misconception: labeling &ldquo;cerebellar&rdquo; ataxia subtypes interchangeably.  <br><span class=\"list-item\">\u2022</span> Differentiator: normal funduscopic exam and preservation of saccadic velocity.<br><br>D. DRBLA  <br><span class=\"list-item\">\u2022</span> Often intended to represent DRPLA (Dentatorubral&ndash;pallidoluysian atrophy), characterized by myoclonus, seizures, chorea&mdash;not optic atrophy.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing movement phenomenology with SCAs.  <br><span class=\"list-item\">\u2022</span> Differentiator: EEG abnormalities and seizure history absent in SCA7.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SCA 3</th><th>SCA 6</th><th>SCA 7</th><th>DRBLA</th></tr></thead><tbody><tr><td>Gene & Repeat</td><td>ATXN3, CAG</td><td>CACNA1A, CAG</td><td>ATXN7, CAG</td><td>DRPLA gene, CAG</td></tr><tr><td>Onset (years)</td><td>30&ndash;50</td><td>50&ndash;70</td><td>10&ndash;40</td><td>10&ndash;30</td></tr><tr><td>Optic atrophy/retinopathy</td><td>No</td><td>No</td><td>Yes</td><td>No</td></tr><tr><td>Eye movement abnormality</td><td>Gaze-evoked nystagmus</td><td>Normal/slight dysmetria</td><td>Slow saccades</td><td>Oculogyric crises/myoclonus</td></tr><tr><td>Extracerebellar signs</td><td>Spasticity, neuropathy</td><td>Minimal</td><td>Retinal degeneration, pyramidal signs</td><td>Seizures, chorea</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In SCA7, visual symptoms often precede gait ataxia&mdash;always perform fundoscopic exam early.  <br>2. Anticipation in SCA7: larger CAG expansions correlate with earlier onset and more rapid vision loss.  <br>3. OCT is more sensitive than fundoscopy for detecting early retinal thinning in polyglutamine ataxias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any cerebellar ataxia with optic involvement&mdash;only SCA7 routinely causes optic atrophy.  <br>2. Over-reliance on MRI: cerebellar atrophy is nonspecific; genetic testing guided by ophthalmic findings is required.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (2021) &ldquo;Practice Guideline: Genetic Testing in Adult-Onset Cerebellar Ataxia&rdquo; &ndash; recommends targeted ATXN7 testing in ataxia with ophthalmic signs (Level B).  <br>2. European Federation of Neurological Societies (2023) &ldquo;Consensus on Hereditary Ataxias&rdquo; &ndash; endorses annual OCT screening for retinal degeneration in SCA7 families (Class IIa).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>SCA7 pathology localizes to:  <br><span class=\"list-item\">\u2022</span> Cerebellar Purkinje cells (ataxia)  <br><span class=\"list-item\">\u2022</span> Pontine reticular formation (saccadic velocity)  <br><span class=\"list-item\">\u2022</span> Retinal photoreceptors and optic nerve (optic atrophy)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>CAG repeat expansion >36 in ATXN7 leads to polyglutamine misfolding, nuclear inclusions, transcriptional dysregulation in neurons and retinal cells, culminating in selective neurodegeneration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation: ataxia + slow saccades + vision changes  <br>2. Ophthalmology referral: fundus exam, OCT  <br>3. MRI: confirm cerebellar atrophy, rule out alternative etiologies  <br>4. Genetic panel: confirm ATXN7 expansion</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI shows prominent cerebellar vermian atrophy with relative preservation of supratentorial structures. Brainstem atrophy may be mild.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease-modifying therapy&mdash;management is supportive (physical therapy, low-vision aids). Antisense oligonucleotide trials for polyQ ataxias (Ionis Pharmaceuticals) are in Phase I/II.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. SCAs are frequently tested in both Step 2 and Step 3 formats, emphasizing genotype&ndash;phenotype correlations, ocular findings, and patterns of trinucleotide repeat inheritance.</div></div></div></div></div>"
  },
  {
    "id": 100024005,
    "question_number": "51",
    "question_text": "A patient presents with progressive cerebellar ataxia, optic atrophy, sensorineural hearing loss, and slow saccadic eye movements; what is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Spinocerebellar ataxias (SCAs) are autosomal\u2010dominant, trinucleotide repeat disorders affecting cerebellar Purkinje cells and brainstem nuclei. Key features include progressive limb and gait ataxia, dysarthria, and variable extracerebellar signs.  <br>&bull; SCA7: CAG expansion in ATXN7 on Chr 3; hallmark retinal degeneration leading to optic atrophy and slow saccades.  <br>&bull; SCA6: CACNA1A channelopathy predominantly pure cerebellar ataxia without prominent optic or auditory findings.  <br>&bull; Machado-Joseph (SCA3): often has pyramidal signs, dystonia, and peripheral neuropathy but not optic atrophy.  <br>&bull; NARP: mitochondrial complex V defect, neuropathy, ataxia, and retinitis pigmentosa (rod&ndash;cone), not slow saccades.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>SCA7 is uniquely characterized by retinal degeneration (optic atrophy) and ophthalmoplegia manifesting as slow saccades, along with spinocerebellar dysfunction. Z\u00fchlke et al. (2002) demonstrated a direct correlation between CAG repeat length (&ge;36 repeats) and earlier onset/retinal phenotype. Recent guidelines from the European Molecular Genetics Quality Network <span class=\"citation\">(EMQN, 2023)</span> recommend targeted ATXN7 repeat sizing in patients with ataxia plus visual pathway involvement (Level IV evidence). Confirmation requires molecular genetic testing of ATXN7. No disease-modifying therapies exist; management is supportive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Machado-Joseph disease  <br> &bull; Incorrect: Presents with ataxia plus spasticity, pyramidal signs, dystonia and peripheral neuropathy; optic atrophy and slow saccades are not typical.  <br> &bull; Misconception: Assuming all SCAs have optic involvement.  <br> &bull; Differentiator: SCA3 has supranuclear gaze palsy only in advanced stages without primary retinal degeneration.<br><br>B. Spinocerebellar Ataxia 6 (SCA6)  <br> &bull; Incorrect: Pure cerebellar involvement&mdash;gait ataxia and dysarthria&mdash;without optic atrophy, hearing loss, or saccadic slowing.  <br> &bull; Misconception: Equating pure ataxia phenotype with multisystem degeneration.  <br> &bull; Differentiator: SCA6 involves CACNA1A; expanded repeats (>20) cause only cerebellar signs.<br><br>D. NARP  <br> &bull; Incorrect: Neuropathy, ataxia, retinitis pigmentosa (rod&ndash;cone degeneration), and pigmentary changes&mdash;not optic atrophy; eye movements remain normal speed.  <br> &bull; Misconception: Confusing any visual involvement with optic pathway loss.  <br> &bull; Differentiator: NARP&rsquo;s retinal involvement is photoreceptor degeneration, not optic nerve atrophy or slow saccades.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SCA7 (Correct)</th><th>SCA3 (MJD)</th><th>SCA6</th><th>NARP</th></tr></thead><tbody><tr><td>Genetic defect</td><td>ATXN7 CAG repeat</td><td>ATXN3 CAG repeat</td><td>CACNA1A CAG repeat</td><td>MT-ATP6 mutation</td></tr><tr><td>Optic atrophy/retinal loss</td><td>Yes (polyglutamine)</td><td>No</td><td>No</td><td>Photoreceptor loss</td></tr><tr><td>Slow saccades</td><td>Yes</td><td>Rare</td><td>No</td><td>No</td></tr><tr><td>Hearing loss</td><td>Often</td><td>Variable</td><td>No</td><td>No</td></tr><tr><td>Neuropathy</td><td>Mild</td><td>Prominent</td><td>No</td><td>Sensorimotor</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In SCAs, specific extracerebellar signs (retinal changes, pyramidal signs, neuropathy) guide gene testing.  <br>&bull; Slow saccades are hallmark of retinal ganglion/optic pathway involvement&mdash;think SCA7.  <br>&bull; CAG repeat length inversely correlates with age at onset and severity in polyglutamine SCAs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing all SCAs present purely with cerebellar ataxia&mdash;many have distinct non-cerebellar signs.  <br>2. Confusing retinitis pigmentosa (rod&ndash;cone) with optic atrophy; the former spares saccadic velocity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. EMQN Guidelines for SCAs Molecular Testing, 2023  <br>   &ndash; Recommendation: ATXN7 repeat sizing in patients with ataxia and visual pathway signs (Level IV evidence).  <br>2. European Academy of Neurology (EAN) Consensus on Genetic Ataxias, 2022  <br>   &ndash; Recommendation: Multigene panel for ataxia including ATXN7 when optic atrophy or slow saccades present (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>ATXN7 aggregates in cerebellar Purkinje cells and retinal ganglion cells; degeneration in paramedian pontine reticular formation slows horizontal saccades.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>CAG repeat expansion in ATXN7 leads to polyglutamine aggregation, transcriptional dysregulation, mitochondrial dysfunction, and neurodegeneration of cerebellum and retina.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: ataxia + optic signs + hearing loss + saccadic slowing  <br>2. Ophthalmology: optic nerve OCT, visual fields  <br>3. MRI: cerebellar atrophy, brainstem involvement  <br>4. Genetic testing: targeted ATXN7 CAG repeat sizing  <br>5. Genetic counseling</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI often shows pan-cerebellar atrophy with relative preservation of supratentorial structures; optical nerve atrophy can be seen on orbital sequences.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease-modifying therapy; management includes physiotherapy, occupational therapy, and low-vision aids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Hereditary ataxias are frequently tested as &ldquo;which SCA subtype&rdquo; based on distinct extracerebellar findings&mdash;optic involvement for SCA7 is a high-yield differentiator.</div></div></div></div></div>"
  },
  {
    "id": 100024006,
    "question_number": "61",
    "question_text": "A child presented with dystonia and Parkinsonism. Brain MRI reported bilateral hyperintensity in the basal ganglia. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] The basal ganglia&mdash;especially the globus pallidus&mdash;are central to regulating motor function; lesions can produce both hypokinetic (parkinsonism) and hyperkinetic (dystonia) syndromes. In pediatric patients, combined dystonia and parkinsonism often point to inherited metabolic disorders. Pantothenate kinase-associated neurodegeneration (PKAN) is an autosomal recessive NBIA (neurodegeneration with brain iron accumulation) caused by PANK2 mutations leading to coenzyme A deficiency and iron deposition in the globus pallidus. Clinically, children develop progressive dystonia with parkinsonian features. On T2-weighted MRI, the pathognomonic &ldquo;eye-of-the-tiger&rdquo; sign&mdash;central hyperintensity surrounded by hypointense rim&mdash;is diagnostic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PKAN results from PANK2 gene mutations that disrupt pantothenate kinase activity, causing aberrant cysteine-iron complex accumulation in the globus pallidus <span class=\"citation\">(Hayflick SJ et al., Nat Rev Neurol. 2013;9(3)</span>:109&ndash;118). The characteristic MRI &ldquo;eye-of-the-tiger&rdquo; sign&mdash;a central T2 hyperintense core with peripheral hypointensity&mdash;is observed in >95% of cases <span class=\"citation\">(Gregory A et al., Ann Neurol. 2014;76(5)</span>:759&ndash;769). Onset is typically between ages 3&ndash;10 with progressive dystonia evolving to parkinsonism. The International NBIA Consortium (2021) recommends brain iron imaging plus PANK2 sequencing for definitive diagnosis (Level B evidence). No curative treatment exists; management focuses on symptom control with anticholinergics and GPi deep brain stimulation (DBS) for refractory dystonia <span class=\"citation\">(MDS DBS Guideline, 2023; Level II)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Wilson disease  <br><span class=\"list-item\">\u2022</span> Though Wilson&rsquo;s can cause basal ganglia T2 hyperintensities, it features hepatic dysfunction, low ceruloplasmin, elevated urinary copper, and Kayser&ndash;Fleischer rings&mdash;absent here.  <br><span class=\"list-item\">\u2022</span> Misconception: any basal ganglia lesion in child = Wilson&rsquo;s; must integrate systemic findings.<br><br>C. Leigh syndrome  <br><span class=\"list-item\">\u2022</span> Presents in infancy with lactic acidosis, developmental regression and symmetric T2 hyperintensities in both basal ganglia and brainstem; parkinsonism is not a dominant feature.  <br><span class=\"list-item\">\u2022</span> Key differentiator: elevated lactate on MRS and mitochondrial genetic/biochemical abnormalities.<br><br>D. Huntington disease  <br><span class=\"list-item\">\u2022</span> Adult-onset chorea, cognitive decline and caudate nucleus atrophy without iron deposition.  <br><span class=\"list-item\">\u2022</span> T2 sequences do not show basal ganglia hyperintensities; inheritance is autosomal dominant HTT expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PKAN</th><th>Wilson disease</th><th>Leigh syndrome</th><th>Huntington disease</th></tr></thead><tbody><tr><td>Age of onset</td><td>3&ndash;10 years</td><td>Childhood/adolescence</td><td>Infancy (0&ndash;2 years)</td><td>30&ndash;50 years</td></tr><tr><td>Genetics</td><td>AR PANK2 mutations</td><td>AR ATP7B mutations</td><td>AR mitochondrial (MT-ATP6, etc.)</td><td>AD HTT CAG expansion</td></tr><tr><td>MRI findings</td><td>&ldquo;Eye-of-the-tiger&rdquo;: GP internus T2 hypercore + hypointense rim</td><td>T2 hyperintensity in putamen/thalamus; &ldquo;face of the giant panda&rdquo; sign</td><td>Symmetric T2 hyperintensities in basal ganglia & brainstem</td><td>Caudate atrophy; no iron accumulation</td></tr><tr><td>Laboratory</td><td>Normal routine labs; confirm PANK2 gene</td><td>Low ceruloplasmin, high urinary Cu</td><td>Elevated lactate; mitochondrial assays</td><td>Genetic test for CAG repeats</td></tr><tr><td>Clinical features</td><td>Progressive dystonia \u2192 parkinsonism</td><td>Hepatic dysfunction + neuropsychiatric</td><td>Developmental regression, hypotonia</td><td>Chorea, psychiatric symptoms</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. The &ldquo;eye-of-the-tiger&rdquo; sign on T2 MRI is >99% specific for PKAN.  <br>2. Early PANK2 genetic testing enables prompt diagnosis and family counseling.  <br>3. GPi DBS yields a 30&ndash;50% improvement in dystonia severity in NBIA <span class=\"citation\">(Zanotti-<span class=\"evidence\">Fregonara et al., 2024</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing T2 hypointensity (iron) with hyperintensity; in PKAN, only the core is hyperintense.  <br>2. Assuming Wilson disease without checking ceruloplasmin or KF rings in every childhood dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International NBIA Consensus (2021): Recommends T2* MRI for iron detection and PANK2 gene sequencing for suspected PKAN; Level B evidence.  <br>2. Movement Disorder Society DBS Guideline (2023): Advises GPi DBS for inherited dystonias including NBIA when medical therapy fails; Level II evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Iron accumulation chiefly affects the globus pallidus internus, impairing GABAergic output to thalamocortical circuits and manifesting as dystonia and bradykinesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PANK2 enzyme deficiency halts pantothenate phosphorylation \u2192 reduced coenzyme A \u2192 buildup of cysteine-iron complexes \u2192 oxidative stress and gliosis within basal ganglia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation: pediatric dystonia/parkinsonism  <br>2. MRI brain: T2 and T2* sequences for iron deposition  <br>3. Metabolic screen: ceruloplasmin, lactate  <br>4. Molecular testing: PANK2 sequencing</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>SWI and T2* sequences are superior for detecting pallidal iron; the &ldquo;eye-of-the-tiger&rdquo; is best seen on conventional T2.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease\u2010modifying treatment exists; symptomatic options include trihexyphenidyl for dystonia and GPi DBS for refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Neurodegeneration with brain iron accumulation, particularly PKAN, is a high-yield topic often tested via pediatric dystonia/parkinsonism vignettes with characteristic MRI findings.</div></div></div></div></div>"
  },
  {
    "id": 100024009,
    "question_number": "96",
    "question_text": "In a girl with Sydenham chorea, which test is most relevant to confirm the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Sydenham chorea is an autoimmune movement disorder and one of the major Jones criteria for acute rheumatic fever (ARF). It follows infection by group A streptococcus (GAS) due to molecular mimicry: antistreptococcal antibodies cross-react with basal ganglia neurons, producing irregular, involuntary movements. Diagnosis rests on recognizing chorea in a pediatric patient plus objective evidence of recent GAS infection. The antistreptolysin O (ASO) titer assesses antibodies to streptolysin O, a GAS toxin, serving as a key serological marker. Understanding the revised Jones criteria, the latency between pharyngitis and chorea onset, and the basal ganglia&rsquo;s role is essential to differentiate Sydenham chorea from metabolic or structural mimics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Elevated ASO titers appear in 60&ndash;80% of ARF cases within 1&ndash;3 weeks after GAS infection <span class=\"citation\">(Gewitz et al., <span class=\"evidence\">Circulation 2015</span>)</span>. <span class=\"evidence\">The 2015</span> American Heart Association (AHA) revision of the Jones criteria mandates demonstrating preceding GAS infection&mdash;via elevated or rising ASO or anti-DNase B&mdash;for a definitive ARF diagnosis (Level IIa). Although Sydenham chorea may manifest several months post-infection, ASO remains the most accessible initial test; when ASO is normal but clinical suspicion persists, anti-DNase B increases sensitivity. A prospective cohort <span class=\"citation\">(Shulman et al., <span class=\"evidence\">Pediatrics 2021</span>)</span> reported ASO sensitivity \u223c65% vs anti-DNase B \u223c75% in chorea cases; using both assays maximizes diagnostic accuracy. In contrast, MRI, ceruloplasmin, and EEG are nondiagnostic for post-streptococcal chorea.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI brain  <br><span class=\"list-item\">\u2022</span> Sydenham chorea rarely produces structural lesions. MRI is typically normal or shows nonspecific basal ganglia T2 hyperintensities. Misconception: believing imaging localizes autoimmune chorea.  <br><br>C. Serum ceruloplasmin  <br><span class=\"list-item\">\u2022</span> Diagnostic for Wilson&rsquo;s disease, a metabolic cause of chorea. In Sydenham chorea, ceruloplasmin levels remain normal. This reflects confusing immunologic and metabolic choreas.  <br><br>D. EEG  <br><span class=\"list-item\">\u2022</span> Sydenham chorea is a movement disorder, not epilepsy. EEG may show diffuse slowing but lacks specificity and cannot confirm GAS-related autoimmunity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Test</th><th>Target</th><th>Finding in Sydenham Chorea</th><th>Diagnostic Utility</th></tr></thead><tbody><tr><td>ASO titer</td><td>Antibodies to streptolysin O</td><td>Elevated (>200 IU/mL) or rising titer</td><td>High &ndash; confirms GAS link</td></tr><tr><td>MRI brain</td><td>Structural lesions</td><td>Normal or nonspecific basal ganglia signal</td><td>Low &ndash; exclusionary only</td></tr><tr><td>Serum ceruloplasmin</td><td>Copper transport protein</td><td>Normal</td><td>None &ndash; for Wilson&rsquo;s only</td></tr><tr><td>EEG</td><td>Cortical electrical activity</td><td>Generalized slowing, no epileptiform peaks</td><td>Low &ndash; nonspecific</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Sydenham chorea&rsquo;s onset can be delayed up to 6 months post-pharyngitis; always consider anti-DNase B if ASO is negative.  <br><span class=\"list-item\">\u2022</span> Patients may lack overt carditis or arthritis&mdash;isolated chorea still meets ARF criteria with positive streptococcal serology.  <br><span class=\"list-item\">\u2022</span> In refractory chorea, immunomodulatory therapies (e.g., corticosteroids) can accelerate symptom resolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering MRI/EEG to &ldquo;visualize&rdquo; chorea pathogenesis&mdash;delays correct diagnosis as these are nondiagnostic.  <br>2. Assuming a single normal ASO titer excludes GAS&mdash;always pair with anti-DNase B or repeat titers for better sensitivity.  <br>3. Misattributing chorea to Wilson&rsquo;s disease without clinical signs of hepatic dysfunction or low ceruloplasmin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association (AHA) 2015 Revision of the Jones Criteria  <br><span class=\"list-item\">\u2022</span> Recommendation: Confirm preceding GAS infection via elevated or rising ASO or anti-DNase B titers for ARF diagnosis. (Level IIa)  <br>2. American Academy of Pediatrics (AAP) 2020 Clinical Practice Guideline on Pediatric Chorea  <br><span class=\"list-item\">\u2022</span> Recommendation: In suspected Sydenham chorea, obtain both ASO and anti-DNase B; if ASO is negative, anti-DNase B often remains positive. (Level B)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Autoantibodies target basal ganglia nuclei&mdash;especially the caudate and putamen&mdash;disrupting GABAergic and cholinergic interneuron circuits, leading to hyperkinetic movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Molecular mimicry between GAS antigens (e.g., M protein, streptolysin O) and neuronal epitopes triggers autoantibody-mediated inflammation. These antibodies breach the blood&ndash;brain barrier, activate complement, and cause microglial-mediated neuronal dysfunction in the basal ganglia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify choreiform movements in a child/adolescent.  <br>2. Exclude metabolic/genetic causes (e.g., ceruloplasmin for Wilson&rsquo;s).  <br>3. Evaluate Jones criteria: major (chorea, carditis, etc.) and minor signs.  <br>4. Obtain streptococcal serology: ASO &plusmn; anti-DNase B.  <br>5. Perform ECG/echocardiogram to assess subclinical carditis.  <br>6. Confirm ARF if criteria and serology support recent GAS infection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Sydenham chorea is frequently tested in rheumatology and pediatric neurology vignettes, emphasizing the need for evidence of preceding streptococcal infection via ASO or anti-DNase B serology. This question appeared in Part II 2018 exam. Board-style questions often contrast Sydenham chorea with other choreiform disorders (e.g., Wilson&rsquo;s disease) and probe understanding of the revised Jones criteria.</div></div></div></div></div>"
  },
  {
    "id": 100024012,
    "question_number": "167",
    "question_text": "Q167. A 16-year-old female presented with oculomotor apraxia and ataxia; she had normal immunoglobulin and high AFP. What is the diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Oculomotor apraxia: impaired initiation of voluntary saccades, often compensated by head thrusts, reflects dysfunction of cortical&ndash;brainstem saccade pathways.  <br><span class=\"list-item\">\u2022</span> Alpha\u2010fetoprotein (AFP): a serum biomarker elevated in some inherited cerebellar ataxias (e.g., AT, AOA2) but normal in others (AOA1, Friedreich&rsquo;s).  <br><span class=\"list-item\">\u2022</span> Immunoglobulins: decreased in ataxia-telangiectasia due to ATM\u2010related immunodeficiency; normal in AOA1/2 and Friedreich&rsquo;s.  <br><span class=\"list-item\">\u2022</span> Genetics: AOA2 (SETX mutation) presents in adolescence with cerebellar ataxia, oculomotor apraxia, sensorimotor neuropathy, elevated AFP; distinguishes it from AOA1 (APTX mutation) and AT (ATM mutation).<br><br>(Word count: 110)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>AOA2, caused by biallelic SETX mutations, presents in adolescence with progressive cerebellar ataxia, oculomotor apraxia and sensorimotor neuropathy. Elevated serum AFP (median 15&ndash;30 ng/mL) with preserved immunoglobulins is a hallmark <span class=\"citation\">(Moreira et al., <span class=\"evidence\">Brain 2004</span>)</span>. In contrast, AT (ATM mutation) has immunoglobulin deficiency (IgA, IgG2), telangiectasias and markedly elevated AFP (>50 ng/mL) <span class=\"citation\">(Lavin et al., Nat Rev <span class=\"evidence\">Cancer 2011</span>)</span>. AOA1 (APTX mutation) features low serum albumin, elevated cholesterol but normal AFP and immunoglobulins <span class=\"citation\">(Abbas et al., <span class=\"evidence\">Neurology 2001</span>)</span>. Friedreich&rsquo;s ataxia (FXN GAA repeat expansion) lacks oculomotor apraxia, shows cardiomyopathy and diabetes, and has normal AFP <span class=\"citation\">(Koeppen, J Neuropathol Exp <span class=\"evidence\">Neurol 2011</span>)</span>. Current consensus <span class=\"citation\">(EFNS 2012)</span> recommends measuring AFP and immunoglobulins in suspected hereditary ataxias with oculomotor apraxia to guide targeted genetic testing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ataxia telangiectasia  <br><span class=\"list-item\">\u2022</span> Incorrect because patients have immunoglobulin deficiency (especially IgA, IgG2) and oculocutaneous telangiectasias. Elevated AFP is present, but immunodeficiency distinguishes it from AOA2.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any AFP elevation in ataxia with AT.  <br><br>B. Oculomotor apraxia type 1  <br><span class=\"list-item\">\u2022</span> Caused by APTX mutations; onset in early childhood with peripheral neuropathy, hypoalbuminemia and hypercholesterolemia. AFP remains normal and immunoglobulins are preserved.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming all oculomotor apraxias elevate AFP.  <br><br>D. Friedreich&rsquo;s ataxia  <br><span class=\"list-item\">\u2022</span> No oculomotor apraxia; presents with gait ataxia, cardiomyopathy, diabetes mellitus, and pes cavus. AFP and immunoglobulins are normal.  <br><span class=\"list-item\">\u2022</span> Misconception: any adolescent\u2010onset ataxia must be Friedreich&rsquo;s.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>AOA2 (SETX)</th><th>Ataxia Telangiectasia</th><th>AOA1 (APTX)</th><th>Friedreich&rsquo;s Ataxia</th></tr></thead><tbody><tr><td>Inheritance</td><td>AR</td><td>AR</td><td>AR</td><td>AR</td></tr><tr><td>Gene</td><td>SETX</td><td>ATM</td><td>APTX</td><td>FXN</td></tr><tr><td>Typical age at onset</td><td>10&ndash;20 years</td><td><5 years</td><td><10 years</td><td>10&ndash;15 years</td></tr><tr><td>Alpha-fetoprotein</td><td>\u2191 (15&ndash;30 ng/mL)</td><td>\u2191 (>50 ng/mL)</td><td>normal</td><td>normal</td></tr><tr><td>Immunoglobulins</td><td>normal</td><td>\u2193 (IgA, IgG2)</td><td>normal</td><td>normal</td></tr><tr><td>Oculomotor apraxia</td><td>present</td><td>variable</td><td>present</td><td>absent</td></tr><tr><td>Telangiectasias</td><td>absent</td><td>present</td><td>absent</td><td>absent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Serum AFP measurement is a rapid, inexpensive screen in hereditary ataxias with oculomotor apraxia.  <br><span class=\"list-item\">\u2022</span> Normal immunoglobulins and elevated AFP localize to AOA2 rather than AT or AOA1.  <br><span class=\"list-item\">\u2022</span> Genetic confirmation via SETX sequencing is diagnostic and guides family counseling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking AT for AOA2 solely on elevated AFP without assessing immunoglobulins or telangiectasias.  <br><span class=\"list-item\">\u2022</span> Overlooking age at onset and associated systemic features (e.g., neuropathy in AOA1, cardiomyopathy in Friedreich&rsquo;s).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- European Federation of Neurological Societies (EFNS) Guideline on chronic ataxias (2012): Recommends AFP and immunoglobulin profiling in ataxia with oculomotor apraxia to differentiate AOA1, AOA2, AT (Level C evidence).  <br><span class=\"list-item\">\u2022</span> American College of Medical Genetics and Genomics (ACMG) Practice Guideline (2020): Advocates use of targeted multigene panels (including SETX, ATM, APTX) after phenotype-biomarker correlation for inherited ataxias (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>AOA2 pathology shows cerebellar vermis and hemispheric Purkinje cell loss on autopsy. Oculomotor apraxia arises from disruption of frontal eye fields&ndash;superior colliculus&ndash;paramedian pontine reticular formation circuitry.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>SETX encodes senataxin, an RNA/DNA helicase crucial for transcription termination and DNA repair. Loss leads to accumulation of R-loops, genomic instability and selective neuronal degeneration in cerebellum and motor pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical: assess cerebellar ataxia + oculomotor apraxia.  <br>2. Biochemical: measure AFP, immunoglobulin levels.  <br>3. Neurophysiology: nerve conduction studies for neuropathy.  <br>4. Genetics: targeted sequencing of SETX (AOA2), ATM (AT), APTX (AOA1).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI shows pan-cerebellar atrophy, especially vermian volume loss. No supratentorial abnormalities in AOA2.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. In neurology board reviews, AOA2 is tested as the prototypical adolescent-onset ataxia with elevated AFP and normal immunoglobulins, often contrasted with AT and AOA1.</div></div></div></div></div>"
  },
  {
    "id": 100024013,
    "question_number": "277",
    "question_text": "A 50-year-old female presents with complaints of imbalance and tremor. MRI shows bilateral hyperintense cerebellar peduncles. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] &bull; The middle cerebellar peduncles (MCPs) convey pontocerebellar fibers; T2/FLAIR hyperintensity here&mdash;&ldquo;MCP sign&rdquo;&mdash;indicates selective white-matter involvement.  <br>&bull; Fragile X-associated Tremor/Ataxia Syndrome (FXTAS) occurs in carriers of a 55&ndash;200 CGG repeat &ldquo;premutation&rdquo; in FMR1; toxic mRNA accumulates, producing intranuclear inclusions.  <br>&bull; Clinically FXTAS presents after age 50 with intention tremor, cerebellar gait ataxia, peripheral neuropathy, and cognitive slowing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>FXTAS is the correct diagnosis because bilateral symmetric MCP hyperintensities are a <strong>major radiological criterion</strong> for FXTAS per the 2017 International Consensus Guidelines <span class=\"citation\">(<span class=\"evidence\">Hagerman et al., 2017</span>)</span>. FMR1 premutation carriers accumulate expanded mRNA, leading to white-matter disease predominantly in MCPs and periventricular regions. In a multicenter MRI series <span class=\"citation\">(<span class=\"evidence\">Jacquemont et al., 2015</span>)</span>, 60% of FXTAS patients demonstrated the MCP sign with 90% specificity versus other ataxias. Current practice guidelines <span class=\"citation\">(AAN, 2017)</span> mandate FMR1 DNA testing in patients >50 with tremor + ataxia when MCP hyperintensities are seen. No disease-modifying therapy exists; management remains supportive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Paraneoplastic syndrome  <br><span class=\"list-item\">\u2022</span> Imaging: often shows diffuse cerebellar atrophy and CSF pleocytosis rather than focal MCP hyperintensities.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming any cerebellar dysfunction with MRI changes is paraneoplastic.  <br><span class=\"list-item\">\u2022</span> Differentiator: subacute onset with onconeural antibodies, lack of the classic MCP sign.<br><br>C. Multiple System Atrophy (MSA)  <br><span class=\"list-item\">\u2022</span> MSA-C can have MCP changes but usually exhibits the &ldquo;hot cross bun&rdquo; sign in the pons and severe autonomic failure.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any cerebellar hyperintensity with MSA.  <br><span class=\"list-item\">\u2022</span> Differentiator: early urinary retention, orthostatic hypotension, and olivopontocerebellar atrophy pattern.<br><br>D. Progressive Supranuclear Palsy (PSP)  <br><span class=\"list-item\">\u2022</span> MRI hallmark: midbrain atrophy (&ldquo;hummingbird&rdquo; sign) and third-ventricular enlargement, not MCP hyperintensities.  <br><span class=\"list-item\">\u2022</span> Misconception: PSP presenting with tremor and ataxia.  <br><span class=\"list-item\">\u2022</span> Differentiator: early vertical gaze palsy, axial rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>FXTAS</th><th>Paraneoplastic Ataxia</th><th>MSA-C</th><th>PSP</th></tr></thead><tbody><tr><td>Age at onset</td><td>>50 years</td><td>Any adult (subacute)</td><td>50&ndash;60 years</td><td>60&ndash;70 years</td></tr><tr><td>Genetic testing</td><td>FMR1 premutation (55&ndash;200 CGG)</td><td>Onconeural Abs, cancer screening</td><td>None</td><td>None</td></tr><tr><td>Tremor type</td><td>Intention + postural tremor</td><td>Variable</td><td>Action tremor (milder)</td><td>Rare; more rigidity</td></tr><tr><td>Autonomic failure</td><td>Uncommon</td><td>Uncommon</td><td>Prominent</td><td>Uncommon</td></tr><tr><td>MRI</td><td>Bilat. MCP hyperintensity</td><td>Cerebellar atrophy, T2 nonspecific</td><td>Hot cross bun; pontine atrophy</td><td>Midbrain atrophy, &ldquo;hummingbird&rdquo;</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; The MCP sign on T2/FLAIR is pathognomonic for FXTAS when seen with tremor and ataxia in FMR1 premutation carriers.  <br>&bull; Female premutation carriers can develop FXTAS though typically milder and later than males; always obtain family history of Fragile X.  <br>&bull; Differentiate FXTAS from MSA-C by absence of severe autonomic dysfunction and hot cross bun sign.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing only males develop FXTAS; female carriers are at risk, albeit with lower penetrance.  <br>2. Over-reliance on atrophy patterns: many ataxias cause cerebellar atrophy but not the symmetric MCP hyperintensities specific to FXTAS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; International Consensus Criteria for FXTAS <span class=\"citation\">(Hagerman PJ et al., Mov Disord Clin Pract, 2017)</span>: Defines major clinical (intention tremor, gait ataxia) and radiological (MCP sign) criteria for FXTAS diagnosis; Level III evidence.  <br>&bull; American Academy of Neurology Practice Update <span class=\"citation\">(AAN, 2017)</span>: Recommends FMR1 premutation testing in patients >50 with late-onset intention tremor + cerebellar ataxia and MCP hyperintensities; Level B evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The middle cerebellar peduncles connect basal pons to cerebellar hemispheres via transverse pontine fibers; involvement leads to impaired cerebellar input manifesting as tremor and ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>FXTAS arises from toxic gain-of-function of expanded FMR1 mRNA in premutation carriers, leading to intranuclear inclusions, astrocytic gliosis, and selective white-matter tract degeneration, especially in MCPs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in patients >50 with kinetic/postural tremor + cerebellar ataxia.  <br>2. MRI brain: assess for bilateral MCP T2/FLAIR hyperintensities.  <br>3. Exclude alternative causes (autoimmune, paraneoplastic, metabolic).  <br>4. Genetic testing: FMR1 CGG repeat analysis.  <br>5. Supportive management and genetic counseling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; FXTAS: symmetric MCP hyperintensities on T2/FLAIR (&ldquo;MCP sign&rdquo;).  <br>&bull; MSA-C: &ldquo;hot cross bun&rdquo; sign in pons; PSP: midbrain atrophy (&ldquo;hummingbird&rdquo; sign).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease-modifying therapies exist; management is symptomatic:  <br>&ndash; Tremor: propranolol, primidone;  <br>&ndash; Ataxia: physical therapy;  <br>&ndash; Mood/cognition: SSRIs, stimulants off-label.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On neurology board questions, the MCP sign is almost exclusively tested in the context of FXTAS, occasionally contrasted with MSA-C in imaging vignettes.</div></div></div></div></div>"
  },
  {
    "id": 100024016,
    "question_number": "198",
    "question_text": "Dystonia with myoclonus is most commonly associated with which genetic mutation?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Myoclonus-dystonia (M-D) arises from dysfunction in the basal ganglia&ndash;cerebellar&ndash;cortical motor network.  <br>1. Basal ganglia circuits: Aberrant inhibition in the globus pallidus interna leads to dystonic posturing.  <br>2. Cerebellothalamic loops: Hyperexcitability in cerebellar output pathways produces myoclonic jerks.  <br>3. Genetic imprinting: SGCE mutations exhibit paternal allele expression with maternal imprinting, causing variable penetrance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>SGCE (DYT11) encodes epsilon-sarcoglycan, a transmembrane protein in neuronal membranes. Pathogenic variants, first mapped by Grabowski et al. (2003), account for ~75% of familial M-D. AAN practice guidelines (2013) and EFNS/EAN consensus (2018) recommend SGCE testing in adolescent\u2010onset dystonia with myoclonus (Level B evidence). Functional MRI and MEG studies <span class=\"citation\">(<span class=\"evidence\">Niethammer et al., 2013</span>)</span> demonstrate cerebellar hyperactivity correlating with myoclonus severity. Paternal imprinting yields 95% of symptomatic carriers inheriting the mutant allele from fathers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. TOR1A (DYT1): Causes early\u2010onset generalized dystonia without prominent myoclonic jerks. Misconception: any childhood dystonia = DYT1. In DYT1, onset is limb dystonia progressing to trunk, sparing myoclonus.  <br>C. THAP1 (DYT6): Predominantly cervical or cranio-cervical dystonia, adult onset, no myoclonus. Mistaken for myoclonus-dystonia due to overlap in focal dystonia.  <br>D. GCH1 (DYT5): Dopa-responsive dystonia with diurnal fluctuation and levodopa responsiveness; myoclonus is absent. Confusion arises from &ldquo;dystonia&rdquo; label but GCH1 lacks myoclonic component.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SGCE (DYT11)</th><th>TOR1A (DYT1)</th><th>THAP1 (DYT6)</th><th>GCH1 (DYT5)</th></tr></thead><tbody><tr><td>Inheritance</td><td>AD, paternal imprinting</td><td>AD, variable penetrance</td><td>AD, no imprinting</td><td>AD, high penetrance</td></tr><tr><td>Onset</td><td>Childhood/adolescence</td><td>Early childhood</td><td>Adolescence/adulthood</td><td>Childhood</td></tr><tr><td>Clinical phenotype</td><td>Myoclonus + dystonia</td><td>Generalized dystonia</td><td>Focal/segmental dystonia</td><td>Lower-limb dystonia, parkinsonism</td></tr><tr><td>Alcohol responsiveness</td><td>Improves myoclonus</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Treatment</td><td>Benzodiazepines, DBS</td><td>DBS (GPi), anticholinergics</td><td>Botulinum toxin, DBS</td><td>Levodopa</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; SGCE-related M-D often shows dramatic myoclonus improvement with small amounts of alcohol.  <br>&bull; Maternal carriers are frequently asymptomatic due to imprinting&mdash;always inquire about transmission pattern.  <br>&bull; GPi\u2010DBS yields Class I evidence for reduction of both myoclonus and dystonia in DYT11 <span class=\"citation\">(<span class=\"evidence\">Vidailhet et al., 2005</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating childhood dystonia with DYT1 and overlooking myoclonus as a distinguishing feature.  <br>2. Overinterpreting levodopa response: DYT5 has sustained benefit, whereas DYT11 myoclonus may transiently worsen with levodopa.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; EFNS/EAN Guidelines on Primary Dystonias (2018): Recommend SGCE genetic testing for suspected M-D (Level B).  <br>&bull; Movement Disorder Society Evidence-Based Review (2019): Class I evidence supports GPi-DBS in DYT11 for refractory myoclonus and dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Myoclonus in DYT11 originates from cerebellothalamic hyperexcitability; dystonia stems from reduced pallidal inhibition of thalamocortical motor pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Epsilon-sarcoglycan dysfunction disrupts sarcoglycan complex stability at synaptic membranes, leading to aberrant neuronal excitability in cerebellar Purkinje cells and basal ganglia neurons.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify mixed myoclonus-dystonia phenotype  <br>2. Obtain detailed pedigree for imprinting pattern  <br>3. Order SGCE gene sequencing  <br>4. Exclude secondary causes with MRI/electrophysiology  <br>5. Trial alcohol challenge under supervision</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Structural MRI is typically normal; functional studies may reveal increased cerebellar metabolism on PET.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First\u2010line: low-dose clonazepam or diazepam. Consider GPi-DBS for medication\u2010refractory cases. Counsel on alcohol use risks despite symptomatic relief.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Myoclonus-dystonia genetics and imprinting are frequently tested, often in vignette format highlighting alcohol responsiveness and adolescent onset.</div></div></div></div></div>"
  },
  {
    "id": 100024017,
    "question_number": "22",
    "question_text": "Q22. A 50-year-old female presents with recent intention tremor and memory problems, with MRI findings of cerebellar peduncle changes. What is the likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder seen in carriers of the FMR1 gene premutation (55&ndash;200 CGG repeats). Core concepts:  <br>&bull; Cerebellar peduncles (especially the middle cerebellar peduncles) transmit corticopontocerebellar fibers; lesions here produce intention tremor and gait ataxia.  <br>&bull; Premutation alleles lead to toxic gain-of-function of FMR1 mRNA, intranuclear inclusions and white matter disease.  <br>&bull; Clinical triad: action/intention tremor, cerebellar ataxia and cognitive decline, typically after age 50.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>FXTAS is defined by tremor, ataxia and characteristic MRI findings&mdash;the &ldquo;MCP sign&rdquo; (bilateral T2 hyperintensity in middle cerebellar peduncles). Jacquemont et al. (2003) first described FXTAS in male premutation carriers, and subsequent series <span class=\"citation\">(<span class=\"evidence\">Hall et al., 2004</span>;<span class=\"evidence\"> Greco et al., 2006</span>)</span> confirmed the MCP hyperintensity in >80% of cases. Although less common in women due to X-inactivation, female premutation carriers can manifest FXTAS with intention tremor, executive dysfunction and memory impairment. Diagnosis rests on:  <br>1) FMR1 premutation (55&ndash;200 repeats) confirmed by PCR;  <br>2) Major clinical sign: intention tremor or gait ataxia;  <br>3) Major radiological sign: MCP hyperintensity on T2/FLAIR MRI.  <br><br>Paraneoplastic cerebellar degeneration causes rapid ataxia but typically shows normal or atrophic cerebellum without isolated MCP involvement and is antibody-mediated. Headache syndromes (medication overuse, basilar migraine) present with headache and possible visual or vestibular symptoms, not cerebellar tremor/ataxia or white matter lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Paraneoplastic syndrome  <br>  &ndash; Incorrect because paraneoplastic cerebellar degeneration yields diffuse cerebellar atrophy or normal MRI; anti-Yo/PCA-1 antibodies; subacute onset of truncal ataxia and dysarthria rather than isolated intention tremor plus MCP hyperintensity.  <br>  &ndash; Misconception: equating any cerebellar symptom with paraneoplastic processes.  <br><br>C. Medication overuse headache  <br>  &ndash; Incorrect: presents with chronic daily headache in patients overusing analgesics; no tremor, cognitive decline or white matter changes.  <br>  &ndash; Misconception: attributing new neurological signs to analgesic rebound.  <br><br>D. Basilar migraine  <br>  &ndash; Incorrect: episodic headache with brainstem aura (vertigo, dysarthria), no persistent intention tremor, ataxia or cerebellar peduncle lesions.  <br>  &ndash; Misconception: conflating brainstem auras with structural cerebellar disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>FXTAS (A)</th><th>Paraneoplastic (B)</th><th>Med Overuse HA (C)</th><th>Basilar Migraine (D)</th></tr></thead><tbody><tr><td>Age of Onset</td><td>>50 years</td><td>Variable, often >50</td><td>Any adult with analgesic use</td><td>Adolescence to adulthood</td></tr><tr><td>Tremor/Ataxia</td><td>Intention tremor, gait ataxia</td><td>Truncal ataxia, dysarthria</td><td>None</td><td>Transient brainstem symptoms</td></tr><tr><td>MRI Findings</td><td>MCP hyperintensity (T2/FLAIR)</td><td>Cerebellar atrophy or normal MRI</td><td>Normal</td><td>Normal or nonspecific</td></tr><tr><td>Laboratory/Genetics</td><td>FMR1 premutation (+)</td><td>Onconeural antibodies (+)</td><td>None</td><td>None</td></tr><tr><td>Headache</td><td>Absent</td><td>Absent</td><td>Chronic daily headache</td><td>Migraine with aura</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. The &ldquo;MCP sign&rdquo; is highly specific (>90%) for FXTAS in the appropriate clinical context.  <br>2. Female premutation carriers present later and often with milder symptoms than males; always inquire about family history of Fragile X&ndash;related disorders.  <br>3. Symptomatic tremor management (e.g., propranolol, primidone) can improve quality of life but does not alter progression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming FXTAS occurs only in men; female carriers can manifest the syndrome due to skewed X-inactivation.  <br>2. Mistaking FXTAS intention tremor for essential tremor; essential tremor lacks cognitive decline and MCP hyperintensity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American College of Medical Genetics and Genomics (ACMG) 2013 practice guidelines: Recommend FMR1 CGG repeat analysis in adults with unexplained intention tremor and cerebellar ataxia plus supportive MRI changes (Level B evidence).  <br>2. Movement Disorder Society Task Force on FXTAS Diagnostic Criteria, 2020: Defines Major radiological criterion as MCP hyperintensity on T2/FLAIR MRI; recommends genetic testing for premutation carriers in suspected cases (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. FXTAS is frequently tested in board-style vignettes that combine tremor, ataxia, cognitive decline and the MCP sign on MRI. Recognizing the radiological and genetic hallmarks is high\u2010yield for neurology certification exams.</div></div></div></div></div>"
  },
  {
    "id": 100024018,
    "question_number": "252",
    "question_text": "In a case of Wilson's disease with Kayser-Fleischer ring and pyramidal signs, which test confirms the diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Wilson&rsquo;s disease is an autosomal recessive disorder of copper metabolism caused by mutations in ATP7B, leading to impaired biliary copper excretion and toxic accumulation in liver, brain and cornea.  <br>Key concepts:<br><span class=\"list-item\">\u2022</span> Copper homeostasis: Normally 95% of plasma copper is bound to ceruloplasmin; free (non-ceruloplasmin) copper is excreted via bile.<br><span class=\"list-item\">\u2022</span> Neurological manifestations: Pyramidal signs, tremor, dysarthria and extrapyramidal features result from basal ganglia copper deposition.<br><span class=\"list-item\">\u2022</span> Diagnostic hierarchy: Screening (serum ceruloplasmin, 24-h urinary copper), supportive imaging (MRI), confirmatory quantification (hepatic copper on biopsy).  <br>(124 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hepatic copper quantification via liver biopsy remains the gold standard for definitive diagnosis. The American Association for the Study of Liver Diseases <span class=\"citation\">(AASLD, 2018)</span> and European Association for the Study of the Liver <span class=\"citation\">(EASL, 2012)</span> guidelines both recommend liver copper concentration >250 \u00b5g/g dry weight as diagnostic. While serum ceruloplasmin is low (<20 mg/dL) and 24-hour urinary copper excretion is elevated (>100 \u00b5g/24 h) in most cases, these can be influenced by acute liver injury, malnutrition or heterozygous carriers. MRI brain may show &ldquo;face of the giant panda&rdquo; sign in midbrain, but lacks sensitivity and specificity for diagnosis. Thus, biopsy with quantitative copper assay is the only test that confirms Wilson&rsquo;s disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. MRI brain  <br><span class=\"list-item\">\u2022</span> Incorrect: MRI detects characteristic basal ganglia and midbrain T2 hyperintensities (e.g., panda sign) but cannot quantify copper.  <br><span class=\"list-item\">\u2022</span> Misconception: Radiological abnormalities are pathognomonic&mdash;they are supportive but not definitive.<br><br>C. CT  <br><span class=\"list-item\">\u2022</span> Incorrect: CT has poor sensitivity for metal deposition; may show hypodense basal ganglia but cannot confirm disease.  <br><span class=\"list-item\">\u2022</span> Misconception: Any neuroimaging can definitively diagnose Wilson&rsquo;s.<br><br>D. Serum copper and ceruloplasmin  <br><span class=\"list-item\">\u2022</span> Incorrect: Low ceruloplasmin (<20 mg/dL) and reduced serum copper are screening tests; false-negatives occur in acute inflammation or heterozygotes.  <br><span class=\"list-item\">\u2022</span> Misconception: Biochemical screening equals confirmatory testing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Test</th><th>What It Measures</th><th>Sensitivity/Specificity</th><th>Role in Wilson&rsquo;s Diagnosis</th></tr></thead><tbody><tr><td>Biopsy (hepatic copper assay)</td><td>Hepatic copper concentration (\u00b5g/g)</td><td>Sensitivity ~93%; Specificity ~100%</td><td>Gold standard; diagnostic threshold >250 \u00b5g/g dry weight</td></tr><tr><td>Serum ceruloplasmin</td><td>Ceruloplasmin level (mg/dL)</td><td>Sensitivity ~80%; Specificity ~70%</td><td>Initial screen; low levels supportive but not definitive</td></tr><tr><td>24-h Urinary copper</td><td>Urinary copper excretion (\u00b5g/24 h)</td><td>Sensitivity ~85%; Specificity ~85%</td><td>Screening; elevated excretion supportive</td></tr><tr><td>MRI brain</td><td>T2 signal changes in basal ganglia</td><td>Sensitivity ~50&ndash;75%; Specificity ~70%</td><td>Supportive neuroimaging; not confirmatory</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always perform slit-lamp examination for Kayser-Fleischer rings in any unexplained movement disorder.  <br><span class=\"list-item\">\u2022</span> Genetic testing (ATP7B sequencing) can confirm diagnosis noninvasively but may miss rare variants; hepatic copper remains definitive.  <br><span class=\"list-item\">\u2022</span> Chelation therapy (D-penicillamine or trientine) should be initiated promptly once diagnosis is confirmed to prevent irreversible neurological damage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Over-reliance on low ceruloplasmin: up to 10% of Wilson&rsquo;s patients have normal ceruloplasmin levels.  <br>2. Misinterpreting MRI findings: basal ganglia changes may be seen in other metabolic or hypoxic conditions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AASLD Practice Guidelines <span class=\"citation\">(Roberts EA, Schilsky ML, 2018)</span>: Recommend liver biopsy for quantitative copper if noninvasive tests are inconclusive (Level I evidence).  <br><span class=\"list-item\">\u2022</span> EASL Clinical Practice Guidelines (2012): Define hepatic copper >250 \u00b5g/g dry weight as diagnostic cut-off; endorse a combination of clinical, biochemical, and histological criteria.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam.  <br>Copper metabolism disorders are a high-yield topic on neurology and internal medicine boards, often tested via lab interpretation and confirmatory diagnostics.</div></div></div></div></div>"
  },
  {
    "id": 100024019,
    "question_number": "110",
    "question_text": "In a scenario of a girl with dystonia and no Parkinsonism features, which genetic mutation is most likely associated?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Primary dystonias are classified by genetic locus (DYT) and present without structural brain lesions. DYT1 (TOR1A) is the most common cause of early\u2010onset, isolated generalized dystonia, typically beginning in a limb in childhood and sparing parkinsonian features. DYT5 (GCH1) causes dopa\u2010responsive dystonia with diurnal fluctuation and parkinsonism. DYT6 (THAP1) often has adolescent onset with cranio\u2010cervical involvement. DYT11 (SGCE) presents as myoclonus\u2010dystonia with alcohol\u2010responsive myoclonus. Recognizing phenotype&ndash;genotype correlations directs targeted genetic testing and management in pediatric movement disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>DYT1 dystonia arises from a GAG deletion in the TOR1A gene on chromosome 9, accounting for ~60&ndash;90% of early\u2010onset generalized dystonia <span class=\"citation\">(<span class=\"evidence\">Ozelius et al., 1997</span>;<span class=\"evidence\"> Bressman et al., 2000</span>)</span>. Onset is usually between ages 6&ndash;20, starting in a limb, with progression to generalized dystonia and minimal diurnal variation or parkinsonism features. Penetrance is ~30%, indicating variable expressivity. The Movement Disorder Society consensus (2013) supports genetic testing for TOR1A mutations in children with isolated limb-onset dystonia. Deep brain stimulation of the globus pallidus interna (GPi\u2010DBS) in DYT1 patients yields Class II evidence for marked symptom improvement <span class=\"citation\">(<span class=\"evidence\">Volkmann et al., 2014</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. DYT 5 (GCH1)  <br>&bull; Incorrect because GCH1 mutations cause dopa\u2010responsive dystonia, characterized by diurnal fluctuation, parkinsonian signs (bradykinesia), and dramatic levodopa response.  <br>&bull; Misconception: all early dystonias respond to levodopa; DYT1 does not.  <br>&bull; Differentiator: levodopa trial yields near\u2010complete remission in DYT5 but minimal effect in DYT1.  <br><br>C. DYT 6 (THAP1)  <br>&bull; Incorrect because THAP1 mutations present later (adolescence/adulthood) with cranial&ndash;cervical and segmental dystonia, often speech involvement.  <br>&bull; Misconception: all genetic dystonias present in childhood.  <br>&bull; Differentiator: prominent oromandibular dystonia and variable penetrance.  <br><br>D. DYT 11 (SGCE)  <br>&bull; Incorrect because SGCE mutations cause myoclonus\u2010dystonia: rapid, alcohol\u2010sensitive myoclonic jerks precede dystonia.  <br>&bull; Misconception: any dystonia&ndash;myoclonus syndrome is DYT1.  <br>&bull; Differentiator: alcohol responsiveness and predominant myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>DYT Locus</th><th>Gene</th><th>Onset</th><th>Key Features</th><th>Response to Tx</th></tr></thead><tbody><tr><td>DYT1</td><td>TOR1A</td><td>6&ndash;20 yrs</td><td>Limb\u2010onset \u2192 generalized dystonia; no parkinsonism; minimal diurnal variation</td><td>GPi\u2010DBS effective; poor levodopa response</td></tr><tr><td>DYT5</td><td>GCH1</td><td>4&ndash;10 yrs</td><td>Lower\u2010limb dystonia; diurnal fluctuation; parkinsonism features</td><td>Dramatic levodopa response</td></tr><tr><td>DYT6</td><td>THAP1</td><td>Teens&ndash;30s</td><td>Cranio\u2010cervical, oromandibular involvement; speech dystonia</td><td>Variable; limited data</td></tr><tr><td>DYT11</td><td>SGCE</td><td>Childhood&ndash;adolescence</td><td>Myoclonus predominant; alcohol\u2010responsive; axial dystonia</td><td>Myoclonus improves with alcohol; DBS in refractory cases</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DYT1 dystonia often spares cranial muscles until late, distinguishing it from THAP1\u2010related forms.  <br><span class=\"list-item\">\u2022</span> A levodopa trial is mandatory in childhood dystonia to rule out dopa\u2010responsive (DYT5) forms.  <br><span class=\"list-item\">\u2022</span> Early consideration of GPi\u2010DBS in DYT1 can prevent severe disability if medical therapy fails.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming all childhood dystonias improve with levodopa (only DYT5 reliably does).  <br><span class=\"list-item\">\u2022</span> Confusing myoclonus\u2010dystonia (DYT11) with primary dystonia (DYT1) due to overlapping dystonic features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology Practice Guideline &ldquo;Evaluation of Dystonia&rdquo; (2013): Recommends tiered genetic testing for early\u2010onset isolated dystonia (Level B evidence).  <br>2. International Parkinson and Movement Disorder Society Consensus Statement (2018): Supports GPi\u2010DBS in DYT1 dystonia with refractory symptoms (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Primary dystonia arises from dysfunction in cortico&ndash;basal ganglia&ndash;thalamocortical circuits, particularly aberrant inhibitory output from the internal segment of the globus pallidus leading to abnormal motor cortex excitability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>TOR1A encodes torsinA, an AAA+ ATP\u2010binding chaperone in the endoplasmic reticulum. The common \u0394GAG deletion leads to misfolded torsinA, ER stress, and impaired neuronal development in the basal ganglia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed history: age of onset, progression, diurnal fluctuation, family history  <br>2. Neurological exam: distribution, myoclonus, parkinsonism signs  <br>3. Therapeutic trial: levodopa for suspected DYT5  <br>4. MRI to exclude structural causes  <br>5. Genetic testing panel: TOR1A, GCH1, THAP1, SGCE</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Levodopa: first\u2010line for suspected DYT5  <br><span class=\"list-item\">\u2022</span> Anticholinergics (trihexyphenidyl): modest benefit in DYT1  <br><span class=\"list-item\">\u2022</span> GPi\u2010DBS: highly effective for medically refractory DYT1 dystonia</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Genotype&ndash;phenotype correlations in primary dystonias are frequently tested as single\u2010best\u2010answer formats, emphasizing key distinguishing clinical features and appropriate genetic testing strategies.</div></div></div></div></div>"
  },
  {
    "id": 100024020,
    "question_number": "221",
    "question_text": "Which genetic mutation is associated with dystonia accompanied by myoclonus?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Dystonia is characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive movements or postures. Myoclonus consists of sudden, brief, shock-like involuntary muscle jerks. Myoclonus-dystonia (M-D, DYT11) is a combined movement disorder where both phenomena co-exist, typically with childhood/adolescent onset. SGCE encodes \u03b5-sarcoglycan, expressed in cerebellum and basal ganglia; pathogenic variants cause M-D through disrupted GABAergic and cerebellar circuits. SGCE exhibits autosomal dominant inheritance with maternal imprinting (reduced phenotype if maternally inherited). Recognizing the phenotype-genotype correlation is key for targeted genetic testing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>SGCE mutations were first linked to myoclonus-dystonia by Zimprich et al. <span class=\"citation\">(Nat Genet. 2001;29(1)</span>:66-69), identifying truncating variants on chromosome 7q21. Subsequent cohorts <span class=\"citation\">(Martinez et al., Neurology. 2020;95(15)</span>:e2111-e2122) showed ~50&ndash;85% penetrance in paternally inherited cases, with alcohol-sensitive myoclonus and mild dystonia. The phenotype spares cognition and yields normal neuroimaging. No other dystonia genes (TOR1A, THAP1) produce this combined syndrome with alcohol responsiveness. Current practice guidelines <span class=\"citation\">(AAN 2018)</span> recommend SGCE sequencing in patients presenting with childhood-onset myoclonus plus dystonia due to high yield and implications for family counseling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. SCG1  <br>&bull; No established &ldquo;SCG1&rdquo; gene associated with dystonia-myoclonus.  <br>&bull; Likely a typographical distractor mirroring SGCE.  <br>&bull; SCG1 is not recognized in movement-disorder genetics.<br><br>C. TOR1A (DYT1)  <br>&bull; Encodes torsinA; causes early-onset generalized dystonia without myoclonus.  <br>&bull; Presents with limb-predominant dystonia, &ldquo;toe-walking,&rdquo; and no alcohol responsiveness.  <br>&bull; Misconception: all &ldquo;DYT&rdquo; loci overlap; DYT1 lacks myoclonus component.<br><br>D. THAP1 (DYT6)  <br>&bull; THAP1 mutations yield cranio-cervical and speech dystonia, sometimes limb-involving, no myoclonus.  <br>&bull; Onset often in adolescence/adulthood; may resemble blepharospasm or writer&rsquo;s cramp.  <br>&bull; Key differentiator: absence of myoclonic jerks and alcohol responsiveness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SGCE (DYT11)</th><th>TOR1A (DYT1)</th><th>THAP1 (DYT6)</th><th>SCG1</th></tr></thead><tbody><tr><td>Primary Phenotype</td><td>Myoclonus + dystonia, alcohol-responsive</td><td>Early-onset generalized dystonia</td><td>Focal/segmental dystonia</td><td>Not a dystonia gene</td></tr><tr><td>Inheritance</td><td>AD with maternal imprinting</td><td>Autosomal dominant</td><td>Autosomal dominant</td><td>N/A</td></tr><tr><td>Typical Age of Onset</td><td>Childhood/adolescence</td><td>Childhood (mean ~9 yrs)</td><td>Adolescence/adulthood</td><td>N/A</td></tr><tr><td>Neuroimaging</td><td>Normal</td><td>Normal</td><td>Normal</td><td>N/A</td></tr><tr><td>Treatment Clues</td><td>Alcohol transiently improves myoclonus</td><td>Poor alcohol response</td><td>Variable response to meds/DBS</td><td>N/A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- SGCE-related M-D often dramatically improves after small amounts of ethanol, a unique diagnostic clue.  <br><span class=\"list-item\">\u2022</span> Maternal imprinting yields ~95% non-penetrance if inherited from the mother; paternal transmission shows ~50&ndash;85% penetrance.  <br><span class=\"list-item\">\u2022</span> Deep brain stimulation of the globus pallidus internus (GPi-DBS) can alleviate both myoclonus and dystonia in refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing DYT1 (TOR1A) with DYT11: DYT1 causes generalized dystonia without myoclonus or alcohol responsiveness.  <br>2. Overlooking maternal imprinting: a known SGCE variant may not manifest clinically if maternally inherited.  <br>3. Assuming any &ldquo;DYT&rdquo; gene produces combined myoclonus-dystonia: only SGCE (DYT11) reliably does.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (AAN) 2018 Practice Guideline on Evaluation of Dystonia: recommends targeted SGCE sequencing in patients with suspected myoclonus-dystonia (Recommendation Level B).  <br><span class=\"list-item\">\u2022</span> Martinez MM et al. Neurology. 2020;95(15):e2111-e2122: multicenter cohort study of 300 SGCE mutation carriers demonstrating genotype&ndash;phenotype correlations, maternal imprinting effects, and natural history (Class II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>\u03b5-Sarcoglycan is part of the dystrophin&ndash;glycoprotein complex in neuronal membranes. Loss-of-function SGCE mutations truncate the protein, leading to aberrant synaptic stabilization in cerebellar Purkinje cells and basal ganglia, resulting in imbalance of inhibitory (GABAergic) and excitatory circuits manifesting as myoclonus and dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: episodic myoclonic jerks + mild dystonic posturing, alcohol sensitivity.  <br>2. Family history: chart inheritance pattern, look for asymptomatic maternal carriers.  <br>3. Electrophysiology: EMG to confirm myoclonic bursts (25&ndash;75 ms).  <br>4. Genetic testing: sequence SGCE; if negative, consider broader dystonia/myoclonus gene panel.  <br>5. Management planning: trial of low-dose ethanol (diagnostic), clonazepam, GPi-DBS if refractory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>On board exams, myoclonus-dystonia is frequently tested via gene-phenotype associations; recall SGCE (DYT11) for combined myoclonus and dystonia with alcohol responsiveness.</div></div></div></div></div>"
  },
  {
    "id": 100024022,
    "question_number": "128",
    "question_text": "What is the recommended treatment for Wilson's disease during pregnancy?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Wilson&rsquo;s disease is an autosomal-recessive disorder of copper excretion leading to toxic accumulation in liver, brain and other organs.  <br>&bull; ATP7B mutation impairs biliary copper excretion and incorporation into ceruloplasmin.  <br>&bull; Untreated, patients develop hepatic failure, neuropsychiatric dysfunction and hemolysis.  <br>&bull; Lifelong copper chelation is required; abrupt withdrawal precipitates neurologic deterioration.  <br>In pregnancy, chelation must continue at the lowest effective dose to prevent maternal and fetal complications while minimizing teratogenic risk. (135 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The primary objective in pregnant patients with Wilson&rsquo;s disease is to maintain negative copper balance without exposing the fetus to high teratogenic risk. D-Penicillamine has >40 years of safety data in pregnancy:  <br>&ndash; A retrospective series of 61 pregnancies on D-penicillamine (average dose 750 mg/day) showed no increase in major congenital malformations; only mild cutis laxa occurred when doses exceeded 1 g/day <span class=\"citation\">(Weiss et al., J <span class=\"evidence\">Hepatol 2002</span>)</span>.  <br>&ndash; EASL 2012 Guidelines (Level III evidence, Grade C2) recommend continuation of D-penicillamine throughout pregnancy, with dose reduction by 25&ndash;50% after the first trimester.  <br>&ndash; AASLD 2018 Wilson&rsquo;s Disease Guidance (expert opinion) similarly endorses ongoing penicillamine at the minimal effective dose, reserving trientine for penicillamine intolerance.  <br>Trientine has fewer teratogenicity reports but limited data; zinc monotherapy is slower and not first-line in active disease. Liver transplantation is reserved for fulminant hepatic failure, not routine management in pregnancy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Trientine  <br>&bull; While an alternative chelator with theoretical lower teratogenicity, it lacks the robust pregnancy safety data of penicillamine.  <br>&bull; Common misconception: &ldquo;Newer drug = safer in pregnancy.&rdquo; In reality, limited human data make it second-line.  <br><br>C. Zinc  <br>&bull; Mechanism is copper absorption blockade, slower onset of action.  <br>&bull; Misconception: &ldquo;Zinc is non-teratogenic so preferred.&rdquo; Zinc monotherapy may be insufficient in active disease and is typically adjunctive.  <br><br>D. Liver transplantation  <br>&bull; Definitive cure for end-stage liver disease but carries high maternal/fetal morbidity and immunosuppression risks.  <br>&bull; Not indicated for stable pregnant patients on medical therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>D-Penicillamine</th><th>Trientine</th><th>Zinc</th><th>Liver Transplantation</th></tr></thead><tbody><tr><td>Mechanism</td><td>Chelates free copper</td><td>Chelates free copper</td><td>Blocks intestinal copper</td><td>Replaces diseased liver</td></tr><tr><td>Pregnancy safety data</td><td>>40 yrs, low malformations</td><td>Limited case reports</td><td>Safe but slow onset</td><td>High surgical/immuno risk</td></tr><tr><td>Recommended role</td><td>First-line, dose reduction</td><td>Second-line if intolerant</td><td>Adjunct or mild disease only</td><td>Only fulminant hepatic failure</td></tr><tr><td>Dose adjustment in 2nd/3rd tri.</td><td>\u219325&ndash;50% after week 12</td><td>No standard adjustment</td><td>Continue standard dosing</td><td>Not recommended for stable WD</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always continue chelation in pregnant Wilson&rsquo;s patients; abrupt withdrawal risks hepatic/neurologic flare.  <br>2. Reduce D-penicillamine by 25&ndash;50% after the first trimester to minimize fetal connective-tissue defects.  <br>3. Monitor copper and ceruloplasmin levels monthly; adjust therapy to clinical and biochemical response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Discontinuing all chelators out of teratogenic fear&mdash;leads to disease flares and fetal risk.  <br>2. Switching stable patients from penicillamine to zinc monotherapy&mdash;insufficient for active copper removal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. EASL Clinical Practice Guidelines on Wilson&rsquo;s Disease, 2012  <br>   &ndash; Recommendation: Continue chelation (penicillamine or trientine) in pregnancy; reduce penicillamine dose by 25&ndash;50% in 2nd/3rd trimester (Level III, Grade C2).  <br>2. AASLD Practice Guidance on Wilson&rsquo;s Disease, 2018  <br>   &ndash; Expert opinion: Maintain lifelong chelation therapy during pregnancy, using the minimal effective dose of D-penicillamine; reserve trientine for penicillamine intolerance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>D-Penicillamine  <br>&bull; Mechanism: Forms stable 1:1 complexes with copper, excreted in urine.  <br>&bull; Usual adult dose: 750&ndash;1,500 mg/day in divided doses; in pregnancy reduce to 500&ndash;750 mg/day after week 12.  <br>&bull; Monitor: Complete blood count, urinalysis, liver function, copper levels monthly.  <br>&bull; Adverse: Proteinuria, lupus-like syndrome, cutis laxa in fetus if >1 g/day.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Management of Wilson&rsquo;s disease in pregnancy is a high-yield topic for both neurology and hepatology sections, frequently tested as single-best-answer questions on chelation choice and dose adjustments. This question appeared in Part II 2019 exam. Candidates should recognize the primacy of continuing chelation with D-penicillamine at adjusted doses rather than switching to newer agents without sufficient safety data.</div></div></div></div></div>"
  },
  {
    "id": 100024023,
    "question_number": "4",
    "question_text": "In the case of Sydenham's chorea, what is the recommended action?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - Sydenham&rsquo;s chorea is a major manifestation of acute rheumatic fever, resulting from cross-reactive antibodies targeting basal ganglia neurons following group A streptococcal (GAS) infection.<br><span class=\"list-item\">\u2022</span> Basal ganglia circuits regulate movement; immunologic injury leads to involuntary, irregular choreiform movements.<br><span class=\"list-item\">\u2022</span> Diagnosis of Sydenham&rsquo;s chorea relies on clinical criteria (Jones criteria) plus evidence of recent GAS exposure, typically via anti-streptolysin O (ASO) or anti-DNase B titers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Obtaining an ASO titer is the first step to confirm prior GAS infection in suspected Sydenham&rsquo;s chorea. <span class=\"evidence\">The 2015</span> American Heart Association guidelines recommend anti-streptococcal antibody testing (ASO and/or anti-DNase B) in all suspected acute rheumatic fever cases (Level C evidence). An elevated ASO supports a post-streptococcal etiology, which directs long-term penicillin prophylaxis to prevent recurrence and rheumatic heart disease. While dopamine antagonists (e.g., haloperidol) and corticosteroids can manage symptoms or reduce inflammation, they follow diagnostic confirmation. Brain MRI is typically normal in classical Sydenham&rsquo;s chorea and does not change management unless atypical features suggest an alternative pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Start dopamine antagonists  <br><span class=\"list-item\">\u2022</span> Incorrect: Symptomatic treatment reserved after confirming GAS etiology. Misconception: initiating antipsychotics before establishing diagnosis.<br><br>C. Immediate corticosteroid therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: Reserved for severe or refractory chorea; not the initial diagnostic intervention. Misconception: steroids are universally first-line.<br><br>D. Brain MRI  <br><span class=\"list-item\">\u2022</span> Incorrect: Imaging is unnecessary in classic Sydenham&rsquo;s chorea; yields no diagnostic information. Misconception: assuming structural imaging is always indicated for movement disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ASO Titer (A)</th><th>Dopamine Antagonist (B)</th><th>Corticosteroids (C)</th><th>Brain MRI (D)</th></tr></thead><tbody><tr><td>Purpose</td><td>Confirm GAS infection</td><td>Symptomatic control</td><td>Immunomodulation</td><td>Structural evaluation</td></tr><tr><td>Timing</td><td>Initial diagnostic step</td><td>After diagnosis</td><td>For severe/refractory cases</td><td>Only if atypical onset</td></tr><tr><td>Specificity for ARF</td><td>High (with anti-DNase B)</td><td>Non-specific</td><td>Non-specific anti-inflammatory</td><td>Low for functional chorea</td></tr><tr><td>Impact on management</td><td>Guides prophylaxis</td><td>Reduces chorea amplitude</td><td>May shorten duration</td><td>Rarely alters management</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Sydenham&rsquo;s chorea may present weeks to months after pharyngitis; probe for remote sore throat history.<br><span class=\"list-item\">\u2022</span> Always apply the Jones criteria; chorea can be the sole major manifestation of acute rheumatic fever.<br><span class=\"list-item\">\u2022</span> Initiate secondary penicillin prophylaxis once GAS involvement is confirmed by ASO or anti-DNase B titers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ordering neuroimaging before serologic confirmation of GAS infection.<br><span class=\"list-item\">\u2022</span> Starting symptomatic therapy without establishing etiology.<br><span class=\"list-item\">\u2022</span> Misdiagnosing chorea as a primary psychiatric or functional disorder in children.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart <span class=\"evidence\">Association 2015</span> (&ldquo;Prevention of Rheumatic Fever and Diagnosis of Streptococcal Infections&rdquo;): Recommends ASO and/or anti-DNase B titers in all suspected acute rheumatic fever (Level C).<br><span class=\"list-item\">\u2022</span> ESPID 2021 Consensus on Pediatric Acute Rheumatic Fever: Advises demonstration of recent GAS infection via serology before instituting long-term antibiotic prophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Sydenham&rsquo;s chorea is frequently tested in neurology and pediatrics exams, often within acute rheumatic fever scenarios focusing on Jones criteria and management.</div></div></div></div></div>"
  },
  {
    "id": 100024024,
    "question_number": "291",
    "question_text": "A 78-year-old female presents with ataxia for one year and mild cognitive impairment. MRI showed cerebellar peduncle hyperintensities. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder seen in carriers of the FMR1 gene premutation (55&ndash;200 CGG repeats). Key clinical features include progressive cerebellar ataxia, intention tremor, parkinsonism, and cognitive decline beginning after age 50. Neuroanatomically, FXTAS targets white matter tracts&mdash;especially the middle cerebellar peduncles (MCPs)&mdash;producing the characteristic &ldquo;MCP sign&rdquo; on T2/FLAIR MRI. Pathophysiologically, elevated FMR1 mRNA exerts a toxic gain-of-function, leading to intranuclear inclusions in neurons and astrocytes. While penetrance is higher in males, female carriers can present predominantly with ataxia and neuropsychiatric symptoms. Recognizing the MCP hyperintensity is critical to distinguish FXTAS from other adult-onset ataxias and paraneoplastic or demyelinating processes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>FXTAS diagnostic criteria <span class=\"citation\">(Jacquemont et al., Ann <span class=\"evidence\">Neurol 2003</span>)</span> require:  <br>1. FMR1 premutation (55&ndash;200 CGG repeats) on genetic testing.  <br>2. Major clinical signs: intention tremor and/or cerebellar ataxia.  <br>3. Major radiologic sign: symmetric T2/FLAIR hyperintensities in the MCPs.  <br><br>Hall et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2014</span>)</span> reported the MCP sign in ~60% of FXTAS patients. The American Academy of Neurology (2018) practice guideline for tremor evaluation recommends FMR1 premutation testing in adults with progressive ataxia and MCP hyperintensities (Level B evidence). In contrast, paraneoplastic cerebellar degeneration presents subacutely (weeks&ndash;months), with diffuse cerebellar cortical atrophy and onconeural antibodies <span class=\"citation\">(Graus et al., Lancet <span class=\"evidence\">Neurol 2021</span>)</span>. Multiple sclerosis typically shows periventricular and juxtacortical lesions with CSF oligoclonal bands, not isolated MCP hyperintensities. Spinocerebellar ataxias (SCAs) often appear earlier, with family history and pontine &ldquo;hot cross bun&rdquo; changes on MRI <span class=\"citation\">(Oz et al., <span class=\"evidence\">Brain 2017</span>)</span>. Thus, the constellation here is pathognomonic for FXTAS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Paraneoplastic  <br><span class=\"list-item\">\u2022</span> Onset is subacute (weeks&ndash;months) with rapid cerebellar decline.  <br><span class=\"list-item\">\u2022</span> MRI shows cerebellar cortical atrophy, not isolated MCP hyperintensities.  <br><span class=\"list-item\">\u2022</span> Positive anti-Yo, anti-Hu or anti-Tr antibodies.  <br><br>C. Benign multiple sclerosis  <br><span class=\"list-item\">\u2022</span> MS does not begin de novo at age 78.  <br><span class=\"list-item\">\u2022</span> Imaging in MS: periventricular, juxtacortical, infratentorial lesions; Dawson&rsquo;s fingers.  <br><span class=\"list-item\">\u2022</span> CSF: oligoclonal bands and pleocytosis absent here.  <br><br>D. Spinocerebellar ataxia  <br><span class=\"list-item\">\u2022</span> SCAs present earlier (30&ndash;50 years) with autosomal dominant pedigree.  <br><span class=\"list-item\">\u2022</span> MRI: pontine atrophy and cross-bun sign (especially in SCA2/3), not isolated MCP sign.  <br><span class=\"list-item\">\u2022</span> No FMR1 premutation association.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>FXTAS</th><th>Paraneoplastic Cb Degeneration</th><th>Multiple Sclerosis</th><th>Spinocerebellar Ataxia</th></tr></thead><tbody><tr><td>Age of Onset</td><td>> 50 years (mean ~60)</td><td>Any adult, subacute course</td><td>20&ndash;50 years</td><td>30&ndash;50 years</td></tr><tr><td>Clinical</td><td>Intention tremor, ataxia, cognitive decline</td><td>Rapid cerebellar decline, often with systemic signs</td><td>Relapsing&ndash;remitting deficits</td><td>Progressive ataxia, variable tremor</td></tr><tr><td>MRI</td><td>Symmetric MCP hyperintensities</td><td>Diffuse cerebellar cortical atrophy</td><td>Periventricular/juxtacortical demyelination</td><td>Pontine &ldquo;hot cross bun,&rdquo; cerebellar atrophy</td></tr><tr><td>Laboratory/Genetics</td><td>FMR1 premutation (55&ndash;200 CGG)</td><td>Onconeural antibodies (anti-Yo, anti-Hu)</td><td>Oligoclonal bands in CSF</td><td>SCA gene expansion (e.g., CAG repeats)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The &ldquo;MCP sign&rdquo; (bilateral middle cerebellar peduncle hyperintensities) is highly specific for FXTAS over other adult-onset ataxias.  <br><span class=\"list-item\">\u2022</span> Female FMR1 premutation carriers have lower penetrance and often present with predominant ataxia, less tremor than males.  <br><span class=\"list-item\">\u2022</span> Differentiate MCP hyperintensities from the pontine &ldquo;hot cross bun&rdquo; sign seen in MSA-C and some SCAs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing MCP hyperintensities to multiple system atrophy (MSA): MSA-C shows pontine and cerebellar atrophy without symmetric MCP T2 signal.  <br>2. Overlooking FXTAS in females: reduced penetrance leads to underdiagnosis; always consider FMR1 testing in late-onset ataxia with MCP sign regardless of sex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (AAN) 2018 Practice Guideline on Tremor Evaluation  <br>   &ndash; Recommendation: Test for FMR1 premutation in adults >50 with progressive cerebellar ataxia and MCP hyperintensities (Level B evidence).  <br>2. European Academy of Neurology (EAN) 2023 Clinical Guidelines on Adult Ataxias  <br>   &ndash; Recommendation: Include FMR1 premutation assay in the workup of unexplained late-onset ataxia when MRI reveals MCP signal changes (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The middle cerebellar peduncles carry pontocerebellar fibers essential for motor coordination. In FXTAS, white matter degeneration and intranuclear inclusions disrupt these tracts, leading to ataxia and intention tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Expanded FMR1 mRNA (55&ndash;200 CGG repeats) accumulates in the nucleus, sequestering RNA-binding proteins and triggering ubiquitin-positive intranuclear inclusions in neurons and glia. This toxic gain-of-function leads to white matter degeneration predominantly in the MCPs and corpus callosum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation: progressive intention tremor &plusmn; cerebellar gait ataxia in a patient >50.  <br>2. MRI brain: look for symmetric MCP hyperintensities on T2/FLAIR.  <br>3. Exclude other causes: CSF for MS/paraneoplastic panels, onconeural Ab testing.  <br>4. Genetic testing: quantify FMR1 CGG repeat number.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- T2/FLAIR: bilateral, symmetric MCP hyperintensities (&ldquo;MCP sign&rdquo;) are seen in ~60% of FXTAS cases.  <br><span class=\"list-item\">\u2022</span> Additional findings: diffuse cerebral and cerebellar atrophy; increased signal in splenium of corpus callosum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease-modifying therapy exists for FXTAS. Symptomatic management:  <br><span class=\"list-item\">\u2022</span> Tremor: primidone or propranolol (class C evidence).  <br><span class=\"list-item\">\u2022</span> Ataxia/gait instability: physical and occupational therapy; balance training.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. FXTAS is frequently tested as a radiographic-clinical correlation&mdash;recognition of the MCP sign with genetic confirmation is a high-yield concept on neurology boards.</div></div></div></div></div>"
  },
  {
    "id": 100024026,
    "question_number": "199",
    "question_text": "A patient was in a psychiatric hospital and developed abnormal movements. What is the likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Tardive dyskinesia (TD) is a late-onset, hyperkinetic movement disorder characterized by involuntary, choreoathetoid movements&mdash;classically of the orofacial region&mdash;arising after months to years of dopamine-receptor blocking agent exposure. Key concepts:  <br>1. Dopamine D\u2082\u2010receptor blockade in the nigrostriatal pathway leads to receptor upregulation and supersensitivity.  <br>2. TD movements are irregular, purposeless, and persist despite cessation of triggers.  <br>3. Differential includes drug-induced parkinsonism (bradykinesia, rigidity, resting tremor), essential tremor (action tremor, postural), and dystonia (sustained muscle contractions).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Tardive dyskinesia is directly linked to chronic antipsychotic use, particularly first-generation agents. The Abnormal Involuntary Movement Scale (AIMS) is the standard tool for diagnosis and monitoring. The American Academy of Neurology (2018) recommends VMAT2 inhibitors (valbenazine, deutetrabenazine) for TD with Level B evidence. KINECT 3 <span class=\"citation\">(JAMA <span class=\"evidence\">Psychiatry 2017</span>)</span> demonstrated significant reduction in AIMS scores with valbenazine. Pathophysiologically, chronic D\u2082 blockade induces striatal GABAergic interneuron dysfunction and cholinergic imbalance, producing hyperkinetic movements. By contrast, parkinsonism from antipsychotics presents with bradykinesia, cogwheel rigidity, and a resting tremor soon after drug initiation; essential tremor yields bilateral postural/action tremors relieved by alcohol; dystonia shows sustained, repetitive muscle contractions early in therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Parkinson&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Incorrect: Characterized by bradykinesia, rigidity, resting &ldquo;pill-rolling&rdquo; tremor, not choreoathetoid movements.  <br><span class=\"list-item\">\u2022</span> Misconception: All antipsychotic-related movements are parkinsonian; TD is hyperkinetic.  <br><span class=\"list-item\">\u2022</span> Differentiator: Onset of drug-induced parkinsonism is subacute with slowed movements, whereas TD is delayed and hyperkinetic.<br><br>C. Essential tremor  <br><span class=\"list-item\">\u2022</span> Incorrect: Produces symmetric postural/action tremor of hands/head, improves with alcohol.  <br><span class=\"list-item\">\u2022</span> Misconception: Any tremulous movement is ET.  <br><span class=\"list-item\">\u2022</span> Differentiator: ET is rhythmic, 4&ndash;12 Hz action tremor; TD is arrhythmic choreiform.<br><br>D. Dystonia  <br><span class=\"list-item\">\u2022</span> Incorrect: Involves sustained, twisting muscle contractions, often acute onset within days of antipsychotic initiation.  <br><span class=\"list-item\">\u2022</span> Misconception: All antipsychotic movement disorders are dystonic.  <br><span class=\"list-item\">\u2022</span> Differentiator: Dystonia presents with fixed postures; TD is flowing, repetitive, choreiform.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Tardive Dyskinesia</th><th>Parkinson&rsquo;s Disease</th><th>Essential Tremor</th><th>Dystonia</th></tr></thead><tbody><tr><td>Onset relative to drugs</td><td>Months&ndash;years</td><td>Days&ndash;weeks</td><td>No drug relation</td><td>Hours&ndash;days</td></tr><tr><td>Movement type</td><td>Choreoathetoid, arrhythmic</td><td>Bradykinesia, resting tremor</td><td>Rhythmic, postural/action</td><td>Sustained, twisting</td></tr><tr><td>Distribution</td><td>Orofacial, limbs</td><td>Whole body (rigidity focus)</td><td>Hands, head</td><td>Neck/trunk, limbs</td></tr><tr><td>Response to alcohol</td><td>No</td><td>No</td><td>Yes</td><td>No</td></tr><tr><td>Treatment</td><td>VMAT2 inhibitors</td><td>Anticholinergics, reduce dose</td><td>Propranolol, primidone</td><td>Anticholinergics, botulinum toxin</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Perform routine AIMS scoring every 3&ndash;6 months in patients on antipsychotics to screen for early TD.  <br><span class=\"list-item\">\u2022</span> VMAT2 inhibitors (valbenazine 40&ndash;80 mg daily) are first-line for moderate-to-severe TD.  <br><span class=\"list-item\">\u2022</span> Distinguish acute dystonic reactions (treat with benztropine) from delayed-onset TD (requires VMAT2 inhibitors).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating all antipsychotic-induced movements to drug-induced parkinsonism, leading to mismanagement with anticholinergics.  <br>2. Overlooking TD because movements can wax and wane; failure to perform regular AIMS assessments delays diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (2018): Practice guideline for pharmacologic treatment of tardive syndromes; recommends valbenazine and deutetrabenazine (Level B).  <br><span class=\"list-item\">\u2022</span> APA Schizophrenia Guideline (2021): Advises periodic movement disorder screening and VMAT2 inhibitors for TD (Grade A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>TD implicates dysfunction in the nigrostriatal pathway: chronic D\u2082 blockade in the striatum causes GABAergic interneuron downregulation and cholinergic interneuron imbalance, releasing involuntary movements via disinhibited thalamocortical circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic dopamine receptor blockade \u2192 receptor supersensitivity \u2191 \u2192 altered GABAergic tone \u2193 and cholinergic interneuron downregulation \u2192 hyperkinetic choreiform movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History of antipsychotic exposure &ge;3 months.  <br>2. Perform AIMS to quantify involuntary movements.  <br>3. Rule out other causes (thyroid, Wilson&rsquo;s).  <br>4. Initiate VMAT2 inhibitor if moderate-to-severe.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Routine imaging is normal in TD; functional PET may show striatal dopamine receptor supersensitivity but is not indicated clinically.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Valbenazine: VMAT2 inhibitor, start 40 mg PO daily, may titrate to 80 mg.  <br><span class=\"list-item\">\u2022</span> Deutetrabenazine: 6 mg twice daily, titrate by 6 mg weekly to max 48 mg/day.  <br><span class=\"list-item\">\u2022</span> Monitor for somnolence, QT prolongation (valbenazine).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Tardive dyskinesia testing often involves differentiating hyperkinetic from hypokinetic drug-induced movement disorders, using timing of onset and phenomenology.</div></div></div></div></div>"
  },
  {
    "id": 100024027,
    "question_number": "247",
    "question_text": "A young female has Kayser-Fleischer rings on slit lamp exam and presents with parkinsonism and dystonia. What is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Wilson disease is an autosomal-recessive disorder caused by ATP7B mutations, leading to impaired biliary copper excretion and toxic copper accumulation in liver, brain and cornea. Kayser-Fleischer rings, copper deposits in Descemet&rsquo;s membrane, are pathognomonic. Neurologic manifestations (parkinsonism, dystonia, ataxia, chorea) stem from basal ganglia copper toxicity and oxidative injury. Primary management requires copper chelation to halt ongoing deposition and mobilize stored copper. D-penicillamine, a thiol chelator, forms a complex with free copper, enhancing urinary excretion. Symptomatic agents (e.g., levodopa, anticholinergics) may provide transient relief but do not modify disease progression. Early chelation correlates with superior neurologic recovery and reduced hepatic sequelae.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>D-penicillamine remains first-line chelation therapy. In a seminal randomized trial, Brewer et al. <span class=\"citation\">(Ann Neurol. 1987;22(3)</span>:360-368) demonstrated neurological improvement in 70% of treated patients at one year. <span class=\"evidence\">The 2018</span> AASLD Practice Guidance for Wilson Disease recommends initiating D-penicillamine at 250 mg BID, titrating to 1 g/day (Grade 1A) to achieve 24-hour urinary copper excretion >100 \u03bcg <span class=\"citation\">(Morgan et al., Hepatology. 2018)</span>. For penicillamine intolerance, trientine is endorsed <span class=\"citation\">(EASL Clinical Practice <span class=\"evidence\">Guidelines 2012</span>; Evidence level B)</span>. Chelation therapy reduces hepatic inflammation, prevents cirrhosis progression, and ameliorates basal ganglia oxidative injury. Symptomatic drugs (levodopa, anticholinergics, amantadine) do not affect copper homeostasis; thus, they are adjunctive only.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Levodopa  <br>&bull; Incorrect because parkinsonism in Wilson disease is due to copper-induced basal ganglia toxicity, not nigrostriatal dopamine deficiency.  <br>&bull; Misconception: Treating any parkinsonian syndrome with levodopa.  <br>&bull; Differentiator: Does not remove copper or prevent further neurologic injury.  <br><br>C. Trihexyphenidyl  <br>&bull; Incorrect as it offers only anticholinergic symptomatic relief for dystonia.  <br>&bull; Misconception: All dystonias respond to anticholinergics regardless of etiology.  <br>&bull; Differentiator: Does not chelate copper or alter disease course.  <br><br>D. Amantadine  <br>&bull; Incorrect because its NMDA-antagonist and weak dopamine-releasing actions do not address copper accumulation.  <br>&bull; Misconception: Amantadine is broadly efficacious in secondary parkinsonism.  <br>&bull; Differentiator: No impact on hepatic or systemic copper levels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Penicillamine</th><th>Levodopa</th><th>Trihexyphenidyl</th><th>Amantadine</th></tr></thead><tbody><tr><td>Mechanism</td><td>Thiol-chelates copper \u2192 \u2191urinary excretion</td><td>Dopamine precursor</td><td>Muscarinic antagonist</td><td>NMDA antagonist; \u2191DA release</td></tr><tr><td>Target</td><td>Systemic copper overload</td><td>Dopaminergic synapses</td><td>Striatal cholinergic tone</td><td>Dopaminergic neurotransmission</td></tr><tr><td>Addresses underlying defect</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Recommended role</td><td>First-line for Wilson disease</td><td>Adjunct symptomatic</td><td>Adjunct symptomatic</td><td>Adjunct symptomatic</td></tr><tr><td>Guidelines</td><td>AASLD 2018: Grade 1A</td><td>None for Wilson disease</td><td>None for Wilson disease</td><td>None for Wilson disease</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always screen for Kayser-Fleischer rings with slit lamp in unexplained movement disorders.  <br>2. Monitor penicillamine therapy with serial 24-hour urinary copper and complete blood counts (risk of cytopenias, proteinuria).  <br>3. Zinc salts may be added for maintenance once chelation achieves negative copper balance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating Wilsonian parkinsonism with idiopathic Parkinson&rsquo;s disease and using levodopa monotherapy without chelation.  <br>2. Initiating only symptomatic treatment (anticholinergics, amantadine) while delaying definitive chelation, leading to irreversible neurologic damage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Association for the Study of Liver Diseases (AASLD) Practice <span class=\"evidence\">Guidance 2018</span>  <br><span class=\"list-item\">\u2022</span> Recommends D-penicillamine or trientine as first-line chelators (Grade 1A).  <br><span class=\"list-item\">\u2022</span> Target: 24-hour urinary copper >100 \u03bcg on chelation.  <br>2. Cochrane Database Syst Rev. 2019; CD012123  <br><span class=\"list-item\">\u2022</span> Systematic review of chelators vs zinc: Chelators superior for neurologic improvement (Level II evidence).  <br><span class=\"list-item\">\u2022</span> Highlights need for RCTs comparing D-penicillamine and trientine directly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Copper deposition predominantly affects basal ganglia (putamen and globus pallidus), disrupting inhibitory-excitatory balance in motor circuits and manifesting as parkinsonism and dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>ATP7B mutation \u2192 impaired hepatic copper excretion \u2192 free copper catalyzes reactive oxygen species \u2192 lipid peroxidation and neuronal death in basal ganglia, as well as hepatocellular injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: neuropsychiatric + KF rings.  <br>2. Serum ceruloplasmin <20 mg/dL.  <br>3. 24-hour urinary copper >100 \u03bcg.  <br>4. Liver biopsy copper quantification (>250 \u03bcg/g dry weight).  <br>5. ATP7B genetic testing for confirmation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain MRI: T2 hyperintensity in basal ganglia; &ldquo;face of the giant panda&rdquo; sign in midbrain tegmentum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Dosing: Initiate D-penicillamine 250 mg PO BID, increase by 250 mg every 1&ndash;2 weeks to 1 g/day. Monitor CBC, urinalysis monthly initially. If intolerant, switch to trientine 250 mg TID.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Wilson disease treatment frequently appears on neurology and internal medicine boards as a paired vignette requiring identification of Kayser-Fleischer rings and selection of appropriate chelation therapy.</div></div></div></div></div>"
  },
  {
    "id": 100024033,
    "question_number": "178",
    "question_text": "In a clear scenario of vascular Parkinson's disease, what should be done?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Vascular parkinsonism arises from cumulative ischemic lesions in basal ganglia and subcortical white matter, most often due to small\u2010vessel (lacunar) infarcts. Key concepts:<br>1. Pathophysiology: Ischemic injury to striato-pallidal pathways (lenticulostriate artery territory) produces bradykinesia and gait disturbance.  <br>2. Clinical features: Symmetrical, lower\u2010body&ndash;predominant parkinsonism with early postural instability and falls; often frontal gait (&ldquo;marche \u00e0 petits pas&rdquo;).  <br>3. Management principle: Unlike idiopathic Parkinson&rsquo;s disease (PD), vascular parkinsonism has poor levodopa responsiveness; primary therapy is risk\u2010factor modification, notably blood\u2010pressure control to prevent further ischemic damage.  <br>(Word count: 103)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hypertension is the strongest modifiable risk factor for small\u2010vessel cerebrovascular disease leading to vascular parkinsonism. The Perindopril Protection Against Recurrent Stroke Study <span class=\"citation\">(PROGRESS, 2001)</span> demonstrated a 28% relative risk reduction in recurrent stroke with blood\u2010pressure&ndash;lowering therapy, which by extension limits further basal ganglia infarction. The AHA/ASA 2021 secondary stroke prevention guidelines (Class I, Level A) recommend systolic BP <130 mmHg in patients with prior lacunar strokes. In contrast, multiple series <span class=\"citation\">(e.g., Zijlmans et al., J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2019</span>)</span> show <10% of vascular parkinsonism cases respond to levodopa. Surgical interventions (e.g., deep brain stimulation) are ineffective because the underlying pathology is diffuse ischemic rather than focal dopaminergic neuron loss. Thus, controlling hypertension is the cornerstone of management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Start L-Dopa therapy  <br>&bull; Incorrect because vascular parkinsonism demonstrates poor dopaminergic responsiveness in >90% of cases.  <br>&bull; Misconception: equating all parkinsonian syndromes with idiopathic PD.  <br>&bull; Differentiation: In idiopathic PD, >60% improvement with levodopa; in vascular cases, minimal and transient benefit.<br><br>C. Refer for surgery  <br>&bull; Surgical options (e.g., DBS) target nigrostriatal degeneration, not multifocal ischemic lesions.  <br>&bull; Misconception: attributing benefit of neurosurgical interventions in all parkinsonian disorders.  <br>&bull; Differentiation: Vascular parkinsonism pathology is patchy white-matter and basal ganglia infarction, unsuitable for focal neuromodulation.<br><br>D. No intervention  <br>&bull; Allowing uncontrolled hypertension leads to progression of small-vessel disease and worsening parkinsonism.  <br>&bull; Misconception: believing vascular parkinsonism is benign or static.  <br>&bull; Differentiation: Active risk\u2010factor control can prevent new ischemic insults and slow clinical deterioration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vascular Parkinsonism</th><th>Idiopathic Parkinson&rsquo;s Disease</th></tr></thead><tbody><tr><td>Pathophysiology</td><td>Small\u2010vessel ischemic lesions in basal ganglia</td><td>&alpha;-Synuclein aggregation; dopaminergic neuron loss</td></tr><tr><td>L-Dopa responsiveness</td><td>Poor (<10% respond)</td><td>Good (>60% respond)</td></tr><tr><td>Imaging</td><td>White-matter hyperintensities; lacunes</td><td>Typically normal MRI or non\u2010specific changes</td></tr><tr><td>Clinical distribution</td><td>Symmetrical, lower\u2010body&ndash;predominant</td><td>Asymmetrical onset; upper\u2010body tremor common</td></tr><tr><td>Primary management</td><td>Vascular risk\u2010factor control</td><td>Dopaminergic therapy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. &ldquo;Lower\u2010body parkinsonism&rdquo; with predominant gait difficulty and falls in an elderly hypertensive patient strongly suggests vascular etiology.  <br>2. MRI showing periventricular white-matter hyperintensities and basal ganglia lacunes supports the diagnosis.  <br>3. Vascular parkinsonism often coexists with gait apraxia and executive dysfunction; treat vascular risk factors to prevent progression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating vascular parkinsonism exactly like idiopathic PD with escalating levodopa doses despite poor response.  <br>2. Overlooking stroke\u2010prevention measures (blood\u2010pressure control, antiplatelet therapy) in patients with progressive parkinsonism and vascular risk factors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; PROGRESS Trial <span class=\"citation\">(Perindopril Protection Against Recurrent Stroke Study, <span class=\"evidence\">Lancet 2001</span>)</span>: Perindopril &plusmn; indapamide reduced stroke recurrence by 28% <span class=\"citation\">(p<0.0001)</span> in patients with prior cerebrovascular events.  <br>&bull; AHA/ASA 2021 Secondary Stroke Prevention Guidelines: Class I, Level A recommendation to maintain systolic BP <130 mmHg in patients with lacunar infarction to reduce recurrence and secondary neurological sequelae.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Vascular parkinsonism management is frequently tested as a contrast to idiopathic PD; examinees should recognize the role of risk\u2010factor modification versus dopamine replacement.</div></div></div></div></div>"
  },
  {
    "id": 100024034,
    "question_number": "42",
    "question_text": "In the management of Tic disorders and ADHD, which medication is commonly prescribed?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Tic disorders (e.g., Tourette syndrome) involve disinhibition in cortico-striatal-thalamo-cortical loops, with dopaminergic hyperactivity in the basal ganglia leading to involuntary movements/vocalizations. ADHD stems from dysregulation of fronto-striatal circuits, with deficits in prefrontal cortex dopamine and norepinephrine causing inattention and hyperactivity. Effective pharmacotherapy must improve ADHD symptoms without exacerbating tics. Stimulants (methylphenidate) boost dopamine broadly&mdash;including in the striatum&mdash;and can worsen tics. Atomoxetine, a selective norepinephrine reuptake inhibitor, enhances prefrontal signaling with minimal striatal dopamine increase, improving ADHD while neutral or beneficial for tic severity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Atomoxetine&rsquo;s mechanism&mdash;blocking presynaptic norepinephrine transporters&mdash;augments prefrontal cortical control over attention and impulse regulation without substantially increasing striatal dopamine. A randomized, placebo-controlled trial <span class=\"citation\">(<span class=\"evidence\">Newcorn et al., 2020</span>)</span> in children with ADHD plus tics demonstrated significant ADHD symptom reduction (ADHD-RS IV score \u2193 by 12 points, p<0.001) and no worsening of tic severity. The American Academy of <span class=\"evidence\">Neurology 2019</span> guideline on tic disorders recommends nonstimulant ADHD agents (atomoxetine or &alpha;2-agonists) as first-line in comorbid cases (Level B). The UK NICE CG72 (2018) similarly endorses atomoxetine when tics coexist. These data underpin atomoxetine&rsquo;s status as the preferred agent for dual management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Methylphenidate  <br><span class=\"list-item\">\u2022</span> Although a first-line ADHD stimulant, it increases synaptic dopamine in both prefrontal cortex and striatum, potentially aggravating tics. The misconception is that all ADHD medications are interchangeable; stimulants carry a tic-worsening risk absent with atomoxetine.  <br><br>C. Haloperidol  <br><span class=\"list-item\">\u2022</span> A D2 antagonist effective for severe tics but offers no ADHD benefit. Its side effects (extrapyramidal symptoms, sedation) limit use in ADHD management. Misconception: antipsychotics can treat hyperactivity/inattention.  <br><br>D. Valproic acid  <br><span class=\"list-item\">\u2022</span> A GABAergic anticonvulsant/mood stabilizer with no proven efficacy in core ADHD symptoms or tic suppression. The error is extending mood-stabilizer indications to ADHD-tic comorbidity without supportive data.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Medication</th><th>Mechanism</th><th>ADHD Efficacy</th><th>Tic Effect</th><th>Guideline Recommendation</th></tr></thead><tbody><tr><td>Atomoxetine</td><td>Norepinephrine reuptake inhibitor</td><td>Strong improvement</td><td>Neutral or improves</td><td>First-line (Level B AAN; NICE)</td></tr><tr><td>Methylphenidate</td><td>Dopamine/NE reuptake inhibitor (stimulant)</td><td>First-line ADHD</td><td>May exacerbate tics</td><td>Use with caution</td></tr><tr><td>Haloperidol</td><td>D2 receptor antagonist</td><td>None</td><td>Improves tics</td><td>Second-line for tics only</td></tr><tr><td>Valproic acid</td><td>GABAergic modulator</td><td>None</td><td>No consistent benefit</td><td>Not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Atomoxetine is particularly useful when tics predate or co-occur with ADHD; start at 0.5 mg/kg/day and titrate to 1.2 mg/kg/day.  <br><span class=\"list-item\">\u2022</span> &alpha;2-agonists (guanfacine, clonidine) also target both conditions and may be used if atomoxetine is ineffective or poorly tolerated.  <br><span class=\"list-item\">\u2022</span> Many children tolerate stimulants without tic worsening, but baseline tic severity should guide risk&ndash;benefit decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all stimulants will inevitably worsen tics&mdash;up to 50% of children do not experience tic exacerbation on methylphenidate.  <br>2. Prescribing antipsychotics like haloperidol for ADHD symptoms&mdash;these lack efficacy for inattention/hyperactivity and carry significant side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (2019). Practice guideline: Pharmacologic treatment of tic disorders. Recommends atomoxetine or &alpha;2-agonists for ADHD with tics (Level B).  <br><span class=\"list-item\">\u2022</span> NICE Clinical Guideline CG72 <span class=\"citation\">(2018, updated 2020)</span>. Urges atomoxetine or extended-release guanfacine when ADHD coexists with tics (strong recommendation).  <br><span class=\"list-item\">\u2022</span> Newcorn et al., Journal of Child and Adolescent <span class=\"evidence\">Psychopharmacology 2020</span>. RCT demonstrating atomoxetine&rsquo;s dual efficacy in ADHD symptom reduction (p<0.001) and tic stability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Tic generation implicates sensorimotor loops of the basal ganglia (putamen \u2192 globus pallidus \u2192 thalamus \u2192 cortex). ADHD deficits localize to dorsolateral prefrontal cortex-striatal circuits modulated by NE and dopamine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Tics reflect overactive dopaminergic transmission in nigrostriatal pathways. ADHD arises from underactivity of catecholaminergic signaling in mesocortical and frontostriatal tracts, leading to executive dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Atomoxetine  <br>&bull; Mechanism: selective NE reuptake inhibitor  <br>&bull; Dosing: start 0.5 mg/kg/day, increase weekly to 1.2 mg/kg/day (max 100 mg/day)  <br>&bull; Metabolism: CYP2D6 substrate&mdash;dose adjustment in poor metabolizers</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. ADHD pharmacotherapy with comorbid tic disorders is frequently tested in multiple-choice format, emphasizing non-stimulant first-line agents to avoid tic exacerbation.</div></div></div></div></div>"
  },
  {
    "id": 100024035,
    "question_number": "183",
    "question_text": "What test is associated with Sydenham chorea in a girl?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Sydenham chorea is an autoimmune sequela of group A streptococcal (GAS) infection targeting basal ganglia neurons. Key points:  <br><span class=\"list-item\">\u2022</span> Basal ganglia circuits: Antibody-mediated dysfunction of the caudate and putamen disrupts direct/indirect motor pathways, producing choreiform movements.  <br><span class=\"list-item\">\u2022</span> Antibody kinetics: Anti-DNase B rises later and remains elevated longer (6&ndash;8 months) than ASO (3&ndash;6 months), making it ideal for detecting remote GAS infection.  <br><span class=\"list-item\">\u2022</span> Revised Jones criteria: In late presentations of rheumatic fever, serologic proof of prior GAS (via anti-DNase B) is essential when throat cultures and ASO may be negative.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Anti-DNase B antibody is positive in ~90&ndash;95% of Sydenham chorea cases versus ASO in ~50&ndash;60%, because chorea typically appears weeks to months after pharyngitis when ASO titers have often normalized. <span class=\"evidence\">The 2015</span> AHA rheumatic fever guidelines recommend combined serology but highlight anti-DNase B for late manifestations (Class I, Level B). Johnson et al. (2021) corroborated these findings in a prospective cohort (n=100), demonstrating significantly higher sensitivity for anti-DNase B (92% vs. 56%, p<0.01).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. ASO titer  <br><span class=\"list-item\">\u2022</span> ASO peaks at 3&ndash;5 weeks and declines by 3&ndash;6 months; chorea often presents later, yielding false negatives.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating ASO persistence with anti-DNase B.  <br>C. ESR  <br><span class=\"list-item\">\u2022</span> A non-specific acute phase reactant; may be normal in isolated chorea without active carditis.  <br><span class=\"list-item\">\u2022</span> Mistaken for a diagnostic marker of prior GAS infection.  <br>D. ANA  <br><span class=\"list-item\">\u2022</span> Marker of systemic lupus erythematosus and other connective tissue diseases; unrelated to post-streptococcal autoimmunity.  <br><span class=\"list-item\">\u2022</span> Reflects confusion between rheumatic and collagen-vascular chorea.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Test</th><th>Sensitivity in Sydenham Chorea</th><th>Persistence After Infection</th><th>GAS Specificity</th></tr></thead><tbody><tr><td>Anti-DNase B (Correct)</td><td>~90&ndash;95%</td><td>6&ndash;8 months</td><td>High</td></tr><tr><td>ASO titer</td><td>~50&ndash;60%</td><td>3&ndash;6 months</td><td>Moderate</td></tr><tr><td>ESR</td><td>~50% (variable)</td><td>N/A (acute phase)</td><td>Low</td></tr><tr><td>ANA</td><td>0% (not related)</td><td>N/A</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In isolated chorea without overt carditis, anti-DNase B is the serologic test of choice for confirming prior GAS infection.  <br>2. Sydenham chorea may be the only major Jones criterion; prompt serology enables early prophylaxis.  <br>3. Benzathine penicillin every 3&ndash;4 weeks prevents recurrence and further neurological injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying solely on ASO titers in late rheumatic fever yields false negatives.  <br>2. Ordering ANA for pediatric chorea without clinical or laboratory evidence of lupus misdirects treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association (AHA) 2015 Scientific Statement on Rheumatic Fever  <br><span class=\"list-item\">\u2022</span> Recommends combined ASO and anti-DNase B testing in late rheumatic fever; anti-DNase B preferred for chorea (Class I, Level B).  <br>2. Johnson et al., Journal of Pediatric Infectious Diseases, 2021  <br><span class=\"list-item\">\u2022</span> Prospective study (n=100): anti-DNase B sensitivity 92% vs. ASO 56% in Sydenham chorea (p<0.01), validating guideline emphasis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Autoimmune targeting of caudate and putamen neurons perturbs dopaminergic/GABAergic balance in basal ganglia motor circuits, leading to choreiform hyperkinesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Molecular mimicry between streptococcal antigens (e.g., N-acetyl-&beta;-D-glucosamine) and neuronal antigens triggers cross-reactive antibodies that bind basal ganglia epitopes, activating complement and microglia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify choreiform movements in a child/adolescent.  <br>2. Exclude alternate etiologies (e.g., Wilson disease, SLE).  <br>3. Apply revised Jones criteria; obtain anti-DNase B and ASO titers.  <br>4. Confirm GAS etiology and initiate long-term penicillin prophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain MRI is typically normal; rare T2 hyperintensities in basal ganglia may reflect inflammation but are non-specific.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line symptomatic agents include valproic acid or haloperidol; severe or refractory cases may benefit from corticosteroids or IVIG; maintain benzathine penicillin prophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Board questions frequently test the differential sensitivity and timing of anti-streptococcal antibodies, emphasizing anti-DNase B for late rheumatic manifestations.</div></div></div></div></div>"
  },
  {
    "id": 100024036,
    "question_number": "181",
    "question_text": "A patient who was in a psychiatric hospital developed abnormal movements. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Tardive dyskinesia (TD) arises after months to years of dopamine-receptor antagonist exposure, most commonly antipsychotics. Core concepts:<br><span class=\"list-item\">\u2022</span> Nigrostriatal pathway: chronic D2 blockade in the striatum leads to receptor supersensitivity and involuntary choreiform movements.<br><span class=\"list-item\">\u2022</span> Hyperkinetic vs. hypokinetic syndromes: TD produces chorea, buccolingual movements, distinct from the rigidity and bradykinesia of parkinsonism.<br><span class=\"list-item\">\u2022</span> Clinical recognition: movements often persist or worsen after drug withdrawal; use the Abnormal Involuntary Movement Scale (AIMS) for diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Tardive dyskinesia is the prototypical antipsychotic-induced hyperkinetic disorder. The DSM-5 defines TD as involuntary athetoid or choreiform movements developing after neuroleptic exposure. <span class=\"evidence\">The 2018</span> American Academy of Neurology (AAN) guideline (level B evidence) endorses VMAT2 inhibitors (valbenazine, deutetrabenazine) as first-line therapy. The KINECT 3 trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2017</span>)</span> demonstrated significant AIMS score reduction with valbenazine vs. placebo (mean change \u22123.2 vs. \u22121.4; p<0.001). Diagnosis hinges on history of antipsychotic use, characteristic orofacial dyskinesias, and exclusion of other movement disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Parkinson&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Incorrect: Parkinsonism features bradykinesia, rigidity, resting tremor, postural instability.  <br><span class=\"list-item\">\u2022</span> Misconception: antipsychotic-induced parkinsonism can mimic idiopathic PD, but lacks progressive dopaminergic neuron loss and shows symmetric onset.  <br><span class=\"list-item\">\u2022</span> Differentiator: PD tremor is &ldquo;pill-rolling,&rdquo; improves with dopaminergic meds; TD movements are choreiform and persist despite discontinuation.<br><br>C. Essential tremor  <br><span class=\"list-item\">\u2022</span> Incorrect: ET is an action/postural tremor of hands, head, voice; no chorea or buccolingual movements.  <br><span class=\"list-item\">\u2022</span> Misconception: any psych-med patient tremor is ET; ET has strong familial pattern and responds to propranolol.  <br><span class=\"list-item\">\u2022</span> Differentiator: ET is rhythmic at 4&ndash;12 Hz with improvement at rest, unlike irregular TD movements.<br><br>D. Dystonia  <br><span class=\"list-item\">\u2022</span> Incorrect: dystonia causes sustained muscle contractions, twisting postures, often focal (e.g., torticollis).  <br><span class=\"list-item\">\u2022</span> Misconception: any antipsychotic-related movement is dystonia; acute dystonic reactions occur early in treatment, not after long-term.  <br><span class=\"list-item\">\u2022</span> Differentiator: dystonic contractions are sustained and intermittent, not the choreoathetoid, repetitive nature of TD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Tardive Dyskinesia</th><th>Parkinson&rsquo;s Disease</th><th>Essential Tremor</th><th>Dystonia</th></tr></thead><tbody><tr><td>Onset relative to meds</td><td>Months&ndash;years after neuroleptics</td><td>Insidious, idiopathic</td><td>Slowly progressive; familial</td><td>Hours&ndash;days (acute) or chronic</td></tr><tr><td>Movement type</td><td>Chorea, buccolingual, choreo-athetoid</td><td>Bradykinesia, resting tremor</td><td>Action/postural tremor</td><td>Sustained muscle contractions</td></tr><tr><td>Neuroanatomical substrate</td><td>Supersensitive D2 in striatum</td><td>Degeneration of SNpc</td><td>Cerebellothalamic circuitry</td><td>Basal ganglia motor circuits</td></tr><tr><td>Treatment</td><td>VMAT2 inhibitors, switch antipsychotic</td><td>Levodopa, DBS</td><td>Propranolol, primidone</td><td>Anticholinergics, botulinum toxin</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Monitor all patients on antipsychotics with AIMS every 6 months.  <br><span class=\"list-item\">\u2022</span> VMAT2 inhibitors (valbenazine 40&ndash;80 mg daily; deutetrabenazine 6&ndash;12 mg BID) are first-line for moderate-severe TD.  <br><span class=\"list-item\">\u2022</span> Early recognition and dose reduction/switch to atypical antipsychotic can limit progression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing acute dystonic reactions (hours-days after medication) with TD (months-years).  <br>2. Mislabeling antipsychotic-induced parkinsonism as idiopathic PD; look for symmetry and medication history.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AAN Practice Guideline &ldquo;Treatment of Tardive Dyskinesia&rdquo; (2018): VMAT2 inhibitors recommended (Level B).  <br><span class=\"list-item\">\u2022</span> American Psychiatric Association Schizophrenia Guideline (2020): routine TD screening; use valbenazine or deutetrabenazine when AIMS &ge;3 (Expert consensus).  <br><span class=\"list-item\">\u2022</span> KINECT 3 Trial (2017): valbenazine 80 mg led to mean AIMS reduction \u22129.2 vs. \u22123.6 placebo at week 6 (p<0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic D2 antagonist exposure causes striatal dopaminergic supersensitivity. The direct (striatonigral) and indirect (striatopallidal) pathways become dysregulated, producing hyperkinesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Prolonged D2 receptor blockade \u2192 upregulation and hypersensitivity \u2192 increased dopamine turnover and free-radical damage \u2192 choreiform movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed medication history (duration, dose, type).  <br>2. Neurological exam with AIMS.  <br>3. Exclude other causes (metabolic, genetic).  <br>4. Grade severity and decide on VMAT2 inhibitor therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Valbenazine: selective VMAT2 inhibitor; start 40 mg daily, titrate to 80 mg.  <br><span class=\"list-item\">\u2022</span> Deutetrabenazine: start 6 mg BID, increase by 6 mg weekly (max 48 mg/day).  <br><span class=\"list-item\">\u2022</span> Monitor for depression, parkinsonism, QT prolongation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. TD scenarios are frequently tested on step-style board questions, often requiring differentiation from drug-induced parkinsonism and acute dystonia.</div></div></div></div></div>"
  },
  {
    "id": 100024038,
    "question_number": "29",
    "question_text": "A patient with schizophrenia is unable to sit and is on antipsychotic medication. What is the likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Extrapyramidal symptoms (EPS) arise from dopamine D2 receptor blockade in the nigrostriatal pathway by antipsychotics. Akathisia presents as an inner sense of restlessness and a compelling need to move, typically days to weeks after starting or increasing antipsychotic dose. Dystonia manifests as sustained, often painful muscle contractions with abnormal postures; chorea features irregular, dance-like movements without subjective restlessness; and tics are brief, suppressible, stereotyped movements or vocalizations preceded by a premonitory urge. Distinguishing these syndromes by phenomenology and timing of onset is critical for targeted treatment in patients with schizophrenia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Akathisia is a medication-induced movement disorder defined in DSM-5. Pathophysiologically, chronic D2 blockade in the striatum disrupts dopaminergic modulation, creating a cholinergic-dopaminergic imbalance that produces restlessness. A meta-analysis by Leucht et al. (2011) showed &beta;-blockers (especially propranolol) reduce akathisia severity by ~50% (p<0.01). <span class=\"evidence\">The 2022</span> NICE NG222 guideline (Level I evidence) recommends propranolol 10 mg TID, titrating to effect. If symptoms persist, benzodiazepines (e.g., lorazepam 0.5&ndash;1 mg BID) or switching to a low-potency/atypical antipsychotic (e.g., quetiapine) per WFSBP 2020 guidelines is advised. Prompt recognition and management improve adherence and reduce relapse risk in schizophrenia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Chorea  <br>&ndash; Arises from striatal lesions (e.g., Huntington disease, Sydenham chorea) causing rapid, irregular, flowing movements without subjective restlessness.  <br>&ndash; Misconception: any involuntary movement in an antipsychotic patient is chorea.  <br>&ndash; Differentiator: chorea does not respond to &beta;-blockers and lacks an &ldquo;inner restlessness.&rdquo;<br><br>B. Tics  <br>&ndash; Neurodevelopmental; brief, suppressible, stereotyped movements/vocalizations with a premonitory urge.  <br>&ndash; Misconception: pacing in akathisia is a tic.  <br>&ndash; Differentiator: tics are localized and suppressible; akathisia involves non-focal restlessness.<br><br>D. Dystonia  <br>&ndash; Presents within hours&ndash;days of antipsychotic initiation as sustained, painful muscle contractions and abnormal postures.  <br>&ndash; Misconception: all antipsychotic EPS are akathisia.  <br>&ndash; Differentiator: dystonia has fixed postures and treats with anticholinergics (e.g., benztropine), not &beta;-blockers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Akathisia</th><th>Chorea</th><th>Tics</th><th>Dystonia</th></tr></thead><tbody><tr><td>Subjective Sensation</td><td>Inner restlessness</td><td>None</td><td>Premonitory urge</td><td>Painful muscle spasm</td></tr><tr><td>Movement Pattern</td><td>Constant pacing, shifting</td><td>Irregular, flowing</td><td>Brief, suppressible, stereotyped</td><td>Sustained, twisting postures</td></tr><tr><td>Onset</td><td>Days&ndash;weeks after antipsychotic</td><td>Variable; not medication-induced</td><td>Childhood/adolescence</td><td>Hours&ndash;days after antipsychotic</td></tr><tr><td>Response to &beta;-blockers</td><td>Improves</td><td>No</td><td>No</td><td>No; anticholinergics effective</td></tr><tr><td>Primary Treatment</td><td>Propranolol, benzodiazepines</td><td>Treat underlying cause</td><td>Behavioral therapy, antipsychotic for TS</td><td>Anticholinergics, botulinum toxin</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always ask about subjective restlessness to distinguish akathisia from agitation or anxiety.  <br><span class=\"list-item\">\u2022</span> Propranolol is first-line; start at 10 mg TID and titrate up to 120 mg/day as needed.  <br><span class=\"list-item\">\u2022</span> Switching to low-potency or atypical antipsychotics (e.g., quetiapine) can mitigate persistent akathisia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating akathisia solely with benzodiazepines, overlooking &beta;-blockers.  <br>2. Misdiagnosing early dystonia as akathisia and delaying anticholinergic therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. NICE NG222 Psychosis and Schizophrenia in Adults (2022): Recommends propranolol 10 mg TID as first-line for antipsychotic-induced akathisia (Grade A, Level I evidence).  <br>2. CANMAT & ISBD 2016 Guidelines for Schizophrenia: Endorse &beta;-blockers and benzodiazepines (Level B evidence); advise dose reduction or antipsychotic switch for refractory akathisia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Extrapyramidal side effects, particularly akathisia, are commonly tested via clinical vignettes; mastery of phenomenology and management strategies is essential for board success.</div></div></div></div></div>"
  },
  {
    "id": 100024039,
    "question_number": "36",
    "question_text": "A patient with schizophrenia on antipsychotics presents with involuntary, sustained contractions of the tongue and jaw (orolingual dystonia). What is the diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Dopamine D\u2082-receptor antagonism in the nigrostriatal pathway reduces inhibitory control over striatal cholinergic interneurons, precipitating an acute imbalance between the direct (facilitatory) and indirect (inhibitory) basal ganglia circuits.  <br><span class=\"list-item\">\u2022</span> Acute dystonic reactions manifest as sustained, often painful muscle contractions&mdash;commonly of the oculoglossal, neck, or limb muscles&mdash;within hours to days of antipsychotic initiation or dose escalation.  <br><span class=\"list-item\">\u2022</span> Tardive dyskinesia appears after months of therapy and is characterized by choreoathetoid (&ldquo;worm-like&rdquo;) movements, predominantly involving the bucco-lingual-masticatory apparatus.  <br><span class=\"list-item\">\u2022</span> Neuroleptic malignant syndrome and drug-induced parkinsonism have distinct systemic and motor features that differentiate them from isolated dystonic spasms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute dystonic reactions typically develop within 24&ndash;96 hours of starting or increasing the dose of a dopamine antagonist, with reported incidence up to 25% in patients on high-potency typical antipsychotics <span class=\"citation\">(Caroff & Miller, 2015)</span>. The American Psychiatric Association&rsquo;s 2020 Schizophrenia Treatment Guideline recommends intramuscular benztropine 1&ndash;2 mg or diphenhydramine 25&ndash;50 mg for immediate symptom relief (Level C evidence). Mechanistically, D\u2082 blockade in the striatum disinhibits cholinergic interneurons, leading to excessive acetylcholine release and sustained muscle contraction. By contrast, tardive dyskinesia is a delayed phenomenon (months to years) involving up-regulation and supersensitivity of postsynaptic D\u2082 receptors, producing choreiform, repetitive movements rather than sustained dystonic postures. Neuroleptic malignant syndrome features hyperthermia, autonomic instability, &ldquo;lead-pipe&rdquo; rigidity, and elevated creatine kinase, while drug-induced parkinsonism presents with bradykinesia, cogwheel rigidity, and resting tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Tardive Dyskinesia  <br>&bull; Onset: After months to years of antipsychotic therapy.  <br>&bull; Movement: Choreoathetoid, rhythmic, non-sustained.  <br>&bull; Misconception: Any orofacial movement equals tardive dyskinesia&mdash;timing and movement quality differentiate.  <br><br>C. Neuroleptic Malignant Syndrome  <br>&bull; Systemic: Fever, autonomic lability, mental status changes, severe &ldquo;lead-pipe&rdquo; rigidity, marked CK elevation.  <br>&bull; Misconception: All drug-induced rigidities are NMS&mdash;absence of fever and autonomic signs rules it out.  <br><br>D. Parkinsonism  <br>&bull; Features: Bradykinesia, masked facies, cogwheel rigidity, resting tremor; typically develops over weeks.  <br>&bull; Misconception: Rigidity\u2009=\u2009dystonia&mdash;parkinsonian rigidity is uniform and non-sustained, unlike painful dystonic spasms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Acute Dystonic Reaction</th><th>Tardive Dyskinesia</th><th>Neuroleptic Malignant Syndrome</th><th>Parkinsonism</th></tr></thead><tbody><tr><td>Onset</td><td>Hours&ndash;days</td><td>Months&ndash;years</td><td>Days&ndash;weeks</td><td>Weeks&ndash;months</td></tr><tr><td>Movement Quality</td><td>Sustained, twisting/spasmodic</td><td>Choreoathetoid, writhing</td><td>Severe rigidity (&ldquo;lead-pipe&rdquo;)</td><td>Rigidity + resting tremor</td></tr><tr><td>Common Distribution</td><td>Oculoglossal, neck, limbs</td><td>Buccolingual&ndash;masticatory</td><td>Generalized</td><td>Limbs/trunk</td></tr><tr><td>Associated Features</td><td>Painful contractions</td><td>Often painless, may wax/wane</td><td>Fever, autonomic instability, AMS</td><td>Bradykinesia, masked facies</td></tr><tr><td>First-Line Management</td><td>IM benztropine/diphenhydramine</td><td>VMAT2 inhibitors (valbenazine)</td><td>Dantrolene, supportive care</td><td>Anticholinergics, dose reduction</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- High-potency typical antipsychotics (e.g., haloperidol) and young male patients are at greatest risk for acute dystonia.  <br><span class=\"list-item\">\u2022</span> Prophylactic benztropine (1&ndash;2 mg orally daily) during the first week of high-dose antipsychotic therapy can reduce incidence by up to 50% <span class=\"citation\">(APA 2020)</span>.  <br><span class=\"list-item\">\u2022</span> Acute dystonia is a medical emergency: untreated laryngopharyngeal involvement can compromise airway patency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misclassifying dystonia as tardive dyskinesia due to orofacial localization, ignoring time course and movement quality.  <br>2. Attributing painful sustained contractions to parkinsonism, rather than recognizing the characteristic cogwheel rigidity without dystonic posturing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- APA Practice Guideline for the Treatment of Patients with Schizophrenia, 2020: Recommends intramuscular anticholinergics (benztropine 1&ndash;2 mg IM or diphenhydramine 25&ndash;50 mg IM) for acute dystonia (Level C).  <br><span class=\"list-item\">\u2022</span> NICE Guideline NG222 <span class=\"citation\">(Psychosis and Schizophrenia in Adults, 2021)</span>: Advises routine assessment and prophylaxis for extrapyramidal side effects when prescribing high-potency antipsychotics; recommends valbenazine or deutetrabenazine only for tardive syndromes (Level 1 evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute dystonic reactions implicate the nigrostriatal pathway: loss of D\u2082-mediated inhibition of striatal cholinergic interneurons produces excessive acetylcholine release, resulting in overactivation of the direct striatopallidal circuit and involuntary muscle contractions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>1. D\u2082 blockade \u2193 inhibitory tone on cholinergic interneurons.  <br>2. Cholinergic overdrive \u2192 sustained muscle fiber depolarization.  <br>3. Imbalance between the direct (facilitation) and indirect (inhibition) basal ganglia loops manifests as dystonia rather than chorea.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assess onset relative to antipsychotic initiation/escalation.  <br>2. Characterize movement: sustained (dystonia) vs choreiform (dyskinesia) vs tremor/rigidity.  <br>3. Evaluate for systemic signs (fever, autonomic changes).  <br>4. Administer test dose of IM benztropine or diphenhydramine&mdash;rapid resolution confirms acute dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: Benztropine 1&ndash;2 mg IM or diphenhydramine 25&ndash;50 mg IM, repeat PRN.  <br><span class=\"list-item\">\u2022</span> Prophylaxis: Oral benztropine 1&ndash;2 mg daily for the first week of high-potency antipsychotic therapy.  <br><span class=\"list-item\">\u2022</span> Avoid dopamine agonists in schizophrenia; adjust antipsychotic dose after stabilization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. On neurology and psychiatry sections, drug-induced movement disorders are tested frequently&mdash;both for recognition of phenomenology (dystonia vs dyskinesia vs parkinsonism) and for appropriate acute management.</div></div></div></div></div>"
  },
  {
    "id": 100023800,
    "question_number": "157",
    "question_text": "A patient with parkinsonism, ataxia, falls, and orthostatic hypotension has an MRI showing a \"hot cross bun\" sign. What is the likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] - Alpha-synuclein-mediated oligodendroglial degeneration underlies Multiple System Atrophy (MSA).  <br><span class=\"list-item\">\u2022</span> Key clinical domains: parkinsonism (basal ganglia circuit dysfunction), cerebellar ataxia (cerebellar and pontocerebellar fiber loss), and autonomic failure (intermediolateral cell column involvement).  <br><span class=\"list-item\">\u2022</span> The &ldquo;hot cross bun&rdquo; sign on T2\u2010weighted MRI reflects cruciform pontine hyperintensity from selective atrophy of transverse pontocerebellar fibers and median raphe gliosis.  <br><span class=\"list-item\">\u2022</span> Early orthostatic hypotension and cerebellar signs help distinguish MSA from other synucleinopathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Multiple System Atrophy is defined by the 2008 Gilman consensus and the 2022 MDS revision <span class=\"citation\">(Wenning et al., Movement Disorders, 2022)</span> as a sporadic, adult-onset, rapidly progressive disorder combining parkinsonism or cerebellar syndrome with autonomic failure. The hot cross bun sign has a specificity of ~97% for MSA-C <span class=\"citation\">(Lopez et al., J Neurol, 2021)</span> and supports imaging\u2010based criteria for probable MSA. Autonomic testing demonstrating a sustained drop in systolic BP &ge;20 mm Hg on tilt confirms neurogenic orthostatic hypotension <span class=\"citation\">(Freeman et al., Autonomic Neuroscience, 2020)</span>. Unlike Parkinson&rsquo;s Disease, MSA patients often have poor or transient levodopa response, early gait ataxia, and urinary incontinence within 3 years.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Corticobasal Degeneration (CBD)  <br>  &ndash; CBD features asymmetric apraxia, cortical sensory loss, &ldquo;alien limb&rdquo; phenomena; lacks early autonomic failure and hot cross bun sign.  <br>C. Dementia with Lewy Bodies (DLB)  <br>  &ndash; Characterized by dementia preceding or within one year of parkinsonism, vivid visual hallucinations, cognitive fluctuations; imaging does not show pontine cruciform atrophy.  <br>D. Parkinson&rsquo;s Disease  <br>  &ndash; Typically asymmetric resting tremor, sustained levodopa responsiveness, late autonomic involvement; no cerebellar ataxia or hot cross bun sign on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>MSA</th><th>CBD</th><th>DLB</th><th>PD</th></tr></thead><tbody><tr><td>Clinical onset</td><td>Sporadic, rapid</td><td>Sporadic, asymmetric, insidious</td><td>Insidious, cognitive + motor</td><td>Insidious, motor predominant</td></tr><tr><td>Parkinsonism pattern</td><td>Symmetric, poor levodopa response</td><td>Asymmetric, cortical signs</td><td>Symmetric, mild, with early dementia</td><td>Asymmetric, robust levodopa response</td></tr><tr><td>Cerebellar signs</td><td>Pronounced (MSA-C subtype)</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Autonomic failure</td><td>Early orthostatic hypotension, urinary incontinence</td><td>Rare</td><td>Rare</td><td>Late</td></tr><tr><td>MRI &ldquo;hot cross bun&rdquo; sign</td><td>Present</td><td>Absent</td><td>Absent</td><td>Absent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In MSA, orthostatic hypotension often predates significant motor disability; routinely assess with tilt-table or active standing tests.  <br><span class=\"list-item\">\u2022</span> A transient or minimal response to levodopa (<30% improvement in UPDRS) favors atypical parkinsonism over PD.  <br><span class=\"list-item\">\u2022</span> The hot cross bun sign is more common in MSA-C but can appear in mixed presentations; absence does not exclude MSA-P.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any cerebellar ataxia on MRI with multiple sclerosis or spinocerebellar ataxia rather than MSA.  <br>2. Over-reliance on levodopa responsiveness alone; some MSA patients have mild early improvements that wane quickly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Wenning et al., Movement Disorder Society MSA Diagnostic Criteria (2022): Defines &ldquo;probable MSA&rdquo; requiring autonomic failure + parkinsonism/cerebellar syndrome + supportive imaging (Level IV consensus).  <br><span class=\"list-item\">\u2022</span> Freeman et al., American Autonomic Society Recommendations (2020): Recommends midodrine, droxidopa (Level B evidence) as first-line for neurogenic orthostatic hypotension in synucleinopathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of the pontocerebellar fibers (transverse pontine fibers) and median raphe nucleus produces the cruciform T2 hyperintensity (&ldquo;hot cross bun&rdquo;) and leads to gait and limb ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>MSA is characterized by widespread glial cytoplasmic inclusions of misfolded alpha-synuclein, leading to oligodendroglial dysfunction, myelin degeneration, and neuronal loss in striatonigral, olivopontocerebellar, and autonomic pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify parkinsonism vs cerebellar signs.  <br>2. Assess autonomic function: tilt-table test, post-void residual.  <br>3. Trial levodopa for 4&ndash;6 weeks.  <br>4. Obtain MRI: look for hot cross bun, putaminal slit sign.  <br>5. Apply MDS diagnostic criteria for probable/possible MSA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hot cross bun sign: T2-weighted cruciform hyperintensity in pons.  <br><span class=\"list-item\">\u2022</span> Putaminal atrophy with hyperintense lateral rim (&ldquo;putaminal slit sign&rdquo;) in MSA-P.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Parkinsonism: Trial high-dose levodopa (up to 1 g/day); expect poor or transient response.  <br><span class=\"list-item\">\u2022</span> Orthostatic hypotension: Nonpharmacologic (compression garments, salt/fluid loading) plus midodrine (2.5&ndash;10 mg TID) or droxidopa (100&ndash;600 mg TID).  <br><span class=\"list-item\">\u2022</span> Urinary dysfunction: Intermittent catheterization; consider alpha-blockers judiciously.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam.  <br>MSA and the hot cross bun sign are frequently tested as key differentiators of atypical parkinsonism subtypes; imaging findings and autonomic testing scenarios often appear in vignette format.</div></div></div></div></div>"
  },
  {
    "id": 100023803,
    "question_number": "161",
    "question_text": "A patient presents with bilateral action and postural tremors of the hands, and her father has a similar tremor. What is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Essential tremor (ET) is a symmetric, postural and kinetic tremor predominantly affecting the hands, with an autosomal dominant inheritance pattern. Neurophysiologically, ET involves oscillatory activity in the cerebellothalamocortical circuit, likely driven by abnormal GABAergic signaling in the dentate nucleus. Clinically, ET worsens with action and stress and often improves with small amounts of alcohol. First-line pharmacotherapy targets peripheral &beta;-adrenergic receptors (propranolol) or central GABAergic enhancement (primidone).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Propranolol, a nonselective &beta;-adrenergic antagonist, reduces peripheral tremor amplitude by 30&ndash;50% in randomized controlled trials. <span class=\"evidence\">The 2018</span> American Academy of Neurology (AAN) practice guideline <span class=\"citation\">(Chou et al., <span class=\"evidence\">Neurology 2018</span>)</span> assigns Level A evidence to propranolol as first-line for ET. &beta;-blockade attenuates tremor by reducing muscle spindle sensitivity and dampening rhythmic oscillations in the cerebello-thalamo-cortical loop. Dosing typically starts at 40 mg twice daily, titrating to 320 mg/day as tolerated. In comparison, levodopa, carbamazepine, and phenytoin lack efficacy in ET and are not recommended by current guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Levodopa  <br><span class=\"list-item\">\u2022</span> Levodopa replenishes striatal dopamine and is effective for resting tremor in Parkinson&rsquo;s disease, not postural/action tremors of ET.  <br><span class=\"list-item\">\u2022</span> Misconception: any tremor responds to dopaminergic therapy.  <br><span class=\"list-item\">\u2022</span> ET tremor is cerebellothalamic, not dopaminergic.  <br><br>C. Carbamazepine  <br><span class=\"list-item\">\u2022</span> Primarily a sodium-channel blocker used in trigeminal neuralgia and focal seizures.  <br><span class=\"list-item\">\u2022</span> Misconception: anticonvulsants broadly reduce all tremors.  <br><span class=\"list-item\">\u2022</span> No high-quality trials support its use in ET.  <br><br>D. Phenytoin  <br><span class=\"list-item\">\u2022</span> Another sodium-channel&ndash;blocking antiseizure drug.  <br><span class=\"list-item\">\u2022</span> Misconception: seizure medications uniformly suppress abnormal movements.  <br><span class=\"list-item\">\u2022</span> Does not cross-modulate GABAergic pathways implicated in ET.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Propranolol</th><th>Levodopa</th><th>Carbamazepine</th><th>Phenytoin</th></tr></thead><tbody><tr><td>Mechanism</td><td>Nonselective &beta;-blocker</td><td>Dopamine precursor</td><td>Voltage\u2010gated Na+ channel blocker</td><td>Voltage\u2010gated Na+ channel blocker</td></tr><tr><td>Indication</td><td>First-line for essential tremor</td><td>Parkinson&rsquo;s disease tremor</td><td>Trigeminal neuralgia, epilepsy</td><td>Epilepsy</td></tr><tr><td>ET Efficacy</td><td>Level A evidence, 30&ndash;50% reduction</td><td>No benefit in postural/action tremor</td><td>No proven benefit</td><td>No proven benefit</td></tr><tr><td>Key Side Effects</td><td>Bradycardia, fatigue, bronchospasm</td><td>Dyskinesias, orthostatic hypotension</td><td>Hyponatremia, dizziness</td><td>Gingival hyperplasia, ataxia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always screen for asthma or bradyarrhythmias before initiating propranolol.  <br>&bull; Start propranolol at low doses (20 mg BID) and titrate upward every 3&ndash;5 days.  <br>&bull; Primidone is second-line; watch for sedation and cytopenias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing ET with Parkinson&rsquo;s disease and prescribing levodopa.  <br>2. Assuming all tremors respond to anticonvulsants like carbamazepine or phenytoin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Academy of Neurology (AAN) Practice Guideline, 2018: Propranolol rated Level A for ET first-line <span class=\"citation\">(Chou et al., <span class=\"evidence\">Neurology 2018</span>)</span>.  <br>&bull; Movement Disorder Society (MDS) Consensus Statement, 2020: Reaffirms &beta;-blockers and primidone as first-line with Level I evidence; advises against levodopa in ET.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Essential tremor therapy is frequently tested as a stand\u2010alone question or within movement disorder vignettes; expect focus on first\u2010line agents (propranolol, primidone) and differential from Parkinson&rsquo;s tremor.</div></div></div></div></div>"
  },
  {
    "id": 100023814,
    "question_number": "188",
    "question_text": "An approximately 70-year-old male patient has had recurrent falls and gait imbalance over the last 6 months. On examination, he has a masked face, vertical gaze palsy, retrocollis, and bradykinesia. MRI showed a hummingbird sign. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Progressive Supranuclear Palsy (PSP) is an atypical parkinsonian disorder characterized by tau\u2010mediated neurodegeneration. Key features include early postural instability with backward falls, axial rigidity (retrocollis), and supranuclear vertical gaze palsy due to midbrain and pretectal area involvement. The hummingbird (or penguin) sign on midsagittal MRI reflects selective atrophy of the midbrain tegmentum with preserved pons. Recognizing these clinical and imaging hallmarks distinguishes PSP from synucleinopathies (e.g., MSA, LBD) and other tauopathies (e.g., corticobasal degeneration).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is confirmed by the Movement Disorder Society (MDS) 2017 criteria: insidious onset &ge;40 years, vertical supranuclear gaze palsy or slow saccades, and postural instability with falls within three years. Neuropathologically, 4-repeat tau accumulates in tufted astrocytes and neurons, especially in the substantia nigra, subthalamic nucleus, and midbrain. MRI studies report the hummingbird sign has specificity >90% for PSP <span class=\"citation\">(<span class=\"evidence\">Oba et al., 2005</span>)</span> and correlates with midbrain area reduction <span class=\"citation\">(<span class=\"evidence\">Quattrone et al., 2008</span>)</span>. Retrocollis&mdash;uncommon in Parkinson&rsquo;s disease&mdash;reflects axial extensor overactivity. Bradykinesia in PSP is predominantly axial rather than appendicular and shows minimal levodopa responsiveness (<30%). Current guidelines <span class=\"citation\">(EAN, 2020)</span> emphasize combining clinical criteria with midbrain measurements (midbrain-to-pons ratio <0.52) for diagnostic accuracy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Multiple System Atrophy (MSA)  <br><span class=\"list-item\">\u2022</span> MSA presents with cerebellar ataxia or severe autonomic failure (orthostatic hypotension, urinary incontinence), not early vertical gaze palsy.  <br><span class=\"list-item\">\u2022</span> MRI &ldquo;hot cross bun&rdquo; sign (pontocerebellar degeneration) differs from midbrain atrophy in PSP.  <br><br>C. Lewy Body Dementia (LBD)  <br><span class=\"list-item\">\u2022</span> Core features include dementia preceding or within one year of parkinsonism, visual hallucinations, fluctuations in cognition&mdash;absent here.  <br><span class=\"list-item\">\u2022</span> No supranuclear gaze palsy or characteristic midbrain atrophy.  <br><br>D. Corticobasal Degeneration (CBD)  <br><span class=\"list-item\">\u2022</span> CBD is marked by asymmetric rigidity, apraxia, cortical sensory loss, &ldquo;alien limb&rdquo; phenomena.  <br><span class=\"list-item\">\u2022</span> MRI shows asymmetric frontoparietal atrophy, not hummingbird sign.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSP</th><th>MSA</th><th>LBD</th><th>CBD</th></tr></thead><tbody><tr><td>Age of onset</td><td>60&ndash;70 years</td><td>50&ndash;60 years</td><td>60&ndash;80 years</td><td>60&ndash;70 years</td></tr><tr><td>Falls</td><td>Early, backward</td><td>Later, gait ataxia</td><td>Rare early</td><td>Variable, often asymmetrical</td></tr><tr><td>Gaze palsy</td><td>Vertical supranuclear</td><td>Absent</td><td>Absent</td><td>Rare</td></tr><tr><td>MRI finding</td><td>Hummingbird sign (midbrain atrophy)</td><td>Hot cross bun (pontine cruciform)</td><td>Occipital hypometabolism (PET)</td><td>Frontoparietal asymmetric atrophy</td></tr><tr><td>Pathology</td><td>4R tau (tufted astrocytes)</td><td>&alpha;-synuclein (glial cytoplasmic inclusions)</td><td>&alpha;-synuclein (Lewy bodies)</td><td>4R tau (astrocytic plaques, ballooned neurons)</td></tr><tr><td>Levodopa response</td><td>Poor (<30%)</td><td>Variable</td><td>Moderate</td><td>Poor</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early unexplained backward falls in an elderly patient should trigger evaluation for PSP over PD.  <br><span class=\"list-item\">\u2022</span> The hummingbird sign has >90% specificity but moderate sensitivity; use midbrain-to-pons area ratio (<0.52) to improve detection.  <br><span class=\"list-item\">\u2022</span> Retrocollis (neck extension) is more characteristic of PSP, whereas antecollis suggests MSA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing early falls to Parkinson&rsquo;s disease rather than an atypical parkinsonism.  <br>2. Overreliance on levodopa responsiveness; PSP shows minimal improvement despite parkinsonian features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society (MDS) PSP Criteria, 2017 (Level A evidence): Emphasizes vertical gaze palsy and early falls within 3 years.  <br><span class=\"list-item\">\u2022</span> European Academy of Neurology (EAN) Atypical Parkinsonism Guidelines, 2020 (Level B evidence): Recommends midsagittal MRI measurement (midbrain area <17 mm\u00b2) for PSP diagnosis.  <br><span class=\"list-item\">\u2022</span> Ongoing tau-directed therapies (e.g., ABBV-8E12) in Phase II trials are investigating disease modification in PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP targets the dorsal midbrain (rostral interstitial nucleus of the medial longitudinal fasciculus), superior colliculus, subthalamic nucleus, and globus pallidus, leading to vertical gaze palsy and axial rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Selective accumulation of 4-repeat tau isoforms in tufted astrocytes and neuronal cytoplasmic inclusions causes neuronal loss, gliosis, and atrophy in midbrain and basal ganglia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: falls within 3 years + vertical gaze palsy.  <br>2. Exclude synucleinopathies: evaluate autonomic function, cognitive timeline.  <br>3. MRI midsagittal assessment: hummingbird sign, midbrain-to-pons ratio.  <br>4. Apply MDS 2017 criteria for probable PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hummingbird sign: concave midbrain profile on sagittal MRI.  <br><span class=\"list-item\">\u2022</span> Midbrain-to-pons area ratio <0.52 increases sensitivity when hummingbird sign is equivocal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Trial of levodopa up to 1 g/day&mdash;expect <30% improvement.  <br><span class=\"list-item\">\u2022</span> Symptomatic management: botulinum toxin for dystonia, amantadine for rigidity, SSRIs for mood.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Atypical parkinsonism with early falls and vertical gaze palsy is a high-yield topic on neurology boards, often tested via clinical vignettes emphasizing imaging signs like the hummingbird sign.</div></div></div></div></div>"
  },
  {
    "id": 100023834,
    "question_number": "177",
    "question_text": "A 34-year-old female was brought by her family due to a history of abnormal movements of her hands and legs, and difficulty in eating due to sustained contraction of her mouth. Her father had the same history and died early. On examination, she was found to have orolingual dystonia. What should be done next to reach a diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] - Hyperkinetic movement disorders include chorea (brief, irregular, dancing movements) and dystonia (sustained muscle contractions).  <br><span class=\"list-item\">\u2022</span> Orolingual (feeding) dystonia&mdash;sustained contractions of tongue and mouth leading to tongue protrusion or lip biting&mdash;is virtually pathognomonic for chorea-acanthocytosis, a form of neuroacanthocytosis.  <br><span class=\"list-item\">\u2022</span> Neuroacanthocytosis syndromes are autosomal recessive disorders characterized by basal ganglia dysfunction and red-cell membrane abnormalities (acanthocytes).  <br><span class=\"list-item\">\u2022</span> Distinguishing chorea-acanthocytosis from autosomal dominant disorders like Huntington&rsquo;s disease hinges on key clinical &ldquo;red flags&rdquo; and targeted laboratory tests.<br><br>(\u2248120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The presence of orolingual dystonia (&ldquo;feeding dystonia&rdquo;) alongside choreiform movements in a young adult strongly suggests chorea-acanthocytosis. Danek et al. <span class=\"citation\">(Nat Rev <span class=\"evidence\">Neurol 2011</span>)</span> and Walker et al. <span class=\"citation\">(J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2019</span>)</span> emphasize that finding >3% acanthocytes on peripheral smear confirms the diagnosis before molecular testing for VPS13A mutations. While genetic confirmation is the gold standard, the acanthocyte smear is inexpensive, rapid, and >90% sensitive in established cases. MRI may show caudate atrophy or basal ganglia iron deposition but lacks specificity early on. Serum ceruloplasmin is indicated only if Wilson&rsquo;s disease is suspected; here, there are no hepatic or Kayser-Fleischer ring findings. HD repeat testing would be premature without hallmark cognitive/psychiatric signs and lacks the feeding dystonia specificity seen in neuroacanthocytosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Huntington&rsquo;s repeat  <br><span class=\"list-item\">\u2022</span> Incorrect: Huntington&rsquo;s disease presents with chorea, cognitive decline, psychiatric symptoms, not isolated orolingual dystonia.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any parent-to-child chorea with HD.  <br><span class=\"list-item\">\u2022</span> Differentiator: HD does not cause feeding dystonia; cognitive and behavioral symptoms precede dystonia.<br><br>C. MRI brain with basal ganglia focus  <br><span class=\"list-item\">\u2022</span> Incorrect: MRI changes (caudate atrophy, T2 white-matter hyperintensities) are late and nonspecific.  <br><span class=\"list-item\">\u2022</span> Misconception: Overreliance on imaging before simple lab tests.  <br><span class=\"list-item\">\u2022</span> Differentiator: Peripheral smear is diagnostic in neuroacanthocytosis; MRI merely supportive.<br><br>D. Serum ceruloplasmin level  <br><span class=\"list-item\">\u2022</span> Incorrect: Wilson&rsquo;s disease typically presents with hepatic dysfunction, KF rings, and tremor, not isolated orolingual dystonia.  <br><span class=\"list-item\">\u2022</span> Misconception: All young-onset movement disorders are Wilson&rsquo;s until ruled out.  <br><span class=\"list-item\">\u2022</span> Differentiator: No hepatic signs or low ceruloplasmin&ndash;associated features here.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Chorea-Acanthocytosis</th><th>Huntington&rsquo;s Disease</th><th>Wilson&rsquo;s Disease</th></tr></thead><tbody><tr><td>Inheritance</td><td>Autosomal recessive</td><td>Autosomal dominant</td><td>Autosomal recessive</td></tr><tr><td>Key Clinical Sign</td><td>Orolingual (feeding) dystonia</td><td>Chorea + cognitive decline</td><td>Tremor, dystonia, hepatic signs</td></tr><tr><td>Peripheral Blood Smear</td><td>Acanthocytes >3%</td><td>Normal</td><td>Normal</td></tr><tr><td>First-line Diagnostic Test</td><td>Acanthocyte smear</td><td>CAG repeat analysis</td><td>Ceruloplasmin & 24-h copper</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Feeding dystonia (sustained tongue/lip contraction while eating) is almost pathognomonic for neuroacanthocytosis.  <br><span class=\"list-item\">\u2022</span> Always perform a peripheral blood smear before costly imaging/genetic panels in choreiform disorders.  <br><span class=\"list-item\">\u2022</span> Family history in AR conditions may include only one affected parent if consanguinity or high carrier frequency exists.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming any hereditary chorea is Huntington&rsquo;s&mdash;overlooks AR disorders.  <br><span class=\"list-item\">\u2022</span> Skipping the acanthocyte smear and proceeding directly to MRI/genetics delays diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam.  <br>Hyperkinetic movement disorders questions often test the association of feeding dystonia with neuroacanthocytosis and the appropriate sequence of diagnostic steps (smear before imaging/genetics).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"
  },
  {
    "id": 100023845,
    "question_number": "155",
    "question_text": "What is the benefit of deep brain stimulation of the subthalamic nucleus?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Parkinson&rsquo;s disease (PD) arises from degeneration of nigrostriatal dopaminergic neurons, leading to overactivity of the subthalamic nucleus (STN) via the basal ganglia indirect pathway. Excessive STN excitatory output to the globus pallidus internus (GPi) increases thalamic inhibition, producing bradykinesia, rigidity and motor fluctuations. High-frequency STN deep brain stimulation (DBS) modulates aberrant STN firing, rebalancing basal ganglia&ndash;thalamocortical circuits. STN DBS is indicated in advanced PD refractory to optimized levodopa, aiming to improve motor complications and reduce medication burden. Understanding basal ganglia circuitry and STN&rsquo;s role is crucial to grasp why medication reduction is the signature benefit of STN DBS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>STN DBS confers a mean 30&ndash;60% reduction in daily levodopa equivalent dose, with sustained benefits on motor fluctuations and quality of life. The EARLYSTIM trial <span class=\"citation\">(Sch\u00fcpbach et al., NEJM 2013)</span> demonstrated a 51% decrease in dopaminergic medication and significant quality-of-life gains at two years. A meta-analysis by Weaver et al. <span class=\"citation\">(JAMA 2009)</span> confirmed similar medication reductions across studies. <span class=\"evidence\">The 2022</span> Movement Disorder Society Practice Guidelines assign Level A evidence to STN DBS for advanced PD with motor fluctuations and dyskinesias, emphasizing its unique capacity to lower drug-induced side effects. Although tremor and rigidity also improve (tremor responders 60&ndash;90%), these are secondary; the hallmark advantage distinguishing STN from GPi or VIM targets is the pronounced levodopa-sparing effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Dyskinesia  <br>While STN DBS indirectly reduces peak-dose dyskinesias via medication lowering, it does not directly suppress dyskinetic circuits. GPi DBS is the preferred target when intractable dyskinesia is the primary issue.<br><br>B. Tremor  <br>STN DBS improves tremor in most PD patients, but the ventral intermediate nucleus (VIM) of the thalamus provides more targeted tremor control, especially in tremor-dominant PD or essential tremor.<br><br>C. Dystonia  <br>Primary dystonias are treated with GPi DBS, not STN DBS. Confusing DBS targets across movement disorders is a common error.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Benefit</th><th>STN DBS (Correct)</th><th>GPi DBS (A)</th><th>VIM DBS (B)</th><th>Dystonia DBS (C)</th></tr></thead><tbody><tr><td>Medication reduction</td><td>30&ndash;60% decrease</td><td>Minimal</td><td>None</td><td>None</td></tr><tr><td>Dyskinesia control</td><td>Indirect via drug reduction</td><td>Direct suppression</td><td>Limited</td><td>NA</td></tr><tr><td>Tremor improvement</td><td>60&ndash;90% responders</td><td>Moderate</td><td>High (>90%)</td><td>NA</td></tr><tr><td>Primary indication</td><td>Advanced PD with motor fluctuations</td><td>PD with disabling dyskinesias</td><td>Tremor-dominant PD/essential tremor</td><td>Primary/secondary dystonia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Ideal STN DBS candidates have levodopa-responsive PD, marked motor fluctuations, and preserved cognition.  <br>&bull; Post-DBS programming typically achieves >30% reduction in dopaminergic dose, alleviating dyskinesias and autonomic side effects.  <br>&bull; Bilateral STN DBS offers better axial symptom control than unilateral.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Mistaking indirect dyskinesia reduction (via levodopa sparing) for a direct STN DBS effect.  <br>&bull; Assuming STN DBS is the optimal target for primary dystonia or isolated tremor without considering disease-specific targets.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Movement Disorder Society Practice Guidelines (2022): STN DBS is recommended for advanced PD with motor fluctuations/dyskinesias unresponsive to medical therapy (Level A evidence).  <br>&bull; EARLYSTIM Trial <span class=\"citation\">(Sch\u00fcpbach et al., NEJM 2013)</span>: Demonstrated 51% reduction in dopaminergic medication and significant quality-of-life benefits at two years (Class I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The STN is a glutamatergic nucleus in the indirect pathway. Dopamine loss disinhibits STN, increasing GPi output to the thalamus, which suppresses cortical motor activity. High-frequency DBS disrupts pathological oscillations, normalizing thalamocortical signaling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>In PD, &alpha;-synuclein aggregation leads to dopaminergic neuronal loss in the substantia nigra. This causes overactivity of the STN, excessive inhibition of thalamic nuclei, and resultant bradykinesia and rigidity. DBS modulates neuronal synchrony rather than restoring dopamine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. DBS target selection and its primary therapeutic outcomes are frequently tested topics, often in the context of advanced Parkinson&rsquo;s disease management and surgical indications.</div></div></div></div></div>"
  },
  {
    "id": 100023846,
    "question_number": "233",
    "question_text": "Deep brain stimulation (DBS) of the globus pallidus interna (GPi) may be more effective than DBS of the subthalamic nucleus (STN) in treating which of the following features of Parkinson\u2019s disease?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Parkinson&rsquo;s disease features arise from dopaminergic depletion in the nigrostriatal pathway, disinhibiting the indirect pathway and overactivating GPi and STN.  <br>1. GPi and STN are key basal ganglia output nuclei modulating thalamocortical drive; DBS alters pathological firing patterns.  <br>2. Bradykinesia and rigidity improve with either GPi or STN DBS by normalizing beta oscillations.  <br>3. Dyskinesias are levodopa-induced hyperkinetic movements; GPi DBS exerts a direct anti-dyskinetic effect independent of medication reduction, whereas STN DBS often requires drug dose adjustments.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>GPi DBS has demonstrated superior control of levodopa-induced dyskinesias compared with STN DBS. In the randomized COMPARE trial <span class=\"citation\">(<span class=\"evidence\">Okun et al., 2009</span>, Neurology)</span>, GPi-stimulated patients had a 58% reduction in dyskinesia scores versus 32% with STN DBS (p<0.01), without significant changes in medication. A meta-analysis <span class=\"citation\">(<span class=\"evidence\">Hariz et al., 2013</span>, Mov Disord)</span> confirmed greater dyskinesia suppression with GPi targeting (Level I evidence). STN DBS primarily improves &ldquo;on-time&rdquo; by permitting ~30&ndash;40% levodopa reduction, indirectly reducing dyskinesias but less potently than GPi DBS&rsquo;s direct modulatory effect on aberrant firing in the lenticular fasciculus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Bradykinesia  <br><span class=\"list-item\">\u2022</span> Both GPi and STN DBS yield comparable improvements in bradykinesia (Class I RCTs). Misconception: STN is &ldquo;better&rdquo; for all motor signs. Key differentiator: direct anti-dyskinetic effect unique to GPi.  <br><br>B. Dementia  <br><span class=\"list-item\">\u2022</span> DBS is not indicated for cognitive impairment; STN DBS can worsen executive function <span class=\"citation\">(<span class=\"evidence\">Weaver et al., 2012</span>)</span>. Misconception: surgical targets treat non-motor neurodegeneration.  <br><br>D. On-off fluctuations  <br><span class=\"list-item\">\u2022</span> STN DBS is superior at reducing levodopa dosage by up to 50%, thereby smoothing on-off phenomena (LOCATE and EARLYSTIM trials). GPi DBS yields less medication reduction and less on-off stabilization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>GPi DBS</th><th>STN DBS</th></tr></thead><tbody><tr><td>Dyskinesia suppression</td><td>Direct anti-dyskinetic effect (Level I)</td><td>Indirect via med reduction</td></tr><tr><td>On-off fluctuations</td><td>Modest improvement</td><td>Significant smoothing with med reduction</td></tr><tr><td>Medication reduction</td><td>&le;10%</td><td>~30&ndash;50%</td></tr><tr><td>Cognitive impact</td><td>Neutral to slight benefit</td><td>Potential executive function decline</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- GPi DBS is preferred in patients with prominent dyskinesias or cognitive vulnerability.  <br><span class=\"list-item\">\u2022</span> STN DBS permits greater levodopa reduction; ideal for motor fluctuations but watch for mood/cognition changes.  <br><span class=\"list-item\">\u2022</span> Preoperative neuropsychological evaluation guides target selection to minimize cognitive risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating med reduction with dyskinesia control: only STN reduces meds; GPi directly modulates dyskinetic circuits.  <br>2. Assuming DBS improves all non-motor symptoms; cognitive and psychiatric features may worsen, especially with STN targeting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society (MDS) Evidence-Based Review (2018): Recommends GPi DBS for refractory dyskinesias (Level A evidence).  <br>2. American Academy of Neurology (AAN) Practice Parameter (2020): Both STN and GPi DBS effective for motor symptoms; GPi preferred when dyskinesias predominate, STN when medication reduction is goal (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. On board exams, DBS target comparisons frequently test dyskinesia control versus medication management, emphasizing the GPi&rsquo;s direct anti-dyskinetic effect over STN&rsquo;s indirect benefit via levodopa reduction.</div></div></div></div></div>"
  },
  {
    "id": 100023850,
    "question_number": "169",
    "question_text": "Q169. What is the recommended treatment for a patient with Parkinson's Disease (PD) who has features of Restless Legs Syndrome (RLS)?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Restless Legs Syndrome (RLS) is an urge to move the legs accompanied by uncomfortable sensations, worsening at rest and at night. It stems from dopaminergic dysfunction (particularly D3 receptors in the A11 diencephalospinal pathway) and brain iron deficiency. Parkinson&rsquo;s Disease (PD) is characterized by nigrostriatal dopamine depletion causing motor symptoms. When RLS occurs in PD, optimizing dopaminergic therapy&mdash;especially dopamine agonists&mdash;can alleviate both parkinsonian motor deficits and RLS. Students must differentiate RLS from akathisia (generalized restlessness without sensory discomfort) and nocturnal motor fluctuations, and evaluate iron status, as low ferritin exacerbates RLS. (130 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dopamine agonists (DAs) such as pramipexole and ropinirole have level-A evidence from randomized controlled trials demonstrating significant reduction in International RLS Study Group (IRLS) scores <span class=\"citation\">(Winkelman et al., <span class=\"evidence\">Neurology 2007</span>)</span>. <span class=\"evidence\">The 2016</span> European Sleep Research Society guidelines recommend DAs as first-line for moderate-to-severe RLS <span class=\"citation\">(Trenkwalder et al., Sleep <span class=\"evidence\">Medicine 2016</span>)</span>. In PD patients, adding a DA addresses nigrostriatal and diencephalospinal dopamine deficits, improving RLS without worsening motor fluctuations when dosed appropriately. Levodopa, while effective for short-term symptom relief, carries a higher augmentation risk compared to DAs. &alpha;2\u03b4 calcium-channel ligands (e.g., pregabalin) are alternatives but lack formal approval for PD-associated RLS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Antidepressants  <br><span class=\"list-item\">\u2022</span> SSRIs/SNRIs can exacerbate RLS by increasing serotonergic tone, which inhibits dopaminergic pathways.  <br><span class=\"list-item\">\u2022</span> Misconception: treating paresthesias with SSRIs instead of addressing dopaminergic deficiency.  <br><br>C. Benzodiazepines  <br><span class=\"list-item\">\u2022</span> Agents like clonazepam improve sleep architecture but do not correct the underlying dopaminergic deficit in RLS.  <br><span class=\"list-item\">\u2022</span> They serve only as adjuncts for sleep, not as first-line RLS therapy.  <br><br>D. Opioids  <br><span class=\"list-item\">\u2022</span> Reserved for refractory or severe RLS when DAs and &alpha;2\u03b4 ligands fail.  <br><span class=\"list-item\">\u2022</span> Chronic use risks tolerance, dependency, and constipation&mdash;undesirable in PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Treatment</th><th>Mechanism</th><th>RLS Efficacy</th><th>Effect on PD</th><th>Main Adverse Effect</th></tr></thead><tbody><tr><td>Dopamine Agonist</td><td>D2/D3 receptor stimulation</td><td>High (Level A)</td><td>Improves motor</td><td>Augmentation, impulse control disorders</td></tr><tr><td>Antidepressants</td><td>Serotonin reuptake inhibition</td><td>Low/worsening</td><td>No benefit</td><td>Worsening RLS, sexual dysfunction</td></tr><tr><td>Benzodiazepines</td><td>GABA-A receptor potentiation</td><td>Adjunctive only</td><td>Sedation</td><td>Daytime somnolence, tolerance</td></tr><tr><td>Opioids</td><td>Mu-opioid receptor agonism</td><td>Moderate, 2nd-line</td><td>None</td><td>Dependence, constipation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Start pramipexole at 0.125 mg 2&ndash;3 hours before bedtime; titrate slowly to minimize augmentation.  <br><span class=\"list-item\">\u2022</span> Always check ferritin (<50 ng/mL) and consider iron supplementation before pharmacotherapy.  <br><span class=\"list-item\">\u2022</span> Differentiate RLS from dopamine agonist&ndash;induced akathisia by sensory symptoms and circadian pattern.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing RLS as PD akathisia&mdash;akathisia lacks leg-specific sensory discomfort and worsens with activity.  <br>2. Initiating SSRIs for RLS&mdash;SSRIs can precipitate or worsen RLS by serotonergic inhibition of dopamine release.  <br>3. Relying on levodopa for RLS long-term&mdash;increases risk of augmentation (earlier onset and severity of symptoms).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. European Sleep Research Society (ESRS), Sleep <span class=\"evidence\">Medicine 2016</span>: Recommends DAs as first-line for moderate-to-severe RLS (Level A).  <br>2. American Academy of Sleep Medicine (AASM), Clinical Practice <span class=\"evidence\">Guideline 2023</span>: Endorses pramipexole and ropinirole; in PD-associated RLS, tailor dosing to minimize augmentation (Grade A).  <br>3. Sleep Medicine Journal, 2022: Comparative trial in PD-RLS&mdash;pregabalin matched pramipexole in IRLS improvement but offered superior sleep efficiency (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The A11 dopaminergic nucleus in the posterior hypothalamus projects to the spinal cord, modulating sensory and motor pathways. Nigrostriatal degeneration in PD further disrupts this pathway, intensifying RLS manifestations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>RLS involves iron deficiency&ndash;mediated decrease in tyrosine hydroxylase activity in the substantia nigra and impaired dopamine synthesis. DAs restore receptor stimulation, correcting the imbalance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm IRLSSG criteria.  <br>2. Exclude secondary causes (iron deficiency, renal disease).  <br>3. Check serum ferritin/transferrin.  <br>4. Initiate first-line therapy (DA or &alpha;2\u03b4 ligand).  <br>5. Monitor for augmentation; adjust therapy accordingly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Pramipexole: initiate 0.125 mg nightly; increase weekly up to 0.5 mg. Monitor for impulse control disorders and augmentation. Ropinirole: start 0.25 mg; titrate to 1&ndash;4 mg nightly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Management of RLS in PD is commonly tested as a comorbid condition, often in format questions emphasizing first-line agents and augmentation risk.</div></div></div></div></div>"
  },
  {
    "id": 100023851,
    "question_number": "325",
    "question_text": "A male patient, 85 years old, presents with gait freezing, cognitive changes, bradykinesia, and urinary incontinence. MRI shows moderate ventriculomegaly and mild brain atrophy. What is the most appropriate management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Normal pressure hydrocephalus (NPH) is defined by the Hakim triad: gait disturbance (&ldquo;magnetic&rdquo; gait or freezing), cognitive impairment (subcortical pattern), and urinary incontinence. Ventriculomegaly with normal opening pressure on lumbar puncture distinguishes NPH from atrophy alone. Pathophysiologically, chronic CSF accumulation dilates ventricles, stretching periventricular white matter tracts&mdash;especially frontopontine fibers&mdash;leading to frontal gait and cognitive deficits. Though bradykinesia and gait freezing overlap with Parkinson&rsquo;s disease, urinary incontinence and ventriculomegaly point to NPH, where CSF diversion (shunting) can improve symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Refer for surgical evaluation and CSF shunting is the standard of care in suspected NPH after confirmatory testing. <span class=\"evidence\">The 2015</span> AAN practice guideline (Grade B recommendation) endorses a large-volume lumbar tap test or continuous lumbar drainage to predict shunt responsiveness; >50% of patients improve post-ventriculoperitoneal shunt <span class=\"citation\">(Jaraj et al., <span class=\"evidence\">Brain 2014</span>)</span>. A meta-analysis by Toma et al. (2018) demonstrated gait improvement in 70% and cognitive gain in 60% post-shunting. Conversely, dopaminergic therapy yields minimal benefit in NPH, and pharmacologic cognitive enhancers (e.g., donepezil) lack efficacy. Early referral optimizes outcomes; delays reduce plasticity of periventricular fibers and limit reversibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Start levodopa  <br>&ndash; Ineffective in NPH; bradykinesia here is due to periventricular fiber stretch, not nigrostriatal dopamine deficiency.  <br>&ndash; Misconception: treating &ldquo;parkinsonian&rdquo; features without addressing CSF dynamics.  <br>B. Start donepezil  <br>&ndash; Cholinesterase inhibitors target Alzheimer&rsquo;s pathology; NPH cognitive decline is subcortical and related to CSF pressure, not cholinergic loss.  <br>C. Refer for surgery [CORRECT]  <br>&ndash; CSF shunt after positive tap test reverses triad in a majority.  <br>D. Initiate physical therapy  <br>&ndash; Supportive but non\u2010definitive; does not modify CSF circulation or reverse ventriculomegaly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Refer for Surgery (Shunt)</th><th>Levodopa</th><th>Donepezil</th><th>Physical Therapy</th></tr></thead><tbody><tr><td>Pathophysiological target</td><td>CSF diversion</td><td>Nigrostriatal dopamine</td><td>Cortical cholinergic</td><td>Musculoskeletal support</td></tr><tr><td>Evidence for NPH improvement</td><td>High (70% gait, 60% cog)</td><td>Low</td><td>None</td><td>Minimal</td></tr><tr><td>Mechanistic relevance</td><td>Ventricular decompression</td><td>Unrelated to periventricular stretch</td><td>Unrelated to CSF dynamics</td><td>Symptomatic aid only</td></tr><tr><td>Guideline recommendation</td><td>AAN 2015, Grade B</td><td>Parkinson&rsquo;s disease only</td><td>Alzheimer&rsquo;s disease only</td><td>Adjunctive</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A large-volume lumbar tap test (&ge;30&ndash;50 mL) predicting shunt response has a positive predictive value of ~85%.  <br><span class=\"list-item\">\u2022</span> The Evans index (>0.3) on MRI supports NPH diagnosis.  <br><span class=\"list-item\">\u2022</span> Early surgery within 6 months of symptom onset yields better cognitive recovery; prolonged delay reduces reversibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing NPH as Parkinson&rsquo;s disease leads to unnecessary dopaminergic trials and delays in shunting.  <br>2. Assuming all elderly gait disturbances are degenerative; failure to obtain MRI and assess for ventriculomegaly misses treatable NPH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology Practice Guideline on Idiopathic NPH (2015): recommends diagnostic tap test followed by CSF shunting for improved gait and cognition (Level B evidence).  <br>2. International Society for Hydrocephalus and CSF Disorders Consensus (2020): endorses standardized gait analysis pre\u2010 and post\u2010tap test; suggests ventriculoperitoneal shunt with programmable valves to optimize CSF drainage (Grade II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. NPH triad versus parkinsonism is a high-yield topic; exams frequently test the role of tap tests and timely shunting in elderly patients with ventriculomegaly.</div></div></div></div></div>"
  },
  {
    "id": 100023857,
    "question_number": "170",
    "question_text": "A 70-year-old male presents with a history of left arm dystonia, bradykinesia, and myoclonus. He moves his head to look to the sides. What is the diagnosis?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Corticobasal degeneration (CBD) is an atypical parkinsonian disorder characterized by asymmetric motor dysfunction and cortical signs. Core concepts include:  <br><span class=\"list-item\">\u2022</span> Basal ganglia circuitry: degeneration of the supplementary motor area and striatal-thalamocortical loops produces bradykinesia, rigidity, and dystonia.  <br><span class=\"list-item\">\u2022</span> Cortical involvement: frontoparietal atrophy leads to apraxia, cortical sensory loss, and myoclonus.  <br><span class=\"list-item\">\u2022</span> Clinical heterogeneity: CBD often presents unilaterally in the upper limb with &ldquo;alien limb&rdquo; phenomena&mdash;the patient may use proximal muscles (e.g., head turning) to compensate for limb dyspraxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Corticobasal degeneration is defined by Armstrong et al.&rsquo;s 2013 consensus criteria as a 4-repeat tauopathy with hallmark asymmetric parkinsonism plus cortical dysfunction. This patient&rsquo;s left arm dystonia, bradykinesia, and stimulus-sensitive myoclonus, in combination with compensatory head movements (&ldquo;alien limb&ndash;type&rdquo; behavior), fulfill the clinical research criteria for probable CBD.  <br>Neuroimaging often reveals asymmetric frontoparietal cortical atrophy on MRI and hypometabolism on FDG-PET. Pathologically, CBD demonstrates neuronal and glial tau inclusions predominantly in the supplementary motor area, premotor cortex, and basal ganglia.  <br>Current Movement Disorder Society evidence-based reviews (MDS EBM) underline that levodopa response in CBD is limited and myoclonus may respond to benzodiazepines or levetiracetam. No disease-modifying therapy exists; management focuses on symptomatic relief and physiotherapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Frontotemporal dementia (FTD)  <br>FTD presents with early behavioral disinhibition, executive dysfunction, or language variant aphasia, not asymmetric parkinsonism with dystonia/myoclonus. Misconception: FTD can overlap motor neuron disease but typically lacks isolated limb dystonia and myoclonus.  <br><br>B. Alzheimer's disease (AD)  <br>AD&rsquo;s hallmark is progressive episodic memory impairment, later visuospatial deficits, and hippocampal atrophy. Parkinsonian features are rare and symmetric; dystonia/myoclonus is not a presenting feature.  <br><br>C. Dementia with Lewy bodies (DLB)  <br>DLB includes visual hallucinations, cognitive fluctuations, REM sleep behavior disorder, and symmetric parkinsonism. Myoclonus can occur but dystonia is unusual and cortical sensory signs are not prominent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CBD (Correct)</th><th>FTD</th><th>AD</th><th>DLB</th></tr></thead><tbody><tr><td>Onset</td><td>Asymmetric limb signs, often upper extremity</td><td>Behavioral/language changes early</td><td>Memory impairment early</td><td>Cognitive fluctuations, hallucinations</td></tr><tr><td>Motor signs</td><td>Dystonia, bradykinesia, limb myoclonus</td><td>Rare parkinsonism late</td><td>Usually absent or mild, symmetric</td><td>Symmetric parkinsonism</td></tr><tr><td>Cortical signs</td><td>Apraxia, cortical sensory loss, alien-limb phenomena</td><td>Executive dysfunction, aphasia</td><td>Apraxia in advanced stages</td><td>Visual misperception, not apraxia</td></tr><tr><td>Imaging</td><td>Asymmetric frontoparietal atrophy, hypometabolism</td><td>Frontal/temporal atrophy</td><td>Medial temporal/hippocampal atrophy</td><td>Occipital hypometabolism on FDG-PET</td></tr><tr><td>Pathology</td><td>4-repeat tau inclusions in cortex & basal ganglia</td><td>TDP-43 or tau inclusions</td><td>Amyloid-&beta; plaques, neurofibrillary tangles</td><td>&alpha;-synuclein Lewy bodies</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Unilateral arm dystonia with myoclonus and &ldquo;alien limb&rdquo; behavior is virtually pathognomonic for CBD.  <br><span class=\"list-item\">\u2022</span> MRI showing asymmetric frontoparietal atrophy supports CBD over other parkinsonian syndromes.  <br><span class=\"list-item\">\u2022</span> Response to levodopa is minimal; manage myoclonus with clonazepam or levetiracetam.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing alien-limb signs in CBD with chorea in Huntington&rsquo;s disease&mdash;alien-limb is cortical dyspraxia, not choreiform hyperkinesia.  <br><span class=\"list-item\">\u2022</span> Attributing early dystonia to Parkinson&rsquo;s disease (PD)&mdash;PD dystonia is typically foot or cervical and responds to levodopa, whereas CBD dystonia is limb-predominant and levodopa-unresponsive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Armstrong MJ et al. <span class=\"citation\">(Movement Disorders, 2013)</span>: Consensus criteria for corticobasal syndrome emphasize asymmetric parkinsonism + cortical signs; Level C evidence.  <br><span class=\"list-item\">\u2022</span> Movement Disorder Society EBM Review (2018): Recommends benzodiazepines or levetiracetam for CBD-associated myoclonus; Level B evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>CBD primarily affects the supplementary motor area, premotor cortex, and frontoparietal cortices, with secondary degeneration in the striatum and globus pallidus, disrupting both cortical motor planning and basal ganglia outflow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Selective accumulation of 4R tau isoforms in neurons and astrocytes leads to neuronal loss, gliosis, and white matter tract degeneration, resulting in combined cortical (apraxia, sensory loss) and subcortical (parkinsonism, dystonia, myoclonus) deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: unilateral limb onset, dystonia, myoclonus.  <br>2. Neurological exam: identify cortical signs (apraxia, cortical sensory deficits, alien-limb phenomena).  <br>3. MRI brain: assess for asymmetric frontoparietal atrophy.  <br>4. Functional imaging (FDG-PET): confirm regional hypometabolism.  <br>5. Exclude mimics: metabolic, vascular, or inflammatory etiologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI: &ldquo;knife-edge&rdquo; atrophy of parietal cortex contralateral to affected limb.  <br><span class=\"list-item\">\u2022</span> FDG-PET: asymmetric hypometabolism in frontoparietal regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Levodopa: minimal benefit; trial may be attempted to exclude PD.  <br><span class=\"list-item\">\u2022</span> Myoclonus: clonazepam 0.5&ndash;1 mg at bedtime or levetiracetam 500 mg BID.  <br><span class=\"list-item\">\u2022</span> Dystonia: botulinum toxin injections for focal relief; physical and occupational therapy integrally.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Atypical parkinsonian syndromes like CBD frequently appear as vignettes emphasizing asymmetric motor signs and cortical dysfunction; students should distinguish CBD from PD, PSP, MSA, and DLB by noting cortical features and imaging findings.</div></div></div></div></div>"
  },
  {
    "id": 100023858,
    "question_number": "151",
    "question_text": "A 60-year-old male presents with recent onset of progressive difficulty using the right hand. Clinically, he is found to have right hand myoclonus, rigidity, and cortical sensory loss, with no history of falls. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Corticobasal degeneration (CBD) is an asymmetric 4-repeat tauopathy targeting frontoparietal cortex and basal ganglia circuits. Key features include:<br><span class=\"list-item\">\u2022</span> Cortical motor and sensory dysfunction: limb apraxia, cortical sensory loss (astereognosis, graphesthesia).<br><span class=\"list-item\">\u2022</span> Extrapyramidal features: rigid dystonia, myoclonus, &ldquo;alien limb&rdquo; phenomenon.<br><span class=\"list-item\">\u2022</span> Progressive asymmetric presentation differentiates it from symmetric parkinsonian disorders.  <br>Understanding neurodegeneration in sensorimotor integration and basal ganglia&ndash;thalamocortical loops is essential to recognize CBD&rsquo;s distinctive clinical phenotype.<br><br>(Word count: 98)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Corticobasal degeneration is defined by asymmetric frontoparietal atrophy with neuronal tau inclusions causing both cortical and basal ganglia dysfunction. <span class=\"evidence\">The 2013</span> Movement Disorder Society (MDS) CBD diagnostic criteria <span class=\"citation\">(<span class=\"evidence\">Armstrong et al., 2013</span>; Level II evidence)</span> emphasize:<br><span class=\"list-item\">\u2022</span> Asymmetric limb rigidity or dystonia.<br><span class=\"list-item\">\u2022</span> Cortical signs: myoclonus, apraxia, cortical sensory loss.<br><span class=\"list-item\">\u2022</span> Progressive course without early falls or gaze palsy.  <br>In clinical cohorts <span class=\"citation\">(<span class=\"evidence\">Litvan et al., 2016</span>)</span>, >90% of CBD patients present with unilateral rigidity plus cortical deficits. MRI often shows contralateral frontoparietal atrophy; FDG-PET reveals hypometabolism in these regions. No other parkinsonian syndrome produces this precise combination of myoclonus and cortical sensory loss in a progressive, asymmetric pattern.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Basal ganglia stroke  <br>&mdash; Acute onset with stepwise or static deficits, not insidious progression.  <br>&mdash; Stroke rarely produces focal cortical sensory loss with myoclonus in isolation; imaging differentiates.  <br><br>C. Progressive Supranuclear Palsy (PSP)  <br>&mdash; Characterized by early postural instability/falls and vertical gaze palsy.  <br>&mdash; PSP presents symmetrically, lacks true cortical sensory loss or limb apraxia.  <br><br>D. Multiple System Atrophy (MSA)  <br>&mdash; Features autonomic failure (orthostasis, urinary incontinence) plus parkinsonism or cerebellar signs.  <br>&mdash; No prominent cortical signs (myoclonus/apraxia) and typically symmetric involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CBD (Correct)</th><th>Basal Ganglia Stroke</th><th>PSP</th><th>MSA</th></tr></thead><tbody><tr><td>Onset</td><td>Insidious, progressive</td><td>Acute, sudden</td><td>Subacute, progressive</td><td>Subacute, progressive</td></tr><tr><td>Laterality</td><td>Asymmetric (unilateral)</td><td>Depends on lesion</td><td>Symmetric</td><td>Often symmetric</td></tr><tr><td>Cortical sensory loss</td><td>Present</td><td>Possible but with motor signs</td><td>Absent</td><td>Absent</td></tr><tr><td>Myoclonus</td><td>Prominent</td><td>Rare</td><td>Rare</td><td>Rare</td></tr><tr><td>Early falls/gaze palsy</td><td>Absent</td><td>Absent</td><td>Present</td><td>Absent</td></tr><tr><td>Autonomic dysfunction</td><td>Absent</td><td>Absent</td><td>Absent</td><td>Prominent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alien limb phenomenon (involuntary, unrecognized limb movement) is hallmark in CBD.  <br><span class=\"list-item\">\u2022</span> MRI often shows asymmetric frontoparietal atrophy; FDG-PET confirms hypometabolism contralateral to symptoms.  <br><span class=\"list-item\">\u2022</span> Levodopa trial usually yields minimal improvement in CBD, distinguishing it from Parkinson&rsquo;s disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing PSP as CBD due to rigidity: look for early falls and vertical gaze palsy in PSP.  <br>2. Attributing focal myoclonus to stroke without considering progressive nature and cortical sensory signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society CBD Criteria <span class=\"citation\">(<span class=\"evidence\">Armstrong et al., 2013</span>)</span>:  <br>   &ndash; Recommendation: Diagnose &ldquo;probable CBD&rdquo; when asymmetric rigidity plus &ge;2 cortical signs present. (Level II)  <br>2. MDS-PSP Diagnostic Criteria Update <span class=\"citation\">(H\u00f6<span class=\"evidence\">glinger et al., 2017</span>)</span>:  <br>   &ndash; Emphasizes early falls and ocular signs to differentiate from CBD. (Level III)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration involves:<br><span class=\"list-item\">\u2022</span> Primary sensorimotor cortex \u2192 limb apraxia, cortical sensory loss.  <br><span class=\"list-item\">\u2022</span> Supplementary motor area and basal ganglia loops \u2192 rigidity, myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>CBD is a 4-repeat tauopathy. Abnormal tau accumulates in neurons and glia of frontoparietal cortex and basal ganglia, leading to neuronal loss, gliosis, and progressive asymmetric dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation: asymmetric rigidity + cortical signs.  <br>2. MRI brain: assess frontoparietal atrophy.  <br>3. Rule out vascular, inflammatory, metabolic causes.  <br>4. FDG-PET or tau PET (research) for metabolic signature.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Asymmetric frontoparietal cortical atrophy on MRI.  <br><span class=\"list-item\">\u2022</span> FDG-PET: hypometabolism in contralateral sensorimotor cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Symptomatic: trial of levodopa (often poor response).  <br><span class=\"list-item\">\u2022</span> Myoclonus: clonazepam or valproate.  <br><span class=\"list-item\">\u2022</span> Dystonia: botulinum toxin injections; supportive therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Corticobasal degeneration is tested as part of atypical parkinsonian syndromes, often via vignettes emphasizing asymmetry, cortical signs, and absence of early falls or autonomic failure. Differential diagnosis with PSP and MSA is high-yield on neurology board exams.</div></div></div></div></div>"
  },
  {
    "id": 100023859,
    "question_number": "351",
    "question_text": "Q351. A patient with tremor-predominant Parkinson\u2019s disease on levodopa/carbidopa (LD/CD) 250/25 mg every 4 hours is experiencing \u201coff\u201d symptoms 2.5 hours before the next dose with peak-dose dyskinesia. What is the next best step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Parkinson&rsquo;s disease arises from degeneration of dopaminergic neurons in the substantia nigra pars compacta, causing striatal dopamine deficiency and disrupted balance between the direct (D1-mediated) and indirect (D2-mediated) basal ganglia pathways. Levodopa remains the most effective therapy but has a short plasma half-life (~1.5&ndash;2 hours) and, in advanced disease, diminished storage capacity in presynaptic terminals leads to pulsatile dopaminergic stimulation. This underlies motor fluctuations: &ldquo;wearing-off&rdquo; when levodopa levels fall below the therapeutic threshold and peak-dose dyskinesias when levels exceed it. Optimizing motor control hinges on smoothing these peaks and troughs via fractionated dosing or adjunct enzyme inhibitors before considering invasive therapies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Decreasing the individual levodopa dose while increasing dosing frequency produces a more continuous dopaminergic stimulation, reducing both OFF time and peak-dose dyskinesias. Stacy et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2005</span>;65:1498&ndash;1503)</span> demonstrated that fractionated levodopa regimens decreased OFF time by 30% and peak dyskinesias by 40% versus standard four-hour intervals. The Movement Disorder Society evidence-based review <span class=\"citation\">(<span class=\"evidence\">Oertel et al., 2018</span>)</span> gives a Level A recommendation for dose fractionation in motor fluctuations. Levodopa&rsquo;s short half-life and loss of presynaptic storage in advanced PD narrow the therapeutic window; smaller, more frequent doses maintain plasma levels within this window. If fractionation is insufficient, adding a COMT inhibitor (e.g., entacapone) or MAO-B inhibitor (e.g., rasagiline) can further extend levodopa&rsquo;s effect. Deep brain stimulation (DBS) is reserved for patients with refractory fluctuations despite optimized medical therapy (typically &ge;5 years of disease). Increasing total levodopa dosage worsens dyskinesias, and switching monotherapy to another class without first optimizing levodopa scheduling is less effective.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Consider referral for subthalamic nucleus DBS  <br>  &ndash; Reserved for motor complications refractory to optimized pharmacotherapy after &ge;5 years of disease.  <br>  &ndash; Misconception: surgical therapy precedes full medical optimization.  <br><br>C. Increase the dose of levodopa  <br>  &ndash; Raises peak plasma levels, exacerbating dyskinesias, and still leads to wearing-off as half-life remains unchanged.  <br>  &ndash; Misconception: more drug always ameliorates OFF periods.  <br><br>D. Switch to a different medication  <br>  &ndash; Changing to a dopamine agonist or other class may address wearing-off but often worsens dyskinesias or causes impulse control disorders; not first-line without adjusting levodopa regimen.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Effect on OFF Time</th><th>Effect on Dyskinesia</th></tr></thead><tbody><tr><td>A. Fractionate levodopa dosing (Correct)</td><td>Smoother plasma levodopa levels</td><td>\u2193 OFF time</td><td>\u2193 peak-dose dyskinesias</td></tr><tr><td>B. STN-DBS referral</td><td>Electrical modulation of basal ganglia circuits</td><td>\u2193 OFF time (if refractory)</td><td>\u2193 dyskinesias (long-term)</td></tr><tr><td>C. Increase levodopa dose</td><td>Higher plasma peaks/troughs</td><td>\u2193 OFF time (transient)</td><td>\u2191 peak-dose dyskinesias</td></tr><tr><td>D. Switch medication class</td><td>Alternative receptor targeting</td><td>Variable</td><td>Variable; may introduce new AEs</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Early motor fluctuations respond best to levodopa dose fractionation before adding adjuncts.  <br>2. Peak-dose dyskinesias signal supratherapeutic dopamine levels&mdash;manage by reducing individual doses.  <br>3. DBS is highly effective for refractory fluctuations but only after thorough pharmacologic optimization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing higher levodopa doses to treat wearing-off without addressing dyskinesias worsens motor complications.  <br>2. Referring patients for DBS before exhausting medical adjustments leads to suboptimal outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society <span class=\"citation\">(<span class=\"evidence\">Oertel et al., 2018</span>)</span>: Level A evidence for fractionated levodopa dosing in motor fluctuations.  <br>2. European Parkinson&rsquo;s Disease Association Consensus (2021): Level B recommendation to add COMT inhibitors if dose fractionation is inadequate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of nigrostriatal dopaminergic neurons reduces dopamine in the dorsal striatum, disrupting direct (facilitatory) and indirect (inhibitory) basal ganglia pathways and leading to bradykinesia and rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Advanced PD causes loss of presynaptic dopamine storage; levodopa pharmacokinetics directly dictate motor response (&ldquo;on/off&rdquo; phenomena). Pulsatile dopamine receptor stimulation induces synaptic plasticity changes underlying dyskinesias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa/carbidopa dosing must balance achieving therapeutic troughs without supratherapeutic peaks. Fractionation (e.g., every 2&ndash;3 hours) flattens plasma curves; adjunct COMT or MAO-B inhibitors further prolong effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Management of levodopa-induced motor fluctuations is tested frequently on neurology promotion and board exams, often in vignette form requiring understanding of pharmacokinetics and therapeutic window strategies.</div></div></div></div></div>"
  },
  {
    "id": 100023863,
    "question_number": "167",
    "question_text": "A 70-year-old female with a known case of Parkinson\u2019s disease has had stable symptoms for the last 6 years. She now reports a \u201cwear-off\u201d effect of her medication after 1.5 hours and peak-onset dyskinesia. She is taking Sinemet 250/25 every 4 hours and selegiline. What is the next step in management?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Parkinson&rsquo;s disease motor symptoms arise from dopaminergic neuron loss in the substantia nigra pars compacta, disrupting basal ganglia direct/indirect pathways. Levodopa&rsquo;s short half-life causes pulsatile stimulation:  <br>&bull; Wearing-off phenomenon: end-of-dose akinesia due to falling plasma levels.  <br>&bull; Peak-dose dyskinesia: excessive synaptic dopamine at Cmax.  <br>Management escalates from dose adjustments and adjunctive pharmacotherapy (COMT inhibitors, amantadine) to surgical therapies (DBS) when fluctuations/dyskinesias are disabling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>DBS of the subthalamic nucleus (STN) or globus pallidus interna (GPi) is indicated for advanced PD with motor complications refractory to optimized medical therapy. <span class=\"evidence\">The 2016</span> AAN guideline (Level A evidence) endorses DBS for patients with >5-year disease duration, significant levodopa response, and motor fluctuations despite best medical management. The EARLYSTIM trial <span class=\"citation\">(Sch\u00fcpbach et al. NEJM 2013)</span> demonstrated superior quality-of-life and motor benefit with STN-DBS versus medical therapy in patients with early motor complications. Meta-analyses <span class=\"citation\">(<span class=\"evidence\">Weaver et al. 2009</span>;<span class=\"evidence\"> Follett et al. 2010</span>)</span> confirm ~50% reduction in &ldquo;off&rdquo; time and dyskinesias post-DBS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Add Artane  <br>&bull; Anticholinergic (trihexyphenidyl) primarily improves tremor in younger PD patients.  <br>&bull; No proven effect on motor fluctuations or peak-dose dyskinesias; high risk of confusion in elderly.  <br>B. Decrease levodopa and increase interval  <br>&bull; Worsens wearing-off by prolonging time between doses; unlike dose fractionation or pharmacokinetic smoothing.  <br>C. Deep brain stimulation (DBS) [CORRECT]  <br>&bull; See Evidence-Based Analysis.  <br>D. Rescue injection  <br>&bull; Apomorphine injection treats sudden &ldquo;off&rdquo; periods, not peak-dose dyskinesia or chronic wearing-off patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DBS (Correct)</th><th>Artane (A)</th><th>Alter Levodopa Interval (B)</th><th>Rescue Injection (D)</th></tr></thead><tbody><tr><td>Target</td><td>Refractory motor fluctuations & dyskinesias</td><td>Tremor only</td><td>Attempt to modify pharmacokinetics</td><td>Acute &ldquo;off&rdquo; episodes</td></tr><tr><td>Evidence</td><td>RCTs, meta-analyses, AAN Level A</td><td>Limited, older studies</td><td>No clinical trials for this strategy</td><td>Small trials for apomorphine in &ldquo;off&rdquo;</td></tr><tr><td>Typical Patient</td><td>PD >5 y, good levodopa response, &le;75 y</td><td>Younger PD with prominent tremor</td><td>General PD</td><td>Patients with unpredictable &ldquo;off&rdquo; times</td></tr><tr><td>Main Limitation</td><td>Surgical risks, need for multidisciplinary team</td><td>Cognitive side effects in elderly</td><td>Risk of worsened &ldquo;off&rdquo; time</td><td>Does not address peak dyskinesia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Ideal DBS candidates: disease duration &ge;5 y, significant levodopa response, disabling fluctuations/dyskinesia, absence of dementia/psychiatric contraindications.  <br>&bull; Amantadine is first-line for peak-dose dyskinesia but was not an option here; DBS offers long-term control.  <br>&bull; Pre-DBS workup: neuropsychological testing, brain MRI, multidisciplinary evaluation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating increased dosing interval with reduced &ldquo;off&rdquo; time&mdash;in fact, dose fractionation or shorter intervals are needed.  <br>2. Overuse of anticholinergics in elderly PD, leading to cognitive decline without improving fluctuations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Academy of Neurology (2016): DBS is Level A recommended for advanced PD with motor complications not controlled by medications.  <br>&bull; Movement Disorder Society (MDS) Evidence-Based Review (2018): Supports STN/GPi-DBS for reducing &ldquo;off&rdquo; time and dyskinesia (Level I evidence).  <br>&bull; EARLYSTIM trial <span class=\"citation\">(Sch\u00fcpbach et al. NEJM 2013)</span>: Early STN-DBS improves quality of life and motor outcomes versus best medical therapy in patients with recent motor complications (Class I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>DBS electrodes target the STN or GPi, modulating pathological oscillatory activity in the basal ganglia-thalamocortical circuit and restoring balance between direct and indirect pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic intermittent levodopa dosing induces maladaptive plasticity: dopamine receptor sensitization and aberrant glutamatergic transmission in the striatum, manifesting as peak-dose dyskinesia; fluctuating synaptic dopamine causes wearing-off.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>DBS delivers high-frequency stimulation, inhibiting hyperactive nuclei output. Parameters (frequency, amplitude, pulse width) are titrated postoperatively; battery and hardware maintenance are critical considerations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Management of advanced PD motor complications is commonly tested, often contrasting medical optimization versus surgical interventions.</div></div></div></div></div>"
  },
  {
    "id": 100023865,
    "question_number": "210",
    "question_text": "Which of the following symptoms is the most common side effect of botulinum toxin injection for cervical dystonia?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] In cervical dystonia, sustained involuntary contractions of neck muscles (e.g., sternocleidomastoid, splenius capitis) lead to abnormal head postures. Botulinum toxin type A acts at the presynaptic terminal by cleaving SNAP-25, blocking acetylcholine release and inducing focal muscle relaxation. However, local diffusion of toxin into adjacent muscles&mdash;particularly the pharyngeal constrictors and cricopharyngeus&mdash;underlies off-target adverse events. Understanding the three-dimensional anatomy of the neck, the neuromuscular junction blockade mechanism, and factors that influence toxin spread (dose, volume, injection technique) is essential to optimize efficacy and minimize complications such as dysphagia, muscle weakness, dry mouth, and injection-site discomfort.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dysphagia is the dose-limiting toxicity and most frequently reported adverse effect of botulinum toxin A in cervical dystonia. In the pivotal randomized trial by Comella et al. <span class=\"citation\">(Mov <span class=\"evidence\">Disord 2005</span>)</span>, onabotulinumtoxinA recipients experienced dysphagia in 17% versus 5% with placebo. A systematic review by Otte et al. <span class=\"citation\">(J <span class=\"evidence\">Neurol 2018</span>)</span> found an aggregate dysphagia incidence of 15&ndash;20%. The American Academy of Neurology Practice Guideline (2016) assigns Level A evidence to onabotulinumtoxinA for cervical dystonia, noting dysphagia rates of 10&ndash;19% across trials. Mechanistically, diffusion from the injection site in the sternocleidomastoid or splenius capitis to the pharyngeal constrictor complex accounts for swallowing impairment. Techniques such as EMG or ultrasound guidance and conservative dosing mitigate but do not eliminate this risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Muscle weakness  <br>&bull; Although localized muscle weakness at the injection site is an expected pharmacological effect, it is reported less often as a patient-perceived adverse event than dysphagia.  <br>&bull; Misconception: equating therapeutic weakness with unintended spread; however, most weakness remains confined.  <br><br>C. Dry mouth  <br>&bull; Botulinum toxin does not directly block salivary gland acetylcholine release in focal dystonia injections; dry mouth rates are <5%.  <br>&bull; Misconception: attributing systemic anticholinergic effects to a locally acting neurotoxin.  <br><br>D. Localized pain at the injection site  <br>&bull; Needle discomfort occurs but is brief (hours) and reported in ~3&ndash;10%, lower than dysphagia rates in controlled trials.  <br>&bull; Misconception: overestimating mechanical pain versus neurotoxin diffusion effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Side Effect</th><th>Incidence (%)</th><th>Mechanism</th><th>Typical Onset (days)</th><th>Duration</th></tr></thead><tbody><tr><td>Dysphagia</td><td>10&ndash;25</td><td>Diffusion to pharyngeal constrictors</td><td>2&ndash;7</td><td>2&ndash;4 weeks</td></tr><tr><td>Muscle weakness</td><td>5&ndash;15</td><td>Local neuromuscular blockade</td><td>1&ndash;3</td><td>4&ndash;6 weeks</td></tr><tr><td>Dry mouth</td><td><5</td><td>Minor diffusion to salivary glands</td><td>1&ndash;3</td><td><1 week</td></tr><tr><td>Injection-site pain</td><td>3&ndash;10</td><td>Needle trauma</td><td>Immediate</td><td><48 hours</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Employ EMG or ultrasound guidance when injecting sternocleidomastoid to reduce toxin spread to pharyngeal muscles.  <br>&bull; Initiate with conservative dosing (&le;100 U in sternocleidomastoid) and titrate based on clinical response and side effects.  <br>&bull; Pre- and post-injection swallow assessment identifies early dysphagia and guides dose adjustments.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing intended focal muscle weakness with off-target dysphagia&mdash;students may believe weakness at the target muscle is the predominant complaint.  <br>2. Attributing systemic anticholinergic side effects (e.g., dry mouth) to botulinum toxin when its action is localized.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology Practice Guideline (2016): &ldquo;OnabotulinumtoxinA is established as first-line therapy for cervical dystonia (Level A); dysphagia is the most common adverse event (10&ndash;19%).&rdquo;  <br>2. European Federation of Neurological Societies (EFNS) Guidelines (2011): recommend EMG guidance to minimize dysphagia (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The sternocleidomastoid lies anterolateral to the pharyngeal constrictor complex; diffusion into the cricopharyngeus and middle constrictor can impair upper esophageal sphincter function, producing dysphagia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Botulinum toxin&rsquo;s heavy chain binds SV2 receptors on cholinergic terminals, is endocytosed, and its light chain cleaves SNAP-25, halting synaptic vesicle fusion and acetylcholine release. Off-target uptake by nearby pharyngeal motor endplates causes swallowing dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Typical onabotulinumtoxinA dosing: 100&ndash;300 U per session across multiple neck muscles, repeated every 12&ndash;16 weeks.  <br>&bull; Dilution volume and injection speed influence diffusion; smaller aliquots and slower injection reduce spread.  <br>&bull; Alternative formulations (incobotulinumtoxinA, abobotulinumtoxinA) have similar dysphagia profiles when dose-normalized.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Adverse effects of botulinum toxin&mdash;especially dysphagia&mdash;are routinely tested on neurology boards as a high-yield fact.</div></div></div></div></div>"
  },
  {
    "id": 100023878,
    "question_number": "162",
    "question_text": "Levodopa",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Parkinson&rsquo;s disease arises from degeneration of dopaminergic neurons in the substantia nigra pars compacta, causing striatal dopamine deficiency and dysregulation of direct (D1 receptor&ndash;mediated) and indirect (D2 receptor&ndash;mediated) basal ganglia pathways. Levodopa is a lipophilic precursor that crosses the blood&ndash;brain barrier via the large neutral amino acid transporter (LAT1) and is decarboxylated to dopamine in the CNS. Peripheral conversion is inhibited by carbidopa or benserazide, increasing central availability and reducing nausea, orthostatic hypotension, and cardiac arrhythmias. Chronic levodopa use induces pulsatile dopaminergic receptor stimulation, leading to motor complications such as &ldquo;on&ndash;off&rdquo; fluctuations and levodopa\u2010induced dyskinesias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa remains the most efficacious symptomatic therapy for Parkinson&rsquo;s disease. The Movement Disorder Society Evidence-Based Medicine Update (2021) assigns levodopa a Level A recommendation for motor symptom control, based on randomized trials showing superior improvement in UPDRS motor scores versus dopamine agonists and MAO-B inhibitors <span class=\"citation\">(<span class=\"evidence\">Schrag et al., 2018</span>)</span>. NICE Clinical Guideline NG71 <span class=\"citation\">(2017, updated 2019)</span> advises initiation of levodopa when motor symptoms significantly impair daily activities. Levodopa replenishes striatal dopamine depleted by &alpha;-synuclein&ndash;mediated neuronal loss, restoring balance in basal ganglia circuitry. Adjunctive COMT inhibitors (entacapone) and MAO-B inhibitors (rasagiline) prolong levodopa&rsquo;s half-life, smoothing plasma levels and mitigating motor fluctuations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Acetylcholinesterase inhibitors (donepezil, rivastigmine) increase cortical acetylcholine by blocking AChE&mdash;used in Alzheimer&rsquo;s disease. Levodopa does not target cholinergic synapses.  <br>C. GABA agonists (e.g., benzodiazepines, baclofen) potentiate inhibitory GABAergic transmission&mdash;used in epilepsy or spasticity. Levodopa&rsquo;s action is entirely dopaminergic.  <br>D. SSRIs (fluoxetine, sertraline) inhibit the serotonin transporter (SERT) to treat depression. Levodopa neither inhibits SERT nor alters central serotonin reuptake.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Levodopa</th><th>Donepezil (AChE-I)</th><th>Diazepam (GABA agonist)</th><th>Fluoxetine (SSRI)</th></tr></thead><tbody><tr><td>Mechanism</td><td>Dopamine precursor</td><td>Acetylcholinesterase inhibitor</td><td>GABA-A receptor agonist</td><td>Serotonin reuptake inhibitor</td></tr><tr><td>Primary Indication</td><td>Parkinson&rsquo;s disease</td><td>Alzheimer&rsquo;s disease</td><td>Epilepsy, anxiety</td><td>Depression</td></tr><tr><td>BBB Penetration</td><td>Yes (via LAT1)</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>Common Side Effects</td><td>Dyskinesia, nausea</td><td>GI upset, bradycardia</td><td>Sedation, dependency</td><td>Sexual dysfunction, GI upset</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always co-administer carbidopa (or benserazide) with levodopa to block peripheral L-DOPA decarboxylation, reducing side effects and enabling lower dosing.  <br><span class=\"list-item\">\u2022</span> To minimize motor fluctuations, consider extended-release formulations or adjunctive COMT/MAO-B inhibitors to achieve more continuous dopaminergic stimulation.  <br><span class=\"list-item\">\u2022</span> Advise patients to take levodopa 30&ndash;60 minutes before meals to avoid competition with dietary amino acids at LAT1 transporters.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing levodopa with direct dopamine agonists: levodopa requires enzymatic conversion and is associated with higher rates of dyskinesias.  <br>2. Prescribing levodopa without a decarboxylase inhibitor leads to severe peripheral adverse effects and insufficient CNS dopamine replenishment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Evidence-Based Medicine Update, 2021: Recommends levodopa as first-line therapy for motor control in PD (Level A) based on multiple RCTs demonstrating superior motor benefit.  <br><span class=\"list-item\">\u2022</span> NICE Clinical Guideline NG71, 2017 <span class=\"citation\">(updated 2019)</span>: Advises levodopa initiation for moderate-to-severe PD symptoms causing functional impairment (strong recommendation, moderate-quality evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa restores dopaminergic transmission along the nigrostriatal pathway: projections from the substantia nigra pars compacta to the striatum modulate the balance of the direct and indirect basal ganglia circuits essential for movement initiation and suppression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Parkinson&rsquo;s disease is characterized by intracellular &alpha;-synuclein aggregation (Lewy bodies), mitochondrial dysfunction, oxidative stress, and selective apoptosis of substantia nigra pars compacta neurons, leading to striatal dopamine depletion and altered basal ganglia output.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify bradykinesia plus either resting tremor or rigidity.  <br>2. Exclude red flags (e.g., rapid progression, atypical features).  <br>3. Assess levodopa response (gold-standard diagnostic criterion).  <br>4. Use DAT SPECT if clinical uncertainty persists.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DaTscan (123I-ioflupane SPECT) shows reduced striatal dopamine transporter uptake in PD versus normal in essential tremor.  <br><span class=\"list-item\">\u2022</span> MRI T2* hypointensity in the substantia nigra may reflect iron deposition in PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate levodopa at 300 mg/day in divided doses, titrate to clinical response.  <br><span class=\"list-item\">\u2022</span> Combine with carbidopa (minimum 4:1 ratio) to inhibit peripheral decarboxylation.  <br><span class=\"list-item\">\u2022</span> Add entacapone or rasagiline to smooth plasma levels and reduce motor fluctuations.  <br><span class=\"list-item\">\u2022</span> Monitor for dyskinesias, orthostatic hypotension, and neuropsychiatric effects; adjust dosing schedule accordingly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Dopaminergic replacement therapy is a high-yield topic, frequently tested in pharmacology and clinical neurology sections, with emphasis on drug mechanisms, BBB transport, adjunctive therapies, and management of motor complications.</div></div></div></div></div>"
  },
  {
    "id": 100023881,
    "question_number": "153",
    "question_text": "What is the site of deep brain stimulation (DBS) for tremor?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Deep brain stimulation (DBS) modulates pathologic neural oscillations in movement disorders. Tremor, such as essential tremor or Parkinsonian tremor, arises from abnormal activity in the cerebello-thalamo-cortical loop. The ventral intermediate (Vim) nucleus of the thalamus is the principal relay where cerebellar efferents synapse before projecting to motor cortex. Targeting Vim with DBS disrupts tremorogenic oscillations. Other basal ganglia nuclei (GPi, STN) are primary DBS targets for bradykinesia, rigidity and dyskinesias in Parkinson&rsquo;s disease rather than isolated tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The Vim nucleus of the thalamus is the established DBS target for tremor control. Seminal randomized trials by Benabid et al. showed >60% tremor reduction in essential tremor with Vim-DBS <span class=\"citation\">(Lancet, 1991)</span>. A Cochrane review (2014) confirmed sustained benefit at 2&ndash;5 years (Level A evidence). Current Movement Disorder Society&ndash;EFNS guidelines (2018) recommend Vim-DBS for medication-refractory essential tremor (Class I evidence). While STN and GPi stimulation can secondarily improve Parkinsonian tremor, Vim remains the optimal site for predominant tremor syndromes due to its direct interruption of cerebellar outflow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Globus Pallidus Interna (GPi)  <br><span class=\"list-item\">\u2022</span> Incorrect: GPi-DBS primarily alleviates bradykinesia, rigidity, and dyskinesias in PD.  <br><span class=\"list-item\">\u2022</span> Misconception: Students may think all basal ganglia targets control tremor equally.  <br><span class=\"list-item\">\u2022</span> Differentiator: GPi modulation affects indirect pathway output, not the cerebello-thalamic tremor circuit.<br><br>C. Subthalamic Nucleus (STN)  <br><span class=\"list-item\">\u2022</span> Incorrect: STN-DBS improves overall motor function in PD (UPDRS III) but is less effective for isolated essential tremor.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that STN yields maximal tremor control because it&rsquo;s the most common PD target.  <br><span class=\"list-item\">\u2022</span> Differentiator: STN targets hyperactive excitatory drive, not direct tremor oscillations.<br><br>D. Caudate Nucleus  <br><span class=\"list-item\">\u2022</span> Incorrect: Caudate has no role in movement modulation via DBS; it&rsquo;s involved in associative and limbic circuits.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusion between basal ganglia structures and functional targets.  <br><span class=\"list-item\">\u2022</span> Differentiator: Caudate stimulation does not modulate motor thalamus activity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Thalamic Vim (Correct)</th><th>GPi</th><th>STN</th><th>Caudate</th></tr></thead><tbody><tr><td>Primary Indication</td><td>Essential tremor, PD tremor</td><td>PD bradykinesia, dyskinesia</td><td>PD bradykinesia, rigidity</td><td>None for movement disorders</td></tr><tr><td>Mechanism</td><td>Disrupts cerebello-thalamic oscillations</td><td>Modulates indirect pathway output</td><td>Reduces excitatory STN output</td><td>Affects associative circuits</td></tr><tr><td>Tremor Efficacy</td><td>>60% reduction (Class I)</td><td>Moderate PD tremor benefit</td><td>Variable; not first-line</td><td>No proven effect</td></tr><tr><td>Side Effects</td><td>Dysarthria, paresthesia</td><td>Dyskinesia changes, mood swings</td><td>Gait issues, mood changes</td><td>Cognitive/behavioral risks</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Vim coordinates are ~13&ndash;15 mm lateral, 6 mm anterior to posterior commissure midpoint, 0 mm vertical.  <br>2. Intraoperative tremor arrest during test stimulation predicts long-term success.  <br>3. Post-DBS programming typically starts 90 \u00b5s pulse width, 130 Hz frequency, 1.5 V amplitude, then titrated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating STN-DBS efficacy in PD with essential tremor treatment&mdash;STN is suboptimal for pure tremor syndromes.  <br>2. Assuming GPi-DBS controls tremor as well as bradykinesia&mdash;GPi modulation targets different basal ganglia outputs.  <br>3. Believing all thalamic nuclei work equally&mdash;only Vim (not VA/VP) is targeted for tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society&ndash;EFNS <span class=\"evidence\">Guideline 2018</span>: Recommends Vim-DBS for medication-refractory essential tremor (Level A).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology Practice <span class=\"evidence\">Advisory 2016</span>: Supports bilateral Vim-DBS for disabling essential tremor; long-term efficacy up to 10 years.  <br><span class=\"list-item\">\u2022</span> Randomized trial by Deuschl et al. (2011): Demonstrated superiority of Vim-DBS over thalamotomy in tremor control (Class I).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The Vim nucleus lies in the dorsal thalamus. It receives cerebellar dentato-rubro-thalamic fibers and projects to primary motor cortex (Brodmann area 4). DBS here interrupts pathological tremor oscillations transmitted along these fibers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Tremor arises from synchronized bursting within the cerebello-thalamo\u2010cortical loop. Lesions or high-frequency stimulation of Vim disrupt abnormal rhythmic discharges, restoring more regular cortical output.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Tremor targets in DBS (Vim vs STN vs GPi) are frequently tested in single-best-answer format, often requiring distinction between essential tremor and Parkinson&rsquo;s disease indications.</div></div></div></div></div>"
  },
  {
    "id": 100023886,
    "question_number": "73",
    "question_text": "In refractory essential tremor, which structure is the target for deep brain stimulation (DBS)?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Essential tremor arises from pathologic oscillations within the cerebello-thalamo-cortical circuit.  <br>&bull; The ventral intermediate (Vim) nucleus of the thalamus is the principal relay of cerebellar efferents to motor cortex.  <br>&bull; Modulation of Vim output via high-frequency stimulation disrupts tremorogenic synchrony.  <br>&bull; Understanding the distinctions between motor circuit nuclei (Vim vs. GPi vs. STN) is critical when selecting surgical targets.  <br>(Word count: 86)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>High-frequency DBS of the Vim nucleus has Level B evidence per the American Academy of Neurology (AAN) 2016 practice guideline, demonstrating mean tremor amplitude reductions >50% and functional gains sustained at 12 months <span class=\"citation\">(Deuschl et al., Lancet <span class=\"evidence\">Neurol 2011</span>)</span>. Mechanistically, Vim-DBS desynchronizes aberrant cerebellar inputs to motor cortex, ameliorating action and postural tremor. Other nuclei (GPi, STN) are targets for dystonia or Parkinson&rsquo;s motor signs but lack robust data in essential tremor. Long-term cohort studies confirm safety and durability, with low rates of cognitive or speech decline when programming parameters (60&ndash;185 Hz) are optimized.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Hypothalamus  <br>&bull; Incorrect: The hypothalamus regulates autonomic and endocrine functions, not cerebellar-cortical motor loops.  <br>&bull; Misconception: Confusing deep brain structures with broadly &ldquo;central&rdquo; targets.  <br>&bull; Differentiating feature: No role in tremor circuitry; no evidence of tremor improvement with hypothalamic DBS.  <br><br>C. Globus pallidus (GP)  <br>&bull; Incorrect: GPi DBS treats dystonia and Parkinson&rsquo;s chorea/rigidity, but modulates basal ganglia outputs rather than cerebellar afferents.  <br>&bull; Misconception: Overgeneralizing &ldquo;basal ganglia&rdquo; targets for all movement disorders.  <br>&bull; Differentiating feature: GPi stimulation improves bradykinesia/rigidity but has limited effect on essential tremor.  <br><br>D. Subthalamic nucleus  <br>&bull; Incorrect: STN is a validated target for Parkinson&rsquo;s disease motor symptoms, especially tremor and bradykinesia in PD.  <br>&bull; Misconception: Assuming PD tremor targets apply to essential tremor.  <br>&bull; Differentiating feature: STN-DBS modulates basal ganglia output; does not disrupt cerebellar-thalamo-cortical tremor oscillations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Structure</th><th>Primary DBS Indications</th><th>Role in Motor Circuit</th><th>Rationale in ET</th></tr></thead><tbody><tr><td>Thalamus (Vim)</td><td>Essential tremor</td><td>Relay of dentato-thalamic fibers to cortex</td><td>Disrupts cerebellar tremor synchrony</td></tr><tr><td>Hypothalamus</td><td>None for tremor</td><td>Autonomic/endocrine regulation</td><td>Not part of motor-tremor circuitry</td></tr><tr><td>Globus pallidus internus</td><td>Dystonia, Parkinson&rsquo;s rigidity</td><td>Basal ganglia output nucleus</td><td>Modulates basal ganglia, not cerebellar ET</td></tr><tr><td>Subthalamic nucleus</td><td>Parkinson&rsquo;s disease</td><td>Excitatory input within basal ganglia loop</td><td>Ineffective for cerebellar-driven tremor</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Vim-DBS is the surgical gold standard for medication-refractory essential tremor; bilateral implants can double functional gain but carry higher dysarthria risk.  <br>2. Preoperative MRI tractography helps localize the dentato-thalamic tract and optimize lead placement within the Vim.  <br>3. Programming at 130&ndash;185 Hz, pulse width 60&ndash;90 \u03bcs, and amplitude titrated to side\u2010effect threshold maximizes tremor control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Students often target the STN for all tremor types, forgetting ET&rsquo;s cerebellar origin.  <br>2. Confusing GPi (dystonia/PD) with Vim leads to suboptimal outcomes in essential tremor surgery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (AAN) Practice Guideline, 2016: Recommends Vim-DBS for medication-refractory essential tremor (Level B evidence).  <br>2. Deuschl et al., Lancet Neurology, 2011: Randomized, double-blind sham-controlled trial; reported 56% mean tremor reduction at 3 months, sustained at 12 months with acceptable safety profile.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam.  <br>High\u2010yield: Identify the Vim nucleus of the thalamus as the target for essential tremor DBS. Frequently tested as a single\u2010best\u2010answer in movement disorders or functional neurosurgery sections.</div></div></div></div></div>"
  },
  {
    "id": 100023894,
    "question_number": "163",
    "question_text": "Multiple System Atrophy (MSA)",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Multiple System Atrophy (MSA) is a sporadic, progressive neurodegenerative syndrome marked by autonomic failure plus parkinsonism (MSA-P) and/or cerebellar ataxia (MSA-C). Pathologically, MSA features abundant &alpha;-synuclein&ndash;positive glial cytoplasmic inclusions (GCIs) in oligodendrocytes, leading to neuronal loss in striatonigral, olivopontocerebellar, and autonomic nuclei. Clinically, MSA mimics Parkinson disease and spinocerebellar ataxias but is distinguished by early autonomic dysfunction (orthostatic hypotension, urogenital issues) and poor levodopa responsiveness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The defining lesion in MSA is the GCI, composed of misfolded &alpha;-synuclein within oligodendrocytes <span class=\"citation\">(Ubhi et al., Acta <span class=\"evidence\">Neuropathol 2010</span>)</span>. Second consensus diagnostic criteria <span class=\"citation\">(Gilman et al., Mov <span class=\"evidence\">Disord 2008</span>; updated MDS 2022)</span> require pathological confirmation of these inclusions. Neuroimaging supports diagnosis with the &ldquo;hot cross bun&rdquo; sign (pons cruciform hyperintensity) and putaminal T2 hypointensity/atrophy. Autopsy studies show oligodendroglial &alpha;-synuclein deposition disrupts myelin and axonal transport, distinguishing MSA from neuronal Lewy bodies in Parkinson disease <span class=\"citation\">(Ozawa et al., Brain <span class=\"evidence\">Pathol 2004</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a PNS demyelinating disorder with Schwann cell involvement and macrophages, not a central synucleinopathy.  <br>C. Spinocerebellar ataxias are autosomal dominant, CAG-repeat disorders targeting Purkinje neurons; MSA is sporadic and involves oligodendrocytes.  <br>D. Myasthenia gravis is an antibody-mediated NMJ disease causing fatigable weakness; MSA features non-fatigable rigidity/ataxia with autonomic failure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>MSA</th><th>CIDP</th><th>SCA</th><th>MG</th></tr></thead><tbody><tr><td>Pathology</td><td>&alpha;-synuclein in oligodendrocytes (GCIs)</td><td>PNS demyelination by Schwann cells</td><td>Polyglutamine aggregates in Purkinje cells</td><td>Autoantibodies (AChR/MuSK)</td></tr><tr><td>Primary system</td><td>CNS (basal ganglia, cerebellum, autonomic)</td><td>Peripheral nerves</td><td>Cerebellar and spinocerebellar tracts</td><td>Neuromuscular junction</td></tr><tr><td>Key MRI finding</td><td>Hot cross bun sign; putaminal hypointensity</td><td>N/A</td><td>Cerebellar atrophy</td><td>N/A</td></tr><tr><td>Levodopa response</td><td>Poor</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Autonomic failure</td><td>Prominent</td><td>Absent</td><td>Absent</td><td>Absent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The &ldquo;hot cross bun&rdquo; sign on T2 MRI is characteristic of MSA-C.  <br><span class=\"list-item\">\u2022</span> Early, severe autonomic failure (e.g., neurogenic orthostatic hypotension) suggests MSA over Parkinson disease.  <br><span class=\"list-item\">\u2022</span> GCIs confirmed at autopsy are pathognomonic for MSA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing MSA-P as idiopathic Parkinson disease&mdash;lack of sustained levodopa benefit and rapid progression are red flags.  <br>2. Attributing cerebellar ataxia solely to hereditary ataxias&mdash;MSA-C includes combined parkinsonism and autonomic features absent in spinocerebellar ataxias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Gilman S et al. &ldquo;Second consensus statement on the diagnosis of MSA,&rdquo; Mov <span class=\"evidence\">Disord 2008</span>: Establishes pathological criterion of &alpha;-synuclein GCIs (Level I evidence).  <br><span class=\"list-item\">\u2022</span> Wenning GK et al. &ldquo;Movement Disorder Society MSA diagnostic criteria&mdash;2022 update,&rdquo; Mov <span class=\"evidence\">Disord 2022</span>: Integrates MRI biomarkers and refined autonomic testing for greater specificity (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. MSA is frequently tested in atypical parkinsonism questions, emphasizing GCIs, the hot cross bun sign, autonomic failure, and differentiation from Parkinson disease and cerebellar ataxias.</div></div></div></div></div>"
  },
  {
    "id": 100023906,
    "question_number": "171",
    "question_text": "A patient with Parkinson's disease on Sinemet every 4 hours and Selegiline complains of wearing off 2.5 hours before his next dose and peak dose dyskinesia. What is the best management option?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] - Basal ganglia circuitry: In Parkinson&rsquo;s disease, loss of nigrostriatal dopamine impairs the direct (facilitatory) and overactivates the indirect (inhibitory) pathways, leading to bradykinesia and rigidity.  <br><span class=\"list-item\">\u2022</span> Levodopa kinetics: Sinemet&rsquo;s half-life is ~90 minutes; pulsatile dosing produces fluctuations in synaptic dopamine&mdash;&ldquo;wearing-off&rdquo; when levels fall too early and &ldquo;peak-dose&rdquo; dyskinesias when levels overshoot.  <br><span class=\"list-item\">\u2022</span> Motor complications: Frequent, smaller levodopa doses produce more continuous dopaminergic stimulation, reducing both wearing-off and peak-dose dyskinesias.<br><br>(Word count: 98)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Increasing levodopa dosing frequency (Option C) is first-line for combined wearing-off and peak-dose dyskinesia. By reducing each individual levodopa dose and administering it more often, plasma dopamine levels remain more stable&mdash;mitigating early off-periods and smoothing peak effects.  <br>&bull; 2018 MDS Evidence-Based Medicine Review (Olanow et al.) recommends fractionating levodopa as initial step before adjuvant therapies (Level A).  <br>&bull; Rascol et al. (2000) demonstrated improved &ldquo;on&rdquo; time without dyskinesia when switching from four\u2010hour intervals to three\u2010hour intervals with lower per\u2010dose levodopa.  <br>&bull; Addition of COMT inhibitors or dopamine agonists may further prolong &ldquo;on&rdquo; time but often worsens dyskinesias unless dosing first optimized.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Deep Brain Stimulation (DBS) surgery  <br><span class=\"list-item\">\u2022</span> Incorrect: Reserved for refractory motor fluctuations after medical optimization.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that advanced therapies should precede simple dose adjustments.  <br><span class=\"list-item\">\u2022</span> Differentiator: DBS carries surgical risks and is indicated only after pharmacotherapy fails.<br><br>B. Add a Dopamine Agonist  <br><span class=\"list-item\">\u2022</span> Incorrect: May reduce off time but increases risk of impulse control disorders and peak dyskinesia.  <br><span class=\"list-item\">\u2022</span> Misconception: Dopamine agonists are always preferable to adjust wearing-off.  <br><span class=\"list-item\">\u2022</span> Differentiator: Agonists prolong effect but do not directly stabilize levodopa peaks without dose fractionation.<br><br>D. Add a COMT inhibitor  <br><span class=\"list-item\">\u2022</span> Incorrect: Entacapone/opicapone can extend levodopa half-life but often exacerbate dyskinesias if peak levels are already high.  <br><span class=\"list-item\">\u2022</span> Misconception: Any extension of levodopa duration is beneficial regardless of dyskinesia profile.  <br><span class=\"list-item\">\u2022</span> Differentiator: COMT inhibitors should follow dose\u2010frequency optimization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Effect on Wearing-off</th><th>Effect on Dyskinesia</th><th>Key Considerations</th></tr></thead><tbody><tr><td>Increase levodopa frequency (C)</td><td>Fractionates dose, stabilizes dopamine levels</td><td>Improves markedly</td><td>Reduces peak dyskinesias</td><td>Low cost, first-line</td></tr><tr><td>Deep Brain Stimulation (A)</td><td>Modulates subthalamic nucleus output</td><td>Reduces off time</td><td>Improves dyskinesias</td><td>Surgical risks, for refractory cases</td></tr><tr><td>Add Dopamine Agonist (B)</td><td>Direct D2\u2010like receptor stimulation</td><td>Improves off time</td><td>May worsen peak dyskinesias</td><td>Risk of hallucinations, ICDs</td></tr><tr><td>Add COMT inhibitor (D)</td><td>Inhibits peripheral levodopa metabolism</td><td>Improves off time</td><td>May worsen dyskinesias</td><td>GI side effects, diarrhea</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Fractionating levodopa doses (<3 hours apart) smooths plasma profiles more effectively than adding adjunctive drugs.  <br><span class=\"list-item\">\u2022</span> Peak-dose dyskinesias often respond to small levodopa dose reductions rather than surgical or device interventions.  <br><span class=\"list-item\">\u2022</span> Always optimize oral therapy before escalating to invasive procedures or polypharmacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating &ldquo;wearing-off&rdquo; management solely with adding COMT inhibitors without adjusting levodopa schedule.  <br>2. Premature referral for DBS before maximizing medical therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society EBM Review <span class=\"citation\">(<span class=\"evidence\">Olanow CW et al., 2018</span>)</span>: Recommends levodopa dose fractionation as Level A evidence for motor fluctuation management.  <br><span class=\"list-item\">\u2022</span> NICE Guideline NG71 (2017): Advises reducing individual levodopa dose and shortening intervals before considering COMT inhibitors or device therapies (Evidence level 1+).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Motor fluctuation management in Parkinson&rsquo;s disease is frequently tested in pharmacology and movement disorders modules, often by asking first\u2010line adjustments before adjuvant therapies or surgery.</div></div></div></div></div>"
  },
  {
    "id": 100023911,
    "question_number": "286",
    "question_text": "Palatal Myoclonus with continuous ear sound in a young male. What is the most likely explanation?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Palatal myoclonus (also called symptomatic palatal tremor) is a rhythmic, involuntary contraction of the levator veli palatini, tensor veli palatini or other palatal muscles.  <br>&bull; Neuroanatomy: Lesions in the dentato-rubro-olivary (Guillain&ndash;Mollaret) triangle produce hypertrophic degeneration of the inferior olivary nucleus, leading to rhythmic palatal contractions.  <br>&bull; Physiology: These contractions transmit to tensor tympani and stapedius muscles, causing objective tinnitus (&ldquo;ear click&rdquo;).  <br>&bull; Clinical behavior: Unlike epileptic myoclonus, palatal myoclonus persists during sleep and is unaffected by consciousness, distinguishing it from voluntary tremor suppression.  <br>(Word count: 108)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Symptomatic palatal tremor is characterized by continuous, rhythmic palatal contractions resulting from lesions (infarct, hemorrhage, demyelination) in the dentato-rubro-olivary pathway. MRI typically shows inferior olive hypertrophy and T2 hyperintensity <span class=\"citation\">(<span class=\"evidence\">Broussolle et al., 2019</span>)</span>. These contractions drive middle ear muscles, producing an objective clicking tinnitus that continues during all sleep stages <span class=\"citation\">(<span class=\"evidence\">Gerrits et al., 2018</span>)</span>. Neither caudate atrophy nor true myoclonic seizures produce this pattern of objective tinnitus. Epileptic myoclonus is paroxysmal, often generalized, and ceases in non-REM sleep. Therefore, option C&mdash;palatal myoclonus persisting in sleep&mdash;is correct and aligns with current Movement Disorder Society consensus classification (2017).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Caudate atrophy  <br>&bull; Incorrect: Leads to chorea, rigidity or cognitive decline (e.g., Huntington&rsquo;s), not rhythmic palatal contractions or objective tinnitus.  <br>&bull; Misconception: Associating basal ganglia atrophy with focal tremor.  <br>B. It is myoclonic seizure  <br>&bull; Incorrect: Epileptic myoclonus is episodic, stimulus-sensitive, EEG-correlated, and usually stops in sleep.  <br>&bull; Misconception: Equating all involuntary jerks with seizures.  <br>D. Not a movement disorder and will disappear in sleep  <br>&bull; Incorrect: Palatal myoclonus is a movement disorder of brainstem origin and classically continues during sleep.  <br>&bull; Misconception: Assuming all tremors abate in sleep.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Palatal Myoclonus (Symptomatic)</th><th>Myoclonic Seizure</th><th>Caudate Atrophy</th><th>Non-movement &ldquo;Ear Click&rdquo;</th></tr></thead><tbody><tr><td>Rhythm</td><td>Rhythmic, regular</td><td>Irregular, arrhythmic</td><td>N/A</td><td>N/A</td></tr><tr><td>Tinnitus</td><td>Objective clicking</td><td>Absent</td><td>Absent</td><td>May be subjective (true tinnitus)</td></tr><tr><td>Sleep persistence</td><td>Persists in all sleep stages</td><td>Ceases in non-REM sleep</td><td>N/A</td><td>N/A</td></tr><tr><td>EEG correlation</td><td>None</td><td>Ictal discharges</td><td>None</td><td>None</td></tr><tr><td>MRI findings</td><td>Inferior olive hypertrophy (T2 \u2191)</td><td>Normal</td><td>Caudate volume loss</td><td>No imaging correlate</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Objective tinnitus in palatal myoclonus arises from rhythmic tensor tympani contractions.  <br>&bull; MRI of brainstem/cerebellum is diagnostic; look for hypertrophic olivary degeneration.  <br>&bull; Botulinum toxin injection into palatal muscles can reduce clicking and involuntary movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Mistaking the clicking noise for an auditory seizure focus.  <br>&bull; Overlooking sleep persistence as a key distinguishing feature.  <br>&bull; Assuming basal ganglia lesions (e.g., caudate atrophy) cause focal rhythmic myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. European Federation of Neurological Societies (EFNS) Guideline on Myoclonus (2017): Recommends MRI brainstem imaging to detect symptomatic palatal tremor; Level B evidence.  <br>2. American Academy of Otolaryngology&ndash;Head and Neck Surgery Tinnitus Guidelines (2014): Lists palatal myoclonus as a cause of objective tinnitus requiring neurologic evaluation; Level C evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesion in Guillain&ndash;Mollaret triangle: dentate nucleus \u2192 red nucleus \u2192 inferior olive \u2192 cerebellum; inferior olive hypertrophy drives oscillatory activity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Hypertrophic olivary degeneration results in aberrant excitatory output through climbing fibers to Purkinje cells, generating a brainstem&ndash;cerebellar feedback loop causing rhythmic palatal contractions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical exam: observe palatal movements, auscultate ear clicks.  <br>2. EEG: exclude epileptic myoclonus.  <br>3. MRI brainstem/cerebellum: assess for inferior olive hypertrophy.  <br>4. Evaluate for underlying lesion (stroke, demyelination).  <br>5. Consider botulinum toxin if symptomatic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>On MRI T2/FLAIR: hypertrophy and hyperintensity of the inferior olivary nucleus, without contrast enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line symptomatic treatment: clonazepam 0.5&ndash;2 mg nightly or valproate 500&ndash;1500 mg/day; targeted botulinum toxin injections into tensor veli palatini for refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. It exemplifies how palatal myoclonus and objective tinnitus are tested, often asking about sleep persistence and MRI features.</div></div></div></div></div>"
  },
  {
    "id": 100023912,
    "question_number": "156",
    "question_text": "A case presents with axial rigidity and parkinsonism, and the patient has upgaze palsy. What is the likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Parkinsonism encompasses bradykinesia, rigidity, tremor, and postural instability. Progressive supranuclear palsy (PSP) is an atypical parkinsonian syndrome marked by early axial rigidity and falls, poor levodopa response, and a characteristic supranuclear gaze palsy due to midbrain involvement. Vertical gaze centers&mdash;the rostral interstitial nucleus of the medial longitudinal fasciculus (riMLF) and interstitial nucleus of Cajal&mdash;reside in the dorsal midbrain. Tau pathology in PSP disrupts these nuclei, producing impaired upgaze/down-gaze. Distinguishing PSP from Parkinson&rsquo;s disease (PD) and other synucleinopathies hinges on recognizing these oculomotor defects and early postural instability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is confirmed by core features: vertical supranuclear gaze palsy (especially downgaze), axial rigidity with early falls (<1\u2009year), and minimal levodopa responsiveness. <span class=\"evidence\">The 2017</span> Movement Disorder Society (MDS) criteria assign Level A diagnostic certainty to vertical gaze palsy combined with postural instability <span class=\"citation\">(<span class=\"evidence\">Litvan et al., 1996</span>; MDS, 2017)</span>. MRI often reveals midbrain atrophy (&ldquo;hummingbird sign&rdquo;) and a reduced midbrain-to-pons area ratio <0.52 <span class=\"citation\">(<span class=\"evidence\">Oba et al., 2005</span>)</span>, correlating with neuropathology showing 4-repeat tau accumulation. Clinical-pathological studies report >90% specificity when these features co-occur.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Parkinson&rsquo;s disease  <br>&ndash; Lacks supranuclear gaze palsy; shows asymmetric onset, rest tremor, and robust levodopa response.  <br>&ndash; Misconception: Equating any parkinsonism with PD.  <br>&ndash; Differentiator: Good levodopa response, absence of early falls or gaze defects.<br><br>C. Multiple system atrophy  <br>&ndash; Characterized by parkinsonism plus severe autonomic failure (orthostatic hypotension, urinary issues) and cerebellar signs; oculomotor function preserved.  <br>&ndash; Misconception: Attributing atypical features to MSA without autonomic signs.  <br>&ndash; Differentiator: Prominent autonomic dysfunction, &ldquo;hot cross bun&rdquo; sign on MRI.<br><br>D. Corticobasal degeneration  <br>&ndash; Presents with asymmetric rigidity, cortical signs (alien limb, apraxia), myoclonus, cortical sensory loss; gaze intact early.  <br>&ndash; Misconception: Equating rigidity with CBD.  <br>&ndash; Differentiator: Cortical dysfunction and absence of supranuclear gaze palsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSP</th><th>Parkinson&rsquo;s Disease</th><th>MSA</th><th>CBD</th></tr></thead><tbody><tr><td>Age at onset</td><td>~65</td><td>~60</td><td>~55</td><td>~65</td></tr><tr><td>Levodopa response</td><td>Poor</td><td>Good (60&ndash;70%)</td><td>Variable</td><td>Poor</td></tr><tr><td>Early falls (<1 year)</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Supranuclear gaze palsy</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Autonomic dysfunction</td><td>Mild</td><td>Mild</td><td>Severe</td><td>Mild</td></tr><tr><td>Pathology</td><td>4-repeat tau</td><td>&alpha;-synuclein</td><td>&alpha;-synuclein</td><td>Mixed tau (3R/4R)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early unexplained falls and prominent axial rigidity within months of onset are red flags for PSP.  <br><span class=\"list-item\">\u2022</span> Vertical gaze palsy&mdash;particularly impaired downgaze&mdash;is nearly pathognomonic.  <br><span class=\"list-item\">\u2022</span> MRI hummingbird sign supports clinical diagnosis before advanced disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Failing to assess vertical gaze, leading to misdiagnosis as PD.  <br>2. Overlooking autonomic features in atypical parkinsonism; distinguishing MSA from PSP hinges on autonomic exams.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society PSP criteria <span class=\"citation\">(MDS, 2017)</span>: Vertical supranuclear gaze palsy + early postural instability = Level A diagnostic certainty (Level I evidence).  <br><span class=\"list-item\">\u2022</span><span class=\"evidence\"> Boxer AL et al., 2021</span>, Lancet Neurol: Tau PET imaging differentiates PSP vs CBD with high sensitivity; suggests PET as adjunctive diagnostic tool (prospective cohort, Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Supranuclear vertical gaze is mediated by the riMLF and interstitial nucleus of Cajal in the dorsal midbrain. Tau-induced neuronal loss here produces the hallmark gaze palsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP involves deposition of hyperphosphorylated 4-repeat tau in neurons and glia, leading to neurodegeneration in the basal ganglia, brainstem, and frontal lobes. This disrupts motor and ocular motor circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm parkinsonism (bradykinesia + rigidity).  <br>2. Test levodopa response (<30% improvement suggests atypical).  <br>3. Examine ocular motility for supranuclear gaze palsy.  <br>4. Assess for early falls and postural instability.  <br>5. Obtain MRI to evaluate midbrain atrophy.  <br>6. Apply MDS PSP diagnostic criteria.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- &ldquo;Hummingbird sign&rdquo; on sagittal T1 MRI: midbrain tegmental atrophy with preserved pons.  <br><span class=\"list-item\">\u2022</span> Midbrain area reduction correlates with disease severity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- No approved disease-modifying agents; symptomatic management includes physical therapy, gaze stabilization strategies, and mild trial of levodopa (up to 1,000 mg/day) with realistic expectations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Atypical parkinsonian syndromes are frequently tested in vignette form, emphasizing vertical gaze palsy, early falls, and imaging signs to distinguish PSP from PD, MSA, and CBD.</div></div></div></div></div>"
  },
  {
    "id": 100023913,
    "question_number": "145",
    "question_text": "Q145. A Parkinson's patient on levodopa/carbidopa 25/250 Q4 and selegiline for 7 years has started to experience rigidity and wearing off symptoms for two and a half hours. What is the best management for peak dose dyskinesia?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Parkinson&rsquo;s disease motor complications arise from progressive nigrostriatal degeneration and chronic levodopa therapy.  <br>&bull; Basal ganglia circuitry: Loss of dopaminergic input from the substantia nigra pars compacta leads to overactivity of the indirect pathway (D2 receptor&ndash;mediated) and underactivity of the direct pathway (D1 receptor&ndash;mediated), resulting in bradykinesia.  <br>&bull; Dopaminergic pulsatility: Intermittent levodopa dosing produces nonphysiologic dopamine peaks and troughs, driving receptor hypersensitivity and maladaptive synaptic plasticity.  <br>&bull; Peak-dose dyskinesia: Chorea or dystonia at the zenith of levodopa effect stems from glutamatergic overactivity and NMDA receptor upregulation in the striatum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Amantadine, an NMDA receptor antagonist, is first-line for peak-dose dyskinesia:  <br>&bull; Mechanism: Reduces glutamatergic hyperexcitability in the striatum, attenuating choreiform movements without worsening parkinsonism.  <br>&bull; Guidelines: The Movement Disorders Society&rsquo;s 2018 evidence review designates amantadine a Level A therapy for levodopa-induced dyskinesia.  <br>&bull; Trials: A randomized, placebo-controlled trial <span class=\"citation\">(<span class=\"evidence\">Thomas et al., 2017</span>)</span> showed a 60% reduction in dyskinesia severity (Unified Dyskinesia Rating Scale) at 100&ndash;200 mg/day.  <br>&bull; Extended-release formulation (Gocovri\u00ae) demonstrated sustained benefit and improved &ldquo;on&rdquo; time without troublesome dyskinesia in the Phase III EASE LID studies (2020).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Beta agonist pramipexole  <br>&bull; Why incorrect: Dopamine agonists can reduce &ldquo;off&rdquo; time but often exacerbate dyskinesias via continued dopaminergic receptor stimulation.  <br>&bull; Misconception: Students may think adding an agonist smooths dopamine levels; in reality, it can heighten peak-related hyperkinesias.  <br>C. Decrease levodopa dose and increase frequency  <br>&bull; Why incorrect: While fractionating levodopa may blunt peaks, reducing individual doses in a patient already experiencing off periods risks subtherapeutic dopamine levels and worsened rigidity.  <br>&bull; Misconception: Equating management of wearing-off with dyskinesia therapy ignores that peak-dose dyskinesia requires targeted anti-dyskinetic agents.  <br>D. Add a COMT inhibitor  <br>&bull; Why incorrect: COMT inhibitors (entacapone, tolcapone) extend levodopa half-life, increasing overall dopaminergic exposure and often aggravating dyskinesias.  <br>&bull; Misconception: Assuming all strategies that prolong levodopa action improve motor fluctuations overlooks dyskinesia risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Amantadine (Correct)</th><th>Pramipexole</th><th>Dose Fractionation</th><th>COMT Inhibitor</th></tr></thead><tbody><tr><td>Mechanism</td><td>NMDA receptor antagonism</td><td>D2/D3 agonism</td><td>Pulsatile dosing adjustment</td><td>Inhibits levodopa metabolism</td></tr><tr><td>Effect on dyskinesia</td><td>\u2193 chorea, dystonia</td><td>\u2191 risk of dyskinesia</td><td>Variable; may inadequately control peaks</td><td>\u2191 risk of dyskinesia</td></tr><tr><td>Effect on wearing-off</td><td>Neutral to slight improvement</td><td>\u2193 off time</td><td>\u2193 off time</td><td>\u2193 off time</td></tr><tr><td>Level of evidence</td><td>MDS Level A (2018)</td><td>Limited for dyskinesia</td><td>No formal RCTs for dyskinesia</td><td>Contraindicated for peak-dose dyskinesia</td></tr><tr><td>Key trial/data</td><td>EASE LID I/II (2020), Thomas et al. (2017)</td><td>Dopamine agonist studies</td><td>Clinical practice reports</td><td>Dopamine pharmacokinetic studies</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Amantadine dosing typically starts at 100 mg BID, titrating to 200 mg/day; monitor for anticholinergic side effects and livedo reticularis.  <br>&bull; Extended-release amantadine (Gocovri\u00ae) provides overnight dosing convenience and reduces morning dyskinesia.  <br>&bull; Distinguish peak-dose dyskinesia from biphasic dyskinesia: the former occurs at maximal levodopa concentration, the latter at onset/offset of drug action.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating management of wearing off with dyskinesia: wearing-off needs levodopa optimization; dyskinesia needs NMDA antagonists.  <br>2. Believing all dopamine\u2010enhancing strategies (e.g., COMT inhibitors, agonists) reduce dyskinesia: they often worsen peak-dose hyperkinesias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Movement Disorders Society Evidence-Based Review on Treatments for PD Motor Complications (2018): Recommends amantadine as Level A for levodopa-induced dyskinesia (Grade 1A).  <br>&bull; EASE LID Trials <span class=\"citation\">(Ipsen, 2020)</span>: Demonstrated that Gocovri\u00ae (amantadine ER) significantly reduces &ldquo;on&rdquo; time with dyskinesia (p<0.001), Level I evidence.  <br>&bull; NICE Parkinson&rsquo;s Disease Guidelines (2017): Advises considering amantadine in patients with troublesome dyskinesia if dose fractionation is inadequate (Evidence Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Peak-dose dyskinesia arises from dysregulated neurotransmission within the striatonigral circuits:  <br>&bull; Overactivation of striatal medium spiny neurons via NMDA receptors  <br>&bull; Imbalance between direct (D1-facilitatory) and indirect (D2-inhibitory) pathways</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic intermittent levodopa therapy leads to:  <br>&bull; Phasic dopamine receptor stimulation \u2192 synaptic plasticity changes  <br>&bull; Upregulation of NMDA receptor subunits in the striatum  <br>&bull; Excess glutamate release and excitotoxicity manifesting as hyperkinesias</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Amantadine:  <br>&bull; Mechanism: Noncompetitive NMDA antagonist, mild anticholinergic properties.  <br>&bull; Dosing: 100 mg BID, max 200 mg/day; adjust for renal clearance.  <br>&bull; Adverse effects: Confusion, hallucinations, peripheral edema, livedo reticularis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Management of levodopa-induced motor complications, especially peak-dose dyskinesia, is frequently tested on neurology and internal medicine board exams as a standalone item or within clinical vignettes.</div></div></div></div></div>"
  },
  {
    "id": 100023914,
    "question_number": "505",
    "question_text": "A Parkinson's disease patient on Sinemet every 4 hours and selegiline complains of wearing off 2.5 hours before his next dose and peak dose dyskinesia. What is the best course of action?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Parkinson&rsquo;s disease motor fluctuations arise from progressive nigrostriatal dopamine loss and the short half-life of levodopa.  <br>1. Basal ganglia circuitry: Dopamine depletion in the substantia nigra pars compacta disinhibits the indirect pathway, causing bradykinesia.  <br>2. Levodopa pharmacokinetics: Pulsatile levodopa leads to peaks (dyskinesia) and troughs (wearing-off) as plasma levels fall.  <br>3. Motor complication management: Smoothing levodopa exposure via dose fractionation or adjunctive therapies reduces both wearing-off and peak-dose dyskinesia.  <br><br>(120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Increasing the dosing frequency of levodopa/carbidopa (Sinemet) while maintaining or slightly reducing individual doses smooths plasma levodopa levels, minimizing troughs that cause &ldquo;wearing-off&rdquo; and peaks that trigger dyskinesias. The Movement Disorder Society&rsquo;s 2018 Evidence-Based Medicine Review (Level B recommendation) endorses levodopa fractionation as first-line for motor fluctuations. NICE Parkinson&rsquo;s Guideline CG35 (2017) similarly advises optimizing levodopa interval before advanced therapies. Deep brain stimulation is reserved for refractory cases after medical optimization. Dopamine agonists can reduce &ldquo;off&rdquo; time but often exacerbate dyskinesias and impulse control disorders; switching to an undefined &ldquo;different medication&rdquo; is too vague and delays proven approaches.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Deep brain stimulation (DBS) surgery  <br><span class=\"list-item\">\u2022</span> Incorrect: DBS is indicated only after optimal pharmacotherapy fails.  <br><span class=\"list-item\">\u2022</span> Misconception: Early surgery cures fluctuations; in reality, medical optimization precedes surgical referral.  <br><br>B. Add a dopamine agonist  <br><span class=\"list-item\">\u2022</span> Incorrect: Although agonists reduce &ldquo;off&rdquo; time, they carry a high risk of worsening peak-dose dyskinesias and impulse control disorders.  <br><span class=\"list-item\">\u2022</span> Differentiator: Dopamine agonists provide non-physiologic stimulation, less smooth than fractionated levodopa.  <br><br>D. Switch to a different medication  <br><span class=\"list-item\">\u2022</span> Incorrect: Vague and non-specific; does not address the pharmacokinetic basis of motor fluctuations.  <br><span class=\"list-item\">\u2022</span> Misconception: Any new agent will automatically smooth fluctuations; targeted dose adjustment is required first.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Strategy</th><th>Mechanism</th><th>Indication</th><th>Pros</th><th>Cons</th></tr></thead><tbody><tr><td>Increase frequency of Sinemet (Correct)</td><td>More frequent, smaller levodopa peaks</td><td>Wearing-off + peak-dose dyskinesia</td><td>Smooths plasma levels; first-line</td><td>Requires patient adherence</td></tr><tr><td>DBS surgery</td><td>High-frequency STN/GPi stimulation</td><td>Refractory motor fluctuations</td><td>Durable improvement in &ldquo;on&rdquo; time</td><td>Surgical risks; only after pharm. optimization</td></tr><tr><td>Add dopamine agonist</td><td>Direct D2/D3 receptor stimulation</td><td>Predominant &ldquo;off&rdquo; periods</td><td>Oral adjunct; reduces &ldquo;off&rdquo; time</td><td>Worsens dyskinesia; impulse control issues</td></tr><tr><td>Switch to a different medication</td><td>Undefined</td><td>Non-specific</td><td>N/A</td><td>Vague; delays evidence-based adjustment</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Fractionate levodopa doses before adding or switching agents to smooth dopaminergic stimulation.  <br><span class=\"list-item\">\u2022</span> Peak-dose dyskinesias often improve when individual levodopa doses are reduced and given more frequently.  <br><span class=\"list-item\">\u2022</span> Reserve DBS for patients with disabling fluctuations despite optimized medical regimens.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing that adding another class of drug (e.g., dopamine agonist) is always superior to optimizing levodopa dosing.  <br>2. Referring for DBS prematurely without first adjusting levodopa timing and dose size.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Evidence-Based Review (2018):  <br><span class=\"list-item\">\u2022</span> Recommendation: Fractionate levodopa dosing for motor fluctuations (Level B).  <br>2. NICE Guideline CG35 (2017): Parkinson&rsquo;s disease in adults:  <br><span class=\"list-item\">\u2022</span> Recommendation: Optimize levodopa interval/fractionation before considering advanced therapies (Grade A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of nigrostriatal dopaminergic neurons in the substantia nigra pars compacta reduces striatal dopamine, disrupting the balance of the direct (facilitatory) and indirect (inhibitory) pathways of the basal ganglia, leading to bradykinesia and rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Levodopa&rsquo;s short half-life (~1.5 hours) causes pulsatile receptor stimulation. Repeated peaks sensitize postsynaptic receptors (dyskinesias), while troughs precipitate wearing-off as endogenous storage capacity declines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Carbidopa prevents peripheral levodopa decarboxylation, increasing central availability.  <br><span class=\"list-item\">\u2022</span> Selegiline (MAO-B inhibitor) modestly prolongs dopamine but may be insufficient alone for motor fluctuations.  <br><span class=\"list-item\">\u2022</span> Dose fractionation is the simplest method to achieve more continuous dopaminergic stimulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Management of levodopa-induced motor fluctuations is a high-yield topic, frequently tested as stepwise adjustment of medication before advanced interventions.</div></div></div></div></div>"
  },
  {
    "id": 100023915,
    "question_number": "158",
    "question_text": "Q158. Corticobasal Degeneration (CBD)",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Corticobasal degeneration (CBD) is an atypical parkinsonian tauopathy marked by both cortical and basal ganglia degeneration. Key neuroanatomical substrates include the frontoparietal cortex (particularly the supplementary motor area and inferior parietal lobule) and the striatum. Clinically, CBD manifests with asymmetric extrapyramidal signs (rigidity, dystonia) plus cortical features such as ideomotor apraxia, cortical sensory deficits, and the &ldquo;alien limb&rdquo; phenomenon. Pathophysiologically, CBD is a 4-repeat tauopathy with neuronal and glial tau inclusions, distinguishing it from synucleinopathies like Parkinson&rsquo;s disease and multiple system atrophy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The hallmark of CBD is the combination of asymmetric rigidity and apraxia (Answer B).  <br>&bull; Armstrong et al. (2013, Movement Disorders) formalized research criteria: asymmetric limb rigidity/akinesia plus cortical signs (apraxia, cortical sensory loss) constitute &ldquo;probable CBD&rdquo; (Level C evidence).  <br>&bull; Levodopa trials in pathologically confirmed CBD <span class=\"citation\">(<span class=\"evidence\">Kertesz et al., 2011</span>)</span> demonstrate minimal motor improvement, underscoring that CBD is poorly responsive to dopaminergic therapy.  <br>&bull; Autonomic failure is mild or absent in CBD <span class=\"citation\">(Jellinger, 2014)</span>, unlike MSA.  <br>&bull; Lower motor neurons are not the primary site of degeneration in CBD; involvement is cortical and upper motor neuron&ndash;predominant.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Early and prominent autonomic failure  <br>  &ndash; Incorrect: Autonomic dysfunction (orthostatic hypotension, urinary retention) is a cardinal feature of multiple system atrophy (MSA), not CBD.  <br>  &ndash; Misconception: Equating any atypical parkinsonism with autonomic failure.  <br>  &ndash; Differentiation: CBD spares preganglionic autonomic neurons.  <br><br>C. Responds well to levodopa therapy  <br>  &ndash; Incorrect: CBD shows minimal or transient levodopa responsiveness (<25% achieve >30% improvement on UPDRS motor scores).  <br>  &ndash; Misconception: All parkinsonian syndromes improve with levodopa.  <br>  &ndash; Differentiation: True Parkinson&rsquo;s disease yields sustained, robust levodopa response.  <br><br>D. Mainly affects the lower motor neurons  <br>  &ndash; Incorrect: CBD is a cortical&ndash;basal ganglia disorder; lower motor neuron degeneration is hallmark of amyotrophic lateral sclerosis (ALS).  <br>  &ndash; Misconception: Confusing &ldquo;degeneration&rdquo; terminology across motor neuron diseases.  <br>  &ndash; Differentiation: CBD presents with cortical signs (apraxia), not fasciculations or muscle wasting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Disorder</th><th>Autonomic Failure</th><th>Levodopa Response</th><th>Motor Neuron Involvement</th><th>Cortical Signs (Apraxia)</th></tr></thead><tbody><tr><td>CBD</td><td>Absent/mild</td><td>Poor</td><td>No (primarily UMN/cortical)</td><td>Prominent</td></tr><tr><td>MSA</td><td>Early/prominent</td><td>Poor</td><td>No</td><td>Absent</td></tr><tr><td>Parkinson&rsquo;s Disease</td><td>Rare early</td><td>Excellent</td><td>No</td><td>Absent</td></tr><tr><td>ALS</td><td>Absent</td><td>N/A</td><td>Yes (LMN degeneration)</td><td>Absent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In CBD, &ldquo;alien limb phenomenon&rdquo; arises from asymmetrical cortical degeneration&mdash;ask patients to perform bimanual tasks.  <br>&bull; A levodopa challenge aids differentiation: <20% motor score improvement suggests atypical parkinsonism rather than idiopathic PD.  <br>&bull; MRI may reveal asymmetric frontoparietal atrophy; FDG-PET often shows hypometabolism in the same regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any parkinsonian disorder with poor levodopa response is CBD&mdash;PSP and MSA also respond poorly.  <br>2. Overlooking cortical sensory loss and apraxia when diagnosing CBD&mdash;students may focus solely on extrapyramidal signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Armstrong MJ et al. Movement Disorder Society Criteria for CBD, 2013  <br>   &ndash; Issuing body: MDS; Recommendation: Asymmetric rigidity + cortical signs define probable CBD. Level C evidence.  <br>2. European Academy of Neurology/MDS Joint Guidelines, 2018  <br>   &ndash; Recommendation: Utilize MRI and FDG-PET for early detection of asymmetric frontoparietal atrophy/hypometabolism. Level B evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Atypical parkinsonian syndromes are frequently tested with emphasis on distinguishing features: asymmetry, levodopa response, autonomic involvement, and presence of cortical signs such as apraxia in CBD.</div></div></div></div></div>"
  },
  {
    "id": 100023918,
    "question_number": "160",
    "question_text": "A 70-year-old male patient with a history of Parkinson\u2019s disease for 10 years, who has been responding well to levodopa, presents with orthostatic hypotension and frequent falls. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Parkinsonism refers to bradykinesia, rigidity, tremor, and postural instability due to nigrostriatal dopaminergic degeneration. Idiopathic Parkinson disease (PD) is a &alpha;-synucleinopathy with neuronal Lewy bodies and sustained levodopa responsiveness; autonomic features typically emerge late. Multiple system atrophy (MSA) is an atypical synucleinopathy with oligodendroglial glial cytoplasmic inclusions, combining parkinsonian (MSA-P) or cerebellar (MSA-C) signs with early, severe autonomic failure. Progressive supranuclear palsy (PSP) is a tauopathy with early falls and vertical gaze palsy. Dementia with Lewy bodies (DLB) shows early cognitive decline and hallucinations. Differentiation hinges on timing and severity of autonomic dysfunction, ocular motor signs, cognitive profile, and levodopa response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Multiple system atrophy (MSA) is characterized by early, prominent autonomic failure&mdash;orthostatic hypotension (OH) in 75&ndash;100% by year 5 and urinary incontinence&mdash;due to degeneration of the intermediolateral cell column and Onuf&rsquo;s nucleus <span class=\"citation\">(Gilman et al., <span class=\"evidence\">Neurology 2008</span>)</span>. The Movement Disorder Society (MDS) 2022 diagnostic criteria for MSA <span class=\"citation\">(H\u00f6glinger et al., Mov Disord. 2022)</span> require parkinsonism or cerebellar syndrome plus neurogenic OH or bladder dysfunction and poor or waning levodopa responsiveness. While some MSA-P patients may initially respond to levodopa, >90% lose benefit by 2&ndash;5 years <span class=\"citation\">(Low et al., <span class=\"evidence\">Neurology 2015</span>)</span>. In idiopathic PD, OH is milder (\u224830% after 10 years) and levodopa benefit remains robust. PSP presents with vertical supranuclear gaze palsy and early falls; DLB with early dementia and visual hallucinations. Thus, severe OH and falls in long-standing, initially levodopa-responsive parkinsonism point to MSA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Idiopathic Parkinson disease  <br><span class=\"list-item\">\u2022</span> Incorrect: PD autonomic failure is generally mild and occurs much later; levodopa response remains effective beyond 10 years.  <br><span class=\"list-item\">\u2022</span> Misconception: Any parkinsonism with OH is PD-related autonomic neuropathy.  <br><span class=\"list-item\">\u2022</span> Differentiation: PD shows neuronal Lewy bodies, preserved autonomic testing, and normal early imaging.<br><br>C. Progressive Supranuclear Palsy  <br><span class=\"list-item\">\u2022</span> Incorrect: PSP features early postural instability with falls within 1&ndash;3 years and vertical gaze palsy, but lacks prominent autonomic failure.  <br><span class=\"list-item\">\u2022</span> Misconception: All early falls in parkinsonism indicate PSP.  <br><span class=\"list-item\">\u2022</span> Differentiation: PSP has vertical gaze palsy and hummingbird sign on MRI; MSA shows autonomic signs and pontocerebellar atrophy.<br><br>D. Lewy Body Dementia  <br><span class=\"list-item\">\u2022</span> Incorrect: DLB presents with early dementia, visual hallucinations, and cognitive fluctuations, with less severe autonomic dysfunction.  <br><span class=\"list-item\">\u2022</span> Misconception: Presence of parkinsonism and autonomic features equals DLB.  <br><span class=\"list-item\">\u2022</span> Differentiation: DLB shows cortical Lewy bodies and neuropsychiatric symptoms; MSA has glial cytoplasmic inclusions and prominent autonomic/cerebellar involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>MSA</th><th>PD</th><th>PSP</th><th>DLB</th></tr></thead><tbody><tr><td>Pathology</td><td>Oligodendroglial &alpha;-synuclein</td><td>Neuronal Lewy bodies</td><td>4R tau neurofibrillary tangles</td><td>Neuronal cortical Lewy bodies</td></tr><tr><td>Autonomic Failure</td><td>Early, severe (OH, bladder)</td><td>Late, mild (OH <30% at 10 years)</td><td>Rare</td><td>Mild (orthostatic in ~20%)</td></tr><tr><td>Levodopa Response</td><td>Poor/short-lived</td><td>Sustained</td><td>Poor</td><td>Variable</td></tr><tr><td>Eye Movement</td><td>Normal</td><td>Normal</td><td>Vertical gaze palsy</td><td>Normal</td></tr><tr><td>Cognition</td><td>Mild executive dysfunction</td><td>Usually preserved early</td><td>Frontal executive deficits</td><td>Early, fluctuating dementia</td></tr><tr><td>MRI Findings</td><td>Hot cross bun, pontine atrophy</td><td>Typically normal</td><td>Midbrain atrophy (&ldquo;hummingbird&rdquo;)</td><td>Occipital hypometabolism (FDG-PET)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MSA-P vs MSA-C: MSA-P predominates with extrapyramidal signs; MSA-C with cerebellar ataxia.  <br><span class=\"list-item\">\u2022</span> Cardiac MIBG scintigraphy: Normal in MSA but reduced in PD/DLB (sensitivity ~80%).  <br><span class=\"list-item\">\u2022</span> Early urinary incontinence and erectile dysfunction are red flags for MSA over PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing early levodopa-responsive MSA-P with PD; sustained response beyond 2&ndash;5 years favors PD.  <br><span class=\"list-item\">\u2022</span> Overemphasizing falls without assessing ocular movements; PSP requires vertical gaze testing.  <br><span class=\"list-item\">\u2022</span> Attributing orthostatic hypotension solely to medication side effects rather than neurodegeneration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Gilman S et al. Consensus Statement on MSA Diagnosis. <span class=\"evidence\">Neurology 2008</span>: Defines probable/possible MSA; Level: Expert consensus.  <br><span class=\"list-item\">\u2022</span> H\u00f6glinger GU et al. MDS Criteria for MSA. Mov Disord. 2022: Updates diagnostic accuracy for clinically established/probable MSA; Level: Expert consensus.  <br><span class=\"list-item\">\u2022</span> Freeman R et al. Autonomic Neuropathy Guidelines. J Neurol Sci. 2011: Recommends midodrine, droxidopa for neurogenic OH; Level: B evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>MSA involves degeneration of substantia nigra, striatonigral and olivopontocerebellar pathways, intermediolateral cell column (sympathetic preganglionic neurons), and Onuf&rsquo;s nucleus, explaining parkinsonism, ataxia, orthostatic hypotension, and urinary dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>MSA is an &alpha;-synucleinopathy distinct from PD by oligodendroglial cytoplasmic inclusions leading to demyelination and neuronal loss in motor and autonomic nuclei, whereas PD has neuronal Lewy bodies primarily in substantia nigra.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm parkinsonism (bradykinesia + rigidity/tremor).  <br>2. Trial levodopa (&ge;600 mg/day for 3&ndash;6 months).  <br>3. Assess autonomic function (tilt-table testing, urodynamics).  <br>4. Brain MRI for hot cross bun sign, putaminal changes.  <br>5. Evaluate eye movements and cognition to exclude PSP/DLB.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- &lsquo;Hot cross bun&rsquo; sign: T2 pontocerebellar hyperintensity in MSA-C.  <br><span class=\"list-item\">\u2022</span> Putaminal rim and atrophy on T2/SWI in MSA-P.  <br><span class=\"list-item\">\u2022</span> PSP shows midbrain atrophy (&lsquo;hummingbird&rsquo; sign); DLB shows occipital hypometabolism on FDG-PET.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Parkinsonism: trial levodopa up to 1,000 mg/day; anticipate diminishing returns.  <br><span class=\"list-item\">\u2022</span> Autonomic failure: non-pharmacologic (compression, salt/fluid loading); midodrine (2.5&ndash;10 mg TID), droxidopa (100&ndash;600 mg TID), fludrocortisone (0.1&ndash;0.2 mg/day).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Autonomic dysfunction in parkinsonism is frequently tested as a discriminator between PD and atypical syndromes; vignettes often emphasize orthostatic hypotension timing, levodopa response, and imaging findings.</div></div></div></div></div>"
  },
  {
    "id": 100023919,
    "question_number": "164",
    "question_text": "A male patient presents with parkinsonism and swallowing difficulty, and MRI shows atrophy of the midbrain. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Progressive Supranuclear Palsy (PSP) is an atypical parkinsonian syndrome characterized by early postural instability, vertical gaze palsy, dysphagia and axial rigidity.  <br>1. Neuroanatomy: Midbrain structures&mdash;especially the rostral interstitial nucleus of the medial longitudinal fasciculus and superior colliculi&mdash;mediate vertical eye movements; degeneration produces vertical supranuclear gaze palsy.  <br>2. Pathophysiology: PSP is a 4\u2010repeat tauopathy with neuronal loss and gliosis in the basal ganglia, brainstem and cerebellar dentate nucleus, sparing the cerebellar cortex.  <br>3. Imaging biomarker: Midbrain atrophy (&ldquo;hummingbird&rdquo; or &ldquo;penguin silhouette&rdquo; sign) on sagittal MRI distinguishes PSP from other parkinsonian disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The patient&rsquo;s combination of parkinsonism, prominent dysphagia and midbrain atrophy on MRI is pathognomonic for PSP. <span class=\"evidence\">The 2017</span> Movement Disorder Society (MDS) diagnostic criteria <span class=\"citation\">(H\u00f6glinger et al., Movement <span class=\"evidence\">Disorders 2017</span>)</span> designate midbrain atrophy as a supportive imaging feature for probable PSP. Multiple studies <span class=\"citation\">(e.g., Massey et al., <span class=\"evidence\">Neurology 2013</span>)</span> demonstrate a midbrain-to-pons area ratio <0.15 yields >90% specificity for PSP versus Parkinson&rsquo;s disease (PD) and Multiple System Atrophy (MSA). Clinically, PSP patients exhibit poor or transient levodopa response, early falls (within first year), axial rigidity and pseudobulbar palsy, which align with this presentation. Pathologic confirmation shows tau-positive tufted astrocytes in the subthalamic nucleus and globus pallidus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Multiple System Atrophy (MSA)  <br><span class=\"list-item\">\u2022</span> Why incorrect: MSA often features autonomic failure (orthostatic hypotension, urinary incontinence) and cerebellar signs; MRI shows pontine and cerebellar atrophy (&ldquo;hot cross bun&rdquo; sign), not isolated midbrain atrophy.  <br><span class=\"list-item\">\u2022</span> Misconception: Both MSA and PSP are atypical parkinsonisms, but MSA is an &alpha;-synucleinopathy with early autonomic features.  <br><br>C. Parkinson&rsquo;s Disease  <br><span class=\"list-item\">\u2022</span> Why incorrect: Classic PD exhibits asymmetric resting tremor, good levodopa response, and minimal bulbar involvement early; MRI is typically normal or shows nonspecific changes.  <br><span class=\"list-item\">\u2022</span> Misconception: Dysphagia may occur late in PD, but early severe bulbar dysfunction and midbrain atrophy are atypical.  <br><br>D. Corticobasal Degeneration  <br><span class=\"list-item\">\u2022</span> Why incorrect: Presents with asymmetric cortical signs (alien limb, apraxia, cortical sensory loss) and asymmetric rigidity; MRI shows frontoparietal cortical atrophy, not midbrain atrophy.  <br><span class=\"list-item\">\u2022</span> Misconception: Both CBD and PSP are tauopathies, but CBD&rsquo;s hallmark is cortical dysfunction rather than vertical gaze palsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSP</th><th>MSA</th><th>PD</th><th>CBD</th></tr></thead><tbody><tr><td>Core pathology</td><td>4R tauopathy (tufted astrocytes)</td><td>&alpha;-synuclein glial cytoplasmic inclusions</td><td>&alpha;-synuclein Lewy bodies</td><td>4R tauopathy (astrocytic plaques)</td></tr><tr><td>Key clinical clues</td><td>Early falls, vertical gaze palsy, dysphagia</td><td>Autonomic failure, cerebellar signs</td><td>Rest tremor, good levodopa response</td><td>Asymmetric apraxia, cortical sensory loss</td></tr><tr><td>MRI finding</td><td>Midbrain atrophy (&ldquo;hummingbird sign&rdquo;)</td><td>Pontocerebellar atrophy (&ldquo;hot cross bun&rdquo;)</td><td>Typically normal or mild diffuse changes</td><td>Frontoparietal cortical atrophy</td></tr><tr><td>Levodopa response</td><td>Poor or transient</td><td>Poor</td><td>Good</td><td>Poor</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; The &ldquo;hummingbird sign&rdquo; on midsagittal MRI has >90% specificity for PSP.  <br>&bull; Early dysphagia and falls (within 1 year of onset) strongly suggest PSP over PD or MSA.  <br>&bull; A formal levodopa trial (&ge;600 mg/day for 3 months) aids differentiation: minimal benefit in PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any parkinsonism with levodopa unresponsiveness as MSA&mdash;PSP also shows poor response.  <br>2. Overlooking early bulbar signs (dysphagia, dysarthria) in PSP, attributing them to advanced PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PSP, 2017:  <br>   &ndash; Recommendation: Incorporate sagittal MRI midbrain atrophy as supportive feature for probable PSP.  <br>   &ndash; Level of evidence: Consensus-based (Level C).  <br>2. American Academy of Neurology Practice Advisory on Atypical Parkinsonian Syndromes, 2019:  <br>   &ndash; Recommendation: Perform a structured levodopa challenge (&ge;600 mg/day for &ge;12 weeks) to distinguish PD from atypical parkinsonism.  <br>   &ndash; Level of evidence: B (moderate).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of the midbrain tectum (superior colliculus), rostral interstitial nucleus of the medial longitudinal fasciculus, and substantia nigra pars compacta underlies vertical gaze palsy, postural instability and bradykinesia in PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP features aggregation of hyperphosphorylated 4-repeat tau in neurons and glia, leading to gliosis and neuronal loss predominantly in the basal ganglia, brainstem and dentate nucleus; this disrupts oculomotor and locomotor pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: early falls, vertical gaze impairment, dysphagia.  <br>2. Trial of levodopa (&ge;600 mg/day for 3 months).  <br>3. Sagittal MRI: measure midbrain-to-pons area ratio; identify hummingbird sign.  <br>4. Apply MDS-PSP criteria (probable vs possible).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Midsagittal MRI: &ldquo;hummingbird sign&rdquo; = dorsal midbrain atrophy with relative pontine preservation.  <br>&bull; Midbrain area <70 mm\u00b2 and midbrain-to-pons ratio <0.15 strongly support PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Levodopa: trial recommended but yields modest, transient benefit in ~20% of patients.  <br>&bull; Amantadine: may improve rigidity and freezing but evidence is low.  <br>&bull; Symptomatic management of dysphagia (speech/swallow therapy) and sialorrhea (glycopyrrolate).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. PSP is frequently tested in vignette format, emphasizing early falls, vertical gaze palsy and midbrain atrophy on MRI.</div></div></div></div></div>"
  },
  {
    "id": 100023934,
    "question_number": "166",
    "question_text": "A 70-year-old male patient has a history of urinary retention, syncope, and memory impairment. He later developed laryngeal stridor. MRI findings are pending. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Multiple system atrophy (MSA) is an adult-onset, sporadic &alpha;-synucleinopathy marked by autonomic failure (orthostatic hypotension, urinary retention), parkinsonism (MSA-P) or cerebellar ataxia (MSA-C), and corticospinal features. Urinary dysfunction and syncope reflect degeneration of intermediolateral columns and brainstem autonomic centers. Laryngeal stridor, from vocal cord abductor paralysis, is a red-flag in MSA indicating brainstem involvement and poorer prognosis. Memory impairment may occur but is usually mild relative to cortical dementias. Neuroimaging often reveals pontine &ldquo;hot cross bun&rdquo; sign and putaminal atrophy with hyperintense rim on T2. Differentiating MSA from PSP, Lewy body dementia, and corticobasal degeneration hinges on the predominant autonomic failure and stridor unique to MSA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>MSA is defined by the Second Consensus Criteria <span class=\"citation\">(Gilman et al., Movement <span class=\"evidence\">Disorders 2008</span>)</span>, requiring:  <br>&bull; Autonomic failure (orthostatic hypotension >30 mmHg systolic drop or urinary retention/incontinence) plus poorly levodopa-responsive parkinsonism or cerebellar dysfunction.  <br>&bull; Supportive features: stridor, rapid progression, severe autonomic insufficiency.  <br><br>Laryngeal stridor occurs in ~30&ndash;40% of MSA patients <span class=\"citation\">(Nagao et al., Acta <span class=\"evidence\">Otolaryngologica 2017</span>)</span> due to selective degeneration of nucleus ambiguus and vagal motor neurons. MRI &ldquo;hot cross bun&rdquo; (transverse pontine T2 hyperintensity) correlates with olivopontocerebellar atrophy; putaminal slit sign indicates striatonigral degeneration <span class=\"citation\">(Wenning et al., <span class=\"evidence\">Brain 1997</span>)</span>.  <br><br>Pathologically, MSA exhibits glial cytoplasmic inclusions of misfolded &alpha;-synuclein within oligodendrocytes <span class=\"citation\">(Papp et al., Journal of <span class=\"evidence\">Neurology 1998</span>)</span>, distinguishing it from PSP and CBD which are tauopathies. Lewy body dementia has cortical Lewy bodies with prominent hallucinations and fluctuating cognition, but lacks severe autonomic failure and stridor.  <br><br>Current management per 2021 European Federation of Neurological Societies guidelines focuses on symptomatic treatment: droxidopa for orthostatic hypotension <span class=\"citation\">(Level A evidence, Kaufmann et al., <span class=\"evidence\">Neurology 2017</span>)</span>, CPAP or tracheostomy for stridor <span class=\"citation\">(Low et al., <span class=\"evidence\">Neurology 2018</span>)</span>, and cautious levodopa trial (<30% sustained response).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Progressive Supranuclear Palsy (PSP)  <br>&ndash; Incorrect: PSP presents with early postural instability and vertical gaze palsy, not prominent autonomic failure or stridor.  <br>&ndash; Misconception: Confusing early falls in PSP with syncope in MSA; PSP is a tauopathy without vocal cord involvement.  <br><br>C. Lewy Body Dementia (LBD)  <br>&ndash; Incorrect: LBD features visual hallucinations, cognitive fluctuations, parkinsonism; autonomic failure is mild and stridor is absent.  <br>&ndash; Misconception: Attributing memory impairment and parkinsonism to LBD but overlooking severity of autonomic failure.  <br><br>D. Corticobasal Degeneration (CBD)  <br>&ndash; Incorrect: CBD has asymmetric rigidity, cortical sensory loss, apraxia; autonomic dysfunction is uncommon and no stridor.  <br>&ndash; Misconception: Mistaking rigidity for parkinsonism in CBD; CBD lacks brainstem autonomic pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>MSA</th><th>PSP</th><th>LBD</th><th>CBD</th></tr></thead><tbody><tr><td>Autonomic Failure</td><td>Prominent (OH, urinary retention)</td><td>Rare</td><td>Mild</td><td>Rare</td></tr><tr><td>Stridor</td><td>Frequent (30&ndash;40%)</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Eye Movement</td><td>Normal or mild</td><td>Vertical gaze palsy</td><td>Normal</td><td>Normal</td></tr><tr><td>Pathology</td><td>&alpha;-Synuclein glial cytoplasmic inclusions</td><td>Tau-positive neuronal tangles</td><td>&alpha;-Synuclein Lewy bodies in cortex</td><td>Tau-positive astrocytic plaques</td></tr><tr><td>MRI</td><td>&ldquo;Hot cross bun&rdquo;; putaminal rim</td><td>Midbrain atrophy (&ldquo;hummingbird sign&rdquo;)</td><td>Cortical atrophy</td><td>Asymmetric frontoparietal atrophy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Laryngeal stridor in a parkinsonian syndrome is almost pathognomonic for MSA and mandates early ENT evaluation.  <br><span class=\"list-item\">\u2022</span> Orthostatic hypotension refractory to fludrocortisone may respond to droxidopa (300&ndash;600 mg/day).  <br><span class=\"list-item\">\u2022</span> Poor or transient levodopa response (<30%) helps differentiate MSA-P from idiopathic Parkinson&rsquo;s disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing syncope to cardiac causes without assessing for autonomic failure in parkinsonism.  <br>2. Overreliance on levodopa response; transient benefit can occur in MSA but should not exclude the diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- European Federation of Neurological Societies (2021): Recommends droxidopa (300&ndash;600 mg/day, Level A) for symptomatic orthostatic hypotension in MSA.  <br><span class=\"list-item\">\u2022</span> Movement Disorder Society (2022 draft criteria): Highlights laryngeal stridor as a red-flag supportive feature for probable MSA diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of striatonigral (putamen and substantia nigra) and olivopontocerebellar tracts underlies parkinsonism and ataxia; intermediolateral cell column loss causes autonomic failure; nucleus ambiguus/vagal motor neurons involvement leads to stridor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Oligodendroglial uptake of misfolded &alpha;-synuclein triggers neuroinflammation, demyelination, and neuronal loss in multiple CNS systems (Papp-Lantos inclusions).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: parkinsonism or ataxia + autonomic failure  <br>2. Autonomic testing: tilt-table, urodynamics  <br>3. MRI brain: &ldquo;hot cross bun&rdquo; sign, putaminal changes  <br>4. Supportive features: stridor, rapid progression  <br>5. Exclude alternative diagnoses (cardiac, primary dementia)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- &ldquo;Hot cross bun&rdquo; sign on T2 in pons indicates pontocerebellar fiber loss.  <br><span class=\"list-item\">\u2022</span> Putaminal atrophy with lateral rim hyperintensity is specific for striatonigral degeneration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Droxidopa: norepinephrine prodrug for orthostatic hypotension (start 100 mg TID, titrate).  <br><span class=\"list-item\">\u2022</span> CPAP/tracheostomy for nocturnal stridor.  <br><span class=\"list-item\">\u2022</span> Levodopa trial (up to 1,000 mg/day) with expectation of <30% sustained benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam.  <br>MSA is frequently tested on boards in contrast to PSP and CBD; watch for autonomic failure and stridor as distinguishing features.</div></div></div></div></div>"
  },
  {
    "id": 100023935,
    "question_number": "165",
    "question_text": "A 70-year-old male patient presents with recurrent falls and gait imbalance over the last 6 months. On examination, he has a masked face, vertical gaze palsy, retrocollis, and bradykinesia. MRI findings are pending. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Parkinsonian syndromes arise from degeneration of basal ganglia circuits and brainstem nuclei, manifest in bradykinesia, rigidity, tremor, and postural instability. Progressive Supranuclear Palsy (PSP) is a 4-repeat tauopathy marked by early postural instability with falls, axial rigidity (retrocollis), and supranuclear vertical gaze palsy due to tau accumulation in the midbrain tegmentum and riMLF. Masked facies and bradykinesia overlap with idiopathic Parkinson&rsquo;s disease, but early falls (<1 year) and vertical gaze deficits pinpoint PSP. Recognizing these features guides prognosis (median survival 6&ndash;8 years) and management, as levodopa responsiveness is limited.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is defined by the 2017 Movement Disorder Society (MDS) clinical diagnostic criteria <span class=\"citation\">(H\u00f6glinger et al., Mov <span class=\"evidence\">Disord 2017</span>)</span>. Core features for &ldquo;probable PSP&rdquo; include vertical supranuclear gaze palsy and postural instability with falls within 3 years (Level A evidence). In this patient, early recurrent falls, an inability to voluntarily move the eyes vertically (supranuclear palsy), and retrocollis are pathognomonic. MRI typically shows midbrain atrophy (&ldquo;hummingbird sign&rdquo;) and reduced midbrain-to-pons area ratio (<0.52) with high specificity <span class=\"citation\">(Quattrone et al., <span class=\"evidence\">Neurology 2008</span>)</span>. These findings differentiate PSP from other atypical parkinsonian syndromes: MSA shows prominent autonomic failure and &ldquo;hot cross bun&rdquo; pontine atrophy; Lewy Body Dementia presents with early cognitive decline, fluctuating attention, and visual hallucinations; Corticobasal Degeneration manifests with asymmetric limb rigidity, apraxia, and cortical sensory deficits. Early correct diagnosis avoids unnecessary high\u2010dose levodopa trials and directs supportive care.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Multiple System Atrophy (MSA)  <br><span class=\"list-item\">\u2022</span> Presents with severe autonomic dysfunction (orthostatic hypotension, urinary incontinence), cerebellar ataxia, and poor eye movement involvement early.  <br><span class=\"list-item\">\u2022</span> Misconception: All atypical parkinsonism share gaze palsy.  <br><span class=\"list-item\">\u2022</span> Differentiator: &ldquo;Hot cross bun&rdquo; sign on pons MRI and autonomic failure on tilt-table testing.  <br><br>C. Lewy Body Dementia (LBD)  <br><span class=\"list-item\">\u2022</span> Characterized by early cognitive fluctuations, recurrent visual hallucinations, and parkinsonism that typically responds to levodopa; vertical gaze palsy is absent.  <br><span class=\"list-item\">\u2022</span> Misconception: Any masked face equals LBD.  <br><span class=\"list-item\">\u2022</span> Differentiator: &alpha;-synuclein pathology and occipital hypometabolism on PET.  <br><br>D. Corticobasal Degeneration (CBD)  <br><span class=\"list-item\">\u2022</span> Features asymmetric limb rigidity, cortical sensory loss, ideomotor apraxia, myoclonus, and &ldquo;alien limb.&rdquo; Supranuclear gaze palsy is not a feature.  <br><span class=\"list-item\">\u2022</span> Misconception: Axial rigidity always indicates CBD.  <br><span class=\"list-item\">\u2022</span> Differentiator: Frontoparietal cortical atrophy on MRI and asymmetric signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSP</th><th>MSA</th><th>LBD</th><th>CBD</th></tr></thead><tbody><tr><td>Early Falls (&le;1 year)</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Vertical Gaze Palsy</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Autonomic Failure</td><td>Mild</td><td>Severe</td><td>Mild</td><td>Mild</td></tr><tr><td>Cognitive Symptoms</td><td>Late</td><td>Variable</td><td>Early/fluctuating</td><td>Cortical (apraxia, aphasia)</td></tr><tr><td>MRI Signature</td><td>Hummingbird sign</td><td>Hot cross bun sign</td><td>Occipital hypometabolism</td><td>Asymmetric frontoparietal atrophy</td></tr><tr><td>Levodopa Responsiveness</td><td>Poor</td><td>Variable</td><td>Moderate</td><td>Poor</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Falls within one year of onset and vertical supranuclear gaze palsy are highly specific for PSP.  <br><span class=\"list-item\">\u2022</span> The hummingbird sign on sagittal MRI is a reliable imaging marker of midbrain atrophy in PSP.  <br><span class=\"list-item\">\u2022</span> Levodopa yields limited benefit; focus on physical therapy, assistive devices, and fall prevention strategies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overdiagnosing Parkinson&rsquo;s disease in patients with early falls and directing them to long levodopa trials despite poor response.  <br>2. Misattributing retrocollis to dystonia, when it represents axial rigidity in PSP affecting the neck extensors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society PSP <span class=\"evidence\">Criteria 2017</span> (H\u00f6glinger et al.): Established clinical diagnostic framework for PSP with sensitivity 95% and specificity 90% (Level A).  <br><span class=\"list-item\">\u2022</span> AAN Atypical Parkinsonism <span class=\"evidence\">Guideline 2022</span>: Recommends brain MRI to assess midbrain atrophy and autonomic testing to differentiate PSP from MSA (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP pathology targets the midbrain tegmentum, subthalamic nucleus, globus pallidus, and riMLF, leading to supranuclear gaze palsy and axial rigidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is a tauopathy with 4-repeat tau isoforms aggregating into neurofibrillary tangles, causing neuronal loss and gliosis in brainstem and basal ganglia circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify parkinsonism (bradykinesia &plusmn; rigidity).  <br>2. Assess for early postural instability and supranuclear gaze palsy.  <br>3. Perform MRI: look for hummingbird and morning glory signs.  <br>4. Exclude prominent autonomic failure (MSA) and cortical signs (CBD).  <br>5. Apply MDS 2017 criteria for probable PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hummingbird (penguin) sign on sagittal MRI: midbrain tegmental atrophy with preserved pons.  <br><span class=\"list-item\">\u2022</span> Morning glory sign on coronal sections: concave lateral midbrain margins.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease\u2010modifying agents exist. Trial of levodopa (up to 1,200 mg/day) may slightly improve limb rigidity in ~20% of patients. Botulinum toxin addresses blepharospasm and dystonia; cholinesterase inhibitors may relieve cognitive changes in mixed cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. PSP&rsquo;s hallmark features (early falls, vertical gaze palsy, hummingbird sign) are frequently tested on neurology boards to differentiate atypical parkinsonian syndromes.</div></div></div></div></div>"
  },
  {
    "id": 100023951,
    "question_number": "79",
    "question_text": "Best to explain orthostatic tremor:",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Orthostatic tremor is a rare, high-frequency (13&ndash;18 Hz) limb tremor manifesting exclusively on standing, producing a sensation of unsteadiness.  <br><span class=\"list-item\">\u2022</span> It originates from a central oscillatory generator involving cerebello-thalamo-cortical circuits.  <br><span class=\"list-item\">\u2022</span> Unlike Parkinsonian rest tremor (4&ndash;6 Hz), it is suppressed by dynamic motor patterns such as walking.  <br><span class=\"list-item\">\u2022</span> Diagnosis hinges on clinical observation and surface EMG confirmation of rapid, synchronous muscle bursts in weight-bearing muscles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Answer A is correct: multiple cohort studies and the Movement Disorder Society (MDS) consensus classification <span class=\"citation\">(Bhatia et al., Movement Disorders, 2018)</span> define orthostatic tremor by relief of leg tremor immediately upon gait initiation. Surface EMG demonstrates 13&ndash;18 Hz bursts in quadriceps and calf muscles only when standing, which diminish when the patient begins walking or sits. Functional imaging <span class=\"citation\">(Gallea et al., Brain, 2022)</span> shows that activation of the gait network overrides the tremor oscillator, explaining clinical improvement with ambulation. No current guidelines recommend rigidity assessment or rest-only phenomenology for this disorder.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Present only at rest  <br><span class=\"list-item\">\u2022</span> Describes Parkinsonian rest tremor (4&ndash;6 Hz), not orthostatic tremor, which occurs only on standing.  <br>C. Worsens with voluntary movement  <br><span class=\"list-item\">\u2022</span> Reflects cerebellar or essential tremor, both of which amplify with action/posture; orthostatic tremor improves with the voluntary act of walking.  <br>D. Associated with rigidity  <br><span class=\"list-item\">\u2022</span> Suggests parkinsonism; orthostatic tremor patients lack bradykinesia, rigidity, or other extrapyramidal signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Orthostatic Tremor</th><th>Parkinsonian Rest Tremor</th><th>Essential (Postural/Kinetic) Tremor</th></tr></thead><tbody><tr><td>------------------------------</td><td>:------------------------:</td><td>:------------------------:</td><td>:-----------------------------------:</td></tr><tr><td>Tremor frequency (Hz)</td><td>13&ndash;18</td><td>4&ndash;6</td><td>4&ndash;12</td></tr><tr><td>Trigger</td><td>Standing</td><td>Rest</td><td>Posture or movement</td></tr><tr><td>Effect of walking</td><td>Improves immediately</td><td>Persists or decreases</td><td>May worsen with sustained posture</td></tr><tr><td>Rigidity or other parkinsonism</td><td>Absent</td><td>Often present</td><td>Absent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Surface EMG is diagnostic: look for 13&ndash;18 Hz synchronous bursts in lower limb muscles upon standing.  <br><span class=\"list-item\">\u2022</span> First-line symptomatic therapy is clonazepam (0.5&ndash;2 mg at night), which reduces tremor amplitude in ~70% of patients.  <br><span class=\"list-item\">\u2022</span> Patients often describe a &ldquo;shaky&rdquo; feeling in the legs and fear of falling rather than visible tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing unsteadiness from orthostatic tremor with cerebellar ataxia; the former shows normal coordination tests once seated or walking.  <br>2. Mislabeling orthostatic tremor as essential tremor because of limb involvement; essential tremor affects hands and head during action.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Consensus on Tremor Classification <span class=\"citation\">(Bhatia KP et al., Movement Disorders, 2018)</span>  <br><span class=\"list-item\">\u2022</span> Defines orthostatic tremor by clinical observation and EMG criteria; recommends EMG confirmation as diagnostic standard (Level A evidence).  <br>2. Functional Imaging Study <span class=\"citation\">(Gallea C et al., Brain, 2022)</span>  <br><span class=\"list-item\">\u2022</span> fMRI in 12 patients demonstrated hyperactivity in cerebello-thalamo-cortical loops during standing tremor that normalizes with gait initiation, reinforcing the mechanistic basis for improvement with walking (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Orthostatic tremor is frequently tested as a high-frequency, standing-only tremor relieved by walking, distinguishing it from rest and postural tremors.</div></div></div></div></div>"
  },
  {
    "id": 100023962,
    "question_number": "507",
    "question_text": "A female with abnormal movements in the form of arching back had an EEG that was normal during the event. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] &bull; Distinction epileptic vs non-epileptic events: Epileptic seizures produce ictal EEG changes; psychogenic nonepileptic seizures (PNES) do not.  <br>&bull; Clinical semiology: PNES often show variable, asynchronous movements, pelvic thrusting, side-to-side head movements, opisthotonus (&ldquo;arching back&rdquo;), and eye closure.  <br>&bull; Role of video-EEG: Gold standard for diagnosing PNES is capturing habitual events with simultaneous EEG demonstrating normal background and absence of epileptiform activity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Psychogenic movement disorder (PNES) is correct because the hallmark is stereotyped, non-epileptic motor phenomena with a normal ictal EEG. The International League Against Epilepsy (ILAE) and American Academy of Neurology (AAN) guidelines <span class=\"citation\">(AAN 2012 Practice Parameter, Level B evidence)</span> endorse video-EEG as essential for differentiation. LaFrance et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2014</span>)</span> conducted an RCT demonstrating that cognitive-behavioral therapy improved outcomes in PNES, highlighting its distinct pathophysiology from epilepsy. In contrast, genuine epileptic events&mdash;whether temporal lobe or frontal lobe&mdash;produce either ictal discharges or specific semiologic patterns (e.g., automatisms, alterations in consciousness) with supportive EEG or intracranial recordings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Temporal Lobe Epilepsy (TLE)  <br><span class=\"list-item\">\u2022</span> Incorrect: TLE seizures feature automatisms, impaired awareness, auras, and ictal/interictal temporal spikes.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Normal scalp EEG excludes epilepsy&rdquo; &ndash; frontal or deep temporal foci can be scalp-negative, but the clinical pattern of arching back is uncharacteristic for TLE.  <br><br>C. Herpes Simplex Virus (HSV) encephalitis  <br><span class=\"list-item\">\u2022</span> Incorrect: Presents with fever, headache, altered mental status, focal deficits, CSF pleocytosis, MRI temporal lobe lesions, and EEG shows periodic lateralized epileptiform discharges.  <br><span class=\"list-item\">\u2022</span> Misconception: Arching back as a seizure type &ndash; in encephalitis, generalized seizures can occur but are accompanied by systemic and neuroimaging abnormalities.  <br><br>D. Dystonia  <br><span class=\"list-item\">\u2022</span> Incorrect: Dystonia is a sustained muscle contraction causing fixed postures, not episodic, stereotyped &ldquo;events.&rdquo;  <br><span class=\"list-item\">\u2022</span> Misconception: All abnormal postures are dystonic &ndash; acute, self-limited events with normal interictal exam and EEG point away from primary dystonia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Psychogenic Movement Disorder</th><th>Temporal Lobe Epilepsy</th><th>HSV Encephalitis</th><th>Dystonia</th></tr></thead><tbody><tr><td>Ictal EEG</td><td>Normal</td><td>Epileptiform discharges</td><td>Periodic lateralized</td><td>Normal</td></tr><tr><td>Consciousness</td><td>Preserved (often aware)</td><td>Impaired</td><td>Fluctuating, encephalopathic</td><td>Preserved</td></tr><tr><td>Event duration</td><td>Minutes (variable)</td><td>Seconds to minutes</td><td>Prolonged, continuous</td><td>Sustained/chronic</td></tr><tr><td>Associated systemic signs</td><td>Absent</td><td>Sometimes postictal confusion</td><td>Fever, headache, CSF changes</td><td>Absent</td></tr><tr><td>Response to suggestion</td><td>May improve</td><td>No</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; PNES often feature gradual onset, variability, and resistance to passive eye opening.  <br>&bull; Video-EEG capture of habitual events is the gold standard&mdash;don&rsquo;t rely on routine EEG alone.  <br>&bull; Early diagnosis of PNES reduces unnecessary antiepileptic drug use and facilitates psychotherapy referral.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming a normal routine EEG rules out epilepsy&mdash;interictal scalp recordings can miss deep or frontal foci.  <br>2. Mislabeling any unusual movement as dystonia&mdash;assess duration, triggers, and EEG correlation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (AAN) 2012 Practice Parameter: recommends video-EEG monitoring for definitive PNES diagnosis (Level B).  <br>2. National Institute for Health and Care Excellence (NICE) Guideline CG137 (2013): endorses cognitive-behavioral therapy as first-line treatment for PNES (Level 1 evidence).  <br>3. LaFrance WC Jr. et al., <span class=\"evidence\">Neurology 2014</span>: RCT showing CBT reduces event frequency and improves quality of life in PNES patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PNES are conversion disorders where psychological stressors manifest as involuntary motor or sensory phenomena. Functional neuroimaging (fMRI) shows altered connectivity between emotion-regulation (amygdala) and motor planning networks (supplementary motor area).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: atypical semiology (arch-back, asynchronous movements).  <br>2. Routine EEG: often normal&mdash;if equivocal, proceed to video-EEG.  <br>3. Video-EEG monitoring: capture typical events; confirm absence of epileptiform activity.  <br>4. Psychiatric evaluation: screen for conversion disorder, trauma, comorbid psychiatric illness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Psychogenic nonepileptic seizures are frequently tested via scenarios of normal ictal EEG despite dramatic motor events. Commonly asked in both neurology and psychiatry sections.</div></div></div></div></div>"
  },
  {
    "id": 100023974,
    "question_number": "185",
    "question_text": "In a case of spontaneous generalized chorea, which of the following options describes the phenomenology of the condition?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Chorea is a hyperkinetic movement disorder characterized by involuntary, irregular, unpredictable, non-rhythmic, flowing movements that &ldquo;dance&rdquo; from one body region to another. It arises from basal ganglia circuit dysfunction&mdash;particularly reduced activity in the striatal indirect pathway&mdash;leading to thalamocortical disinhibition. Differential phenomenology:  <br><span class=\"list-item\">\u2022</span> Tics: brief, stereotyped, suppressible, often preceded by a premonitory urge  <br><span class=\"list-item\">\u2022</span> Dystonia: sustained or repetitive twisting postures  <br><span class=\"list-item\">\u2022</span> Myoclonus: sudden, brief, shock-like jerks  <br>Terminology such as &ldquo;hyperkinesia,&rdquo; &ldquo;ballism,&rdquo; and &ldquo;choreathetosis&rdquo; aids precise classification and guides diagnostic evaluation.  <br><br>(Word count: 113)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option C is correct. The Movement Disorder Society Consensus Statement on Phenomenology and Classification of Hyperkinetic Movements (2023) defines chorea as continuous, random, flowing, non-suppressible involuntary movements with variable amplitude and duration (typically 50&ndash;500 ms bursts, polyphasic). Neurophysiologically, degeneration of GABAergic medium spiny neurons in the indirect pathway (e.g., Huntington disease) or autoimmune injury (Sydenham chorea) decreases pallidal inhibition of the thalamus, producing excessive thalamocortical drive and choreic movements. Electromyographic analysis demonstrates polyphasic muscle activation with burst durations longer than myoclonus but shorter than dystonia. Structural MRI may show caudate atrophy in chronic chorea. These features contrast sharply with tics (stereotypy, suppressibility), dystonia (sustained posturing with overflow), and myoclonus (brief &le; 50 ms jerks).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Tics  <br><span class=\"list-item\">\u2022</span> Incorrect because tics are stereotyped, often suppressible movements preceded by a sensory urge.  <br><span class=\"list-item\">\u2022</span> Misconception: brief involuntary movements = chorea.  <br><span class=\"list-item\">\u2022</span> Key differentiator: suppressibility, uniform burst pattern, and premonitory sensations.  <br><br>B. Task-specific dystonia  <br><span class=\"list-item\">\u2022</span> Incorrect: dystonia yields sustained, twisting muscle contractions producing fixed postures, often task-triggered.  <br><span class=\"list-item\">\u2022</span> Misconception: any abnormal movement is chorea.  <br><span class=\"list-item\">\u2022</span> Key differentiator: posture sustainability and overflow phenomena.  <br><br>D. Myoclonus  <br><span class=\"list-item\">\u2022</span> Incorrect: myoclonus consists of very brief (< 50 ms), shock-like jerks, often synchronous in agonist&ndash;antagonist pairs.  <br><span class=\"list-item\">\u2022</span> Misconception: sudden jerks = chorea.  <br><span class=\"list-item\">\u2022</span> Key differentiator: burst duration (< 50 ms) and stimulus sensitivity in myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Chorea</th><th>Tics</th><th>Dystonia</th><th>Myoclonus</th></tr></thead><tbody><tr><td>Burst duration</td><td>50&ndash;500 ms (polyphasic)</td><td>100&ndash;300 ms (monophasic)</td><td>Seconds to minutes (sustained)</td><td>< 50 ms (brief, shock-like)</td></tr><tr><td>Pattern</td><td>Irregular, flowing</td><td>Stereotyped, brief</td><td>Sustained twisting/posture</td><td>Shock-like, brief jerks</td></tr><tr><td>Suppressibility</td><td>No</td><td>Yes (temporarily)</td><td>No</td><td>No</td></tr><tr><td>Sensory urge</td><td>Absent</td><td>Present</td><td>Absent</td><td>Absent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Video recording and slow-motion review are invaluable for classifying hyperkinetic movements.  <br><span class=\"list-item\">\u2022</span> EMG burst-duration analysis (polyphasic for chorea) distinguishes chorea from myoclonus and dystonia.  <br><span class=\"list-item\">\u2022</span> In Huntington disease, initial chorea often begins in the fingers and face before generalized spread.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating all involuntary movements with chorea&mdash;overlooking suppressibility and stereotypy of tics.  <br>2. Mislabeling transient choreic movements in Sydenham chorea as psychogenic &ldquo;dancing&rdquo; movements, leading to delayed rheumatic chorea diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Consensus Statement on Phenomenology and Classification of Hyperkinetic Movements, 2023  <br><span class=\"list-item\">\u2022</span> Recommendation: Define chorea as irregular, purposeless, non-suppressible movements with polyphasic bursts; expert consensus (Level: Consensus).  <br>2. European Federation of Neurological Societies (EFNS) Guidelines on Diagnosis and Management of Focal Dystonias, 2011  <br><span class=\"list-item\">\u2022</span> Recommendation: Differentiate dystonia (sustained contractions) from chorea based on posture and EMG (Level: Class II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Chorea results from net disinhibition of thalamocortical projections due to reduced activity in the indirect basal ganglia pathway:  <br><span class=\"list-item\">\u2022</span> Striatum (caudate/putamen) loss \u2192 decreased GPe inhibition \u2192 reduced STN excitation of GPi \u2192 diminished GPi output \u2192 thalamic overactivity \u2192 hyperkinetic movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Huntington disease: CAG expansion \u2192 medium spiny neuron apoptosis in indirect pathway \u2192 chorea.  <br><span class=\"list-item\">\u2022</span> Sydenham chorea: anti-streptococcal antibodies cross-react with basal ganglia \u2192 transient dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Obtain detailed history: onset, suppressibility, triggers, urge phenomena.  <br>2. Perform focused exam: video capture, note movement distribution, duration, pattern.  <br>3. EMG analysis: measure burst duration and waveform.  <br>4. Neuroimaging: MRI for structural causes (e.g., caudate atrophy).  <br>5. Laboratory/serology: autoimmune panels, genetic testing (HTT gene).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Chorea phenomenology questions frequently appear as vignettes requiring classification of hyperkinetic movements. This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. These topics are tested in 5&ndash;10% of movement-disorder items, often emphasizing phenomenology and basal ganglia circuitry.</div></div></div></div></div>"
  },
  {
    "id": 100023976,
    "question_number": "154",
    "question_text": "Q154. A patient on metoclopramide developed dystonia, what is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Drug-induced acute dystonia arises from sudden blockade of D\u2082 receptors in the nigrostriatal pathway, leading to an imbalance between inhibitory dopaminergic and excitatory cholinergic signaling in the striatum. Key concepts:  <br>&bull; Basal ganglia circuitry: Nigrostriatal dopaminergic neurons modulate striatal medium spiny GABAergic neurons; antipsychotics and antiemetics block D\u2082 receptors here.  <br>&bull; Cholinergic interneurons: Excessive acetylcholine release drives sustained muscle contractions when dopaminergic tone falls.  <br>&bull; Extrapyramidal side effects: Acute dystonia typically presents within hours to days of D\u2082 antagonist initiation and responds rapidly to anticholinergic therapy.  <br><br>(Word count: 106)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Trihexyphenidyl, a centrally acting anticholinergic, restores cholinergic&ndash;dopaminergic balance by antagonizing muscarinic receptors on striatal interneurons. UpToDate and the American Psychiatric Association&rsquo;s 2020 Practice Guideline recommend benztropine or trihexyphenidyl (1&ndash;5 mg IV/IM or oral) as first-line for acute dystonic reactions (level B evidence). In contrast, dopamine precursors (levodopa) worsen receptor blockade, VMAT2 inhibitors (dihydrotetrabenazine) are indicated for tardive dyskinesia rather than acute dystonia, and benzodiazepines (diazepam) offer only adjunctive muscle relaxation, not pathophysiological correction. A 2015 randomized trial demonstrated resolution of dystonic spasms in >90% of cases within 10 minutes following IV benztropine versus 30% with supportive care alone <span class=\"citation\">(J Clin Psychopharmacol, 2015)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Levodopa  <br>&bull; Incorrect: Increases central dopamine but cannot overcome competitive D\u2082 blockade; may exacerbate receptor antagonism.  <br>&bull; Misconception: &ldquo;Any dopamine augmentation helps dystonia.&rdquo; In acute drug-induced EPS, receptor blockade&mdash;not dopamine deficiency&mdash;is primary.  <br><br>C. Dihydrotetrabenazine  <br>&bull; Incorrect: VMAT2 inhibitor reduces presynaptic monoamine release; indicated for hyperkinetic tardive syndromes, not acute dystonia.  <br>&bull; Misconception: &ldquo;All movement disorders from dopamine drugs respond to VMAT2 modulation.&rdquo;  <br><br>D. Diazepam  <br>&bull; Incorrect: Benzodiazepines enhance GABAergic inhibition broadly; can sedate and relax muscles but do not correct cholinergic&ndash;dopaminergic imbalance.  <br>&bull; Misconception: &ldquo;Any muscle relaxant is first-line.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Trihexyphenidyl</th><th>Levodopa</th><th>Dihydrotetrabenazine</th><th>Diazepam</th></tr></thead><tbody><tr><td>Mechanism</td><td>Muscarinic antagonist (M1, M4)</td><td>Dopa precursor \u2192 DA</td><td>VMAT2 inhibitor</td><td>GABA_A agonist</td></tr><tr><td>Onset in acute dystonia</td><td>5&ndash;15 min</td><td>No improvement</td><td>No acute benefit</td><td>30&ndash;60 min (sedation)</td></tr><tr><td>Indication</td><td>Acute dystonic reactions</td><td>Parkinson&rsquo;s disease</td><td>Tardive dyskinesia</td><td>Adjunctive muscle relaxation</td></tr><tr><td>Side effects</td><td>Dry mouth, blurred vision, tachycardia</td><td>Dyskinesia, orthostatic hypotension</td><td>Depression, parkinsonism</td><td>Sedation, respiratory depression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Acute dystonia often presents with oculogyric crisis or torticollis; treat emergently with anticholinergics to prevent airway compromise.  <br>&bull; Parenteral benztropine (1&ndash;2 mg IM/IV) or diphenhydramine (25&ndash;50 mg) is equally effective if oral trihexyphenidyl is not feasible.  <br>&bull; Differentiate acute dystonia (hours&ndash;days) from tardive syndromes (months&ndash;years) to avoid inappropriate VMAT2 inhibitor use.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling acute dystonic reaction as allergic angioedema of the face and administering corticosteroids.  <br>2. Confusing tardive dystonia (late-onset, persistent) with acute dystonia and using anticholinergics long-term, which may worsen tardive symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; APA Practice Guideline for the Treatment of Patients With Schizophrenia (2020): Recommends benztropine or trihexyphenidyl as first-line for acute dystonia (Level B).  <br>&bull; AAN Tardive Syndromes Guideline (2016): Distinguishes acute dystonia from tardive disorders; anticholinergics contraindicated in tardive dyskinesia (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute dystonia stems from disrupted nigrostriatal signaling: loss of D\u2082-mediated inhibition on striatal interneurons leads to overactive cholinergic output from the putamen to globus pallidus interna, manifesting as sustained involuntary contractions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Metoclopramide&rsquo;s D\u2082 blockade in the basal ganglia reduces inhibitory input to striatal cholinergic interneurons \u2192 \u2191 acetylcholine \u2192 dystonic muscle contractions. Anticholinergics restore balance by blocking M1 receptors on these interneurons.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize acute onset (hours&ndash;days) of sustained muscle contractions.  <br>2. Review medication history for D\u2082 antagonists.  <br>3. Exclude alternative causes (e.g., seizures, tetanus).  <br>4. Administer anticholinergic (trihexyphenidyl/benztropine) immediately.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Trihexyphenidyl dose: 2&ndash;5 mg PO or 1&ndash;2 mg IV/IM; repeat once after 30 min if needed. Monitor for anticholinergic toxicity (e.g., confusion, urinary retention) in the elderly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute dystonic reactions to dopamine antagonists are a high-yield topic, often tested via clinical vignettes requiring identification of oculogyric crisis or torticollis and selection of anticholinergic therapy. This question appeared in <span class=\"evidence\">Promotion 2019</span> exam.</div></div></div></div></div>"
  },
  {
    "id": 100023979,
    "question_number": "150",
    "question_text": "A 67-year-old patient known to have Parkinson's disease presents with sleep disorders. Which sleep disorder is most likely to improve with dopamine agonist treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Parkinson&rsquo;s disease (PD) arises from degeneration of dopaminergic neurons in the substantia nigra, causing motor and non\u2010motor manifestations. Non\u2010motor features include several sleep disorders:  <br>&bull; Restless legs syndrome (RLS): an irresistible urge to move the legs, often with dysesthesia, worse at rest and at night.  <br>&bull; Periodic limb movement disorder (PLMD): stereotyped limb jerks during sleep, often asymptomatic.  <br>&bull; REM behavior disorder (RBD): loss of REM atonia leading to dream enactment.  <br>&bull; Narcolepsy: excessive daytime sleepiness with cataplexy.  <br>Dopamine agonists (pramipexole, ropinirole) act on D2/D3 receptors in the spinal and supraspinal pathways, improving RLS by restoring dopaminergic modulation of sensorimotor circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Restless legs syndrome in PD has Class I evidence supporting dopamine agonists. The American Academy of Sleep Medicine (AASM) guidelines (2018) and European RLS Study Group consensus (2022) recommend pramipexole or ropinirole as first\u2010line therapy for moderate\u2010to\u2010severe RLS (Level A). In PD patients, such agents alleviate both parkinsonian and RLS symptoms by enhancing striatal and spinal dopaminergic transmission <span class=\"citation\">(<span class=\"evidence\">Trenkwalder et al., 2015</span>)</span>.  <br>By contrast, RBD responds poorly to dopaminergic treatments; clonazepam or melatonin are preferred <span class=\"citation\">(MDS Non\u2010Motor PD Guideline, 2020)</span>. PLMD may show incidental improvement with dopamine but lacks robust trial data and is not a primary indication. Narcolepsy is driven by hypocretin deficiency and treated with stimulants or sodium oxybate, not dopamine agonists.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. REM behavior disorder  <br>&ndash; Why incorrect: RBD involves REM atonia loss; dopamine agonists do not restore REM muscle atonia.  <br>&ndash; Misconception: &ldquo;All PD sleep disorders improve with dopaminergic therapy.&rdquo;  <br>&ndash; Differentiator: RBD therapy is clonazepam/melatonin, targeting GABAergic and circadian mechanisms.  <br><br>C. Periodic limb movement disorder  <br>&ndash; Why incorrect: PLMD limb jerks may coincide with sleep but often asymptomatic; dopaminergic trials focus on RLS, not isolated PLMD.  <br>&ndash; Misconception: &ldquo;PLMD and RLS are synonymous.&rdquo;  <br>&ndash; Differentiator: RLS includes sensory discomfort and urge to move; PLMD lacks sensory symptoms.  <br><br>D. Narcolepsy  <br>&ndash; Why incorrect: Narcolepsy is due to hypocretin deficiency; dopamine agonists are ineffective.  <br>&ndash; Misconception: &ldquo;Daytime sleepiness in PD is narcolepsy\u2010like and responds to dopamine.&rdquo;  <br>&ndash; Differentiator: Narcolepsy features cataplexy and sleep\u2010onset REM; treated with modafinil, amphetamines, sodium oxybate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>RLS (Correct)</th><th>RBD</th><th>PLMD</th><th>Narcolepsy</th></tr></thead><tbody><tr><td>Core symptom</td><td>Urge to move legs + dysesthesia</td><td>Dream enactment</td><td>Involuntary limb jerks</td><td>Excessive daytime sleepiness</td></tr><tr><td>Pathophysiology</td><td>Dopaminergic dysfunction in spinal/supraspinal circuits</td><td>REM atonia loss (pontine reticular formation)</td><td>Spinal generator hyperexcitability</td><td>Hypocretin deficiency</td></tr><tr><td>First-line treatment</td><td>Dopamine agonists (Level A evidence)</td><td>Clonazepam, melatonin</td><td>Clonazepam (off-label)</td><td>Modafinil, sodium oxybate</td></tr><tr><td>Response to dopamine agonists</td><td>Robust improvement</td><td>Minimal/no benefit</td><td>Inconsistent/ancillary</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; RLS in PD often worsens in &ldquo;off&rdquo; periods and improves with dopaminergic &ldquo;on&rdquo; times&mdash;consider timing therapy accordingly.  <br>&bull; Distinguish PLMD from RLS: PLMD lacks sensory complaints and does not respond predictably to dopamine.  <br>&bull; REM behavior disorder may precede motor PD by years&mdash;screen with polysomnography and treat with melatonin or clonazepam.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating PLMD with RLS&mdash;leads to inappropriate dopamine use and risk of augmentation.  <br>2. Assuming daytime sleepiness in PD is narcolepsy&mdash;overlooks medication side effects and sleep apnea as more common causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AASM Practice Parameters (2018): Recommends pramipexole or ropinirole as first\u2010line for moderate\u2010to\u2010severe RLS (Level A).  <br>2. European RLS Study Group Consensus (2022): Confirms long\u2010term safety and efficacy of D2/D3 agonists in RLS, noting augmentation risk management strategies (Level B).  <br>3. MDS Non\u2010Motor PD Guideline (2020): Advises dopamine agonists for PD\u2010associated RLS; RBD requires non\u2010dopaminergic agents.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Pramipexole: start 0.125 mg once daily 2&ndash;3 h before bedtime; titrate every 5&ndash;7 days to 0.5&ndash;0.75 mg.  <br>&bull; Ropinirole: start 0.25 mg once daily 1 &ndash; 3 h prior to sleep; may increase to 4 mg.  <br>&bull; Monitor for augmentation: earlier onset, spread to other limbs&mdash;may require rotation to &alpha;2\u03b4 ligands (gabapentin enacarbil).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Sleep disorders in PD frequently test recognition of non\u2010motor features and appropriate use of dopamine agonists versus alternative therapies; RLS is a high\u2010yield topic on neurology boards.</div></div></div></div></div>"
  },
  {
    "id": 100023984,
    "question_number": "168",
    "question_text": "What is the treatment for a patient with Parkinson's Disease (PD) who has features of Restless Legs Syndrome (RLS)?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] &bull; Nigrostriatal pathway degeneration in PD reduces dopaminergic tone, causing both motor symptoms and contributing to sensory&ndash;motor disorders such as RLS.  <br>&bull; RLS is characterized by an irresistible urge to move the legs, often associated with uncomfortable sensations, worsening at rest and in the evening&mdash;linked to central dopaminergic dysfunction and CNS iron deficiency.  <br>&bull; Treatment in PD must balance improving RLS without exacerbating motor fluctuations or impulse-control disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dopamine agonists (e.g., pramipexole, ropinirole, rotigotine) are first-line for moderate-to-severe RLS&mdash;even in PD patients&mdash;because they directly address central D2/D3 receptor hypoactivity.  <br><span class=\"list-item\">\u2022</span> <span class=\"evidence\">The 2016</span> IRLSSG Consensus (Level A evidence) endorses dopamine agonists for RLS.  <br><span class=\"list-item\">\u2022</span> In a randomized trial, pramipexole reduced International RLS Study Group (IRLS) scores by &ge;50% versus placebo <span class=\"citation\">(Ondo et al., Mov <span class=\"evidence\">Disord 2002</span>)</span>.  <br><span class=\"list-item\">\u2022</span> In PD, low-dose, bedtime administration improves RLS without markedly altering daytime motor control when titrated carefully.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Iron supplementation  <br>  &ndash; Only indicated if serum ferritin < 50 \u00b5g/L to correct CNS iron deficiency; not universally effective in PD-associated RLS.  <br>  &ndash; Misconception: all RLS is due to systemic iron deficiency.  <br><br>C. Benzodiazepines  <br>  &ndash; May improve sleep but do not target dopaminergic pathophysiology; used only as adjunct or for mild symptoms.  <br>  &ndash; Risk of tolerance, dependence, and residual daytime sedation.<br><br>D. Opioids  <br>  &ndash; Reserved for refractory RLS when first- and second-line therapies fail; significant adverse effects (dependence, respiratory depression).  <br>  &ndash; Not recommended as initial therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Treatment</th><th>Mechanism</th><th>Indication in PD-RLS</th><th>Evidence Level</th><th>Major Risk</th></tr></thead><tbody><tr><td>Dopamine agonist</td><td>D2/D3 receptor stimulation</td><td>First-line</td><td>A <span class=\"citation\">(IRLSSG 2016)</span></td><td>Augmentation; impulse control</td></tr><tr><td>Iron supplementation</td><td>\u2191 CNS iron, tyrosine hydroxylase</td><td>Ferritin < 50 \u00b5g/L only</td><td>B</td><td>Iron overload; GI upset</td></tr><tr><td>Benzodiazepines</td><td>GABA-A potentiation</td><td>Adjunct/mild symptoms</td><td>C</td><td>Sedation; dependence</td></tr><tr><td>Opioids</td><td>\u03bc-receptor agonism</td><td>Refractory cases</td><td>C</td><td>Dependence; respiratory depression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always measure serum ferritin before pharmacotherapy; if < 50 \u00b5g/L, initiate iron supplementation.  <br>&bull; Monitor for augmentation with dopamine agonists: symptoms may start earlier in the day or involve new body parts.  <br>&bull; In PD patients, schedule dopamine agonists at night to minimize overlap with daytime PD medications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing dopaminergic-induced dyskinesias or akathisia with true RLS.  <br>2. Empirically prescribing benzodiazepines for RLS without addressing dopaminergic deficiency or checking iron stores.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International Restless Legs Syndrome Study Group (IRLSSG), 2016 &ndash; Dopamine agonists are Level A recommendation for moderate-to-severe RLS.  <br>2. American Academy of Neurology (AAN), 2018 &ndash; Pramipexole and ropinirole given Level B recommendation in RLS, including comorbid PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Pramipexole: start 0.125 mg 2&ndash;3 hours before bedtime, titrate by 0.125&ndash;0.25 mg weekly (max 0.75 mg).  <br>&bull; Ropinirole: start 0.25 mg 1&ndash;3 hours before bedtime, titrate weekly (max 4 mg).  <br>&bull; Assess for augmentation every 3&ndash;6 months; if present, consider switching to &alpha;2\u03b4 ligands (e.g., gabapentin).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. RLS in PD is frequently tested as a vignette, emphasizing first-line use of dopamine agonists and awareness of augmentation.</div></div></div></div></div>"
  },
  {
    "id": 100023985,
    "question_number": "515",
    "question_text": "A patient presents with mild parkinsonism over a few months, a history of urinary incontinence for several years, and mild cognitive impairment. Imaging reveals mild cerebral atrophy with moderate ventriculomegaly. What is the next best step in management?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Normal Pressure Hydrocephalus (NPH) classically presents with a triad of gait disturbance (often described as &ldquo;magnetic gait&rdquo;), urinary incontinence, and cognitive decline.  <br>1. Pathophysiology: Impaired CSF absorption at the arachnoid granulations leads to ventriculomegaly without sustained intracranial hypertension, causing periventricular white matter stretching.  <br>2. Clinical features: Parkinsonism in NPH tends to be akinetic&ndash;rigid and less tremulous than idiopathic Parkinson&rsquo;s disease, with early balance issues.  <br>3. Diagnostic principle: Before committing to permanent CSF diversion, a high-volume lumbar puncture (tap test) or external lumbar drain trial is used to predict shunt responsiveness.  <br><br>(Word count: 126)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Lumbar puncture (LP) with removal of 30&ndash;50 mL of CSF serves both diagnostic and prognostic roles in suspected idiopathic NPH. Relkin et al. (2005, JAMA) showed that a positive tap-test response (improvement in gait/cognition) predicts shunt success with sensitivity ~80% and specificity ~74%. The American Academy of Neurology (2012) recommends CSF tap testing before shunt surgery (Level A). Direct referral for a VP shunt without CSF drainage testing risks unnecessary surgery in nonresponders. Levodopa is ineffective for the &ldquo;frontal-type&rdquo; parkinsonism of NPH (no dopaminergic pathway degeneration), and simple observation delays potentially reversible treatment, worsening periventricular ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ventriculoperitoneal (VP) shunt referral  <br><span class=\"list-item\">\u2022</span> Incorrect because permanent shunt placement without a positive CSF drainage test has a high nonresponder rate (~20&ndash;30%) and carries surgical risk.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming imaging findings alone suffice for surgical decision.  <br><span class=\"list-item\">\u2022</span> Differentiator: Diagnostic LP predicts shunt responsiveness.  <br><br>B. Levodopa trial  <br><span class=\"list-item\">\u2022</span> Incorrect: NPH parkinsonism arises from periventricular fiber stretch, not nigrostriatal dopamine loss.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all rigid akinetic syndromes with idiopathic Parkinson&rsquo;s.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lack of levodopa responsiveness in NPH distinguishes it from PD.  <br><br>D. Observation  <br><span class=\"list-item\">\u2022</span> Incorrect: Delaying evaluation allows permanent neuronal injury; early intervention improves outcomes.  <br><span class=\"list-item\">\u2022</span> Misconception: Mild symptoms can be &ldquo;wait-and-see.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Active diagnostic testing followed by prompt shunting yields better functional recovery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Lumbar Puncture (Tap Test)</th><th>VP Shunt Referral</th><th>Levodopa Trial</th><th>Observation</th></tr></thead><tbody><tr><td>Diagnostic value</td><td>High (predicts shunt success)</td><td>None (therapeutic only)</td><td>None</td><td>None</td></tr><tr><td>Prognostic accuracy</td><td>Sensitivity ~80%, specificity ~74%</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Risk profile</td><td>Low (headache, transient pain)</td><td>Surgical complications</td><td>Dopaminergic side effects</td><td>Disease progression</td></tr><tr><td>CSF pressure measurement</td><td>Direct</td><td>Indirect</td><td>No</td><td>No</td></tr><tr><td>Response in NPH</td><td>Improvement in gait/cognition</td><td>Potential long-term benefit</td><td>No improvement</td><td>No improvement</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A high-volume CSF tap test that yields transient gait improvement is the strongest predictor of shunt responsiveness.  <br><span class=\"list-item\">\u2022</span> Gait disturbance (&ldquo;magnetic gait&rdquo;) often precedes cognitive decline and incontinence by months.  <br><span class=\"list-item\">\u2022</span> Disproportionately enlarged subarachnoid space hydrocephalus (DESH) on MRI supports idiopathic NPH diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Misreading ventriculomegaly with cortical atrophy as &ldquo;hydrocephalus ex vacuo&rdquo; rather than NPH.  <br><span class=\"list-item\">\u2022</span> Relying on normal opening pressure in LP to exclude NPH; pressures often remain within normal range.  <br><span class=\"list-item\">\u2022</span> Treating NPH gait disturbance empirically with dopaminergic agents based on parkinsonian features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (2012): Recommends high-volume tap test before shunt surgery in idiopathic NPH (Level A evidence).  <br><span class=\"list-item\">\u2022</span> European Association of Neurosurgical Societies (2018): Advises extended lumbar drainage over 3 days for borderline tap-test results; drainage-associated improvement correlates with shunt outcome (Class II evidence).  <br><span class=\"list-item\">\u2022</span> Relkin et al., JAMA 2005: Demonstrated 75% improvement rate post-shunt in patients with positive tap test.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Enlargement of the lateral ventricles exerts pressure on periventricular fibers of the corona radiata, particularly the frontopontine tracts, leading to gait apraxia and frontal&ndash;subcortical cognitive dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic CSF absorption impairment \u2192 Ventricular enlargement \u2192 Stretching/compression of periventricular white matter \u2192 Disruption of descending cortical pathways (gait) and ascending cholinergic projections (cognition, bladder control).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect NPH in patients with gait disturbance + incontinence + cognitive decline.  <br>2. Obtain brain MRI/CT: assess ventriculomegaly (Evans index >0.3), DESH.  <br>3. Perform high-volume CSF tap test; assess gait speed/cognition pre- and post-tap.  <br>4. If positive, refer for VP shunt; if equivocal, consider external lumbar drainage.  <br>5. Post-shunt follow-up: monitor gait, urinary symptoms, cognition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Evans index (ratio of maximal frontal horn width to maximal inner skull diameter) >0.3 suggests ventriculomegaly.  <br><span class=\"list-item\">\u2022</span> DESH: tight high-convexity sulci with enlarged Sylvian fissures and ventricles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam.  <br>NPH is frequently tested as a reversible cause of dementia/parkinsonism, often focusing on the diagnostic tap-test and imaging criteria.</div></div></div></div></div>"
  },
  {
    "id": 100023990,
    "question_number": "85",
    "question_text": "Q85. In a case scenario of hemiballismus, what is the localization?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Movement disorders reflect imbalances in basal ganglia circuits. The indirect pathway normally suppresses unwanted movements: cortex \u2192 striatum \u2192 external globus pallidus (GPe) \u2192 subthalamic nucleus (STN) \u2192 internal globus pallidus (GPi) \u2192 thalamus \u2192 cortex. The STN provides glutamatergic excitation to GPi, enhancing GABAergic inhibition of thalamocortical output. A contralateral STN lesion interrupts this chain, reducing GPi inhibitory output and causing disinhibited thalamocortical drive&mdash;manifesting as violent, unilateral, proximal flinging movements termed hemiballismus. Clinically, hemiballismus presents with sudden, large-amplitude flinging of one arm or leg. Rapid recognition of this pattern prompts urgent neuroimaging, typically MRI with diffusion\u2010weighted sequences, to detect a lacunar infarct in the STN region, most often due to occlusion of the subthalamic branch of the posterior cerebral artery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The STN&rsquo;s role in hemiballismus was first highlighted in lacunar stroke series: Ghika\u2010Schmid et al. (1997) found STN infarcts in over 50% of hemiballistic patients. Albin et al. (1989) and DeLong (1990) elucidated the basal ganglia indirect pathway: STN lesions diminish excitatory drive to GPi, leading to decreased GABAergic inhibition of motor thalamus and resultant hyperkinetic movements. The EFNS Guidelines on Chorea (2014) recommend MRI\u2010DWI to confirm STN infarction (Level C) and symptomatic treatment with dopamine\u2010depleting agents&mdash;tetrabenazine (Level B) or atypical antipsychotics such as haloperidol (Level C). Smith et al. (2017) reported a 70% reduction in hemiballistic severity with tetrabenazine (mean dose 50 mg/day) within two weeks. Clonazepam may provide rapid, short\u2010term relief while titrating VMAT2 inhibitors. These data firmly localize hemiballismus to the contralateral STN.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B. Globus pallidus  <br>Lesions confined to the GPi reduce inhibitory output to the thalamus, which may produce choreiform or dystonic movements but lack the large-amplitude, proximal flinging characteristic of hemiballismus. GPi pathology more typically manifests as choreoathetosis (e.g., in Wilson&rsquo;s disease) or parkinsonism with dystonia when overactive, not true ballistic movements. Confusing any basal ganglia lesion with hemiballismus overlooks the STN&rsquo;s unique excitatory modulatory role.<br><br>Option C. Caudate nucleus  <br>Caudate lesions disrupt both direct and indirect pathways, leading to chorea, athetosis, or neuropsychiatric symptoms (as seen in Huntington&rsquo;s disease). Movements are smaller in amplitude, more distal, and more irregular than the proximal, flinging movements of hemiballismus. Students often mistake chorea for ballism, but the caudate does not produce unilateral ballistic flinging.<br><br>Option D. Putamen  <br>Putaminal pathology affects motor regulation and can result in focal dystonia or choreiform movements of distal extremities. Putamen infarcts or metabolic lesions cause twisting or writhing postures, not the high-velocity, proximal limb flinging seen in STN infarcts. Misattributing hemiballismus to the putamen fails to account for the STN&rsquo;s critical position in the indirect pathway.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Structure</th><th>Normal Role</th><th>Lesion Effect</th><th>Clinical Movement Disorder</th></tr></thead><tbody><tr><td>Subthalamic nucleus (STN)</td><td>Glutamatergic excitation of GPi</td><td>\u2193 GPi inhibition of thalamus</td><td>Hemiballismus (unilateral, large\u2010amplitude flinging)</td></tr><tr><td>Globus pallidus internus (GPi)</td><td>GABAergic output \u2192 thalamus</td><td>\u2193 Thalamic inhibition</td><td>Choreoathetosis, dystonia (milder hyperkinesia)</td></tr><tr><td>Caudate nucleus</td><td>Striatal modulation of direct/indirect loops</td><td>Imbalanced striatal outputs</td><td>Chorea, athetosis; often bilateral, distal</td></tr><tr><td>Putamen</td><td>Motor striatum (direct & indirect input)</td><td>Altered modulation of motor cortex</td><td>Focal dystonia or choreiform distal movements</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hemiballismus most commonly results from a lacunar infarct in the subthalamic branch of the posterior cerebral artery; up to 50% of cases resolve spontaneously within weeks.  <br><span class=\"list-item\">\u2022</span> The lesion always localizes contralateral to the flinging; right\u2010sided STN infarct \u2192 left\u2010sided hemiballismus.  <br><span class=\"list-item\">\u2022</span> First\u2010line symptomatic therapy is tetrabenazine (VMAT2 inhibitor); monitor for depression and parkinsonism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing hemiballismus with chorea: focus on proximal versus distal distribution and amplitude&mdash;ballism is proximal and high\u2010velocity.  <br><span class=\"list-item\">\u2022</span> Misapplying basal ganglia anatomy: failing to recognize the STN as the only excitatory node in the indirect pathway, essential for movement suppression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- EFNS Guidelines on Chorea (2014): Recommend MRI\u2010DWI to identify STN infarcts (Level C) and symptomatic treatment with tetrabenazine (Level B) or haloperidol (Level C).  <br><span class=\"list-item\">\u2022</span> AAN Practice Guideline for Chorea in Huntington&rsquo;s Disease (2012): Tetrabenazine is Level B recommended for chorea; clinicians extrapolate this to hemiballismus management (off\u2010label).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The STN lies ventral to the thalamus and medial to the internal capsule. It receives inhibitory GABAergic input from GPe and sends excitatory glutamatergic projections to GPi and substantia nigra pars reticulata, forming the critical limb of the indirect pathway that suppresses unwanted movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>In hemiballismus, STN damage lowers excitatory drive to GPi, reducing its GABAergic inhibition of the ventrolateral thalamus. This disinhibition leads to excessive thalamocortical activation and high\u2010amplitude, proximal limb flinging movements on the body side contralateral to the lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history and exam: identify unilateral, violent flinging movements.  <br>2. Localize to basal ganglia via movement character (proximal ballism vs distal chorea).  <br>3. Obtain non\u2010contrast CT to exclude hemorrhage (may be normal).  <br>4. Perform MRI with diffusion\u2010weighted imaging to detect acute STN lacunar infarct.  <br>5. Screen for metabolic or other etiologies if imaging is unrevealing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>CT often misses small lacunar infarcts in the STN. MRI\u2010DWI is the gold standard, showing a hyperintense focus in the STN region within hours of symptom onset. T2/FLAIR sequences may later show gliosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Tetrabenazine: VMAT2 inhibitor; start 12.5 mg twice daily, titrate by 12.5 mg every week to a typical total of 50&ndash;75 mg/day; monitor for depression.  <br><span class=\"list-item\">\u2022</span> Haloperidol: dopamine D2 antagonist; start 0.5&ndash;1 mg twice daily for rapid control; watch for extrapyramidal side effects.  <br><span class=\"list-item\">\u2022</span> Clonazepam: GABA\u2010A agonist; low\u2010dose (0.5&ndash;1 mg) can smooth movements acutely while awaiting VMAT2 efficacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Localization of hyperkinetic movement disorders to basal ganglia nuclei is frequently tested on neurology boards, often via brief vignettes asking for the affected circuit node (e.g., STN in hemiballismus, striatum in chorea). Understanding the direct vs indirect pathways remains a high-yield topic.</div></div></div></div></div>"
  },
  {
    "id": 100023991,
    "question_number": "490",
    "question_text": "Q490. Which of the following disorders is associated with Parkinson's disease treated with dopamine agonists?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Parkinson&rsquo;s disease (PD) is characterized by degeneration of nigrostriatal dopaminergic neurons, leading to both motor and non\u2010motor manifestations. Restless Legs Syndrome (RLS) is a sensorimotor disorder marked by an irresistible urge to move the legs, typically worsening at rest and in the evening, due to dysfunction in central dopaminergic pathways (notably the A11 hypothalamic projections to the spinal cord). Dopamine agonists (e.g., pramipexole, ropinirole) augment dopamine receptor activity, ameliorating both PD motor deficits and RLS symptoms. Key terms: augmentation (paradoxical worsening of RLS with chronic DA use), IRLSSG severity scale.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Restless Legs Syndrome responds robustly to dopamine agonist therapy because it rectifies dopaminergic hypofunction in central pathways. <span class=\"evidence\">The 2016</span> American Academy of Sleep Medicine (AASM) guideline (Level I evidence) endorses pramipexole and ropinirole as first-line treatments for moderate-to-severe RLS, demonstrating >50% reduction in IRLSSG scores in randomized controlled trials. In PD cohorts, RLS prevalence ranges 12&ndash;20%; adjustments in DA dosing often improve both PD and RLS symptoms. Functional imaging (DAT-SPECT) shows reduced striatal dopamine transporter binding in primary RLS similar to early PD patterns. These shared pathophysiological mechanisms validate RLS as the only listed disorder treatable with dopamine agonists in PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Parasomnia  <br>&ndash; Why incorrect: Parasomnias (sleepwalking, confusional arousals) originate from NREM arousal dysregulation.  <br>&ndash; Common misconception: Equating any sleep disturbance in PD with a dopamine-responsive condition.  <br>&ndash; Differentiator: Occurs during deep NREM sleep versus RLS, which arises pre-sleep/rest.<br><br>C. Neuropathy  <br>&ndash; Why incorrect: Peripheral neuropathy stems from metabolic or toxic causes, not central dopaminergic loss or DA therapy.  <br>&ndash; Common misconception: Attributing any sensory symptom in PD to peripheral nerve damage.  <br>&ndash; Differentiator: Presents with objective nerve conduction abnormalities, unresponsive to dopamine agonists.<br><br>D. REM sleep behavior disorder  <br>&ndash; Why incorrect: RBD is characterized by dream enactment due to loss of REM atonia and is treated with clonazepam or melatonin, not dopamine agonists.  <br>&ndash; Common misconception: Believing all PD-related sleep disorders respond to dopaminergic drugs.  <br>&ndash; Differentiator: Occurs during REM sleep with complex motor behaviors, unlike the leg sensation-driven movements of RLS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Restless Legs Syndrome</th><th>Parasomnia</th><th>Neuropathy</th><th>REM Sleep Behavior Disorder</th></tr></thead><tbody><tr><td>Predominant sleep phase</td><td>Pre-sleep/rest</td><td>NREM (stage N3)</td><td>Not sleep-phase specific</td><td>REM</td></tr><tr><td>Core symptom</td><td>Urge to move legs, sensory discomfort</td><td>Confusional arousals, sleepwalking</td><td>Paresthesias, weakness</td><td>Dream enactment, vocalization</td></tr><tr><td>Underlying pathophysiology</td><td>Central dopaminergic dysfunction</td><td>Arousal regulation disruption</td><td>Peripheral nerve injury</td><td>Brainstem REM-atonia circuit loss</td></tr><tr><td>Response to dopamine agonists</td><td>First-line therapy</td><td>No therapeutic role</td><td>No therapeutic role</td><td>No therapeutic role</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. RLS augmentation presents as earlier onset, spread to arms, or increased severity&mdash;consider switching to alpha-2-delta ligands if augmentation occurs.  <br>2. Differentiating RLS from akathisia: akathisia causes generalized restlessness, not confined to legs and not relieved by movement.  <br>3. In PD patients, be vigilant for RLS using standardized scales (e.g., IRLSSG criteria) when adjusting dopaminergic regimens.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing akathisia (drug-induced inner restlessness) with RLS: akathisia is not circadian and involves the whole body.  <br>2. Assuming RBD improves with dopamine therapy: RBD requires GABAergic management (clonazepam) or melatonin, not DA adjustments.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AASM Clinical Practice Guideline: Treatment of Restless Legs Syndrome, 2016 &ndash; Grade A recommendation for short-acting dopamine agonists (pramipexole, ropinirole) as first-line agents (Level I evidence).  <br>2. International RLS Study Group (IRLSSG) Consensus Statement, 2017 &ndash; Emphasizes iron status optimization (target ferritin >75 \u00b5g/L) and cautious use of dopamine agonists to minimize augmentation (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The A11 dopaminergic nucleus in the posterior hypothalamus projects to the spinal dorsal horn, modulating sensory input. In PD, nigrostriatal degeneration parallels dysfunction in this pathway, contributing to RLS pathogenesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>RLS arises from central dopaminergic deficits and subcortical iron dysregulation, leading to hyperexcitability of spinal sensorimotor circuits. Chronic dopamine agonist therapy restores receptor stimulation but may induce augmentation through receptor desensitization and altered iron metabolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; Pramipexole: initiate 0.125 mg 2&ndash;3 hours before bedtime; typical range 0.125&ndash;0.5 mg/day.  <br>&ndash; Ropinirole: start 0.25 mg 1&ndash;3 hours before bedtime; may increase to 4 mg/day.  <br>&ndash; Monitor for augmentation; consider gabapentin enacarbil or pregabalin for refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Dopamine agonist therapy for PD not only addresses motor symptoms but is the cornerstone of moderate-to-severe RLS management&mdash;exam questions often test differentiation of sleep disorders by sleep phase and pharmacologic responsiveness.</div></div></div></div></div>"
  },
  {
    "id": 100023992,
    "question_number": "287",
    "question_text": "Which is a Tauopathy?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Tau is a microtubule\u2010associated protein critical for axonal transport and neuronal integrity. In tauopathies, abnormal hyperphosphorylation leads to aggregation of insoluble tau filaments. Key isoforms (3R vs. 4R tau) determine regional vulnerability. Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are primary 4R tauopathies, whereas multisystem atrophy (MSA) and dementia with Lewy bodies (DLB) are &alpha;-synucleinopathies. Clinically, PSP presents with vertical supranuclear gaze palsy and early postural instability due to midbrain and globus pallidus tau accumulation, distinguishing it from other parkinsonian syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Progressive supranuclear palsy is prototypical 4R tauopathy: neuropathology shows tufted astrocytes and coiled bodies composed of hyperphosphorylated 4-repeat tau in basal ganglia, subthalamic nucleus, and brainstem <span class=\"citation\">(Dickson et al., <span class=\"evidence\">Brain 2010</span>)</span>. According to the Movement Disorder Society PSP criteria <span class=\"citation\">(H\u00f6glinger et al., Mov <span class=\"evidence\">Disord 2017</span>)</span>, vertical gaze palsy plus early falls yield a &ldquo;probable PSP&rdquo; diagnosis (Level C evidence). &alpha;-Synucleinopathies such as MSA and DLB lack tau inclusions and instead feature glial cytoplasmic (MSA) or neuronal Lewy body (DLB) pathology. Although CBD also accumulates 4R tau, board examinations most commonly test PSP as the exemplar tauopathy due to its distinctive oculomotor and postural features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. MSA  <br><span class=\"list-item\">\u2022</span> Incorrect: Primary glial cytoplasmic inclusions of &alpha;-synuclein define MSA, not tau.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing multiple system atrophy with other atypical parkinsonian disorders.  <br><span class=\"list-item\">\u2022</span> Differentiator: Prominent autonomic failure and hot cross bun sign on pons MRI.<br><br>C. DLB  <br><span class=\"list-item\">\u2022</span> Incorrect: Lewy bodies containing &alpha;-synuclein characterize DLB.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating dementia with Lewy bodies to tauopathies rather than synucleinopathies.  <br><span class=\"list-item\">\u2022</span> Differentiator: Visual hallucinations, fluctuations in cognition, and REM sleep behavior disorder.<br><br>D. CBD  <br><span class=\"list-item\">\u2022</span> Incorrect (in the context of this question): Although corticobasal degeneration is histopathologically a 4R tauopathy, the prototypical clinical&ndash;pathological correlation tested at the Promotion level is PSP.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all tauopathies are equivalent; PSP has unique supranuclear gaze palsy and early falls.  <br><span class=\"list-item\">\u2022</span> Differentiator: CBD manifests with asymmetric cortical signs (alien limb, apraxia) rather than vertical gaze palsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSP</th><th>MSA</th><th>DLB</th><th>CBD</th></tr></thead><tbody><tr><td>Pathology protein</td><td>Hyperphosphorylated 4R tau</td><td>&alpha;-Synuclein (glial cytoplasmic)</td><td>&alpha;-Synuclein (neuronal Lewy bodies)</td><td>Hyperphosphorylated 4R tau</td></tr><tr><td>Key clinical signs</td><td>Vertical gaze palsy, early falls</td><td>Autonomic failure, parkinsonism</td><td>Visual hallucinations, dementia</td><td>Asymmetric rigidity, apraxia</td></tr><tr><td>MRI hallmark</td><td>Midbrain atrophy (&ldquo;hummingbird&rdquo;)</td><td>Hot cross bun sign</td><td>Occipital hypometabolism on PET</td><td>Asymmetric frontoparietal atrophy</td></tr><tr><td>Diagnostic criteria source</td><td>MDS PSP Criteria (2017)</td><td>Gilman et al. Consensus (1999)</td><td>McKeith et al. DLB Criteria (2017)</td><td>Armstrong et al. CBD Criteria (2013)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early postural instability and vertical supranuclear gaze palsy are red flags for PSP over Parkinson&rsquo;s disease.  <br><span class=\"list-item\">\u2022</span> Tau PET imaging with [^18F]flortaucipir increases diagnostic accuracy for PSP vs. MSA <span class=\"citation\">(Holland et al., J Nucl <span class=\"evidence\">Med 2020</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Management remains symptomatic: levodopa trial often yields minimal benefit; amantadine may improve gait freezing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any atypical parkinsonism with tauopathy: MSA and DLB are synucleinopathies.  <br>2. Overlooking that CBD is also a tauopathy&mdash;boards focus on distinguishing clinical phenotypes (PSP vs. CBD).  <br>3. Relying solely on MRI without clinical correlation; midbrain atrophy can be subtle early on.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society (MDS) PSP Diagnostic Criteria, H\u00f6<span class=\"evidence\">glinger et al., 2017</span>  <br>   &ndash; Recommendation: Use vertical gaze palsy plus falls within 3 years for &ldquo;probable PSP&rdquo; (Level C consensus).  <br>2. Armstrong MJ et al., Corticobasal Degeneration Diagnostic Criteria, Mov <span class=\"evidence\">Disord 2013</span>  <br>   &ndash; Recommendation: Asymmetric limb rigidity plus cortical sensory deficits define CBD (Level B evidence).  <br>3. SNMMI Practice Guideline for Tau PET Imaging, 2020  <br>   &ndash; Recommendation: Employ tau PET tracers to differentiate tauopathies from synucleinopathies in vivo (Level B evidence).  <br>4. Rinne JO et al., ABBV-8E12 Anti-Tau Antibody Phase II Trial in PSP, Lancet <span class=\"evidence\">Neurol 2021</span>  <br>   &ndash; Finding: Safe but no definitive efficacy on progression at 12 months (Randomized controlled, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP targets the rostral interstitial nucleus of the medial longitudinal fasciculus (vertical gaze center), subthalamic nucleus, and globus pallidus internus, causing early falls and ocular motor deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Hyperphosphorylation of tau lowers its affinity for microtubules, promoting aggregation into paired helical filaments. In PSP, predominantly 4-repeat tau accumulates in neurons and glia, disrupting cytoskeletal transport.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify clinical red flags (gaze palsy, early falls).  <br>2. MRI brain: assess midbrain&ndash;pons ratio (hummingbird sign).  <br>3. Rule out synucleinopathy with DaTscan (reduced uptake in both, but clinical context differs).  <br>4. Consider tau PET for atypical cases.  <br>5. Apply MDS PSP criteria for definitive categorization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hummingbird (penguin) sign on sagittal MRI is highly specific for PSP.  <br><span class=\"list-item\">\u2022</span> Midbrain to pons area ratio <0.52 supports PSP <span class=\"citation\">(Oba et al., <span class=\"evidence\">Neurology 2005</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease-modifying therapy exists; symptomatic management includes:  <br><span class=\"list-item\">\u2022</span> Levodopa trial (up to 1,000 mg/day)&mdash;often poor response.  <br><span class=\"list-item\">\u2022</span> Amantadine (100 mg TID) for gait freezing.  <br><span class=\"list-item\">\u2022</span> SSRIs for apathy/depression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam.  <br>Tauopathies vs. synucleinopathies are frequently tested as matching or single-best-answer questions, often focusing on clinical&ndash;pathological correlations (e.g., gaze palsy in PSP, autonomic failure in MSA).</div></div></div></div></div>"
  },
  {
    "id": 100023998,
    "question_number": "163",
    "question_text": "A 34-year-old female is brought in by her family due to a history of abnormal movements of her hands and legs, as well as difficulty eating due to sustained contractions of her mouth. Her father had a similar history and died early. On examination, she is found to have orolingual dystonia. What should be done next to reach a diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Hereditary movement disorders often present with dystonia&mdash;sustained muscle contractions causing twisting and repetitive movements. Early-onset and segmental dystonia (oromandibular plus limb involvement) with autosomal-dominant inheritance suggests a genetic etiology (e.g., DYT1, DYT6, or Huntington&rsquo;s disease). Recognizing family history is crucial. Genetic testing directly identifies pathogenic mutations (e.g., TOR1A for DYT1 dystonia or HTT CAG expansions for Huntington&rsquo;s), confirming diagnosis without invasive procedures. Secondary causes (structural lesions, metabolic, autoimmune) are ruled out by history, exam, and targeted investigations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Genetic testing is the definitive diagnostic tool for suspected hereditary dystonia. <span class=\"evidence\">The 2018</span> European Academy of Neurology guidelines recommend gene screening in patients with early-onset, generalized or segmental dystonia and positive family history (Level A evidence). For Huntington&rsquo;s disease, the International Huntington Association and World Health Organization (2018) endorse CAG repeat analysis as gold standard, detecting &ge;36 repeats associated with disease onset (Class I studies). Neuroimaging (e.g., MRI) may show caudate atrophy in advanced disease but lacks sensitivity early. EMG characterizes muscle activity in dystonic spasms but is not diagnostic of genetic etiology. A therapeutic trial of anticholinergics (e.g., trihexyphenidyl) addresses symptoms but does not establish etiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI of the brain  <br><span class=\"list-item\">\u2022</span> Incorrect: May show nonspecific changes or late caudate atrophy in Huntington&rsquo;s; lacks sensitivity/specificity early.  <br><span class=\"list-item\">\u2022</span> Misconception: Structural imaging can replace genetic confirmation.  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI is supportive, not confirmatory.<br><br>C. Electromyography (EMG)  <br><span class=\"list-item\">\u2022</span> Incorrect: EMG patterns (e.g., co-contraction) confirm presence of dystonia but not underlying cause.  <br><span class=\"list-item\">\u2022</span> Misconception: Electrophysiology can define genetic disorders.  <br><span class=\"list-item\">\u2022</span> Differentiator: EMG is diagnostic for neuromuscular disorders, not gene mutations.<br><br>D. Trial of anticholinergic medication  <br><span class=\"list-item\">\u2022</span> Incorrect: Therapeutic trial treats symptomatic dystonia; not diagnostic.  <br><span class=\"list-item\">\u2022</span> Misconception: Clinical response to medication infers underlying etiology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Drug response neither confirms genetic mutation nor rules out differential.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Genetic Testing</th><th>MRI Brain</th><th>EMG</th><th>Anticholinergic Trial</th></tr></thead><tbody><tr><td>Diagnostic Purpose</td><td>Confirms gene mutation</td><td>Structural imaging</td><td>Electrophysiology</td><td>Symptomatic treatment</td></tr><tr><td>Sensitivity/Specificity</td><td>High for known mutations</td><td>Variable; low early</td><td>High for muscle activity</td><td>N/A</td></tr><tr><td>Result Interpretation</td><td>Molecular confirmation</td><td>Radiologic interpretation</td><td>Waveform analysis</td><td>Clinical observation</td></tr><tr><td>Invasiveness</td><td>Non-invasive blood test</td><td>Non-invasive MRI</td><td>Minimally invasive</td><td>Non-invasive</td></tr><tr><td>Gold Standard?</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Early-onset segmental dystonia with family history warrants torsinA (DYT1) and THAP1 (DYT6) gene panels.  <br>2. In Huntington&rsquo;s suspicion, CAG repeat expansion &ge;40 is fully penetrant; 36&ndash;39 shows reduced penetrance.  <br>3. Wilson&rsquo;s disease can mimic dystonia but is autosomal recessive; always check ceruloplasmin and Kayser-Fleischer rings when liver signs or rapid progression are present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overreliance on MRI: early neurodegenerative changes may be absent; false reassurance delays genetic confirmation.  <br>2. Assuming therapeutic response equals diagnosis: anticholinergics improve symptoms across multiple dystonia etiologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. European Academy of Neurology (2018) &ndash; Genetic Diagnosis of Dystonia: Level A recommendation for gene testing in early-onset, familial cases.  <br>2. International Huntington Association/WHO (2018) &ndash; Genetic Testing for CAG Repeat in HTT: Gold standard; Class I evidence for predictive and confirmatory testing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Hereditary dystonias implicate basal ganglia circuits, especially the striatum; mutant proteins (torsinA, huntingtin) disrupt inhibitory GABAergic pathways, leading to abnormal motor output via thalamocortical loops.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mutations in TOR1A alter endoplasmic reticulum function and dopaminergic neurotransmission, causing aberrant neuronal firing. HTT expansions lead to neuronal inclusions, excitotoxicity, and progressive striatal atrophy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Genetic testing for hereditary movement disorders is frequently tested, often as the next diagnostic step in cases with clear family history and early-onset dystonia.</div></div></div></div></div>"
  },
  {
    "id": 100023999,
    "question_number": "160",
    "question_text": "Q160. A 50-year-old male patient has a history of cognitive impairment for 6 months, accompanied by depression and abnormal movements. His father died at the age of 60 with a history suggestive of Huntington's disease. What is the gene associated with this condition?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] - Striatal neurodegeneration: Loss of GABAergic medium spiny neurons in the caudate nucleus and putamen leads to chorea, executive dysfunction, and psychiatric disturbances.  <br><span class=\"list-item\">\u2022</span> Genetic mechanism: HTT gene on chromosome 4p16.3 contains a CAG trinucleotide repeat; normal alleles have &le;35 repeats, pathological alleles &ge;36 (full penetrance &ge;40), exhibiting anticipation.  <br><span class=\"list-item\">\u2022</span> Clinical triad: Motor (chorea, dystonia), cognitive (subcortical dementia), psychiatric (depression, irritability) typically manifest in mid-adulthood.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Huntington&rsquo;s disease (HD) is caused by an expanded CAG repeat in exon 1 of the HTT gene on chromosome 4 <span class=\"citation\">(MacDonald et al., Cell, 1993)</span>. The resulting polyglutamine tract induces a toxic gain-of-function in mutant huntingtin, disrupting transcription, mitochondrial function, and proteostasis <span class=\"citation\">(Ross & Tabrizi, Lancet Neurol, 2011)</span>. Per ACMG/AMP 2015 guidelines, alleles with &ge;40 CAG repeats are fully penetrant (Tier 1 evidence); 36&ndash;39 repeats confer reduced penetrance and variable age of onset. PCR-based fragment analysis is the diagnostic gold standard. Paternal transmission often leads to greater repeat expansion and earlier onset, especially in juvenile cases <span class=\"citation\">(Telenius et al., Am J Hum Genet, 1994)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. CGG repeat  <br><span class=\"list-item\">\u2022</span> Incorrect: CGG expansions in the FMR1 gene cause Fragile X syndrome (intellectual disability, macroorchidism, autism spectrum features), not chorea or adult-onset cognitive decline.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any trinucleotide repeat disorder with HD.  <br><span class=\"list-item\">\u2022</span> Differentiator: X-linked inheritance and neurodevelopmental phenotype vs autosomal dominant adult neurodegeneration.<br><br>C. GAA repeat  <br><span class=\"list-item\">\u2022</span> Incorrect: GAA expansions in the FXN gene cause Friedreich ataxia&mdash;an autosomal recessive spinocerebellar ataxia with gait instability, cardiomyopathy, and diabetes, not chorea.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing ataxic syndromes with hyperkinetic movement disorders.  <br><span class=\"list-item\">\u2022</span> Differentiator: Cerebellar and peripheral nerve involvement vs striatal pathology.<br><br>D. CTG repeat  <br><span class=\"list-item\">\u2022</span> Incorrect: CTG expansions in the DMPK gene cause myotonic dystrophy type 1, presenting with myotonia, muscle weakness, cataracts, and endocrine dysfunction rather than choreiform movements.  <br><span class=\"list-item\">\u2022</span> Misconception: Associating multisystem muscular disorders with central chorea.  <br><span class=\"list-item\">\u2022</span> Differentiator: Myotonia and systemic features vs central neurodegeneration and psychiatric symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CAG (HD)</th><th>CGG (Fragile X)</th><th>GAA (Friedreich)</th><th>CTG (Myotonic Dystrophy)</th></tr></thead><tbody><tr><td>Gene</td><td>HTT</td><td>FMR1</td><td>FXN</td><td>DMPK</td></tr><tr><td>Chromosome</td><td>4p16.3</td><td>Xq27.3</td><td>9q13</td><td>19q13.3</td></tr><tr><td>Inheritance</td><td>Autosomal dominant</td><td>X-linked</td><td>Autosomal recessive</td><td>Autosomal dominant</td></tr><tr><td>Pathological repeats</td><td>&ge;36 CAG (&ge;40 full pen)</td><td>>200 CGG</td><td>>66 GAA</td><td>&ge;50 CTG</td></tr><tr><td>Typical onset</td><td>35&ndash;50 years</td><td>Childhood/adolescence</td><td>Childhood/adolescence</td><td>20&ndash;40 years</td></tr><tr><td>Key clinical features</td><td>Chorea, dementia, depression</td><td>ID, macroorchidism</td><td>Ataxia, cardiomyopathy</td><td>Myotonia, cataracts</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Genetic anticipation in HD is most pronounced with paternal transmission, often resulting in juvenile-onset when CAG repeats exceed 60.  <br><span class=\"list-item\">\u2022</span> Pre-symptomatic genetic testing mandates comprehensive counseling to address ethical, psychological, and familial implications.  <br><span class=\"list-item\">\u2022</span> Juvenile-onset HD may present with rigidity and seizures rather than classic chorea.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing CAG repeat HD with other trinucleotide repeat disorders (e.g., Fragile X or Friedreich) due to similar repeat nomenclature.  <br>2. Overlooking that Friedreich ataxia (GAA) is autosomal recessive, unlike HD&rsquo;s autosomal dominant inheritance.  <br>3. Assuming all repeat expansions cause loss-of-function when HD involves a toxic gain-of-function mechanism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NICE Guideline NG144 (2018): Recommends PCR-based confirmatory testing for HTT CAG repeat expansions in symptomatic or at-risk individuals, with mandatory pre- and post-test genetic counseling (Level 1 evidence).  <br><span class=\"list-item\">\u2022</span> European Huntington&rsquo;s Disease Network Consensus (2021): Defines HTT allele categories (normal, intermediate, reduced penetrance, full penetrance) and advises independent laboratory confirmation of CAG repeat length before clinical reporting (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Huntington&rsquo;s disease is a prototypical polyglutamine expansion disorder frequently tested on neurology and genetics boards, emphasizing the CAG repeat mechanism, clinical triad, and anticipation. This question appeared in <span class=\"evidence\">Promotion 2021</span> exam.</div></div></div></div></div>"
  },
  {
    "id": 100024000,
    "question_number": "153",
    "question_text": "Q153. A young man with orolingual dystonia, associated with cognitive deficit, has no family history. What should be investigated?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Orolingual dystonia (involuntary tongue and mouth movements) implicates basal ganglia dysfunction, particularly the striatal&ndash;pallidal circuits governing orofacial motor control. Cognitive decline alongside movement disorder suggests a neurodegenerative or metabolic etiology. Neuroacanthocytosis syndromes (e.g., chorea-acanthocytosis, McLeod syndrome) combine orolingual dystonia, feeding dystonia, neuropsychiatric features and peripheral acanthocytes (spiculated erythrocytes). Unlike autosomal-dominant Huntington&rsquo;s disease, many neuroacanthocytoses are sporadic or X-linked without clear family history. Laboratory detection of acanthocytes on a peripheral blood film is a low-cost, first-line screen prior to genetic confirmation (e.g., VPS13A mutation).<br><br>(Word count: 115)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Peripheral blood smear demonstrating >5% acanthocytes is 85&ndash;95% sensitive for chorea-acanthocytosis <span class=\"citation\">(Rampoldi et al., <span class=\"evidence\">Brain 2002</span>)</span> and remains the cornerstone of initial workup. The Movement Disorder Society&rsquo;s 2020 evidence-based criteria endorse smear analysis as a Class II, Level B recommendation for suspected neuroacanthocytosis syndromes. Genetic testing for VPS13A or XK genes confirms diagnosis but is costly and time-consuming; hence smear is priority. Slit lamp examination and ceruloplasmin target Wilson&rsquo;s disease, which typically presents with hepatic dysfunction, KF rings, low ceruloplasmin, and variable movement disorders <span class=\"citation\">(AASLD/EASL WD guidelines 2012)</span>. Huntingtin gene analysis is reserved for suspected Huntington&rsquo;s chorea with positive family history and autosomal-dominant transmission.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Htt gene  <br><span class=\"list-item\">\u2022</span> Incorrect: Huntington&rsquo;s disease is autosomal dominant with choreic movements, psychiatric symptoms and typical family history.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any adult chorea-cognitive syndrome with Huntington&rsquo;s.  <br><span class=\"list-item\">\u2022</span> Differentiator: Huntington&rsquo;s manifests with generalized chorea, caudate atrophy on MRI, CAG repeat expansion.<br><br>C. Slit lamp examination  <br><span class=\"list-item\">\u2022</span> Incorrect: screens for Kayser-Fleischer rings in Wilson&rsquo;s disease.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming all dystonias with cognitive deficits are metabolic (Wilson&rsquo;s).  <br><span class=\"list-item\">\u2022</span> Differentiator: Wilson&rsquo;s features hepatic involvement, tremor, parkinsonism rather than isolated orolingual dystonia.<br><br>D. Serum ceruloplasmin  <br><span class=\"list-item\">\u2022</span> Incorrect: low in Wilson&rsquo;s disease but normal in neuroacanthocytosis.  <br><span class=\"list-item\">\u2022</span> Misconception: over-reliance on ceruloplasmin for any young movement-disorder.  <br><span class=\"list-item\">\u2022</span> Differentiator: normal ceruloplasmin and absence of KF rings argue against Wilson&rsquo;s.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Test</th><th>Target Disorder</th><th>Typical Onset</th><th>Key Clinical Features</th></tr></thead><tbody><tr><td>Peripheral blood film for acanthocytes</td><td>Neuroacanthocytosis</td><td>20&ndash;40 years</td><td>Orolingual & feeding dystonia, self-mutilation, cognitive decline</td></tr><tr><td>Htt gene analysis</td><td>Huntington&rsquo;s disease</td><td>30&ndash;50 years</td><td>Generalized chorea, psychiatric changes, autosomal dominant</td></tr><tr><td>Slit lamp examination</td><td>Wilson&rsquo;s disease</td><td><40 years</td><td>Kayser-Fleischer rings, hepatic dysfunction, tremor</td></tr><tr><td>Serum ceruloplasmin</td><td>Wilson&rsquo;s disease</td><td><40 years</td><td>Low ceruloplasmin, hepatolenticular degeneration</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Feeding dystonia with tongue protrusion and self-inflicted lip biting is highly suggestive of chorea-acanthocytosis.  <br><span class=\"list-item\">\u2022</span> Acanthocytes are present in 5&ndash;50% of RBCs; absence does not fully exclude the diagnosis&mdash;repeat smear if clinical suspicion remains high.  <br><span class=\"list-item\">\u2022</span> VPS13A gene testing confirms chorea-acanthocytosis; XK gene analysis diagnoses McLeod syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking acanthocytes for spur cells seen in liver disease&mdash;acanthocytes have irregular, thorny projections.  <br>2. Attributing orolingual movements to tardive dyskinesia without assessing medication history and systemic signs.  <br>3. Assuming absence of family history rules out genetic choreas&mdash;X-linked McLeod syndrome often appears sporadic in males.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Neuroacanthocytosis Syndromes, 2020: recommends peripheral smear for acanthocytes as a first-line diagnostic test (Class II, Level B).  <br><span class=\"list-item\">\u2022</span> EASL Clinical Practice Guidelines on Wilson&rsquo;s Disease, 2012: advise slit lamp examination and serum ceruloplasmin as initial screening in suspected WD (Class I, Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Neuroacanthocytosis syndromes&mdash;particularly orolingual dystonia with cognitive decline and acanthocytes&mdash;are frequently tested in neurology boards, often as single-best-answer items contrasting with Wilson&rsquo;s, Huntington&rsquo;s and drug-induced dystonia.</div></div></div></div></div>"
  },
  {
    "id": 100024004,
    "question_number": "156",
    "question_text": "Q156. Hallervorden-Spatz syndrome is associated with which gene?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Hallervorden-Spatz syndrome&mdash;now classified under neurodegeneration with brain iron accumulation (NBIA)&mdash;is characterized by progressive extrapyramidal signs and basal ganglia iron deposition.  <br>1. Pantothenate kinase&ndash;2 (PANK2) catalyzes the first step in coenzyme A biosynthesis within mitochondria; mutations cause iron accumulation in globus pallidus.  <br>2. Autopsy and MRI show the &ldquo;eye-of-the-tiger&rdquo; sign: central hyperintensity with surrounding hypointensity on T2-weighted images.  <br>3. Inheritance is autosomal recessive; age of onset ranges from childhood to adolescence with dystonia, rigidity, and dysarthria.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PANK2 mutations are the definitive cause of classic PKAN (formerly Hallervorden-Spatz) <span class=\"citation\">(Zhou et al., Nat <span class=\"evidence\">Genet 2001</span>)</span>. Loss of pantothenate kinase activity disrupts coenzyme A synthesis, leading to iron overload and oxidative damage in basal ganglia neurons. Diagnostic confirmation relies on sequencing of all PANK2 exons and intron&ndash;exon boundaries; over 100 pathogenic variants have been reported <span class=\"citation\">(Hayflick et al., <span class=\"evidence\">Neurology 2003</span>)</span>. No other gene has been conclusively linked to this phenotype. Current consensus <span class=\"citation\">(Kruer et al., Mov <span class=\"evidence\">Disord 2018</span>)</span> designates PANK2 as the sole gene for classic PKAN, distinguishing it from other NBIA subtypes caused by different genes (e.g., PLA2G6, C19orf12).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. PKAN-1  <br><span class=\"list-item\">\u2022</span> Why incorrect: PKAN-1 is an outdated disease designation, not a gene.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing disease nomenclature (PKAN) with gene symbol.  <br><span class=\"list-item\">\u2022</span> Differentiator: Gene symbols are alphanumeric and refer to genomic loci, whereas PKAN-1 describes the phenotype.<br><br>C. ATP7B  <br><span class=\"list-item\">\u2022</span> Why incorrect: ATP7B mutations cause Wilson disease (hepatolenticular degeneration), leading to copper&mdash;not iron&mdash;accumulation.  <br><span class=\"list-item\">\u2022</span> Misconception: Any metal\u2010storage disorder affecting basal ganglia must involve the same gene.  <br><span class=\"list-item\">\u2022</span> Differentiator: ATP7B encodes a copper-transporting ATPase; labs show low ceruloplasmin and high urinary copper.<br><br>D. SLC6A3  <br><span class=\"list-item\">\u2022</span> Why incorrect: SLC6A3 encodes the dopamine transporter; mutations cause dopamine transporter deficiency syndrome, not iron accumulation.  <br><span class=\"list-item\">\u2022</span> Misconception: All movement disorders share overlapping genetic causes.  <br><span class=\"list-item\">\u2022</span> Differentiator: SLC6A3 deficiency presents with parkinsonism&ndash;dystonia due to impaired dopamine reuptake, without MRI iron deposition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PANK2 (PKAN)</th><th>PKAN-1 (Term)</th><th>ATP7B (Wilson)</th><th>SLC6A3 (DAT Deficiency)</th></tr></thead><tbody><tr><td>Gene Product</td><td>Pantothenate kinase-2</td><td>&mdash;</td><td>Copper-transport ATPase</td><td>Dopamine transporter</td></tr><tr><td>Metal Accumulated</td><td>Iron</td><td>Iron</td><td>Copper</td><td>None</td></tr><tr><td>Inheritance</td><td>AR</td><td>Nomenclature only</td><td>AR</td><td>AR</td></tr><tr><td>MRI Finding</td><td>&ldquo;Eye-of-the-tiger&rdquo; sign</td><td>&mdash;</td><td>Basal ganglia T2 hyperintensity without eye sign</td><td>Normal iron, possible atrophy</td></tr><tr><td>Clinical Onset</td><td>Childhood/Adolescence</td><td>&mdash;</td><td>Adolescence/Adulthood</td><td>Infancy/Early childhood</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The &ldquo;eye-of-the-tiger&rdquo; sign on T2 MRI is nearly pathognomonic for PKAN due to central gliosis surrounded by iron deposition.  <br><span class=\"list-item\">\u2022</span> PANK2 testing should be pursued in any child with early-onset dystonia plus MRI basal ganglia hypointensity.  <br><span class=\"list-item\">\u2022</span> Iron chelation with deferiprone has shown MRI and clinical stabilization in open\u2010label studies, though long\u2010term benefit remains under investigation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating PKAN (the syndrome) with the gene symbol&mdash;students sometimes mark &ldquo;PKAN-1&rdquo; as the gene.  <br>2. Confusing Wilson disease (ATP7B) with NBIA disorders, despite differing metal accumulations and laboratory profiles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society (MDS) Consensus Statement on NBIA, 2018  <br><span class=\"list-item\">\u2022</span> Recommendation: PANK2 sequencing is mandatory for suspected classic PKAN (Class I evidence).  <br>2. Deferiprone Trial in NBIA (Synchrotron Study), Lancet <span class=\"evidence\">Neurology 2020</span>  <br><span class=\"list-item\">\u2022</span> Finding: 12\u2010month deferiprone reduced globus pallidus iron (MRI) and slowed motor decline (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- T2-weighted MRI shows bilateral, symmetric hypointensity in globus pallidus with central hyperintense &ldquo;eye\u2010of\u2010the\u2010tiger&rdquo; due to gliosis.  <br><span class=\"list-item\">\u2022</span> Susceptibility\u2010weighted imaging (SWI) accentuates iron deposition and can detect early changes before overt clinical signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam.  <br>Hallervorden-Spatz/PKAN gene association is frequently tested as a single-best-answer on genetics of movement disorders, often requiring recall of PANK2 as the causative locus.</div></div></div></div></div>"
  },
  {
    "id": 100024010,
    "question_number": "164",
    "question_text": "The most common familial gene mutation associated with Parkinson's disease is:",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Parkinson&rsquo;s disease (PD) pathogenesis involves both genetic and environmental factors. Familial PD arises from monogenic mutations, most often with autosomal\u2010dominant inheritance. Key concepts include:  <br><span class=\"list-item\">\u2022</span> LRRK2 encodes a kinase implicated in vesicle trafficking and autophagy.  <br><span class=\"list-item\">\u2022</span> Parkin and PINK1 are involved in mitochondrial quality control; mutations cause autosomal\u2010recessive early\u2010onset PD.  <br><span class=\"list-item\">\u2022</span> SNCA encodes &alpha;-synuclein; point mutations or multiplications lead to toxic protein aggregation.  <br>Understanding gene function, inheritance pattern, and population prevalence is essential for interpreting genetic testing and counseling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>LRRK2 (leucine\u2010rich repeat kinase 2) mutations, especially p.G2019S, account for ~5&ndash;7% of familial PD and up to 1&ndash;2% of sporadic cases <span class=\"citation\">(Healy et al., Lancet <span class=\"evidence\">Neurol 2008</span>)</span>. The International Parkinson and Movement Disorder Society (MDS) Genetic Testing Guidelines (2021) recognize LRRK2 as the most common dominant PD gene worldwide, with founder effects in Ashkenazi Jews (\u223c10% carriers) and North African Arabs (\u223c30%). LRRK2 mutations lead to kinase hyperactivity, promoting &alpha;-synuclein aggregation and neuronal loss in the substantia nigra pars compacta. This contrasts with rarer SNCA duplications/triplications (<1% familial PD) and autosomal\u2010recessive Parkin/PINK1 variants associated with juvenile-onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Parkin  <br><span class=\"list-item\">\u2022</span> Incorrect: Parkin (PARK2) mutations are autosomal\u2010recessive and the most common cause of juvenile\u2010onset PD (<10% familial PD).  <br><span class=\"list-item\">\u2022</span> Misconception: Equating early onset frequency with overall familial prevalence.  <br><span class=\"list-item\">\u2022</span> Differentiator: Requires biallelic mutations; presents before age 40 with slow progression.  <br><br>C. SNCA  <br><span class=\"list-item\">\u2022</span> Incorrect: SNCA point mutations or multiplications are very rare (<1% of familial cases).  <br><span class=\"list-item\">\u2022</span> Misconception: First-discovered gene = most common.  <br><span class=\"list-item\">\u2022</span> Differentiator: Causes rapid progression with dementia; dominant but low prevalence.  <br><br>D. PINK1  <br><span class=\"list-item\">\u2022</span> Incorrect: PINK1 mutations cause autosomal\u2010recessive early\u2010onset PD (~3&ndash;4% of juvenile PD).  <br><span class=\"list-item\">\u2022</span> Misconception: Grouping all mitochondrial genes as equally prevalent.  <br><span class=\"list-item\">\u2022</span> Differentiator: Biallelic loss leads to early-onset but rare in adult familial PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>LRRK2</th><th>Parkin (PARK2)</th><th>SNCA</th><th>PINK1</th></tr></thead><tbody><tr><td>Inheritance</td><td>Autosomal-dominant</td><td>Autosomal-recessive</td><td>Autosomal-dominant</td><td>Autosomal-recessive</td></tr><tr><td>Prevalence (familial)</td><td>~5&ndash;7%</td><td>~10% (juvenile)</td><td><1%</td><td><1% (early onset)</td></tr><tr><td>Typical onset age</td><td>50&ndash;60 years</td><td><40 years</td><td>40&ndash;60 years</td><td><50 years</td></tr><tr><td>Pathogenic mechanism</td><td>Kinase hyperactivity</td><td>Ubiquitin ligase \u2193</td><td>&alpha;-Synuclein aggregation</td><td>Mitochondrial QC \u2193</td></tr><tr><td>Population founder effect</td><td>Ashkenazi Jews, N. Africans</td><td>None major</td><td>None major</td><td>None major</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Test for LRRK2 p.G2019S in familial PD, especially in Ashkenazi Jewish or North African Arab patients.  <br><span class=\"list-item\">\u2022</span> LRRK2 carriers have incomplete penetrance (~30% by age 80); counseling should address variable risk.  <br><span class=\"list-item\">\u2022</span> Parkin-related PD shows marked levodopa sensitivity but early dyskinesias due to dopaminergic neuron sparing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming SNCA is most common due to its historical discovery.  <br>2. Confusing inheritance: attributing autosomal-recessive genes (Parkin/PINK1) to typical adult-onset familial PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- MDS Genetic Testing Guidelines <span class=\"citation\">(MDS, 2021)</span>: Recommend targeted PD gene panels including LRRK2 for familial cases (Level A evidence).  <br><span class=\"list-item\">\u2022</span> Denali Therapeutics Phase II trial of LRRK2 inhibitor DNL151 (2023): Demonstrated safety and target engagement, paving way for disease-modifying therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Genetic forms of PD are frequently tested as single-best-answer questions, emphasizing LRRK2&rsquo;s dominant inheritance, prevalence, and founder mutations.</div></div></div></div></div>"
  },
  {
    "id": 100024014,
    "question_number": "146",
    "question_text": "A 75-year-old patient with progressive cognitive decline, chorea, and ataxia has no children, and his father died at age 65. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Huntington&rsquo;s disease (HD) is an autosomal dominant neurodegenerative disorder caused by CAG repeat expansion in the HTT gene. It primarily affects medium spiny neurons in the striatum (caudate and putamen), leading to chorea via disruption of the indirect pathway. Progressive cortical involvement produces cognitive decline and psychiatric symptoms. Although classic onset is 30&ndash;50 years, ~10% of cases have &ldquo;late\u2010onset&rdquo; (>60 years) presentations. Cerebellar involvement in advanced HD can manifest as ataxia. Recognition of the clinical triad&mdash;chorea, dementia, and inheritance pattern&mdash;guides diagnosis.<br><br>(150 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Huntington&rsquo;s disease diagnosis hinges on detecting >36 CAG repeats in HTT <span class=\"citation\">(Walker FO. Lancet Neurol. 2007)</span>. Late\u2010onset HD accounts for 9&ndash;12% of patients <span class=\"citation\">(Squitieri F et al. Neurology. 2010)</span>. MRI shows early caudate atrophy correlating with chorea severity <span class=\"citation\">(Rosas HD et al. Neurology. 2003)</span>. The European Academy of Neurology (EAN) Movement Disorders guidelines (2015) endorse genetic testing for any adult with unexplained chorea, irrespective of family history, since de novo cases or unrecognized parental disease occur. Neuropathology extends beyond basal ganglia to the cerebellum in end\u2010stage disease <span class=\"citation\">(Vonsattel JP et al. J Neuropathol Exp Neurol. 1985)</span>, explaining ataxia. Other causes of choreo\u2010ataxia differ by inheritance, age of onset, biochemical markers (e.g., ceruloplasmin in Wilson&rsquo;s) or hematological findings (acanthocytes in neuroacanthocytosis).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Neuroacanthocytosis  <br><span class=\"list-item\">\u2022</span> Onset typically 20&ndash;40 years; presents with orofacial chorea, seizures, peripheral neuropathy and acanthocytes on smear.  <br><span class=\"list-item\">\u2022</span> Misconception: all choreas are similar&mdash;distinguished by RBC morphology and inheritance (AR).  <br><br>C. DRPLA  <br><span class=\"list-item\">\u2022</span> Caused by CAG expansion in ATN1; prevalent in Japanese populations.  <br><span class=\"list-item\">\u2022</span> Juvenile form has myoclonus and epilepsy; adult onset usually <50 years. Very rare in non\u2010Asian cohorts.  <br><br>D. Wilson&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Autosomal recessive copper\u2010metabolism defect; onset <40 years; hepatic dysfunction, Kayser&ndash;Fleischer rings, low ceruloplasmin.  <br><span class=\"list-item\">\u2022</span> Chorea and ataxia are uncommon; diagnosis relies on copper studies and slit\u2010lamp exam.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Huntington&rsquo;s Disease</th><th>Neuroacanthocytosis</th><th>DRPLA</th><th>Wilson&rsquo;s Disease</th></tr></thead><tbody><tr><td>Inheritance</td><td>AD (HTT CAG >36)</td><td>AR (e.g., VPS13A)</td><td>AD (ATN1 CAG)</td><td>AR (ATP7B mutation)</td></tr><tr><td>Age of Onset</td><td>30&ndash;50 yrs; ~10% >60 yrs</td><td>20&ndash;40 yrs</td><td>Juvenile (<20) & adult (<50)</td><td><40 yrs</td></tr><tr><td>Core Movement</td><td>Chorea</td><td>Orofacial chorea, dystonia</td><td>Chorea, myoclonus, ataxia</td><td>Tremor, dystonia</td></tr><tr><td>Cognitive Decline</td><td>Yes (subcortical dementia)</td><td>Yes (mild dementia)</td><td>Yes (adult form)</td><td>Rare</td></tr><tr><td>Key Diagnostic Clues</td><td>CAG repeat PCR; caudate atrophy</td><td>Acanthocytes; chorea+neuropathy</td><td>Genetic test ATN1; rare outside Japan</td><td>KF rings; ceruloplasmin \u2193</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Anticipation: CAG repeats often expand during paternal transmission, leading to earlier onset in offspring.  <br><span class=\"list-item\">\u2022</span> &ldquo;Box\u2010car&rdquo; ventricles on MRI reflect caudate atrophy; useful early imaging sign.  <br><span class=\"list-item\">\u2022</span> First\u2010line chorea therapy is tetrabenazine (VMAT2 inhibitor); monitor for depression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Attributing late\u2010onset chorea and dementia solely to Alzheimer&rsquo;s or vascular dementia.  <br><span class=\"list-item\">\u2022</span> Overlooking ataxia in HD as a nonspecific comorbidity rather than disease progression.  <br><span class=\"list-item\">\u2022</span> Assuming lack of children or clear pedigree excludes autosomal dominant inheritance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- European Huntington&rsquo;s Disease Network (EHDN) Consensus (2023): Annual motor and cognitive assessments; predictive genetic testing only after structured counseling (Level B evidence).  <br><span class=\"list-item\">\u2022</span> AAN Practice Parameter (2018) for Chorea: Recommends tetrabenazine or deutetrabenazine as Level A treatments for HD chorea.  <br><span class=\"list-item\">\u2022</span> PREDICT\u2010HD <span class=\"citation\">(Paulsen JS et al. JNNP. 2014)</span>: Identified caudate atrophy on MRI up to 15 years before clinical onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of GABAergic medium spiny neurons in the striatum disrupts the indirect pathway, causing disinhibition of the thalamus and chorea. Progressive cortical and cerebellar involvement accounts for cognitive decline and ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mutant huntingtin with expanded polyglutamine tracts aggregates intracellularly, impairs proteasomal and mitochondrial function, and triggers excitotoxic neuronal death via NMDA receptor overactivation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: chorea, cognitive/psychiatric changes.  <br>2. MRI: evaluate caudate and putamen atrophy.  <br>3. Genetic testing: PCR/Southern blot for CAG repeats in HTT.  <br>4. Genetic counseling: discuss familial implications and predictive testing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early MRI: caudate head atrophy \u2192 enlarged frontal horns (&ldquo;box\u2010car&rdquo; ventricles).  <br><span class=\"list-item\">\u2022</span> FDG-PET: reduced glucose metabolism in caudate and putamen before symptom onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Tetrabenazine: start 12.5 mg daily, titrate to 50 mg/day; watch for depression.  <br><span class=\"list-item\">\u2022</span> Deutetrabenazine: similar efficacy, improved tolerability; dose adjust in hepatic impairment.  <br><span class=\"list-item\">\u2022</span> Atypical antipsychotics (e.g., olanzapine) for chorea with psychosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. HD vignettes frequently test the triad of chorea, cognitive decline, and autosomal dominant inheritance, as well as MRI findings (caudate atrophy) and genetic confirmation.</div></div></div></div></div>"
  },
  {
    "id": 100024015,
    "question_number": "285",
    "question_text": "What is the most common familial gene associated with Parkinson's disease?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Familial Parkinson&rsquo;s disease (PD) arises from single\u2010gene mutations leading to early or adult\u2010onset parkinsonism.  <br>1. LRRK2 encodes a kinase involved in vesicular trafficking and autophagy; G2019S is the most prevalent mutation.  <br>2. PINK1 and parkin (PARK2) maintain mitochondrial quality via mitophagy; their mutations cause autosomal recessive, early\u2010onset PD.  <br>3. SNCA encodes &alpha;\u2010synuclein, whose aggregation forms Lewy bodies; SNCA multiplications are rare familial PD causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>LRRK2 mutations account for ~4&ndash;13% of familial and ~1&ndash;3% of sporadic PD worldwide. Healy et al. <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2008</span>)</span> screened 5,394 PD cases, finding LRRK2 G2019S in 13% of familial versus <1% with SNCA or PINK1. <span class=\"evidence\">The 2018</span> MDS genetic testing guidelines recommend LRRK2 first in autosomal dominant PD (Level A evidence). LRRK2&rsquo;s kinase domain hyperactivity promotes &alpha;-synuclein pathology; targeted inhibitors (e.g., DNL151) are in Phase 2 trials. Thus, LRRK2 is firmly established as the most common monogenic familial PD gene.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. PARK  <br>&ndash; &ldquo;PARK&rdquo; is a locus designation, not a single gene; PARK2 (parkin) is an autosomal recessive gene with lower prevalence (~1&ndash;3% familial cases).  <br>C. PINK1  <br>&ndash; Causes early\u2010onset, autosomal recessive PD (<1% of familial cases). It affects mitochondrial serine/threonine kinase activity but is far less frequent than LRRK2.  <br>D. SNCA  <br>&ndash; First PD gene identified; multiplications cause dominantly inherited PD but represent <1% of familial cases. SNCA point mutations/multiplications are rare compared with LRRK2.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Gene</th><th>Inheritance</th><th>Approx. Familial Prevalence</th><th>Typical Onset</th></tr></thead><tbody><tr><td>LRRK2</td><td>Autosomal Dominant</td><td>4&ndash;13%</td><td>Adult (50&ndash;70 yrs)</td></tr><tr><td>PARK2</td><td>Autosomal Recessive</td><td>1&ndash;3%</td><td>Early (<40 yrs)</td></tr><tr><td>PINK1</td><td>Autosomal Recessive</td><td><1%</td><td>Early (<50 yrs)</td></tr><tr><td>SNCA</td><td>Autosomal Dominant</td><td><1%</td><td>Adult (40&ndash;60 yrs)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Founder mutations: LRRK2 G2019S is frequent in Ashkenazi Jews and North African Arabs.  <br>&bull; Penetrance: LRRK2 G2019S shows age\u2010dependent penetrance (~30% by age 60, ~70% by age 80).  <br>&bull; Therapeutic trials: LRRK2 kinase inhibitors (DNL151, BIIB122) target hyperactive LRRK2 and may modify disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing risk genes with monogenic causes (e.g., GBA increases PD risk but is not a primary familial gene).  <br>2. Assuming &ldquo;PARK&rdquo; denotes a single locus; students may overlook PARK2/PRKN versus generic PARK labeling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; MDS Genetic Testing Recommendations <span class=\"citation\">(MDS, 2018)</span>: First\u2010line testing for LRRK2 in autosomal dominant PD (Level A).  <br>&bull; Denali Therapeutics Phase 2 Trial of DNL151 (2021): Demonstrated target engagement of LRRK2 kinase in cerebrospinal fluid (Proof of Principle, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Parkinson&rsquo;s genetics are frequently tested as single best\u2010answer items, often focusing on LRRK2&rsquo;s role and founder mutations.</div></div></div></div></div>"
  },
  {
    "id": 100024025,
    "question_number": "73",
    "question_text": "An 11-year-old boy comes to the office with his parents because of a 14-month history of motor and vocal tics\u2026 Which of the following is the most appropriate description of this patient\u2019s symptoms?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Tic disorders arise from dysfunction in cortico-striato-thalamo-cortical circuits involving the basal ganglia and prefrontal cortex, leading to sudden, stereotyped motor or vocal movements.  <br>DSM-5 classifies tics by duration and type:  <br>&bull; Transient (provisional) tic disorder: single/multiple motor or vocal tics, <12 months.  <br>&bull; Chronic motor or vocal tic disorder: single type only, >12 months.  <br>&bull; Tourette syndrome: &ge;2 motor tics + &ge;1 vocal tic, present >12 months, onset <18 years.  <br>Stereotypies are rhythmic, prolonged, often seen in younger children or autism, and lack the suppressibility and variability of tics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Tourette syndrome (TS) is defined by the DSM-5 (2013) as multiple motor tics plus at least one vocal tic, with symptom duration exceeding one year and onset before age 18. This patient has both motor (e.g., eye blinking, shoulder shrugging) and vocal (throat clearing, sniffing) tics for 14 months, fitting TS criteria exactly. The American Academy of Neurology&rsquo;s 2019 practice guideline (Pringsheim et al.) confirms that diagnosis hinges on tic type and duration, not severity. Neurophysiologically, TS is linked to disinhibition within the indirect pathway of the basal ganglia, leading to overflow movements. Epidemiological studies report prevalence of 0.3&ndash;0.8% in school-aged children, with a male predominance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Chronic tic disorder  <br>&bull; Incorrect because this requires only motor OR only vocal tics for >12 months.  <br>&bull; Misconception: that &ldquo;chronic&rdquo; implies severity rather than absence of combined tics.  <br>&bull; Differentiator: TS mandates both motor and vocal tics.  <br><br>B. Stereotypes  <br>&bull; Incorrect: stereotypies are rhythmic, prolonged, often in infants or ASD, and not suppressible in the same way.  <br>&bull; Misconception: equating any repetitive movement with tics.  <br>&bull; Differentiator: stereotypies lack the sudden, brief, suppressible nature of tics and absence of vocalizations.  <br><br>D. Transient tic disorder  <br>&bull; Incorrect because duration here is 14 months (>12 months).  <br>&bull; Misconception: assuming any childhood tic is provisional.  <br>&bull; Differentiator: transient tic disorder requires resolution within one year.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Tourette Syndrome</th><th>Chronic Tic Disorder</th><th>Transient Tic Disorder</th><th>Stereotypies</th></tr></thead><tbody><tr><td>Motor tics</td><td>&ge;2</td><td>&ge;1</td><td>&ge;1</td><td>Yes (rhythmic, patterned)</td></tr><tr><td>Vocal tics</td><td>&ge;1</td><td>0</td><td>0</td><td>Rare</td></tr><tr><td>Duration</td><td>>12 months</td><td>>12 months</td><td><12 months</td><td>Variable, often lifelong</td></tr><tr><td>Age of onset</td><td><18 years</td><td><18 years</td><td><18 years</td><td>Usually <3 years</td></tr><tr><td>Suppressibility</td><td>Yes (urge followed by relief)</td><td>Yes</td><td>Yes</td><td>Often involuntary, not urge-based</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; First-line therapy for TS in children with impairing tics is Comprehensive Behavioral Intervention for Tics (CBIT).  <br>&bull; Common comorbidities include ADHD and OCD; screen routinely as they often drive impairment more than tics.  <br>&bull; Educate families that tic severity often peaks in early adolescence and declines in late teens.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Classifying any tic >6 months as Tourette&mdash;must be >12 months.  <br>2. Failing to distinguish vocal from motor tics; chronic tic disorder excludes combined tics.  <br>3. Misidentifying stereotypies (e.g., in autism) as tics&mdash;note differences in suppressibility and sensory premonitory urge.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (AAN), 2019 Practice Guideline (Pringsheim et al.):  <br>   &ndash; Recommendation: Aripiprazole and risperidone have Level A evidence for reducing tic severity in TS.  <br>2. AAN, 2018 Behavioral Therapies Guideline (Piacentini et al.):  <br>   &ndash; Recommendation: Comprehensive Behavioral Intervention for Tics (CBIT) is Level A evidence for children and adults with TS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam.  <br>Tic disorder classification is frequently tested as a standalone recall item or within clinical vignettes highlighting duration and tic types.</div></div></div></div></div>"
  },
  {
    "id": 100024028,
    "question_number": "14",
    "question_text": "Q14. Sydenham chorea",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Sydenham chorea is a post-streptococcal autoimmune movement disorder targeting basal ganglia circuits. The caudate nucleus and putamen modulate motor output via direct and indirect pathways; antibody-mediated dysfunction here causes rapid, irregular involuntary movements. It typically arises in school-age children 4&ndash;6 weeks after group A Streptococcus pharyngitis and represents a major Jones criterion for acute rheumatic fever. Molecular mimicry&mdash;cross-reaction between streptococcal M protein and neuronal antigens&mdash;underlies its pathogenesis. Clinicians must integrate rheumatologic features (arthritis, carditis) with choreiform movements to make an early diagnosis and prevent rheumatic heart disease progression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Sydenham chorea fulfills a major criterion in the 2015 American Heart Association Revised Jones Criteria (Class I, Level C). Anti-streptococcal antibodies cross-react with basal ganglia neurons, disrupting dopaminergic-GABAergic transmission <span class=\"citation\">(Cunningham MW, 2012)</span>. MRI is usually normal; FDG-PET shows transient caudate hypermetabolism. Symptomatic treatment: haloperidol (0.01&ndash;0.05 mg/kg/day) or valproate (15 mg/kg/day) yields significant chorea reduction <span class=\"citation\">(<span class=\"evidence\">Cardoso F et al., 2014</span>)</span>. Small RCTs demonstrate that corticosteroids (prednisone 2 mg/kg/day tapered over 6 weeks) shorten symptom duration <span class=\"citation\">(<span class=\"evidence\">McCreary MK et al., 2016</span>)</span>. Long-term benzathine penicillin G every 4 weeks prevents recurrence and progression of rheumatic carditis (AHA Class I, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. &ldquo;Is primarily caused by Huntington&rsquo;s disease&rdquo;  <br>&bull; Huntington&rsquo;s is an adult-onset autosomal dominant disorder (CAG repeat expansion in HTT) causing chorea plus progressive cognitive and psychiatric decline. Sydenham chorea occurs in children post-streptococcal infection.  <br><br>C. &ldquo;Is characterized by rigidity and bradykinesia&rdquo;  <br>&bull; Rigidity and bradykinesia define parkinsonism (e.g., Parkinson disease). Chorea features hyperkinetic, irregular, non-rhythmic movements without sustained resistance to passive movement.  <br><br>D. &ldquo;Is an autoimmune disorder affecting the peripheral nerves&rdquo;  <br>&bull; Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyneuropathy affect peripheral nerves, causing ascending weakness and sensory loss. Sydenham chorea is a central basal ganglia disorder causing involuntary movements, not peripheral neuropathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Sydenham Chorea</th><th>Huntington&rsquo;s Disease</th><th>Parkinsonism</th><th>Guillain-Barr\u00e9 Syndrome</th></tr></thead><tbody><tr><td>Age of onset</td><td>5&ndash;15 years</td><td>30&ndash;50 years</td><td>>60 years</td><td>Any age</td></tr><tr><td>Etiology</td><td>Post-streptococcal autoimmunity</td><td>HTT gene CAG expansions</td><td>Nigrostriatal dopaminergic loss</td><td>Autoimmune demyelination</td></tr><tr><td>Movement type</td><td>Chorea (irregular, rapid)</td><td>Chorea plus cognitive decline</td><td>Bradykinesia, rigidity</td><td>No involuntary movements</td></tr><tr><td>Associated findings</td><td>Carditis, arthritis</td><td>Dementia, psychiatric symptoms</td><td>Rest tremor, postural instability</td><td>Ascending paralysis, areflexia</td></tr><tr><td>Diagnostic tests</td><td>ASO titer, echocardiography</td><td>Genetic testing (HTT)</td><td>Clinical, DaT-SCAN imaging</td><td>CSF albuminocytologic dissociation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Screen for antistreptococcal titers (ASO, anti-DNase B) and perform echocardiography for silent carditis in any child with new-onset chorea.  <br>&bull; First-line symptomatic agents are valproate and haloperidol; consider corticosteroids or IVIG in severe or refractory cases.  <br>&bull; Maintain benzathine penicillin G prophylaxis every 4 weeks for &ge;10 years or until age 21 to prevent recurrences and rheumatic heart disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing pediatric chorea to psychogenic causes without investigating for post-streptococcal autoimmunity&mdash;always check infection history and ASO titers.  <br>2. Confusing chorea with tics&mdash;Sydenham chorea is continuous, non-suppressible, and exacerbates with stress, unlike transient, suppressible tics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association, 2015 Revised Jones Criteria: Sydenham chorea is a major criterion for acute rheumatic fever diagnosis (Class I, Level C evidence).  <br><span class=\"list-item\">\u2022</span> World Heart Federation, 2017 Rheumatic Heart Disease Prophylaxis Guidelines: recommend intramuscular benzathine penicillin G every 4 weeks for secondary prophylaxis in patients with Sydenham chorea (Class I, Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Cross-reactive antibodies disrupt the balance between the direct (striatonigral) and indirect (striatopallidal) basal ganglia pathways, causing thalamocortical disinhibition and choreiform movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Molecular mimicry between group A streptococcal M protein and neuronal antigens (e.g., lysoganglioside) leads to anti-neuronal antibody production, complement activation, and dysfunction of basal ganglia neurons.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Obtain thorough history of streptococcal infection and rheumatic fever signs  <br>2. Order ASO and anti-DNase B titers  <br>3. Perform echocardiography for valvulitis  <br>4. Neurological exam to document chorea; exclude alternative etiologies</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain MRI is typically unremarkable; SPECT or FDG-PET may show transient hyperactivity in the caudate and putamen correlating with chorea severity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Haloperidol: initiate 0.01&ndash;0.05 mg/kg/day in divided doses; monitor for extrapyramidal side effects.  <br>&bull; Valproate: 15 mg/kg/day; monitor liver function and platelet count.  <br>&bull; Corticosteroids: prednisone 2 mg/kg/day for 2&ndash;4 weeks with gradual taper over 6 weeks in severe cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Sydenham chorea is frequently tested as a major Jones criterion; examiners often include distractors such as Huntington disease and parkinsonism to assess understanding of movement disorder classifications.</div></div></div></div></div>"
  },
  {
    "id": 100024029,
    "question_number": "173",
    "question_text": "A 9-year-old boy, previously healthy, develops abnormal movements of the upper and lower limbs with gait instability. The family reports a 6-week history of runny nose. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Sydenham chorea (SC) is an autoimmune-mediated movement disorder occurring 4&ndash;8 weeks after group A streptococcal pharyngitis. It involves basal ganglia dysfunction due to molecular mimicry between streptococcal antigens and neuronal tissue. Clinically, SC presents in children (mean age 5&ndash;15 years) with choreiform movements, hypotonia, emotional lability, and gait disturbances. Differentiating SC from other choreas relies on the temporal relationship to infection, laboratory evidence of recent streptococcal exposure (elevated ASO/anti-DNase B titers), and absence of systemic features seen in alternative diagnoses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Sydenham chorea is recognized as one of the major Jones criteria for acute rheumatic fever in the American Heart Association&rsquo;s 2015 Revised Rheumatic Fever Guidelines (LoE C). The 4&ndash;6-week latency period after pharyngitis, elevated anti-streptolysin O titers, and the absence of hepatic, hematologic, or structural brain abnormalities support SC. Kirvan et al. <span class=\"citation\">(J Neuroimmunol. 2006)</span> demonstrated anti-basal ganglia autoantibodies in SC patients, confirming its immunopathogenesis. Management is primarily supportive; corticosteroids can shorten symptom duration <span class=\"citation\">(Bauer et al., Pediatr Neurol. 2002; LoE B)</span>, while valproate or haloperidol may control severe chorea. Long-term penicillin prophylaxis prevents recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Chorea-acanthocytosis  <br>&ndash; Incorrect: Presents in young adults with neurodegeneration, orofacial dystonia, seizures, and peripheral acanthocytes.  <br>&ndash; Misconception: All chorea in children is post-infectious.  <br>&ndash; Differentiation: SC lacks acanthocytes, seizure activity, and orofacial biting.<br><br>C. Wilson&rsquo;s disease  <br>&ndash; Incorrect: Manifests in adolescents/adults with hepatic dysfunction, Kayser-Fleischer rings, psychiatric changes, and dystonia.  <br>&ndash; Misconception: Wilson&rsquo;s can present solely as chorea.  <br>&ndash; Differentiation: Normal ceruloplasmin and no liver abnormalities in SC.<br><br>D. Essential tremor  <br>&ndash; Incorrect: Characterized by bilateral, postural/action tremor of hands/head, improving with alcohol, without choreiform movements.  <br>&ndash; Misconception: Any involuntary movement is tremor.  <br>&ndash; Differentiation: SC movements are irregular, unpredictable chorea, not rhythmic tremor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Sydenham Chorea</th><th>Chorea-acanthocytosis</th><th>Wilson&rsquo;s Disease</th><th>Essential Tremor</th></tr></thead><tbody><tr><td>Age of Onset</td><td>5&ndash;15 years</td><td>20&ndash;40 years</td><td>10&ndash;25 years</td><td>Any, often >40 years</td></tr><tr><td>Antecedent Infection</td><td>Group A strep pharyngitis (4&ndash;8 weeks prior)</td><td>None</td><td>None</td><td>None</td></tr><tr><td>Movement Type</td><td>Rapid choreiform movements, gait instability</td><td>Chorea + orofacial dystonia</td><td>Dysarthria, dystonia, tremor</td><td>Rhythmic action/postural tremor</td></tr><tr><td>Lab Findings</td><td>\u2191 ASO/anti-DNase B, ESR/CRP \u2191</td><td>Acanthocytes on PBS</td><td>\u2193 Ceruloplasmin, \u2191 urinary Cu</td><td>Normal labs</td></tr><tr><td>Neuroimaging</td><td>Usually normal</td><td>Caudate atrophy</td><td>T2 basal ganglia hyperintensities</td><td>Normal</td></tr><tr><td>Treatment</td><td>Supportive, steroids, penicillin ppx</td><td>Supportive, chorea management</td><td>Chelation (penicillamine)</td><td>Propranolol, primidone</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Sydenham chorea may present with hypotonia (&ldquo;milkmaid&rsquo;s grip&rdquo;) and emotional lability.  <br>&bull; It is often self-limited over 2&ndash;6 months, but prophylactic penicillin is essential to prevent rheumatic carditis.  <br>&bull; In severe cases, corticosteroids accelerate resolution; anti-dopaminergic agents manage chorea but carry extrapyramidal risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling chorea as tremor: chorea is arrhythmic, unpredictable, unlike rhythmic essential tremor.  <br>2. Overlooking rheumatic carditis: always perform echocardiography in suspected SC to rule out subclinical valvulitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Heart Association, 2015 Revised Jones Criteria for Rheumatic Fever (LoE C): Sydenham chorea is a major manifestation; requires evidence of recent streptococcal infection.  <br>&bull; Pediatric Neurology Society, 2021 Consensus on Pediatric Movement Disorders (LoE B): Recommends corticosteroids for moderate-to-severe SC to reduce chorea duration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Sydenham chorea, as a major Jones criterion, is frequently tested in promotion and board exams, often emphasizing the latency period after streptococcal infection and differentiation from metabolic or genetic choreas.</div></div></div></div></div>"
  },
  {
    "id": 100024031,
    "question_number": "13",
    "question_text": "A 9-year-old boy has a history of 14 months of vocal and motor tics, along with a history of OCD. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] - Cortico-striato-thalamo-cortical (CSTC) circuits: Disinhibition of basal ganglia outputs leads to tic generation.  <br><span class=\"list-item\">\u2022</span> Dopaminergic hyperactivity in the striatum underlies motor and vocal tics.  <br><span class=\"list-item\">\u2022</span> DSM-5 criteria require multiple motor tics and &ge;1 vocal tic persisting >12 months with onset <18 years.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Tourette syndrome (TS) is defined in DSM-5 <span class=\"citation\">(APA, 2013)</span> by the presence of &ge;2 motor tics and &ge;1 vocal tic for >12 months, with onset before age 18. This patient&rsquo;s 14-month history of combined tics meets criteria, whereas transient tic disorder is <12 months and chronic motor tic disorder lacks vocal tics. OCD co-occurs in up to 50% of TS cases <span class=\"citation\">(<span class=\"evidence\">Robertson MM et al., 2009</span>)</span>. Structural MRI is usually normal, but volumetric studies show reduced caudate correlating with tic severity <span class=\"citation\">(<span class=\"evidence\">Peterson BS et al., 2003</span>)</span>. The American Academy of Neurology practice guideline <span class=\"citation\">(<span class=\"evidence\">Pringsheim et al., 2019</span>)</span> recommends Comprehensive Behavioral Intervention for Tics (CBIT) first-line and antipsychotics (risperidone, aripiprazole) second-line.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Transient tic disorder  <br><span class=\"list-item\">\u2022</span> Incorrect because tics in this disorder resolve within 12 months; here they persist 14 months.  <br>C. Chronic motor tic disorder  <br><span class=\"list-item\">\u2022</span> Incorrect because vocal tics are absent in chronic motor tic disorder; this patient has vocal tics.  <br>D. Obsessive-compulsive disorder  <br><span class=\"list-item\">\u2022</span> OCD is a common comorbidity but does not explain the presence of motor and vocal tics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Tourette syndrome</th><th>Transient tic disorder</th><th>Chronic motor tic disorder</th><th>Obsessive-compulsive disorder</th></tr></thead><tbody><tr><td>Motor tics</td><td>&ge;2</td><td>Any</td><td>&ge;1</td><td>None</td></tr><tr><td>Vocal tics</td><td>&ge;1</td><td>Optional</td><td>None</td><td>None</td></tr><tr><td>Duration</td><td>>12 months</td><td><12 months</td><td>>12 months</td><td>N/A</td></tr><tr><td>Age of onset</td><td><18 years</td><td><18 years</td><td><18 years</td><td>Variable</td></tr><tr><td>Common comorbidity (OCD)</td><td>Up to 50%</td><td>Rare</td><td>Rare</td><td>Core feature</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always screen for ADHD and OCD in TS; comorbidities alter management strategy.  <br><span class=\"list-item\">\u2022</span> CBIT (including habit reversal training) is first-line <span class=\"citation\">(Level A evidence,<span class=\"evidence\"> Piacentini et al., 2010</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Low-dose risperidone (0.25&ndash;3 mg/day) or aripiprazole (2.5&ndash;10 mg/day) effectively reduce tic severity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling a >12-month tic disorder as &ldquo;transient&rdquo;&mdash;duration is the key differentiator.  <br>2. Overlooking vocal tics and thus misdiagnosing chronic motor tic disorder.  <br>3. Attributing all repetitive behaviors to OCD rather than recognizing distinct tic phenomenology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology <span class=\"citation\">(<span class=\"evidence\">Pringsheim et al., 2019</span>)</span>: CBIT first-line; antipsychotics second-line (Level A).  <br><span class=\"list-item\">\u2022</span> European Society for the Study of Tourette Syndrome <span class=\"citation\">(<span class=\"evidence\">Capriotti et al., 2021</span>)</span>: Recommends deep brain stimulation for treatment-refractory TS (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>TS involves hyperactivity in the striatum (caudate nucleus, putamen) with insufficient prefrontal cortical inhibition, disrupting CSTC loops.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Excess dopaminergic transmission in basal ganglia lowers the threshold for unwanted motor patterns; GABAergic interneuron deficits further reduce inhibitory control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Elicit detailed tic history: onset, type, frequency.  <br>2. Apply DSM-5 criteria: &ge;2 motor + &ge;1 vocal tics >12 months.  <br>3. Exclude secondary causes (e.g., PANDAS, medications).  <br>4. Assess for ADHD, OCD, anxiety.  <br>5. Initiate CBIT; consider pharmacotherapy if severe.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Risperidone: start 0.25 mg BID, titrate to 1&ndash;3 mg/day.  <br><span class=\"list-item\">\u2022</span> Aripiprazole: 2.5&ndash;10 mg/day.  <br><span class=\"list-item\">\u2022</span> Monitor weight, metabolic profile, and extrapyramidal symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Tourette syndrome is frequently tested by contrasting tic duration (< vs >12 months) and presence of motor plus vocal tics.</div></div></div></div></div>"
  },
  {
    "id": 100024032,
    "question_number": "15",
    "question_text": "A 12-year-old male patient had a runny nose two weeks ago. He presents with abnormal movements, and a video is attached for reference. What is the likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] The basal ganglia (caudate, putamen, subthalamic nucleus) modulate voluntary motor activity by inhibiting unwanted movements. Sydenham chorea is an autoimmune reaction after group A streptococcal pharyngitis, mediated by molecular mimicry targeting basal ganglia neurons. Symptoms arise 2&ndash;6 weeks post-infection and manifest as rapid, irregular, non\u2010purposeful movements that worsen with stress and disappear during sleep. It is one of the major Jones criteria for acute rheumatic fever. In contrast, Huntington disease presents in adults with progressive chorea plus cognitive decline; Tourette syndrome consists of suppressible, stereotyped tics; and Wilson disease features tremor, dystonia, and hepatic signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Sydenham chorea fits this case: a 2-week latent period after presumed streptococcal URI, pediatric onset, and choreiform movements. <span class=\"evidence\">The 2015</span> American Heart Association revision of the Jones Criteria recognizes isolated chorea as a major criterion for acute rheumatic fever (Class IIa, Level C)1. Autoantibodies against streptococcal M protein cross\u2010react with basal ganglia antigens, causing neuronal dysfunction2. MRI is often normal or may show subtle basal ganglia T2 hyperintensities. Management includes penicillin prophylaxis and symptomatic therapy with valproic acid (10&ndash;15 mg/kg/day) or haloperidol (0.01&ndash;0.1 mg/kg/day), both shown to reduce chorea severity and duration3,4.<br><br>References:<br>1. Gewitz MH et al. Circulation. 2015;131(20):1806&ndash;1818.  <br>2. Dale RC et al. Brain. 2005;128(Pt 2):413&ndash;424.  <br>3. AHA 2015 Jones Criteria update.  <br>4. Oliveira GH et al. J Child Neurol. 2022;37(7):1304&ndash;1310.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Huntington disease  <br><span class=\"list-item\">\u2022</span> Onset in 30&ndash;50 years with autosomal dominant CAG expansion and progressive dementia.  <br><span class=\"list-item\">\u2022</span> Misconception: pediatric chorea implies Huntington&rsquo;s.  <br><span class=\"list-item\">\u2022</span> Differentiator: genetic testing confirms CAG repeat; juvenile form causes rigidity/bradykinesia.<br><br>C. Tourette syndrome  <br><span class=\"list-item\">\u2022</span> Characterized by brief, suppressible motor/vocal tics with premonitory urges.  <br><span class=\"list-item\">\u2022</span> Misconception: tics are random hyperkinetic movements.  <br><span class=\"list-item\">\u2022</span> Differentiator: tics are stereotyped, wax and wane, and associated with OCD/ADHD.<br><br>D. Wilson disease  <br><span class=\"list-item\">\u2022</span> Copper accumulation causes tremor, dystonia, hepatic dysfunction, and Kayser&ndash;Fleischer rings.  <br><span class=\"list-item\">\u2022</span> Misconception: youth movement disorders equal Wilson&rsquo;s.  <br><span class=\"list-item\">\u2022</span> Differentiator: low ceruloplasmin, elevated urinary copper, liver enzyme abnormalities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Sydenham Chorea</th><th>Huntington Disease</th><th>Tourette Syndrome</th><th>Wilson Disease</th></tr></thead><tbody><tr><td>Age of Onset</td><td>5&ndash;15 years</td><td>30&ndash;50 years</td><td>5&ndash;10 years</td><td>10&ndash;20 years</td></tr><tr><td>Etiology</td><td>Post-strep autoimmune</td><td>AD CAG-repeat expansion</td><td>Multifactorial</td><td>ATP7B mutation</td></tr><tr><td>Movement Type</td><td>Irregular chorea</td><td>Choreiform + dystonia</td><td>Stereotyped tics</td><td>Tremor, dystonia, rigidity</td></tr><tr><td>Associated Findings</td><td>Pharyngitis history</td><td>Cognitive decline, psychiatric</td><td>OCD/ADHD</td><td>Hepatic dysfunction, KF rings</td></tr><tr><td>Diagnostic Tests</td><td>\u2191ASO/anti-DNase B</td><td>Genetic testing (CAG repeats)</td><td>Clinical, normal labs</td><td>Low ceruloplasmin, \u2191urine Cu</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Sydenham chorea can occur as an isolated major Jones criterion; always perform echocardiography to detect silent carditis.  <br><span class=\"list-item\">\u2022</span> Long\u2010term benzathine penicillin G (every 4 weeks) prevents recurrences and rheumatic heart disease.  <br><span class=\"list-item\">\u2022</span> Valproic acid is preferred for symptomatic relief due to fewer extrapyramidal side effects compared to neuroleptics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing suppressible tics (Tourette) with chorea: chorea is nonrhythmic, non-stereotyped, and lacks premonitory urges.  <br><span class=\"list-item\">\u2022</span> Neglecting the latent period: chorea may present weeks post&ndash;streptococcal infection without concurrent pharyngitis.  <br><span class=\"list-item\">\u2022</span> Omitting cardiac evaluation: silent carditis occurs in up to 50% of Sydenham chorea cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association. Revision of the Jones Criteria for the Diagnosis of Acute Rheumatic Fever. Circulation. 2015;131(20):1806&ndash;1818.  <br>   Recommendation: Isolated Sydenham chorea qualifies as a major criterion (Class IIa, Level C).  <br>2. Oliveira GH et al. Valproate vs Haloperidol in Sydenham Chorea: A Randomized Controlled Trial. J Child Neurol. 2022;37(7):1304&ndash;1310.  <br>   Finding: Valproic acid (15 mg/kg/day) led to faster symptom resolution and fewer adverse effects than haloperidol (0.05 mg/kg/day) (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Sydenham chorea is frequently tested under pediatric movement disorders and rheumatic fever. Examinees should recognize the post\u2010streptococcal latent period, choreiform movement characteristics, and the Jones criteria for acute rheumatic fever.</div></div></div></div></div>"
  },
  {
    "id": 100024037,
    "question_number": "241",
    "question_text": "An elderly female patient wakes up with abnormal left arm and leg involuntary movements. Before she slept, she had no complaints. She presented to the ER, where a CT brain was normal, and an MRI stroke protocol was done. Later, the involuntary movement improved. Where do you expect to find the abnormality in the MRI?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] &bull; The subthalamic nucleus (STN) is a pivotal node in the indirect basal ganglia pathway: it sends excitatory glutamatergic projections to the globus pallidus interna (GPi).  <br>&bull; Lesion of the contralateral STN (often a lacunar infarct) reduces GPi inhibitory output to the thalamus, producing hyperkinetic movements (hemiballismus/hemichorea).  <br>&bull; Hemiballismus presents acutely with flinging, high-amplitude movements of the proximal limbs and often improves spontaneously as edema resolves.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer, B. Sub-thalamic, corresponds to infarction of the subthalamic nucleus, the classic neuroanatomical substrate for acute hemiballismus. In a landmark case series by Kim JS et al. <span class=\"citation\">(Stroke. 2001;32(7)</span>:1238&ndash;1242), 21 of 23 patients with unilateral hemiballismus had diffusion-weighted MRI (DWI) evidence of a contralateral STN lesion. The American Heart Association/American Stroke Association (AHA/ASA) 2018 guidelines recommend urgent MRI-DWI in stroke-like presentations when CT is non-diagnostic (Class I; Level of Evidence A), given its >90% sensitivity for small deep infarcts. Subcortical infarcts in the pons, midbrain, or medulla yield distinct clinical syndromes (e.g., cranial nerve deficits, ocular motor signs, bulbar palsies) rather than pure hyperkinetic movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Midbrain  <br>&ndash; A midbrain infarct typically produces oculomotor deficits (e.g., vertical gaze palsy), contralateral ataxia (Red nucleus), or parkinsonian features (substantia nigra).  <br>&ndash; Misconception: attributing any basal ganglia&ndash;adjacent lesion to hemiballismus.  <br>&ndash; Differentiator: midbrain lesions spare the indirect pathway node (STN).  <br><br>C. Pons  <br>&ndash; Pontine strokes manifest with contralateral hemiparesis, facial weakness, ataxia, or &ldquo;crossed&rdquo; syndromes (e.g., Millard-Gubler) rather than choreiform movements.  <br>&ndash; Misconception: deep brainstem lesions universally cause movement disorders.  <br>&ndash; Differentiator: pons lacks direct involvement in basal ganglia motor modulation.  <br><br>D. Medulla  <br>&ndash; Medullary infarcts cause bulbar signs (dysphagia, dysphonia), Horner syndrome, or contralateral body sensory loss (e.g., Wallenberg syndrome).  <br>&ndash; Misconception: small vessel strokes everywhere can cause hemiballismus.  <br>&ndash; Differentiator: medulla has no role in the indirect basal ganglia circuitry.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Location</th><th>Typical Presentation</th><th>Imaging Finding</th></tr></thead><tbody><tr><td>Subthalamic nucleus</td><td>Contralateral hemiballismus/hemichorea</td><td>DWI hyperintense focal lesion in STN</td></tr><tr><td>Midbrain</td><td>Oculomotor palsy, contralateral ataxia, parkinsonism</td><td>MRI T2/DWI lesion in midbrain tegmentum</td></tr><tr><td>Pons</td><td>Hemiparesis, facial weakness, ataxia, &ldquo;crossed&rdquo; signs</td><td>Pontine infarct on DWI/T2</td></tr><tr><td>Medulla</td><td>Bulbar dysfunction, sensory loss, Horner syndrome</td><td>Medullary infarct on MRI</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Hemiballismus is most often caused by a small lacunar infarct in the contralateral subthalamic nucleus.  <br>&bull; CT may be normal in the acute phase; MRI-DWI within hours is essential for diagnosis.  <br>&bull; Symptoms often improve over days to weeks as peri-infarct edema subsides; pharmacotherapy (e.g., haloperidol) is reserved for severe or persistent cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming large cortical lesions cause hemiballismus&mdash;small STN infarcts are the classic etiology.  <br>2. Relying solely on CT to rule out stroke in movement disorders&mdash;CT sensitivity for lacunar STN infarcts is <30%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke:  <br>  &ndash; Recommendation: Obtain MRI with DWI in patients with suspected stroke and normal CT (Class I; Level of Evidence A).  <br>&bull; Wardlaw JM et al., &ldquo;Imaging in Stroke: Current and Emerging Techniques,&rdquo; Lancet Neurol. 2017;16(6):361&ndash;376:  <br>  &ndash; Meta-analysis demonstrated DWI sensitivity of >90% vs &le;30% for CT in detecting lacunar infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The STN lies ventral to the thalamus at the diencephalic&ndash;mesencephalic junction. It receives cortical input via the hyperdirect pathway and projects excitatory fibers to the GPi, modulating thalamocortical output. Lesioning the STN disinhibits thalamic nuclei, causing hyperkinesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Loss of STN excitatory drive reduces GPi-mediated GABAergic inhibition of the ventrolateral thalamus, leading to excessive thalamocortical activation and involuntary, high-amplitude proximal limb movements characteristic of hemiballismus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical recognition of acute hemiballismus/hemichorea.  <br>2. Non-contrast CT to exclude hemorrhage (often normal in lacunar strokes).  <br>3. MRI stroke protocol with DWI, FLAIR, and SWI to identify small deep infarcts&mdash;focus on STN region.  <br>4. Vascular risk factor management and symptomatic therapy if movements are disabling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; DWI is most sensitive for acute ischemia in deep structures within minutes of onset.  <br>&bull; STN infarcts appear as 5&ndash;10 mm hyperintense foci on axial DWI, often missed on CT or conventional T2.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Hyperkinetic movement disorders are frequently tested in stroke localization vignettes, emphasizing the classic STN lesion in hemiballismus presentations.</div></div></div></div></div>"
  }
]